Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-acylglycerophosphocholine o-acyltransferase deficiency
Small Intestine but Not Liver Lysophosphatidylcholine Acyltransferase 3 (Lpcat3) Deficiency Has a Dominant Effect on Plasma Lipid Metabolism.
abc-type xenobiotic transporter deficiency
ABCB4 mutations underlie hormonal cholestasis but not pediatric idiopathic gallstones.
abc-type xenobiotic transporter deficiency
ABCC4, a plasma membrane transporter modulating platelet aggregation.
abc-type xenobiotic transporter deficiency
Abcg2 deficiency augments oxidative stress and cognitive deficits in Tg-SwDI transgenic mice.
abc-type xenobiotic transporter deficiency
ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics.
abc-type xenobiotic transporter deficiency
ABCG2 deficiency in skin impairs re-epithelialization in cutaneous wound healing.
abc-type xenobiotic transporter deficiency
ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer's disease.
abc-type xenobiotic transporter deficiency
Behavioural consequences of P-glycoprotein deficiency in mice, with special focus on stress related mechanisms.
abc-type xenobiotic transporter deficiency
Biliary excretion of technetium-99m-sestamibi in wild-type dogs and in dogs with intrinsic (ABCB1-1Delta mutation) and extrinsic (ketoconazole treated) P-glycoprotein deficiency.
abc-type xenobiotic transporter deficiency
Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats.
abc-type xenobiotic transporter deficiency
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
abc-type xenobiotic transporter deficiency
Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
abc-type xenobiotic transporter deficiency
Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice.
abc-type xenobiotic transporter deficiency
Dietary cholesterol does not normalize low plasma cholesterol levels but induces hyperbilirubinemia and hypercholanemia in Mdr2 P-glycoprotein-deficient mice.
abc-type xenobiotic transporter deficiency
Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response.
abc-type xenobiotic transporter deficiency
Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism.
abc-type xenobiotic transporter deficiency
Expression profiles of cytokines and chemokines in murine MDR1a-/- colitis.
abc-type xenobiotic transporter deficiency
Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.
abc-type xenobiotic transporter deficiency
Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to Hypoxia.
abc-type xenobiotic transporter deficiency
Loss of TLR2 worsens spontaneous colitis in MDR1A deficiency through commensally induced pyroptosis.
abc-type xenobiotic transporter deficiency
MARCKS: a case of molecular exaptation?
abc-type xenobiotic transporter deficiency
mdr1a deficiency corrects sterility in Niemann-Pick C1 protein deficient female mice.
abc-type xenobiotic transporter deficiency
MDR1A deficiency restrains tumor growth in murine colitis-associated carcinogenesis.
abc-type xenobiotic transporter deficiency
Mdr1a plays a crucial role in regulating the analgesic effect and toxicity of aconitine by altering its pharmacokinetic characteristics.
abc-type xenobiotic transporter deficiency
Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase--effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice.
abc-type xenobiotic transporter deficiency
Multidrug resistance protein 1 deficiency promotes doxorubicin-induced ovarian toxicity in female mice.
abc-type xenobiotic transporter deficiency
Murine P-glycoprotein Deficiency Alters Intestinal Injury Repair and Blunts Lipopolysaccharide-Induced Radioprotection.
abc-type xenobiotic transporter deficiency
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model.
abc-type xenobiotic transporter deficiency
P-glycoprotein deficiency enhances metabolic activation of and platelet response to clopidogrel through marked up-regulation of Cyp3a11 in mice: Direct evidence for the interplay between P-glycoprotein and Cyp3a.
abc-type xenobiotic transporter deficiency
P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity.
abc-type xenobiotic transporter deficiency
Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice.
abc-type xenobiotic transporter deficiency
Protoporphyrin IX accumulation disrupts mitochondrial dynamics and function in ABCG2-deficient hepatocytes.
abc-type xenobiotic transporter deficiency
Rotor-type hyperbilirubinaemia has no defect in the canalicular bilirubin export pump.
abc-type xenobiotic transporter deficiency
Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes.
abc-type xenobiotic transporter deficiency
Synergistic influence of Abcb1 and Abcc2 on disposition and sterol lowering effects of ezetimibe in rats.
abc-type xenobiotic transporter deficiency
The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria.
Abortion, Spontaneous
Expression analysis of mammalian mitochondrial ribosomal protein genes.
Abortion, Spontaneous
Loss of Placental P-Glycoprotein May Be a Common Pathophysiologic Pathway for First Trimester Spontaneous Miscarriages.
Abscess
Calcium-binding proteins MRP 8 and 14 in a Staphylococcus aureus infection model: role of therapy, inflammation, and infection persistence.
Acidosis
Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38.
Acidosis
Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: in vivo imaging with 68Ga-labelled PET tracer.
Acidosis
Drug resistance and cellular adaptation to tumor acidic pH microenvironment.
Acidosis
Hypoxia-Induced Extracellular Acidosis Increases p-Glycoprotein Activity and Chemoresistance in Tumors in Vivo via p38 Signaling Pathway.
Acidosis
Impact of hypoxia-related tumor acidosis on cytotoxicity of different chemotherapeutic drugs in vitro and in vivo.
Acidosis
Mechanisms of bilirubin toxicity: clinical implications.
Acidosis
PET Imaging of the Impact of Extracellular pH and MAP Kinases on the p-Glycoprotein (Pgp) Activity.
Acidosis, Lactic
Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells.
Acidosis, Lactic
[Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs].
Acne Vulgaris
Involvement of adenosine triphosphate-binding cassette subfamily B member 1 in the augmentation of triacylglycerol excretion by Propionibacterium acnes in differentiated hamster sebocytes.
Acquired Immunodeficiency Syndrome
A new, striking morphological alteration of P-glycoprotein expression in NK cells from AIDS patients.
Acquired Immunodeficiency Syndrome
ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohort.
Acquired Immunodeficiency Syndrome
Altered P-glycoprotein expression in AIDS patients with HIV encephalitis.
Acquired Immunodeficiency Syndrome
An MDR-EGFP gene fusion allows for direct cellular localization, function and stability assessment of P-glycoprotein.
Acquired Immunodeficiency Syndrome
Discordant Associations Between SLCO1B1 521T?C and Plasma Levels of Ritonavir-boosted Protease Inhibitors in AIDS Clinical Trials Group Study A5146.
Acquired Immunodeficiency Syndrome
Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?
Acquired Immunodeficiency Syndrome
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.
Acquired Immunodeficiency Syndrome
Elevated serum macrophage inhibitory factor-related protein (MRP) 8/14 levels in advanced HIV infection and during disease exacerbation.
Acquired Immunodeficiency Syndrome
Intestinal absorption mechanisms of 2'-deoxy-2'-?-fluoro-4'-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein.
Acquired Immunodeficiency Syndrome
Investigating appearance and regulation of the MXR phenotype in early embryo stages of the Mediterranean mussel (Mytilus galloprovincialis).
Acquired Immunodeficiency Syndrome
LC determination of indinavir in biological matrices with electrochemical detection.
Acquired Immunodeficiency Syndrome
Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors.
Acquired Immunodeficiency Syndrome
The expression of P-glycoprotein and cellular kinases is modulated at the transcriptional level by infection and highly active antiretroviral therapy in a primate model of AIDS.
Acquired Immunodeficiency Syndrome
The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy.
Acute Coronary Syndrome
Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.
Acute Coronary Syndrome
Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Acute Coronary Syndrome
CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban.
Acute Coronary Syndrome
Distribution of polymorphisms in the CYP2C19 and ABCB1 genes among patients with acute coronary syndrome in Lower Silesian population.
Acute Coronary Syndrome
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Acute Coronary Syndrome
Effects of the ABCB1 C3435T single nucleotide polymorphism on major adverse cardiovascular events in acute coronary syndrome or coronary artery disease patients undergoing percutaneous coronary intervention and treated with clopidogrel: A systematic review and meta-analysis.
Acute Coronary Syndrome
Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
Acute Coronary Syndrome
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Acute Coronary Syndrome
Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes.
Acute Coronary Syndrome
The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes.
Acute Coronary Syndrome
[Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome].
Acute Coronary Syndrome
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Acute Kidney Injury
Acute kidney injury in a preterm infant homozygous for the C3435T polymorphism in the ABCB1 gene given oral morphine.
Acute Kidney Injury
Deficiency of either P-glycoprotein or Breast Cancer Resistance Protein protect against acute kidney injury.
Acute Kidney Injury
Downregulated expression of intestinal P-glycoprotein in rats with cisplatin-induced acute kidney injury causes amplification of its transport capacity to maintain "gatekeeper" function.
Acute Kidney Injury
Effect of experimental acute renal and hepatic failure on absorption of tacrolimus in rat small intestine.
Acute Kidney Injury
Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure.
Acute Kidney Injury
Factors affecting the expression and function of P-glycoprotein in rats: drug treatments and diseased states.
Acute Kidney Injury
Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients.
Acute Kidney Injury
Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1/3 and ABCG2.
Acute Kidney Injury
Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation.
Acute Kidney Injury
Renal excretion of rhodamine 123, a P-glycoprotein substrate, in rats with glycerol-induced acute renal failure.
Acute Kidney Injury
Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.
Acute Lung Injury
Inhibition of MRP4 alleviates sepsis-induced acute lung injury in rats.
Adenocarcinoma
8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1.
Adenocarcinoma
A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene.
Adenocarcinoma
A case of pulmonary adenocarcinoma with overexpression of multidrug resistance-associated protein and p53 aberration.
Adenocarcinoma
A combination of curcumin with either gramicidin or ouabain selectively kills cells that express the multidrug resistance-linked ABCG2 transporter.
Adenocarcinoma
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
Adenocarcinoma
ABCA2 transporter deficiency reduces incidence of TRAMP prostate tumor metastasis and cellular chemotactic migration.
Adenocarcinoma
ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.
Adenocarcinoma
Biocompatible fluorescent nanocrystals for immunolabeling of membrane proteins and cells.
Adenocarcinoma
Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
Adenocarcinoma
Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test, and MDR1, MRP1, and MRP2 mRNA expression in human colorectal adenocarcinomas.
Adenocarcinoma
CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway.
Adenocarcinoma
Defining the role of MRP-mediated efflux and glutathione in detoxification of oxaliplatin.
Adenocarcinoma
Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies.
Adenocarcinoma
Detection of P-glycoprotein in human urogenital carcinomas and its relationship to epidermal growth factor receptor expression.
Adenocarcinoma
Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis.
Adenocarcinoma
Doxorubicin delivery enhanced by electroporation to gastrointestinal adenocarcinoma cells with P-gp overexpression.
Adenocarcinoma
Dual role of cAMP in the transcriptional regulation of multidrug resistance-associated protein 4 (MRP4) in pancreatic adenocarcinoma cell lines.
Adenocarcinoma
Effect of Cinnamic acid and FOLFOX in diminishing side population and downregulating cancer stem cell markers in colon cancer cell line HT-29.
Adenocarcinoma
Effect of new oxicam derivatives on efflux pumps overexpressed in resistant a human colorectal adenocarcinoma cell line.
Adenocarcinoma
Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon the growth of parent and multidrug resistant human lung cancer cells in vitro.
Adenocarcinoma
Enhancing the Therapeutic Efficacy of Daunorubicin and Mitoxantrone with Bavachinin, Candidone, and Tephrosin.
Adenocarcinoma
Entinostat reverses P-glycoprotein activation in snail-overexpressing adenocarcinoma HCC827 cells.
Adenocarcinoma
Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein.
Adenocarcinoma
Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance.
Adenocarcinoma
Expression and localization of ATP binding cassette (ABC) family of drug transporters in gastric hepatoid adenocarcinomas.
Adenocarcinoma
Expression of Breast Cancer Resistance Protein (BCRP-1) in Canine Mammary Adenocarcinomas and Adenomas.
Adenocarcinoma
Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Adenocarcinoma
Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Adenocarcinoma
Expression of mutant p53 and of the multidrug resistant proteins P-glycoprotein and glutathione S-transferase-pi correlated in colorectal adenocarcinoma.
Adenocarcinoma
Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas.
Adenocarcinoma
Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer.
Adenocarcinoma
Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer.
Adenocarcinoma
Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas.
Adenocarcinoma
Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer.
Adenocarcinoma
Extracellular high mobility group box chromosomal protein 1 promotes drug resistance by increasing the expression of P?glycoprotein expression in gastric adenocarcinoma cells.
Adenocarcinoma
Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material.
Adenocarcinoma
Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2).
Adenocarcinoma
Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
Adenocarcinoma
Functionalized nanocrystal-tagged fluorescent polymer beads: synthesis, physicochemical characterization, and immunolabeling application.
Adenocarcinoma
Genetic susceptibility of lung cancer associated with common variants in the 3' untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export.
Adenocarcinoma
Helioscopianoids A-Q, bioactive jatrophane diterpenoid esters from Euphorbia helioscopia.
Adenocarcinoma
High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
Adenocarcinoma
Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy.
Adenocarcinoma
Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein.
Adenocarcinoma
Identification of MRP4/ABCC4 as a Target for Reducing the Proliferation of Pancreatic Ductal Adenocarcinoma Cells by Modulating the cAMP Efflux.
Adenocarcinoma
Immunohistochemical assessment of proliferation markers and altered gene expression in archival specimens of ovarian epithelial tumors.
Adenocarcinoma
Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung.
Adenocarcinoma
Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma.
Adenocarcinoma
Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung.
Adenocarcinoma
Impact of genetic variants of ABCB1, APOB, CAV1, and NAMPT on susceptibility to pancreatic ductal adenocarcinoma in Chinese patients.
Adenocarcinoma
Increased lipid peroxidation, apoptosis and selective cytotoxicity in colon cancer cell line LoVo and its doxorubicin-resistant subline LoVo/Dx in the presence of newly synthesized phenothiazine derivatives.
Adenocarcinoma
Influence of ABCB1 (1236C?>?T,?2677G?>?T and?3435C?>?T) polymorphisms on the transport ability of P-gp-mediated sunitinib in Caco-2 cell line.
Adenocarcinoma
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.
Adenocarcinoma
Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers.
Adenocarcinoma
Inhibitory Effects of Highly Oxygenated Lanostane Derivatives from the Fungus Ganoderma lucidum on P-Glycoprotein and ?-Glucosidase.
Adenocarcinoma
Integrative systematic review meta-analysis and bioinformatics identifies MicroRNA-21 and its target genes as biomarkers for colorectal adenocarcinoma.
Adenocarcinoma
Intensely potent doxorubicin analogues: structure-activity relationship.
Adenocarcinoma
Involvement of Vitamin D receptor in the intestinal induction of human ABCB1.
Adenocarcinoma
Isobavachalcone as an Active Membrane Perturbing Agent and Inhibitor of ABCB1 Multidrug Transporter.
Adenocarcinoma
Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer.
Adenocarcinoma
Mechanism of P-glycoprotein Expression in the SGC7901 Human Gastric Adenocarcinoma Cell Line Induced by Cyclooxygenase-2.
Adenocarcinoma
Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP).
Adenocarcinoma
Modulation of daunorubicin intracellular accumulation in P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia.
Adenocarcinoma
Multidrug resistance gene and P-glycoprotein expression in gastric adenocarcinoma and precursor lesions.
Adenocarcinoma
Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.
Adenocarcinoma
Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines.
Adenocarcinoma
New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors.
Adenocarcinoma
Oncogenic PITX2 Facilitates Tumor Cell Drug Resistance by Inverse Regulation of hOCT3/SLC22A3 and ABC Drug Transporters in Colon and Kidney Cancers.
Adenocarcinoma
Overexpression of P16 reversed the MDR1-mediated DDP resistance in the cervical adenocarcinoma by activating the ERK1/2 signaling pathway.
Adenocarcinoma
P-glycoprotein as a prognostic indicator in pre- and postchemotherapy ovarian adenocarcinoma.
Adenocarcinoma
P-glycoprotein expression in gastroesophageal adenocarcinomas, their metastases, and surrounding mucosa: a mapping study.
Adenocarcinoma
P-glycoprotein inhibition by glibenclamide and related compounds.
Adenocarcinoma
Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung.
Adenocarcinoma
Protein expression of ABCC2 and SLC22A3 associates with prognosis of pancreatic adenocarcinoma.
Adenocarcinoma
Quaternized starch-based carrier for siRNA delivery: from cellular uptake to gene silencing.
Adenocarcinoma
R-verapamil decreases anti-estrogen resistance in a breast cancer model.
Adenocarcinoma
Regulation of ABCG2 expression by Wnt5a through FZD7 in human pancreatic cancer cells.
Adenocarcinoma
Reversal of the multidrug resistance of human ileocecal adenocarcinoma cells by acetyl-11-keto-?-boswellic acid via downregulation of P-glycoprotein signals.
Adenocarcinoma
Reverse correlation between P-glycoprotein expression and proliferative activity in endometrial adenocarcinoma.
Adenocarcinoma
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.
Adenocarcinoma
Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells.
Adenocarcinoma
Stemness and anti-cancer drug resistance in ATP-binding cassette subfamily G member 2 highly expressed pancreatic cancer is induced in 3D culture conditions.
Adenocarcinoma
Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium.
Adenocarcinoma
Synthesis, and the antioxidant, neuroprotective and P-glycoprotein induction activity of 4-arylquinoline-2-carboxylates.
Adenocarcinoma
The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.
Adenocarcinoma
The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma.
Adenocarcinoma
The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels.
Adenocarcinoma
The expression of multidrug resistance protein in human gastrointestinal tract carcinomas.
Adenocarcinoma
The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines.
Adenocarcinoma
The influence of passage number for Caco2 cell models when evaluating P-gp mediated drug transport.
Adenocarcinoma
The multidrug resistance modulator SDZ-PSC 833 potentiates the photodynamic activity of chlorin e6 independently of P-glycoprotein in multidrug resistant human breast adenocarcinoma cells.
Adenocarcinoma
VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese.
Adenocarcinoma
Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation.
Adenocarcinoma
[Clinical significance of multidrug resistance-associated protein(MRP) gene expression in non-small cell lung cancer]
Adenocarcinoma
[Expression and Clinical Significance of ABCC10 in the Patients with Non-small Cell Lung Cancer.]
Adenocarcinoma
[Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma]
Adenocarcinoma
[Expression of LRP, MRP and MDR1 in non-small-cell lung cancer and its clinical significance]
Adenocarcinoma
[Expression of multidrug resistance-associated protein in human non-small cell lung cancer]
Adenocarcinoma
[The expression of MRP gene relates to the pathological features of lung cancer]
Adenocarcinoma of Lung
Anti-ABCG2 scFv antibody of lung adenocarcinoma increases chemosensitivity and induces apoptosis through the activation of mitochondrial pathway.
Adenocarcinoma of Lung
Asiatic Acid (AA) Sensitizes Multidrug-Resistant Human Lung Adenocarcinoma A549/DDP Cells to Cisplatin (DDP) via Downregulation of P-Glycoprotein (MDR1) and Its Targets.
Adenocarcinoma of Lung
Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression.
Adenocarcinoma of Lung
Cholesterol reduces the sensitivity to platinum-based chemotherapy via upregulating ABCG2 in lung adenocarcinoma.
Adenocarcinoma of Lung
Co-transfection of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells.
Adenocarcinoma of Lung
Cytotoxicity determination without photochemical artifacts.
Adenocarcinoma of Lung
Downregulation of breast cancer resistance protein by long-term fractionated radiotherapy sensitizes lung adenocarcinoma to SN-38.
Adenocarcinoma of Lung
Elevated Expression of Nrf-2 and ABCG2 Involved in Multi-drug Resistance of Lung Cancer SP Cells.
Adenocarcinoma of Lung
Functional expression and characterization in Xenopus laevis oocytes of the ABCG2 transporter derived from A549 human lung adenocarcinoma cells.
Adenocarcinoma of Lung
Genetic susceptibility of lung cancer associated with common variants in the 3' untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export.
Adenocarcinoma of Lung
Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line.
Adenocarcinoma of Lung
Induction of fetal hemoglobin and ABCB1 gene expression in 9-?-D-arabinofuranosylguanine-resistant MOLT-4 cells.
Adenocarcinoma of Lung
Multidrug resistance-associated protein 3 and Bcl-2 contribute to multidrug resistance by vinorelbine in lung adenocarcinoma.
Adenocarcinoma of Lung
Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
Adenocarcinoma of Lung
Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma.
Adenocarcinoma of Lung
Overcoming drug-resistance in lung cancer cells by paclitaxel loaded galactoxyloglucan nanoparticles.
Adenocarcinoma of Lung
Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells.
Adenocarcinoma of Lung
Prognostic significance of ABCB1 in stage I lung adenocarcinoma.
Adenocarcinoma of Lung
Regulation of ABCG2 by nuclear factor kappa B affects the sensitivity of human lung adenocarcinoma A549 cells to arsenic trioxide.
Adenocarcinoma of Lung
Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
Adenocarcinoma of Lung
Secreted phosphoprotein 1 upstream invasive network construction and analysis of lung adenocarcinoma compared with human normal adjacent tissues by integrative biocomputation.
Adenocarcinoma of Lung
[Effects of hypoxia on expression of P-glycoprotein and multidrug resistance protein in human lung adenocarcinoma A549 cell line]
Adenocarcinoma of Lung
[Isolation and Biological Characterization of Lung Cancer Stem Cells].
Adenocarcinoma of Lung
[Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line]
Adenocarcinoma, Bronchiolo-Alveolar
Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression.
Adenoma
Detecting parathyroid adenoma using technetium-99m tetrofosmin: comparison with P-glycoprotein and multidrug resistance related protein expression--a preliminary report.
Adenoma
Differentiation dependent expression of P-glycoprotein in the normal and neoplastic human kidney.
Adenoma
Downregulation of breast cancer resistance protein in colon adenomas reduces cellular xenobiotic resistance and leads to accumulation of a food-derived carcinogen.
Adenoma
Expression of Breast Cancer Resistance Protein (BCRP-1) in Canine Mammary Adenocarcinomas and Adenomas.
Adenoma
Expression of P-glycoprotein and C-MOAT in human hepatocellular carcinoma: detection by immunostaining.
Adenoma
High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence.
Adenoma
Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors.
Adenoma
Influence of Genetic Polymorphisms in Prostaglandin E2 Pathway (COX-2/HPGD/SLCO2A1/ABCC4) on the Risk for Colorectal Adenoma Development and Recurrence after Polypectomy.
Adenoma
Integrative systematic review meta-analysis and bioinformatics identifies MicroRNA-21 and its target genes as biomarkers for colorectal adenocarcinoma.
Adenoma
Low ABCB1 Gene Expression Is an Early Event in Colorectal Carcinogenesis.
Adenoma
Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer.
Adenoma
Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas.
Adenoma
Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice.
Adenoma
Technetium-99m methoxyisobutylisonitrile imaging for parathyroid adenoma: relationship to P-glycoprotein or multidrug resistance-related protein expression.
Adenoma, Liver Cell
Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoxetic Acid-enhanced MR Imaging.
Adenomatous Polyposis Coli
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Adenomatous Polyposis Coli
The action mechanism of lncRNA-HOTAIR on the drug resistance of non-small cell lung cancer by regulating Wnt signaling pathway.
Adenomatous Polyps
A novel miR-203-DNMT3b-ABCG2 regulatory pathway predisposing colorectal cancer development.
Adenomatous Polyps
Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer.
Adrenal Cortex Neoplasms
Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer.
Adrenocortical Carcinoma
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Adrenocortical Carcinoma
Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours.
Adrenocortical Carcinoma
Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer.
Adrenocortical Carcinoma
P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells.
Adrenocortical Carcinoma
P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma.
Adrenocortical Carcinoma
Regulation of P-glycoprotein expression in cyclic AMP-dependent protein kinase mutants.
Adrenocortical Carcinoma
Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo.
Adrenocortical Carcinoma
Variable p-glycoprotein immunoreactivity unrelated to cytotoxic drug-resistance in-vitro of human adrenocortical carcinoma.
Adrenoleukodystrophy
A de-novo large deletion of 2.8 kb produced in the ABCD1 gene causing adrenoleukodystrophy disease.
Adrenoleukodystrophy
ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.
Adrenoleukodystrophy
Adenoassociated Virus Serotype 9-Mediated Gene Therapy for X-Linked Adrenoleukodystrophy.
Adrenoleukodystrophy
CRISPR/Cas9-mediated knockout of Abcd1 and Abcd2 genes in BV-2 cells: novel microglial models for X-linked Adrenoleukodystrophy.
Adrenoleukodystrophy
Evidence of oxidative stress in very long chain fatty acid--treated oligodendrocytes and potentialization of ROS production using RNA interference-directed knockdown of ABCD1 and ACOX1 peroxisomal proteins.
Adrenoleukodystrophy
Generation of a WA14 hESC sub-line carrying a hemizygous ABCD1 (C.1696_1710 del) mutation introduced by CRISPR/Cas9 technology.
Adrenoleukodystrophy
Generation of an induced pluripotent stem cell (iPSC) line from a 42-year-old adult cerebral type X-linked adrenoleukodystrophy (X-ALD) patient.
Adrenoleukodystrophy
Generation of two induced pluripotent stem cell (iPSC) lines from X-linked adrenoleukodystrophy (X-ALD) patients with adrenomyeloneuropathy (AMN).
Adrenoleukodystrophy
Hexacosenoyl-CoA is the most abundant very long-chain acyl-CoA in ATP-binding cassette transporter D1-deficient cells.
Adrenoleukodystrophy
Impaired plasticity of macrophages in X-linked adrenoleukodystrophy.
Adrenoleukodystrophy
Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator.
Adrenoleukodystrophy
The Arabidopsis pxa1 mutant is defective in an ATP-binding cassette transporter-like protein required for peroxisomal fatty acid beta-oxidation.
Adrenoleukodystrophy
The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein.
Adrenoleukodystrophy
Transport of fatty acids and metabolites across the peroxisomal membrane.
Adrenoleukodystrophy
X-linked adrenoleukodystrophy.
Adrenoleukodystrophy
X-linked adrenoleukodystrophy: molecular and functional analysis of the ABCD1 gene in Argentinean patients.
Adrenoleukodystrophy
[PMP70, the 70-kDa peroxisomal membrane protein: a member of the ATP-binding cassette transporters]
Agranulocytosis
Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population.
Agranulocytosis
Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients.
Agranulocytosis
Relation of the Allelic Variants of Multidrug Resistance Gene to Agranulocytosis Associated With Clozapine.
Alagille Syndrome
Paucity of Interlobular Bile Ducts in Multidrug-Resistant P-Glycoprotein 3 (MDR3) Deficiency.
Albuminuria
Cyclodextrin protects podocytes in diabetic kidney disease.
Alopecia
Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer.
Alopecia
Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis.
Alzheimer Disease
A Benzopyrane Derivative as a P-Glycoprotein Stimulator: A Potential Agent to Decrease ?-Amyloid Accumulation in Alzheimer's Disease.
Alzheimer Disease
A new approach for Alzheimer's disease treatment through P-gp regulation via ibuprofen.
Alzheimer Disease
A novel intronic polymorphism of ABCA1 gene reveals risk for sporadic Alzheimer's disease in Chinese.
Alzheimer Disease
A Role for P-Glycoprotein in Clearance of Alzheimer Amyloid ? -Peptide from the Brain.
Alzheimer Disease
A?40 Reduces P-Glycoprotein at the Blood-Brain Barrier through the Ubiquitin-Proteasome Pathway.
Alzheimer Disease
ABC Transporters in Neurological Disorders: An Important Gateway for Botanical Compounds Mediated Neuro-Therapeutics.
Alzheimer Disease
ABCA1 deficiency and cellular cholesterol accumulation increases islet amyloidogenesis in mice.
Alzheimer Disease
ABCA7 Deficiency Accelerates Amyloid-? Generation and Alzheimer's Neuronal Pathology.
Alzheimer Disease
ABCA7 genotype altered A? levels in cerebrospinal fluid in Alzheimer's disease without dementia.
Alzheimer Disease
ABCA7 Loss of Function Alters Alzheimer Amyloid Processing.
Alzheimer Disease
ABCB1 C3435T polymorphism influences the risk for Alzheimer's disease.
Alzheimer Disease
ABCB1 Genotype and CSF {beta}-Amyloid in Alzheimer Disease.
Alzheimer Disease
ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer's disease.
Alzheimer Disease
Abundance of P-glycoprotein and other drug transporters at the human blood-brain barrier in Alzheimer's Disease: a quantitative targeted proteomic study.
Alzheimer Disease
Accumulation of murine amyloid-? mimics early Alzheimer's disease.
Alzheimer Disease
Activity of P-Glycoprotein, a ?-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease.
Alzheimer Disease
Adenosine triphosphate Binding Cassette subfamily C member 1 (ABCC1) overexpression reduces APP processing and increases alpha- versus beta-secretase activity, in vitro.
Alzheimer Disease
Age-dependent decline of blood-brain barrier P-glycoprotein expression in the canine brain.
Alzheimer Disease
Age-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier.
Alzheimer Disease
Alzheimer's Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway.
Alzheimer Disease
An automated method measures variability in P-glycoprotein and ABCG2 densities across brain regions and brain matter.
Alzheimer Disease
An Investigation into the Role of P-Glycoprotein in Alzheimer's Disease Lesion Pathogenesis.
Alzheimer Disease
Assessing the Impact of Lithium Chloride on the Expression of P-Glycoprotein at the Blood-Brain Barrier.
Alzheimer Disease
Association between ABCB1 polymorphisms and haplotypes and Alzheimer's disease: a meta-analysis.
Alzheimer Disease
Association between the ABCG2 C421A polymorphism and Alzheimer's disease.
Alzheimer Disease
Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease.
Alzheimer Disease
ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.
Alzheimer Disease
BACE1 inhibitors: a head group scan on a series of amides.
Alzheimer Disease
Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: still a suspect?
Alzheimer Disease
Blood-brain barrier P-glycoprotein function in Alzheimer's disease.
Alzheimer Disease
Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene.
Alzheimer Disease
Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model.
Alzheimer Disease
Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease.
Alzheimer Disease
Comparative evaluation of two dye probes in the rat everted gut sac model for unambiguous classification of P-gp substrate and inhibitor.
Alzheimer Disease
Decreased blood-brain barrier expression of P-glycoprotein in Alzheimer's disease: impact on pathogenesis and brain access of therapeutic agents.
Alzheimer Disease
Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans.
Alzheimer Disease
Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Alzheimer Disease
Effect of Colloidal Aqueous Solution of Fullerene (C60) in the Presence of a P-Glycoprotein Inhibitor (Verapamil) on Spatial Memory and Hippocampal Expression of Sirtuin6, SELADIN1, and AQP1 Genes in a Rat Model of Alzheimer's Disease.
Alzheimer Disease
Effects of P-Glycoprotein on the Transport of DL0410, a Potential Multifunctional Anti-Alzheimer Agent.
Alzheimer Disease
Ethnicity-dependent genetic association of ABCA2 with sporadic Alzheimer's disease.
Alzheimer Disease
Evidence against a role of P-glycoprotein in the clearance of the Alzheimer's disease A?1-42 peptides.
Alzheimer Disease
Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer's disease.
Alzheimer Disease
Gene expression profiling of peripheral blood leukocytes identifies and validates ABCB1 as a novel biomarker for Alzheimer's disease.
Alzheimer Disease
Imaging P-glycoprotein Induction at the Blood-Brain Barrier of a Beta-Amyloidosis Mouse Model with 11C-Metoclopramide PET.
Alzheimer Disease
Impact of CYP2D6, CYP3A5, and ABCB1 Polymorphisms on Plasma Concentrations of Donepezil and Its Metabolite in Patients With Alzheimer Disease.
Alzheimer Disease
Impact of reduced P-glycoprotein function on digoxin concentrations in patients with dementia.
Alzheimer Disease
Increased ATP-Binding Cassette Transporter A1 Expression in Alzheimer's Disease Hippocampal Neurons.
Alzheimer Disease
Increasing Intracellular Levels of Iron with Ferric Ammonium Citrate Leads to Reduced P-glycoprotein Expression in Human Immortalised Brain Microvascular Endothelial Cells.
Alzheimer Disease
Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer's disease.
Alzheimer Disease
Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier: Protection by the antioxidant N-acetylcysteine.
Alzheimer Disease
Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer's disease and vascular dementia.
Alzheimer Disease
Ketogenic diet enhances neurovascular function with altered gut microbiome in young healthy mice.
Alzheimer Disease
Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
Alzheimer Disease
Lysophosphatidylcholine export by human ABCA7.
Alzheimer Disease
Meta-Analysis of the Association between Variants in ABCA7 and Alzheimer's Disease.
Alzheimer Disease
Meta-Analysis on Association Between the ATP-binding cassette transporter A1 Gene (ABCA1) and Alzheimer's disease.
Alzheimer Disease
Metalloprobes: synthesis, characterization, and potency of a novel gallium(III) complex in human epidermal carcinoma cells.
Alzheimer Disease
Modulation and Absorption of Xenobiotics: the Synergistic Role of CYP450 AND P-gp Activities in Cancer and Neurodegenerative Disorders.
Alzheimer Disease
Natural Products based P-glycoprotein Activators for Improved ?-amyloid Clearance in Alzheimer's Disease: An in silico Approach.
Alzheimer Disease
Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier.
Alzheimer Disease
Neuroscience and hormesis: overview and general findings.
Alzheimer Disease
No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds.
Alzheimer Disease
Overlap between Parkinson disease and Alzheimer disease in ABCA7 functional variants.
Alzheimer Disease
P-glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer's Disease.
Alzheimer Disease
P-Glycoprotein Altered Expression in Alzheimer's Disease: Regional Anatomic Variability.
Alzheimer Disease
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model.
Alzheimer Disease
P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations.
Alzheimer Disease
PET radiotracers for imaging P-glycoprotein: the challenge for early diagnosis in AD.
Alzheimer Disease
Pregnane X Receptor and P-glycoprotein: a connexion for Alzheimer's disease management.
Alzheimer Disease
Protecting P-glycoprotein at the blood-brain barrier from degradation in an Alzheimer's disease mouse model.
Alzheimer Disease
Quantitative assessment of the effect of ABCA1 gene polymorphism on the risk of Alzheimer's disease.
Alzheimer Disease
Radiopharmaceuticals for assessing ABC transporters at the blood-brain barrier.
Alzheimer Disease
Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice.
Alzheimer Disease
Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease.
Alzheimer Disease
Role of ABCA7 in Human Health and in Alzheimer's Disease.
Alzheimer Disease
Role of P-glycoprotein in mediating rivastigmine effect on amyloid-? brain load and related pathology in Alzheimer's disease mouse model.
Alzheimer Disease
St. John's Wort Reduces Beta-Amyloid Accumulation in a Double Transgenic Alzheimer's Disease Mouse Model-Role of P-Glycoprotein.
Alzheimer Disease
Study on Lentivirus-Mediated ABCA7 Improves Neurocognitive Function and Related Mechanisms in the C57BL/6 Mouse Model of Alzheimer's Disease.
Alzheimer Disease
Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood-Brain Barrier.
Alzheimer Disease
The multidrug resistance pump ABCB1 is a substrate for the ubiquitin ligase NEDD4-1.
Alzheimer Disease
The Polymorphism of the ATP-Binding Cassette Transporter 1 Gene Modulates Alzheimer Disease Risk in Chinese Han Ethnic Population.
Alzheimer Disease
The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease.
Alzheimer Disease
The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration.
Alzheimer Disease
The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease.
Alzheimer Disease
Transport and uptake of clausenamide enantiomers in CYP3A4-transfected Caco-2 cells: An insight into the efflux-metabolism alliance.
Alzheimer Disease
Transport of Alzheimer's associated amyloid-? catalyzed by P-glycoprotein.
Alzheimer Disease
Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease.
Alzheimer Disease
Using a qPCR device to screen for modulators of ABC transporter activity: A step-by-step protocol.
Alzheimer Disease
Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ?4,and the risk of late-onset Alzheimer disease in African Americans.
Alzheimer Disease
[Correlation of cholesterol 24-hydroxylase and ATP-binding cassette transporter A1 polymorphisms with Alzheimer's disease]
Ameloblastoma
Detection of CD133, Bmi-1, and ABCG2 in ameloblastic tumors.
Amyotrophic Lateral Sclerosis
Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-Glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies.
Amyotrophic Lateral Sclerosis
Excess glutamate secreted from astrocytes drives upregulation of P-glycoprotein in endothelial cells in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients.
Amyotrophic Lateral Sclerosis
Lysophosphatidic acid and amitriptyline signal through LPA1R to reduce P-glycoprotein transport at the blood-brain barrier.
Amyotrophic Lateral Sclerosis
P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Verapamil and riluzole cocktail liposomes overcome pharmacoresistance by inhibiting P-glycoprotein in brain endothelial and astrocyte cells: A potent approach to treat amyotrophic lateral sclerosis.
Anemia
Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach.
Anemia
Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy.
Anemia
Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.
Anemia
Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the -1774delG polymorphism in the Abcc2 gene.
Anemia
Expression levels of ABCG2 on cord red blood cells and study of fetal anemia associated with anti-Jr(a).
Anemia
Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy.
Anemia, Aplastic
Allopurinol-induced aplastic anemia in a patient with chronic kidney disease.
Anemia, Aplastic
Decreased activity of the multidrug resistance P-glycoprotein in acquired aplastic anaemia: possible pathophysiologic implications.
Anemia, Aplastic
Reduced function of the multidrug resistance P-glycoprotein in CD34+ cells of patients with aplastic anaemia.
Anemia, Sickle Cell
Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the -1774delG polymorphism in the Abcc2 gene.
Anemia, Sideroblastic
Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis.
Angina, Stable
Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma.
Angina, Unstable
Co-administration of cyclosporine and ticagrelor may lead to a higher exposure to cyclosporine: a case report of a 49-year old man.
Aniridia
Expression of retinoic acid signaling components ADH7 and ALDH1A1 is reduced in aniridia limbal epithelial cells and a siRNA primary cell based aniridia model.
Aniridia
Human aniridia limbal epithelial cells lack expression of keratins K3 and K12.
Aniridia
Immunohistochemical expression of epithelial cell markers in corneas with congenital aniridia and ocular cicatrizing pemphigoid.
Aortic Aneurysm
An observational study examining the effects of a surgically induced inflammatory response on the distribution of morphine and its metabolites into cerebrospinal fluid.
Arrhythmias, Cardiac
Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.
Arteriosclerosis
Intracellular Localization of Endogenous Mouse ABCG1 Is Mimicked by Both ABCG1-L550 and ABCG1-P550-Brief Report.
Arthritis
ABCB1 and ABCC3 Gene Polymorphisms Are Associated with First-year Response to Methotrexate in Juvenile Idiopathic Arthritis.
Arthritis
ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases.
Arthritis
Clinical relevance of P-glycoprotein activity on peripheral blood mononuclear cells and polymorphonuclear neutrophils to methotrexate in systemic lupus erythematosus patients.
Arthritis
Hereditary hemochromatosis disrupts uric acid homeostasis and causes hyperuricemia via altered expression/activity of xanthine oxidase and ABCG2.
Arthritis
Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis.
Arthritis
Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome.
Arthritis
The absorption enhancement of norisoboldine in the duodenum of adjuvant-induced arthritis rats involves the impairment of P-glycoprotein.
Arthritis
Validation of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis and Its Clinical Application in Evidencio.
Arthritis
[Rheumatoid arthritis (RA) disease activity predicts function of ABCB1 (P-gp) and ABCG2 (BCRP1) drug-efflux transporters].
Arthritis, Experimental
Decreased activity of hepatic P-glycoprotein in the isolated perfused liver of the adjuvant arthritis rat.
Arthritis, Experimental
Decreased hepatobiliary transport of methotrexate in adjuvant arthritis rats.
Arthritis, Experimental
Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis.
Arthritis, Experimental
Regulation of CP-25 on P-glycoprotein in synoviocytes of rats with adjuvant arthritis.
Arthritis, Experimental
Tissue-specific regulation of expression and activity of P-glycoprotein in adjuvant arthritis rats.
Arthritis, Gouty
Genetic analysis of ABCG2 and SLC2A9 gene polymorphisms in gouty arthritis in a Korean population.
Arthritis, Gouty
Pharmacologic inducers of the uric acid exporter ABCG2 as potential drugs for treatment of gouty arthritis.
Arthritis, Juvenile
ABCB1 and ABCC3 Gene Polymorphisms Are Associated with First-year Response to Methotrexate in Juvenile Idiopathic Arthritis.
Arthritis, Psoriatic
Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis.
Arthritis, Psoriatic
Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A: modulation of P-glycoprotein function.
Arthritis, Psoriatic
The impacts of gene polymorphisms on methotrexate in Chinese psoriatic patients.
Arthritis, Rheumatoid
ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients.
Arthritis, Rheumatoid
ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Association between ABCB1 C3435T polymorphism and methotrexate treatment outcomes in rheumatoid arthritis patients: a meta-analysis.
Arthritis, Rheumatoid
Association of the ABCB1 C3435T polymorphism with responsiveness to and toxicity of DMARDs in rheumatoid arthritis : A meta-analysis.
Arthritis, Rheumatoid
Decreased activity of hepatic P-glycoprotein in the isolated perfused liver of the adjuvant arthritis rat.
Arthritis, Rheumatoid
Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis.
Arthritis, Rheumatoid
Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone.
Arthritis, Rheumatoid
Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study.
Arthritis, Rheumatoid
Good response to methotrexate is associated with a decrease in the gene expression of ABCG2, a drug transporter, in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
IL-17A upregulates P-glycoprotein expression in peripheral blood lymphocytes of patients with rheumatoid arthritis through TAK1.
Arthritis, Rheumatoid
Impact of MTHFR rs1801133, MTHFR rs1801131 and ABCB1 rs1045642 polymorphisms with increased susceptibility of rheumatoid arthritis in the West Algerian population: A case-control study.
Arthritis, Rheumatoid
Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Increased expression of multidrug resistance of P-glycoprotein on Th1 cells correlates with drug resistance in rheumatoid arthritis.
Arthritis, Rheumatoid
Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis.
Arthritis, Rheumatoid
Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide.
Arthritis, Rheumatoid
MDR1a/1b gene silencing enhances drug sensitivity in rat fibroblast-like synoviocytes.
Arthritis, Rheumatoid
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.
Arthritis, Rheumatoid
Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome.
Arthritis, Rheumatoid
No correlation between MTHFR c.677 C?>?T, MTHFR c.1298 A?>?C, and ABCB1 c.3435 C?>?T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.
Arthritis, Rheumatoid
Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis.
Arthritis, Rheumatoid
Overexpression of P-glycoprotein on fibroblast-like synoviocytes in refractory rheumatoid arthritis patients: a potential mechanism for multidrug resistance in rheumatoid arthritis treatment.
Arthritis, Rheumatoid
Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.
Arthritis, Rheumatoid
Relevance of P-glycoprotein on CXCR4(+) B cells to organ manifestation in highly active rheumatoid arthritis.
Arthritis, Rheumatoid
Rheumatoid Arthritis Disease Activity Is Determinant for ABCB1 and ABCG2 Drug-Efflux Transporters Function.
Arthritis, Rheumatoid
Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.
Arthritis, Rheumatoid
Serum P-glycoprotein level: a potential biomarker of DMARD failure in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis.
Arthritis, Rheumatoid
Tissue-specific regulation of expression and activity of P-glycoprotein in adjuvant arthritis rats.
Arthritis, Rheumatoid
[Rheumatoid arthritis (RA) disease activity predicts function of ABCB1 (P-gp) and ABCG2 (BCRP1) drug-efflux transporters].
Asthma
A Role of the ABCC4 Gene Polymorphism in Airway Inflammation of Asthmatics.
Asthma
Allergic asthma aggravated atherosclerosis increases cholesterol biosynthesis and foam cell formation in apolipoprotein E-deficient mice.
Asthma
Candidate gene analysis of asthma in a population of Arab descent: a case-control study in Jordan.
Asthma
Evaluation of the Prevalence of Mucous Retention Pseudocyst and its Correlation with the Associated Risk Factors Using Panoramic Radiography and Cone-Beam Computed Tomography.
Asthma
Genetic basis of respiratory distress syndrome.
Asthma
P-glycoprotein expression in circulating blood leukocytes of patients with steroid-resistant asthma.
Asthma
The impact of cigarette smoke exposure, COPD, or asthma status on ABC transporter gene expression in human airway epithelial cells.
Astrocytoma
Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines.
Astrocytoma
Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes.
Astrocytoma
Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes.
Astrocytoma
Effect of PSC 833, a potent inhibitor of P-glycoprotein, on the growth of astrocytoma cells in vitro.
Astrocytoma
Expression of multidrug resistance-associated protein (MRP) in human gliomas.
Astrocytoma
Heterogeneity in the expression of markers for drug resistance in brain tumors.
Astrocytoma
Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy.
Astrocytoma
Targeting hyaluronan interactions in spinal cord astrocytomas and diffuse pontine gliomas.
Astrocytoma
The usefulness of Tc-99m MIBI for evaluating brain tumors: comparative study with Tl-201 and relation with P-glycoprotein
Astrocytoma
[Expression of P-glycoprotein as a multidrug resistance gene product in human reactive astrocytes and astrocytoma]
Ataxia
ABCB1-1 Delta (MDR1-1 Delta) genotype is associated with adverse reactions in dogs treated with milbemycin oxime for generalized demodicosis.
Ataxia
Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis.
Ataxia
Neurotoxic effects of ivermectin administration in genetically engineered mice with targeted insertion of the mutated canine ABCB1 gene.
Ataxia Telangiectasia
AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer.
Ataxia Telangiectasia
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Atherosclerosis
A pyrene based fluorescence approach to study conformation of apolipoprotein E3 in macrophage-generated nascent high density lipoprotein.
Atherosclerosis
ABCG1 rs57137919G>a polymorphism is functionally associated with varying gene expression and apoptosis of macrophages.
Atherosclerosis
Advanced oxidation protein products exacerbates lipid accumulation and atherosclerosis through downregulation of ATP-binding cassette transporter A1 and G1 expression in apolipoprotein E knockout mice.
Atherosclerosis
Antagonism of Betulinic Acid on LPS-Mediated Inhibition of ABCA1 and Cholesterol Efflux through Inhibiting Nuclear Factor-kappaB Signaling Pathway and miR-33 Expression.
Atherosclerosis
Association studies of several cholesterol-related genes (ABCA1, CETP and LIPC) with serum lipids and risk of Alzheimer's disease.
Atherosclerosis
ATP-binding cassette transporter 1 C69T and V825I polymorphisms in the development of atherosclerosis: a meta-analysis of 18,320 subjects.
Atherosclerosis
ATP-Binding Cassette Transporter A1 in Lipoprotein Metabolism and Atherosclerosis: A New Piece of the Complex Puzzle.
Atherosclerosis
ATP-binding cassette transporter A1, fatty acids, and cholesterol absorption.
Atherosclerosis
ATP-binding cassette transporter hallmarks tissue macrophages and modulates cytokine-triggered polarization programs.
Atherosclerosis
Carotid strain measurement in patients with pseudoxanthoma elasticum - Hint for a different pathomechanism?
Atherosclerosis
Carvedilol Ameliorates Experimental Atherosclerosis by Regulating Cholesterol Efflux and Exosome Functions.
Atherosclerosis
Chalcone Derivatives Enhance ATP-Binding Cassette Transporters A1 in Human THP-1 Macrophages.
Atherosclerosis
Chlamydia pneumoniae negatively regulates ABCA1 expression via TLR2-Nuclear factor-kappa B and miR-33 pathways in THP-1 macrophage-derived foam cells.
Atherosclerosis
Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice.
Atherosclerosis
Common gene polymorphism in ATP-binding cassette transporter A1 and coronary artery disease: A genetic association study and a structural analysis.
Atherosclerosis
Common genetic variation in the ATP-binding cassette transporter A1, plasma lipids, and risk of coronary heart disease.
Atherosclerosis
Comparative Analysis on Single- and Multiherb Strategies in Coronary Artery Atherosclerosis Therapy.
Atherosclerosis
Cyclosporin A decreases apolipoprotein E secretion from human macrophages via a protein phosphatase 2B-dependent and ATP-binding cassette transporter A1 (ABCA1)-independent pathway.
Atherosclerosis
Deficiency of ATP-Binding Cassette Transporter B6 in Megakaryocyte Progenitors Accelerates Atherosclerosis in Mice.
Atherosclerosis
Diosgenin inhibits atherosclerosis via suppressing the MiR-19b-induced downregulation of ATP-binding cassette transporter A1.
Atherosclerosis
DNA topoisomerase II inhibitors induce macrophage ABCA1 expression and cholesterol efflux-An LXR-dependent mechanism.
Atherosclerosis
Dysfunctional HDL and atherosclerotic cardiovascular disease.
Atherosclerosis
Dysfunctional high-density lipoprotein.
Atherosclerosis
Editorial Expression of Concern: "Diosgenin inhibits atherosclerosis via suppressing the MiR-19b-induced downregulation of ATP-binding cassette transporter A1" [Atherosclerosis Volume 240, Issue 1, May 2015, Pages 80-89].
Atherosclerosis
Editorial expression of concern: "MicroRNA-19b promotes macrophage cholesterol accumulation and aortic atherosclerosis by targeting ATP-binding cassette transporter A1" [Atherosclerosis Volume 236, Issue 1, September 2014, Pages 215-226].
Atherosclerosis
ER stress is associated with reduced ABCA-1 protein levels in macrophages treated with advanced glycated albumin - reversal by a chemical chaperone.
Atherosclerosis
Erythrodiol, an Olive Oil Constituent, Increases the Half-Life of ABCA1 and Enhances Cholesterol Efflux from THP-1-Derived Macrophages.
Atherosclerosis
Exposure to High Glucose Concentration Decreases Cell Surface ABCA1 and HDL Biogenesis in Hepatocytes.
Atherosclerosis
Genetic disruption of multidrug resistance-associated protein 1 improves endothelial function and attenuates atherosclerosis in MRP1(-/-) LDLr(-/-) double knockout mice.
Atherosclerosis
Genotypic effect of the -565C>T polymorphism in the ABCA1 gene promoter on ABCA1 expression and severity of atherosclerosis.
Atherosclerosis
HDL Cholesterol - Third Annual International Conference. Metabolic Pathways and Drug Development. 25-26 February 2002, Boston, MA, USA.
Atherosclerosis
Heat shock factor-1 knockout enhances cholesterol 7?-hydroxylase (CYP7A1) and multidrug transporter (MDR1) gene expressions to attenuate atherosclerosis.
Atherosclerosis
HIF-1beta determines ABCA1 expression under hypoxia in human macrophages.
Atherosclerosis
HIV-1 protein Nef inhibits activity of ATP-binding cassette transporter A1 by targeting endoplasmic reticulum chaperone calnexin.
Atherosclerosis
Human macrophage cathepsin B-mediated C-terminal cleavage of apolipoprotein A-I at Ser228 severely impairs antiatherogenic capacity.
Atherosclerosis
Hyperglycemia suppresses ABCA1 expression in vascular smooth muscle cells.
Atherosclerosis
Identification of an amino acid residue in ATP-binding cassette transport G1 critical for mediating cholesterol efflux.
Atherosclerosis
Impact of bone marrow ATP-binding cassette transporter A1 deficiency on atherogenesis is independent of the presence of the low-density lipoprotein receptor.
Atherosclerosis
Increased atherosclerosis in mice with vascular ATP-binding cassette transporter G1 deficiency--brief report.
Atherosclerosis
Independent protective roles for macrophage Abcg1 and Apoe in the atherosclerotic lesion development.
Atherosclerosis
Influence of ATP-binding cassette transporter 1 R219K and M883I polymorphisms on development of atherosclerosis: a meta-analysis of 58 studies.
Atherosclerosis
Inhibition of ATP-Binding Cassette Transporter A1 Protein Degradation Promotes HDL Cholesterol Efflux Capacity and Reverse Cholesterol Transport and Reduces Atherosclerosis in Mice.
Atherosclerosis
Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux.
Atherosclerosis
Innate Immunity Signaling Process Suppresses Macrophage ABCA1 Expression through IRAK-1 mediated down-regulation of RAR{alpha} and NFATc2.
Atherosclerosis
Involvement of Cdc42 signaling in apoA-I-induced cholesterol efflux.
Atherosclerosis
Kimchi methanol extract and the kimchi active compound, 3'-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid, downregulate CD36 in THP-1 macrophages stimulated by oxLDL.
Atherosclerosis
Liver X receptor agonist methyl-3?-hydroxy-5?,6?-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
Atherosclerosis
Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis.
Atherosclerosis
Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo.
Atherosclerosis
Medicinal plants and atherosclerosis: A review on molecular aspects.
Atherosclerosis
MicroRNA 33 Regulates the Population of Peripheral Inflammatory Ly6Chigh Monocytes through Dual Pathways.
Atherosclerosis
MicroRNA-19b promotes macrophage cholesterol accumulation and aortic atherosclerosis by targeting ATP-binding cassette transporter A1.
Atherosclerosis
Mycophenolic acid induces ATP-binding cassette transporter A1 (ABCA1) expression through the PPAR?-LXR?-ABCA1 pathway.
Atherosclerosis
Myeloid cell-specific ATP-binding cassette transporter A1 deletion has minimal impact on atherogenesis in atherogenic diet-fed low-density lipoprotein receptor knockout mice.
Atherosclerosis
Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein.
Atherosclerosis
Pharmacological inhibition of EZH2 by GSK126 decreases atherosclerosis by modulating foam cell formation and monocyte adhesion in apolipoprotein E-deficient mice.
Atherosclerosis
Photobiomodulation therapy promotes the ATP-binding cassette transporter A1-dependent cholesterol efflux in macrophage to ameliorate atherosclerosis.
Atherosclerosis
PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage apoB-48 receptor.
Atherosclerosis
Proliferation of Vascular Smooth Muscle Cells under ox-LDL Is Regulated by Alismatis rhizoma Decoction via InhibitingERK1/2 and miR-17?92a Cluster Activation.
Atherosclerosis
Propofol up-regulates expression of ABCA1, ABCG1, and SR-B1 through the PPAR?/LXR? signaling pathway in THP-1 macrophage-derived foam cells.
Atherosclerosis
Protective effect of Astragalus polysaccharides on ATP binding cassette transporter A1 in THP-1 derived foam cells exposed to tumor necrosis factor-alpha.
Atherosclerosis
Protein tyrosine phosphatase inhibition down-regulates ligand-induced ABCA1 expression.
Atherosclerosis
Quercetin enhances ABCA1 expression and cholesterol efflux through a p38-dependent pathway in macrophages.
Atherosclerosis
Regulations of the key mediators in inflammation and atherosclerosis by aspirin in human macrophages.
Atherosclerosis
Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.
Atherosclerosis
S-Allylcysteine, a Garlic Compound, Increases ABCA1 Expression in Human THP-1 Macrophages.
Atherosclerosis
Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis.
Atherosclerosis
So Much Cholesterol: the unrecognized importance of smooth muscle cells in atherosclerotic foam cell formation.
Atherosclerosis
Sortilin promotes macrophage cholesterol accumulation and aortic atherosclerosis through lysosomal degradation of ATP-binding cassette transporter A1 protein.
Atherosclerosis
The association of the R219K polymorphism in the ATP-binding cassette transporter 1 ( ABCA1) gene with coronary heart disease and hyperlipidaemia.
Atherosclerosis
The detection of autoantibodies to ATP-binding cassette transporter A1 and its role in the pathogenesis of atherosclerosis in patients with systemic lupus erythematosus.
Atherosclerosis
The Hexane Fraction of cyperus rotundus Prevents Non-Alcoholic Fatty Liver Disease Through the Inhibition of Liver X Receptor ?-Mediated Activation of Sterol Regulatory Element Binding Protein-1c.
Atherosclerosis
The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport.
Atherosclerosis
The role of ATP-binding-cassette-transporter-A1 (ABCA1) gene polymorphism on coronary artery disease risk.
Atherosclerosis
TLR2 stimulates ABCA1 expression via PKC-? and PLD2 pathway.
Atherosclerosis
Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a phospholipase D2 pathway.
Atherosclerosis
Vascular effects of TZDs: new implications.
Atherosclerosis
[Effects of Chinese herbal medicine Guanxinkang on expression of PPAR?-LXR?-ABCA1 pathway in ApoE-knockout mice with atherosclerosis].
Atherosclerosis
[Expression of ABCA1 in vascular endothelial cells and its significance in the pathogenesis of atherosclerosis]
Atrial Fibrillation
ABCB1 and SLCO1B3 Gene Polymorphisms and Their Impact on Digoxin Pharmacokinetics in Atrial Fibrillation Patients among the Tunisian Population.
Atrial Fibrillation
ABCB1 polymorphism and acenocoumarol safety in patients with valvular atrial fibrillation.
Atrial Fibrillation
An Exploratory Association Analysis of ABCB1 rs1045642 and ABCB1 rs4148738 with Non-Major Bleeding Risk in Atrial Fibrillation Patients Treated with Dabigatran or Apixaban.
Atrial Fibrillation
CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban.
Atrial Fibrillation
Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.
Atrial Fibrillation
Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
Atrial Fibrillation
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Atrial Fibrillation
Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation.
Atrial Fibrillation
Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report.
Atrial Fibrillation
Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.
Atrial Fibrillation
Pharmacogenetics role in the safety of acenocoumarol therapy.
Atrial Fibrillation
Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
Atrial Fibrillation
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Atrial Fibrillation
Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
Atrial Fibrillation
Real world Data on the Concurrent Use of P-glycoprotein or Cytochrome 3A4 Drugs and Non-vitamin K Antagonist Oral Anticoagulants in Non-Valvular Atrial Fibrillation.
Atrial Fibrillation
The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation.
Atrial Fibrillation
The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation.
Atrial Fibrillation
[Association of ATP-binding cassette transporter A1 R219K polymorphism with atrial fibrillation.]
Autoimmune Diseases
ABCB1 gene is associated with the risk of bullous pemphigoid in a polish population.
Autoimmune Diseases
Association of ABCB1 gene polymorphisms and haplotypes with therapeutic efficacy of glucocorticoids in Chinese patients with immune thrombocytopenia.
Autoimmune Diseases
Genotype and haplotype analysis of ABCB1 at 1236, 2677 and 3435 among systemic sclerosis patients.
Autoimmune Diseases
Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases.
Autoimmune Diseases
P-glycoprotein and drug resistance in systemic autoimmune diseases.
Autoimmune Diseases
P-glycoprotein gene MDR1 polymorphisms and susceptibility to systemic lupus erythematosus in Guangxi population: a case-control study.
Autoimmune Diseases
P-glycoprotein in autoimmune diseases.
Autoimmune Diseases
Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes.
Autoimmune Diseases
Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease.
Autoimmune Diseases
[Future perspectives in epilepsy treatment]
Azoospermia
Adenosine triphosphate-binding cassette superfamily transporter gene expression in severe male infertility.
Azotemia
Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney.
Bacterial Infections
Breast cancer resistance protein (Bcrp/Abcg2) is selectively modulated by lipopolysaccharide (LPS) in the mouse yolk sac.
Bile Duct Neoplasms
Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer.
Biliary Atresia
Hepatic expression of multidrug resistance protein 2 in biliary atresia.
Biliary Atresia
Interleukin 2 Promotes Hepatic Regulatory T Cell Responses and Protects From Biliary Fibrosis in Murine Sclerosing Cholangitis.
Biliary Atresia
Up-regulation of miR-let7a-5p Leads to Decreased Expression of ABCC2 in Obstructive Cholestasis.
Biliary Tract Neoplasms
Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas.
Blast Crisis
Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
Blast Crisis
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Blast Crisis
Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model.
Blast Crisis
Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase.
Blast Crisis
Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias.
Blast Crisis
Expression of multidrug resistance 1 gene in association with CXCL12 in chronic myelogenous leukaemia.
Blast Crisis
Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis.
Blast Crisis
Extended multidrug resistance in haemopoietic cells.
Blast Crisis
Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells.
Blast Crisis
MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias.
Blast Crisis
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.
Blast Crisis
[P-glycoprotein and treatment with plicamycin + hydroxyurea in myeloid blastic crisis of chronic myeloid leukemia]
Blindness
An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4-/- Mice.
Blindness
Molecular genetic basis for fluoroquinolone-induced retinal degeneration in cats.
Blindness
Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence.
Blister
Ultrastructural features and P-glycoprotein immunolocalization in Saos-2/DX580 multidrug-resistant human osteosarcoma cells.
Brain Death
CT and MR perfusion can discriminate severe cerebral hypoperfusion from perfusion absence: evaluation of different commercial software packages by using digital phantoms.
Brain Diseases
Actin filament-associated protein 1 (AFAP-1) is a key mediator in inflammatory signaling-induced rapid attenuation of intrinsic P-gp function in human brain capillary endothelial cells.
Brain Diseases
Alterations in expression of genes coding for proteins of the neurovascular unit in ischemic liver failure.
Brain Diseases
Biallelic mutations in ABCB1 display recurrent reversible encephalopathy.
Brain Diseases
Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells.
Brain Diseases
Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis.
Brain Diseases
Head-to-head comparison of (R)-[11C]verapamil and [18F]MC225 in non-human primates, tracers for measuring P-glycoprotein function.
Brain Diseases
Host genetic and epigenetic factors in toxoplasmosis.
Brain Diseases
Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.
Brain Diseases
Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats.
Brain Diseases
Inhibition of P-glycoprotein at the blood-brain barrier by phytochemicals derived from traditional Chinese medicine.
Brain Diseases
Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain.
Brain Diseases
Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis.
Brain Diseases
Novel Intrinsic Mechanisms of Active Drug Extrusion at the Blood-Brain Barrier: Potential Targets for Enhancing Drug Delivery to the Brain?
Brain Diseases
Novel therapies for epilepsy in the pipeline.
Brain Diseases
Repression of adenosine triphosphate-binding cassette transporter ABCG2 by estrogen increases intracellular glutathione in brain endothelial cells following ischemic reperfusion injury.
Brain Diseases
Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy.
Brain Diseases
[Expression of P-glycoprotein as a multidrug resistance gene product in human reactive astrocytes and astrocytoma]
Brain Edema
Spatial and temporal expression of P-glycoprotein in the congenitally hydrocephalic HTX rat brain.
Brain Infarction
Reduction of Brain Infarction Induced by a Transient Brain Ischemia in mdr1a Knockout Mice.
Brain Injuries
Deactivation of ATP-Binding Cassette Transporters ABCB1 and ABCC1 Does Not Influence Post-ischemic Neurological Deficits, Secondary Neurodegeneration and Neurogenesis, but Induces Subtle Microglial Morphological Changes.
Brain Injuries
Role of drug efflux carriers in the healthy and diseased brain.
Brain Injuries, Traumatic
ABCG2 c.421C>A Is Associated with Outcomes after Severe Traumatic Brain Injury.
Brain Injuries, Traumatic
Effect of single nucleotide polymorphisms in the ATP-binding cassette B1 gene on the clinical outcome of traumatic brain injury.
Brain Injuries, Traumatic
Expression of ATP-Binding Cassette Transporters B1 and C1 after Severe Traumatic Brain Injury in Humans.
Brain Injuries, Traumatic
Influence of ATP-Binding Cassette Polymorphisms on Neurological Outcome After Traumatic Brain Injury.
Brain Injuries, Traumatic
P-glycoprotein Expression Is Upregulated in a Pre-Clinical Model of Traumatic Brain Injury.
Brain Ischemia
Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia.
Brain Ischemia
Penetration of verapamil across blood brain barrier following cerebral ischemia depending on both paracellular pathway and P-glycoprotein transportation.
Brain Ischemia
Reduction of Brain Infarction Induced by a Transient Brain Ischemia in mdr1a Knockout Mice.
Brain Ischemia
Role of P-Glycoprotein in Regulating Cilnidipine Distribution to Intact and Ischemic Brain.
Brain Neoplasms
ABC-transporters as stem-cell markers in brain dysplasia/tumor epilepsies.
Brain Neoplasms
ABCB1 in children's brain tumours.
Brain Neoplasms
Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain.
Brain Neoplasms
Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography.
Brain Neoplasms
Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies.
Brain Neoplasms
Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers.
Brain Neoplasms
Breast Cancer Resistance Protein and P-glycoprotein in Brain Cancer: Two Gatekeepers Team Up.
Brain Neoplasms
Confocal imaging of xenobiotic transport across the blood-brain barrier.
Brain Neoplasms
Critical role of ABCG2 in ALA-photodynamic diagnosis and therapy of human brain tumor.
Brain Neoplasms
Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice.
Brain Neoplasms
Disappearance of a metastatic brain tumor and achievement of long-term survival with a good quality of life after a combination of systemic chemotherapy with the P-glycoprotein inhibitor nifedipine in a patient with ovarian cancer.
Brain Neoplasms
Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer.
Brain Neoplasms
Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats.
Brain Neoplasms
Drug resistance and apoptosis in ENU-induced rat brain tumors treated with anti-cancer drugs.
Brain Neoplasms
Effect of cyclosporin on distribution of methotrexate into the brain of rats.
Brain Neoplasms
Effect of expression of P-glycoprotein on technetium-99m methoxyisobutylisonitrile single photon emission computed tomography of brain tumors.
Brain Neoplasms
Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes.
Brain Neoplasms
Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors.
Brain Neoplasms
Expression of P-gp in Glioblastoma: What we can Learn from Brain Development.
Brain Neoplasms
Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors.
Brain Neoplasms
Expression pattern of chemoresistance-related genes in human malignant brain tumors: a working knowledge for proper selection of anticancer drugs.
Brain Neoplasms
Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cells.
Brain Neoplasms
HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285.
Brain Neoplasms
HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and in vivo antitumor efficacy of paclitaxel in an orthotopic brain tumor model.
Brain Neoplasms
Human brain tumors: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells.
Brain Neoplasms
Increased transendothelial permeability of anti-cancer agent carboplatin with the aid of hyperbaric oxygenation.
Brain Neoplasms
Inhibition of P-glycoprotein at the blood-brain barrier by phytochemicals derived from traditional Chinese medicine.
Brain Neoplasms
Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells.
Brain Neoplasms
Investigation of brain tumours with (99m)Tc-MIBI SPET.
Brain Neoplasms
Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma.
Brain Neoplasms
Issues in developing drugs for primary brain tumors: barriers and toxicities.
Brain Neoplasms
Lack of P-glycoprotein expression in melanoma brain metastases of different melanoma types.
Brain Neoplasms
Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?
Brain Neoplasms
Multidrug resistance gene (MDR1) expression in human brain tumors.
Brain Neoplasms
Multidrug resistance in human cancer.
Brain Neoplasms
Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively.
Brain Neoplasms
Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Brain Neoplasms
Oral paclitaxel chemotherapy for brain tumors: ideal combination treatment of paclitaxel and P-glycoprotein inhibitor.
Brain Neoplasms
P-glycoprotein expression in brain tumors.
Brain Neoplasms
P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model.
Brain Neoplasms
Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine.
Brain Neoplasms
Phenylcinnamides as Novel Antimitotic Agents.
Brain Neoplasms
Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant.
Brain Neoplasms
Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors.
Brain Neoplasms
Role of drug efflux carriers in the healthy and diseased brain.
Brain Neoplasms
Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Brain Neoplasms
Significance of P-glycoprotein expression in childhood malignant tumors.
Brain Neoplasms
Strategies to inhibit ABCB1- and ABCG2-mediated efflux transport of erlotinib at the blood-brain barrier: a PET study in non-human primates.
Brain Neoplasms
Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro.
Brain Neoplasms
The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice.
Brain Neoplasms
The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy.
Brain Neoplasms
The usefulness of Tc-99m MIBI for evaluating brain tumors: comparative study with Tl-201 and relation with P-glycoprotein
Brain Neoplasms
Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier.
Brain Neoplasms
Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors.
Brain Neoplasms
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.
Breast Neoplasms
"Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".
Breast Neoplasms
(-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.
Breast Neoplasms
(18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
Breast Neoplasms
(67/68)Galmydar: A metalloprobe for monitoring breast cancer resistance protein (BCRP)-mediated functional transport activity.
Breast Neoplasms
(Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies.
Breast Neoplasms
(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
Breast Neoplasms
1236 C/T and 3435 C/T polymorphisms of the ABCB1 gene in Mexican breast cancer patients.
Breast Neoplasms
15-Deoxy-delta 12, 14-prostaglandin J2 induces upregulation of multidrug resistance-associated protein 1 via Nrf2 activation in human breast cancer cells.
Breast Neoplasms
17-beta-Estradiol: a powerful modulator of blood-brain barrier BCRP activity.
Breast Neoplasms
1H and 13C NMR spectral assignments of chalcones bearing pyrazoline-carbothioamide groups.
Breast Neoplasms
2-Hydroxypropyl-?-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
Breast Neoplasms
3D organoids derived from the small intestine: An emerging tool for drug transport research.
Breast Neoplasms
4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).
Breast Neoplasms
5-Fluorouracil treatment alters the expression of intestinal transporters in rats.
Breast Neoplasms
5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Breast Neoplasms
6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline amides and corresponding ester isosteres as multidrug resistance reversers.
Breast Neoplasms
6-halogenochromones bearing tryptamine: one-step access to potent and highly selective inhibitors of breast cancer resistance protein.
Breast Neoplasms
7-ketocholesterol and 27-hydroxycholesterol decreased doxorubicin sensitivity in breast cancer cells: estrogenic activity and mTOR pathway.
Breast Neoplasms
7-O-geranylquercetin contributes to reverse P-gp-mediated adriamycin resistance in breast cancer.
Breast Neoplasms
9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein.
Breast Neoplasms
99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
Breast Neoplasms
99mTc-sestamibi to monitor treatment with antisense oligodeoxynucleotide complementary to MRP mRNA in human breast cancer cells.
Breast Neoplasms
99Tcm-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer.
Breast Neoplasms
?-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer.
Breast Neoplasms
?-Sitosterol Reverses Multidrug Resistance via BCRP Suppression by Inhibiting the p53-MDM2 Interaction in Colorectal Cancer.
Breast Neoplasms
?Np73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report.
Breast Neoplasms
A catenary model to study transport and conjugation of baicalein, a bioactive flavonoid, in the Caco-2 cell monolayer: demonstration of substrate inhibition.
Breast Neoplasms
A Combination of Clioquinol, Zinc and Copper Increases the Abundance and Function of Breast Cancer Resistance Protein in Human Brain Microvascular Endothelial Cells.
Breast Neoplasms
A combination of curcumin with either gramicidin or ouabain selectively kills cells that express the multidrug resistance-linked ABCG2 transporter.
Breast Neoplasms
A Combined Bioinformatic and Nanoparticle-Based Study Reveal the Role of ABCG2 in the Resistance of Breast Cancer.
Breast Neoplasms
A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration.
Breast Neoplasms
A Comprehensive Analysis of Ontogeny of Renal Drug Transporters: mRNA Analyses, Quantitative Proteomics, and Localization.
Breast Neoplasms
A Decade's Review of miRNA: a Center of Transcriptional Regulation of Drug-Metabolizing Enzymes and Transporters Under Hypoxia.
Breast Neoplasms
A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2).
Breast Neoplasms
A functional steroid-binding element in an ATP-binding cassette multidrug transporter.
Breast Neoplasms
A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity.
Breast Neoplasms
A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).
Breast Neoplasms
A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer.
Breast Neoplasms
A model of secreting murine mammary epithelial HC11 cells comprising endogenous Bcrp/Abcg2 expression and function.
Breast Neoplasms
A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1.
Breast Neoplasms
A morphological and functional comparison of proximal tubule cell lines established from human urine and kidney tissue.
Breast Neoplasms
A multidrug resistance transporter from human MCF-7 breast cancer cells.
Breast Neoplasms
A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.
Breast Neoplasms
A new functional role for P-glycoprotein: efflux pump for benzo(alpha)pyrene in human breast cancer MCF-7 cells.
Breast Neoplasms
A New Intestinal Cell Culture Model To Discriminate the Relative Contribution of P-gp and BCRP on Transport of Substrates Such as Imatinib.
Breast Neoplasms
A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Breast Neoplasms
A new multidrug resistance protein at the blood-brain barrier.
Breast Neoplasms
A New Strategy to Rapidly Evaluate Kinetics of Glucuronide Efflux by Breast Cancer Resistance Protein (BCRP/ABCG2).
Breast Neoplasms
A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
Breast Neoplasms
A novel anthracene derivative, MHY412, induces apoptosis in doxorubicin-resistant MCF-7/Adr human breast cancer cells through cell cycle arrest and downregulation of P-glycoprotein expression.
Breast Neoplasms
A novel biosensor based on intestinal 3D organoids for detecting the function of BCRP.
Breast Neoplasms
A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
Breast Neoplasms
A novel compound RY10-4 downregulates P-glycoprotein expression and reverses multidrug-resistant phenotype in human breast cancer MCF-7/ADR cells.
Breast Neoplasms
A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells.
Breast Neoplasms
A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells.
Breast Neoplasms
A novel nuclear localization region in SIPA1 determines protein nuclear distribution and epirubicin-sensitivity of breast cancer cells.
Breast Neoplasms
A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.
Breast Neoplasms
A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells.
Breast Neoplasms
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.
Breast Neoplasms
A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.
Breast Neoplasms
A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer.
Breast Neoplasms
A Practical Perspective on the Evaluation of Small Molecule CNS Penetration in Drug Discovery.
Breast Neoplasms
A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method.
Breast Neoplasms
A Promising Microtubule Inhibitor Deoxypodophyllotoxin Exhibits Better Efficacy to Multidrug-Resistant Breast Cancer than Paclitaxel via Avoiding Efflux Transport.
Breast Neoplasms
A Review of Daclatasvir Drug-Drug Interactions.
Breast Neoplasms
A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow.
Breast Neoplasms
A simple method for the isolation and detailed characterization of primary human proximal tubule cells for renal replacement therapy.
Breast Neoplasms
A structural analysis of in vitro catalytic activities of hammerhead ribozymes.
Breast Neoplasms
A systematic evaluation of solubility enhancing excipients to enable the generation of permeability data for poorly soluble compounds in caco-2 model.
Breast Neoplasms
A systematic review of pharmacokinetic studies on herbal drug Fuzi: Implications for Fuzi as personalized medicine.
Breast Neoplasms
A Triple Culture Model of the Blood-Brain Barrier Using Porcine Brain Endothelial cells, Astrocytes and Pericytes.
Breast Neoplasms
A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells.
Breast Neoplasms
A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.
Breast Neoplasms
A Y1 receptor ligand synergized with a P-glycoprotein inhibitor improves the therapeutic efficacy of multidrug resistant breast cancer.
Breast Neoplasms
ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast.
Breast Neoplasms
ABC efflux transporters in brain vasculature of Alzheimer's subjects.
Breast Neoplasms
ABC Family Transporters.
Breast Neoplasms
ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.
Breast Neoplasms
ABC transporter regulation by signaling at the blood-brain barrier: relevance to pharmacology.
Breast Neoplasms
ABC Transporter-Mediated Multidrug-Resistant Cancer.
Breast Neoplasms
ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.
Breast Neoplasms
ABC transporters and the blood-brain barrier.
Breast Neoplasms
ABC transporters as mediators of drug resistance and contributors to cancer cell biology.
Breast Neoplasms
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.
Breast Neoplasms
ABC transporters as phenotypic markers and functional regulators of stem cells.
Breast Neoplasms
ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy.
Breast Neoplasms
ABC transporters in extrahepatic tissues: Pharmacological regulation in heart and intestine.
Breast Neoplasms
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development.
Breast Neoplasms
ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice.
Breast Neoplasms
ABC transporters: Regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma.
Breast Neoplasms
ABCB1 (rs1128503) polymorphism and response to chemotherapy in patients with malignant tumors-evidences from a meta-analysis.
Breast Neoplasms
ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
Breast Neoplasms
ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen.
Breast Neoplasms
ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.
Breast Neoplasms
ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) May Lead to Increased Drug Exposure.
Breast Neoplasms
ABCB1 and GST polymorphisms associated with TP53 status in breast cancer.
Breast Neoplasms
ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.
Breast Neoplasms
ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients.
Breast Neoplasms
ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis.
Breast Neoplasms
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
Breast Neoplasms
ABCB1 Single Nucleotide Polymorphism Genotypes as Predictors of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer.
Breast Neoplasms
ABCB1, FCGR2A, and FCGR3A Polymorphisms in Patients with HER2-Positive Metastatic Breast Cancer Who Were Treated with First-Line Taxane plus Trastuzumab Chemotherapy.
Breast Neoplasms
ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells.
Breast Neoplasms
ABCC1-exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1 Shortens Survival of Mice and Patients with Breast Cancer.
Breast Neoplasms
ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells.
Breast Neoplasms
ABCC2 (MRP2, cMOAT) Localized in the Nuclear Envelope of Breast Carcinoma Cells Correlates with Poor Clinical Outcome.
Breast Neoplasms
ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects.
Breast Neoplasms
Abcc4 together with Abcb1 and Abcg2 form a robust co-operative drug efflux system that restricts the brain entry of camptothecin analogs.
Breast Neoplasms
ABCG transporters: structure, substrate specificities and physiological roles : a brief overview.
Breast Neoplasms
ABCG2 aptamer selectively delivers doxorubicin to drug-resistant breast cancer cells.
Breast Neoplasms
ABCG2 c.421C>A polymorphism alters nifedipine transport to breast milk in hypertensive breastfeeding women.
Breast Neoplasms
ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion.
Breast Neoplasms
ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition.
Breast Neoplasms
ABCG2 expression, function, and promoter methylation in human multiple myeloma.
Breast Neoplasms
ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
Breast Neoplasms
ABCG2 is a potential marker of tumor-initiating cells in breast cancer.
Breast Neoplasms
ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma.
Breast Neoplasms
ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
Breast Neoplasms
ABCG2 localizes to the nucleus and modulates CDH1 expression in lung cancer cells.
Breast Neoplasms
ABCG2 Overexpression Confers Poor Outcomes in Hepatocellular Carcinoma of Elderly Patients.
Breast Neoplasms
ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations.
Breast Neoplasms
ABCG2 protects kidney side population cells from hypoxia/reoxygenation injury through activation of the MEK/ERK pathway.
Breast Neoplasms
ABCG2 regulatory single-nucleotide polymorphisms alter in-vivo enhancer activity and expression.
Breast Neoplasms
ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy.
Breast Neoplasms
ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.
Breast Neoplasms
Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine.
Breast Neoplasms
ABCG2/BCRP: Specific and Nonspecific Modulators.
Breast Neoplasms
ABCG2: a perspective.
Breast Neoplasms
Absence of both MDR1 (ABCB1) and BCRP (ABCG2) Transporters Significantly Alter Rivaroxaban Disposition and CNS Entry.
Breast Neoplasms
Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression.
Breast Neoplasms
Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum.
Breast Neoplasms
Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes.
Breast Neoplasms
Absorption and efflux characteristics of CP-25 in plasma and peripheral blood mononuclear cells of rats by UPLC-MS/MS.
Breast Neoplasms
Absorption characteristic of paeoniflorin-6'-O-benzene sulfonate (CP-25) in in situ single-pass intestinal perfusion in rats.
Breast Neoplasms
Absorption characteristics of the total alkaloids from Mahonia bealei in an in situ single-pass intestinal perfusion assay.
Breast Neoplasms
Absorption of folate by Caco-2 cells is not affected by high glucose concentration.
Breast Neoplasms
Abundance of P-glycoprotein and Breast Cancer Resistance Protein Measured by Targeted Proteomics in Human Epileptogenic Brain Tissue.
Breast Neoplasms
Abundant blood supply and low P-glycoprotein expression on dynamic 99mTc-MIBI imaging predicted better chemotherapy sensitivity for a breast cancer patient: a case report.
Breast Neoplasms
Abundant Expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1, and xCT Transporters in Blood-Arachnoid Barrier of Pig and Polarized Localizations at CSF- and Blood-Facing Plasma Membranes.
Breast Neoplasms
Aconitum alkaloids, the major components of Aconitum species, affect expression of multidrug resistance-associated protein 2 and breast cancer resistance protein by activating the Nrf2-mediated signalling pathway.
Breast Neoplasms
Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways.
Breast Neoplasms
Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2.
Breast Neoplasms
Acryloylphenylcarboxamides: A New Class of Breast Cancer Resistance Protein (ABCG2) Modulators.
Breast Neoplasms
Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation.
Breast Neoplasms
Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells.
Breast Neoplasms
Active efflux of dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly-targeted agents.
Breast Neoplasms
Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5.
Breast Neoplasms
Activity of ABCG2 Is Regulated by Its Expression and Localization in DHT and Cyclopamine Treated Breast Cancer Cells.
Breast Neoplasms
Acute regulation of apical ABC transporters in the gut. Potential influence on drug bioavailability.
Breast Neoplasms
Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity.
Breast Neoplasms
Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis.
Breast Neoplasms
Adenovirus ANT2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells.
Breast Neoplasms
Adjudin disrupts spermatogenesis by targeting drug transporters: Lesson from the breast cancer resistance protein (BCRP).
Breast Neoplasms
ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning.
Breast Neoplasms
Advanced oxidation protein products upregulate efflux transporter expression and activity through activation of the Nrf-2-mediated signaling pathway in vitro and in vivo.
Breast Neoplasms
Age-associated differences in transporter gene expression in kidneys of male rats.
Breast Neoplasms
Age-related changes in hepatic expression and activity of drug metabolizing enzymes in male wild-type and breast cancer resistance protein knockout mice.
Breast Neoplasms
Age-related changes in mRNA levels of hepatic transporters, cytochrome P450 and UDP-glucuronosyltransferase in female rats.
Breast Neoplasms
Algerian propolis: between protection of normal cells and potentialisation of the anticancer effects of doxorubicin against breast cancer cells via P-glycoprotein inhibition and cell cycle arrest in the S phase.
Breast Neoplasms
All-trans retinoic acid enhances the transport of phase II metabolites of benzo[a]pyrene by inducing the Breast Cancer Resistance Protein expression in Caco-2 cells.
Breast Neoplasms
Alleviating the Intestinal Absorption of Rhein in Rhubarb through Herb Compatibility in Tiaowei Chengqi Tang in Caco-2 Cells.
Breast Neoplasms
Allocrite Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1).
Breast Neoplasms
Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine.
Breast Neoplasms
Alterations in Expression and Function of ABC Family Transporters at Blood-Brain Barrier under Liver Failure and Their Clinical Significances.
Breast Neoplasms
Alterations in Hepatic mRNA Expression of Phase-II Enzymes and Xenobiotic Transporters after Targeted Disruption of Hepatocyte Nuclear Factor 4 alpha.
Breast Neoplasms
Altered Function and Expression of ABC Transporters at the Blood-Brain Barrier and Increased Brain Distribution of Phenobarbital in Acute Liver Failure Mice.
Breast Neoplasms
Altered methotrexate clearance in the treatment of CNS lymphoma with concurrent use of nitrofurantoin for a urinary tract infection.
Breast Neoplasms
Altered Umbilical Cord Blood Nutrient Levels, Placental Cell Turnover and Transporter Expression in Human Term Pregnancies Conceived by Intracytoplasmic Sperm Injection (ICSI).
Breast Neoplasms
Amine linked flavonoid dimers as modulators for p-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
Breast Neoplasms
Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer.
Breast Neoplasms
An altered tissue distribution of flaxseed lignans and their metabolites in Abcg2 knockout mice.
Breast Neoplasms
An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.
Breast Neoplasms
An easy and fast adenosine 5'-diphosphate quantification procedure based on hydrophilic interaction liquid chromatography-high resolution tandem mass spectrometry for determination of the in vitro adenosine 5'-triphosphatase activity of the human breast cancer resistance protein ABCG2.
Breast Neoplasms
An Electrically Tight In Vitro Blood-Brain Barrier Model Displays Net Brain-to-Blood Efflux of Substrates for the ABC Transporters, P-gp, Bcrp and Mrp-1.
Breast Neoplasms
An Experimental Approach To Evaluate the Impact of Impaired Transport Function on Hepatobiliary Drug Disposition Using Mrp2-Deficient TR(-) Rat Sandwich-Cultured Hepatocytes in Combination with Bcrp Knockdown.
Breast Neoplasms
An immortalised astrocyte cell line maintains the in vivo phenotype of a primary porcine in vitro blood-brain barrier model.
Breast Neoplasms
An immunohistochemical study of pi class glutathione S-transferase expression in normal human tissue.
Breast Neoplasms
An in vitro Mechanistic Study of the Distribution of Lascufloxacin into the Epithelial Lining Fluid.
Breast Neoplasms
An investigation of heat shock protein 27 and P-glycoprotein mediated multi-drug resistance in breast cancer using liquid chromatography-tandem mass spectrometry-based targeted proteomics.
Breast Neoplasms
An N-myristoylated protein kinase C-alpha pseudosubstrate peptide that functions as a multidrug resistance reversal agent in human breast cancer cells is not a P-glycoprotein substrate.
Breast Neoplasms
An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016).
Breast Neoplasms
An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus.
Breast Neoplasms
Analysis of drug metabolism activities in a miniaturized liver cell bioreactor for use in pharmacological studies.
Breast Neoplasms
Analysis of the resveratrol-binding protein using phage-displayed random peptide library.
Breast Neoplasms
Animal models of acute moderate hypoxia are associated with a down-regulation of CYP1A1, 1A2, 2B4, 2C5, and 2C16 and up-regulation of CYP3A6 and P-glycoprotein in liver.
Breast Neoplasms
Annexin-I expression modulates drug resistance in tumor cells.
Breast Neoplasms
Anti-tumor compound RY10-4 suppresses multidrug resistance in MCF-7/ADR cells by inhibiting PI3K/Akt/NF-?B signaling.
Breast Neoplasms
Antibody C219 recognizes an alpha-helical epitope on P-glycoprotein.
Breast Neoplasms
Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.
Breast Neoplasms
Antiepileptic medication during pregnancy: does fetal genotype affect outcome?
Breast Neoplasms
Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate.
Breast Neoplasms
Antioxidant effect of ascorbic acid against cisplatin-induced nephrotoxicity and P-glycoprotein expression in rats.
Breast Neoplasms
Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell lines.
Breast Neoplasms
Antipsychotic drugs inhibit the function of breast cancer resistance protein.
Breast Neoplasms
Antitubercular agent delamanid and metabolites as substrates and inhibitors of ABC and SLC transporters.
Breast Neoplasms
Antitumor activity of TZT-1027 (Soblidotin).
Breast Neoplasms
Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.
Breast Neoplasms
Apparent differences in mechanisms of harmol sulfate biliary excretion in mice and rats.
Breast Neoplasms
Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients.
Breast Neoplasms
Application of Human Placental Villous Tissue Explants to Study ABC Transporter Mediated Efflux of 2,4-Dinitrophenyl-S-Glutathione.
Breast Neoplasms
Approach for differentiating trophoblast cell lineage from human induced pluripotent stem cells with retinoic acid in the absence of bone morphogenetic protein 4.
Breast Neoplasms
Aptamer-functionalized Hybrid Nanoparticles to Enhance the Delivery of Doxorubicin into Breast Cancer Cells by Silencing P-glycoprotein.
Breast Neoplasms
Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.
Breast Neoplasms
Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2).
Breast Neoplasms
Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding.
Breast Neoplasms
Aromatic 2-(thio)ureidocarboxylic acids as a new family of modulators of multidrug resistance-associated protein 1: synthesis, biological evaluation, and structure-activity relationships.
Breast Neoplasms
Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
Aryl hydrocarbon receptor ligands increase ABC transporter activity and protein expression in killifish (Fundulus heteroclitus) renal proximal tubules.
Breast Neoplasms
Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier.
Breast Neoplasms
Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
Breast Neoplasms
Asperjinone, a Nor-Neolignan, and Terrein, a Suppressor of ABCG2-Expressing Breast Cancer Cells, from Thermophilic Aspergillus terreus.
Breast Neoplasms
Assessing the Functional Redundancy between P-gp and BCRP in Controlling the Brain Distribution and Biliary Excretion of Dual Substrates with PET Imaging in Mice.
Breast Neoplasms
Assessment of 99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study.
Breast Neoplasms
Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography.
Breast Neoplasms
Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach.
Breast Neoplasms
Assessment of contribution of BCRP to intestinal absorption of various drugs using portal-systemic blood concentration difference model in mice.
Breast Neoplasms
Assessment of drug transporter function using fluorescent cell imaging.
Breast Neoplasms
Assessment of drug transporters involved in the urinary secretion of [99mTc]dimercaptosuccinic acid.
Breast Neoplasms
Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
Breast Neoplasms
Assessment of transporter-mediated efflux of nintedanib using in vitro cell line models of idiopathic pulmonary fibrosis.
Breast Neoplasms
Association between ABCB1 C3435T polymorphism and breast cancer risk: a Moroccan case-control study and meta-analysis.
Breast Neoplasms
Association between ABCB1 G2677T/A Polymorphism and Breast Cancer Risk: A Meta-Analysis.
Breast Neoplasms
Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer.
Breast Neoplasms
Association between ABCB1, ABCG2 carrier protein and COX-2 enzyme gene polymorphisms and breast cancer risk in a Turkish population.
Breast Neoplasms
Association between DNA Methylation in the miR-328 5'-Flanking Region and Inter-individual Differences in miR-328 and BCRP Expression in Human Placenta.
Breast Neoplasms
Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy.
Breast Neoplasms
Association between Twist and multidrug resistance gene-associated proteins in Taxol
Breast Neoplasms
Association between two polymorphisms of ABCB1 and breast cancer risk in the current studies: a meta-analysis.
Breast Neoplasms
Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer.
Breast Neoplasms
Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients.
Breast Neoplasms
Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis.
Breast Neoplasms
Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients.
Breast Neoplasms
Association of ABCB1, ? tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.
Breast Neoplasms
Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms.
Breast Neoplasms
Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen.
Breast Neoplasms
Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma.
Breast Neoplasms
Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.
Breast Neoplasms
Association of plasma docetaxel levels with ABCB1 gene polymorphisms and tumour response in locally advanced breast cancer patients of South India on neo-adjuvant chemotherapy.
Breast Neoplasms
Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia.
Breast Neoplasms
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.
Breast Neoplasms
Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma.
Breast Neoplasms
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.
Breast Neoplasms
Associations Between ABCG2 Gene Polymorphisms and Isolated Septal Defects in a Han Chinese Population.
Breast Neoplasms
Associations between genetic polymorphisms of membrane transporter genes and prognosis after chemotherapy: meta-analysis and finding from Seoul Breast Cancer Study (SEBCS).
Breast Neoplasms
Astragali radix and its main bioactive compounds activate the Nrf2-mediated signaling pathway to induce P-glycoprotein and breast cancer resistance protein.
Breast Neoplasms
ATF3 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an N6-Methyladenosine-Based Epitranscriptomic Mechanism.
Breast Neoplasms
Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity.
Breast Neoplasms
ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate.
Breast Neoplasms
ATP-binding cassette (ABC) transporters in normal and pathological lung.
Breast Neoplasms
ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells.
Breast Neoplasms
ATP-binding Cassette Efflux Transporters in Human Placenta.
Breast Neoplasms
ATP-binding cassette transporters in primary central nervous system lymphoma: decreased expression of MDR1 P-glycoprotein and breast cancer resistance protein in tumor capillary endothelial cells.
Breast Neoplasms
ATP-binding cassette transporters P-glycoprotein and breast cancer related protein are reduced in capillary cerebral amyloid angiopathy.
Breast Neoplasms
ATP-binding Cassette Transporters Substantially Reduce Estimates of ALDH-positive Cancer Cells based on Aldefluor and AldeRed588 Assays.
Breast Neoplasms
ATP-dependent activity and mitochondrial localization of drug efflux pumps in doxorubicin-resistant breast cancer cells.
Breast Neoplasms
ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.
Breast Neoplasms
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Breast Neoplasms
Avian renal proximal tubule urate secretion is inhibited by cellular stress-induced AMP-activated protein kinase.
Breast Neoplasms
Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2.
Breast Neoplasms
BCRP at the Blood-Brain Barrier: Genomic Regulation by 17?-Estradiol.
Breast Neoplasms
BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.
Breast Neoplasms
BCRP expression in schwannoma, plexiform neurofibroma and MPNST.
Breast Neoplasms
BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia.
Breast Neoplasms
BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma.
Breast Neoplasms
BCRP Inhibition: from Data Collection to Ligand-Based Modeling.
Breast Neoplasms
BCRP mRNA expression v. clinical outcome in 40 adult AML patients.
Breast Neoplasms
BCRP transports dipyridamole and is inhibited by calcium channel blockers.
Breast Neoplasms
BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications.
Breast Neoplasms
BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization.
Breast Neoplasms
BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
Breast Neoplasms
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Breast Neoplasms
BCRP/ABCG2 Transporter Regulates Accumulation of Cadmium in Kidney Cells: Role of the Q141K Variant in Modulating Nephrotoxicity.
Breast Neoplasms
BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.
Breast Neoplasms
Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites.
Breast Neoplasms
Beneficial effect of Calculus Bovis Sativus on 17?-ethynylestradiol-induced cholestasis in the rat.
Breast Neoplasms
Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells.
Breast Neoplasms
Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1.
Breast Neoplasms
Beta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells.
Breast Neoplasms
Beyond the Diketopiperazine Family with Alternatively Bridged Brevianamide F Analogues.
Breast Neoplasms
Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins.
Breast Neoplasms
Bifendate-chalcone hybrids: a new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
Breast Neoplasms
Bile duct ligation causes opposite impacts on the expression and function of BCRP and P-gp in rat brain partly via affecting membrane expression of ezrin/radixin/moesin proteins.
Breast Neoplasms
Bile duct ligation enhances AZT CNS toxicity partly by impairing the expression and function of BCRP in rat brain.
Breast Neoplasms
Bile Duct Obstruction Leads to Increased Intestinal Expression of Breast Cancer Resistance Protein With Reduced Gastrointestinal Absorption of Imatinib.
Breast Neoplasms
Bile Salt Homeostasis in Normal and Bsep Gene Knockout Rats with Single and Repeated Doses of Troglitazone.
Breast Neoplasms
Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes.
Breast Neoplasms
Binary and ternary combinations of anti-HIV protease inhibitors: effect on gene expression and functional activity of CYP3A4 and efflux transporters.
Breast Neoplasms
Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.
Breast Neoplasms
Bioavailability of the Glucuronide and Sulfate Conjugates of Genistein and Daidzein in Bcrp1 Knockout Mice.
Breast Neoplasms
Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Breast Neoplasms
Bioengineered kidney tubules efficiently excrete uremic toxins.
Breast Neoplasms
Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
Breast Neoplasms
BioPerine Encapsulated Nanoformulation for Overcoming Drug-Resistant Breast Cancers.
Breast Neoplasms
Bisphenol A Inhibits the Transporter Function of the Blood-Brain Barrier by Directly Interacting with the ABC Transporter Breast Cancer Resistance Protein (BCRP).
Breast Neoplasms
Bleomycin Induces Drug Efflux in Lungs: A pitfall for Pharmacological Studies of Pulmonary Fibrosis.
Breast Neoplasms
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.
Breast Neoplasms
Blood-Brain Barrier and Breast Cancer Resistance Protein: a limit to the therapy of CNS tumors and neurodegenerative diseases.
Breast Neoplasms
Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice.
Breast Neoplasms
Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
Breast Neoplasms
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Breast Neoplasms
Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
Breast Neoplasms
Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Breast Neoplasms
Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Breast Neoplasms
Brain distribution and bioavailability of elacridar after different routes of administration in the mouse.
Breast Neoplasms
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
Breast Neoplasms
Brain distribution of a panel of EGFR inhibitors using cassette-dosing in wild-type and Abcb1/Abcg2 deficient mice.
Breast Neoplasms
Brain Distribution of Cediranib Is Limited by Active Efflux at the BBB.
Breast Neoplasms
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Breast Neoplasms
Brain Metastases from Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors.
Breast Neoplasms
Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
Breast Neoplasms
Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.
Breast Neoplasms
Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer.
Breast Neoplasms
Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.
Breast Neoplasms
Breast Cancer Resistance Protein (ABCG2) Determines Distribution of Genistein Phase II Metabolites: Reevaluation of the Roles of ABCG2 in the Disposition of Genistein.
Breast Neoplasms
Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design.
Breast Neoplasms
Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer.
Breast Neoplasms
Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy.
Breast Neoplasms
Breast Cancer Resistance Protein (BCRP) and Sulfotransferases Contribute Significantly to the Disposition of Genistein in Mouse Intestine.
Breast Neoplasms
Breast cancer resistance protein (Bcrp) and the testis--an unexpected turn of events.
Breast Neoplasms
Breast cancer resistance protein (BCRP) gene expression in a cohort of adult Egyptian patients with acute myeloid leukemia.
Breast Neoplasms
Breast cancer resistance protein (BCRP) in acute leukemia.
Breast Neoplasms
Breast cancer resistance protein (BCRP)-containing circulating microvesicles contribute to chemoresistance in breast cancer.
Breast Neoplasms
Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism.
Breast Neoplasms
Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699).
Breast Neoplasms
Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.
Breast Neoplasms
Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells.
Breast Neoplasms
Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.
Breast Neoplasms
Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibits Extra Villous Trophoblast Migration: The Impact of Bacterial and Viral Infection.
Breast Neoplasms
Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
Breast Neoplasms
Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences.
Breast Neoplasms
Breast cancer resistance protein (Bcrp/Abcg2) is selectively modulated by lipopolysaccharide (LPS) in the mouse yolk sac.
Breast Neoplasms
Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells.
Breast Neoplasms
Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion.
Breast Neoplasms
Breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Breast Neoplasms
Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach.
Breast Neoplasms
Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.
Breast Neoplasms
Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival.
Breast Neoplasms
Breast cancer resistance protein (Bcrp1/Abcg2) in mouse placenta and yolk sac: ontogeny and its regulation by progesterone.
Breast Neoplasms
Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX.
Breast Neoplasms
Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides.
Breast Neoplasms
Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.
Breast Neoplasms
Breast cancer resistance protein 1 limits fetal distribution of nitrofurantoin in the pregnant mouse.
Breast Neoplasms
Breast Cancer Resistance Protein Abundance, but Not mRNA Expression, Correlates With Estrone-3-Sulfate Transport in Caco-2.
Breast Neoplasms
Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide.
Breast Neoplasms
Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Mediate the Disposition of Leonurine-10-O-?-glucuronide.
Breast Neoplasms
Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Regulate the Disposition of Acacetin Glucuronides.
Breast Neoplasms
Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls.
Breast Neoplasms
Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
Breast Neoplasms
Breast Cancer Resistance Protein and P-glycoprotein in Brain Cancer: Two Gatekeepers Team Up.
Breast Neoplasms
Breast Cancer Resistance Protein and P-glycoprotein Influence In Vivo Disposition of 11C-Erlotinib.
Breast Neoplasms
Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
Breast Neoplasms
Breast cancer resistance protein BCRP (ABCG2)-mediated transepithelial nitrofurantoin secretion and its regulation in human intestinal epithelial (Caco-2) layers.
Breast Neoplasms
Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.
Breast Neoplasms
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.
Breast Neoplasms
Breast cancer resistance protein exports sulfated estrogens but not free estrogens.
Breast Neoplasms
Breast cancer resistance protein expression and 5-fluorouracil resistance.
Breast Neoplasms
Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia.
Breast Neoplasms
Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients.
Breast Neoplasms
Breast cancer resistance protein identifies clonogenic keratinocytes in human interfollicular epidermis.
Breast Neoplasms
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.
Breast Neoplasms
Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia.
Breast Neoplasms
Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.
Breast Neoplasms
Breast Cancer Resistance Protein Interacts with Various Compounds in vitro, but Plays a Minor Role in Substrate Efflux at the Blood-Brain Barrier.
Breast Neoplasms
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
Breast Neoplasms
Breast cancer resistance protein is the enemy of hypericin accumulation and toxicity of hypericin-mediated photodynamic therapy.
Breast Neoplasms
Breast cancer resistance protein regulates apical ectoplasmic specialization dynamics stage-specifically in the rat testis.
Breast Neoplasms
Breast cancer resistance protein substrate and inhibition evaluation: why, when, and how?
Breast Neoplasms
Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
Breast Neoplasms
Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells.
Breast Neoplasms
Breast cancer resistance protein/ABCG2 is differentially regulated downstream of extracellular signal-regulated kinase.
Breast Neoplasms
Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer.
Breast Neoplasms
Breast cancer resistance protein: mediating the trans-placental transfer of glyburide across the human placenta.
Breast Neoplasms
Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.
Breast Neoplasms
Breast cancer, side population cells and ABCG2 expression.
Breast Neoplasms
Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics.
Breast Neoplasms
Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.
Breast Neoplasms
Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells.
Breast Neoplasms
Buprenorphine, Norbuprenorphine, R-Methadone, and S-Methadone Upregulate BCRP/ABCG2 Expression by Activating Aryl Hydrocarbon Receptor in Human Placental Trophoblasts.
Breast Neoplasms
Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation.
Breast Neoplasms
C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
Breast Neoplasms
Caffeic Acid Inhibits the Uptake of 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by Inducing the Efflux Transporters Expression in Caco-2 Cells.
Breast Neoplasms
Calcitriol and Calcipotriol Modulate Transport Activity of ABC Transporters and Exhibit Selective Cytotoxicity in MRP1-overexpressing Cells.
Breast Neoplasms
Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Breast Neoplasms
Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient.
Breast Neoplasms
Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines.
Breast Neoplasms
Cannabidiol Effects on Phospholipid Metabolism in Keratinocytes from Patients with Psoriasis Vulgaris.
Breast Neoplasms
Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study.
Breast Neoplasms
Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations.
Breast Neoplasms
Carboxylesterase 2 and Intestine Transporters Contribute to the Low Bioavailability of Allisartan, a Prodrug of Exp3174 for Hypertension Treatment in Humans.
Breast Neoplasms
Carrier-mediated placental transport of cimetidine and valproic acid across differentiating JEG-3 cell layers.
Breast Neoplasms
CD147 mediates chemoresistance in breast cancer via ABCG2 by affecting its cellular localization and dimerization.
Breast Neoplasms
CD34- hematopoietic stem cells: current concepts and controversies.
Breast Neoplasms
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.
Breast Neoplasms
CD44(+)CD133(+) population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma.
Breast Neoplasms
Celastrol Inhibits the Proliferation and Decreases Drug Resistance of Cisplatin-Resistant Gastric Cancer SGC7901/DDP Cells.
Breast Neoplasms
Celecoxib Up Regulates the Expression of Drug Efflux Transporter ABCG2 in Breast Cancer Cell Lines.
Breast Neoplasms
Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
Breast Neoplasms
Cellular and regional specific changes in multidrug efflux transporter expression during recovery of vasogenic edema in the rat hippocampus and piriform cortex.
Breast Neoplasms
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
Breast Neoplasms
Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP.
Breast Neoplasms
CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function.
Breast Neoplasms
Ceramide 1-Phosphate Increases P-Glycoprotein Transport Activity at the Blood-Brain Barrier via Prostaglandin E2 Signaling.
Breast Neoplasms
Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.
Breast Neoplasms
Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and p-glycoprotein substrates.
Breast Neoplasms
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Breast Neoplasms
Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters.
Breast Neoplasms
Changes of Absorptive and Secretory Transporting System of (1 ? 3) ?-D-glucan Based on Efflux Transporter in Indomethacin-induced Rat.
Breast Neoplasms
Chapter 4 molecular mechanisms of adaptation to folate deficiency.
Breast Neoplasms
Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier.
Breast Neoplasms
Characterisation of the hepatic progenitor cell compartment in normal liver and in hepatitis: An immunohistochemical comparison between dog and man.
Breast Neoplasms
Characteristic Analysis of Intestinal Transport in Enterocyte-Like Cells Differentiated from Human Induced Pluripotent Stem Cells.
Breast Neoplasms
Characterization and localization of side population cells in mouse skin.
Breast Neoplasms
Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity.
Breast Neoplasms
Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier.
Breast Neoplasms
Characterization of ABC Transporters in EpiAirway, a Cellular Model of Normal Human Bronchial Epithelium.
Breast Neoplasms
Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug.
Breast Neoplasms
Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.
Breast Neoplasms
Characterization of efflux transporters involved in distribution and disposition of apixaban.
Breast Neoplasms
Characterization of Formononetin Sulfonation in SULT1A3 Overexpressing HKE293 Cells: Involvement of Multidrug Resistance-Associated Protein 4 in Excretion of Sulfate.
Breast Neoplasms
Characterization of P-Glycoprotein Inhibitors for Evaluating the Effect of P-Glycoprotein on the Intestinal Absorption of Drugs.
Breast Neoplasms
Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Breast Neoplasms
Characterization of polarized expression of point- or deletion-mutated human BCRP/ABCG2 in LLC-PK1 cells.
Breast Neoplasms
Characterization of renal tubular apical efflux of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in humans.
Breast Neoplasms
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics.
Breast Neoplasms
Characterization of secretory intestinal transport of the lactone form of CPT-11.
Breast Neoplasms
Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.
Breast Neoplasms
Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Breast Neoplasms
Characterization of the Human Intestinal Drug Transport with Ussing Chamber System Incorporating Freshly Isolated Human Jejunum.
Breast Neoplasms
Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients.
Breast Neoplasms
Characterization of the intestinal absorption of morroniside from Cornus officinalis Sieb. et Zucc via a Caco-2 cell monolayer model.
Breast Neoplasms
Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats.
Breast Neoplasms
Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides.
Breast Neoplasms
Chemo-sensitizing activity of natural cadinanes from Heterotheca inuloides in human uterine sarcoma cells and their in silico interaction with ABC transporters.
Breast Neoplasms
Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.
Breast Neoplasms
Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression.
Breast Neoplasms
Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.
Breast Neoplasms
Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-transporters.
Breast Neoplasms
CIAPIN1 gene silencing enhances chemosensitivity in a drug-resistant animal model in vivo.
Breast Neoplasms
Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells.
Breast Neoplasms
Circadian Clock Is Involved in Regulation of Hepatobiliary Transport Mediated by Multidrug Resistance-Associated Protein 2.
Breast Neoplasms
Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines.
Breast Neoplasms
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
Breast Neoplasms
Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases.
Breast Neoplasms
Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells.
Breast Neoplasms
Cisplatin in 5% Ethanol Eradicates Cisplatin-Resistant Lung Tumor by Killing Lung Cancer Side Population (SP) Cells and Non-SP Cells.
Breast Neoplasms
Clinical drug interaction profile of idelalisib in healthy subjects.
Breast Neoplasms
Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects.
Breast Neoplasms
Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.
Breast Neoplasms
Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar.
Breast Neoplasms
Clinical relevance of drug efflux pumps in the gut.
Breast Neoplasms
Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma.
Breast Neoplasms
Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.
Breast Neoplasms
Clinical significance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer.
Breast Neoplasms
Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients.
Breast Neoplasms
Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.
Breast Neoplasms
Clinicopathologic Analysis of Fas, Fas Ligand, and Other Biomarkers in Locally Advanced Breast Carcinoma.
Breast Neoplasms
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.
Breast Neoplasms
Cloning, expression of the truncation of recombinant peroxidase derived from millet bran and its reversal effects on 5-Fu resistance in colorectal cancer.
Breast Neoplasms
Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats.
Breast Neoplasms
CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy.
Breast Neoplasms
Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.
Breast Neoplasms
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Breast Neoplasms
Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
Breast Neoplasms
Co-delivery of Cyclopamine and Doxorubicin Mediated by Bovine Serum Albumin Nanoparticles Reverses Doxorubicin Resistance in Breast Cancer by Down-regulating P-glycoprotein Expression.
Breast Neoplasms
Co-delivery of doxorubicin and P-glycoprotein siRNA by multifunctional triblock copolymers for enhanced anticancer efficacy in breast cancer cells.
Breast Neoplasms
Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice.
Breast Neoplasms
Cobalt Chloride Induces Expression and Function of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Renal Proximal Tubular Epithelial Cell Line HK-2.
Breast Neoplasms
Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, In Vitro.
Breast Neoplasms
Codelivery of an Optimal Drug/siRNA Combination Using Mesoporous Silica Nanoparticles To Overcome Drug Resistance in Breast Cancer in Vitro and in Vivo.
Breast Neoplasms
Coexpression of Multiple ABC-Transporters is Strongly Associated with Treatment Response in Childhood Acute Myeloid Leukemia.
Breast Neoplasms
Coffee induces breast cancer resistance protein expression in Caco-2 cells.
Breast Neoplasms
Colonic treatments and targets: issues and opportunities.
Breast Neoplasms
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Breast Neoplasms
Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp).
Breast Neoplasms
Combined Contributions of Impaired Hepatic CYP2C11 and Intestinal Bcrp Activities and Expressions to Increased Exposure of Oral Glibenclamide in Streptozotocin-induced Diabetic Rats.
Breast Neoplasms
Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport.
Breast Neoplasms
Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin.
Breast Neoplasms
Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.
Breast Neoplasms
Commentary: "Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer".
Breast Neoplasms
Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas.
Breast Neoplasms
Comparative Hepatic and Intestinal Efflux Transport of Statins.
Breast Neoplasms
Comparative Pharmacokinetics of ?9-Tetrahydrocannabinol in Adolescent and Adult Male Mice.
Breast Neoplasms
Comparative pharmacokinetics of tedizolid in rat plasma and cerebrospinal fluid.
Breast Neoplasms
Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier.
Breast Neoplasms
Comparison of bisulfite sequencing PCR with pyrosequencing for measuring differences in DNA methylation.
Breast Neoplasms
Comparison of LC-MS/MS-based targeted proteomics and conventional analytical methods for monitoring breast cancer resistance protein expression.
Breast Neoplasms
Comparison of liquid chromatography-tandem mass spectrometry-based targeted proteomics and conventional analytical methods for the determination of P-glycoprotein in human breast cancer cells.
Breast Neoplasms
Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
Breast Neoplasms
Compartmental modelling of the pharmacokinetics of a breast cancer resistance protein.
Breast Neoplasms
Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.
Breast Neoplasms
Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
Breast Neoplasms
Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression.
Breast Neoplasms
Compound 968 reverses adriamycin resistance in breast cancer MCF-7ADR cells via inhibiting P-glycoprotein function independently of glutaminase.
Breast Neoplasms
Comprehensive Analysis of ABCG2 Genetic Variation in the Polish Population and Its Inter-Population Comparison.
Breast Neoplasms
Comprehensive Preclinical Pharmacokinetic Evaluations of Trastuzumab Deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in Cynomolgus Monkeys.
Breast Neoplasms
Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
Breast Neoplasms
Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines.
Breast Neoplasms
Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein.
Breast Neoplasms
Conditionally immortalized syncytiotrophoblast cell lines as new tools for study of the blood-placenta barrier.
Breast Neoplasms
Conditionally replicative adenovirus-based mda-7/IL-24 expression enhances sensitivity of colon cancer cells to 5-fluorouracil and doxorubicin.
Breast Neoplasms
Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity.
Breast Neoplasms
Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2.
Breast Neoplasms
Consequences of cell-to-cell P-glycoprotein transfer on acquired multidrug resistance in breast cancer: a cell population dynamics model.
Breast Neoplasms
Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier.
Breast Neoplasms
Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.
Breast Neoplasms
Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer.
Breast Neoplasms
Contribution of TRPV1 and multidrug resistance proteins in the permeation of capsaicin across different intestinal regions.
Breast Neoplasms
Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide.
Breast Neoplasms
Contributions of Drug Transporters to Blood-Placental Barrier.
Breast Neoplasms
Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
Breast Neoplasms
Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells.
Breast Neoplasms
Coordinated expression of multidrug resistance-associated proteins (Mrps) in mouse liver during toxicant-induced injury.
Breast Neoplasms
Correlation Analysis of Potential Breast Cancer Resistance Protein Probes in Different Monolayer Systems.
Breast Neoplasms
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Breast Neoplasms
Correlation between Membrane Protein Expression Levels and Transcellular Transport Activity for Breast Cancer Resistance Protein.
Breast Neoplasms
Correlation Between PXR and ABCG2 Patterns of mRNA Expression in a MCF7 Breast Carcinoma Cell Derivative upon Induction by Proinflammatory Cytokines.
Breast Neoplasms
Correlation of Aldo-Ketoreductase (AKR) 1C3 Genetic Variant with Doxorubicin Pharmacodynamics in Asian Breast Cancer Patients.
Breast Neoplasms
Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers.
Breast Neoplasms
Correlation of P-glycoprotein overexpression and cellular prognostic factors in formalin-fixed, paraffin-embedded tumor samples from breast cancer patients.
Breast Neoplasms
Correlations of ALDH1 expression with molecular subtypes and ABCG2 in breast cancer.
Breast Neoplasms
Correlations of MRP1 gene with serum TGF-?1 and IL-8 in breast cancer patients during chemotherapy.
Breast Neoplasms
Cost of home vs clinic administration of paclitaxel in metastatic breast cancer.
Breast Neoplasms
Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin.
Breast Neoplasms
Cover Image, Volume 117, Number 10, October 2016.
Breast Neoplasms
Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells.
Breast Neoplasms
Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure.
Breast Neoplasms
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Breast Neoplasms
Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.
Breast Neoplasms
Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides.
Breast Neoplasms
Cryptotanshinone Inhibits ER?-Dependent and -Independent BCRP Oligomer Formation to Reverse Multidrug Resistance in Breast Cancer.
Breast Neoplasms
Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells.
Breast Neoplasms
Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.
Breast Neoplasms
Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells.
Breast Neoplasms
Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells.
Breast Neoplasms
CXCR4 promotes growth and sphere formation of hypoxic breast cancer side 7 population cells via activation of c-Jun/ABCG2 pathway.
Breast Neoplasms
Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer.
Breast Neoplasms
Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line.
Breast Neoplasms
Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population.
Breast Neoplasms
Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?
Breast Neoplasms
Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Breast Neoplasms
Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
Breast Neoplasms
CYP1A1 induction and CYP3A4 inhibition by the fungicide imazalil in the human intestinal Caco-2 cells-comparison with other conazole pesticides.
Breast Neoplasms
Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions.
Breast Neoplasms
Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.
Breast Neoplasms
Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation.
Breast Neoplasms
Cytosolic phospholipase A2 is a key regulator of blood-brain barrier function in epilepsy.
Breast Neoplasms
Cytotoxicity and mechanism of action of a new ROS-generating microsphere formulation for circumventing multidrug resistance in breast cancer cells.
Breast Neoplasms
Cytotoxicity of cucurbitacin E from Citrullus colocynthis against multidrug-resistant cancer cells.
Breast Neoplasms
Cytotoxicity of herbal extracts used for treatment of prostatic disease on head and neck carcinoma cell lines and non-malignant primary mucosal cells.
Breast Neoplasms
Cytotoxicity of nimbolide towards multidrug-resistant tumor cells and hypersensitivity via cellular metabolic modulation.
Breast Neoplasms
Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.
Breast Neoplasms
Decitabine response in breast cancer requires efficient drug processing and is not limited by multidrug resistance.
Breast Neoplasms
Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
Breast Neoplasms
Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.
Breast Neoplasms
Decreased expression of breast cancer resistance protein in the duodenum in patients with obstructive cholestasis.
Breast Neoplasms
Decreased hepatic breast cancer resistance protein expression and function in multidrug resistance-associated protein 2-deficient (TR?) rats.
Breast Neoplasms
Decreased P-glycoprotein in a tamoxifen-tolerant breast carcinoma model.
Breast Neoplasms
Deficiency of either P-glycoprotein or Breast Cancer Resistance Protein protect against acute kidney injury.
Breast Neoplasms
Defying Multidrug Resistance! Modulation of Related Transporters by Flavonoids and Flavonolignans.
Breast Neoplasms
Deletion of Abcg2 Has Differential Effects on Excretion and Pharmacokinetics of Probe Substrates in Rats.
Breast Neoplasms
Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.
Breast Neoplasms
Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents.
Breast Neoplasms
Designing pregnancy centered medications: drugs which do not cross the human placenta.
Breast Neoplasms
Detection of frequent ABCB1 polymorphisms by high-resolution melting curve analysis and their effect on breast carcinoma prognosis.
Breast Neoplasms
Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells.
Breast Neoplasms
Detection of putative cancer stem cells of the side population phenotype in human tumor cell cultures.
Breast Neoplasms
Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).
Breast Neoplasms
Determination and prediction of P-glycoprotein and multidrug-resistance-related protein expression in breast cancer with double-phase technetium-99m sestamibi scintimammography. Visual and quantitative analyses.
Breast Neoplasms
Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
Breast Neoplasms
Detoxification of 1-chloro-2,4-dinitrobenzene in MCF7 breast cancer cells expressing glutathione S-transferase P1-1 and/or multidrug resistance protein 1.
Breast Neoplasms
Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
Breast Neoplasms
Development and Validation of a Computational Model Ensemble for the Early Detection of BCRP/ABCG2 Substrates during the Drug Design Stage.
Breast Neoplasms
Development of a Model for Functional Studies of ABCG2 (Breast Cancer Resistance Protein) Efflux Employing a Standard BeWo Clone (B24).
Breast Neoplasms
Development of a Support Vector Machine-Based System to Predict Whether a Compound Is a Substrate of a Given Drug Transporter Using Its Chemical Structure.
Breast Neoplasms
Development of a Ternary Solid Dispersion Formulation of LW6 to Improve the In Vivo Activity as a BCRP Inhibitor: Preparation and In Vitro/In Vivo Characterization.
Breast Neoplasms
Development of conformation independent computational models for the early recognition of breast cancer resistance protein substrates.
Breast Neoplasms
Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with Positron Emission Tomography.
Breast Neoplasms
Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance.
Breast Neoplasms
Development of Human in vitro Brain-blood Barrier Model from Induced Pluripotent Stem Cell-derived Endothelial Cells to Predict the in vivo Permeability of Drugs.
Breast Neoplasms
Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition.
Breast Neoplasms
Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2.
Breast Neoplasms
Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha.
Breast Neoplasms
Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label.
Breast Neoplasms
Developmental patterns in human blood-brain barrier and blood-cerebrospinal fluid barrier ABC drug transporter expression.
Breast Neoplasms
Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells.
Breast Neoplasms
Dexamethasone downregulates BCRP mRNA and protein expression in breast cancer cell lines.
Breast Neoplasms
Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier.
Breast Neoplasms
Dexamethasone induces an imbalanced fetal-placental-maternal bile acid circulation: involvement of placental transporters.
Breast Neoplasms
Dexamethasone reduces side population fraction through downregulation of ABCG2 transporter in MCF-7 breast cancer cells.
Breast Neoplasms
Diclofenac and Its Acyl Glucuronide: Determination of In Vivo Exposure in Human Subjects and Characterization as Human Drug Transporter Substrates In Vitro.
Breast Neoplasms
Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
Different Efflux Transporter Affinity and Metabolism of 99mTc-2-Methoxyisobutylisonitrile and 99mTc-Tetrofosmin for Multidrug Resistance Monitoring in Cancer.
Breast Neoplasms
Different Modalities of Intercellular Membrane Exchanges Mediate Cell-to-cell P-glycoprotein Transfers in MCF-7 Breast Cancer Cells.
Breast Neoplasms
Differential effect of phenothiazines on MRP1 and P-glycoprotein activity.
Breast Neoplasms
Differential effects of chrysin on nitrofurantoin pharmacokinetics mediated by intestinal breast cancer resistance protein in rats and mice.
Breast Neoplasms
Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
Breast Neoplasms
Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins.
Breast Neoplasms
Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma.
Breast Neoplasms
Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Breast Neoplasms
Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.
Breast Neoplasms
Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells.
Breast Neoplasms
Differential regulation of drug transporter expression by all-trans retinoic acid in hepatoma HepaRG cells and human hepatocytes.
Breast Neoplasms
Differential regulation of drug transporter expression by hepatocyte growth factor in primary human hepatocytes.
Breast Neoplasms
Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats.
Breast Neoplasms
Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: A strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Breast Neoplasms
Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).
Breast Neoplasms
Direct and indirect P-glycoprotein transfers in MCF7 breast cancer cells.
Breast Neoplasms
Direct Comparison of the Prediction of the Unbound Brain-to-Plasma Partitioning Utilizing Machine Learning Approach and Mechanistic Neuropharmacokinetic Model.
Breast Neoplasms
Discovery of 4-acetyl-3-(4-fluorophenyl)-1-(p-tolyl)-5-methylpyrrole as a dual inhibitor of human P-glycoprotein and Staphylococcus aureus Nor A efflux pump.
Breast Neoplasms
Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
Breast Neoplasms
Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
Breast Neoplasms
Dishevelled1-3 contribute to multidrug resistance in colorectal cancer via activating Wnt/?-catenin signaling.
Breast Neoplasms
Disposition of Mianserin and Cyclizine in UGT2B10-Overexpressing Human Embryonic Kidney 293 Cells: Identification of UGT2B10 as a Novel N-Glucosidation Enzyme and Breast Cancer Resistance Protein as an N-Glucoside Transporter.
Breast Neoplasms
Disposition of Naringenin via Glucuronidation Pathway Is Affected by Compensating Efflux Transporters of Hydrophilic Glucuronides.
Breast Neoplasms
Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer.
Breast Neoplasms
Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics.
Breast Neoplasms
Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract.
Breast Neoplasms
Distribution of Gefitinib to the Brain is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Mediated Active Efflux.
Breast Neoplasms
Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.
Breast Neoplasms
Double-phase Tc-99m sestamibi scintimammography to assess angiogenesis and P-glycoprotein expression in patients with untreated breast cancer.
Breast Neoplasms
Double-Transduced MDCKII Cells To Study Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Interplay in Drug Transport across the Blood-Brain Barrier.
Breast Neoplasms
Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer.
Breast Neoplasms
Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer.
Breast Neoplasms
Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta.
Breast Neoplasms
Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol.
Breast Neoplasms
Downregulated expression of intestinal P-glycoprotein in rats with cisplatin-induced acute kidney injury causes amplification of its transport capacity to maintain "gatekeeper" function.
Breast Neoplasms
Downregulation of BCRP and anti-apoptotic proteins by proadifen (SKF-525A) is responsible for the enhanced mitoxantrone accumulation and toxicity in mitoxantrone-resistant human promyelocytic leukemia cells.
Breast Neoplasms
Downregulation of breast cancer resistance protein by long-term fractionated radiotherapy sensitizes lung adenocarcinoma to SN-38.
Breast Neoplasms
Downregulation of breast cancer resistance protein in colon adenomas reduces cellular xenobiotic resistance and leads to accumulation of a food-derived carcinogen.
Breast Neoplasms
Downregulation of mdr1 and abcg2 genes is a mechanism of inhibition of efflux pumps mediated by polymeric amphiphiles.
Breast Neoplasms
Downregulation of organic cation transporter 1 and breast cancer resistance protein with the induction of Pregnane X receptor in rat kidney impaired by doxorubicin.
Breast Neoplasms
Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
Breast Neoplasms
Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer.
Breast Neoplasms
Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines.
Breast Neoplasms
Drug Clearance from Cerebrospinal Fluid Mediated by Organic Anion Transporters 1 (Slc22a6) and 3 (Slc22a8) at Arachnoid Membrane of Rats.
Breast Neoplasms
Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.
Breast Neoplasms
Drug efflux transport properties of 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM) and its fluorescent free acid, BCECF.
Breast Neoplasms
Drug Efflux Transporters and Multidrug Resistance in Acute Leukemia: Therapeutic Impact and Novel Approaches to Mediation.
Breast Neoplasms
Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells.
Breast Neoplasms
Drug Loaded Nanoparticles of Metal-Organic Frameworks with High Colloidal Stability for Anticancer Application.
Breast Neoplasms
Drug membrane transporters and CYP3A4 are affected by hypericin, hyperforin or aristoforin in colon adenocarcinoma cells.
Breast Neoplasms
Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors HIF1? and HIF2?.
Breast Neoplasms
Drug resistance caused by multidrug resistance-associated proteins.
Breast Neoplasms
Drug resistance in hematologic malignancies.
Breast Neoplasms
Drug resistance in renal tumors of childhood.
Breast Neoplasms
Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2).
Breast Neoplasms
Drug Transport Across the Placenta.
Breast Neoplasms
Drug transport by breast cancer resistance protein.
Breast Neoplasms
Drug transport by the blood-aqueous humor barrier of the eye.
Breast Neoplasms
Drug Transporter Expression and Activity in Human Hepatoma HuH-7 Cells.
Breast Neoplasms
Drug transporters in the lung--do they play a role in the biopharmaceutics of inhaled drugs?
Breast Neoplasms
Drug transporters on arachnoid barrier cells contribute to the blood-cerebrospinal fluid barrier.
Breast Neoplasms
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
Breast Neoplasms
Drug-drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H3 receptor antagonist.
Breast Neoplasms
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Breast Neoplasms
Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro.
Breast Neoplasms
Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers.
Breast Neoplasms
Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
Breast Neoplasms
Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir.
Breast Neoplasms
Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes.
Breast Neoplasms
Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality.
Breast Neoplasms
Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents.
Breast Neoplasms
Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells.
Breast Neoplasms
Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients.
Breast Neoplasms
Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders.
Breast Neoplasms
Ectopic expression of the WWOX gene suppresses stemness of human ovarian cancer stem cells.
Breast Neoplasms
Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon.
Breast Neoplasms
Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice.
Breast Neoplasms
Effect of 5-fluorouracil treatment on SN-38 absorption from intestine in rats.
Breast Neoplasms
Effect of ?-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Breast Neoplasms
Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients.
Breast Neoplasms
Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens.
Breast Neoplasms
Effect of brefeldin A and castanospermine on resistant cell lines as supplements in anticancer therapy.
Breast Neoplasms
Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice.
Breast Neoplasms
Effect of colibacillosis or coccidiosis on expression of breast cancer resistance protein in small intestine and liver of chickens.
Breast Neoplasms
Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers.
Breast Neoplasms
Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir.
Breast Neoplasms
Effect of excipients on breast cancer resistance protein substrate uptake activity.
Breast Neoplasms
Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males.
Breast Neoplasms
Effect of Genetic Polymorphisms on the Pharmacokinetics of Deferasirox in Healthy Chinese Subjects and an Artificial Neural Networks Model for Pharmacokinetic Prediction.
Breast Neoplasms
Effect of GenX on P-Glycoprotein, Breast Cancer Resistance Protein, and Multidrug Resistance-Associated Protein 2 at the Blood-Brain Barrier.
Breast Neoplasms
Effect of GnT-V knockdown on the proliferation, migration and invasion of the SMMC7721/R human hepatocellular carcinoma drug-resistant cell line.
Breast Neoplasms
Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients.
Breast Neoplasms
Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats.
Breast Neoplasms
Effect of interferon-?2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes.
Breast Neoplasms
Effect of lapatinib on oral digoxin absorption in patients.
Breast Neoplasms
Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
Breast Neoplasms
Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Breast Neoplasms
Effect of meta-tetra(hydroxyphenyl)chlorin (mTHPC)-mediated photodynamic therapy on sensitive and multidrug-resistant human breast cancer cells.
Breast Neoplasms
Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats.
Breast Neoplasms
Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells.
Breast Neoplasms
Effect of organic isothiocyanates on breast cancer resistance protein (ABCG2)-mediated transport.
Breast Neoplasms
Effect of oxygen on multidrug resistance in term human placenta.
Breast Neoplasms
Effect of oxygen on multidrug resistance in the first trimester human placenta.
Breast Neoplasms
Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats.
Breast Neoplasms
Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells.
Breast Neoplasms
Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes.
Breast Neoplasms
Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
Breast Neoplasms
Effect of pregnane X receptor expression on drug resistance in breast cancer.
Breast Neoplasms
Effect of prostaglandin E2 on multidrug resistance transporters in human placental cells.
Breast Neoplasms
Effect of quercetin on the toxicokinetics of ochratoxin A in rats.
Breast Neoplasms
Effect of rutin on pharmacokinetic modulation of diclofenac in rats.
Breast Neoplasms
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Breast Neoplasms
Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
Breast Neoplasms
Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
Breast Neoplasms
Effect of Ursolic Acid on Breast Cancer Resistance Protein-mediated Transport of Rosuvastatin In Vivo and Vitro.
Breast Neoplasms
Effect of Variations in the Amounts of P-Glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the Human Small Intestine on PBPK Models for Predicting Intestinal First Pass.
Breast Neoplasms
Effect of venlafaxine and desvenlafaxine on drug efflux protein expression and biodistribution in vivo.
Breast Neoplasms
Effective down-regulation of Breast Cancer Resistance Protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers.
Breast Neoplasms
Effectiveness of Small Interfering RNA Delivery via Arginine-Rich Polyethylenimine-Based Polyplex in Metastatic and Doxorubicin-Resistant Breast Cancer Cells.
Breast Neoplasms
Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Breast Neoplasms
Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport.
Breast Neoplasms
Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs.
Breast Neoplasms
Effects of Catechins and Their Related Compounds on Cellular Accumulation and Efflux Transport of Mitoxantrone in Caco-2 Cell Monolayers.
Breast Neoplasms
Effects of chronic renal failure on brain drug transporters in rats.
Breast Neoplasms
Effects of Chrysin and Its Major Conjugated Metabolites Chrysin-7-Sulfate and Chrysin-7-Glucuronide on Cytochrome P450 Enzymes and on OATP, P-gp, BCRP, and MRP2 Transporters.
Breast Neoplasms
Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Breast Neoplasms
Effects of herbal products on the metabolism and transport of anticancer agents.
Breast Neoplasms
Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
Breast Neoplasms
Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Breast Neoplasms
Effects of morin on the pharmacokinetics of etoposide in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in female Sprague-Dawley rats.
Breast Neoplasms
Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
Breast Neoplasms
Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Breast Neoplasms
Effects of P-gp and Bcrp as brain efflux transporters on the uptake of [18 F]FPEB in the murine brain.
Breast Neoplasms
Effects of Piperine, Cinnamic Acid and Gallic Acid on Rosuvastatin Pharmacokinetics in Rats.
Breast Neoplasms
Effects of R-enantiomer (GR66234A) and L-enantiomer (GR66235A) of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype.
Breast Neoplasms
Effects of Radiation on Drug Metabolism: A Review.
Breast Neoplasms
Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
Breast Neoplasms
Effects of Selected OATP and/or ABC Transporter Inhibitors on the Brain and Whole-Body Distribution of Glyburide.
Breast Neoplasms
Effects of the ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of afatinib in healthy Chinese volunteers.
Breast Neoplasms
Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans.
Breast Neoplasms
Effects of the antiretroviral drug 2'-deoxy-2'-?-fluoro-4'-azidocytidine (FNC) on P-gp, MRP2 and BCRP expressions and functions.
Breast Neoplasms
Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2.
Breast Neoplasms
Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo.
Breast Neoplasms
Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes.
Breast Neoplasms
Effects of Various Pharmaceutical Excipients on the Intestinal Transport and Absorption of Sulfasalazine, a Typical Substrate of Breast Cancer Resistance Protein Transporter.
Breast Neoplasms
Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
Breast Neoplasms
Efflux and uptake transporters as determinants of statin response.
Breast Neoplasms
Efflux excretion of bisdemethoxycurcumin-O-glucuronide in UGT1A1-overexpressing HeLa cells: Identification of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins 1 (MRP1) as the glucuronide transporters.
Breast Neoplasms
Efflux Protein Expression in Human Retinal Pigment Epithelium Cell Lines.
Breast Neoplasms
Efflux transport of N-monodesethylamiodarone by the human intestinal cell-line Caco-2 cells.
Breast Neoplasms
Efflux transport of nicotine, cotinine and trans-3'-hydroxycotinine glucuronides by human hepatic transporters.
Breast Neoplasms
Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles.
Breast Neoplasms
Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease.
Breast Neoplasms
Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
Breast Neoplasms
Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1).
Breast Neoplasms
Efflux transporters of the human placenta.
Breast Neoplasms
Effluxing ABC transporters in human corneal epithelium.
Breast Neoplasms
Egr-1 enhances drug resistance of breast cancer by modulating MDR1 expression in a GGPPS-independent manner.
Breast Neoplasms
Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification.
Breast Neoplasms
Elevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells.
Breast Neoplasms
Elevated survivin mediated multidrug resistance and reduced apoptosis in breast cancer stem cells.
Breast Neoplasms
Elevated system exposures of baicalin after combinatory oral administration of rhein and baicalin: Mainly related to breast cancer resistance protein (ABCG2), not UDP-glucuronosyltransferases.
Breast Neoplasms
Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines.
Breast Neoplasms
Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets.
Breast Neoplasms
Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Breast Neoplasms
Elucidation of the impact of P-glycoprotein and Breast Cancer Resistance Protein on the brain distribution of catechol-O-methyltransferase inhibitors.
Breast Neoplasms
Elucidation of the Intestinal Absorption Mechanism of Celastrol Using the Caco-2 Cell Transwell Model.
Breast Neoplasms
Elucidation of the Intestinal Absorption Mechanism of Loganin in the Human Intestinal Caco-2 Cell Model.
Breast Neoplasms
Emerging role for drug transporters at the blood-testis barrier.
Breast Neoplasms
Enantioselective Drug Recognition by Drug Transporters.
Breast Neoplasms
Endocrine Disruptors Differentially Target ATP-Binding Cassette Transporters in the Blood-Testis Barrier and Affect Leydig Cell Testosterone Secretion In Vitro.
Breast Neoplasms
Endoplasmic reticulum stress: major player in size-dependent inhibition of P-glycoprotein by silver nanoparticles in multidrug-resistant breast cancer cells.
Breast Neoplasms
Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).
Breast Neoplasms
Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
Breast Neoplasms
Enhanced brain disposition and effects of ?9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice.
Breast Neoplasms
Enhanced cytotoxicity and nuclear accumulation of doxorubicin-loaded nanospheres in human breast cancer MCF7 cells expressing MRP1.
Breast Neoplasms
Enhanced de novo ceramide generation through activation of serine palmitoyltransferase by the P-glycoprotein antagonist SDZ PSC 833 in breast cancer cells.
Breast Neoplasms
Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
Breast Neoplasms
Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance.
Breast Neoplasms
Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound.
Breast Neoplasms
Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene.
Breast Neoplasms
Enhancement of zidovudine uptake by dehydroepiandrosterone sulfate in rat syncytiotrophoblast cell line TR-TBT 18d-1.
Breast Neoplasms
Enhancing chemosensitivity of breast cancer stem cells by down regulating SOX2 and ABCG2 using Wedelolactone-encapsulated nanoparticles.
Breast Neoplasms
Enhancing the Therapeutic Efficacy of Daunorubicin and Mitoxantrone with Bavachinin, Candidone, and Tephrosin.
Breast Neoplasms
Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors.
Breast Neoplasms
Epigenetic Regulation of MDR1 and BCRP Transporters by HDAC Inhibition.
Breast Neoplasms
Epithelial cell adhesion molecule promotes breast cancer resistance protein-mediated multidrug resistance in breast cancer by inducing partial epithelial-mesenchymal transition.
Breast Neoplasms
Eradication of cancer stem cells in triple negative breast cancer using doxorubicin/pluronic polymeric micelles.
Breast Neoplasms
Erlotinib antagonizes ABC transporters in acute myeloid leukemia.
Breast Neoplasms
Establishment and characterization of arsenic trioxide resistant KB/ATO cells.
Breast Neoplasms
Establishment of a simplified in vitro porcine blood-brain barrier model with high transendothelial electrical resistance.
Breast Neoplasms
Establishment of human pancreatic cancer gemcitabine?resistant cell line with ribonucleotide reductase overexpression.
Breast Neoplasms
Establishment of recombinant lentiviral vector with ABCG2 overexpression and effects of the recombinant on human breast cancer MCF-7 cells' biological characteristics.
Breast Neoplasms
Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats.
Breast Neoplasms
Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2.
Breast Neoplasms
Estrogen Enhances the Expression of the Multidrug Transporter Gene ABCG2-Increasing Drug Resistance of Breast Cancer Cells through Estrogen Receptors.
Breast Neoplasms
Estrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/Akt/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein.
Breast Neoplasms
Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
Breast Neoplasms
Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.
Breast Neoplasms
Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
Breast Neoplasms
Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism.
Breast Neoplasms
Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods.
Breast Neoplasms
Evaluation of (99m)technetium-mebrofenin and (99m)technetium-sestamibi as specific probes for hepatic transport protein function in rat and human hepatocytes.
Breast Neoplasms
Evaluation of 2,6-diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)- hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistance in vitro.
Breast Neoplasms
Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Breast Neoplasms
Evaluation of alteration in hepatic and intestinal BCRP function in vivo due to ABCG2 c.421C>A polymorphism based on PBPK analysis of rosuvastatin.
Breast Neoplasms
Evaluation of breast cancer resistance protein function in hepatobiliary and renal excretion using PET with 11C-SC-62807.
Breast Neoplasms
Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.
Breast Neoplasms
Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters.
Breast Neoplasms
Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation.
Breast Neoplasms
Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.
Breast Neoplasms
Evaluation of inhibitory effects of flavonoids on breast cancer resistance protein (BCRP): From library screening to biological evaluation to structure-activity relationship.
Breast Neoplasms
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
Breast Neoplasms
Evaluation of Limiting Brain Penetration Related to P-glycoprotein and Breast Cancer Resistance Protein Using [(11)C]GF120918 by PET in Mice.
Breast Neoplasms
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
Breast Neoplasms
Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.
Breast Neoplasms
Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- binding cassette (ABC) drug transporters.
Breast Neoplasms
Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours.
Breast Neoplasms
Evaluation of the Near Infrared Compound Indocyanine Green as a Probe Substrate of P-Glycoprotein.
Breast Neoplasms
Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.
Breast Neoplasms
Evaluation of the Role of Breast Cancer Resistance Protein (BCRP/ABCG2) and Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in The Urinary Excretion of Sulfate and Glucuronide Metabolites of Edaravone (MCI-186; 3-Methyl-1-phenyl-2-pyrazolin-5-one).
Breast Neoplasms
Evaluation of the Usefulness of Breast Cancer Resistance Protein (BCRP) Knockout Mice and BCRP Inhibitor-Treated Monkeys to Estimate the Clinical Impact of BCRP Modulation on the Pharmacokinetics of BCRP Substrates.
Breast Neoplasms
Evaluation of Tissue Stem Cell-Derived Human Intestinal Organoids, a Physiologically Relevant Model to Evaluate Cytochrome P450 Induction in Gut.
Breast Neoplasms
Evaluation of [18F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood-brain barrier in rats: Kinetics, metabolism, and selectivity.
Breast Neoplasms
Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.
Breast Neoplasms
Evidence for P-Glycoprotein Involvement in Cell Volume Regulation Using Coulter Sizing in Flow Cytometry.
Breast Neoplasms
Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein.
Breast Neoplasms
Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
Breast Neoplasms
Examination of multidrug resistance in cell lines and primary breast tumours by flow cytometry.
Breast Neoplasms
Examination of Physiologically-Based Pharmacokinetic Models of Rosuvastatin.
Breast Neoplasms
Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein.
Breast Neoplasms
Expanding the efflux in vitro assay toolbox: A CRISPR-Cas9 edited MDCK cell line with human BCRP and completely lacking canine MDR1.
Breast Neoplasms
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Breast Neoplasms
Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
Breast Neoplasms
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.
Breast Neoplasms
Expression and Activity of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Distal Lung Epithelial Cells In Vitro.
Breast Neoplasms
Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients.
Breast Neoplasms
Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines.
Breast Neoplasms
Expression and function of efflux drug transporters in the intestine.
Breast Neoplasms
Expression and functional activity of breast cancer resistance protein (bcrp, abcg2) transporter in the human choriocarcinoma cell line bewo.
Breast Neoplasms
Expression and functional analyses of breast cancer resistance protein in lung cancer.
Breast Neoplasms
Expression and localisation of breast cancer resistance protein (BCRP) in human fetal membranes and decidua and the influence of labour at term.
Breast Neoplasms
Expression and localization of BCRP, MRP1 and MRP2 in intestines, liver and kidney in horse.
Breast Neoplasms
Expression and Localization of P-Glycoprotein, Multidrug Resistance Protein 4, and Breast Cancer Resistance Protein in the Female Lower Genital Tract of Human and Pigtailed Macaque.
Breast Neoplasms
Expression and regulation of breast cancer resistance protein and multidrug resistance associated protein 2 in BALB/c mice.
Breast Neoplasms
Expression and Transport Activity of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Dually Perfused Rat Placenta and HRP-1 Cell Line.
Breast Neoplasms
Expression levels of ABCG2 and CD61 genes in breast cancer tissues of Iranian population.
Breast Neoplasms
Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes.
Breast Neoplasms
Expression of ABC transporters in human hepatocyte carcinoma cells with cross-resistance to epirubicin and mitoxantrone.
Breast Neoplasms
Expression of ABC transporters is an unfavorable prognostic factor in laryngeal squamous cell carcinoma.
Breast Neoplasms
Expression of ABC-transport proteins in canine mammary cancer: consequences for chemotherapy.
Breast Neoplasms
Expression of ABCG2 (BCRP) in mouse models with enhanced erythropoiesis.
Breast Neoplasms
Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy.
Breast Neoplasms
Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors.
Breast Neoplasms
Expression of ATP-binding cassette membrane transporters in a HIV-1 transgenic rat model.
Breast Neoplasms
Expression of ATP-binding cassette membrane transporters in rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier.
Breast Neoplasms
Expression of BAF57 in ovarian cancer cells and drug sensitivity.
Breast Neoplasms
Expression of Breast Cancer Resistance Protein (BCRP-1) in Canine Mammary Adenocarcinomas and Adenomas.
Breast Neoplasms
Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term before and after labor.
Breast Neoplasms
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia.
Breast Neoplasms
Expression of breast cancer resistance protein in peripheral T cell subsets from HIV?1?infected patients with antiretroviral therapy.
Breast Neoplasms
Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.
Breast Neoplasms
Expression of drug resistance proteins in breast cancer, in relation to chemotherapy.
Breast Neoplasms
Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualized therapy of the breast cancer patients.
Breast Neoplasms
Expression of mdr1 and gst-pi in human breast tumours: comparison to in vitro chemosensitivity.
Breast Neoplasms
Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results.
Breast Neoplasms
Expression of membrane drug efflux transporters in the sigmoid colon of HIV-infected and uninfected men.
Breast Neoplasms
Expression of membrane transporters and metabolic enzymes involved in estrone-3-sulphate disposition in human breast tumour tissues.
Breast Neoplasms
Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy.
Breast Neoplasms
Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
Breast Neoplasms
Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy.
Breast Neoplasms
Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.
Breast Neoplasms
Expression of multidrug resistance associated transporters (MDR1, MRP1, LRP and BCRP) in porcine oocyte.
Breast Neoplasms
Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1?, EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes.
Breast Neoplasms
Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications.
Breast Neoplasms
Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin.
Breast Neoplasms
Expression of multidrug resistance-related transporters in human breast carcinoma.
Breast Neoplasms
Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy.
Breast Neoplasms
Expression of P-glycoprotein and breast cancer resistance protein in three cases of canine lymphoma showing drug resistance.
Breast Neoplasms
Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine.
Breast Neoplasms
Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia.
Breast Neoplasms
Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors.
Breast Neoplasms
Expression of the breast cancer resistance protein and 5-fluorouracil resistance in clinical breast cancer tissue specimens.
Breast Neoplasms
Expression of the breast cancer resistance protein in breast cancer.
Breast Neoplasms
Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver.
Breast Neoplasms
Expression of the multidrug resistance protein (MRP1) in breast cancer.
Breast Neoplasms
Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells.
Breast Neoplasms
Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia.
Breast Neoplasms
Expression profiling of genes modulated by rosmarinic acid (RA) in MCF-7 breast cancer cells.
Breast Neoplasms
Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells.
Breast Neoplasms
Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing.
Breast Neoplasms
Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Breast Neoplasms
Expressions of Topoisomerase II? and BCRP in Metastatic Cells are Associated with Overall Survival in Small Cell Lung Cancer Patients.
Breast Neoplasms
Extending the good diet, good health paradigm: modulation of breast cancer resistance protein (BCRP) by flavonoids.
Breast Neoplasms
Extrahepatic metabolism of ibrutinib.
Breast Neoplasms
Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases.
Breast Neoplasms
Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier.
Breast Neoplasms
Farnesiferol A from Ferula persica and Galbanic Acid from Ferula szowitsiana Inhibit P-Glycoprotein-Mediated Rhodamine Efflux in Breast Cancer Cell Lines.
Breast Neoplasms
Fast, Stable Induction of P-Glycoprotein-mediated Drug Resistance in BT-474 Breast Cancer Cells by Stable Transfection of ABCB1 Gene.
Breast Neoplasms
Fatty acid-bearing albumin but not fatty acid-depleted albumin induces HIF-1 activation in human renal proximal tubular epithelial cell line HK-2.
Breast Neoplasms
FBLN-4 and BCRP genes as two prognostic markers are downregulated in breast cancer tissue.
Breast Neoplasms
Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
Breast Neoplasms
Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy.
Breast Neoplasms
Flavonoid dimers as bivalent modulators for p-glycoprotein-based multidrug resistance: structure-activity relationships.
Breast Neoplasms
Flavonoid permeability across an in situ model of the blood-brain barrier.
Breast Neoplasms
Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
Breast Neoplasms
Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
Breast Neoplasms
Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators.
Breast Neoplasms
Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Breast Neoplasms
Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Breast Neoplasms
Flavonol-stimulated efflux of 7,12-dimethylbenz(a)anthracene in multidrug-resistant breast cancer cells.
Breast Neoplasms
Flow cytometric analysis of breast cancer resistance protein expression and function.
Breast Neoplasms
Flow cytometric evaluation of multidrug resistance proteins.
Breast Neoplasms
FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia.
Breast Neoplasms
Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells.
Breast Neoplasms
Fluorescence-Based Transport Assays Revisited in a Human Renal Proximal Tubule Cell Line.
Breast Neoplasms
Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
Breast Neoplasms
Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.
Breast Neoplasms
Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis.
Breast Neoplasms
Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.
Breast Neoplasms
Food constituent- and herb-drug interactions in oncology: Influence of quantitative modelling on Drug labelling.
Breast Neoplasms
Forced expression of Hsp27 reverses P-glycoprotein (ABCB1) mediated drug efflux and MDR1 gene expression in adriamycin resistant human breast cancer cells.
Breast Neoplasms
Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.
Breast Neoplasms
Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.
Breast Neoplasms
Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material.
Breast Neoplasms
Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
Breast Neoplasms
Fructose suppresses uric acid excretion to the intestinal lumen as a result of the induction of oxidative stress by NADPH oxidase activation.
Breast Neoplasms
Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.
Breast Neoplasms
Function of Multidrug Resistance Transporters is Disrupted by Infection Mimics in Human Brain Endothelial Cells.
Breast Neoplasms
Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.
Breast Neoplasms
Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.
Breast Neoplasms
Functional Alterations of Multidrug Resistance-Associated Proteins 2 and 5, and Breast Cancer Resistance Protein upon Snail-Induced Epithelial-Mesenchymal Transition in HCC827 Cells.
Breast Neoplasms
Functional analysis of candidate ABC transporter proteins for sitosterol transport.
Breast Neoplasms
Functional analysis of SNPs variants of BCRP/ABCG2.
Breast Neoplasms
Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N.
Breast Neoplasms
Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.
Breast Neoplasms
Functional characterization of rainbow trout (Oncorhynchus mykiss) Abcg2a (Bcrp) transporter.
Breast Neoplasms
Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.
Breast Neoplasms
Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
Breast Neoplasms
Functional expression of breast cancer resistance protein and cholesterol effect in human erythrocyte membranes.
Breast Neoplasms
Functional expression of the human breast cancer resistance protein in Pichia pastoris.
Breast Neoplasms
Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.
Breast Neoplasms
Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.
Breast Neoplasms
Functional Significance of Genetic Polymorphisms in P-glycoprotein (MDR1, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2).
Breast Neoplasms
Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.
Breast Neoplasms
Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein.
Breast Neoplasms
Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Breast Neoplasms
G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance.
Breast Neoplasms
Galectin-1 knockdown improves drug sensitivity of breast cancer by reducing P-glycoprotein expression through inhibiting the Raf-1/AP-1 signaling pathway.
Breast Neoplasms
Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.
Breast Neoplasms
Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP).
Breast Neoplasms
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Breast Neoplasms
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Breast Neoplasms
Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Breast Neoplasms
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
Breast Neoplasms
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
Breast Neoplasms
Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
Breast Neoplasms
Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells.
Breast Neoplasms
Gender differences in mRNA expression of ATP-binding cassette efflux and bile acid transporters in kidney, liver, and intestine of 5/6 nephrectomized rats.
Breast Neoplasms
Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.
Breast Neoplasms
Gene expression and pathologic response to neoadjuvant chemotherapy in breast cancer.
Breast Neoplasms
Gene-by-Environment Interaction of Bcrp-/- and MCD Diet-Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition.
Breast Neoplasms
Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model.
Breast Neoplasms
Genetic analysis of the xenobiotic resistance-associated ABC gene subfamilies of the Lepidoptera.
Breast Neoplasms
Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter.
Breast Neoplasms
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Breast Neoplasms
Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Breast Neoplasms
Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer.
Breast Neoplasms
Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes.
Breast Neoplasms
Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population.
Breast Neoplasms
Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy.
Breast Neoplasms
Genistein and Glyceollin Effects on ABCC2 (MRP2) and ABCG2 (BCRP) in Caco-2 Cells.
Breast Neoplasms
Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol.
Breast Neoplasms
Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases.
Breast Neoplasms
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.
Breast Neoplasms
Gestational Age-Dependent Abundance of Human Placental Transporters as Determined by Quantitative Targeted Proteomics.
Breast Neoplasms
Gestational age-dependent gene expression profiling of ATP-binding cassette transporters in the healthy human placenta.
Breast Neoplasms
Ginkgo biloba leaf extract suppresses intestinal human breast cancer resistance protein expression in mice: Correlation with gut microbiota.
Breast Neoplasms
Glucocorticoid regulation of placental breast cancer resistance protein (Bcrp1) in the mouse.
Breast Neoplasms
Glucocorticoids modulate multidrug resistance transporters in the first trimester human placenta.
Breast Neoplasms
Glucose-induced alteration of accumulation of organotechnetium complexes accumulation in Pgp-negative tumor-bearing mice.
Breast Neoplasms
Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Breast Neoplasms
Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3.
Breast Neoplasms
Glutamate-Mediated Down-Regulation of the Multidrug-Resistance Protein BCRP/ABCG2 in Porcine and Human Brain Capillaries.
Breast Neoplasms
Glyburide for the treatment of gestational diabetes mellitus.
Breast Neoplasms
GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells.
Breast Neoplasms
Graphene Quantum Dots Downregulate Multiple Multidrug-Resistant Genes via Interacting with Their C-Rich Promoters.
Breast Neoplasms
Grid-Independent Descriptors (GRIND) analysis and SAR Guided Molecular Docking Studies to Probe Selectivity Profiles of Inhibitors of Multidrug Resistance Transporters ABCB1 and ABCG2.
Breast Neoplasms
Growth and differentiation of progenitor/stem cells derived from the human mammary gland.
Breast Neoplasms
Guajadial reverses multidrug resistance by inhibiting ABC transporter expression and suppressing the PI3K/Akt pathway in drug-resistant breast cancer cells.
Breast Neoplasms
Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells.
Breast Neoplasms
Guggulsterone regulates the function and expression of P-glycoprotein in rat brain microvessel endothelial cells.
Breast Neoplasms
H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein.
Breast Neoplasms
Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting.
Breast Neoplasms
HDAC1 was involved in placental breast cancer resistance protein regulation in vitro: A preliminary study.
Breast Neoplasms
HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
Breast Neoplasms
Heat Shock Protein 90 Triggers Multi-Drug Resistance of Ovarian Cancer via AKT/GSK3?/?-Catenin Signaling.
Breast Neoplasms
Heme Oxygenase-1 and Breast Cancer Resistance Protein Protect Against heme-induced toxicity.
Breast Neoplasms
Hepatic and renal Bcrp transporter expression in mice treated with perfluorooctanoic acid.
Breast Neoplasms
Hepatic Basolateral Efflux Contributes Significantly to Rosuvastatin Disposition:I. Characterization of Basolateral vs. Biliary Clearance Using a Novel Protocol in Sandwich-Cultured Hepatocytes.
Breast Neoplasms
Hepatic Basolateral Efflux Contributes Significantly to Rosuvastatin Disposition:II. Characterization of Hepatic Elimination by Basolateral, Biliary, and Metabolic Clearance Pathways in Rat Isolated Perfused Liver.
Breast Neoplasms
Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters.
Breast Neoplasms
Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents.
Breast Neoplasms
Hepatic synthesis and urinary elimination of acetaminophen glucuronide are exacerbated in bile duct-ligated rats.
Breast Neoplasms
Hepatobiliary disposition of 3alpha,6alpha,7alpha,12alpha-tetrahydroxy-cholanoyl taurine: a substrate for multiple canalicular transporters.
Breast Neoplasms
Hepatocellular exposure of troglitazone metabolites in rat sandwich-cultured hepatocytes lacking Bcrp and Mrp2: interplay between formation and excretion.
Breast Neoplasms
Hepatocyte-Specific Deletion of EGFR in Mice Reduces Hepatic Abcg2 Transport Activity Measured by [(11)C]erlotinib and Positron Emission Tomography.
Breast Neoplasms
Herbal Interactions with Anticancer Drugs: Mechanistic and Clinical Considerations.
Breast Neoplasms
Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance.
Breast Neoplasms
High doses of ursodeoxycholic acid up-regulate the expression of placental breast cancer resistance protein in patients affected by intrahepatic cholestasis of pregnancy.
Breast Neoplasms
High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival.
Breast Neoplasms
High Intrinsic Expression of P-glycoprotein and Breast Cancer Resistance Protein in Canine Mammary Carcinomas Regardless of Immunophenotype and Outcome.
Breast Neoplasms
High salt induces P-glycoprotein mediated treatment resistance in breast cancer cells through store operated calcium influx.
Breast Neoplasms
High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
Breast Neoplasms
Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding.
Breast Neoplasms
Higher frequencies of BCRP+ cardiac resident cells in ischaemic human myocardium.
Breast Neoplasms
Higher Level of P-glycoprotein Expression in Human Breast Cancer Cells after Radiation Therapy.
Breast Neoplasms
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Breast Neoplasms
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
Breast Neoplasms
HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications in Antiretroviral Drug Disposition.
Breast Neoplasms
HIV-1 Tat Protein Enhances Expression and Function of Breast Cancer Resistance Protein.
Breast Neoplasms
HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Breast Neoplasms
Homology modeling of breast cancer resistance protein (ABCG2).
Breast Neoplasms
Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Breast Neoplasms
Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.
Breast Neoplasms
Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine.
Breast Neoplasms
Human multidrug resistance associated protein 4 confers resistance to camptothecins.
Breast Neoplasms
Human papilloma virus (HPV) 18 proteins E6 and E7 up-regulate ABC transporters in oropharyngeal carcinoma. Involvement of the nonsense-mediated decay (NMD) pathway.
Breast Neoplasms
Human small intestinal epithelial cells differentiated from adult intestinal stem cells as a novel system for predicting oral drug absorption in humans.
Breast Neoplasms
Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells.
Breast Neoplasms
Hyperglycemic Condition Causes Pro-Inflammatory and Permeability Alterations Associated with Monocyte Recruitment and Deregulated NF?B/PPAR? Pathways on Cerebral Endothelial Cells: Evidence for Polyphenols Uptake and Protective Effect.
Breast Neoplasms
Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells.
Breast Neoplasms
Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP).
Breast Neoplasms
I dentification of Food-derived Isoflavone Sulfates as Inhibition Markers for Intestinal Breast Cancer Resistance Proteins.
Breast Neoplasms
I-387, a Novel Antimitotic Indole, Displays a Potent In vitro and In vivo Antitumor Activity with Less Neurotoxicity.
Breast Neoplasms
Identification and Characterization of Efflux Transporters That Modulate the Subtoxic Disposition of Diclofenac and Its Metabolites.
Breast Neoplasms
Identification and functional assessment of BCRP polymorphisms in a Korean population.
Breast Neoplasms
Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3).
Breast Neoplasms
Identification of 14-3-3{sigma} as a Contributor to Drug Resistance in Human Breast Cancer Cells Using Functional Proteomic Analysis.
Breast Neoplasms
Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line.
Breast Neoplasms
Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene.
Breast Neoplasms
Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists.
Breast Neoplasms
Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
Breast Neoplasms
Identification of carbonic anhydrase?9 as a contributor to pingyangmycin-induced drug resistance in human tongue cancer cells.
Breast Neoplasms
Identification of cytochrome P450s required for fumitremorgin biosynthesis in Aspergillus fumigatus.
Breast Neoplasms
Identification of Functional Transcriptional Binding Sites within Chicken Abcg2 Gene Promoter and Screening Its Regulators.
Breast Neoplasms
Identification of molecular fingerprints of natural products for the inhibition of breast cancer resistance protein (BCRP).
Breast Neoplasms
Identification of Novel Breast Cancer Resistance Protein (BCRP) Inhibitors by Virtual Screening.
Breast Neoplasms
Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
Identification of Proline Residues in or near the Transmembrane Helices of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) That Are Important for Transport Activity and Substrate Specificity.
Breast Neoplasms
Identification of structural fingerprints for ABCG2 inhibition by using Monte Carlo optimization, Bayesian classification, and structural and physicochemical interpretation (SPCI) analysis.
Breast Neoplasms
Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
Breast Neoplasms
Identification of the Interaction between P-Glycoprotein and Anxa2 in Multidrug-resistant Human Breast Cancer Cells.
Breast Neoplasms
Identification of UGTs and BCRP as potential pharmacokinetic determinants of the natural flavonoid alpinetin.
Breast Neoplasms
Imaging of hepatic drug transporters with [131I]6-?-iodomethyl-19-norcholesterol.
Breast Neoplasms
Imaging of multidrug resistance in cancer.
Breast Neoplasms
Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide.
Breast Neoplasms
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.
Breast Neoplasms
Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance.
Breast Neoplasms
Immunohistochemical Analysis of DNA Repair- and Drug-Efflux-Associated Molecules in Tumor and Peritumor Areas of Glioblastoma.
Breast Neoplasms
Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer.
Breast Neoplasms
Immunohistochemical analysis of P-glycoprotein expression in breast cancer: clinical correlations.
Breast Neoplasms
Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation.
Breast Neoplasms
Immunohistochemical Detection of P-glycoprotein in Breast Cancer and Its Significance as a Prognostic Factor.
Breast Neoplasms
Immunohistochemical expression of epithelial cell markers in corneas with congenital aniridia and ocular cicatrizing pemphigoid.
Breast Neoplasms
Immunohistochemical Expression of P-glycoprotein and Breast Cancer Resistance Protein in Canine Mammary Hyperplasia, Neoplasia and Supporting Stroma.
Breast Neoplasms
IMP3 promotes chemo-resistance in breast cancer cells by regulating BCRP (ABCG2) expression.
Breast Neoplasms
Impact of a high-cholesterol diet on expression levels of Niemann-Pick C1-like 1 and intestinal transporters in rats and mice.
Breast Neoplasms
Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients.
Breast Neoplasms
Impact of bacterial and viral challenge on multidrug resistance in first- and third-trimester human placenta.
Breast Neoplasms
Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Breast Neoplasms
Impact of Breast Cancer Resistance Protein Expression on the In Vitro Efficacy of Anticancer Drugs in Pancreatic Cancer Cell Lines.
Breast Neoplasms
Impact of breast cancer resistance protein on cancer treatment outcomes.
Breast Neoplasms
Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.
Breast Neoplasms
Impact of cerebral malaria on brain distribution of mefloquine.
Breast Neoplasms
Impact of drug transporters on cellular resistance towards saquinavir and darunavir.
Breast Neoplasms
Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters.
Breast Neoplasms
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Breast Neoplasms
Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
Breast Neoplasms
Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole.
Breast Neoplasms
Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs.
Breast Neoplasms
Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Breast Neoplasms
Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Gene Dosage on Plasma Pharmacokinetics and Brain Accumulation of Dasatinib, Sorafenib, and Sunitinib.
Breast Neoplasms
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
Breast Neoplasms
Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models.
Breast Neoplasms
Impact of polyinosinic/polycytidylic acid on placental and hepatobiliary drug transporters in pregnant rats.
Breast Neoplasms
Impact of quercetin?induced changes in drug?metabolizing enzyme and transporter expression on the pharmacokinetics of cyclosporine in rats.
Breast Neoplasms
Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
Breast Neoplasms
Impact of Zn2+ on ABC Transporter Function in Intact Isolated Rat Brain Microvessels, Human Brain Capillary Endothelial Cells, and in Rat in Vivo.
Breast Neoplasms
Impaired breast cancer resistance protein mediated drug transport in plasma cells in multiple myeloma.
Breast Neoplasms
Impaired expression and function of breast cancer resistance protein (Bcrp) in brain cortex of streptozocin-induced diabetic rats.
Breast Neoplasms
Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice.
Breast Neoplasms
Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.
Breast Neoplasms
Improved In Vitro-In Vivo Correlation by Using the Unbound-Fraction-Adjusted IC50 for Breast Cancer Resistance Protein Inhibition.
Breast Neoplasms
Improved in vivo effect of chrysin as an absorption enhancer via the preparation of solid dispersion with Brij®L4 and aminoclay.
Breast Neoplasms
Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
Breast Neoplasms
In silico analysis of nsSNPs in ABCB1 gene affecting breast cancer associated protein P-glycoprotein (P-gp).
Breast Neoplasms
In silico and in vitro identification of secoisolariciresinol as a re-sensitizer of P-glycoprotein-dependent doxorubicin-resistance NCI/ADR-RES cancer cells.
Breast Neoplasms
In Silico Prediction of Inhibition of Promiscuous Breast Cancer Resistance Protein (BCRP/ABCG2).
Breast Neoplasms
In Silico Targeting Human Multidrug Transporter ABCG2 in Breast Cancer: Database Screening, Molecular Docking, and Molecular Dynamics Study.
Breast Neoplasms
In Situ shRNA Synthesis on DNA-Polylactide Nanoparticles to Treat Multidrug Resistant Breast Cancer.
Breast Neoplasms
In Vitro and In Vivo Assessment of Renal Drug Transporters in the Disposition of Mesna and Dimesna.
Breast Neoplasms
In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Breast Neoplasms
In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Breast Neoplasms
In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
Breast Neoplasms
In Vitro Approaches to Evaluate Placental Drug Transport by Using Differentiating JEG-3 Human Choriocarcinoma Cells.
Breast Neoplasms
In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Breast Neoplasms
In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants.
Breast Neoplasms
In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters.
Breast Neoplasms
In vitro assessment of the interactions of dopamine ?-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Breast Neoplasms
In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Breast Neoplasms
In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Breast Neoplasms
In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition.
Breast Neoplasms
In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes.
Breast Neoplasms
In vitro evaluation of intestinal absorption of tiliroside from Edgeworthia gardneri (Wall.) Meisn.
Breast Neoplasms
In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Breast Neoplasms
In Vitro Evaluation of the Drug Interaction Potential of Doravirine.
Breast Neoplasms
In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds.
Breast Neoplasms
In Vitro Inhibitory Effects of APINACA on Human Major Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Drug Transporters.
Breast Neoplasms
In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters.
Breast Neoplasms
In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients.
Breast Neoplasms
In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats.
Breast Neoplasms
In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Breast Neoplasms
In Vitro Models used in Drug Discovery: Drug absorption and Metabolism.
Breast Neoplasms
in vitro Modulation of P-glycoprotein, MRP-1 and BCRP Expression by Mangiferin in Doxorubicin-Treated MCF-7 Cells.
Breast Neoplasms
In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells.
Breast Neoplasms
In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
Breast Neoplasms
In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells.
Breast Neoplasms
In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition.
Breast Neoplasms
In vivo and ex vivo assessment of the interaction between ivermectin and danofloxacin in sheep.
Breast Neoplasms
In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator-activated receptor alpha (Ppar?) at the blood-brain barrier.
Breast Neoplasms
In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer.
Breast Neoplasms
In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
Breast Neoplasms
In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance.
Breast Neoplasms
In Vivo Evaluation of Limiting Brain Penetration of Probes for ?(2C)-Adrenoceptor Using Small-Animal Positron Emission Tomography.
Breast Neoplasms
In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.
Breast Neoplasms
In Vivo Exposure of Kaempferol Is Driven by Phase II Metabolic Enzymes and Efflux Transporters.
Breast Neoplasms
In Vivo Gene Expression Profile of Human Intestinal Epithelial Cells: From the Viewpoint of Drug Metabolism and Pharmacokinetics.
Breast Neoplasms
In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus.
Breast Neoplasms
In-Depth Characterization of EpiIntestinal Microtissue as a Model for Intestinal Drug Absorption and Metabolism in Human.
Breast Neoplasms
In-vitro and in situ assessment of the efflux of five antidepressants by breast cancer resistance protein.
Breast Neoplasms
In-vitro evidence of enhanced breast cancer resistance protein-mediated intestinal urate secretion by uremic toxins in Caco-2 cells.
Breast Neoplasms
Increased chemoresistance to paclitaxel in the MCF10AT series of human breast epithelial cancer cells.
Breast Neoplasms
Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298.
Breast Neoplasms
Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model.
Breast Neoplasms
Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML).
Breast Neoplasms
Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Breast Neoplasms
Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Breast Neoplasms
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Breast Neoplasms
Increased Systemic Exposure of Methotrexate by a Polyphenol-Rich Herb via Modulation on Efflux Transporters Multidrug Resistance-Associated Protein 2 and Breast Cancer Resistance Protein.
Breast Neoplasms
Increasing intratumor C/EBP-? LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Breast Neoplasms
Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer's disease.
Breast Neoplasms
Induction of apoptosis in colon cancer cells by a novel topoisomerase I inhibitor TopIn.
Breast Neoplasms
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
Breast Neoplasms
Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein.
Breast Neoplasms
Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine.
Breast Neoplasms
Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha.
Breast Neoplasms
Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases.
Breast Neoplasms
Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?
Breast Neoplasms
Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells.
Breast Neoplasms
Induction of multidrug resistance-associated protein 3 expression by diesel exhaust particle extract in human bronchial epithelial BEAS-2B cells.
Breast Neoplasms
Induction Therapy of Retinoic Acid with a Temozolomide-Loaded Gold Nanoparticle-Associated Ultrasound Effect on Glioblastoma Cancer Stem-Like Colonies.
Breast Neoplasms
Inflammatory Regulation of ABC Efflux Transporter Expression and Function in Microglia.
Breast Neoplasms
Influence of ABC transporters on the excretion of ciprofloxacin assessed with PET imaging in mice.
Breast Neoplasms
Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients.
Breast Neoplasms
Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India.
Breast Neoplasms
Influence of ABCB1 genetic variants in breast cancer treatment outcomes.
Breast Neoplasms
Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients.
Breast Neoplasms
Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.
Breast Neoplasms
Influence of acetaminophen vehicle on regulation of transporter gene expression during hepatotoxicity.
Breast Neoplasms
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
Breast Neoplasms
Influence of biliary cirrhosis on the detoxification and elimination of a food derived carcinogen.
Breast Neoplasms
Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
Breast Neoplasms
Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice.
Breast Neoplasms
Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
Breast Neoplasms
Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease.
Breast Neoplasms
Influence of Drug Transporters and UGT Polymorphisms on Pharmacokinetics of Phenolic glucuronide Metabolite of Mycophenolic Acid in Japanese Renal Transplant Recipients.
Breast Neoplasms
Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment.
Breast Neoplasms
Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances.
Breast Neoplasms
Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects.
Breast Neoplasms
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Breast Neoplasms
Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer.
Breast Neoplasms
Influx and efflux transporters contribute to the increased dermal exposure to active metabolite of regorafenib after repeated oral administration in mice.
Breast Neoplasms
Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
Breast Neoplasms
Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drug-drug interactions of drugs of abuse.
Breast Neoplasms
Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.
Breast Neoplasms
Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines.
Breast Neoplasms
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.
Breast Neoplasms
Inhibition of breast cancer resistance protein (ABCG2) in human myeloid dendritic cells induces potent tolerogenic functions during LPS stimulation.
Breast Neoplasms
Inhibition of Breast Cancer Resistance Protein and Multidrug Resistance Associated Protein 2 by Natural Compounds and Their Derivatives.
Breast Neoplasms
Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin.
Breast Neoplasms
Inhibition of human MDR1 and BCRP transporter ATPase activity by organochlorine and pyrethroid insecticides.
Breast Neoplasms
Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.
Breast Neoplasms
Inhibition of MALAT1 reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer.
Breast Neoplasms
Inhibition of P-glycoprotein and Glutathione S-transferase-pi mediated resistance by fluoxetine in MCF-7/ADM cells.
Breast Neoplasms
Inhibition of P-glycoprotein by natural products in human breast cancer cells.
Breast Neoplasms
Inhibition of P-glycoprotein-induced multidrug resistance by a clerodane-type diterpenoid from Sindora sumatrana.
Breast Neoplasms
Inhibition of P-glycoprotein-mediated multidrug resistance by unfractionated heparin: a new potential chemosensitizer for cancer therapy.
Breast Neoplasms
Inhibition of proliferation and induction of apoptosis in human breast cancer cells by lauryl gallate.
Breast Neoplasms
Inhibition of protein synthesis and JNK activation are not required for cell death induced by anisomycin and anisomycin analogues.
Breast Neoplasms
Inhibition of the Human ABC Efflux Transporters P-gp and BCRP by the BDE-47 Hydroxylated Metabolite 6-OH-BDE-47: Considerations for Human Exposure.
Breast Neoplasms
Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications.
Breast Neoplasms
Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids.
Breast Neoplasms
Inhibitory effects of terpenoids on multidrug resistance-associated protein 2- and breast cancer resistance protein-mediated transport.
Breast Neoplasms
Inner Blood-Retinal Barrier Dominantly Expresses Breast Cancer Resistance Protein: Comparative Quantitative Targeted Absolute Proteomics Study of CNS Barriers in Pig.
Breast Neoplasms
Insight into structural features of phenyltetrazole derivatives as ABCG2 inhibitors for the treatment of multidrug resistance in cancer.
Breast Neoplasms
Insight into the Cooperation of P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) at the Blood-Brain Barrier: A Case Study Examining Sorafenib Efflux Clearance.
Breast Neoplasms
Insight into the transplacental transport mechanism of methoxylated polybrominated diphenyl ethers using a BeWo cell monolayer model.
Breast Neoplasms
Insulin suppresses the expression and function of breast cancer resistance protein in primary cultures of rat brain microvessel endothelial cells.
Breast Neoplasms
Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant.
Breast Neoplasms
Interaction between CD147 and P-glycoprotein and their regulation by ubiquitination in breast cancer cells.
Breast Neoplasms
Interaction between CD9 and PI3K?p85 activates the PI3K/AKT signaling pathway in B?lineage acute lymphoblastic leukemia.
Breast Neoplasms
Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.
Breast Neoplasms
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Breast Neoplasms
Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).
Breast Neoplasms
Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep.
Breast Neoplasms
Interaction of food additives with intestinal efflux transporters.
Breast Neoplasms
Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography.
Breast Neoplasms
Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters.
Breast Neoplasms
Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter.
Breast Neoplasms
Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Breast Neoplasms
Interaction of Oligomeric Breast Cancer Resistant Protein (BCRP) with Adjudin: A Male Contraceptive with Anti-Cancer Activity.
Breast Neoplasms
Interaction of the breast cancer resistance protein with plant polyphenols.
Breast Neoplasms
Interaction of Thiazolidinediones (Glitazones) with the ATP-Binding Cassette Transporters P-Glycoprotein and Breast Cancer Resistance Protein.
Breast Neoplasms
Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
Breast Neoplasms
Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro.
Breast Neoplasms
Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro.
Breast Neoplasms
Interaction with membrane mimics of transmembrane fragments 16 and 17 from the human multidrug resistance ABC transporter 1 (hMRP1/ABCC1) and two of their tryptophan variants.
Breast Neoplasms
Interactions between ABC-transport proteins and the secondary Fusarium metabolites enniatin and beauvericin.
Breast Neoplasms
Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients.
Breast Neoplasms
Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics.
Breast Neoplasms
Interactions between riluzole and ABCG2/BCRP transporter.
Breast Neoplasms
Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging.
Breast Neoplasms
Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).
Breast Neoplasms
Interactions of bilastine, a new oral H? antihistamine, with human transporter systems.
Breast Neoplasms
Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
Breast Neoplasms
Interactions of cyclosporin a with breast cancer resistance protein.
Breast Neoplasms
Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP.
Breast Neoplasms
Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in rats.
Breast Neoplasms
Interactions of retinoids with the ABC transporters P-glycoprotein and Breast Cancer Resistance Protein.
Breast Neoplasms
Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.
Breast Neoplasms
Interactions of tenofovir, Lamivudine, abacavir and Didanosine in primary human cells.
Breast Neoplasms
Interactions of the major effective components in Shengmai formula with breast cancer resistance protein at the cellular and vesicular levels.
Breast Neoplasms
Interindividual regulation of the BCRP/ABCG2 transporter in term human placentas.
Breast Neoplasms
Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype.
Breast Neoplasms
Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX.
Breast Neoplasms
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
Breast Neoplasms
Interplay of Breast Cancer Resistance Protein (BCRP) and Metabolizing Enzymes.
Breast Neoplasms
Interplay of Drug Metabolizing CYP450 Enzymes and ABC Transporters in the Blood-Brain Barrier.
Breast Neoplasms
Interplay of Efflux Transporters with Glucuronidation and Its Impact on Subcellular Aglycone and Glucuronide Disposition: A Case Study with Kaempferol.
Breast Neoplasms
Interplay of metabolizing enzymes and transporter of xenobiotics.
Breast Neoplasms
Interview with irving w wainer.
Breast Neoplasms
Intestinal absorption mechanism of mirabegron, a potent and selective ??-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.
Breast Neoplasms
Intestinal absorption mechanisms of 2'-deoxy-2'-?-fluoro-4'-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein.
Breast Neoplasms
Intestinal absorption mechanisms of araloside A in situ single-pass intestinal perfusion and in vitro Caco-2 cell model.
Breast Neoplasms
Intestinal Absorption of Isoalantolactone and Alantolactone, Two Sesquiterpene Lactones from Radix Inulae, Using Caco-2 Cells.
Breast Neoplasms
Intestinal absorption of raltitrexed and evaluation of the effects of absorption enhancers.
Breast Neoplasms
Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Breast Neoplasms
Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol.
Breast Neoplasms
Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2).
Breast Neoplasms
Intestinal drug efflux: formulation and food effects.
Breast Neoplasms
Intestinal drug transport: ex vivo evaluation of the interactions between ABC transporters and anthelmintic molecules.
Breast Neoplasms
Intestinal efflux transporters and drug absorption.
Breast Neoplasms
Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition.
Breast Neoplasms
Intestinal expression of mouse Abcg2/Bcrp gene is under the control of circadian clock-activating transcription factor-4 pathway.
Breast Neoplasms
Intestinal transport of sophocarpine across the Caco-2 cell monolayer model and quantification by LC/MS.
Breast Neoplasms
Intra-herb pharmacokinetics interaction between quercetin and isorhamentin.
Breast Neoplasms
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes.
Breast Neoplasms
Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression.
Breast Neoplasms
Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates.
Breast Neoplasms
Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).
Breast Neoplasms
Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption.
Breast Neoplasms
Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
Breast Neoplasms
Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
Breast Neoplasms
Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.
Breast Neoplasms
Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
Breast Neoplasms
Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study.
Breast Neoplasms
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
Breast Neoplasms
Investigation of the effect of active efflux at the blood-brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system.
Breast Neoplasms
Investigation of the functional single-nucleotide polymorphisms in the BCRP transporter and susceptibility to colorectal cancer.
Breast Neoplasms
Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse.
Breast Neoplasms
Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin.
Breast Neoplasms
Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones.
Breast Neoplasms
Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect.
Breast Neoplasms
Involvement of breast cancer resistance protein (BCRP/ABCG2) in the secretion of danofloxacin into milk: interaction with ivermectin.
Breast Neoplasms
Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice.
Breast Neoplasms
Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide.
Breast Neoplasms
Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1.
Breast Neoplasms
Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics.
Breast Neoplasms
Involvement of multiple efflux transporters in hepatic disposition of fexofenadine.
Breast Neoplasms
Involvement of NRF2 Signaling in Doxorubicin Resistance of Cancer Stem Cell-Enriched Colonospheres.
Breast Neoplasms
Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity.
Breast Neoplasms
Involvement of P-glycoprotein, Multidrug Resistance Protein 2 and Breast Cancer Resistance Protein in the Transport of Belotecan and Topotecan in Caco-2 and MDCKII Cells.
Breast Neoplasms
Involvement of phospholipase C in heat-shock-induced phosphorylation of P-glycoprotein in multidrug resistant human breast cancer cells.
Breast Neoplasms
Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: the prevention of curcumin.
Breast Neoplasms
Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites.
Breast Neoplasms
Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
Breast Neoplasms
Irinotecan pathway genotype analysis to predict pharmacokinetics.
Breast Neoplasms
Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters.
Breast Neoplasms
Isolation and Characterization of a Stem Cell Side-Population from Mouse Hair Follicles.
Breast Neoplasms
Isolation of endothelial cells, pericytes and astrocytes from mouse brain.
Breast Neoplasms
Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer.
Breast Neoplasms
Isopetasin and S-isopetasin as novel P-glycoprotein inhibitors against multidrug-resistant cancer cells.
Breast Neoplasms
Ixabepilone, a Novel Microtubule-Targeting Agent for Breast Cancer, is a Substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not Breast Cancer Resistance Protein (BCRP/ABCG2).
Breast Neoplasms
Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
Breast Neoplasms
Jatrophane diterpenoids from Euphorbia sororia as potent modulators against P-glycoprotein-based multidrug resistance.
Breast Neoplasms
Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice.
Breast Neoplasms
Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: role for drug transporters?
Breast Neoplasms
Keynote address: multidrug resistance: a pleiotropic response to cytotoxic drugs.
Breast Neoplasms
Kinetic Analysis of the Cooperation of P-glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone.
Breast Neoplasms
Kinetic modelling of the role of the aldehyde dehydrogenase enzyme and the breast cancer resistance protein in drug resistance and transport.
Breast Neoplasms
Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity.
Breast Neoplasms
Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion.
Breast Neoplasms
Korean red ginseng extract enhances paclitaxel distribution to mammary tumors and its oral bioavailability by P-glycoprotein inhibition.
Breast Neoplasms
L1210 cells cultivated under the selection pressure of doxorubicin or vincristine express common mechanisms of multidrug resistance based on the overexpression of P-glycoprotein.
Breast Neoplasms
Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.
Breast Neoplasms
Lack of competition of substrates for P-glycoprotein in MCF-7 breast cancer cells overexpressing MDR1.
Breast Neoplasms
Lack of glutathione conjugation to adriamycin in human breast cancer MCF-7/DOX cells. Inhibition of glutathione S-transferase p1-1 by glutathione conjugates from anthracyclines.
Breast Neoplasms
Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
Breast Neoplasms
Lack of Interactions between Breast Cancer Resistance Protein (BCRP/ABCG2) and Selected Antiepileptic Agents.
Breast Neoplasms
Laminin 221 fragment is suitable for the differentiation of human induced pluripotent stem cells into brain microvascular endothelial-like cells with robust barrier integrity.
Breast Neoplasms
Lathyrol diterpenes as modulators of P-glycoprotein dependent multidrug resistance: structure-activity relationship studies on Euphorbia factor L3 derivatives.
Breast Neoplasms
Layer II of placental syncytiotrophoblasts expresses MDR1 and BCRP at the apical membrane in rodents.
Breast Neoplasms
LC-MS/MS Mediated Absolute Quantification and Comparison of Bile Salt Export Pump and Breast Cancer Resistance Protein in Livers and Hepatocytes across Species.
Breast Neoplasms
Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Breast Neoplasms
Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells.
Breast Neoplasms
Lidocine potentiates the cytotoxicity of 5-fluorouracil to choriocarcinoma cells by downregulating ABC transport proteins expression.
Breast Neoplasms
LightSpot®-FL-1 Fluorescent Probe: An Innovative Tool for Cancer Drug Resistance Analysis by Direct Detection and Quantification of the P-glycoprotein (P-gp) on Monolayer Culture and Spheroid Triple Negative Breast Cancer Models.
Breast Neoplasms
Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics.
Breast Neoplasms
Lipopolysaccharide increases cell surface P-glycoprotein that exhibits diminished activity in intestinal epithelial cells.
Breast Neoplasms
Lipoproteins modulate growth and P-glycoprotein expression in drug-resistant HER2-overexpressed breast cancer cells.
Breast Neoplasms
Liquid chromatography method for the quantitation of the breast cancer resistance protein ABCG2 inhibitor fumitremorgin C and its chemical analogues in mouse plasma and tissues.
Breast Neoplasms
Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver.
Breast Neoplasms
Local Drug-Drug Interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) Increases Drug Accumulation in Heart.
Breast Neoplasms
Localisation of breast cancer resistance protein in microvessel endothelium of human brain.
Breast Neoplasms
Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones.
Breast Neoplasms
Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain.
Breast Neoplasms
Localization of putative binding sites for cyclic guanosine monophosphate and the anti-cancer drug 5-fluoro-2'-deoxyuridine-5'-monophosphate on ABCC11 in silico models.
Breast Neoplasms
Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro.
Breast Neoplasms
Localization of the placental BCRP/ABCG2 transporter to lipid rafts: Role for cholesterol in mediating efflux activity.
Breast Neoplasms
Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.
Breast Neoplasms
Long-term administration of tenofovir or emtricitabine to pregnant rats; effect on Abcb1a, Abcb1b and Abcg2 expression in the placenta and in maternal and fetal organs.
Breast Neoplasms
Long-term PM2.5 exposure increases the risk of non-small cell lung cancer (NSCLC) progression by enhancing interleukin-17a (IL-17a)-regulated proliferation and metastasis.
Breast Neoplasms
Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis.
Breast Neoplasms
Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells.
Breast Neoplasms
Loss of protein kinase C?/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines.
Breast Neoplasms
Loss of TGF? Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
Breast Neoplasms
Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.
Breast Neoplasms
Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor.
Breast Neoplasms
Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer.
Breast Neoplasms
Luteolin enhances the bioavailability of benzo(a)pyrene in human colon carcinoma cells.
Breast Neoplasms
Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells.
Breast Neoplasms
Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy.
Breast Neoplasms
Malaria in pregnancy regulates P-glycoprotein (P-gp/Abcb1a) and ABCA1 efflux transporters in the Mouse Visceral Yolk Sac.
Breast Neoplasms
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.
Breast Neoplasms
Mammalian membrane protein expression in baculovirus-infected insect cells.
Breast Neoplasms
Marine natural products as breast cancer resistance protein inhibitors.
Breast Neoplasms
Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.
Breast Neoplasms
Maternal exposure to bisphenol A induces fetal growth restriction via upregulating the expression of estrogen receptors.
Breast Neoplasms
Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies.
Breast Neoplasms
MDM2 Antagonist Nutlin-3a Reverses Mitoxantrone Resistance by Inhibiting Breast Cancer Resistance Protein Mediated Drug Transport.
Breast Neoplasms
MDR1 causes resistance to the antitumour drug miltefosine.
Breast Neoplasms
MDR1 gene expression in primary and advanced breast cancer.
Breast Neoplasms
MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
Breast Neoplasms
Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [11C]Tariquidar and PET in Humans and Mice.
Breast Neoplasms
Mechanism of selectivity of an angiogenesis inhibitor from screening a genome-wide set of Saccharomyces cerevisiae deletion strains.
Breast Neoplasms
Mechanism of the efflux transport of demethoxycurcumin-O-glucuronides in HeLa cells stably transfected with UDP-glucuronosyltransferase 1A1.
Breast Neoplasms
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breast Neoplasms
Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
Breast Neoplasms
Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Breast Neoplasms
Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.
Breast Neoplasms
Mechanisms of the penetration of blood-borne substances into the brain.
Breast Neoplasms
Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles.
Breast Neoplasms
Mechanistic Basis of Cabotegravir-Glucuronide Disposition in Humans.
Breast Neoplasms
Mechanistic Studies on the Absorption and Disposition of Scutellarin in Humans: Selective OATP2B1-Mediated Hepatic Uptake Is a Likely Key Determinant for Its Unique Pharmacokinetic Characteristics.
Breast Neoplasms
Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence.
Breast Neoplasms
Metabolism and disposition of corylifol A from Psoralea corylifolia: metabolite mapping, isozyme contribution, species differences, and identification of efflux transporters for corylifol A-O-glucuronide in HeLa1A1 cells.
Breast Neoplasms
Metabolism and transport of oxazaphosphorines and the clinical implications.
Breast Neoplasms
Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers.
Breast Neoplasms
Metabolism, Transport and Drug-Drug Interactions of Silymarin.
Breast Neoplasms
Metabolites of ginsenosides as novel BCRP inhibitors.
Breast Neoplasms
Metabolome Analysis Reveals Dermal Histamine Accumulation in Murine Dermatitis Provoked by Genetic Deletion of P-Glycoprotein and Breast Cancer Resistance Protein.
Breast Neoplasms
Methanol Extract of Aerial Parts of Pavetta indica L. Enhances the Cytotoxic Effect of Doxorubicin and Induces Radiation Sensitization in MDA-MB-231 Triple-Negative Breast Cancer Cells.
Breast Neoplasms
Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1.
Breast Neoplasms
Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.
Breast Neoplasms
Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.
Breast Neoplasms
Methylation and its role in the disposition of tanshinol, a cardiovascular carboxylic catechol from Salvia miltiorrhiza roots (Danshen).
Breast Neoplasms
Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells.
Breast Neoplasms
METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner.
Breast Neoplasms
Microdialysis combined with RRLC-MS/MS for the pharmacokinetics of two major alkaloids of Bi qi capsule and the potential roles of P-gp and BCRP on their penetration.
Breast Neoplasms
Microfilament depletion and circumvention of multiple drug resistance by sphinxolides.
Breast Neoplasms
Microfluidic studies of hydrostatic pressure-enhanced doxorubicin resistance in human breast cancer cells.
Breast Neoplasms
Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein.
Breast Neoplasms
MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II.
Breast Neoplasms
MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-?B signaling pathway in breast cancer.
Breast Neoplasms
MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1
Breast Neoplasms
MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1.
Breast Neoplasms
MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells.
Breast Neoplasms
Microtubule-targeting anticancer drug eribulin induces drug efflux transporter P-glycoprotein.
Breast Neoplasms
Microvillus-Specific Protein Tyrosine Phosphatase SAP-1 Plays a Role in Regulating the Intestinal Paracellular Transport of Macromolecules.
Breast Neoplasms
miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1.
Breast Neoplasms
miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1.
Breast Neoplasms
MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
MiR-19b non-canonical binding is directed by HuR and confers chemosensitivity through regulation of P-glycoprotein in breast cancer.
Breast Neoplasms
MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1).
Breast Neoplasms
MiR-331-3p Links to Drug Resistance of Pancreatic Cancer Cells by Activating WNT/?-Catenin Signal via ST7L.
Breast Neoplasms
MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
miR-7 Reverses Breast Cancer Resistance To Chemotherapy By Targeting MRP1 And BCL2.
Breast Neoplasms
miRNA-106a Promotes Breast Cancer Cell Proliferation, Clonogenicity, Migration, and Invasion Through Inhibiting Apoptosis and Chemosensitivity.
Breast Neoplasms
Mitochondria of a human multidrug-resistant hepatocellular carcinoma cell line constitutively express inducible nitric oxide synthase in the inner membrane.
Breast Neoplasms
Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin.
Breast Neoplasms
Mitochondrial autophagosomes as a mechanism of drug resistance in breast carcinoma.
Breast Neoplasms
Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines.
Breast Neoplasms
Mitochondrial localization of P-glycoprotein in the human breast cancer cell line MCF-7/ADM and its functional characterization.
Breast Neoplasms
Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype.
Breast Neoplasms
Modulation of ABCC1 and ABCG2 Proteins by Ouabain in Human Breast Cancer Cells.
Breast Neoplasms
Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.
Breast Neoplasms
Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues.
Breast Neoplasms
Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
Breast Neoplasms
Modulation of breast cancer resistance protein mediated atypical multidrug resistance using RNA interference delivered by adenovirus.
Breast Neoplasms
Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome.
Breast Neoplasms
Modulation of hepatic ABC transporters by Eruca vesicaria intake: Potential diet-drug interactions.
Breast Neoplasms
Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter.
Breast Neoplasms
Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
Breast Neoplasms
Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids.
Breast Neoplasms
Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
Breast Neoplasms
Modulation of P-glycoprotein-mediated resistance by kaempferol derivatives isolated from Zingiber zerumbet.
Breast Neoplasms
Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
Breast Neoplasms
Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.
Breast Neoplasms
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.
Breast Neoplasms
Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Breast Neoplasms
Modulation of Wnt/?-catenin signaling promotes blood-brain barrier phenotype in cultured brain endothelial cells.
Breast Neoplasms
Molecular and functional characterization of p-glycoprotein in vitro.
Breast Neoplasms
Molecular basis of antifolate resistance.
Breast Neoplasms
Molecular biology of breast cancer stem cells: Potential clinical applications.
Breast Neoplasms
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
Breast Neoplasms
Molecular determinants of treatment response in human germ cell tumors.
Breast Neoplasms
Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.
Breast Neoplasms
Molecular mechanism of ATP-dependent solute transport by multidrug resistance-associated protein 1.
Breast Neoplasms
Molecular mechanisms for tumour resistance to chemotherapy.
Breast Neoplasms
Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
Breast Neoplasms
Molecular transport through primary human small intestinal monolayers by culture on a collagen scaffold with a gradient of chemical cross-linking.
Breast Neoplasms
Monoclonal antibodies as a tool for structure-function studies of the MDR1-P-glycoprotein.
Breast Neoplasms
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
Breast Neoplasms
MRP and MDR1 gene expression in primary breast carcinomas.
Breast Neoplasms
MRP as a new predictive marker of tamoxifen efficiency in treatment of estrogen receptor-positive breast cancer.
Breast Neoplasms
MRP isoforms and BCRP mediate sulfate conjugate efflux out of BeWo cells.
Breast Neoplasms
MRP-1 and BCRP Promote the Externalization of Phosphatidylserine in Oxalate-treated Renal Epithelial Cells: Implications for Calcium Oxalate Urolithiasis.
Breast Neoplasms
MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells.
Breast Neoplasms
MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting.
Breast Neoplasms
MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer.
Breast Neoplasms
Multi-gene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19 and ABCB1.
Breast Neoplasms
Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.
Breast Neoplasms
Multidrug resistance in hematological malignancy.
Breast Neoplasms
Multidrug resistance in human tumors--molecular diagnosis and clinical significance.
Breast Neoplasms
Multidrug resistance in locally advanced breast cancer.
Breast Neoplasms
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Breast Neoplasms
Multidrug Resistance Modulation Activity of Silybin Derivatives and Their Anti-inflammatory Potential.
Breast Neoplasms
Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells.
Breast Neoplasms
Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.
Breast Neoplasms
Multidrug resistance protein and glutathione S-transferase P1-1 act in synergy to confer protection from 4-nitroquinoline 1-oxide toxicity.
Breast Neoplasms
Multidrug resistance protein in recurrent breast cancer.
Breast Neoplasms
Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment.
Breast Neoplasms
Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats.
Breast Neoplasms
Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.
Breast Neoplasms
Multidrug resistance related molecules in human and murine lung.
Breast Neoplasms
Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay.
Breast Neoplasms
Multidrug Resistance Reversal Effects of Aminated Thioxanthones and Interaction with Cytochrome P450 3A4.
Breast Neoplasms
Multidrug resistance transporter-1 and breast cancer resistance protein protect against ovarian toxicity, and are essential in ovarian physiology.
Breast Neoplasms
Multidrug resistance transporters and modulation.
Breast Neoplasms
Multidrug Resistance-Associated Protein 1 Mediates 15-Deoxy-?(12,14)-prostaglandin J(2)-Induced Expression of Glutamate Cysteine Ligase Expression via Nrf2 Signaling in Human Breast Cancer Cells.
Breast Neoplasms
Multidrug resistance-associated protein 2 is involved in the efflux of Aconitum alkaloids determined by MRP2-MDCKII cells.
Breast Neoplasms
Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice.
Breast Neoplasms
Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide.
Breast Neoplasms
Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Breast Neoplasms
Multidrug resistance-associated proteins are involved in the transport of the glutathione conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells.
Breast Neoplasms
Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.
Breast Neoplasms
Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1.
Breast Neoplasms
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer.
Breast Neoplasms
Multiple drug resistance, antimutagenesis and anticarcinogenesis.
Breast Neoplasms
Multiple Drug Transporters Contribute to the Placental Transfer of Emtricitabine.
Breast Neoplasms
Multiple drug transporters mediate the placental transport of sulpiride.
Breast Neoplasms
Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine.
Breast Neoplasms
Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression.
Breast Neoplasms
Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1.
Breast Neoplasms
Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.
Breast Neoplasms
Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir.
Breast Neoplasms
Muscle to Brain Partitioning as Measure of Transporter-Mediated Efflux at the Rat Blood-Brain Barrier and Its Implementation into Compound Optimization in Drug Discovery.
Breast Neoplasms
N-desmethyl-Loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier.
Breast Neoplasms
N-glycosylation of ABC transporters is associated with functional activity in sandwich-cultured rat hepatocytes.
Breast Neoplasms
Nanodrug delivery in reversing multidrug resistance in cancer cells.
Breast Neoplasms
Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer.
Breast Neoplasms
Nanoparticles for Local Drug Delivery to the Oral Mucosa: Proof of Principle Studies.
Breast Neoplasms
Nanostructured lipid-carrageenan hybrid carriers (NLCCs) for controlled delivery of mitoxantrone hydrochloride to enhance anticancer activity bypassing the BCRP-mediated efflux.
Breast Neoplasms
Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
Breast Neoplasms
Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.
Breast Neoplasms
Natural products as multidrug resistance modulators in cancer.
Breast Neoplasms
Navigating Transporter Sciences in Pharmacokinetics Characterization Using Extended Clearance Classification System (ECCS).
Breast Neoplasms
neo-Clerodane diterpenoids from Scutellaria barbata mediated inhibition of P-glycoprotein in MCF-7/ADR cells.
Breast Neoplasms
Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer.
Breast Neoplasms
Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP.
Breast Neoplasms
Neonicotinoid pesticides poorly interact with human drug transporters.
Breast Neoplasms
Neuropilin-1 promotes the oncogenic Tenascin-C/integrin ?3 pathway and modulates chemoresistance in breast cancer cells.
Breast Neoplasms
New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors.
Breast Neoplasms
New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.
Breast Neoplasms
New Insights into the Carrier-Mediated Transport of Estrone-3-sulfate in the Caco-2 Cell Model.
Breast Neoplasms
New proteins configure a brain drug resistance map in tuberous sclerosis.
Breast Neoplasms
New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Breast Neoplasms
New structure-activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity.
Breast Neoplasms
New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies.
Breast Neoplasms
New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.
Breast Neoplasms
NHERF1/EBP50 as a Target for Modulation of MRP Function in HepG2 Cells.
Breast Neoplasms
Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice.
Breast Neoplasms
No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer.
Breast Neoplasms
No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.
Breast Neoplasms
Non-coding polymorphisms in nucleotide binding domain 1 in ABCC1 gene associate with transcript level and survival of patients with breast cancer.
Breast Neoplasms
Nongenotoxic ABCB1 activator tetraphenylphosphonium can contribute to doxorubicin resistance in MX-1 breast cancer cell line.
Breast Neoplasms
Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption.
Breast Neoplasms
Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors.
Breast Neoplasms
Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?
Breast Neoplasms
Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
Breast Neoplasms
Novel 3,4-Dihydroisocoumarins Inhibit Human P-gp and BCRP in Multidrug Resistant Tumors and Demonstrate Substrate Inhibition of Yeast Pdr5.
Breast Neoplasms
Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage.
Breast Neoplasms
Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
Breast Neoplasms
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Breast Neoplasms
Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance.
Breast Neoplasms
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
Breast Neoplasms
Novel mechanisms of drug resistance in leukemia.
Breast Neoplasms
Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells.
Breast Neoplasms
Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride.
Breast Neoplasms
Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators.
Breast Neoplasms
Novel Tubulin Polymerization Inhibitors Overcome Multidrug Resistance and Reduce Melanoma Lung Metastasis.
Breast Neoplasms
NP-1250, an ABCG2 inhibitor, induces apoptotic cell death in mitoxantrone-resistant breast carcinoma MCF7 cells via a caspase-independent pathway.
Breast Neoplasms
Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood-brain and blood-spinal cord barriers.
Breast Neoplasms
Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma.
Breast Neoplasms
Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma.
Breast Neoplasms
Nuclear receptors in regulation of biotransformation enzymes and drug transporters in the placental barrier.
Breast Neoplasms
Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.
Breast Neoplasms
Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
Breast Neoplasms
Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1.
Breast Neoplasms
Oleic acid decreases BCRP mediated efflux of mitoxantrone in Caco-2 cell monolayers.
Breast Neoplasms
Oleic acid increases intestinal absorption of the BCRP/ABCG2 substrate, mitoxantrone, in mice.
Breast Neoplasms
Oleic acid increases uptake and decreases the P-gp-mediated efflux of the veterinary anthelmintic Ivermectin.
Breast Neoplasms
Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells.
Breast Neoplasms
Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.
Breast Neoplasms
Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1).
Breast Neoplasms
One ring is not enough to rule them all. Albumin-dependent ABCG2-mediated transport of chlorophyll-derived photosensitizers.
Breast Neoplasms
Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain.
Breast Neoplasms
Opposite regulation of hepatic breast cancer resistance protein in type 1 and 2 diabetes mellitus.
Breast Neoplasms
Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.
Breast Neoplasms
Optimization of Western blotting analysis for the isolation and detection of membrane xenobiotic transporter ABCG2.
Breast Neoplasms
Optimizing the flavanone core toward new selective nitrogen-containing modulators of ABC transporters.
Breast Neoplasms
Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Breast Neoplasms
Oral drug delivery utilizing intestinal OATP transporters.
Breast Neoplasms
Oral hypoglycemic therapy: understanding the mechanisms of transplacental transfer.
Breast Neoplasms
Oral sulfasalazine as a clinical BCRP probe substrate: Pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.
Breast Neoplasms
Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
Breast Neoplasms
Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta.
Breast Neoplasms
Organic cation transporter/solute carrier family 22a is involved in drug transfer into milk in mice.
Breast Neoplasms
Organic Cation Transporters are Involved in Fluoxetine Transport Across the Blood-Brain Barrier in Vivo and in Vitro.
Breast Neoplasms
Overcoming anticancer resistance by photodynamic therapy-related efflux pump deactivation and ultrasound-mediated improved drug delivery efficiency.
Breast Neoplasms
Overcoming drug-resistance in lung cancer cells by paclitaxel loaded galactoxyloglucan nanoparticles.
Breast Neoplasms
Overcoming multidrug resistance by intracellular drug release and inhibiting p-glycoprotein efflux in breast cancer.
Breast Neoplasms
Overcoming multidrug resistance of breast cancer cells by the micellar doxorubicin nanoparticles of mPEG-PCL-graft-cellulose.
Breast Neoplasms
Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics.
Breast Neoplasms
Overcoming Multidrug Resistance: Flavonoid and Terpenoid Nitrogen-Containing Derivatives as ABC Transporter Modulators.
Breast Neoplasms
Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
Breast Neoplasms
Overexpression of RSK4 reverses doxorubicin resistance in human breast cancer cells via PI3K/Akt signaling pathway.
Breast Neoplasms
Overexpression of the ATP binding cassette gene ABCA1 determines resistance to Curcumin in M14 melanoma cells.
Breast Neoplasms
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Breast Neoplasms
Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.
Breast Neoplasms
Overlapping Substrate and Inhibitor Specificity of Human and Murine ABCG2.
Breast Neoplasms
Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.
Breast Neoplasms
Oxidative Stress Promotes Doxorubicin-Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions.
Breast Neoplasms
Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.
Breast Neoplasms
P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas.
Breast Neoplasms
P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Restrict Brain Accumulation of the Active Sunitinib Metabolite N-Desethyl Sunitinib.
Breast Neoplasms
P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
Breast Neoplasms
P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
Breast Neoplasms
P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Breast Neoplasms
P-glycoprotein (Mdr1a/b) and Breast Cancer Resistance Protein (BCRP) decrease the uptake of hydrophobic alkyl triphenylphosphonium cations by the brain.
Breast Neoplasms
p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance.
Breast Neoplasms
P-glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor.
Breast Neoplasms
P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats.
Breast Neoplasms
P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages.
Breast Neoplasms
P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the Aurora-B Kinase Inhibitor barasertib-hQPA.
Breast Neoplasms
P-Glycoprotein and Breast Cancer Resistance Protein in Canine Inflammatory and Noninflammatory Grade III Mammary Carcinomas.
Breast Neoplasms
P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Breast Neoplasms
P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta.
Breast Neoplasms
P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Breast Neoplasms
P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib.
Breast Neoplasms
P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan.
Breast Neoplasms
P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients.
Breast Neoplasms
P-Glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings.
Breast Neoplasms
P-glycoprotein and progesterone receptor in human breast cancer.
Breast Neoplasms
P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells.
Breast Neoplasms
P-glycoprotein down-regulates expression of breast cancer resistance protein in a drug-free state.
Breast Neoplasms
P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis.
Breast Neoplasms
p-Glycoprotein expression as a predictor of breast cancer recurrence.
Breast Neoplasms
P-glycoprotein expression as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Breast Neoplasms
P-glycoprotein expression in canine mammary gland tumours related with myoepithelial cells.
Breast Neoplasms
P-glycoprotein expression in human breast cancer cells.
Breast Neoplasms
P-Glycoprotein Expression in Indian Breast Cancer Patients with Reference to Molecular Subtypes and Response to Anthracycline-Based Chemotherapy-a Prospective Clinical Study from a Developing Country.
Breast Neoplasms
P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy.
Breast Neoplasms
P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies.
Breast Neoplasms
P-glycoprotein expression in primary breast cancer.
Breast Neoplasms
P-glycoprotein expression in treated and untreated human breast cancer.
Breast Neoplasms
P-glycoprotein expression predicts response to NACT in breast cancer.
Breast Neoplasms
P-glycoprotein gene amplification or overexpression is not detected in clinical breast cancer specimens.
Breast Neoplasms
P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer.
Breast Neoplasms
P-glycoprotein in breast cancer.
Breast Neoplasms
P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids.
Breast Neoplasms
P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Breast Neoplasms
P-glycoprotein Inhibitor Tariquidar Potentiates Efficacy of Astragaloside IV in Experimental Autoimmune Encephalomyelitis Mice.
Breast Neoplasms
P-glycoprotein inhibitory activity of two phenolic compounds, (-)-syringaresinol and tricin from Sasa borealis.
Breast Neoplasms
P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model.
Breast Neoplasms
P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models.
Breast Neoplasms
P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.
Breast Neoplasms
P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
Breast Neoplasms
P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
Breast Neoplasms
P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells.
Breast Neoplasms
P-Glycoprotein, Breast Cancer Resistance Protein, Organic Anion Transporter 3, and Transporting Peptide 1a4 during Blood-Brain Barrier Maturation: Involvement of Wnt/?-Catenin and Endothelin-1 Signaling.
Breast Neoplasms
P-glycoprotein, metallothionein and NM23 protein expressions in breast carcinoma.
Breast Neoplasms
P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.
Breast Neoplasms
P-Glycoprotein, not BCRP, Limits the Brain Uptake of [(18)F]Mefway in Rodent Brain.
Breast Neoplasms
P-glycoprotein--a clinical target in drug-refractory epilepsy?
Breast Neoplasms
P-glycoprotein-mediated transport of oxytetracycline in the Caco-2 cell model.
Breast Neoplasms
P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer.
Breast Neoplasms
p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer.
Breast Neoplasms
Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety.
Breast Neoplasms
Paclitaxel-induced cytotoxicity--the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein.
Breast Neoplasms
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Breast Neoplasms
Paeonol reverses paclitaxel resistance in human breast cancer cells by regulating the expression of transgelin 2.
Breast Neoplasms
Paliperidone, a relatively novel atypical antipsychotic drug, is a substrate for breast cancer resistance protein.
Breast Neoplasms
Paracellular tightness and the functional expression of efflux transporters P-gp and BCRP in bEnd3 cells.
Breast Neoplasms
Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
Breast Neoplasms
Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.
Breast Neoplasms
Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide.
Breast Neoplasms
Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Breast Neoplasms
PCNA/cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer. An immunohistochemical, retrospective study.
Breast Neoplasms
PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.
Breast Neoplasms
PDZK1 Regulates Breast Cancer Resistance Protein in Small Intestine.
Breast Neoplasms
Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties.
Breast Neoplasms
Peptide transport by the multidrug resistance protein MRP1.
Breast Neoplasms
Peri-foci adipose-derived stem cells promote chemoresistance in breast cancer.
Breast Neoplasms
Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-?B signaling pathway in a?human breast cancer cell line.
Breast Neoplasms
PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters in Vivo.
Breast Neoplasms
PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein.
Breast Neoplasms
PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Breast Neoplasms
pH-Dependent Transport of Pemetrexed by Breast Cancer Resistance Protein.
Breast Neoplasms
Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.
Breast Neoplasms
Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
Breast Neoplasms
Pharmacogenetic study of deferasirox, an iron chelating agent.
Breast Neoplasms
Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.
Breast Neoplasms
Pharmacogenetics of target genes across doxorubicin disposition pathway: a review.
Breast Neoplasms
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study.
Breast Neoplasms
Pharmacogenomics of MDR and MRP subfamilies.
Breast Neoplasms
Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2).
Breast Neoplasms
Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier.
Breast Neoplasms
Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.
Breast Neoplasms
Pharmacokinetic characterization of decursinol derived from Angelica gigas Nakai in rats.
Breast Neoplasms
Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).
Breast Neoplasms
Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer.
Breast Neoplasms
Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
Breast Neoplasms
Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects.
Breast Neoplasms
Pharmacokinetic properties of wogonin and its herb-drug interactions with docetaxel in rats with mammary tumors.
Breast Neoplasms
Pharmacokinetics and bioavailability of a newly synthesized dihydropyridine compound with multidrug resistance reversal activity.
Breast Neoplasms
Pharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in rats.
Breast Neoplasms
Pharmacokinetics and bioavailability of the flavonoid 7,8-benzoflavone in rats.
Breast Neoplasms
Pharmacokinetics and metabolism of the dipeptidyl peptidase IV inhibitor carmegliptin in rats, dogs, and monkeys.
Breast Neoplasms
Pharmacokinetics and Toxicokinetics Roles of Membrane Transporters at Kidney Level.
Breast Neoplasms
Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Breast Neoplasms
Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals.
Breast Neoplasms
Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans.
Breast Neoplasms
Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies.
Breast Neoplasms
Pharmacological characterization of the 3D MucilAir nasal model.
Breast Neoplasms
Pharmacological Characterization of the RPMI 2650 Model as a Relevant Tool for Assessing the Permeability of Intranasal Drugs.
Breast Neoplasms
Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene.
Breast Neoplasms
Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling.
Breast Neoplasms
Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure.
Breast Neoplasms
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma.
Breast Neoplasms
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Breast Neoplasms
Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.
Breast Neoplasms
Pheophorbide A: Fluorescent Bcrp Substrate to Measure Oral Drug-Drug Interactions in Real-Time In Vivo.
Breast Neoplasms
Phorbol Ester TPA Modulates Chemoresistance in the Drug Sensitive Breast Cancer Cell Line MCF-7 by Inducing Expression of Drug Efflux Transporter ABCG2.
Breast Neoplasms
Phorbol ester-induced P-glycoprotein phosphorylation and functionality in the HTB-123 human breast cancer cell line.
Breast Neoplasms
Photostable and Biocompatible Fluorescent Silicon Nanoparticles for Imaging-Guided Co-Delivery of siRNA and Doxorubicin to Drug-Resistant Cancer Cells.
Breast Neoplasms
Physiological Roles of ERM Proteins and Transcriptional Regulators in Supporting Membrane Expression of Efflux Transporters as Factors of Drug Resistance in Cancer.
Breast Neoplasms
Phytochemical mediated-modulation of the expression and transporter function of breast cancer resistance protein at the blood-brain barrier: An in-vitro study.
Breast Neoplasms
Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate.
Breast Neoplasms
Phytoestrogens Modulate Breast Cancer Resistance Protein Expression and Function at the Blood-Cerebrospinal Fluid Barrier.
Breast Neoplasms
Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
Breast Neoplasms
PI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 breast cancer cell line to mitoxantrone chemotherapy.
Breast Neoplasms
Pien Tze Huang () Overcomes Doxorubicin Resistance and Inhibits Epithelial-Mesenchymal Transition in MCF-7/ADR Cells.
Breast Neoplasms
Pilocarpine-induced convulsive activity is limited by multidrug transporters at the rodent blood-brain barrier.
Breast Neoplasms
Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression.
Breast Neoplasms
Pioglitazone induces hypoxia-inducible factor 1 activation in human renal proximal tubular epithelial cell line HK-2.
Breast Neoplasms
Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2).
Breast Neoplasms
Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues.
Breast Neoplasms
PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism.
Breast Neoplasms
PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression.
Breast Neoplasms
Placental drug disposition and its clinical implications.
Breast Neoplasms
Placental drug transporters and their role in fetal protection.
Breast Neoplasms
Placental expression of the heme transporter, feline leukemia virus subgroup C receptor, is related to maternal iron status in pregnant adolescents.
Breast Neoplasms
Placental P-glycoprotein and breast cancer resistance protein: influence of polymorphisms on fetal drug exposure and physiology.
Breast Neoplasms
Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs).
Breast Neoplasms
Placental transporter-mediated drug interactions and offspring congenital anomalies.
Breast Neoplasms
Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors.
Breast Neoplasms
Poloxamines Display a Multiple Inhibitory Activity of ATP-Binding Cassette (ABC) Transporters in Cancer Cell Lines.
Breast Neoplasms
Poly(L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells.
Breast Neoplasms
Polycyclic aromatic hydrocarbons in food--efflux of the conjugated biomarker 1-hydroxypyrene is mediated by Breast Cancer Resistance Protein (ABCG2) in human intestinal Caco-2 cells.
Breast Neoplasms
Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.
Breast Neoplasms
Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.
Breast Neoplasms
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Breast Neoplasms
Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
Breast Neoplasms
Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study.
Breast Neoplasms
Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
Breast Neoplasms
Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells.
Breast Neoplasms
Poncirin downregulates ATP-binding cassette transporters to enhance cisplatin sensitivity in cisplatin-resistant osteosarcoma cells.
Breast Neoplasms
Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells.
Breast Neoplasms
Positron Emission Tomography Imaging of [11 C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A.
Breast Neoplasms
Post-transcriptional regulation of breast cancer resistance protein after intestinal ischemia-reperfusion.
Breast Neoplasms
Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1.
Breast Neoplasms
Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) Derived from the p-Glycoprotein (ABCB1) Modulator Tariquidar.
Breast Neoplasms
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Breast Neoplasms
Potent modulation of P-glycoprotein activity by naturally occurring phenylbutenoids from Zingiber cassumunar.
Breast Neoplasms
Potential of Central, Eastern and Western Africa Medicinal Plants for Cancer Therapy: Spotlight on Resistant Cells and Molecular Targets.
Breast Neoplasms
Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro.
Breast Neoplasms
Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
Breast Neoplasms
Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.
Breast Neoplasms
Potential pharmacokinetic effect of rifampicin on enrofloxacin in broilers: Roles of P-glycoprotein and BCRP induction by rifampicin.
Breast Neoplasms
Potential role of ATP-binding cassette transporters in the intestinal transport of rhein.
Breast Neoplasms
Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.
Breast Neoplasms
PPAR-?, a lipid-sensing transcription factor, regulates blood-brain barrier efflux transporter expression.
Breast Neoplasms
Practical Synthesis of [18F]Pitavastatin and Evaluation of Hepatobiliary Transport Activity in Rats by Positron Emission Tomography.
Breast Neoplasms
Pre-clinical Characterization of Absorption, Distribution, Metabolism and Excretion Properties of TAK-063.
Breast Neoplasms
Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP).
Breast Neoplasms
Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1).
Breast Neoplasms
Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human.
Breast Neoplasms
Predicting Activators and Inhibitors of the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1) Based on Mechanistic Considerations.
Breast Neoplasms
Predicting multidrug resistance-related protein and P-glycoprotein expression with technetium-99m tetrofosmin mammoscintigraphy.
Breast Neoplasms
Predicting substrates of the human breast cancer resistance protein using a support vector machine method.
Breast Neoplasms
Prediction of a Side Effect and Efficacy of Adjuvant Chemotherapy with Gemcitabine for Post Operative Patient of Pancreatic Cancer by a Genetic Polymorphism Analysis.
Breast Neoplasms
Prediction of chemotherapeutic response by Technetium 99m--MIBI scintigraphy in breast carcinoma patients.
Breast Neoplasms
Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining.
Breast Neoplasms
Prediction of Drug Transfer into Milk Considering Breast Cancer Resistance Protein (BCRP)-Mediated Transport.
Breast Neoplasms
Prediction of Human Brain Penetration of P-gp and BCRP Substrates Using in Vitro Transporter Studies and Animal Models.
Breast Neoplasms
Prediction of Therapy Response and Prognosis in Leukemias by Flow Cytometric MDR Assays.
Breast Neoplasms
Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib.
Breast Neoplasms
Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin.
Breast Neoplasms
Preferential Langerhans cell differentiation from CD34(+) precursors upon introduction of ABCG2 (BCRP).
Breast Neoplasms
Preliminary study of the effects of ?-elemene on MCF-7/ADM breast cancer stem cells.
Breast Neoplasms
Prenatal endotoxemia and placental drug transport in the mouse: placental size-specific effects.
Breast Neoplasms
Prenatal ethanol exposure increases maternal bile acids through placental transport pathway.
Breast Neoplasms
Presystemic metabolism of AZ'0908, a novel mPGES-1 inhibitor: an in vitro and in vivo cross-species comparison.
Breast Neoplasms
Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression.
Breast Neoplasms
Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer.
Breast Neoplasms
Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression.
Breast Neoplasms
Progesterone inhibits folic Acid transport in human trophoblasts.
Breast Neoplasms
Progesterone Negatively Regulates BCRP in Progesterone Receptor-Positive Human Breast Cancer Cells.
Breast Neoplasms
Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells.
Breast Neoplasms
Progesterone Receptor Down-Regulates BCRP Expression via Binding to the Progesterone Response Element in Breast Cancer.
Breast Neoplasms
Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients.
Breast Neoplasms
Prognostic relevance of P-glycoprotein expression in breast cancer.
Breast Neoplasms
Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia.
Breast Neoplasms
Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer.
Breast Neoplasms
Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements.
Breast Neoplasms
Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein.
Breast Neoplasms
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Breast Neoplasms
Prominent expression of xenobiotic efflux transporters in mouse extraembryonic fetal membranes compared with placenta.
Breast Neoplasms
Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene.
Breast Neoplasms
Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
Breast Neoplasms
Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study.
Breast Neoplasms
Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.
Breast Neoplasms
Protective mechanisms of resveratrol against methotrexate-induced renal damage may involve BCRP/ABCG2.
Breast Neoplasms
Protein Abundance of Clinically Relevant Drug Transporters in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens.
Breast Neoplasms
Protein Kinase C-Independent Inhibition of Organic Cation Transporter 1 Activity by the Bisindolylmaleimide Ro 31-8220.
Breast Neoplasms
Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs.
Breast Neoplasms
Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: Implications for chronic kidney disease pathophysiology.
Breast Neoplasms
Purification of breast cancer resistance protein ABCG2 and role of arginine-482.
Breast Neoplasms
PXR and NF-?B correlate with the inducing effects of IL-1? and TNF-? on ABCG2 expression in breast cancer cell lines.
Breast Neoplasms
PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients.
Breast Neoplasms
PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.
Breast Neoplasms
Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1).
Breast Neoplasms
Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1).
Breast Neoplasms
QSAR analysis and molecular modeling of ABCG2-specific inhibitors.
Breast Neoplasms
Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
Breast Neoplasms
Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.
Breast Neoplasms
Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model.
Breast Neoplasms
Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection.
Breast Neoplasms
Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset.
Breast Neoplasms
Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry.
Breast Neoplasms
Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Breast Neoplasms
Quantitative expression of candidate genes affecting eggshell color
Breast Neoplasms
Quantitative expression of candidate genes affecting eggshell color.
Breast Neoplasms
Quantitative expression of human drug transporter proteins in lung tissues: Analysis of regional, gender, and interindividual differences by liquid chromatography-tandem mass spectrometry.
Breast Neoplasms
Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators.
Breast Neoplasms
Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds.
Breast Neoplasms
Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys.
Breast Neoplasms
Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling.
Breast Neoplasms
Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8.
Breast Neoplasms
Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma.
Breast Neoplasms
Quantitative study of cellular heterogeneity in doxorubicin uptake and its pharmacological effect on cancer cells.
Breast Neoplasms
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors.
Breast Neoplasms
Quantitative transporter proteomics by liquid chromatography with tandem mass spectrometry: addressing methodologic issues of plasma membrane isolation and expression-activity relationship.
Breast Neoplasms
Quantum-SAR Extension of the Spectral-SAR Algorithm. Application to Polyphenolic Anticancer Bioactivity.
Breast Neoplasms
Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats.
Breast Neoplasms
Quinacrine and curcumin synergistically increased the breast cancer stem cells death by inhibiting ABCG2 and modulating DNA damage repair pathway.
Breast Neoplasms
Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position.
Breast Neoplasms
R- and S-Warfarin Were Transported by Breast Cancer Resistance Protein: From In Vitro to Pharmacokinetic-Pharmacodynamic Studies.
Breast Neoplasms
Rack1 mediates Src binding to drug transporter P-glycoprotein and modulates its activity through regulating Caveolin-1 phosphorylation in breast cancer cells.
Breast Neoplasms
Rack1 Mediates the Interaction of P-Glycoprotein with Anxa2 and Regulates Migration and Invasion of Multidrug-Resistant Breast Cancer Cells.
Breast Neoplasms
Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier.
Breast Neoplasms
Radiosynthesis and in vivo evaluation of 1-[(18)F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein.
Breast Neoplasms
Radiosynthesis and in vivo evaluation of 11C-labeled BMS-193885 and its desmethyl analog as PET tracers for neuropeptide Y1 receptors.
Breast Neoplasms
Radiosynthesis of [2-(11)C-carbonyl]dantrolene using [(11)C]phosgene for PET.
Breast Neoplasms
Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Breast Neoplasms
RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines.
Breast Neoplasms
Rapid detection of ABC transporter interaction: Potential utility in pharmacology.
Breast Neoplasms
Rapid induction of P-glycoprotein mRNA and protein expression by cytarabine in HL-60 cells.
Breast Neoplasms
Reactive oxygen species derived from xanthine oxidase interrupt dimerization of breast cancer resistance protein, resulting in suppression of uric acid excretion to the intestinal lumen.
Breast Neoplasms
Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.
Breast Neoplasms
Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression.
Breast Neoplasms
Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.
Breast Neoplasms
Reduction of 99mTc-sestamibi and 99mTc-tetrofosmin uptake in MRP-expressing breast cancer cells under hypoxic conditions is independent of MRP function.
Breast Neoplasms
Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases.
Breast Neoplasms
Regional Expression Levels of Drug Transporters and Metabolizing Enzymes along the Pig and Human Intestinal Tract and Comparison with Caco-2 Cells.
Breast Neoplasms
Regional expression of the BCRP/ABCG2 transporter in term human placentas.
Breast Neoplasms
Regioselective Glucuronidation of Diosmetin and Chrysoeriol by the Interplay of Glucuronidation and Transport in UGT1A9-Overexpressing HeLa Cells.
Breast Neoplasms
Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Breast Neoplasms
Regulation of ABC Drug Efflux Transporters in Human T-Cells Exposed to an HIV Pseudotype.
Breast Neoplasms
Regulation of ABC membrane transporters in glial cells: Relevance to the pharmacotherapy of brain HIV-1 infection.
Breast Neoplasms
Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly.
Breast Neoplasms
Regulation of BCRP (ABCG2) and P-Glycoprotein (ABCB1) by Cytokines in a Model of the Human Blood-Brain Barrier.
Breast Neoplasms
Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells.
Breast Neoplasms
Regulation of breast cancer resistance protein and P-glycoprotein by ezrin, radixin and moesin in lung, intestinal and renal cancer cell lines.
Breast Neoplasms
Regulation of Breast Cancer Resistant Protein (BCRP) by Peroxisome Proliferator-Activated Receptor Alpha (PPAR?) in Human Brain Microvessel Endothelial Cells.
Breast Neoplasms
Regulation of drug transporter expression by oncostatin M in human hepatocytes.
Breast Neoplasms
Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6.
Breast Neoplasms
Regulation of drug transporter mRNA expression by interferon-gamma in primary human hepatocytes.
Breast Neoplasms
Regulation of hepatic transporters by xenobiotic receptors.
Breast Neoplasms
Regulation of human hepatic drug transporter activity and expression by diesel exhaust particle extract.
Breast Neoplasms
Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity.
Breast Neoplasms
Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells.
Breast Neoplasms
Regulation of the expression of renal drug transporters in KEAP1-knockdown human tubular cells.
Breast Neoplasms
Regulation of the placental BCRP transporter by PPAR gamma.
Breast Neoplasms
Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
Breast Neoplasms
Regulatory Pathways for ATP-binding Cassette Transport Proteins in Kidney Proximal Tubules.
Breast Neoplasms
REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Breast Neoplasms
Relation between cytochrome P450IA1 expression and estrogen receptor content of human breast cancer cells.
Breast Neoplasms
Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy.
Breast Neoplasms
Relevance of breast cancer resistance protein to brain distribution and central acting drugs: a pharmacokinetic perspective.
Breast Neoplasms
Relevance of Breast Cancer Resistance Protein to Pharmacokinetics of Florfenicol in Chickens: A Perspective from In Vivo and In Vitro Studies.
Breast Neoplasms
Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
Breast Neoplasms
Renal and hepatic transporter expression in type 2 diabetic rats.
Breast Neoplasms
Renal Drug Transporters and Drug Interactions.
Breast Neoplasms
Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment.
Breast Neoplasms
Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.
Breast Neoplasms
Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2.
Breast Neoplasms
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
Breast Neoplasms
Restricting CNS penetration of drugs to minimise adverse events: role of drug transporters.
Breast Neoplasms
Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.
Breast Neoplasms
Resveratrol stereoselectively affected (±)warfarin pharmacokinetics and enhanced the anticoagulation effect.
Breast Neoplasms
Resveratrol-mediated reversal of tumor multi-drug resistance.
Breast Neoplasms
Reversal Effects of Bound Polyphenol from Foxtail Millet Bran on Multidrug Resistance in Human HCT-8/Fu Colorectal Cancer Cell.
Breast Neoplasms
Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs.
Breast Neoplasms
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Breast Neoplasms
Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
Breast Neoplasms
Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells.
Breast Neoplasms
Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
Breast Neoplasms
Reversal of multidrug resistance in breast cancer MCF-7/ADR cells by h-R3-siMDR1-PAMAM complexes.
Breast Neoplasms
Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.
Breast Neoplasms
Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells.
Breast Neoplasms
Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response.
Breast Neoplasms
Reversible inhibition of efflux transporters by hydrogel microdevices.
Breast Neoplasms
Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR).
Breast Neoplasms
Reversing agents for ATP-binding cassette drug transporters.
Breast Neoplasms
Reversing Multidrug Resistance by Multiplexed Gene Silencing for Enhanced Breast Cancer Chemotherapy.
Breast Neoplasms
Reversing P-Glycoprotein-Associated Multidrug Resistance of Breast Cancer by Targeted Acid-Cleavable Polysaccharide Nanoparticles with Lapatinib Sensitization.
Breast Neoplasms
Reversion of multidrug resistance in the P-glycoprotein positive breast cancer cell line (MCF-7/ADR) by introduction of hammerhead ribozyme.
Breast Neoplasms
Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine.
Breast Neoplasms
Rhinacanthin-C enhances doxorubicin cytotoxicity via inhibiting the functions of P-glycoprotein and MRP2 in breast cancer cells.
Breast Neoplasms
Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
Breast Neoplasms
Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
Breast Neoplasms
Riboflavin concentration within ABCG2-rich extracellular vesicles is a novel marker for multidrug resistance in malignant cells.
Breast Neoplasms
RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
Breast Neoplasms
RNA-Seq reveals different mRNA abundance of transporters and their alternative transcript isoforms during liver development.
Breast Neoplasms
Role of ABC Transporters in Veterinary Drug Research and Parasite Resistance.
Breast Neoplasms
Role of ABC transporters in veterinary medicine: pharmaco-toxicological implications.
Breast Neoplasms
Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.
Breast Neoplasms
Role of ABCB1 and ABCC1 gene induction on survival in locally advanced breast cancer.
Breast Neoplasms
Role of ABCB1, ABCG2, ABCC2 and ABCC5 transporters in placental passage of zidovudine.
Breast Neoplasms
Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs.
Breast Neoplasms
Role of Basic Residues Within or Near the Predicted Transmembrane Helix 2 of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport.
Breast Neoplasms
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Breast Neoplasms
Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer.
Breast Neoplasms
Role of Breast Cancer Resistance Protein (ABCG2/BCRP) in the Distribution of Sorafenib to the Brain.
Breast Neoplasms
Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability.
Breast Neoplasms
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
Breast Neoplasms
Role of breast cancer resistance protein (Bcrp/Abcg2) in fetal protection during gestation in rat.
Breast Neoplasms
Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen.
Breast Neoplasms
Role of breast cancer resistance protein in the adaptive response to cholestasis.
Breast Neoplasms
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Breast Neoplasms
Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2.
Breast Neoplasms
Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines.
Breast Neoplasms
Role of efflux pumps and metabolising enzymes in drug delivery.
Breast Neoplasms
Role of Elevated SFLT-1 on the Regulation of Placental Transporters in Women With Pre-Eclampsia.
Breast Neoplasms
Role of Four ABC Transporter Genes in Pharmacogenetic Susceptibility to Breast Cancer in Jordanian Patients.
Breast Neoplasms
Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Breast Neoplasms
Role of Human Breast Cancer Related Protein versus P-Glycoprotein as an Efflux Transporter for Benzylpenicillin: Potential Importance at the Blood-Brain Barrier.
Breast Neoplasms
Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin.
Breast Neoplasms
Role of intestinal efflux transporters in the intestinal absorption of methotrexate in rats.
Breast Neoplasms
Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy.
Breast Neoplasms
Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Breast Neoplasms
Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer--a prospective clinical study.
Breast Neoplasms
Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
Breast Neoplasms
Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.
Breast Neoplasms
Role of the Abcg2 transporter in plasma levels and tissue accumulation of the anti-inflammatory tolfenamic acid in mice.
Breast Neoplasms
Role of the breast cancer resistance protein (ABCG2) in drug transport.
Breast Neoplasms
Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.
Breast Neoplasms
Role of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance.
Breast Neoplasms
Role of transporters in the disposition of a novel ?-lactamase inhibitor: relebactam (MK-7655).
Breast Neoplasms
Role of Transporters in the Disposition of the Selective Phosphodiesterase-4 Inhibitor (+)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic Acid in Rat and Human.
Breast Neoplasms
Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.
Breast Neoplasms
Roles of ABCC1 and ABCC4 in Proliferation and Migration of Breast Cancer Cell Lines.
Breast Neoplasms
Roles of multidrug resistance genes in breast cancer chemoresistance.
Breast Neoplasms
Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.
Breast Neoplasms
ROR1 regulates chemoresistance in Breast Cancer via modulation of drug efflux pump ABCB1.
Breast Neoplasms
Rutin, a Quercetin Glycoside, Restores Chemosensitivity in Human Breast Cancer Cells.
Breast Neoplasms
S-(4-Nitrobenzyl)-6-thioinosine (NBMPR) is Not a Selective Inhibitor of Equilibrative Nucleoside Transporters but Also Blocks Efflux Activity of Breast Cancer Resistance Protein.
Breast Neoplasms
S1 kills MCF-7/ADR cells more than MCF-7 cells: A protective mechanism of endoplasmic reticulum stress.
Breast Neoplasms
Salvianolic acid A reverses paclitaxel resistance in human breast cancer MCF-7 cells via targeting the expression of transgelin 2 and attenuating PI3 K/Akt pathway.
Breast Neoplasms
Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Breast Neoplasms
Scaffold Identification of a New Class of Potent and Selective BCRP Inhibitors.
Breast Neoplasms
Scaling Down of a Clinical Three-Dimensional Perfusion Multicompartment Hollow Fiber Liver Bioreactor Developed for Extracorporeal Liver Support to an Analytical Scale Device Useful for Hepatic Pharmacological In Vitro Studies.
Breast Neoplasms
SDF-1/CXCR4 axis promotes the growth and sphere formation of hypoxic breast cancer SP cells by c-Jun/ABCG2 pathway.
Breast Neoplasms
Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents.
Breast Neoplasms
Secretory transport of irinotecan metabolite SN-38 across isolated intestinal tissue.
Breast Neoplasms
Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.
Breast Neoplasms
Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure.
Breast Neoplasms
Selective Fusion of Heterogeneous Classifiers for Predicting Substrates of Membrane Transporters.
Breast Neoplasms
Selective GPR55 antagonism reduces chemoresistance in cancer cells.
Breast Neoplasms
Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS.
Breast Neoplasms
Selective induction of P-glycoprotein at the CNS barriers during symptomatic stage of an ALS animal model.
Breast Neoplasms
Selective inhibition of the effects of phorbol ester on doxorubicin resistance and P-glycoprotein by the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7) in multidrug-resistant MCF-7/Dox human breast carcinoma cells.
Breast Neoplasms
Selective modulation of P-glycoprotein activity by steroidal saponines from Paris polyphylla.
Breast Neoplasms
Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport.
Breast Neoplasms
Selectivity profiling of BCRP versus P-gp inhibition: from automated collection of polypharmacology data to multi-label learning.
Breast Neoplasms
Self-assembling doxorubicin prodrug forming nanoparticles for cancer chemotherapy: synthesis and anticancer study in vitro and in vivo.
Breast Neoplasms
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Breast Neoplasms
Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.
Breast Neoplasms
Sex-dependent disposition of acetaminophen sulfate and glucuronide in the in situ perfused mouse liver.
Breast Neoplasms
Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.
Breast Neoplasms
Sex-specific expression mechanism of hepatic estrogen inactivating enzyme and transporters in diabetic women.
Breast Neoplasms
SGLT-1 Transport and Deglycosylation inside Intestinal Cells Are Key Steps in the Absorption and Disposition of Calycosin-7-O-?-d-Glucoside in Rats.
Breast Neoplasms
Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine.
Breast Neoplasms
Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Breast Neoplasms
Side population cells and Bcrp1 expression in lung.
Breast Neoplasms
Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood-Brain Barrier.
Breast Neoplasms
Significant association between ABCB1 gene C3435T polymorphism and breast cancer risk.
Breast Neoplasms
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
Breast Neoplasms
Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
Breast Neoplasms
Silencing the breast cancer resistance protein expression and function in caco-2 cells using lentiviral vector-based short hairpin RNA.
Breast Neoplasms
Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.
Breast Neoplasms
Simultaneous determination of tilianin and its metabolites in mice using ultra-high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study.
Breast Neoplasms
Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
Breast Neoplasms
Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients.
Breast Neoplasms
Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells.
Breast Neoplasms
Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.
Breast Neoplasms
siRNAs targeting multidrug transporter genes sensitize breast tumor to doxorubicin in a syngeneic mouse model.
Breast Neoplasms
SIRT1-Mediated FoxO1 Deacetylation Is Essential for Multidrug Resistance-Associated Protein 2 Expression in Tamoxifen-Resistant Breast Cancer Cells.
Breast Neoplasms
SLCO1B1 and ABCG2 Gene Polymorphisms in a Thai Population.
Breast Neoplasms
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Breast Neoplasms
Small molecule kinase inhibitors enhance aminolevulinic acid-mediated protoporphyrin IX fluorescence and PDT response in triple negative breast cancer cell lines.
Breast Neoplasms
Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.
Breast Neoplasms
Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2).
Breast Neoplasms
Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Breast Neoplasms
Solute Carrier Family of the Organic Anion-Transporting Polypeptides 1A2- Madin-Darby Canine Kidney II: A Promising In Vitro System to Understand the Role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier Drug Penetration.
Breast Neoplasms
Species differences in drug transporters and implications for translating preclinical findings to humans.
Breast Neoplasms
Species differences in the drug-drug interaction between atorvastatin and cyclosporine: In vivo study using a stable isotope-IV method in rats and dogs.
Breast Neoplasms
Specific inhibitors of the breast cancer resistance protein (BCRP).
Breast Neoplasms
Spica prunellae and its marker compound rosmarinic acid induced the expression of efflux transporters through activation of Nrf2-mediated signaling pathway in HepG2 cells.
Breast Neoplasms
STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1.
Breast Neoplasms
Stem Cell Characteristics in Prostate Cancer Cell Lines.
Breast Neoplasms
Stereoselectivity of chiral drug transport: a focus on enantiomer-transporter interaction.
Breast Neoplasms
Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis.
Breast Neoplasms
Strategies to inhibit ABCB1- and ABCG2-mediated efflux transport of erlotinib at the blood-brain barrier: a PET study in non-human primates.
Breast Neoplasms
Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain.
Breast Neoplasms
Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.
Breast Neoplasms
Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein.
Breast Neoplasms
Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance.
Breast Neoplasms
Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.
Breast Neoplasms
Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators.
Breast Neoplasms
Structure-Activity Relationship Studies on 6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline Derivatives as Multidrug Resistance Reversers.
Breast Neoplasms
Structure-activity relationship study of permethyl ningalin B analogues as P-glycoprotein chemosensitizers.
Breast Neoplasms
Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).
Breast Neoplasms
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Breast Neoplasms
Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
Breast Neoplasms
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
Breast Neoplasms
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
Breast Neoplasms
Structure-activity relationships of tariquidar analogs as multidrug resistance modulators.
Breast Neoplasms
Structure-Based Discovery of Pyrimidine Aminobenzene Derivatives as Potent Oral Reversal Agents against P-gp- and BCRP-Mediated Multidrug Resistance.
Breast Neoplasms
Structure-function relationships in ABCG2: insights from molecular dynamics simulations and molecular docking studies.
Breast Neoplasms
Studies on pharmacokinetic properties and absorption mechanism of phloretin: In vivo and in vitro.
Breast Neoplasms
Studies on the Intestinal Absorption Characteristics of Sulfasalazine, a Breast Cancer Resistance Protein (BCRP) Substrate.
Breast Neoplasms
Study of ABCB1 polymorphism frequency in breast cancer patients from Poland.
Breast Neoplasms
Study of the Characterization of Side Population Cells in Endometrial Cancer Cell Lines: Chemoresistance, Progestin Resistance, and Radioresistance.
Breast Neoplasms
Study on mechanism of low bioavailability of black tea theaflavins by using Caco-2 cell monolayer.
Breast Neoplasms
Subcellular localization and activity of multidrug resistance proteins.
Breast Neoplasms
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
Breast Neoplasms
Substituents at the C3' and C3'N positions are critical for taxanes to overcome acquired resistance of cancer cells to paclitaxel.
Breast Neoplasms
Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
Breast Neoplasms
Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
Breast Neoplasms
Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.
Breast Neoplasms
Subtle Structural Differences Trigger Inhibitory Activity of Propafenone Analogues at the Two Polyspecific ABC Transporters: P-Glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP).
Breast Neoplasms
Suitability of RPMI 2650 cell models for nasal drug permeability prediction.
Breast Neoplasms
Suitability of tissue prints for immunocytochemical diagnosis of mammary cancer.
Breast Neoplasms
Sulfasalazine alleviates neuropathic pain hypersensitivity in mice through inhibition of SGK-1 in the spinal cord.
Breast Neoplasms
Sulfation disposition of liquiritigenin in SULT1A3 overexpressing HEK293 cells: The role of breast cancer resistance protein (BCRP) and multidrug resistance-associated protein 4 (MRP4) in sulfate efflux of liquiritigenin.
Breast Neoplasms
Sulfonation Disposition of Acacetin: In Vitro and in Vivo.
Breast Neoplasms
Sulfonation of raloxifene in HEK293 cells overexpressing SULT1A3: Involvement of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in excretion of sulfate metabolites.
Breast Neoplasms
Sulfotransferases and Breast Cancer Resistance Protein Determine the Disposition of Calycosin in Vitro and in Vivo.
Breast Neoplasms
Sulindac and Its Metabolites Inhibit Multiple Transport Proteins in Rat and Human Hepatocytes.
Breast Neoplasms
Suppression of ?v?6 downregulates P-glycoprotein and sensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Breast Neoplasms
Suppression Of Aberrant Activation Of NF-?B Pathway In Drug-resistant Leukemia Stem Cells Contributes To Parthenolide-potentiated Reversal Of Drug Resistance In Leukemia.
Breast Neoplasms
Suppression of BCRP Expression and Restoration of Sensitivity to Chemotherapy in Multidrug-Resistant HCC Cell Line HEPG2/ADM by RNA Interference.
Breast Neoplasms
Suramin inhibits the growth of human breast cancer cell lines. Studies on parental lines and corresponding sublines with acquired doxorubicin resistance with and without expression of P-glycoprotein.
Breast Neoplasms
Surface-epitope masking (SEM): an immunological subtraction approach for developing monoclonal antibodies targeting surface-expressed molecules.
Breast Neoplasms
Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-?B expression in MCF-7/5-FU cells.
Breast Neoplasms
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Breast Neoplasms
Susceptibility of juvenile and adult blood-brain barrier to endothelin-1: regulation of P-glycoprotein and breast cancer resistance protein expression and transport activity.
Breast Neoplasms
Suspension State Promotes Drug Resistance of Breast Tumor Cells by Inducing ABCC3 Overexpression.
Breast Neoplasms
Symmetric Bis-chalcones as a New Type of Breast Cancer Resistance Protein Inhibitors with a Mechanism Different from That of Chromones.
Breast Neoplasms
Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition.
Breast Neoplasms
Synergistic cytotoxic effects of arsenite and tetrandrine in human breast cancer cell line MCF-7.
Breast Neoplasms
Synthesis and ABCG2 inhibitory evaluation of 5-N-acetylardeemin derivatives.
Breast Neoplasms
Synthesis and Anticancer Cytotoxicity of Azaaurones Overcoming Multidrug Resistance.
Breast Neoplasms
Synthesis and biological assessment of new pyrimidopyrimidines as inhibitors of breast cancer resistance protein (ABCG2).
Breast Neoplasms
Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents.
Breast Neoplasms
Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
Breast Neoplasms
Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
Breast Neoplasms
Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
Breast Neoplasms
Synthesis and evaluation of 4-(2-fluoro-4-[11C]methoxyphenyl)-5-((2-methylpyridin-4-yl)methoxy)picolinamide for PET imaging of the metabotropic glutamate receptor 2 in the rat brain.
Breast Neoplasms
Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate.
Breast Neoplasms
Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.
Breast Neoplasms
Synthesis and in vivo evaluation of ¹?F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters.
Breast Neoplasms
Synthesis and Investigation of Tetrahydro-?-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
Breast Neoplasms
Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.
Breast Neoplasms
Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein.
Breast Neoplasms
Synthesis of 2-Fluoro N(10)-Substituted Acridones and Their Cytotoxicity Studies in Sensitive and Resistant Cancer Cell Lines and Their DNA Intercalation Studies.
Breast Neoplasms
Synthesis of 2-methyl N10-substituted acridones as selective inhibitors of multidrug resistance (MDR) associated protein in cancer cells.
Breast Neoplasms
Synthesis of 5-Hydroxy-3',4',7-trimethoxyflavone and Related Compounds and Elucidation of Their Reversal Effects on BCRP/ABCG2-Mediated Anticancer Drug Resistance.
Breast Neoplasms
Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
Breast Neoplasms
Synthesis of carbon-11-labeled tariquidar derivatives as new PET agents for imaging of breast cancer resistance protein (ABCG2).
Breast Neoplasms
Systemic Administration of Glibenclamide Fails to Achieve Therapeutic Levels in the Brain and Cerebrospinal Fluid of Rodents.
Breast Neoplasms
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Breast Neoplasms
Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer.
Breast Neoplasms
Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells.
Breast Neoplasms
Tamoxifen inhibits uptake and metabolism of ethanolamine and choline in multidrug-resistant, but not in drug-sensitive, MCF-7 human breast carcinoma cells.
Breast Neoplasms
Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.
Breast Neoplasms
Targeted efflux transporter inhibitors - A solution to improve poor cellular accumulation of anti-cancer agents.
Breast Neoplasms
Targeted nanopore sequencing for the identification of ABCB1 promoter translocations in cancer.
Breast Neoplasms
Targeting an extracellular epitope of the human multidrug resistance protein 1 (MRP1) in malignant cells with a novel recombinant single chain Fv antibody.
Breast Neoplasms
Targeting hyaluronan interactions in spinal cord astrocytomas and diffuse pontine gliomas.
Breast Neoplasms
Targeting intestinal transporters for optimizing oral drug absorption.
Breast Neoplasms
Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Breast Neoplasms
Targeting the Multidrug ABCG2 Transporter with Flavonoidic Inhibitors: In Vitro Optimization and In Vivo Validation.
Breast Neoplasms
Tariquidar and elacridar are dose-dependently transported by p-glycoprotein and bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study.
Breast Neoplasms
Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein.
Breast Neoplasms
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
Breast Neoplasms
Technetium-99m tetrofosmin mammoscintigraphy findings related to the expression of P-glycoprotein mediated multidrug resistance.
Breast Neoplasms
Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
Breast Neoplasms
Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells.
Breast Neoplasms
Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.
Breast Neoplasms
Telmisartan pharmacokinetics in Japanese renal transplant recipients.
Breast Neoplasms
Telomere and microtubule targeting in treatment-sensitive and treatment-resistant human prostate cancer cells.
Breast Neoplasms
Tepoxalin increases chemotherapy efficacy in drug-resistant breast cancer cells overexpressing the multidrug transporter gene ABCB1.
Breast Neoplasms
Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump.
Breast Neoplasms
Tetrabromobisphenol A (TBBPA) Alters ABC Transport at the Blood-Brain Barrier.
Breast Neoplasms
Tetrahydrocannabinol and Its Major Metabolites are Not (or are poor) Substrates or Inhibitors of Human P-glycoprotein (P-gp/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
Breast Neoplasms
Tetrahydroquinoline/4,5-Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2).
Breast Neoplasms
Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein.
Breast Neoplasms
Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein 1.
Breast Neoplasms
TGF-? induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR.
Breast Neoplasms
TGF-?1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis.
Breast Neoplasms
The "comparative growth assay": examining the interplay of anti-cancer agents with cells carrying single gene alterations.
Breast Neoplasms
The "Specific" P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2).
Breast Neoplasms
The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
Breast Neoplasms
The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug-resistant breast cancer cells is NCA, the nonspecific cross-reacting antigen of carcinoembryonic antigen.
Breast Neoplasms
The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system.
Breast Neoplasms
The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.
Breast Neoplasms
The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge.
Breast Neoplasms
The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.
Breast Neoplasms
The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
Breast Neoplasms
The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.
Breast Neoplasms
The association between genetic variants in the genes for cytochrome P450 B1 and ATP-binding cassette transporter genes and breast cancer risk.
Breast Neoplasms
The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases the in vitro drug delivery across blood-brain barrier cells.
Breast Neoplasms
The ATP-binding cassette transporter BCRP1/ABCG2 plays a pivotal role in cardiac repair after myocardial infarction via modulation of microvascular endothelial cell survival and function.
Breast Neoplasms
The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.
Breast Neoplasms
The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells.
Breast Neoplasms
The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters.
Breast Neoplasms
The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.
Breast Neoplasms
The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin.
Breast Neoplasms
The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study.
Breast Neoplasms
The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
Breast Neoplasms
The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk.
Breast Neoplasms
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.
Breast Neoplasms
The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.
Breast Neoplasms
The Challenge of Exploiting ABCG2 in the Clinic.
Breast Neoplasms
The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Breast Neoplasms
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis.
Breast Neoplasms
The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression.
Breast Neoplasms
The colon carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is actively secreted in the distal colon of the rat: an integrated view on the role of PhIP transport and metabolism in PhIP-induced colon carcinogenesis.
Breast Neoplasms
The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
The complexities of hepatic drug transport: current knowledge and emerging concepts.
Breast Neoplasms
The contribution of ABCG2 G34A and C421A polymorphisms to multiple myeloma susceptibility.
Breast Neoplasms
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast cancers.
Breast Neoplasms
The Delta-Subunit Selective GABA
A
Receptor Modulator, DS2, Improves Stroke Recovery via an Anti-inflammatory Mechanism.
Breast Neoplasms
The detoxification responses, damage effects and bioaccumulation in the scallop Chlamys farreri exposed to single and mixtures of benzo[a]pyrene and chrysene.
Breast Neoplasms
The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours.
Breast Neoplasms
The down-regulation of SLC7A11 enhances ROS induced P-gp over-expression and drug resistance in MCF-7 breast cancer cells.
Breast Neoplasms
The Drug-Drug Interaction Profile of Presatovir.
Breast Neoplasms
The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment.
Breast Neoplasms
The Effect of Albumin on MRP2 and BCRP in the Vesicular Transport Assay.
Breast Neoplasms
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
Breast Neoplasms
The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
Breast Neoplasms
The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro.
Breast Neoplasms
The effect of co-administered flavonoids on the metabolism of hesperetin and the disposition of its metabolites in Caco-2 cell monolayers.
Breast Neoplasms
The effect of green tea catechins on breast cancer resistance protein activity and intestinal efflux of aflatoxin B1 via breast cancer resistance protein in Caco-2 cells.
Breast Neoplasms
The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate.
Breast Neoplasms
The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
Breast Neoplasms
The effect of oxidative stress upon the intestinal epithelial uptake of butyrate.
Breast Neoplasms
The Effect of P-Glycoprotein (P-gp), Nuclear Factor-Kappa B (Nf-?b), and Aldehyde Dehydrogenase-1 (ALDH-1) Expression on Metastases, Recurrence and Survival in Advanced Breast Cancer Patients
Breast Neoplasms
The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.
Breast Neoplasms
The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells.
Breast Neoplasms
The Effects of Crinum asiaticum on the Apoptosis Induction and the Reversal of Multidrug Resistance in HL-60/MX2.
Breast Neoplasms
The effects of DMARDs on the expression and function of P-gp, MRPs, BCRP in the treatment of autoimmune diseases.
Breast Neoplasms
The effects of flavonoids on the ABC transporters: consequences for the pharmacokinetics of substrate drugs.
Breast Neoplasms
The effects of human immunodeficiency virus infection on the expression of the drug efflux proteins P-glycoprotein and breast cancer resistance protein in a human intestine model.
Breast Neoplasms
The Efflux Mechanism of Fraxetin-O-Glucuronides in UGT1A9-Transfected HeLa Cells: Identification of Multidrug Resistance-Associated Proteins 3 and 4 (MRP3/4) as the Important Contributors.
Breast Neoplasms
The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient.
Breast Neoplasms
The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).
Breast Neoplasms
The enzymatic basis of drug-drug interactions with systemic triazole antifungals.
Breast Neoplasms
The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study.
Breast Neoplasms
The expression of inflammatory markers and their potential influence on efflux transporters in drug-resistant mesial temporal lobe epilepsy tissue.
Breast Neoplasms
The expression profile of ATP-binding cassette transporter genes in breast carcinoma.
Breast Neoplasms
The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins.
Breast Neoplasms
The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
Breast Neoplasms
The H(2) Receptor Antagonist Nizatidine is a P-Glycoprotein Substrate: Characterization of its Intestinal Epithelial Cell Efflux Transport.
Breast Neoplasms
The harmful effect of ER? on BCRP-mediated drug resistance and cell proliferation in ER?/PR-negative breast cancer.
Breast Neoplasms
The hepatobiliary disposition of timosaponin b2 is highly dependent on influx/efflux transporters but not metabolism.
Breast Neoplasms
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Breast Neoplasms
The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone.
Breast Neoplasms
The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates.
Breast Neoplasms
The identification of two germ-line mutations in the human breast cancer resistance protein gene that result in the expression of a low/non-functional protein.
Breast Neoplasms
The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein.
Breast Neoplasms
The impact of P-glycoprotein and Breast Cancer Resistance Protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.
Breast Neoplasms
The importance of breast cancer resistance protein to the kidneys excretory function and chemotherapeutic resistance.
Breast Neoplasms
The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
Breast Neoplasms
The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.
Breast Neoplasms
The Influence of Paracetamol on the Penetration of Sorafenib and Sorafenib N-Oxide Through the Blood-Brain Barrier in Rats.
Breast Neoplasms
The influence of rhein on the absorption of rehmaionoside D: In vivo, in situ, in vitro, and in silico studies.
Breast Neoplasms
The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
Breast Neoplasms
The interaction between human breast cancer resistance protein (BCRP) and five bisbenzylisoquinoline alkaloids.
Breast Neoplasms
The interaction between moxidectin and MDR transporters in primary cultures of rat hepatocytes.
Breast Neoplasms
The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions.
Breast Neoplasms
The Interplay of ABC Transporters in A? Translocation and Cholesterol Metabolism: Implicating Their Roles in Alzheimer's Disease.
Breast Neoplasms
The kidney and uremic toxin removal: glomerulus or tubule?
Breast Neoplasms
The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport.
Breast Neoplasms
The lncRNA-GAS5/miR-221-3p/DKK2 Axis Modulates ABCB1-Mediated Adriamycin Resistance of Breast Cancer via the Wnt/?-Catenin Signaling Pathway.
Breast Neoplasms
The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.
Breast Neoplasms
The multidrug resistance protein breast cancer resistance protein (BCRP) protects adipose-derived stem cells against ischemic damage.
Breast Neoplasms
The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
Breast Neoplasms
The need for human breast cancer resistance protein substrate and inhibition evaluation in drug discovery and development: why, when, and how?
Breast Neoplasms
The Optimization Design Of Lactoferrin Loaded HupA Nanoemulsion For Targeted Drug Transport Via Intranasal Route.
Breast Neoplasms
The p53-53BP1-Related Survival of A549 and H1299 Human Lung Cancer Cells after Multifractionated Radiotherapy Demonstrated Different Response to Additional Acute X-ray Exposure.
Breast Neoplasms
The phospholipidosis-lnducing potential of the chemopotentiating drug, N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE, tesmilifene) correlates with its stimulation of phosphatidylserine synthesis and exposure on the plasma membrane in MCF-7 breast cancer cells.
Breast Neoplasms
The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells: potential chemosensitizing effect.
Breast Neoplasms
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Breast Neoplasms
The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Breast Neoplasms
The potential of Hypoxis hemerocallidea for herb-drug interaction.
Breast Neoplasms
The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer.
Breast Neoplasms
The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia.
Breast Neoplasms
The prognostic value of breast cancer resistance protein (BCRB/ABCG2) expression in breast carcinomas.
Breast Neoplasms
The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype.
Breast Neoplasms
The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP.
Breast Neoplasms
The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1.
Breast Neoplasms
The role of ATP binding cassette transporters in tissue defense and organ regeneration.
Breast Neoplasms
The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.
Breast Neoplasms
The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Breast Neoplasms
The Role of CD44 and ERM Proteins in Expression and Functionality of P-glycoprotein in Breast Cancer Cells.
Breast Neoplasms
The role of drug efflux pumps in acute myeloid leukemia.
Breast Neoplasms
The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.
Breast Neoplasms
The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
Breast Neoplasms
The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Breast Neoplasms
The role of P-glycoprotein and breast cancer resistance protein (BCRP) in bacterial attachment to human gastrointestinal cells.
Breast Neoplasms
The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel.
Breast Neoplasms
The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta.
Breast Neoplasms
The role of pregnane x receptor in 2-acetylaminofluorene-mediated induction of drug transport and -metabolizing enzymes in mice.
Breast Neoplasms
The role of the efflux carriers Abcg2 and Abcc2 for the hepatobiliary elimination of benzo[a]pyrene and its metabolites in mice.
Breast Neoplasms
The role of various transporters in the placental uptake of ofloxacin in an in vitro model of human villous trophoblasts.
Breast Neoplasms
The roles of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated proteins (MRPs/ABCCs) in the excretion of cycloicaritin-3-O-glucoronide in UGT1A1-overexpressing HeLa cells.
Breast Neoplasms
The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance.
Breast Neoplasms
The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing.
Breast Neoplasms
The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein (BCRP).
Breast Neoplasms
The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme.
Breast Neoplasms
The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2).
Breast Neoplasms
The synthesis and characterization of cellular membrane affinity chromatography columns for the study of human multidrug resistant proteins MRP1, MRP2 and human breast cancer resistant protein BCRP using membranes obtained from Spodoptera frugiperda (Sf9) insect cells.
Breast Neoplasms
The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
Breast Neoplasms
The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance.
Breast Neoplasms
The tissue transglutaminase: a potential target regulating MDR in breast cancer.
Breast Neoplasms
The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines.
Breast Neoplasms
The transepithelial transport mechanism of polybrominated diphenyl ethers in human intestine determined using a Caco-2 cell monolayer.
Breast Neoplasms
The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein.
Breast Neoplasms
The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP.
Breast Neoplasms
The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy.
Breast Neoplasms
The value of Tc-99m tetrofosmin scintimammography in the assessment of P-glycoprotein in patients with breast cancer.
Breast Neoplasms
The xenoestrogens ethinylestradiol and bisphenol A regulate BCRP at the blood-brain barrier of rats.
Breast Neoplasms
Theoretical insight into the multiple interactions of quinazoline inhibitors with breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model.
Breast Neoplasms
Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients in the Chronic Phase.
Breast Neoplasms
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
Breast Neoplasms
Therapy-relevant aberrant expression of MRP3 and BCRP mRNA in TCC-/SCC-bladder cancer tissue of untreated patients.
Breast Neoplasms
Thiazolidinediones Regulate the Level of ABC Transporters Expression on Lung Cancer Cells.
Breast Neoplasms
Three-dimensional structure of the human breast cancer resistance protein (BCRP/ABCG2) in an inward-facing conformation.
Breast Neoplasms
Tissue biodistribution of intravenously administrated titanium dioxide nanoparticles revealed blood-brain barrier clearance and brain inflammation in rat.
Breast Neoplasms
Tissue distribution and elimination of [14C]apixaban in rats.
Breast Neoplasms
Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice.
Breast Neoplasms
Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.
Breast Neoplasms
Tissue Distribution, Ontogeny, and Hormonal Regulation of Xenobiotic Transporters in Mouse Kidneys.
Breast Neoplasms
Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.
Breast Neoplasms
TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
Breast Neoplasms
Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
Breast Neoplasms
Topotecan is a substrate for multidrug resistance associated protein 4.
Breast Neoplasms
Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity.
Breast Neoplasms
Total hepatocellular disposition profiling of rosuvastatin and pitavastatin in sandwich-cultured human hepatocytes.
Breast Neoplasms
Toxicological significance of renal Bcrp: Another potential transporter in the elimination of mercuric ions from proximal tubular cells.
Breast Neoplasms
Trametenolic acid B reverses multidrug resistance in breast cancer cells through regulating the expression level of P-glycoprotein.
Breast Neoplasms
Transcription factor-mediated regulation of the BCRP/ABCG2 efflux transporter: a review across tissues and species.
Breast Neoplasms
Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Breast Neoplasms
Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-kappaB pathway in MCF-7 cells.
Breast Neoplasms
Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Breast Neoplasms
Transcriptional upregulation of breast cancer resistance protein by 17beta-estradiol in ERalpha-positive MCF-7 breast cancer cells.
Breast Neoplasms
Transepithelial transport mechanisms of 7,8-dihydroxyflavone, a small molecular TrkB receptor agonist, in human intestinal Caco-2 cells.
Breast Neoplasms
Transepithelial transport of fusariotoxin nivalenol: mediation of secretion by ABC transporters.
Breast Neoplasms
Transepithelial transport of phenolic acids in Flos Lonicerae Japonicae in intestinal Caco-2 cell monolayers.
Breast Neoplasms
Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein.
Breast Neoplasms
Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir.
Breast Neoplasms
Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.
Breast Neoplasms
Transplacental pharmacokinetics of glyburide, rhodamine 123 and BODIPY FL prazosin; effect of drug efflux transporters and lipid solubility.
Breast Neoplasms
Transport mechanism and affinity of [99mTc]mercaptoacetyltriglycine ([99mTc]MAG3) on the apical membrane of renal proximal tubule cells.
Breast Neoplasms
Transport mechanism of ursodeoxycholic acid in human placental BeWo cells.
Breast Neoplasms
Transport mechanisms for soy isoflavones and microbial metabolites dihydrogenistein and dihydrodaidzein across monolayers and membranes.
Breast Neoplasms
Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.
Breast Neoplasms
Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone.
Breast Neoplasms
Transport of glyburide by placental ABC transporters: implications in fetal drug exposure.
Breast Neoplasms
Transport of ribavirin across the rat and human placental barrier: Roles of nucleoside and ATP-binding cassette drug efflux transporters.
Breast Neoplasms
Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.
Breast Neoplasms
Transport of the Coumarin Metabolite 7-hydroxycoumarin Glucuronide is Mediated Via Multidrug Resistance-Associated Proteins 3 and 4.
Breast Neoplasms
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Breast Neoplasms
Transport Properties of Statins by Organic Anion Transporting Polypeptide 1A2 and Regulation by Transforming Growth Factor-? Signaling in Human Endothelial Cells.
Breast Neoplasms
Transporter Studies with the 3-O-Sulfate Conjugate of 17{alpha}-Ethinylestradiol: Assessment of Human Kidney Drug Transporters.
Breast Neoplasms
Transporter Studies with the 3-O-Sulfate Conjugate of 17{alpha}-Ethinylestradiol: Assessment of Human Liver Drug Transporters.
Breast Neoplasms
Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier.
Breast Neoplasms
Transporter-Mediated Disposition, Clinical Pharmacokinetics and Cholestatic Potential of Glyburide and Its Primary Active Metabolites.
Breast Neoplasms
Transporter-Mediated Drug-Drug Interactions and Their Significance.
Breast Neoplasms
Transporter-mediated drug-drug interactions.
Breast Neoplasms
Transporters and drug-drug interactions: important determinants of drug disposition and effects.
Breast Neoplasms
Transporters in the Mammary Gland-Contribution to Presence of Nutrients and Drugs into Milk.
Breast Neoplasms
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
Breast Neoplasms
Triple negative breast cancer development can be selectively suppressed by sustaining an elevated level of cellular cyclic AMP through simultaneously blocking its efflux and decomposition.
Breast Neoplasms
Troglitazone reverses the multiple drug resistance phenotype in cancer cells.
Breast Neoplasms
Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells.
Breast Neoplasms
Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro.
Breast Neoplasms
Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.
Breast Neoplasms
Tumor endothelial expression of P-glycoprotein upon microvesicular transfer of TrpC5 derived from adriamycin-resistant breast cancer cells.
Breast Neoplasms
Tumorigenic lung tumorospheres exhibit stem-like features with significantly increased expression of CD133 and ABCG2.
Breast Neoplasms
Two novel SNPs of the ABCG2 gene and its associations with milk traits in Chinese Holsteins.
Breast Neoplasms
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
Breast Neoplasms
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
Breast Neoplasms
Tyrosine Kinase Inhibitors Influence ABCG2 Expression in EGFR-Positive MDCK BCRP Cells via the PI3K/Akt Signaling Pathway.
Breast Neoplasms
UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP.
Breast Neoplasms
UMMS-4 enhanced sensitivity of chemotherapeutic agents to ABCB1-overexpressing cells via inhibiting function of ABCB1 transporter.
Breast Neoplasms
Uncompetitive nanomolar dimeric indenoindole inhibitors of the human breast cancer resistance pump ABCG2.
Breast Neoplasms
Unconjugated bilirubin elevation impairs the function and expression of breast cancer resistance protein (BCRP) at the blood-brain barrier in bile duct-ligated rats.
Breast Neoplasms
Unexpected Lower Expression of Oncoprotein Gankyrin in Drug Resistant ABCG2 Overexpressing Breast Cancer Cell Lines
Breast Neoplasms
Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
Breast Neoplasms
Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and in vitro.
Breast Neoplasms
Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
Breast Neoplasms
Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells.
Breast Neoplasms
Upregulation of breast cancer resistance protein and major vault protein in drug resistant epilepsy.
Breast Neoplasms
Upregulation of Breast Cancer Resistance Protein Expression was Decreased in Plasma Membrane of Colon Cancer with Metastasis of Lymphatic Node.
Breast Neoplasms
Upregulation of MDR- and EMT-Related Molecules in Cisplatin-Resistant Human Oral Squamous Cell Carcinoma Cell Lines.
Breast Neoplasms
Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.
Breast Neoplasms
Upregulation of PDZK1 by Calculus Bovis Sativus May Play an Important Role in Restoring Biliary Transport Function in Intrahepatic Cholestasis.
Breast Neoplasms
Uptake and Transport Mechanism of Dihydromyricetin Across Human Intestinal Caco-2 Cells.
Breast Neoplasms
Urate transport function of rat sodium-dependent nucleobase transporter 1.
Breast Neoplasms
Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations.
Breast Neoplasms
Uric acid transporters BCRP and MRP4 involved in chickens uric acid excretion.
Breast Neoplasms
Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
Breast Neoplasms
Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport.
Breast Neoplasms
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.
Breast Neoplasms
USE OF TRANSPORTER KNOCKDOWN CACO-2 CELLS TO INVESTIGATE THE IN VITRO EFFLUX OF STATIN DRUGS.
Breast Neoplasms
Usefulness of novobiocin as a selective inhibitor of intestinal breast cancer resistance protein (Bcrp) in rats.
Breast Neoplasms
Using Ex Vivo Porcine Jejunum to Identify Membrane Transporter Substrates: A Screening Tool for Early-Stage Drug Development.
Breast Neoplasms
Using the lentiviral vector system to stably express chicken P-gp and BCRP in MDCK cells for screening the substrates and studying the interplay of both transporters.
Breast Neoplasms
Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds.
Breast Neoplasms
Utility of B-13 progenitor-derived hepatocytes in hepatotoxicity and genotoxicity studies.
Breast Neoplasms
Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar.
Breast Neoplasms
Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.
Breast Neoplasms
Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration.
Breast Neoplasms
Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.
Breast Neoplasms
Valproate sensitizes human glioblastoma cells to 3-bromopyruvate-induced cytotoxicity.
Breast Neoplasms
Variable isoflavone content of red clover products affects intestinal disposition of biochanin A, formononetin, genistein, and daidzein.
Breast Neoplasms
Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies.
Breast Neoplasms
Vasohibin2 promotes adriamycin resistance of breast cancer cells through regulating ABCG2 via AKT signaling pathway.
Breast Neoplasms
Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.
Breast Neoplasms
Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells.
Breast Neoplasms
Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors.
Breast Neoplasms
VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
Breast Neoplasms
Whole-Body Distribution and Radiation Dosimetry of 11C-Elacridar and 11C-Tariquidar in Humans.
Breast Neoplasms
Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Breast Neoplasms
Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/?-catenin pathway.
Breast Neoplasms
Xanthines Down-Regulate the Drug Transporter ABCG2 and Reverse Multidrug Resistance.
Breast Neoplasms
Xenobiotic Nuclear Receptors Pregnane X Receptor and Constitutive Androstane Receptor Regulate Antiretroviral Drug Efflux Transporters at the Blood-Testis Barrier.
Breast Neoplasms
Xenobiotic transporters: ascribing function from gene knockout and mutation studies.
Breast Neoplasms
Xenobiotic, bile acid, and cholesterol transporters: function and regulation.
Breast Neoplasms
Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
Breast Neoplasms
ZIKV Disrupts Placental Ultrastructure and Drug Transporter Expression in Mice.
Breast Neoplasms
Zinc chloride rapidly stimulates efflux transporters in renal proximal tubules of killifish (Fundulus heteroclitus).
Breast Neoplasms
Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
Breast Neoplasms
[(11)C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: A PET study using Bcrp TGEM knockout rats.
Breast Neoplasms
[(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.
Breast Neoplasms
[131I]MIBG exports via MRP transporters and inhibition of the MRP transporters improves accumulation of [131I]MIBG in neuroblastoma.
Breast Neoplasms
[Absorption and transportation characteristics of scutellarin and scutellarein across Caco-2 monolayer model.]
Breast Neoplasms
[Analysis of BCRP expression in breast cancer patients].
Breast Neoplasms
[Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells]
Breast Neoplasms
[Breast cancer resistance protein and diabetes].
Breast Neoplasms
[Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers]
Breast Neoplasms
[CD147 and matrix metallo-proteinase (MMP) 2 and MMP9 expression in multidrug resistant breast cancer cells treated with P-glycoprotein substrate drugs]
Breast Neoplasms
[CIK cells acquired multidrug resistance and maintained cytotoxic activity to tumor cells after mdr1 gene transfection]
Breast Neoplasms
[Clinical significance of P-glycoprotein expression in breast cancer]
Breast Neoplasms
[Correlation between uptake of 99Tcm-MIBI and expression of multidrug resistant protein in breast cancer]
Breast Neoplasms
[Detection for therapeutic targets specifically expressed in myeloma side population cells].
Breast Neoplasms
[Detection of multidrug-resistance proteins with protein array chips]
Breast Neoplasms
[Development of an In Vitro System for Evaluating Intestinal Drug Disposition Using Human Induced Pluripotent Stem Cell-Derived Intestinal Epithelial Cells].
Breast Neoplasms
[Drug-resistant proteins in breast cancer: recent progress in multidrug resistance]
Breast Neoplasms
[Effect of hypoxia on expression of multidrug resistance protein 2 and its regulation mechanism].
Breast Neoplasms
[Effects of schisandrin B on reversing multidrug resistance in human breast cancer cells transfected with mdr1 gene]
Breast Neoplasms
[Epigenetic Regulation of Pharmacokinetic-related Genes in Human Tissues].
Breast Neoplasms
[Establishment of BCRP expressed pig kidney cell line LLC-PK1/BCRP and its biological profile].
Breast Neoplasms
[Expression and regulation of drug transporters in placenta].
Breast Neoplasms
[Expression establishment and functional analysis of breast cancer resistance protein with doxycycline induced tet regulating system in mouse fibroblast cell line PA317]
Breast Neoplasms
[Expression of ABCG2 and p-glycoprotein in residual breast cancer tissue after chemotherapy and their correlation with epithelial-mesenchymal transition].
Breast Neoplasms
[Expression of breast cancer resistance protein and p-glycoprotein in residual breast cancer tissue after chemotherapy and its correlation with cancer stem cells].
Breast Neoplasms
[Expression of breast cancer resistance protein in liver cirrhosis, hepatocellular carcinoma and peritumoral tissues.]
Breast Neoplasms
[Expression of P-glycoprotein and lung resistance protein in breast carcinoma and its relationship with prognosis]
Breast Neoplasms
[Expression of serum breast drug-resistance protein in predicting chemosensitivity of NSCLC]
Breast Neoplasms
[Functional SNPs of the breast cancer resistance protein (ABCG2) gene altering the pharmacokinetics/pharmacodynamics of anticancer agents]
Breast Neoplasms
[Gene expression of breast cancer resistance protein in adult acute lymphocytic leukemia and its clinical significance.]
Breast Neoplasms
[Growth inhibition and multidrug resistance-reversing effect of tanshinone I A on human breast cancer cell with estrogen receptor negative]
Breast Neoplasms
[Imaging blood-brain barrier function by using positron emission tomography to evaluate drug penetration into the brain].
Breast Neoplasms
[Influence of P-glycoprotein expression on chemotherapeutic response of metastatic breast carcinoma]
Breast Neoplasms
[Influences of PC cell-derived growth factor and breast cancer resistance protein on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer]
Breast Neoplasms
[Interaction of WAVE1 and genes involved in multiple drug resistance in children with acute myeloblastic leukemia.]
Breast Neoplasms
[MDR (multidrug resistance) in hepatocarcinoma clinical-therapeutic implications]
Breast Neoplasms
[Multi-disciplinary research approaches on the brain barrier transport system, a dynamic interface].
Breast Neoplasms
[Preparation and characterization of irinotecan hydrochloride loaded PEO-PPO-PEO micelles and its mechanism of decreasing drug intestinal toxicity].
Breast Neoplasms
[Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Breast Neoplasms
[Relationship between P-glycoprotein function in peripheral blood cells and multidrug resistance in breast carcinoma].
Breast Neoplasms
[Relationship between resistance to chemotherapy and expression of breast cancer resistance protein (BCRP) gene in patients with acute leukemia]
Breast Neoplasms
[Reversal effect and mechanism of lobeline on the multidrug-resistance of human breast cancer cells MCF-7/ADM.]
Breast Neoplasms
[Reversing multidrug resistance in breast cancer cell line MCF-7/ADR by small interfering RNA.]
Breast Neoplasms
[Reversion Mechanism Study of PESV to Multidrug Resistance at Leukemia Stem Cell Level].
Breast Neoplasms
[Role of ABC efflux transporters in the oral bioavailability and drug-induced intestinal toxicity].
Breast Neoplasms
[Role of breast cancer resistance protein in drug disposition].
Breast Neoplasms
[Role of drug transporters in rational use of drugs ?at high altitude area].
Breast Neoplasms
[Study on the relationship between breast cancer resistance protein expression and 5-fluorouracil resistance]
Breast Neoplasms
[The clinical significance of P-glycoprotein, lung resistance protein and multidrug resistance related protein expressions in infiltrating breast carcinoma tissues]
Breast Neoplasms
[The drug-drug interaction mediated by efflux transporters and CYP450 enzymes].
Breast Neoplasms
[The mechanism of topotecan resistance in ovarian cancer cell line]
Breast Neoplasms
[The relationship between 99mTc-MIBI scintimammography of breast cancer and multidrug-resistant proteins]
Breast Neoplasms
[The relationship between multi-drug resistance and proportion of leukemia stem cells and expression of drug transporters in drug-resistant leukemia K562/ADM cells]
Breast Neoplasms
[Therapeutic effect of Jin Long capsule combined with neoadjuvant chemotherapy on invasive breast cancer and the expression change of multidrug resistance proteins].
Breast Neoplasms
[Transcriptional regulation of breast cancer resistance protein].
Breast Neoplasms
[Using Protein Chips to Study Mechanism Underlying Reversion of Drug Resistance in Leukemia Cells in Tetrandrime alone or in Combination with Droloxifen.]
Bronchiolitis Obliterans
Bronchiolitis obliterans syndrome is associated with increased p-glycoprotein expression and loss of glucocorticoid receptor from steroid-resistant proinflammatory CD8
Bronchiolitis Obliterans
Multidrug resistance in lung allograft recipients: possible correlation with the development of acute and chronic rejection.
Candidiasis
Disulfiram is a potent modulator of multidrug transporter Cdr1p of Candida albicans.
Candidiasis, Oral
A d-octapeptide drug efflux pump inhibitor acts synergistically with azoles in a murine oral candidiasis infection model.
Carcinogenesis
A cell motility screen reveals role for MARCKS-related protein in adherens junction formation and tumorigenesis.
Carcinogenesis
A novel miR-203-DNMT3b-ABCG2 regulatory pathway predisposing colorectal cancer development.
Carcinogenesis
A potentially functional polymorphism in ABCG2 predicts clinical outcome of non-small cell lung cancer in a Chinese population.
Carcinogenesis
ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation.
Carcinogenesis
ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer.
Carcinogenesis
Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers.
Carcinogenesis
ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene.
Carcinogenesis
Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites.
Carcinogenesis
Cellular pattern of multidrug-resistance gene expression during chemical hepatocarcinogenesis in the rat.
Carcinogenesis
Correction: Low ABCB1 Gene Expression Is an Early Event in Colorectal Carcinogenesis.
Carcinogenesis
Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.
Carcinogenesis
Down-regulation of intracellular reactive oxygen species attenuates P-glycoprotein-associated chemoresistance in Epstein-Barr virus-positive NK/T-cell lymphoma.
Carcinogenesis
Effect of PSC 833, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats.
Carcinogenesis
Effect of PSC 833, an inhibitor of P-glycoprotein, on 1,2-dimethylhydrazine-induced liver carcinogenesis in rats.
Carcinogenesis
EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.
Carcinogenesis
Evaluation of P-glycoprotein expression in human oral oncogenesis: correlation with clinicopathological features.
Carcinogenesis
Expression of multidrug resistance-related genes (mdrl, MRP, GST-pi and DNA topoisomerase II) in urothelial cancers.
Carcinogenesis
Expression of multidrug resistance-related genes in oral squamous cell carcinomas.
Carcinogenesis
Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers.
Carcinogenesis
Glutathione S-transferase and P-glycoprotein in multidrug resistant Chinese hamster cells.
Carcinogenesis
Glutathione S-transferases and P-glycoprotein in normal rat hepatocytes and hepatoma cells: analysis using flow cytometry.
Carcinogenesis
High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence.
Carcinogenesis
Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival.
Carcinogenesis
Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol.
Carcinogenesis
Lack of association of the MDR1 C3435T polymorphism with susceptibility to gastric cancer and peptic ulcer: a systemic review and meta-analysis.
Carcinogenesis
Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis.
Carcinogenesis
Low ABCB1 Gene Expression Is an Early Event in Colorectal Carcinogenesis.
Carcinogenesis
Malignant transformation of bronchogenic cyst revealed by 99mTc-MIBI-SPECT.
Carcinogenesis
MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese.
Carcinogenesis
MDR1A deficiency restrains tumor growth in murine colitis-associated carcinogenesis.
Carcinogenesis
MicroRNA-320a and microRNA-4496 attenuate Helicobacter pylori cytotoxin-associated gene A (CagA)-induced cancer-initiating potential and chemoresistance by targeting ?-catenin and ATP-binding cassette, subfamily G, member 2.
Carcinogenesis
MRPL13 Promotes Tumor Cell Proliferation, Migration and EMT Process in Breast Cancer Through the PI3K-AKT-mTOR Pathway.
Carcinogenesis
Multidrug resistance protein 3 loss promotes tumor formation by inducing senescence escape.
Carcinogenesis
p53 haploinsufficiency and increased mTOR signaling define a subset of aggressive hepatocellular carcinoma.
Carcinogenesis
PSC 833, an inhibitor of P-glycoprotein inhibits 1,2-dimethylhydrazine-induced colorectal carcinogenesis in male Fischer F344 rats.
Carcinogenesis
RNAi-mediated silencing of ATP-binding cassette C4 protein inhibits cell growth in MGC80-3 gastric cancer cell lines.
Carcinogenesis
Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling.
Carcinogenesis
Suppression of intestinal polyp development in ApcMin/+ mice through inhibition of P-glycoprotein using verapamil.
Carcinogenesis
Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice.
Carcinogenesis
The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.
Carcinogenesis
The deubiquitylase UCHL3 maintains cancer stem-like properties by stabilizing the aryl hydrocarbon receptor.
Carcinogenesis
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.
Carcinogenesis
The role of P-glycoprotein in intestinal tumorigenesis: disruption of mdr1a suppresses polyp formation in Apc(Min/+) mice.
Carcinogenesis
The role of the efflux carriers Abcg2 and Abcc2 for the hepatobiliary elimination of benzo[a]pyrene and its metabolites in mice.
Carcinogenesis
The significance of C3435T point mutation of the MDR1 gene in endometrial cancer.
Carcinogenesis
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster.
Carcinogenesis
Wnt-?-catenin signaling regulates ABCC3 (MRP3) transporter expression in colorectal cancer.
Carcinoid Tumor
Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung.
Carcinoma
3D contrast-enhanced MR portography and direct X-ray portography: a correlation study.
Carcinoma
99mTc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between 99mTc-MIBI uptake and P-glycoprotein expression in tumour tissue.
Carcinoma
?-casein nanovehicles for oral delivery of chemotherapeutic drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells.
Carcinoma
?Np63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis.
Carcinoma
A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma.
Carcinoma
A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin.
Carcinoma
A new class of symmetric bisbenzimidazole-based DNA minor groove-binding agents showing antitumor activity.
Carcinoma
A novel miR-203-DNMT3b-ABCG2 regulatory pathway predisposing colorectal cancer development.
Carcinoma
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
Carcinoma
A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.
Carcinoma
A pilot study of low dose hydroxyurea as a novel resistance modulator in metastatic renal cell cancer.
Carcinoma
A plasma membrane 'vacuum cleaner' for daunorubicin in non-P-glycoprotein multidrug-resistant SW-1573 human non-small cell lung carcinoma cells. A study using fluorescence resonance energy transfer.
Carcinoma
A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines.
Carcinoma
A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.
Carcinoma
ABCB1 Is Upregulated in Acquisition of Taxane Resistance: Lessons from Esophageal Squamous Cell Carcinoma Cell Lines.
Carcinoma
ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells.
Carcinoma
ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.
Carcinoma
ABCC4 copy number variation is associated with susceptibility to esophageal squamous cell carcinoma.
Carcinoma
ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma.
Carcinoma
ABCG2 confers promotion in gastric cancer through modulating downstream CRKL in vitro combining with biostatistics mining.
Carcinoma
ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma.
Carcinoma
ABCG2 is a potential prognostic marker of overall survival in patients with clear cell renal cell carcinoma.
Carcinoma
ABCG2 Overexpression Confers Poor Outcomes in Hepatocellular Carcinoma of Elderly Patients.
Carcinoma
ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib.
Carcinoma
ABCG2 regulated by MAPK pathways is associated with cancer progression in laryngeal squamous cell carcinoma.
Carcinoma
ABO blood type predicts the cytolocalization of anti-P-glycoprotein monoclonal antibody reactivity in human colon and ureter.
Carcinoma
Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38.
Carcinoma
Adrenaline induces chemoresistance in HT-29 colon adenocarcinoma cells.
Carcinoma
Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder.
Carcinoma
Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells.
Carcinoma
Anomalous expression of P-glycoprotein in highly drug-resistant human KB cells.
Carcinoma
Antioxidant, Anti-Inflammatory, and Multidrug Resistance Modulation Activity of Silychristin Derivatives.
Carcinoma
Antitumor activity of KW-2170, a novel pyrazoloacridone derivative.
Carcinoma
Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft.
Carcinoma
Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.
Carcinoma
Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors.
Carcinoma
Associated expression of protein kinase C with resistance to doxorubicin in human lung cancer.
Carcinoma
Association of a genetic variant in ATP-binding cassette sub-family B member 1 gene with poor prognosis in patients with squamous cell carcinoma of the esophagus.
Carcinoma
Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
Carcinoma
Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2 with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Analysis in Japanese Patients.
Carcinoma
Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.
Carcinoma
ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells.
Carcinoma
ATP-binding cassette transporters are enriched in non-caveolar detergent-insoluble glycosphingolipid-enriched membrane domains (DIGs) in human multidrug-resistant cancer cells.
Carcinoma
Autophagy inhibition suppresses the tumorigenic potential of cancer stem cell enriched side population in bladder cancer.
Carcinoma
Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma.
Carcinoma
BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10.
Carcinoma
Basal cytokeratin expression in relation to biological factors in breast cancer.
Carcinoma
Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.
Carcinoma
Bidirectional membrane transport: simulations of transport inhibition in uptake studies explain data obtained with flavonoids.
Carcinoma
Bioengineered ncRNAs selectively change cellular miRNome profiles for cancer therapy.
Carcinoma
Biological markers in transurethral biopsies from bladder-cancer - preliminary-results.
Carcinoma
Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity.
Carcinoma
Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
Carcinoma
Bromocriptine transcriptionally activates the multidrug resistance gene (pgp2/mdr1b) by a novel pathway.
Carcinoma
Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells.
Carcinoma
BSEP and MDR3: Useful Immunohistochemical Markers to Discriminate Hepatocellular Carcinomas From Intrahepatic Cholangiocarcinomas and Hepatoid Carcinomas.
Carcinoma
Cancer stem cell markers in eyelid sebaceous gland carcinoma: high expression of ALDH1, CD133, and ABCG2 correlates with poor prognosis.
Carcinoma
Caveolin-1 expression in ovarian carcinoma is MDR1 independent.
Carcinoma
Cell density-dependent regulation of mdr-1 gene expression in murine colon cancer cells.
Carcinoma
Cellular pattern of multidrug-resistance gene expression during chemical hepatocarcinogenesis in the rat.
Carcinoma
Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein.
Carcinoma
Changes in P-glycoprotein expression in gastric carcinoma with respect to distant gastric mucosa may be influenced by p53.
Carcinoma
Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines.
Carcinoma
Characterization of seven kidney tumors by flow cytometry: analysis of cell cycle, DNA content and P-glycoprotein expression.
Carcinoma
Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Carcinoma
Chemoresistance of renal cell carcinoma: 1986-1994.
Carcinoma
Chemosensitizing multiple drug resistance of human carcinoma by Bicyclol involves attenuated p-glycoprotein, GST-P and Bcl-2.
Carcinoma
Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.
Carcinoma
Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance.
Carcinoma
Chemotherapy-Induced IL8 Upregulates MDR1/ABCB1 in Tumor Blood Vessels and Results in Unfavorable Outcome.
Carcinoma
Chrysosporazines A-E: P-Glycoprotein Inhibitory Piperazines from an Australian Marine Fish Gastrointestinal Tract-Derived Fungus, Chrysosporium sp. CMB-F214.
Carcinoma
Chrysosporazines F-M: P-Glycoprotein Inhibitory Phenylpropanoid Piperazines from an Australian Marine Fish Derived Fungus, Chrysosporium sp. CMB-F294.
Carcinoma
Cimetidine enhances the antiproliferative effect of 5-fluorouracil on colon carcinoma SW620.
Carcinoma
Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma.
Carcinoma
Circ_0109291 Promotes the Cisplatin Resistance of Oral Squamous Cell Carcinoma by Sponging miR-188-3p to Increase ABCB1 Expression.
Carcinoma
Class III ?-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Carcinoma
Clinical significance of multidrug resistance and P-glycoprotein expression in patients with gastric carcinoma.
Carcinoma
Clinical significance of P-glycoprotein and glutathione S-transferase ? expression in gallbladder carcinoma.
Carcinoma
Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42.
Carcinoma
Co-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemo-resistance.
Carcinoma
Coexpression of Ets-1 and p53 in oral carcinomas is associated with P-glycoprotein expression and poor prognosis.
Carcinoma
Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
Carcinoma
Comparison of the mRNA expression of factors related to drug resistance in lung tumors and adjacent normal tissue.
Carcinoma
Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: utility in Caco-2 intestinal absorption studies.
Carcinoma
Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells.
Carcinoma
Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract.
Carcinoma
Correlation of MDR1 expression and oncogenic activation in human epithelial ovarian carcinoma.
Carcinoma
Correlation of P-glycoprotein expression with poor vascularization in human gallbladder carcinomas.
Carcinoma
Correlation of P-glycoprotein overexpression and cellular prognostic factors in formalin-fixed, paraffin-embedded tumor samples from breast cancer patients.
Carcinoma
Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells.
Carcinoma
Correspondence Re: Timothy S. Loy, Paul L. Gelven, Dawn Mullins, and Alberto A. Diaz-Arias. Immunostaining for P-glycoprotein in the diagnosis of thyroid carcinomas. Mod Pathol 5:200, 1992.
Carcinoma
Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression.
Carcinoma
Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.
Carcinoma
Cyclooxygenase-2, angiogenesis, tumor cell proliferation, P-glycoprotein in advanced ovarian serous carcinoma.
Carcinoma
Cyclosporin A-induced oxidative stress is not the consequence of an increase in mitochondrial membrane potential.
Carcinoma
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Carcinoma
Cytosensing and Evaluation of Cell Surface Glycoprotein Based on a Biocompatible Poly(diallydimethylammonium) Doped Poly(dimethylsiloxane) Film.
Carcinoma
Cytosensing and evaluation of cell surface glycoprotein based on a biocompatible poly(diallydimethylammonium) doped poly(dimethylsiloxane) film.
Carcinoma
Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug-resistant lung-cancer cells.
Carcinoma
Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein.
Carcinoma
Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.
Carcinoma
Detection of drug resistance and P-glycoprotein in human renal cell carcinomas.
Carcinoma
Detection of drug resistance in human ovarian carcinoma.
Carcinoma
Detection of multidrug resistance (MDR1) gene RNA expression in human tumors by a sensitive ribonuclease protection assay.
Carcinoma
Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies.
Carcinoma
Detection of P-glycoprotein in human urogenital carcinomas and its relationship to epidermal growth factor receptor expression.
Carcinoma
Detection of P-glycoprotein in squamous cell carcinomas of the head and neck.
Carcinoma
Detection of P-glycoprotein with JSB-1 monoclonal antibody in B-5 fixed and paraffin-embedded cell lines and tissues.
Carcinoma
Detection of soluble P-glycoprotein in culture media and extracellular fluids.
Carcinoma
Detection of the multidrug resistant phenotype in human tumours by monoclonal antibodies and the streptavidin-biotinylated phycoerythrin complex method.
Carcinoma
Detection of tumor stem cell markers in pancreatic carcinoma cell lines.
Carcinoma
Development of a quantitative LC-MS/MS analytical method coupled with turbulent flow chromatography for digoxin for the in vitro P-gp inhibition assay.
Carcinoma
Development of high?resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.
Carcinoma
Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance.
Carcinoma
Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.
Carcinoma
Different response rates to chemotherapy between Japanese and German esophageal squamous cell carcinoma: patients may be influenced by ERCC1 or ABCB1.
Carcinoma
Differential anthracycline sensitivity in two related human colon carcinoma cell lines expressing similar levels of P-glycoprotein.
Carcinoma
Differential Expression of Stem Cell Markers in Ocular Surface Squamous Neoplasia.
Carcinoma
Differential expression of the polyspecific drug transporter OCT1 in rat hepatocarcinoma cells.
Carcinoma
Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro.
Carcinoma
Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum (II).
Carcinoma
DNA-ploidy, morphometric-stereological and P-glycoprotein study of superficial bladder carcinomas.
Carcinoma
Does ABCG2 need a heterodimer partner? Expression and functional evaluation of ABCG2 (Arg 482)*.
Carcinoma
Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1.
Carcinoma
Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
Carcinoma
Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma.
Carcinoma
DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
Carcinoma
Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition.
Carcinoma
Effect of apoptotic and proliferative indices, P-glycoprotein and survivin expression on prognosis in laryngeal squamous cell carcinoma.
Carcinoma
Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Carcinoma
Effect of Procyanidin-rich Extract from Natural Cocoa Powder on Cellular Viability, Cell Cycle Progression, and Chemoresistance in Human Epithelial Ovarian Carcinoma Cell Lines.
Carcinoma
Effect of SILA-409, a new organosilicon multidrug resistance modifier, on human pancreatic cancer xenografts.
Carcinoma
Effects of ATP-binding cassette transporter G2 in extracellular vesicles on drug resistance of laryngeal cancer cells in in vivo and in vitro.
Carcinoma
Effects of Cabazitaxel in Renal Cell Carcinoma Cell Lines.
Carcinoma
Effects of celecoxib on the reversal of multidrug resistance in human gastric carcinoma by downregulation of the expression and activity of P-glycoprotein.
Carcinoma
Effects of chemopreventive citrus phytochemicals on human P-glycoprotein and multidrug resistance protein 1.
Carcinoma
Effects of dietary chemopreventive phytochemicals on P-glycoprotein function.
Carcinoma
Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells.
Carcinoma
Effects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells.
Carcinoma
Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1.
Carcinoma
Effects of self-assembled cell-penetrating peptides and their nano-complexes on ABCB1 expression and activity.
Carcinoma
Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft.
Carcinoma
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Carcinoma
Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Carcinoma
Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.
Carcinoma
Enhanced intracellular drug delivery of pH-sensitive doxorubicin/poly(ethylene glycol)-block-poly(4-vinylbenzylphosphonate) nanoparticles in multi-drug resistant human epidermoid KB carcinoma cells.
Carcinoma
Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and SC236 via inhibiting P-glycoprotein activity.
Carcinoma
Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.
Carcinoma
Establishment and in vivo characterization of multidrug-resistant dunning R3327 rat prostate-carcinoma cell-lines.
Carcinoma
Establishment and use of human mouth epidermal carcinoma (KB) cells overexpressing P-glycoprotein to characterize structure requirements for flavonoids transported by the efflux transporter.
Carcinoma
Euphorbia Species-derived Diterpenes and Coumarins as Multidrug Resistance Modulators in Human Colon Carcinoma Cells.
Carcinoma
Evaluation of aminolevulinic acid-mediated protoporphyrin IX fluorescence and enhancement by ABCG2 inhibitors in renal cell carcinoma cells.
Carcinoma
Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma.
Carcinoma
Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.
Carcinoma
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.
Carcinoma
Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines.
Carcinoma
Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma.
Carcinoma
Expression and significance of glucose transporter-1, P-glycoprotein, multidrug resistance-associated protein and glutathione S-transferase-? in laryngeal carcinoma.
Carcinoma
Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine.
Carcinoma
Expression of a multidrug resistance gene in esophageal adenocarcinoma. Correlation with response to chemotherapy and comparison with gastric adenocarcinoma.
Carcinoma
Expression of ABCG2 and Bmi-1 in oral potentially malignant lesions and oral squamous cell carcinoma.
Carcinoma
Expression of CD44, CD44v9, ABCG2, CD24, Bmi-1 and ALDH1 in stage I and II oral squamous cell carcinoma and their association with clinicopathological factors.
Carcinoma
Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma.
Carcinoma
Expression of drug resistance gene products during progression of lung carcinomas.
Carcinoma
Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Carcinoma
Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome.
Carcinoma
Expression of HSP27, HSP72 and MRP proteins in in vitro co-culture of colon tumour cell spheroids with normal cells after incubation with rhTGF- beta1 and/or CPT-11.
Carcinoma
Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gall bladder cancer tissues.
Carcinoma
Expression of multidrug resistance associated transporters (MDR1, MRP1, LRP and BCRP) in porcine oocyte.
Carcinoma
Expression of multidrug resistance gene product (P-glycoprotein) in transitional cell carcinomas of the upper urinary tract.
Carcinoma
Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.
Carcinoma
Expression of multidrug resistance protein in metastatic colorectal carcinomas.
Carcinoma
Expression of multidrug resistance-associated protein (MRP) in anaplastic carcinoma of the thyroid.
Carcinoma
Expression of multidrug resistance-associated protein (MRP) in head and neck squamous cell carcinoma.
Carcinoma
Expression of multidrug resistance-associated protein (MRP) in thyroid cancers.
Carcinoma
Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis.
Carcinoma
Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays.
Carcinoma
Expression of multidrug resistance-associated protein 2 in human gallbladder carcinoma.
Carcinoma
Expression of multidrug resistance-associated protein in endometrial carcinomas: correlation with clinicopathology and prognosis.
Carcinoma
Expression of multidrug resistance-related genes in oral squamous cell carcinomas.
Carcinoma
Expression of multidrug-associated protein, P-glycoprotein, P53 and Bcl-2 proteins in bladder cancer and clinical implication.
Carcinoma
Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer.
Carcinoma
Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma.
Carcinoma
Expression of P-glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas.
Carcinoma
Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squamous cell carcinoma.
Carcinoma
Expression of PKC?, PKC?, and P-gp in epithelial ovarian carcinoma and the clinical significance.
Carcinoma
Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Carcinoma
Expression of several resistance mechanisms in untreated human kidney and lung carcinomas.
Carcinoma
Expression of the gene for the multidrug resistance-associated protein in human prostate tissue.
Carcinoma
Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma.
Carcinoma
Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy.
Carcinoma
Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas.
Carcinoma
Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma.
Carcinoma
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Carcinoma
Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer.
Carcinoma
Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer.
Carcinoma
Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas.
Carcinoma
Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas.
Carcinoma
Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas.
Carcinoma
Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP),glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney.
Carcinoma
Expressions of ABCG2, CD133, and podoplanin in salivary adenoid cystic carcinoma.
Carcinoma
Factors associated with cytoreducibility among women with ovarian carcinoma.
Carcinoma
Ferrocene and (arene)ruthenium(II) complexes of the natural anticancer naphthoquinone plumbagin with enhanced efficacy against resistant cancer cells and a genuine mode of action.
Carcinoma
Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1).
Carcinoma
Further characterization of two distinct adriamycin-resistant sublines from LoVo human colon carcinoma cells.
Carcinoma
Galectin-3 rs4652 A>C polymorphism is associated with the risk of gastric carcinoma and P-glycoprotein expression level.
Carcinoma
Galium verum aqueous extract strongly inhibits the motility of head and neck cancer cell lines and protects mucosal keratinocytes against toxic DNA damage.
Carcinoma
Gemcitabine in bladder cancer.
Carcinoma
Gene expression of membrane transporters: Importance for prognosis and progression of ovarian carcinoma.
Carcinoma
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.
Carcinoma
Genetically determined differences in P-glycoprotein function: implications for disease risk.
Carcinoma
Glutathione S-transferase and multidrug-resistant phenotype in transitional cell carcinoma of the bladder.
Carcinoma
Heat-induced membrane damage combined with adriamycin on prostate carcinoma PC-3 cells: correlation of cytotoxicity, permeability and P-glycoprotein or metallothionein expression.
Carcinoma
Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
Carcinoma
HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast.
Carcinoma
High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence.
Carcinoma
High expression of multidrug resistance-1 (MDR-1) and its relationship with multiple prognostic factors in gastric carcinomas in patients in Turkey.
Carcinoma
High Intrinsic Expression of P-glycoprotein and Breast Cancer Resistance Protein in Canine Mammary Carcinomas Regardless of Immunophenotype and Outcome.
Carcinoma
Identification of differentially expressed genes in classical and atypical multidrug-resistant gastric carcinoma cells.
Carcinoma
Identification of target antigens in specific immunotherapy for renal cell carcinoma.
Carcinoma
Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma.
Carcinoma
Immune responses against tumour-associated antigen-derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients.
Carcinoma
Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients.
Carcinoma
Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung.
Carcinoma
Immunohistochemical Detection of Proteins Associated with Multidrug Resistance to Anti-Cancer Drugs in Canine and Feline Primary Pulmonary Carcinoma.
Carcinoma
Immunohistochemical detection of the multi-drug-resistance marker P-glycoprotein in uterine cervical carcinomas and normal cervical tissue.
Carcinoma
Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Carcinoma
Immunohistochemical investigation of migration inhibitory factor-related protein (MRP)-14 expression in hepatocellular carcinoma.
Carcinoma
Immunohistochemical markers of prolonged survival in small cell carcinoma of the lung. An immunohistochemical study.
Carcinoma
Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma.
Carcinoma
Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Carcinoma
In silico analysis of differential gene expressions in biliary stricture and hepatic carcinoma.
Carcinoma
In vivo expression of P-glycoprotein in a human colon carcinoma xenograft is modulated by therapy with free and monoclonal antibody-conjugated vinca alkaloids.
Carcinoma
Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein.
Carcinoma
Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival.
Carcinoma
Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists.
Carcinoma
Influences of proton pump inhibitor on Helicobacter pylori adherence to the gastrointestinal cell lines.
Carcinoma
Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals.
Carcinoma
Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma.
Carcinoma
Inhibition of P-glycoprotein activity and chemosensitization of multidrug-resistant ovarian carcinoma 2780AD cells by hexanoylglucosylceramide.
Carcinoma
Inhibition of P-glycoprotein and increasing of drug-sensitivity of a human carcinoma cell line (KB-A-1) by an antisense oligodeoxynucleotide-doxorubicin conjugate in vitro.
Carcinoma
Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals.
Carcinoma
Inhibition of tumor cells multidrug resistance by cucumarioside A2-2, frondoside A and their complexes with cholesterol.
Carcinoma
Inhibitory effects of epigallocatechin-3-gallate on cell proliferation and the expression of HIF-1? and P-gp in the human pancreatic carcinoma cell line PANC-1.
Carcinoma
Intensely potent doxorubicin analogues: structure-activity relationship.
Carcinoma
Interaction of CCN1 with ?v?3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells.
Carcinoma
Interaction of forskolin with the P-glycoprotein multidrug transporter.
Carcinoma
Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells.
Carcinoma
Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1).
Carcinoma
Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Carcinoma
Interrogation of multidrug resistance (MDR1) P-glycoprotein (ABCB1) expression in human pancreatic carcinoma cells: correlation of 99mTc-Sestamibi uptake with western blot analysis.
Carcinoma
Involvement of phosphatidylinositol-3-kinase in membrane ruffling induced by P-glycoprotein substrates in multidrug-resistant carcinoma cells.
Carcinoma
Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
Carcinoma
Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells.
Carcinoma
Low ABCB1 Gene Expression Is an Early Event in Colorectal Carcinogenesis.
Carcinoma
Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution.
Carcinoma
Lung Resistance-Related Protein (LRP) Expression in Malignant Ascitic Cells as a Prognostic Marker for Advanced Ovarian Serous Carcinoma.
Carcinoma
LY294002 enhances inhibitory effect of gemcitabine on proliferation of human pancreatic carcinoma PANC-1 cells.
Carcinoma
Magnetic-affinity cell sorting of human multidrug-resistant cells.
Carcinoma
Markers of drug resistance in relapsing colon cancer.
Carcinoma
MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.
Carcinoma
MDR1 RNA transcripts do not indicate long-term prognosis in colorectal carcinomas.
Carcinoma
Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines.
Carcinoma
Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma.
Carcinoma
Metastasis to ipsilateral medial retropharyngeal and deep cervical lymph nodes in 22 dogs with thyroid carcinoma.
Carcinoma
MicroRNA-328 acts as an anti-oncogene by targeting ABCG2 in gastric carcinoma.
Carcinoma
Mithramycin Represses Basal and Cigarette Smoke-Induced Expression of ABCG2 and Inhibits Stem Cell Signaling in Lung and Esophageal Cancer Cells.
Carcinoma
Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP).
Carcinoma
Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides.
Carcinoma
Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives.
Carcinoma
Modulation of Multidrug Resistance Protein 2 Efflux in the Cisplatin Resistance Human Ovarian Carcinoma Cells A2780/RCIS by Sesquiterpene Coumarins.
Carcinoma
Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
Carcinoma
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
Carcinoma
Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas.
Carcinoma
Monoclonal antibody C219 detection of the multidrug-resistant protein P-glycoprotein in routinely processed tissues: a study of 36 cases of ovarian carcinoma.
Carcinoma
MRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor.
Carcinoma
Mucin antigen expression in gastric carcinomas of young and old adults.
Carcinoma
Multidrug resistance gene and P-glycoprotein expression in anaplastic carcinoma of the thyroid.
Carcinoma
Multidrug resistance gene and P-glycoprotein expression in gastric adenocarcinoma and precursor lesions.
Carcinoma
Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein.
Carcinoma
Multidrug resistance in Yoshida rat ascites hepatoma cell lines.
Carcinoma
Multidrug resistance protein 4 (MRP4/ABCC4) is overexpressed in clear cell renal cell carcinoma (ccRCC) and is essential to regulate cell proliferation.
Carcinoma
Multidrug resistance reversal in human gastric carcinoma cells by neferine.
Carcinoma
Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma.
Carcinoma
Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer.
Carcinoma
Multidrug resistance-associated protein (MRP1) gene is strongly expressed in gastric carcinomas. Analysis by immunohistochemistry and real-time quantitative RT-PCR.
Carcinoma
Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer.
Carcinoma
Multidrug resistance-associated protein expression in clinical gastric carcinoma.
Carcinoma
Multidrug resistance. Clinical opportunities in diagnosis and circumvention.
Carcinoma
Naphthoindole-based analogues of tryptophan and tryptamine: synthesis and cytotoxic properties.
Carcinoma
Nodal is involved in chemoresistance of renal cell carcinoma cells via regulation of ABCB1.
Carcinoma
Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.
Carcinoma
Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents.
Carcinoma
Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression.
Carcinoma
Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cells.
Carcinoma
Oncogenic PITX2 Facilitates Tumor Cell Drug Resistance by Inverse Regulation of hOCT3/SLC22A3 and ABC Drug Transporters in Colon and Kidney Cancers.
Carcinoma
Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
Carcinoma
Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small cell lung carcinomas of smokers.
Carcinoma
Overexpression of P-glycoprotein in human lung carcinoma xenografts after fractionated irradiation in vivo.
Carcinoma
Overexpression of P-glycoprotein in untreated AFP-producing gastric carcinoma.
Carcinoma
P-glycoprotein activity in renal clear cell carcinoma.
Carcinoma
P-Glycoprotein and Breast Cancer Resistance Protein in Canine Inflammatory and Noninflammatory Grade III Mammary Carcinomas.
Carcinoma
P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas.
Carcinoma
P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines.
Carcinoma
P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines.
Carcinoma
P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder.
Carcinoma
P-glycoprotein expression in squamous cell carcinoma of the oral and maxillofacial region.
Carcinoma
P-glycoprotein expression in the squamous cell carcinoma of the tongue base.
Carcinoma
P-glycoprotein expression, tumor differentiation, chemosensitivity of tumor-cells in-vitro and clinical outcome in patients with renal-cell carcinoma.
Carcinoma
P-glycoprotein mediates profound resistance to bisantrene.
Carcinoma
P-glycoprotein substrates and antagonists cluster into two distinct groups.
Carcinoma
P-glycoprotein, glutathione and glutathione S-transferase increase in a colon carcinoma cell line by colchicine.
Carcinoma
P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
Carcinoma
P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro.
Carcinoma
p53 and P-glycoprotein expression do not correlate with survival in nonsmall cell lung cancer: a long-term study and literature review.
Carcinoma
p53 genetic abnormalities and P-glycoprotein expression in stump and primary gastric carcinomas.
Carcinoma
Papers to appear in forthcoming issues
Carcinoma
PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT (MRP2), the multidrug resistance-associated protein.
Carcinoma
Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
Carcinoma
Phytoestrogen Suppresses Efflux of the Diagnostic Marker Protoporphyrin IX in Lung Carcinoma.
Carcinoma
PKC? inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P.
Carcinoma
Podoplanin and ABCG2 expression in oral erythroplakia revisited: Potential evidence for cancer stem cells driving the process of field cancerization.
Carcinoma
Polymorphism of FGD4 and myelosuppression in patients with esophageal squamous cell carcinoma.
Carcinoma
Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines.
Carcinoma
Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
Carcinoma
Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung.
Carcinoma
Preparation of Fab' from murine IgG2a for thiol reactive conjugation.
Carcinoma
Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells.
Carcinoma
Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression.
Carcinoma
Prognostic significance and molecular mechanism of ATP-binding cassette subfamily C member 4 in resistance to neoadjuvant radiotherapy of locally advanced rectal carcinoma.
Carcinoma
Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis.
Carcinoma
Prognostic value of P-glycoprotein and proliferative index in advanced low grade serous ovarian carcinomas.
Carcinoma
Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.
Carcinoma
Protein kinase C epsilon mediates the induction of P-glycoprotein in LNCaP prostate carcinoma cells.
Carcinoma
Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells.
Carcinoma
Purification and reconstitution of functional human P-glycoprotein.
Carcinoma
Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro.
Carcinoma
PXR and NF-?B correlate with the inducing effects of IL-1? and TNF-? on ABCG2 expression in breast cancer cell lines.
Carcinoma
Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin.
Carcinoma
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma
Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma.
Carcinoma
Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice.
Carcinoma
Regulation of Mucin 1 and multidrug resistance protein 1 by honokiol enhances the efficacy of doxorubicin-mediated growth suppression in mammary carcinoma cells.
Carcinoma
Regulation of P-glycoprotein expression in cyclic AMP-dependent protein kinase mutants.
Carcinoma
Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-pi in human lung tumors.
Carcinoma
Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse.
Carcinoma
Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis.
Carcinoma
Resistance mechanisms and their regulation in lung cancer.
Carcinoma
Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression.
Carcinoma
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Carcinoma
Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells.
Carcinoma
Reversal of multidrug resistance in renal cell carcinoma by short hairpin RNA targeting MDR1 gene.
Carcinoma
Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of ?-tocopheryl succinate-based polyphosphoester copolymers.
Carcinoma
Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells.
Carcinoma
RNA interference (RNAi) mediated stable knockdown of protein casein kinase 2-alpha (CK2?) inhibits migration and invasion and enhances cisplatin-induced apoptosis in HEp-2 laryngeal carcinoma cells.
Carcinoma
Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.
Carcinoma
Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma.
Carcinoma
Role of the tumor microenvironment in the activity and expression of the p-glycoprotein in human colon carcinoma cells.
Carcinoma
Scintigraphic prediction of resistance to radiation and chemotherapy in patients with lung carcinoma: technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography study.
Carcinoma
Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance.
Carcinoma
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Carcinoma
Sequence-specific suppression of mdr1a/1b expression in mice via RNA interference.
Carcinoma
Serum-dependent export of protoporphyrin IX by ATP-binding cassette transporter G2 in T24 cells.
Carcinoma
Significance of ATP-binding cassette transporter proteins in multidrug resistance of head and neck squamous cell carcinoma.
Carcinoma
Significance of P-glycoprotein, P53, and survivin expression in renal cell carcinoma.
Carcinoma
Simultaneous delivery of chemotherapeutic and thermal-optical agents to cancer cells by a polymeric (PLGA) nanocarrier: an in vitro study.
Carcinoma
SIRT1 prevents hyperuricemia via the PGC-1?/PPAR?-ABCG2 pathway.
Carcinoma
Structure-activity relationship and mechanism of flavonoids on the inhibitory activity of P-glycoprotein (P-gp)-mediated transport of rhodamine123 and daunorubicin in P-gp overexpressed human mouth epidermal carcinoma (KB/MDR) cells.
Carcinoma
Study of tea polyphenol as a reversal agent for carcinoma cell lines' multidrug resistance (study of TP as a MDR reversal agent).
Carcinoma
Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium.
Carcinoma
Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance.
Carcinoma
Surface-epitope masking (SEM): an immunological subtraction approach for developing monoclonal antibodies targeting surface-expressed molecules.
Carcinoma
Synthesis and biological evaluation of colchicine B-ring analogues tethered with halogenated benzyl moieties.
Carcinoma
Synthesis, characterization, and molecular structure of a novel zinc (II) complex: assessment of impact of MDR1Pgp expression on its cytotoxic activity.
Carcinoma
Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.
Carcinoma
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas Keller G, Schally AV, Nagy A, Halmos G, Baker B, Engel JB, Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, New Orleans, LA.
Carcinoma
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
Carcinoma
Targeted disruption of the PDZK1 gene by homologous recombination.
Carcinoma
Targeting CD133(+) laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles.
Carcinoma
Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
Carcinoma
Targeting of Multidrug-Resistant Human Ovarian Carcinoma Cells With Anti-P-Glycoprotein Antibody Conjugates.
Carcinoma
Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line.
Carcinoma
Technetium-99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma: relation to patient prognosis and chemotherapy response--a preliminary report.
Carcinoma
The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug-resistant breast cancer cells is NCA, the nonspecific cross-reacting antigen of carcinoembryonic antigen.
Carcinoma
The ABCG family of membrane-associated transporters: you don't have to be big to be mighty.
Carcinoma
The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors.
Carcinoma
The association of taxane resistance genes with the clinical course of ovarian carcinoma.
Carcinoma
The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas.
Carcinoma
The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.
Carcinoma
The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma.
Carcinoma
The expression of multidrug resistance protein in human gastrointestinal tract carcinomas.
Carcinoma
The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
Carcinoma
The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.
Carcinoma
The Integration of a Three-Dimensional Spheroid Cell Culture Operation in a Circulating Tumor Cell (CTC) Isolation and Purification Process: A Preliminary Study of the Clinical Significance and Prognostic Role of the CTCs Isolated from the Blood Samples of Head and Neck Cancer Patients.
Carcinoma
The lactate receptor (HCAR1/GPR81) contributes to doxorubicin chemoresistance via ABCB1 transporter up-regulation in human cervical cancer HeLa cells.
Carcinoma
The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification.
Carcinoma
The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein.
Carcinoma
The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
Carcinoma
The multidrug-resistance gene MDR1 is expressed in human glial tumors.
Carcinoma
The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
Carcinoma
The Role of Phenethyl Isothiocyanate on Bladder Cancer ADM Resistance Reversal and Its Molecular Mechanism.
Carcinoma
The role of systemic chemotherapy in the treatment of kidney cancer.
Carcinoma
TLR4 and NF?B signaling is critical for taxol resistance in ovarian carcinoma cells.
Carcinoma
Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1.
Carcinoma
Transport Oligonucleotides-A Novel System for Intracellular Delivery of Antisense Therapeutics.
Carcinoma
Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer.
Carcinoma
Tubulin-?-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
Carcinoma
Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP.
Carcinoma
Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma.
Carcinoma
Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Carcinoma
Ultrasound microbubble-mediated delivery of the siRNAs targeting MDR1 reduces drug resistance of yolk sac carcinoma L2 cells.
Carcinoma
Up-regulation of connexin 32 gene by 5-aza-2'-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling.
Carcinoma
Using 99mTc-sestamibi to evaluate the effects of a chemosensitizer on P-glycoprotein in multidrug-resistant carcinoma cells.
Carcinoma
Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.
Carcinoma
Variable effects of sodium butyrate on the expression and function of the MDR1 (P-glycoprotein) gene in colon carcinoma cell lines.
Carcinoma
Venlafaxine induces P-glycoprotein in human Caco-2 cells.
Carcinoma
[Analysis of expression of cancer stem cell-related markers in orbital adenoid cystic carcinoma].
Carcinoma
[Apoptosis and its role in the mechanisms of growth regulation of tumor cells with multiple drug resistance]
Carcinoma
[Clinical significance of multidrug resistance-associated protein(MRP) gene expression in non-small cell lung cancer]
Carcinoma
[Clinical significance of P-glycoprotein expression and multidrug resistance assessed by in vitro thymidine incorporation assay in patients with gastric carcinoma]
Carcinoma
[Correlation of expression of P-glycoprotein and inhibitor of apoptosis proteins to chemosensitivity in gastrointestinal carcinoma tissues]
Carcinoma
[Detection of P-glycoprotein in squamous cell carcinoma of larynx]
Carcinoma
[Development of new treatment modalities for advanced head and neck carcinomas]
Carcinoma
[Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype]
Carcinoma
[Expression and clinical implication of multidrug resistance gene and multidrug resistant-associated protein gene in patients with hypopharyngeal squamous cell carcinoma]
Carcinoma
[Expression and clinical implication of multidrug resistant-associated protein gene (MRP) in patients with laryngeal squamous cell carcinoma]
Carcinoma
[Expression and Clinical Significance of ABCC10 in the Patients with Non-small Cell Lung Cancer.]
Carcinoma
[Expression and implication of Pgp, MRP, LRP, GST-pi, Topo II alpha in tongue squamous cell carcinoma]
Carcinoma
[Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma]
Carcinoma
[Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma]
Carcinoma
[Expression and significance of P-glycoprotein, glutathione S-transferase-pi and Topoisomerase II in gastric carcinomas]
Carcinoma
[Expression features of P-glycoprotein, glutathione S transferase-pi and inhibitor of apoptosis proteins in lymph node metastases of gastrointestinal carcinomas]
Carcinoma
[Expression of ATP-binding cassette transporter ABCG2 in gastric carcinoma and its significance]
Carcinoma
[Expression of ATP-binding cassette transporter genes in nasopharyngeal carcinoma.]
Carcinoma
[Expression of multidrug resistance-associated protein (MRP) and lung resistance protein (LRP) in human rectal carcinomas and its clinical significance]
Carcinoma
[Expression of multidrug resistance-associated protein gene in non-small cell lung cancer]
Carcinoma
[Expression of P-glycoprotein in benign and malignant gallbladder neoplasms]
Carcinoma
[Hepatocellular Carcinoma Cells with Downregulated ZEB2 Become Resistant to Resveratrol by Concomitant Induction of ABCG2 Expression].
Carcinoma
[Multidrug resistance of testicular cancers. (Detection of P-glycoprotein and MDR1 gene expression and their clinical connection)]
Carcinoma
[Role of ABCB1 and ABCG2 in the multidrug resistance of hypopharyngeal carcinoma FaDu cell line].
Carcinoma
[The expression of MRP gene relates to the pathological features of lung cancer]
Carcinoma
[The expression of MRP, GST-pi, Topo IIalpha and COX-2 in epithelial ovarian cancer and its relationship to drug resistance and prognosis]
Carcinoma
[Treosulfan displays cytotoxic effect on spheroids of primary cell cultures of renal cell carcinoma independent of p-glycoprotein expression]
Carcinoma in Situ
Caveolin-1 expression in ovarian carcinoma is MDR1 independent.
Carcinoma in Situ
Differential Expression of Stem Cell Markers in Ocular Surface Squamous Neoplasia.
Carcinoma, Adenoid Cystic
Expressions of ABCG2, CD133, and podoplanin in salivary adenoid cystic carcinoma.
Carcinoma, Adenoid Cystic
[Analysis of expression of cancer stem cell-related markers in orbital adenoid cystic carcinoma].
Carcinoma, Ductal
ABCG2 is a potential marker of tumor-initiating cells in breast cancer.
Carcinoma, Ductal
ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma.
Carcinoma, Ductal
Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.
Carcinoma, Ductal
Hypoxia-inducible factor-2a is associated with ABCG2 expression, histology-grade and Ki67 expression in breast invasive ductal carcinoma.
Carcinoma, Ductal
Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors.
Carcinoma, Ductal
The prognostic value of breast cancer resistance protein (BCRB/ABCG2) expression in breast carcinomas.
Carcinoma, Ehrlich Tumor
ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines.
Carcinoma, Ehrlich Tumor
Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
Carcinoma, Ehrlich Tumor
Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation.
Carcinoma, Ehrlich Tumor
Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
Carcinoma, Ehrlich Tumor
Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.
Carcinoma, Ehrlich Tumor
Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.
Carcinoma, Ehrlich Tumor
P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin.
Carcinoma, Ehrlich Tumor
pH regulation in sensitive and multidrug resistant Ehrlich ascites tumor cells.
Carcinoma, Ehrlich Tumor
Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells.
Carcinoma, Embryonal
[Multidrug resistance of testicular cancers. (Detection of P-glycoprotein and MDR1 gene expression and their clinical connection)]
Carcinoma, Hepatocellular
7-Ketocholesterol induces P-glycoprotein through PI3K/mTOR signaling in hepatoma cells.
Carcinoma, Hepatocellular
?2-adrenergic receptor-mediated in vitro regulation of human hepatic drug transporter expression by epinephrine.
Carcinoma, Hepatocellular
A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways.
Carcinoma, Hepatocellular
AANG: A natural compound formula for overcoming multidrug resistance via synergistic rebalancing the TGF-?/Smad signalling in hepatocellular carcinoma.
Carcinoma, Hepatocellular
ABCC2 is involved in the hepatocyte perinuclear barrier for small organic compounds.
Carcinoma, Hepatocellular
ABCG2 Overexpression Confers Poor Outcomes in Hepatocellular Carcinoma of Elderly Patients.
Carcinoma, Hepatocellular
Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis.
Carcinoma, Hepatocellular
Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling.
Carcinoma, Hepatocellular
Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Carcinoma, Hepatocellular
Arginase-1 and P-glycoprotein are downregulated in canine hepatocellular carcinoma.
Carcinoma, Hepatocellular
Association between reversal of multidrug resistance by methyl jasmonate and P-glycoprotein ATPase activity in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer.
Carcinoma, Hepatocellular
Augmenter of liver regeneration potentiates doxorubicin anticancer efficacy by reducing the expression of ABCB1 and ABCG2 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity.
Carcinoma, Hepatocellular
Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein.
Carcinoma, Hepatocellular
Bmi-1 gene is upregulated in early-stage hepatocellular carcinoma and correlates with ATP-binding cassette transporter B1 expression.
Carcinoma, Hepatocellular
BSEP and MDR3: Useful Immunohistochemical Markers to Discriminate Hepatocellular Carcinomas From Intrahepatic Cholangiocarcinomas and Hepatoid Carcinomas.
Carcinoma, Hepatocellular
C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein.
Carcinoma, Hepatocellular
Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression.
Carcinoma, Hepatocellular
Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line.
Carcinoma, Hepatocellular
Cellular characterization of multidrug resistance p-glycoprotein, alpha fetoprotein, and neovascular endothelium-associated antigens in canine hepatocellular carcinoma and cirrhotic liver.
Carcinoma, Hepatocellular
Clinical significance of mrp gene in primary hepatocellular carcinoma.
Carcinoma, Hepatocellular
Comparison of Pregnane X Receptor Antagonists for Enhancing the Antitumor Effect of Cisplatin.
Carcinoma, Hepatocellular
Conjugated bilirubin induces multidrug resistance-associated protein 2 mRNA expression and in vivo cisplatin resistance in rat hepatoma AH66 cells.
Carcinoma, Hepatocellular
Constitutive expression of functional P-glycoprotein in rat hepatoma cells.
Carcinoma, Hepatocellular
Coordinated regulation of P-glycoprotein activity and cytochrome P-4501A induction in sublines of rat hepatoma McA RH7777 cells with different levels of colchicine resistance.
Carcinoma, Hepatocellular
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Carcinoma, Hepatocellular
Correlation of expression of multidrug resistance protein and messenger RNA with 99mTc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.
Carcinoma, Hepatocellular
CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
Carcinoma, Hepatocellular
Deletion of tumour necrosis factor ? receptor 1 elicits an increased TH17 immune response in the chronically inflamed liver.
Carcinoma, Hepatocellular
Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Depressive Disorder promotes Hepatocellular Carcinoma metastasis via upregulation of ABCG2 gene expression and maintenance of self-renewal.
Carcinoma, Hepatocellular
Detection of putative cancer stem cells of the side population phenotype in human tumor cell cultures.
Carcinoma, Hepatocellular
Development and characterization of P-glycoprotein 1 (Pgp1, ABCB1)-mediated doxorubicin-resistant PLHC-1 hepatoma fish cell line.
Carcinoma, Hepatocellular
Differential regulation of drug transporter expression by all-trans retinoic acid in hepatoma HepaRG cells and human hepatocytes.
Carcinoma, Hepatocellular
Divergent regulation of the class II P-glycoprotein gene in primary cultures of hepatocytes versus H35 hepatoma by glucocorticoids.
Carcinoma, Hepatocellular
Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells.
Carcinoma, Hepatocellular
Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line.
Carcinoma, Hepatocellular
Downregulation of NPM reverses multidrug resistance in human hepatoma cells via inhibition of P-glycoprotein expression.
Carcinoma, Hepatocellular
Doxorubicin enhances transient expression of p-glycoprotein and modulates activity and isoform expression of protein-kinase-C in ah66 rat hepatoma-cells.
Carcinoma, Hepatocellular
Effect of arsenic trioxide on multidrug resistant hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Effect of P-glycoprotein and multidrug resistance associated protein gene expression on Tc-99m MIBI imaging in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells.
Carcinoma, Hepatocellular
Effects of Astragalus polysaccharides on P-glycoprotein efflux pump function and protein expression in H22 hepatoma cells in vitro.
Carcinoma, Hepatocellular
Elevated expression of hepatic proliferative markers during early hepatocarcinogenesis in hepatitis-B virus transgenic mice lacking mdr1a-encoded P-glycoprotein.
Carcinoma, Hepatocellular
Elimination of cancer stem-like "side population" cells in hepatoma cell lines by chinese herbal mixture "tien-hsien liquid".
Carcinoma, Hepatocellular
Epigallocatechin gallate hinders human hepatoma and colon cancer sphere formation.
Carcinoma, Hepatocellular
Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
Carcinoma, Hepatocellular
Expression of MRP and cMOAT in childhood neuroblastomas and malignant liver tumors and its relevance to clinical behavior.
Carcinoma, Hepatocellular
Expression of Multi-drug Resistance-Related Genes MDR3 and MRP as Prognostic Factors in Clinical Liver Cancer Patients.
Carcinoma, Hepatocellular
Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin.
Carcinoma, Hepatocellular
Expression of multidrug resistance-associated protein 3 and cytotoxic T cell responses in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression of P-glycoprotein and C-MOAT in human hepatocellular carcinoma: detection by immunostaining.
Carcinoma, Hepatocellular
Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation.
Carcinoma, Hepatocellular
Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response.
Carcinoma, Hepatocellular
Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.
Carcinoma, Hepatocellular
Expression of Potential Cancer Stem Cell Marker ABCG2 is Associated with Malignant Behaviors of Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Functional significance of the ATP-binding cassette transporter B6 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response.
Carcinoma, Hepatocellular
Glutathione S-transferases and P-glycoprotein in normal rat hepatocytes and hepatoma cells: analysis using flow cytometry.
Carcinoma, Hepatocellular
Guggulsterone sensitized drug-resistant human hepatocarcinoma cells to doxorubicin through a Cox-2/P-gp dependent pathway.
Carcinoma, Hepatocellular
Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter.
Carcinoma, Hepatocellular
Hedgehog Signaling, a Critical Pathway Governing the Development and Progression of Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression.
Carcinoma, Hepatocellular
Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
Carcinoma, Hepatocellular
Human hepatoma cells rich in P-glycoprotein display enhanced in vitro invasive properties compared to P-glycoprotein-poor hepatoma cells.
Carcinoma, Hepatocellular
Human pharmaceuticals modulate P-gp1 (ABCB1) transport activity in the fish cell line PLHC-1.
Carcinoma, Hepatocellular
Identification and characterization of a hepatoma cell-specific enhancer in the mouse multidrug resistance mdr1b promoter.
Carcinoma, Hepatocellular
Identification of Functional Transcriptional Binding Sites within Chicken Abcg2 Gene Promoter and Screening Its Regulators.
Carcinoma, Hepatocellular
Immunohistochemical studies on the expression of P-glycoprotein and p53 in relation to histological differentiation and cell proliferation in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Increased P-glycoprotein expression in mitochondria is related to acquired multidrug resistance in human hepatoma cells depleted of mitochondrial DNA.
Carcinoma, Hepatocellular
Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression.
Carcinoma, Hepatocellular
Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling.
Carcinoma, Hepatocellular
Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells.
Carcinoma, Hepatocellular
Inhibition of P-glycoprotein expression and reversal of drug resistance of human hepatoma HepG2 cells by multidrug resistance gene (mdr1) antisense RNA.
Carcinoma, Hepatocellular
Inhibition of sirtuins 1 and 2 impairs cell survival and migration and modulates the expression of P-glycoprotein and MRP3 in hepatocellular carcinoma cell lines.
Carcinoma, Hepatocellular
Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein.
Carcinoma, Hepatocellular
Interleukin-18 Down-Regulates Multidrug Resistance-Associated Protein 2 Expression through Farnesoid X Receptor Associated with Nuclear Factor Kappa B and Yin Yang 1 in Human Hepatoma HepG2 Cells.
Carcinoma, Hepatocellular
Inverse relationship between P-glycoprotein expression and its proliferative activity in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1.
Carcinoma, Hepatocellular
Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells.
Carcinoma, Hepatocellular
Involvement of the multidrug resistance P-glycoprotein in acetaminophen-induced toxicity in hepatoma-derived HepG2 and Hep3B cells.
Carcinoma, Hepatocellular
Involvement of Vitamin D receptor in the intestinal induction of human ABCB1.
Carcinoma, Hepatocellular
Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines.
Carcinoma, Hepatocellular
LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.
Carcinoma, Hepatocellular
Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ ABCC1 axis.
Carcinoma, Hepatocellular
MDR1 gene expression in hepatocellular carcinoma and the peritumoral liver of patients with and without cirrhosis.
Carcinoma, Hepatocellular
MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Molecular cloning of the murine cMOAT ATPase.
Carcinoma, Hepatocellular
Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone.
Carcinoma, Hepatocellular
Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells.
Carcinoma, Hepatocellular
Oenothera paradoxa defatted seeds extract containing pentagalloylglucose and procyanidins potentiates the cytotoxicity of vincristine.
Carcinoma, Hepatocellular
Optimization of Canalicular ABC Transporter Function in HuH-7 Cells by Modification of Culture Conditions.
Carcinoma, Hepatocellular
Oroxylin a reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-?B signaling pathway.
Carcinoma, Hepatocellular
Overcoming STC2 mediated drug resistance through drug and gene co-delivery by PHB-PDMAEMA cationic polyester in liver cancer cells.
Carcinoma, Hepatocellular
Overexpression of a p-glycoprotein in hepatocellular carcinomas from woodchuck hepatitis virus-infected woodchucks (Marmota monax).
Carcinoma, Hepatocellular
Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines.
Carcinoma, Hepatocellular
Overexpression of P-glycoprotein in adenomatous hyperplasia of human liver with cirrhosis.
Carcinoma, Hepatocellular
Overexpression of P-glycoprotein in heat- and/or drug-resistant hepatoma variants.
Carcinoma, Hepatocellular
Overexpression of P-glycoprotein in hepatocellular carcinoma and its clinical implication.
Carcinoma, Hepatocellular
Overexpression of P-glycoprotein in rat hepatocellular carcinomas induced with N-nitrosomorpholine.
Carcinoma, Hepatocellular
Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
P-glycoprotein enhances radiation-induced apoptotic cell death through the regulation of miR-16 and Bcl-2 expressions in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro.
Carcinoma, Hepatocellular
P-glycoprotein expression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
P-glycoprotein expression induced by glucose depletion enhanced the chemosensitivity in human hepatocellular carcinoma cell-lines.
Carcinoma, Hepatocellular
P-glycoprotein is overexpressed and functional in severely heat-shocked hepatoma cells.
Carcinoma, Hepatocellular
P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines.
Carcinoma, Hepatocellular
p53 and P-glycoprotein influence chemoresistance in hepatocellular carcinoma.
Carcinoma, Hepatocellular
p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents.
Carcinoma, Hepatocellular
Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines.
Carcinoma, Hepatocellular
Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Photodynamic therapy inhibits P-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a.
Carcinoma, Hepatocellular
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Hepatocellular
Reduced cytotoxicity in doxorubicin-exposed HepG2 cells pretreated with menthol due to upregulation of P-glycoprotein.
Carcinoma, Hepatocellular
Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma.
Carcinoma, Hepatocellular
Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
Carcinoma, Hepatocellular
Retroviral delivery of DNA into the livers of transgenic mice bearing premalignant and malignant hepatocellular carcinomas.
Carcinoma, Hepatocellular
Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs.
Carcinoma, Hepatocellular
Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice.
Carcinoma, Hepatocellular
Sensitization of hepatocellular carcinoma cells towards doxorubicin and sorafenib is facilitated by glucosedependent alterations in reactive oxygen species, P-glycoprotein and DKK4.
Carcinoma, Hepatocellular
SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Stimulus-induced expression of the ABCG2 multidrug transporter in HepG2 hepatocarcinoma model cells involves the ERK1/2 cascade and alternative promoters.
Carcinoma, Hepatocellular
Tc-99m MIBI liver imaging for hepatocellular carcinoma: correlation with P-glycoprotein-multidrug-resistance gene expression.
Carcinoma, Hepatocellular
Tc-99m MIBI SPECT is useful for noninvasively predicting the presence of MDR1 gene-encoded P-glycoprotein in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
TFPI-2 downregulates multidrug resistance protein in 5-FU-resistant human hepatocellular carcinoma BEL-7402/5-FU cells.
Carcinoma, Hepatocellular
TGF-? induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR.
Carcinoma, Hepatocellular
The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma.
Carcinoma, Hepatocellular
The effect of different interventional treatment on P-Glycoprotein in different histopathological types and grades of primary hepatocellular carcinoma.
Carcinoma, Hepatocellular
The function of heat-shock proteins in stress tolerance.
Carcinoma, Hepatocellular
The miR-491-3p/Sp3/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma.
Carcinoma, Hepatocellular
The multidrug resistance-associated protein (MRP) is over-expressed and functional in rat hepatoma cells.
Carcinoma, Hepatocellular
The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance.
Carcinoma, Hepatocellular
The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker.
Carcinoma, Hepatocellular
Transport-metabolism interplay: LXR-mediated induction of human ABC transporter ABCC2 (cMOAT/MRP2) in HepG2 cells.
Carcinoma, Hepatocellular
Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells.
Carcinoma, Hepatocellular
Upregulation of P-glycoprotein in rat hepatoma rho(o) cells: implications for drug-DNA interactions.
Carcinoma, Hepatocellular
Usefulness of technetium-99m tetrofosmin liver imaging to detect hepatocellular carcinoma and related to expression of P-glycoprotein or multidrug resistance associated protein-a preliminary report.
Carcinoma, Hepatocellular
Verapamil and rifampin effect on p-glycoprotein expression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Vitamin E protects DNA from oxidative damage in human hepatocellular carcinoma cell lines.
Carcinoma, Hepatocellular
Woodchuck p-glycoprotein found in virus-induced hepatocellular carcinomas binds anticancer drugs.
Carcinoma, Hepatocellular
[An experimental study of recombinant adenovirus microsphere carrying antisense multidrug resistance-associated protein gene for reversing MRP of hepatocellular carcinoma in vitro]
Carcinoma, Hepatocellular
[Construction of recombinant adeno-associated virus vectors carrying double gene of antisense multidrug resistance-associated protein and antisense multidrug resistance]
Carcinoma, Hepatocellular
[Construction of the recombinant adenovirus vector carrying antisense multidrug resistance-associated protein]
Carcinoma, Hepatocellular
[Expression of breast cancer resistance protein in liver cirrhosis, hepatocellular carcinoma and peritumoral tissues.]
Carcinoma, Hepatocellular
[Methylated oligonucleotide inhibiting expression of human MRP2 and reversing multidrug resistance in hepatocellular carcinoma Cell HepG2]
Carcinoma, Hepatocellular
[Reversal of multidrug resistance gene MDR1 and MRP of drug-resistant human hepatocellular carcinoma cells SMMC-7721/ADM with antisense phosphorothioate oligonucleotides]
Carcinoma, Hepatocellular
[Reversal of the multidrug resistance in human hepatocellular carcinoma cells by recombinant adenoviral delivery of the MRP antisense RNA in vitro]
Carcinoma, Hepatocellular
[Suppression of MDR1 expression and restoration of sensitivity to chemotherapy in multidrug-resistant hepatocellular carcinoma cell line Bel7402/5-Fu by RNA interference]
Carcinoma, Hepatocellular
[The effect of p53 gene on p-glycoprotein expression and chemotherapeutic cytotoxicity of hepatocellular carcinoma]
Carcinoma, Intraductal, Noninfiltrating
Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Utilizing mobile networks for the detection of clinically relevant interactions between chemotherapy regimens and complementary and alternative medicines.
Carcinoma, Large Cell
Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer.
Carcinoma, Large Cell
Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP).
Carcinoma, Lewis Lung
Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma.
Carcinoma, Mucoepidermoid
Multidrug resistance in mucoepidermoid carcinoma of the parotid gland - immunohistochemical investigations of P-glycoprotein expression.
Carcinoma, Mucoepidermoid
[Detection of P-glycoprotein and glutathine S-transferase in mucoepidermoid carcinoma of salivary gland]
Carcinoma, Neuroendocrine
Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung.
Carcinoma, Neuroendocrine
The chemoresistance gene ABCG2 (MXR/BCRP1/ABCP1) is not expressed in melanomas but in single neuroendocrine carcinomas of the skin.
Carcinoma, Non-Small-Cell Lung
A meta-analysis of ABCG2 gene polymorphism and non-small cell lung cancer outcomes.
Carcinoma, Non-Small-Cell Lung
A plasma membrane 'vacuum cleaner' for daunorubicin in non-P-glycoprotein multidrug-resistant SW-1573 human non-small cell lung carcinoma cells. A study using fluorescence resonance energy transfer.
Carcinoma, Non-Small-Cell Lung
A potentially functional polymorphism in ABCG2 predicts clinical outcome of non-small cell lung cancer in a Chinese population.
Carcinoma, Non-Small-Cell Lung
ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy.
Carcinoma, Non-Small-Cell Lung
ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
ABCC3 as a marker for multidrug resistance in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.
Carcinoma, Non-Small-Cell Lung
Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis.
Carcinoma, Non-Small-Cell Lung
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Carcinoma, Non-Small-Cell Lung
Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model.
Carcinoma, Non-Small-Cell Lung
Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance.
Carcinoma, Non-Small-Cell Lung
Circular RNAcirc_0076305 Promotes Cisplatin (DDP) Resistance of Non-Small Cell Lung Cancer Cells by Regulating ABCC1 Through miR-186-5p.
Carcinoma, Non-Small-Cell Lung
Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
Carcinoma, Non-Small-Cell Lung
Clinical Significance of p53, P-glycoprotein, and Glutathione S transferase-pi in Advanced Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Co-delivery of cisplatin and siRNA through hybrid nanocarrier platform for masking resistance to chemotherapy in lung cancer.
Carcinoma, Non-Small-Cell Lung
Co-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemo-resistance.
Carcinoma, Non-Small-Cell Lung
Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug-resistant lung-cancer cells.
Carcinoma, Non-Small-Cell Lung
Development of a double-layer microfluidic chip with flow medium for chemotherapy resistance analysis of lung cancer.
Carcinoma, Non-Small-Cell Lung
DNA Methylation of DKK3 Modulates Docetaxel Chemoresistance in Human Nonsmall Cell Lung Cancer Cell.
Carcinoma, Non-Small-Cell Lung
Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer.
Carcinoma, Non-Small-Cell Lung
Effect of 5-FU and MTX on the Expression of Drug-resistance Related Cancer Stem Cell Markers in Non-small Cell Lung Cancer Cells.
Carcinoma, Non-Small-Cell Lung
Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.
Carcinoma, Non-Small-Cell Lung
Efficacy of Aidi Injection () on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Erratum to: RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China.
Carcinoma, Non-Small-Cell Lung
Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Expression of the multidrug resistance gene (MDR1) in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Carcinoma, Non-Small-Cell Lung
Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas.
Carcinoma, Non-Small-Cell Lung
Expressions of CD44, PCNA and MRP1 in lung cancer tissues and their effects on proliferation and invasion abilities of lung cancer cell line 95D.
Carcinoma, Non-Small-Cell Lung
Functional Alterations of Multidrug Resistance-Associated Proteins 2 and 5, and Breast Cancer Resistance Protein upon Snail-Induced Epithelial-Mesenchymal Transition in HCC827 Cells.
Carcinoma, Non-Small-Cell Lung
Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
Carcinoma, Non-Small-Cell Lung
Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2.
Carcinoma, Non-Small-Cell Lung
Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival.
Carcinoma, Non-Small-Cell Lung
In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells.
Carcinoma, Non-Small-Cell Lung
Integrin-Linked Kinase, Snail and Multidrug Resistance Protein 1: Three concordant players in the progression of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Carcinoma, Non-Small-Cell Lung
Inverse correlation between 99mTc-tetrofosmin uptake and P-glycoprotein in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Lung resistance protein and multidrug resistance protein in non-small cell lung cancer and their clinical significance.
Carcinoma, Non-Small-Cell Lung
MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1.
Carcinoma, Non-Small-Cell Lung
MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.
Carcinoma, Non-Small-Cell Lung
Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively.
Carcinoma, Non-Small-Cell Lung
Multidrug resistance-associated protein (MRP) gene expression in human lung cancer.
Carcinoma, Non-Small-Cell Lung
Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC).
Carcinoma, Non-Small-Cell Lung
Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents.
Carcinoma, Non-Small-Cell Lung
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
p53 and P-glycoprotein expression do not correlate with survival in nonsmall cell lung cancer: a long-term study and literature review.
Carcinoma, Non-Small-Cell Lung
Paclitaxel-Based chemotherapy for non-small cell lung cancer: predicting the response with 99mTc-tetrofosmin chest imaging.
Carcinoma, Non-Small-Cell Lung
Placental isoform glutathione S-transferase and P-glycoprotein expression in advanced nonsmall cell lung cancer: association with response to treatment and survival.
Carcinoma, Non-Small-Cell Lung
Prognostic role of multidrug resistance-associated protein 1 expression and platelet count in operable non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of miR-23b in combination with P-gp, MRP and LRP/MVP expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography.
Carcinoma, Non-Small-Cell Lung
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Non-Small-Cell Lung
RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China.
Carcinoma, Non-Small-Cell Lung
Reverse of non-small cell lung cancer drug resistance induced by cancer-associated fibroblasts via a paracrine pathway.
Carcinoma, Non-Small-Cell Lung
Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Carcinoma, Non-Small-Cell Lung
Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells.
Carcinoma, Non-Small-Cell Lung
SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p.
Carcinoma, Non-Small-Cell Lung
Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
Carcinoma, Non-Small-Cell Lung
Strategies to inhibit ABCB1- and ABCG2-mediated efflux transport of erlotinib at the blood-brain barrier: a PET study in non-human primates.
Carcinoma, Non-Small-Cell Lung
Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells.
Carcinoma, Non-Small-Cell Lung
Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance.
Carcinoma, Non-Small-Cell Lung
Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Technetium-99m tetrofosmin chest imaging related to p-glycoprotein expression for predicting the response with paclitaxel-based chemotherapy for non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.
Carcinoma, Non-Small-Cell Lung
The effect of CHRNA3 rs1051730 C>T and ABCB1 rs3842 A>G polymorphisms on non-small cell lung cancer and nicotine dependence in Iranian population.
Carcinoma, Non-Small-Cell Lung
The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
Carcinoma, Non-Small-Cell Lung
Usefulness of tc-99m MIBI SPECT in predicting multidrug resistance gene expression levels in non-small cell lung cancer--a preliminary report.
Carcinoma, Non-Small-Cell Lung
Van der Waals force-driven indomethacin-ss-paclitaxel nanodrugs for reversing multidrug resistance and enhancing NSCLC therapy.
Carcinoma, Non-Small-Cell Lung
[Clinical significance of multidrug resistance-associated protein(MRP) gene expression in non-small cell lung cancer]
Carcinoma, Non-Small-Cell Lung
[Differential expressions of MDR-1, RRM-1, EGFR and ERCC-1 in primary tumors and metastatic lymph nodes of NSCLC patients].
Carcinoma, Non-Small-Cell Lung
[Expression and Clinical Significance of ABCC10 in the Patients with Non-small Cell Lung Cancer.]
Carcinoma, Non-Small-Cell Lung
[Expression and prognostic significance of multidrug resistance associated protein (MRP) gene in non-small cell lung cancer by in situ hybridization]
Carcinoma, Non-Small-Cell Lung
[Expression of MDR1-mRNA, MRP-mRNA and LRP-mRNA in patients with non-small cell lung cancer.]
Carcinoma, Non-Small-Cell Lung
[Expression of MRP gene in non-small cell lung cancer and its significance.]
Carcinoma, Non-Small-Cell Lung
[Expression of multidrug resistance-associated protein gene in non-small cell lung cancer]
Carcinoma, Non-Small-Cell Lung
[Expression of multidrug resistance-associated protein in human non-small cell lung cancer]
Carcinoma, Non-Small-Cell Lung
[Expression of multiple drug resistance-associated proteins in non-small cell lung cancer tissues and its clinical significance.]
Carcinoma, Non-Small-Cell Lung
[Expression of PTEN, p53 and P-glycoprotein in Non-small cell Lung Cancer and Their Predictive Values.]
Carcinoma, Non-Small-Cell Lung
[Expression of serum breast drug-resistance protein in predicting chemosensitivity of NSCLC]
Carcinoma, Non-Small-Cell Lung
[Influences of PC cell-derived growth factor and breast cancer resistance protein on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer]
Carcinoma, Non-Small-Cell Lung
[MRP expression in non-small cell lung cancer and normal lung tissues and its prognostic significance.]
Carcinoma, Non-Small-Cell Lung
[Predictive value of drug resistance-related genes expression in neoadjuvant chemotherapy in patients with non-small cell lung cancer of stage III]
Carcinoma, Non-Small-Cell Lung
[Relationships among expressions of hTERT, MDR1, MRP mRNA, and C-myc protein in non-small cell lung cancer.]
Carcinoma, Ovarian Epithelial
Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Drug resistance in epithelial ovarian cancer: P-glycoprotein and glutation S-transferase. Can they play an important role in detecting response to platinum-based chemotherapy as a first-line therapy.
Carcinoma, Ovarian Epithelial
Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma.
Carcinoma, Ovarian Epithelial
Expression levels of MRP1, GST-?, and GSK3? in ovarian cancer and the relationship with drug resistance and prognosis of patients.
Carcinoma, Ovarian Epithelial
Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer.
Carcinoma, Ovarian Epithelial
Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance.
Carcinoma, Ovarian Epithelial
Expression of PKC?, PKC?, and P-gp in epithelial ovarian carcinoma and the clinical significance.
Carcinoma, Ovarian Epithelial
Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Immunohistochemical localization of P-glycoprotein in adult human ovary and female genital tract of patients with benign gynecological conditions.
Carcinoma, Ovarian Epithelial
Multidrug resistance gene-1 (Pgp) expression in epithelial ovarian malignancies.
Carcinoma, Ovarian Epithelial
Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
Carcinoma, Ovarian Epithelial
Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
[The expression of MRP, GST-pi, Topo IIalpha and COX-2 in epithelial ovarian cancer and its relationship to drug resistance and prognosis]
Carcinoma, Renal Cell
99mTc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between 99mTc-MIBI uptake and P-glycoprotein expression in tumour tissue.
Carcinoma, Renal Cell
A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma.
Carcinoma, Renal Cell
A novel miR-203-DNMT3b-ABCG2 regulatory pathway predisposing colorectal cancer development.
Carcinoma, Renal Cell
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
Carcinoma, Renal Cell
A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.
Carcinoma, Renal Cell
A pilot study of low dose hydroxyurea as a novel resistance modulator in metastatic renal cell cancer.
Carcinoma, Renal Cell
ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma.
Carcinoma, Renal Cell
ABCG2 is a potential prognostic marker of overall survival in patients with clear cell renal cell carcinoma.
Carcinoma, Renal Cell
ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib.
Carcinoma, Renal Cell
Aberrant promoter methylation of the ABCG2 gene in renal carcinoma.
Carcinoma, Renal Cell
Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft.
Carcinoma, Renal Cell
Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
Carcinoma, Renal Cell
Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2 with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Analysis in Japanese Patients.
Carcinoma, Renal Cell
Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
Carcinoma, Renal Cell
Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Chemoresistance of renal cell carcinoma: 1986-1994.
Carcinoma, Renal Cell
Correlation of expression levels of P-glycoprotein with resistance to adriamycin in a renal adenocarcinoma cell line.
Carcinoma, Renal Cell
Correlations between natural resistance to doxorubicin, proliferative activity, and expression of P-glycoprotein 170 in human kidney tumor cell lines.
Carcinoma, Renal Cell
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Carcinoma, Renal Cell
Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.
Carcinoma, Renal Cell
Detection of drug resistance and P-glycoprotein in human renal cell carcinomas.
Carcinoma, Renal Cell
Detection of low-level expression of P-glycoprotein in ACHN renal adenocarcinoma cells.
Carcinoma, Renal Cell
Detection of P-glycoprotein in human urogenital carcinomas and its relationship to epidermal growth factor receptor expression.
Carcinoma, Renal Cell
Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance.
Carcinoma, Renal Cell
Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.
Carcinoma, Renal Cell
Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1.
Carcinoma, Renal Cell
Effects of Cabazitaxel in Renal Cell Carcinoma Cell Lines.
Carcinoma, Renal Cell
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Carcinoma, Renal Cell
Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Carcinoma, Renal Cell
Evaluation of aminolevulinic acid-mediated protoporphyrin IX fluorescence and enhancement by ABCG2 inhibitors in renal cell carcinoma cells.
Carcinoma, Renal Cell
Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma. A phase I study.
Carcinoma, Renal Cell
Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
Carcinoma, Renal Cell
Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome.
Carcinoma, Renal Cell
Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.
Carcinoma, Renal Cell
Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma.
Carcinoma, Renal Cell
Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Carcinoma, Renal Cell
Expression of several resistance mechanisms in untreated human kidney and lung carcinomas.
Carcinoma, Renal Cell
Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP),glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney.
Carcinoma, Renal Cell
Genetically determined differences in P-glycoprotein function: implications for disease risk.
Carcinoma, Renal Cell
Identification of target antigens in specific immunotherapy for renal cell carcinoma.
Carcinoma, Renal Cell
Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients.
Carcinoma, Renal Cell
Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.
Carcinoma, Renal Cell
Interaction of CCN1 with ?v?3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells.
Carcinoma, Renal Cell
Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma.
Carcinoma, Renal Cell
Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
Carcinoma, Renal Cell
Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas.
Carcinoma, Renal Cell
Multidrug resistance protein 4 (MRP4/ABCC4) is overexpressed in clear cell renal cell carcinoma (ccRCC) and is essential to regulate cell proliferation.
Carcinoma, Renal Cell
Nodal is involved in chemoresistance of renal cell carcinoma cells via regulation of ABCB1.
Carcinoma, Renal Cell
Oncogenic PITX2 Facilitates Tumor Cell Drug Resistance by Inverse Regulation of hOCT3/SLC22A3 and ABC Drug Transporters in Colon and Kidney Cancers.
Carcinoma, Renal Cell
Phase II evaluation of doxorubicin/vinblastine combined with inhibitors trifluoperazine/verapamil of P-glycoprotein in patients with advanced renal carcinoma.
Carcinoma, Renal Cell
PKC? inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P.
Carcinoma, Renal Cell
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Renal Cell
Reversal of multidrug resistance in renal cell carcinoma by short hairpin RNA targeting MDR1 gene.
Carcinoma, Renal Cell
Sequence mutations of the substrate binding pocket of stem cell factor and multidrug resistance protein ABCG2 in renal cell cancer: A possible link to treatment resistance.
Carcinoma, Renal Cell
Significance of P-glycoprotein, P53, and survivin expression in renal cell carcinoma.
Carcinoma, Renal Cell
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas Keller G, Schally AV, Nagy A, Halmos G, Baker B, Engel JB, Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, New Orleans, LA.
Carcinoma, Renal Cell
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
Carcinoma, Renal Cell
The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.
Carcinoma, Renal Cell
The role of systemic chemotherapy in the treatment of kidney cancer.
Carcinoma, Renal Cell
Up-regulation of connexin 32 gene by 5-aza-2'-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling.
Carcinoma, Renal Cell
[Rapidly metastasizing renal carcinoma with intense expression of p53 and P-glycoprotein]
Carcinoma, Renal Cell
[Treosulfan displays cytotoxic effect on spheroids of primary cell cultures of renal cell carcinoma independent of p-glycoprotein expression]
Carcinoma, Small Cell
Cyclosporin A-induced oxidative stress is not the consequence of an increase in mitochondrial membrane potential.
Carcinoma, Small Cell
Immunohistochemical markers of prolonged survival in small cell carcinoma of the lung. An immunohistochemical study.
Carcinoma, Squamous Cell
?Np63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis.
Carcinoma, Squamous Cell
Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Carcinoma, Squamous Cell
Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.
Carcinoma, Squamous Cell
Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
Carcinoma, Squamous Cell
Detection of P-glycoprotein in human urogenital carcinomas and its relationship to epidermal growth factor receptor expression.
Carcinoma, Squamous Cell
Detection of P-glycoprotein in squamous cell carcinomas of the head and neck.
Carcinoma, Squamous Cell
Differential Expression of Stem Cell Markers in Ocular Surface Squamous Neoplasia.
Carcinoma, Squamous Cell
Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines.
Carcinoma, Squamous Cell
Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Carcinoma, Squamous Cell
Expression of multidrug resistance-associated protein (MRP) in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy.
Carcinoma, Squamous Cell
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Carcinoma, Squamous Cell
Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer.
Carcinoma, Squamous Cell
Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer.
Carcinoma, Squamous Cell
Function of P-glycoprotein expressed in placenta and mole.
Carcinoma, Squamous Cell
Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Immune responses against tumour-associated antigen-derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients.
Carcinoma, Squamous Cell
Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung.
Carcinoma, Squamous Cell
In vitro and in vivo induction of apoptosis by sphingosine and N, N-dimethylsphingosine in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells.
Carcinoma, Squamous Cell
In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.
Carcinoma, Squamous Cell
Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer.
Carcinoma, Squamous Cell
Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer.
Carcinoma, Squamous Cell
Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
Carcinoma, Squamous Cell
P-glycoprotein expression in squamous cell carcinoma of the oral and maxillofacial region.
Carcinoma, Squamous Cell
P-glycoprotein expression in the squamous cell carcinoma of the tongue base.
Carcinoma, Squamous Cell
p53 and P-glycoprotein expression do not correlate with survival in nonsmall cell lung cancer: a long-term study and literature review.
Carcinoma, Squamous Cell
Papers to appear in forthcoming issues
Carcinoma, Squamous Cell
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Squamous Cell
Significance of ATP-binding cassette transporter proteins in multidrug resistance of head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
The expression of multidrug resistance protein in human gastrointestinal tract carcinomas.
Carcinoma, Squamous Cell
The Integration of a Three-Dimensional Spheroid Cell Culture Operation in a Circulating Tumor Cell (CTC) Isolation and Purification Process: A Preliminary Study of the Clinical Significance and Prognostic Role of the CTCs Isolated from the Blood Samples of Head and Neck Cancer Patients.
Carcinoma, Squamous Cell
The Multidrug Resistant Modulator HZ08 Reverses Multidrug Resistance via P-glycoprotein Inhibition and Apoptosis Sensitization in Human Epidermoid Carcinoma Cell Line KBv200.
Carcinoma, Squamous Cell
[Detection of P-glycoprotein in squamous cell carcinoma of larynx]
Carcinoma, Squamous Cell
[Expression and Clinical Significance of ABCC10 in the Patients with Non-small Cell Lung Cancer.]
Carcinoma, Squamous Cell
[Expression and implication of Pgp, MRP, LRP, GST-pi, Topo II alpha in tongue squamous cell carcinoma]
Carcinoma, Squamous Cell
[Expression and Significance of Stem Cell Markers CK19, Notch3, CD133, P75NTR, STRO-1 and ABCG2 in Pulmonary Squamous Carcinomas.]
Carcinoma, Squamous Cell
[Expression of multidrug resistance-associated protein in human non-small cell lung cancer]
Carcinoma, Squamous Cell
[The correlation between P-glycoprotein and multidrug resistance of squamous carcinoma in oral and maxillofacial region]
Carcinoma, Transitional Cell
Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder.
Carcinoma, Transitional Cell
Biological markers in transurethral biopsies from bladder-cancer - preliminary-results.
Carcinoma, Transitional Cell
Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract.
Carcinoma, Transitional Cell
Detection of P-glycoprotein in human urogenital carcinomas and its relationship to epidermal growth factor receptor expression.
Carcinoma, Transitional Cell
Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma.
Carcinoma, Transitional Cell
Expression of multidrug resistance gene product (P-glycoprotein) in transitional cell carcinomas of the upper urinary tract.
Carcinoma, Transitional Cell
Expression of multidrug-associated protein, P-glycoprotein, P53 and Bcl-2 proteins in bladder cancer and clinical implication.
Carcinoma, Transitional Cell
Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas.
Carcinoma, Transitional Cell
Gemcitabine in bladder cancer.
Carcinoma, Transitional Cell
Glutathione S-transferase and multidrug-resistant phenotype in transitional cell carcinoma of the bladder.
Carcinoma, Transitional Cell
P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder.
Carcinoma, Transitional Cell
The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
Carcinosarcoma
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Cardiomegaly
The ATP-Binding Cassette Transporter ABCG2 Protects Against Pressure Overload-Induced Cardiac Hypertrophy and Heart Failure by Promoting Angiogenesis and Antioxidant Response.
Cardiomyopathies
Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy.
Cardiomyopathies
The ATP-binding Cassette Transporter ABCG2 (BCRP), a Marker for Side Population Stem Cells, Is Expressed in Human Heart.
Cardiomyopathy, Hypertrophic
Chromophobe renal cell carcinoma with and without sarcomatoid change: a clinicopathological, comparative genomic hybridization, and whole-exome sequencing study.
Cardiotoxicity
ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia.
Cardiotoxicity
Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.
Cardiotoxicity
Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length.
Cardiotoxicity
Dioscorea bulbifera L. delays the excretion of doxorubicin and aggravates doxorubicin-induced cardiotoxicity and nephrotoxicity by inhibiting the expression of P-glycoprotein in mice liver and kidney.
Cardiotoxicity
Does anthracycline-based chemotherapy in pregnant women with cancer offer safe cardiac and neurodevelopmental outcomes for the developing fetus?
Cardiotoxicity
Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.
Cardiotoxicity
Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial.
Cardiotoxicity
Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Cardiotoxicity
Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance.
Cardiotoxicity
Impact of ABCB1 allelic variants on QTc interval prolongation.
Cardiotoxicity
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Cardiotoxicity
Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.
Cardiotoxicity
Loss of multidrug resistance-associated protein 1 potentiates chronic doxorubicin-induced cardiac dysfunction in mice.
Cardiotoxicity
Modulation of doxorubicin-induced expression of the multidrug resistance gene in breast cancer cells by diltiazem and protection against cardiotoxicity in experimental animals.
Cardiotoxicity
Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms.
Cardiotoxicity
Montelukast ameliorates doxorubicin-induced cardiotoxicity via modulation of p-glycoprotein and inhibition of ROS-mediated TNF-?/NF-?B pathways.
Cardiotoxicity
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.
Cardiotoxicity
Notes from the Field: Cardiac Dysrhythmias After Loperamide Abuse - New York, 2008-2016.
Cardiotoxicity
Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Cardiotoxicity
Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.
Cardiotoxicity
Suppression of NF-?B signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin -induced apoptosis in lung cancer.
Cardiotoxicity
The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal.
Cardiotoxicity
Utility of protein structures in overcoming ADMET-related issues of drug-like compounds.
Cardiovascular Diseases
A randomized trial comparing the acute coronary, systemic, and environmental effects of electronic vaping cigarettes versus heat-not-burn cigarettes in smokers of combustible cigarettes undergoing invasive coronary assessment: rationale and design of the SUR-VAPES 3 trial.
Cardiovascular Diseases
ABCB1 C3435T Polymorphism and the Risk of Coronary Heart Disease: A Meta-Analysis.
Cardiovascular Diseases
Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients.
Cardiovascular Diseases
Association of fetal but not maternal P-glycoprotein C3435T polymorphism with fetal growth and birth weight, a possible risk factor for cardiovascular diseases in later life.
Cardiovascular Diseases
Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells.
Cardiovascular Diseases
ATP binding cassette transporter A1--key roles in cellular lipid transport and atherosclerosis.
Cardiovascular Diseases
ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease.
Cardiovascular Diseases
CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
Cardiovascular Diseases
E3317 promotes cholesterol efflux in macrophage cells via enhancing ABCA1 expression.
Cardiovascular Diseases
Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats.
Cardiovascular Diseases
Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin.
Cardiovascular Diseases
Functional rescue of mutant ABCA1 proteins by sodium 4-phenylbutyrate.
Cardiovascular Diseases
Influence of intermittent hypoxia on myocardial and hepatic P-glycoprotein expression in a rodent model.
Cardiovascular Diseases
Lack of association between increased carotid intima-media thickening and decreased HDL-cholesterol in a family with a novel ABCA1 variant, G2265T.
Cardiovascular Diseases
Multidrug resistance proteins preferentially regulate natriuretic peptide-driven cGMP signalling in the heart and vasculature.
Cardiovascular Diseases
New Challenges for HDL-Modifying Therapies as a Strategy to Lower Cardiovascular Disease Events in Statin-Treated Patients : Editorial to: "Statin-Induced Decrease in ATP-Binding Cassette Transporter A1 Expression via microRNA33 Induction may Counteract Cholesterol Efflux to High Density Lipoprotein" by E.J. Niesor et al.
Cardiovascular Diseases
Regulation of ABCA1 functions by signaling pathways.
Cardiovascular Diseases
Resveratrol stereoselectively affected (±)warfarin pharmacokinetics and enhanced the anticoagulation effect.
Cardiovascular Diseases
The effects of subacute inhaled multi-walled carbon nanotube exposure on signaling pathways associated with cholesterol transport and inflammatory markers in the vasculature of wild-type mice.
Cardiovascular Diseases
TLR2 stimulates ABCA1 expression via PKC-? and PLD2 pathway.
Cardiovascular Diseases
Verapamil for cluster headache. Clinical pharmacology and possible mode of action.
Cardiovascular Diseases
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Carotid Stenosis
Finding the optimal deconvolution algorithm for MR perfusion in carotid stenosis: Correlations with angiographic cerebral circulation time.
Catalepsy
Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A.
Cataract
Molecular identification of P-glycoprotein: a role in lens circulation?
Cataract
Up-regulation of P-glycoprotein expression by osmotic stress in rat sugar cataract.
Catatonia
Loperamide overdose-induced catatonia: potential role of brain opioid system and P-glycoprotein.
Central Nervous System Diseases
Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain.
Central Nervous System Diseases
Blood-Brain Barrier and Breast Cancer Resistance Protein: a limit to the therapy of CNS tumors and neurodegenerative diseases.
Central Nervous System Diseases
Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy.
Central Nervous System Diseases
Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe.
Central Nervous System Diseases
Liposomes Coloaded with Elacridar and Tariquidar To Modulate the P-Glycoprotein at the Blood-Brain Barrier.
Central Nervous System Diseases
Significance and Mechanisms of P-glycoprotein in Central Nervous System Diseases.
Central Nervous System Diseases
Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation.
Central Nervous System Diseases
Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach.
Central Nervous System Diseases
The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases.
Central Nervous System Neoplasms
A novel taxane active against an orthotopically growing human glioma xenograft.
Central Nervous System Neoplasms
Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors.
Cerebral Amyloid Angiopathy
ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.
Cerebral Amyloid Angiopathy
ATP-binding cassette transporters P-glycoprotein and breast cancer related protein are reduced in capillary cerebral amyloid angiopathy.
Cerebral Amyloid Angiopathy
Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
Cerebral Amyloid Angiopathy
The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease.
Cerebral Infarction
Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism.
Cerebral Infarction
The R219K polymorphism in the ATP-binding cassette transporter 1 gene has a protective effect on atherothrombotic cerebral infarction in Chinese Han ethnic population.
Cerebrovascular Disorders
Mixed polyethylene glycol-modified breviscapine-loaded solid lipid nanoparticles for improved brain bioavailability: preparation, characterization, and in vivo cerebral microdialysis evaluation in adult sprague dawley rats.
Chemical and Drug Induced Liver Injury
Alterations of canalicular ATP-binding cassette transporter expression in drug-induced liver injury.
Chemical and Drug Induced Liver Injury
Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?
Chemical and Drug Induced Liver Injury
Correction to Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.
Chemical and Drug Induced Liver Injury
Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors.
Chemical and Drug Induced Liver Injury
Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.
Chemical and Drug Induced Liver Injury
Membrane vesicle ABC transporter assays for drug safety assessment.
Chemical and Drug Induced Liver Injury
Meta-analysis method for discovering reliable biomarkers by integrating statistical and biological approaches: An application to liver toxicity.
Chemical and Drug Induced Liver Injury
Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury.
Chemical and Drug Induced Liver Injury
Predicting the presence and mechanism of busulfan drug-drug interactions in hematopoietic stem cell transplantation using pharmacokinetic interaction network-based molecular structure similarity and network pharmacology.
Chickenpox
Management of vaccinations in Italy: a national survey after healthcare regionalization.
Cholangiocarcinoma
Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer.
Cholangiocarcinoma
BSEP and MDR3: Useful Immunohistochemical Markers to Discriminate Hepatocellular Carcinomas From Intrahepatic Cholangiocarcinomas and Hepatoid Carcinomas.
Cholangiocarcinoma
Cytotoxicity, Cell Cycle Arrest, and Apoptosis Induction Activity of Ethyl-p-methoxycinnamate in Cholangiocarcinoma Cell.
Cholangiocarcinoma
Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
Cholangiocarcinoma
Enhanced Gemcitabine Cytotoxicity with Knockdown of Multidrug Resistance Protein Genes in Human Cholangiocarcinoma Cell Lines.
Cholangiocarcinoma
Expression of Multi-drug Resistance-Related Genes MDR3 and MRP as Prognostic Factors in Clinical Liver Cancer Patients.
Cholangiocarcinoma
Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas.
Cholangiocarcinoma
Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
High Expression of ABCC1 Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Cholangiocarcinoma
Inhibition of Wnt/?-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma.
Cholangiocarcinoma
Long non-coding RNA LOXL1-AS1 acts as a ceRNA for miR-324-3p to contribute to cholangiocarcinoma progression via modulation of ATP-binding cassette transporter A1.
Cholangiocarcinoma
Prognostic value of ABCG2 in moderately and poorly differentiated intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium.
Cholangitis
Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice.
Cholangitis
Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis.
Cholangitis
Semiquantitation of intrahepatic MDR3 mRNA levels by reverse transcription/competitive polymerase chain reaction.
Cholangitis, Sclerosing
BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis.
Cholangitis, Sclerosing
Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis.
Cholangitis, Sclerosing
Interleukin 2 Promotes Hepatic Regulatory T Cell Responses and Protects From Biliary Fibrosis in Murine Sclerosing Cholangitis.
Cholangitis, Sclerosing
Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice.
Cholangitis, Sclerosing
The ectonucleotidase ENTPD1/CD39 limits biliary injury and fibrosis in mouse models of sclerosing cholangitis.
Cholangitis, Sclerosing
Vitamin D modulates biliary fibrosis in ABCB4-deficient mice.
Cholelithiasis
ABCB4 mutations underlie hormonal cholestasis but not pediatric idiopathic gallstones.
Cholelithiasis
Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium.
Cholelithiasis
[A bicistronic retroviral vector containing MGMT and MDR1 drug resistance genes transfer into human umbilical cord blood CD34+ cells to improve combination chemotherapy tolerance]
Cholera
Activation of Adenylyl Cyclase Causes Stimulation of Adenosine Receptors.
Cholera
Dissection of the conformational cycle of the multidrug/lipidA ABC exporter MsbA.
Cholera
New structure model for the ATP-binding cassette multidrug transporter LmrA.
Cholera
Retraction of "Structure of MsbA from Vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation" [J. Mol. Biol. (2003) 330 419-430].
Cholera
Structure of MsbA from Vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation.
Cholestasis
17 beta-estradiol glucuronide: an inducer of cholestasis and a physiological substrate for the multidrug resistance transporter.
Cholestasis
Activation of insulin-like growth factor 1 receptor participates downstream of GPR30 in estradiol-17?-D-glucuronide-induced cholestasis in rats.
Cholestasis
Beneficial effect of spironolactone administration on ethynylestradiol-induced cholestasis in the rat: involvement of up-regulation of multidrug resistance-associated protein 2.
Cholestasis
Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice.
Cholestasis
Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles.
Cholestasis
Bile Duct Obstruction Leads to Increased Intestinal Expression of Breast Cancer Resistance Protein With Reduced Gastrointestinal Absorption of Imatinib.
Cholestasis
Biliary excretion of taurolithocholate-sulfate and temocaprilat in cholestatic rats induced by bile duct-ligation and ethinylestradiol.
Cholestasis
Ca(2+)-dependent protein kinase C isoforms are critical to estradiol 17beta-D-glucuronide-induced cholestasis in the rat.
Cholestasis
Calculus Bovis Sativus up-regulates hepatic protein 2 (Mrp2) and Mrp4 in 17?-ethynylestradiol-induced cholestasis via a regulatory effect on ER signaling.
Cholestasis
Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver.
Cholestasis
Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta.
Cholestasis
Cholestasis in a patient with gallstones and a normal gamma-glutamyl transferase.
Cholestasis
Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis.
Cholestasis
Cholestatic properties and hepatic transport of steroid glucuronides.
Cholestasis
Compensatory role of P-glycoproteins in knockout mice lacking the bile salt export pump.
Cholestasis
Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2.
Cholestasis
Coordinated Targeting of Galanin Receptors on Cholangiocytes and Hepatic Stellate Cells Ameliorates Liver Fibrosis in Multidrug Resistance Protein 2 Knockout Mice.
Cholestasis
Danazol induced cholestasis: pathogenetic hypothesis.
Cholestasis
Decreased expression of breast cancer resistance protein in the duodenum in patients with obstructive cholestasis.
Cholestasis
Differential expression of multidrug resistance (mdr) and canalicular multispecific organic anion transporter (cMOAT) genes following extrahepatic biliary obstruction in rats.
Cholestasis
Dioscin protects against ANIT-induced cholestasis via regulating Oatps, Mrp2 and Bsep expression in rats.
Cholestasis
Disturbed colocalization of multidrug resistance protein 2 and radixin in human cholestatic liver diseases.
Cholestasis
Effect of bile acids on biliary excretion of cyclosporin A in the rat.
Cholestasis
Effect of YHHJ on the expression of the hepatocellular bile acid transporters multidrug resistance-associated protein 2 and bile salt export pump in ethinylestradiol-induced cholestasis.
Cholestasis
Effects of microplastics (MPs) and tributyltin (TBT) alone and in combination on bile acids and gut microbiota crosstalk in mice.
Cholestasis
EGFR participates downstream of ER? in estradiol-17?-D-glucuronide-induced impairment of Abcc2 function in isolated rat hepatocyte couplets.
Cholestasis
Elevated hepatic MRP3/ABCC3 expression in human obstructive cholestasis is mediated through TNF? and JNK/SAPK signaling pathway.
Cholestasis
Enhanced expression of basolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPS.
Cholestasis
Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats.
Cholestasis
Etiologic significance of defects in cholesterol, phospholipid, and bile acid metabolism in the liver of patients with intrahepatic calculi.
Cholestasis
Expression of Multidrug Resistance Protein 2 (mrp2) in the Liver and Kidney Cells of Female Rats with Modeled Cholestasis of Pregnancy.
Cholestasis
G-protein-coupled receptor 30/adenylyl cyclase/protein kinase A pathway is involved in estradiol 17ß-D-glucuronide-induced cholestasis.
Cholestasis
Glucocorticoids Cause Gender-Dependent Reversal of Hepatic Fibrosis in the MDR2-Knockout Mouse Model.
Cholestasis
Growth hormone modulation of the rat hepatic bile transporter system in endotoxin-induced cholestasis.
Cholestasis
Hepatic transport of bile salts.
Cholestasis
Hormonal Modulation of Hepatic cAMP Prevents Estradiol 17?-D-Glucuronide-Induced Cholestasis in Perfused Rat Liver.
Cholestasis
Improved hepatic MRP2/ABCC2 transport activity in LPS-induced cholestasis by aquaporin-1 gene transfer.
Cholestasis
Inchinkoto, a herbal medicine, and its ingredients dually exert Mrp2/MRP2-mediated choleresis and Nrf2-mediated antioxidative action in rat livers.
Cholestasis
Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump.
Cholestasis
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
Cholestasis
Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates.
Cholestasis
Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia.
Cholestasis
Investigations of the total flavonoids extracted from flowers of Abelmoschus manihot (L.) Medic against ?-naphthylisothiocyanate-induced cholestatic liver injury in rats.
Cholestasis
LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process.
Cholestasis
Manifestation of Multidrug Resistance Protein 3 (MRP3) in Liver and Kidney Cells in Cholestasis: Effects of Hyperprolactinemia.
Cholestasis
Mechanism for the prevention of cholestasis involving cytochrome P4503A overexpression.
Cholestasis
Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides.
Cholestasis
Modulation of hepatic content and biliary excretion of P-glycoproteins in hepatocellular and obstructive cholestasis in the rat.
Cholestasis
Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats.
Cholestasis
Multidrug resistance protein 3 R652G may reduce susceptibility to idiopathic infant cholestasis.
Cholestasis
Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat.
Cholestasis
Mutation spectrum and biochemical features in infants with neonatal Dubin-Johnson syndrome.
Cholestasis
Neonatal Dubin-Johnson syndrome: biochemical parameters, characteristics, and genetic variants study.
Cholestasis
Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury.
Cholestasis
Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression.
Cholestasis
P-glycoprotein function and expression during obstructive cholestasis in rats.
Cholestasis
Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
Cholestasis
Physiological concentrations of unconjugated bilirubin prevent oxidative stress-induced hepatocanalicular dysfunction and cholestasis.
Cholestasis
Phytosterols promote liver injury and kupffer cell activation in parenteral nutrition-associated liver disease.
Cholestasis
Prevention of estradiol 17{beta}-D-glucuronide-induced canalicular transporter internalization by hormonal modulation of cAMP in rat hepatocytes.
Cholestasis
Protective effects of n-Butanol extract and iridoid glycosides of Veronica ciliata Fisch. against ANIT-induced cholestatic liver injury in mice.
Cholestasis
Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone.
Cholestasis
Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury.
Cholestasis
Role of ABCC2 common variants in intrahepatic cholestasis of pregnancy.
Cholestasis
Role of breast cancer resistance protein in the adaptive response to cholestasis.
Cholestasis
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice.
Cholestasis
Role of Multidrug Resistance Protein 3 in Antifungal-Induced Cholestasis.
Cholestasis
Sequential activation of classic PKC and estrogen receptor ? is involved in estradiol 17ß-D-glucuronide-induced cholestasis.
Cholestasis
Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein.
Cholestasis
Spironolactone ameliorates lipopolysaccharide-induced cholestasis in rats by improving Mrp2 function: Role of transcriptional and post-transcriptional mechanisms.
Cholestasis
Studies on the multidrug resistance gene expression in the livers of rats associated with different susceptibility of hepatocarcinogenesis.
Cholestasis
Taurine supplementation induces multidrug resistance protein 2 and bile salt export pump expression in rats and prevents endotoxin-induced cholestasis.
Cholestasis
The effect of dimerumic acid on LPS-induced downregulation of Mrp2 in the rat.
Cholestasis
The Function of Multidrug Resistance-associated Protein 3 in the Transport of Bile Acids under Normal Physiological and Lithocholic Acid-induced Cholestasis Conditions.
Cholestasis
The role of radixin in altered localization of canalicular conjugate export pump Mrp2 in cholestatic rat liver.
Cholestasis
TNF? Induces Multidrug Resistance-Associated Protein 4 Expression through p38-E2F1-Nrf2 Signaling in Obstructive Cholestasis.
Cholestasis
Unexplained cholestasis in adults and adolescents: diagnostic benefit of genetic examination.
Cholestasis
Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver.
Cholestasis
Up-regulation of miR-let7a-5p Leads to Decreased Expression of ABCC2 in Obstructive Cholestasis.
Cholestasis
Ursodeoxycholate Restores Biliary Excretion of Methotrexate in Rats with Ethinyl Estradiol Induced-Cholestasis by Restoring Canalicular Mrp2 Expression.
Cholestasis
Yinchenhao Decoction Ameliorates Alpha-Naphthylisothiocyanate Induced Intrahepatic Cholestasis in Rats by Regulating Phase II Metabolic Enzymes and Transporters.
Cholestasis
[Paracetamol overdose and experimental cholestasis induced gene expression regulation that codified P-Glycoprotein type 1 in rats]
Cholestasis, Extrahepatic
Expression and function of renal and hepatic organic anion transporters in extrahepatic cholestasis.
Cholestasis, Extrahepatic
Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats.
Cholestasis, Extrahepatic
Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis.
Cholestasis, Extrahepatic
[Paracetamol overdose and experimental cholestasis induced gene expression regulation that codified P-Glycoprotein type 1 in rats]
Cholestasis, Intrahepatic
An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy.
Cholestasis, Intrahepatic
Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy.
Cholestasis, Intrahepatic
Bile acid transport correlative protein mRNA expression profile in human placenta with intrahepatic cholestasis of pregnancy.
Cholestasis, Intrahepatic
Bone marrow transplantation results in donor-derived hepatocytes in an animal model of inherited cholestatic liver disease.
Cholestasis, Intrahepatic
Dearterialization of the liver causes intrahepatic cholestasis due to reduced bile transporter expression.
Cholestasis, Intrahepatic
Ductopenia and cirrhosis in a 32-year-old woman with progressive familial intrahepatic cholestasis type 3: A case report and review of the literature.
Cholestasis, Intrahepatic
Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice.
Cholestasis, Intrahepatic
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis.
Cholestasis, Intrahepatic
Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy.
Cholestasis, Intrahepatic
Genetic variants in adult liver diseases.
Cholestasis, Intrahepatic
High doses of ursodeoxycholic acid up-regulate the expression of placental breast cancer resistance protein in patients affected by intrahepatic cholestasis of pregnancy.
Cholestasis, Intrahepatic
High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (bile salt export pump) to predict drug-induced intrahepatic cholestasis.
Cholestasis, Intrahepatic
Hydrophilic bile acids prevent liver damage caused by lack of biliary phospholipid in Mdr2-/- mice.
Cholestasis, Intrahepatic
Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump.
Cholestasis, Intrahepatic
Kupffer cell-mediated down regulation of rat hepatic CMOAT/MRP2 gene expression.
Cholestasis, Intrahepatic
Liver transplantation in children with progressive familial intrahepatic cholestasis.
Cholestasis, Intrahepatic
Novel compound heterozygous ABCC2 variants in patients with Dubin-Johnson syndrome and intrahepatic cholestasis of pregnancy.
Cholestasis, Intrahepatic
Receptor for activated C-kinase 1 regulates the cellular localization and function of ABCB4.
Cholestasis, Intrahepatic
Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3.
Cholestasis, Intrahepatic
Role of ABCC2 common variants in intrahepatic cholestasis of pregnancy.
Cholestasis, Intrahepatic
Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy.
Cholestasis, Intrahepatic
Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants.
Cholestasis, Intrahepatic
Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein.
Cholestasis, Intrahepatic
Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis.
Cholestasis, Intrahepatic
The effect of 17?-ethynylestradiol induced intrahepatic cholestasis of pregnancy on placental P-glycoprotein in mice: Implications in the individualized transplacental digoxin treatment for fetal heart failure.
Cholestasis, Intrahepatic
Upregulation of PDZK1 by Calculus Bovis Sativus May Play an Important Role in Restoring Biliary Transport Function in Intrahepatic Cholestasis.
Cholestasis, Intrahepatic
Variants Associated with Infantile Cholestatic Syndromes Detected in Extrahepatic Biliary Atresia by Whole Exome Studies: A 20-Case Series from Thailand.
Chondrosarcoma
Amphiregulin promotes cisplatin chemoresistance by upregulating ABCB1 expression in human chondrosarcoma.
Chondrosarcoma
Chemotherapy and P-glycoprotein expression in chondrosarcoma.
Chondrosarcoma
Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance.
Chondrosarcoma
Recurrence rate and progression of chondrosarcoma is correlated with heat shock protein expression.
Chondrosarcoma
siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells.
Chorioamnionitis
Chorioamnionitis Induces a Specific Signature of Placental ABC Transporters Associated with an Increase of miR-331-5p in the Human Preterm Placenta.
Choriocarcinoma
Cadmium inhibits ABCG2 transporter function in BeWo choriocarcinoma cells and MCF-7 cells overexpressing ABCG2.
Choriocarcinoma
Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines.
Choriocarcinoma
Expression and functional activity of breast cancer resistance protein (bcrp, abcg2) transporter in the human choriocarcinoma cell line bewo.
Choriocarcinoma
Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter.
Choriocarcinoma
Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein.
Choriocarcinoma
In Vitro Approaches to Evaluate Placental Drug Transport by Using Differentiating JEG-3 Human Choriocarcinoma Cells.
Choriocarcinoma
Interactions between riluzole and ABCG2/BCRP transporter.
Choriocarcinoma
Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells.
Choriocarcinoma
StarD7 Knockdown Modulates ABCG2 Expression, Cell Migration, Proliferation, and Differentiation of Human Choriocarcinoma JEG-3 Cells.
Choriocarcinoma
Xanthines Down-Regulate the Drug Transporter ABCG2 and Reverse Multidrug Resistance.
Cleft Lip
Maternal medication use, carriership of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate.
Cleft Palate
Maternal medication use, carriership of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate.
Clostridium Infections
Functional reconstruction of human AML reveals stem cell origin and vulnerability of treatment-resistant MLL-rearranged leukemia.
Cluster Headache
Verapamil for cluster headache. Clinical pharmacology and possible mode of action.
Coccidiosis
Effect of colibacillosis or coccidiosis on expression of breast cancer resistance protein in small intestine and liver of chickens.
Coccidiosis
Experimental coccidiosis influences the expression of the ABCB1 gene, a physiological important functional marker of intestinal integrity in chickens.
Coinfection
Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
Coinfection
Comparative study of the effects of anti-tuberculosis drugs and antiretroviral drugs on CYP3A4 and P-glycoprotein.
Coinfection
Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.
Coinfection
Relationship between ABCC4 SNPs and hepatitis B virus suppression during tenofovir-containing antiretroviral therapy in patients with HIV/HBV coinfection.
Colitis
A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis.
Colitis
Absence of ABCG2-mediated mucosal detoxification in patients with active inflammatory bowel disease is due to impeded protein folding.
Colitis
Absence of association between the multidrug resistance (MDR1) gene and inflammatory bowel disease.
Colitis
Altered expression and function of P-glycoprotein in dextran sodium sulfate-induced colitis in mice.
Colitis
Altered generation of induced regulatory T cells in the FVB.mdr1a(-/-) mouse model of colitis.
Colitis
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis.
Colitis
Berberine Upregulates P-Glycoprotein in Human Caco-2 Cells and in an Experimental Model of Colitis in the Rat via Activation of Nrf2-Dependent Mechanisms.
Colitis
BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation.
Colitis
Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis.
Colitis
Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease.
Colitis
Compositional Changes in the Gut Mucus Microbiota Precede the Onset of Colitis-Induced Inflammation.
Colitis
Critical Role For P-Glycoprotein Expression in Hematopoietic Cells In The Fvb.Mdr1a-/- Model of Colitis.
Colitis
Decreased drug penetration in inflamed tissue related to changed mucosal metabolism in experimental colitis.
Colitis
Differential susceptibility of P-glycoprotein deficient mice to colitis induction by environmental insults.
Colitis
Downregulation of CYP3A and P-glycoprotein in the secondary inflammatory response of mice with dextran sulfate sodium-induced colitis and its contribution to cyclosporine A blood concentrations.
Colitis
Dual infection with Helicobacter bilis and Helicobacter hepaticus in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia.
Colitis
Dysfunction in ABCB1A has only a weak effect on susceptibility to dextran sulfate sodium-induced colitis in SAM strains.
Colitis
Early molecular and functional changes in colonic epithelium that precede increased gut permeability during colitis development in mdr1a(-/-) mice.
Colitis
Expression profiles of cytokines and chemokines in murine MDR1a-/- colitis.
Colitis
Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice.
Colitis
Loss of TLR2 worsens spontaneous colitis in MDR1A deficiency through commensally induced pyroptosis.
Colitis
Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Colitis
Stability in metabolic phenotypes and inferred metagenome profiles before the onset of colitis-induced inflammation.
Colitis
The importance of the polymorphisms of the ABCB1 gene in disease susceptibility, behavior and response to treatment in inflammatory bowel disease: A literature review.
Colitis
The mdr1a-/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease.
Colitis
Upregulation of P-glycoprotein by Probiotics in Intestinal Epithelial Cells and in the Dextran Sulfate Sodium Model of Colitis in Mice.
Colitis
[Is C3435T Polymorphism of MDR1 Related to Inflammatory Bowel Disease or Colorectal Cancer in Korean?]
Colitis, Ischemic
Absence of ABCG2-mediated mucosal detoxification in patients with active inflammatory bowel disease is due to impeded protein folding.
Colitis, Ulcerative
A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content.
Colitis, Ulcerative
ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis.
Colitis, Ulcerative
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis.
Colitis, Ulcerative
Association of abcb1 polymorphisms and ulcerative colitis susceptibility.
Colitis, Ulcerative
Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study.
Colitis, Ulcerative
ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis.
Colitis, Ulcerative
Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls.
Colitis, Ulcerative
Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity.
Colitis, Ulcerative
Effect of MicroRNA145 on the multidrug resistance gene of ulcerative colitis in rats.
Colitis, Ulcerative
Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1).
Colitis, Ulcerative
Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
Colitis, Ulcerative
MDR1 C3435T polymorphism is predictive of later onset of ulcerative colitis in Japanese.
Colitis, Ulcerative
MDR1 mRNA expressions in peripheral blood mononuclear cells of patients with ulcerative colitis in relation to glucocorticoid administration.
Colitis, Ulcerative
Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients.
Colitis, Ulcerative
Multidrug resistance gene and its relationship to ulcerative colitis and immune status of ulcerative colitis.
Colitis, Ulcerative
The frequency of C3435T MDR1 gene polymorphism in Iranian patients with ulcerative colitis.
Colitis, Ulcerative
Variable expression of P-glycoprotein in normal, inflamed, and dysplastic areas in ulcerative colitis.
Colitis, Ulcerative
[P-glycoprotein functional activity in peripheral blood lymphocytes in ulcerative colitis]
Colonic Neoplasms
3-Hydroxyflavone and structural analogues differentially activate pregnane X receptor: Implication for inflammatory bowel disease.
Colonic Neoplasms
8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1.
Colonic Neoplasms
A case of colon cancer recurrence with P-glycoprotein treated by methotrexate, fluorouracil, and leucovorin.
Colonic Neoplasms
A novel miR-203-DNMT3b-ABCG2 regulatory pathway predisposing colorectal cancer development.
Colonic Neoplasms
A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells.
Colonic Neoplasms
ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer.
Colonic Neoplasms
ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136.
Colonic Neoplasms
ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patients.
Colonic Neoplasms
ABCG2 and TOP-1 as predictive biomarkers and targets for therapy in colon cancer.
Colonic Neoplasms
ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
Colonic Neoplasms
ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
Colonic Neoplasms
Adrenaline induces chemoresistance in HT-29 colon adenocarcinoma cells.
Colonic Neoplasms
Alkylated monoterpene indole alkaloid derivatives as potent P-glycoprotein inhibitors in resistant cancer cells.
Colonic Neoplasms
An Explorative Analysis of ABCG2/TOP-1 mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 Trial.
Colonic Neoplasms
Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue.
Colonic Neoplasms
Antitumor activity and downregulation of pro-angiogenic molecules in human prostate cancer cells by a novel thiazolidione compound.
Colonic Neoplasms
Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.
Colonic Neoplasms
beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes.
Colonic Neoplasms
Bufalin-loaded vitamin E succinate-grafted-chitosan oligosaccharide/RGD conjugated TPGS mixed micelles demonstrated improved antitumor activity against drug-resistant colon cancer.
Colonic Neoplasms
Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells.
Colonic Neoplasms
Characterization of proapoptotic compounds from the bark of Garcinia oblongifolia.
Colonic Neoplasms
Chemoresistance of CD133(+) colon cancer may be related with increased survivin expression.
Colonic Neoplasms
Chemosensitization by diverging modulation by short-term and long-term TNF-? action on ABCB1 expression and NF-?B signaling in colon cancer.
Colonic Neoplasms
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics.
Colonic Neoplasms
Clofazimine and B4121 sensitize an intrinsically resistant human colon cancer cell line to P-glycoprotein substrates.
Colonic Neoplasms
Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines.
Colonic Neoplasms
Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor.
Colonic Neoplasms
Curcumin Regulates Colon Cancer by Inhibiting P-Glycoprotein in In-situ Cancerous Colon Perfusion Rat Model.
Colonic Neoplasms
Curcumin Reverses 5-Fluorouracil Resistance by Promoting Human Colon Cancer HCT-8/5-FU Cell Apoptosis and Down-regulating Heat Shock Protein 27 and P-Glycoprotein.
Colonic Neoplasms
Cytosolic superoxide dismutase activity after photodynamic therapy, intracellular distribution of Photofrin II and hypericin, and P-glycoprotein localization in human colon adenocarcinoma.
Colonic Neoplasms
Cytotoxic activity of halogenated monoterpenes from Plocamium cartilagineum.
Colonic Neoplasms
Cytotoxic Constituents of the Bark of Hypericum roeperianum towards Multidrug-Resistant Cancer Cells.
Colonic Neoplasms
Data showing the circumvention of oxaliplatin resistance by vatalanib in colon cancer.
Colonic Neoplasms
Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance.
Colonic Neoplasms
Development of drug resistance in the population of colon cancer cells under the effect of multifunctional protein YB-1.
Colonic Neoplasms
Differential activation of pregnane X receptor by carnosic acid, carnosol, ursolic acid, and rosmarinic acid.
Colonic Neoplasms
Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cells.
Colonic Neoplasms
Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy.
Colonic Neoplasms
Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition.
Colonic Neoplasms
Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug resistance in colon cancer cell lines.
Colonic Neoplasms
Effects of P-glycoprotein expression on cyclic AMP and volume-activated ion fluxes and conductances in HT-29 colon adenocarcinoma cells.
Colonic Neoplasms
Effects of the flavonoid biochanin A on gene expression in primary human hepatocytes and human intestinal cells.
Colonic Neoplasms
Electroporation adopting trains of biphasic pulses enhances in vitro and in vivo the cytotoxic effect of doxorubicin on multidrug resistant colon adenocarcinoma cells (LoVo).
Colonic Neoplasms
Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers.
Colonic Neoplasms
Expression of Aldehyde Dehydrogenase (ALDH1) and ATP Binding Cassette Transporter G2 (ABCG2) in Iraqi Patients with Colon Cancer and the Relation with Clinicopathological Features.
Colonic Neoplasms
Expression of ATP-binding Cassette Transporter 11 (ABCC11) Protein in Colon Cancer.
Colonic Neoplasms
Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes.
Colonic Neoplasms
Flow cytometric analysis of multidrug-resistance-associated antigen (P-glycoprotein) and DNA ploidy in human colon cancer.
Colonic Neoplasms
FTY720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1.
Colonic Neoplasms
Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2).
Colonic Neoplasms
Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
Colonic Neoplasms
Growth Inhibitory Effect of (E)-2,4-bis(p-hydroxyphenyl)-2-Butenal Diacetate through Induction of Apoptotic Cell Death by Increasing DR3 Expression in Human Lung Cancer Cells.
Colonic Neoplasms
Hyperin Enhances the Sensitivity of HCT8/VCR Colon Cancer Cell Line to Vincristine by Down-Regulating P-Glycoprotein.
Colonic Neoplasms
Hypoxia-inducible factor-1? induces multidrug resistance protein in colon cancer.
Colonic Neoplasms
Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.
Colonic Neoplasms
Impact of mutant ?-catenin on ABCB1 expression and therapy response in colon cancer cells.
Colonic Neoplasms
Increased JNK1 Signaling Pathway Is Responsible for ABCG2-Mediated Multidrug Resistance in Human Colon Cancer.
Colonic Neoplasms
Influence of combinations of digitonin with selected phenolics, terpenoids, and alkaloids on the expression and activity of P-glycoprotein in leukaemia and colon cancer cells.
Colonic Neoplasms
Inhibition of protein kinase C-alpha isoform enhances the P-glycoprotein expression and the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure.
Colonic Neoplasms
Innovational combination of hetero-bifunctional N-PEG quinoline scaffolds derivatives with improved anticancer activity against breast and colon cancer cell lines and P-glycoprotein, cytochrome p450 enzyme activity prediction.
Colonic Neoplasms
Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors.
Colonic Neoplasms
Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells.
Colonic Neoplasms
IRE1?-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells.
Colonic Neoplasms
Itraconazole synergistically increases therapeutic effect of paclitaxel and 99mTc-MIBI accumulation, as a probe of P-gp activity, in HT-29 tumor-bearing nude mice.
Colonic Neoplasms
Jatrophane Diterpenes from Euphorbia mellifera and Their Activity as P-Glycoprotein Modulators on Multidrug-Resistant Mouse Lymphoma and Human Colon Adenocarcinoma Cells.
Colonic Neoplasms
JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells.
Colonic Neoplasms
KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1.
Colonic Neoplasms
Knockdown of Hypoxia-Inducible Factor 1? Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts.
Colonic Neoplasms
Lamellarins as inhibitors of P-glycoprotein-mediated multidrug resistance in a human colon cancer cell line.
Colonic Neoplasms
Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Colonic Neoplasms
MDR1A deficiency restrains tumor growth in murine colitis-associated carcinogenesis.
Colonic Neoplasms
MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells.
Colonic Neoplasms
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
Colonic Neoplasms
Molecular analysis of two human doxorubicin-resistant cell lines: evidence for differing multidrug resistance mechanisms.
Colonic Neoplasms
N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
Colonic Neoplasms
New Chalcone Derivative Inhibits ABCB1 in Multidrug Resistant T-cell Lymphoma and Colon Adenocarcinoma Cells.
Colonic Neoplasms
NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells.
Colonic Neoplasms
Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells.
Colonic Neoplasms
Nocardioazines: a novel bridged diketopiperazine scaffold from a marine-derived bacterium inhibits P-glycoprotein.
Colonic Neoplasms
Novel association between heterozygous genotype of single nucleotide polymorphism C218T in drug transporter ABCC1 gene and increased risk of colon cancer.
Colonic Neoplasms
Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition.
Colonic Neoplasms
Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Colonic Neoplasms
P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport.
Colonic Neoplasms
P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines.
Colonic Neoplasms
P-Gp and TOPO II Expression and Their Clinical Significance in Colon Cancer.
Colonic Neoplasms
PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein.
Colonic Neoplasms
Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation.
Colonic Neoplasms
Phthalate exposure promotes chemotherapeutic drug resistance in colon cancer cells.
Colonic Neoplasms
Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients.
Colonic Neoplasms
Potent induction of human colon cancer cell uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-alpha (PKC-alpha) pseudosubstrate peptides through a P-glycoprotein-independent mechanism.
Colonic Neoplasms
Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells.
Colonic Neoplasms
Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Colonic Neoplasms
Prediction of doxorubicin resistance in gastrointestinal cancer by P-glycoprotein staining.
Colonic Neoplasms
Prognostic impact of {triangleup}TAp73 isoform levels and their target genes in colon cancer patients.
Colonic Neoplasms
Pyrimido[1?,2?:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
Colonic Neoplasms
Rapid Increase of Gastrointestinal P-Glycoprotein Functional Activity in Response to Etoposide Stimulation.
Colonic Neoplasms
Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Colonic Neoplasms
Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line.
Colonic Neoplasms
Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse.
Colonic Neoplasms
Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis.
Colonic Neoplasms
Relationships among tenascin expression, DNA ploidy patterns, and multidrug resistance gene product (P-glycoprotein) in human colon carcinoma.
Colonic Neoplasms
Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene.
Colonic Neoplasms
Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.
Colonic Neoplasms
Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza.
Colonic Neoplasms
Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin.
Colonic Neoplasms
Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells.
Colonic Neoplasms
Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter.
Colonic Neoplasms
Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells.
Colonic Neoplasms
Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
Colonic Neoplasms
Silica nano supra-assembly for the targeted delivery of therapeutic cargo to overcome chemoresistance in cancer.
Colonic Neoplasms
Study on reversal of ABCB1 mediated multidrug resistance in Colon cancer by acetogenins: An in-silico approach.
Colonic Neoplasms
Subcellular distribution of ezrin/radixin/moesin and their roles in the cell surface localization and transport function of P-glycoprotein in human colon adenocarcinoma LS180 cells.
Colonic Neoplasms
The amplification and expression of MDR1 gene in adriamycine resistant cell line of colon cancer cell HR8348.
Colonic Neoplasms
The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis.
Colonic Neoplasms
The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers.
Colonic Neoplasms
The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter.
Colonic Neoplasms
Tumour-specific cytotoxicity and MDR-reversal activity of dihydropyridines.
Colonic Neoplasms
Twist1 confers multidrug resistance in colon cancer through upregulation of ATP-binding cassette transporters.
Colonic Neoplasms
Understanding the clinical pharmacokinetics of a GABA(A) partial agonist by application of in vitro tools.
Colonic Neoplasms
Upregulation of Breast Cancer Resistance Protein Expression was Decreased in Plasma Membrane of Colon Cancer with Metastasis of Lymphatic Node.
Colonic Neoplasms
Utility of human/human-derived reagents in drug discovery and development: An industrial perspective.
Colonic Neoplasms
Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
Colonic Neoplasms
Wnt-?-catenin signaling regulates ABCC3 (MRP3) transporter expression in colorectal cancer.
Colonic Neoplasms
[c-Myc regulation of ATP-binding cassette transporter reverses chemoresistance in CD133(+) colon cancer stem cells].
Colonic Neoplasms
[Effect and mechanism of DNMT inhibitor on the reversal of multidrug resistance in human colon cancer cell line sw620/L-OHP].
Colonic Neoplasms
[Effect of different concentrations of Gegen Qinlian decoction on expression of P-glycoprotein and multi-drug resistance protein transporter in Caco-2 cells].
Colonic Neoplasms
[Effects of changwelqing on nuclear translocation of Y-box binding protein-1 and expregslon of P-glycoprotein in human colon cancer cell line with drug-resistance induced by vincristine]
Colonic Neoplasms
[Functional activity of ABC transporters (markers of multidrug resistance) in human colon adenocarcinoma and normal colonic mucosa]
Colonic Neoplasms
[Polymerase chain reaction in diagnostic pathology]
Colorectal Neoplasms
?-Sitosterol Reverses Multidrug Resistance via BCRP Suppression by Inhibiting the p53-MDM2 Interaction in Colorectal Cancer.
Colorectal Neoplasms
A Comprehensive Investigation on Common Polymorphisms in the MDR1/ABCB1 Transporter Gene and Susceptibility to Colorectal Cancer.
Colorectal Neoplasms
A multidrug resistance-associated protein inhibitor is a potential enhancer of the benzyl isothiocyanate-induced apoptosis induction in human colorectal cancer cells.
Colorectal Neoplasms
A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients.
Colorectal Neoplasms
A study on the correlations of MRP-1 expression with the pathogenesis and prognosis of colorectal cancer.
Colorectal Neoplasms
ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer.
Colorectal Neoplasms
ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin-1-dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone.
Colorectal Neoplasms
ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells.
Colorectal Neoplasms
ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer.
Colorectal Neoplasms
ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer.
Colorectal Neoplasms
ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients.
Colorectal Neoplasms
ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.
Colorectal Neoplasms
ABCB1 variants C3435T and T129C are not associated with colorectal cancer risk.
Colorectal Neoplasms
ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
Colorectal Neoplasms
ABCB1/MDR1 gene polymorphism and colorectal cancer risk: a meta-analysis of case-control studies.
Colorectal Neoplasms
ABCB1/MDR1 polymorphism and colorectal cancer risk: a meta-analysis of case-control studies.
Colorectal Neoplasms
ABCC2 transporter gene polymorphisms, diet and risk of colorectal cancer: a Danish prospective cohort study.
Colorectal Neoplasms
ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.
Colorectal Neoplasms
ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
Colorectal Neoplasms
ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
Colorectal Neoplasms
ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer.
Colorectal Neoplasms
ANRIL promotes chemoresistance via disturbing expression of ABCC1 by regulating the expression of Let-7a in colorectal cancer.
Colorectal Neoplasms
Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue.
Colorectal Neoplasms
Anticancer Profiling for Coumarins and Related O-Naphthoquinones from Mansonia gagei against Solid Tumor Cells In Vitro.
Colorectal Neoplasms
Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors.
Colorectal Neoplasms
Association between ABCB1 (3435C>T) polymorphism and susceptibility of colorectal cancer: A meta-analysis.
Colorectal Neoplasms
Association between p53 expression and Bcl-2, P-glycoprotein, topoisomerase II alpha, thymidylate synthase and thymidine phosphorylase as potential therapeutic targets in colorectal cancer patients.
Colorectal Neoplasms
Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis.
Colorectal Neoplasms
Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.
Colorectal Neoplasms
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
Colorectal Neoplasms
Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk.
Colorectal Neoplasms
Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Colorectal Neoplasms
Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers.
Colorectal Neoplasms
Associations between the functional polymorphisms in the ABCB1 transporter gene and colorectal cancer risk: a case-control study in Turkish population.
Colorectal Neoplasms
Associations of ABCB1 and XPC Genetic Polymorphisms with Susceptibility to Colorectal Cancer and Therapeutic Prognosis in a Chinese Population.
Colorectal Neoplasms
AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer.
Colorectal Neoplasms
Beta-catenin--a linchpin in colorectal carcinogenesis?
Colorectal Neoplasms
Bufalin reverses ABCB1-mediated drug resistance in colorectal cancer.
Colorectal Neoplasms
CCL21 Facilitates Chemoresistance and Cancer Stem Cell-Like Properties of Colorectal Cancer Cells through AKT/GSK-3?/Snail Signals.
Colorectal Neoplasms
Cellular polarity modulates drug resistance in primary colorectal cancers via orientation of the multidrug resistance protein ABCB1.
Colorectal Neoplasms
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Colorectal Neoplasms
Cetuximab enhances the efficiency of irinotecan through simultaneously inhibiting the MAPK signaling and ABCG2 in colorectal cancer cells.
Colorectal Neoplasms
Chemosensitization by diverging modulation by short-term and long-term TNF-? action on ABCB1 expression and NF-?B signaling in colon cancer.
Colorectal Neoplasms
Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer.
Colorectal Neoplasms
CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
Colorectal Neoplasms
Clinical Pharmacokinetic and Metabolism of PET Radiotracers for Imaging P-glycoprotein in Chemoresistant Tumor of Colorectal Cancer.
Colorectal Neoplasms
Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.
Colorectal Neoplasms
Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan.
Colorectal Neoplasms
Coffee induces breast cancer resistance protein expression in Caco-2 cells.
Colorectal Neoplasms
Colorectal cancer susceptibility: apparent gender-related modulation by ABCB1 gene polymorphisms.
Colorectal Neoplasms
Combined effects of berberine and evodiamine on colorectal cancer cells and cardiomyocytes in vitro.
Colorectal Neoplasms
Comments on: Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer, Fukushima Y, Oshika Y, Tokunaga T, et al., Eur J Cancer 1999, 35, 935-938. Mutant p53 and high expression of MRP are associated in acute myeloblastic leukaemia.
Colorectal Neoplasms
Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability.
Colorectal Neoplasms
Concurrent expressions of metallothionein, glutathione S-transferase-pi, and P-glycoprotein in colorectal cancers.
Colorectal Neoplasms
Could polymorphisms in ATP-binding cassette C3/multidrug resistance associated protein 3 (ABCC3/MRP3) modify colorectal cancer risk?
Colorectal Neoplasms
COX-2 Contributes to P-glycoprotein-Mediated Multidrug Resistance via phosphorylation of c-Jun at Ser63/73 in Colorectal Cancer.
Colorectal Neoplasms
CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients.
Colorectal Neoplasms
Decreased functional activity of multidrug resistance protein in primary colorectal cancer.
Colorectal Neoplasms
Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: comparison with a validated HPLC-fluorescence method.
Colorectal Neoplasms
Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity.
Colorectal Neoplasms
Differential sensitivities of the MRP gene family and gamma-glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status.
Colorectal Neoplasms
Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Colorectal Neoplasms
Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma?
Colorectal Neoplasms
Drug Repositioning for P-Glycoprotein Mediated Co-Expression Networks in Colorectal Cancer.
Colorectal Neoplasms
E-cadherin increasing multidrug resistance protein 1 via hypoxia-inducible factor-1? contributes to multicellular resistance in colorectal cancer.
Colorectal Neoplasms
Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
Colorectal Neoplasms
Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
Colorectal Neoplasms
Effect of UGT, SLCO, ABCB and ABCC polymorphisms on irinotecan toxicity.
Colorectal Neoplasms
Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy
Colorectal Neoplasms
Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans.
Colorectal Neoplasms
Establishment of multidrug resistant human colorectal carcinoma HCT-15 cell lines and their properties.
Colorectal Neoplasms
Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-?B Pathway in Colorectal Cancer.
Colorectal Neoplasms
Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
Colorectal Neoplasms
Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.
Colorectal Neoplasms
Expression of ABCG2 and its significance in colorectal cancer.
Colorectal Neoplasms
Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence.
Colorectal Neoplasms
Expression of multidrug resistance protein in metastatic colorectal carcinomas.
Colorectal Neoplasms
Expression of p-glycoprotein in the normal colorectal epithelium and in colorectal-carcinoma.
Colorectal Neoplasms
Expression of the MDR1 gene in human gastric and colorectal carcinomas.
Colorectal Neoplasms
Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas.
Colorectal Neoplasms
Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas.
Colorectal Neoplasms
FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10.
Colorectal Neoplasms
Frequent coexpression of MRP/GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues.
Colorectal Neoplasms
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients.
Colorectal Neoplasms
Genetic Variability in Key Genes in Prostaglandin E2 Pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and Their Involvement in Colorectal Cancer Development.
Colorectal Neoplasms
Hedyotis diffusa Willd overcomes 5-fluorouracil resistance in human colorectal cancer HCT-8/5-FU cells by downregulating the expression of P-glycoprotein and ATP-binding casette subfamily G member 2.
Colorectal Neoplasms
Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription.
Colorectal Neoplasms
Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells.
Colorectal Neoplasms
Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells.
Colorectal Neoplasms
Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen.
Colorectal Neoplasms
Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.
Colorectal Neoplasms
In vitro modulation of haematoporphyrin derivative photodynamic therapy on colorectal carcinoma multicellular spheroids by verapamil.
Colorectal Neoplasms
Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas.
Colorectal Neoplasms
Induction of MRP1 and gamma-glutamylcysteine synthetase gene expression by interleukin 1beta is mediated by nitric oxide-related signalings in human colorectal cancer cells.
Colorectal Neoplasms
Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells.
Colorectal Neoplasms
Inhibiting ABCG2 could potentially enhance the efficacy of hypericin-mediated photodynamic therapy in spheroidal cell models of colorectal cancer.
Colorectal Neoplasms
Kinetic analysis of the disposition of MRK16, an anti-P-glycoprotein monoclonal antibody, in tumors: comparison between in vitro and in vivo disposition.
Colorectal Neoplasms
Lack of association between expression of MRP2 and early relapse of colorectal cancer in patients receiving FOLFOX-4 chemotherapy.
Colorectal Neoplasms
Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer.
Colorectal Neoplasms
LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
Colorectal Neoplasms
Lupeol alters ER stress-signaling pathway by downregulating ABCG2 expression to induce Oxaliplatin-resistant LoVo colorectal cancer cell apoptosis.
Colorectal Neoplasms
MDR1 RNA transcripts do not indicate long-term prognosis in colorectal carcinomas.
Colorectal Neoplasms
Membranous ABCG2 expression in colorectal cancer independently correlates with shortened patient survival.
Colorectal Neoplasms
Meta-Analysis of ABCB1 3435C>T Polymorphism and Colorectal Cancer.
Colorectal Neoplasms
miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer.
Colorectal Neoplasms
miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.
Colorectal Neoplasms
MRPL35 Is Up-Regulated in Colorectal Cancer and Regulates Colorectal Cancer Cell Growth and Apoptosis.
Colorectal Neoplasms
Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy.
Colorectal Neoplasms
Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer.
Colorectal Neoplasms
Multidrug Resistance-Associated Protein 2 Expression Is Upregulated by Adenosine 5'-Triphosphate in Colorectal Cancer Cells and Enhances Their Survival to Chemotherapeutic Drugs.
Colorectal Neoplasms
Novel dithiane analogues of tiapamil with high activity to overcome multidrug resistance in vitro.
Colorectal Neoplasms
Oligomycins as inhibitors of K-Ras plasma membrane localisation.
Colorectal Neoplasms
Overcoming P-Glycoprotein-Mediated Multidrug Resistance in Colorectal Cancer: Potential Reversal Agents among Herbal Medicines.
Colorectal Neoplasms
Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Colorectal Neoplasms
P-Glycoprotein 1 Affects Chemoactivities of Resveratrol against Human Colorectal Cancer Cells.
Colorectal Neoplasms
P-glycoprotein expression and chemosensitivity in highly purified fresh human gastrointestinal cancer cells.
Colorectal Neoplasms
P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo.
Colorectal Neoplasms
P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers.
Colorectal Neoplasms
Polymorphisms in ATP-binding cassette transporter genes and interaction with diet and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study.
Colorectal Neoplasms
Polymorphisms in DNA repair pathway genes and ABCG2 gene in advanced colorectal cancer: correlation with tumor characteristics and clinical outcome in oxaliplatin-based chemotherapy.
Colorectal Neoplasms
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
Colorectal Neoplasms
Prognostic impact of cancer stem cell markers ABCB1, NEO1 and HIST1H2AE in colorectal cancer.
Colorectal Neoplasms
Prognostic impact of membranous ATP-binding cassette Sub-family G member 2 expression in patients with colorectal carcinoma after surgical resection.
Colorectal Neoplasms
Prognostic significance of DNA ploidy, S-phase fraction, and P-glycoprotein expression in colorectal cancer.
Colorectal Neoplasms
Protective role of ABCG2 against oxidative stress in colorectal cancer and its potential underlying mechanism.
Colorectal Neoplasms
Protein expression of ATP-binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients.
Colorectal Neoplasms
Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
Colorectal Neoplasms
Regulation of prostaglandin transporters in colorectal neoplasia.
Colorectal Neoplasms
Restoration of MARCK enhances chemosensitivity in cancer.
Colorectal Neoplasms
Restoring Treatment Response in Colorectal Cancer Cells by Targeting MACC1-Dependent ABCB1 Expression in Combination Therapy.
Colorectal Neoplasms
S-Adenosylmethionine Increases the Sensitivity of Human Colorectal Cancer Cells to 5-Fluorouracil by Inhibiting P-Glycoprotein Expression and NF-?B Activation.
Colorectal Neoplasms
Sinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expression.
Colorectal Neoplasms
SN38-PEG-PLGA-verapamil nanoparticles inhibit proliferation and downregulate drug transporter ABCG2 gene expression in colorectal cancer cells.
Colorectal Neoplasms
Sorafenib Overcomes Irinotecan Resistance in Colorectal Cancer by Inhibiting the ABCG2 Drug-Efflux Pump.
Colorectal Neoplasms
Stanniocalcin 2 induces oxaliplatin resistance in colorectal cancer cells by upregulating P-glycoprotein.
Colorectal Neoplasms
Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance.
Colorectal Neoplasms
Sulforaphane Regulates NFE2L2/Nrf2-Dependent Xenobiotic Metabolism Phase II and Phase III Enzymes Differently in Human Colorectal Cancer and Untransformed Epithelial Colon Cells.
Colorectal Neoplasms
Temozolomide: Mechanisms of Action, Repair and Resistance.
Colorectal Neoplasms
The Effect of Compound Sophora on Fluorouracil and Oxaliplatin Resistance in Colorectal Cancer Cells.
Colorectal Neoplasms
The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study.
Colorectal Neoplasms
The role of P-glycoprotein (MDR1) polymorphisms and mutations in colorectal cancer.
Colorectal Neoplasms
Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p.
Colorectal Neoplasms
Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil.
Colorectal Neoplasms
Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer.
Colorectal Neoplasms
Two SNPs of ATP-binding cassette B1 gene on the risk and prognosis of colorectal cancer.
Colorectal Neoplasms
Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/?-catenin-ABCG2 signaling pathway in ALDHA1(+) colorectal cancer stem cells.
Colorectal Neoplasms
Variable expression of P-glycoprotein in normal, inflamed, and dysplastic areas in ulcerative colitis.
Colorectal Neoplasms
Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.
Colorectal Neoplasms
Wnt-?-catenin signaling regulates ABCC3 (MRP3) transporter expression in colorectal cancer.
Colorectal Neoplasms
[Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues.]
Colorectal Neoplasms
[Down regulation of multidrug resistance-associated protein 4 expression by RNA interference enhances radiosensitivity of colorectal carcinoma cell lines in vitro].
Colorectal Neoplasms
[Medicated serum prepared with Chinese herbal medicine Zhizhen Recipe down-regulates activity of nuclear factor-?B and expression of P-glycoprotein in human colorectal cancer multidrug-resistant cell line HCT-8/VCR].
Colorectal Neoplasms
[Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients].
Colorectal Neoplasms, Hereditary Nonpolyposis
Temozolomide: Mechanisms of Action, Repair and Resistance.
Coma
Crystal structure of the peptidase domain of Streptococcus ComA, a bifunctional ATP-binding cassette transporter involved in the quorum-sensing pathway.
Coma
Expression and Characterization of the Peptidase Domain of Streptococcus pneumoniae ComA, a Bifunctional ATP-binding Cassette Transporter Involved in Quorum Sensing Pathway.
Coma
Factors Predisposing to Coma and Delirium: Fentanyl and Midazolam Exposure; CYP3A5, ABCB1, and ABCG2 Genetic Polymorphisms; and Inflammatory Factors*.
Coma
Gene expression profiling reveals defined functions of the ATP-binding cassette transporter COMATOSE late in phase II of germination.
Coma
Genetic transformation in Streptococcus pneumoniae: nucleotide sequence analysis shows comA, a gene required for competence induction, to be a member of the bacterial ATP-dependent transport protein family.
Coma
High-throughput Screening of Small Molecule Inhibitors of the Streptococcus Quorum-sensing Signal Pathway.
Coma
Identification potential inhibitors against the Streptococcus quorum-sensing signal pathway.
Coma
Jasmonic acid levels are reduced in COMATOSE ATP-binding cassette transporter mutants. Implications for transport of jasmonate precursors into peroxisomes.
Coma
Peroxisomal ATP-binding cassette transporter COMATOSE and the multifunctional protein abnormal INFLORESCENCE MERISTEM are required for the production of benzoylated metabolites in arabidopsis seeds.
Coma
The COMATOSE ATP-binding cassette transporter is required for full fertility in Arabidopsis.
Communicable Diseases
Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo.
Communicable Diseases
Multiple Drug Transport Pathways through Human P-Glycoprotein.
Communicable Diseases
Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections.
Cone-Rod Dystrophies
Genetic Spectrum of ABCA4-Associated Retinal Degeneration in Poland.
Cone-Rod Dystrophies
Toll-like receptor 3 is required for development of retinopathy caused by impaired all-trans-retinal clearance in mice.
Congenital Abnormalities
Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins.
Congenital Abnormalities
Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice.
Congenital Abnormalities
Placental P-glycoprotein inhibition enhances susceptibility to Di-(2-ethylhexyl)-phthalate induced cardiac malformations in mice: A possibly promising target for congenital heart defects prevention.
Connective Tissue Diseases
Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease.
Coronary Artery Disease
A common Ile 823 Met variant of ATP-binding cassette transporter A1 gene (ABCA1) alters high density lipoprotein cholesterol level in Japanese population.
Coronary Artery Disease
ABCA1 gene polymorphisms and their associations with coronary artery disease and plasma lipids in males from three ethnic populations in Singapore.
Coronary Artery Disease
ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment.
Coronary Artery Disease
ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis.
Coronary Artery Disease
Allergic asthma aggravated atherosclerosis increases cholesterol biosynthesis and foam cell formation in apolipoprotein E-deficient mice.
Coronary Artery Disease
Associations of the ATP-binding cassette transporter A1 R219K polymorphism with HDL-C level and coronary artery disease risk: A meta-analysis.
Coronary Artery Disease
ATP-binding cassette transporter A1 (ABCA1) R219K (G1051A, rs2230806) polymorphism and serum high-density lipoprotein cholesterol levels in a large Japanese population: cross-sectional data from the Daiko Study.
Coronary Artery Disease
ATP-binding cassette transporter A1 gene I823M polymorphism affects plasma high-density lipoprotein cholesterol level and modifies the effect of low high-density lipoprotein cholesterol on the risk of coronary artery disease.
Coronary Artery Disease
ATP-binding cassette transporter A1 R219K polymorphism and coronary artery disease in Chinese population: a meta-analysis of 5,388 participants.
Coronary Artery Disease
Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.
Coronary Artery Disease
Common gene polymorphism in ATP-binding cassette transporter A1 and coronary artery disease: A genetic association study and a structural analysis.
Coronary Artery Disease
Common variants in the ATP-binding cassette transporter 1 gene with decreased HDL-cholesterol levels and coronary artery disease.
Coronary Artery Disease
Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels.
Coronary Artery Disease
CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment.
Coronary Artery Disease
CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019.
Coronary Artery Disease
Effects of the ABCB1 C3435T single nucleotide polymorphism on major adverse cardiovascular events in acute coronary syndrome or coronary artery disease patients undergoing percutaneous coronary intervention and treated with clopidogrel: A systematic review and meta-analysis.
Coronary Artery Disease
Genetic determinants of platelet response to clopidogrel.
Coronary Artery Disease
Heterozygous ATP-binding Cassette Transporter G5 Gene Deficiency and Risk of Coronary Artery Disease.
Coronary Artery Disease
Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease.
Coronary Artery Disease
Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks.
Coronary Artery Disease
Polymorphism in ABCA1 influences CSF 24S-hydroxycholesterol levels but is not a major risk factor of Alzheimer's disease.
Coronary Artery Disease
Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging.
Coronary Artery Disease
The C-565T Polymorphism (rs2422493) of the ATP-binding Cassette Transporter A1 Gene Contributes to the Development and Severity of Coronary Artery Disease in an Iranian Population.
Coronary Artery Disease
[A novel polymorphism in the ATP-binding cassette transporter A1 gene (M233V) in Chinese patients with coronary artery disease]
Coronary Artery Disease
[Significance of -191G/C single nucleotide polymorphisms in the promoter region of ATP-binding cassette transporter gene in coronary artery disease]
Coronary Disease
A SNP involved in alternative splicing of ABCB1 is associated with clopidogrel resistance in coronary heart disease in Chinese population.
Coronary Disease
ABCB1 C3435T Polymorphism and the Risk of Coronary Heart Disease: A Meta-Analysis.
Coronary Disease
Association of ATP-binding cassette transporter A1 gene polymorphisms with plasma lipid variability and coronary heart disease risk.
Coronary Disease
Associations of the uric acid related genetic variants in SLC2A9 and ABCG2 loci with coronary heart disease risk.
Coronary Disease
ATP-binding cassette transporter A1 locus is not a major determinant of HDL-C levels in a population at high risk for coronary heart disease.
Coronary Disease
Common genetic variation in the ATP-binding cassette transporter A1, plasma lipids, and risk of coronary heart disease.
Coronary Disease
Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease.
Coronary Disease
Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease.
Coronary Disease
Genetic variant of V825I in the ATP-binding cassette transporter A1 gene and serum lipid levels in the Guangxi Bai Ku Yao and Han populations.
Coronary Disease
Genetic variation of the ATP-binding cassette transporter A1 and susceptibility to coronary heart disease.
Coronary Disease
Quantitative assessment of the effect of ABCA1 R219K polymorphism on the risk of coronary heart disease.
Coronary Disease
The association of the R219K polymorphism in the ATP-binding cassette transporter 1 ( ABCA1) gene with coronary heart disease and hyperlipidaemia.
Coronary Disease
The R219K polymorphism on ATP-binding cassette transporter A1 gene is associated with coronary heart disease risk in Asia population: evidence from a meta-analysis.
Coronary Disease
[Association between -14 bp and ZNF polymorphisms of ABCA1 gene promoter and high density lipoprotein cholesterol level and cardiovascular disease].
Coronary Disease
[Relationship between the R219K polymorphism of ATP-binding cassette transporter 1 gene and coronary heart disease]
COVID-19
COVID-19 infection can cause chemotherapy resistance development in patients with breast cancer and tamoxifen may cause susceptibility to COVID-19 infection.
COVID-19
COVID-19 Mortality Rate Prediction for India Using Statistical Neural Network Models.
COVID-19
Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors.
COVID-19
Guidance on Short-Term Management of Atrial Fibrillation in Coronavirus Disease 2019.
COVID-19
Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.
COVID-19
Machine learning-based mortality rate prediction using optimized hyper-parameter.
COVID-19
Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.
COVID-19
Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations.
COVID-19
Possible Role of ABCB1 in Lysosomal Accumulation of Azithromycin in COVID-19 Therapy.
COVID-19
Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients.
Craniopharyngioma
Immunohistochemical expression of human chorionic gonadotropin and P-glycoprotein in human pituitary glands and craniopharyngiomas.
Craniopharyngioma
Multidrug resistance gene (MDR1) expression in human brain tumors.
Creutzfeldt-Jakob Syndrome
Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease.
Creutzfeldt-Jakob Syndrome
Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease.
Crohn Disease
A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content.
Crohn Disease
ABCB1 3435C>T and 2677G>T/A polymorphisms in Polish and Bosnian Crohn's disease patients - A preliminary report.
Crohn Disease
Absence of ABCG2-mediated mucosal detoxification in patients with active inflammatory bowel disease is due to impeded protein folding.
Crohn Disease
Associations between variants in the ABCB1 (MDR1) gene and corticosteroid dependence in children with crohn's disease.
Crohn Disease
Associations between variants in the ABCB1 (MDR1) gene and corticosteroid dependence in children with Crohn's disease.
Crohn Disease
Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study.
Crohn Disease
Chronic inflammation up-regulates P-gp in peripheral mononuclear blood cells via the STAT3/Nf-?b pathway in 2,4,6-trinitrobenzene sulfonic acid-induced colitis mice.
Crohn Disease
Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression.
Crohn Disease
Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein.
Crohn Disease
Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.
Crohn Disease
Lipid and Bile Acid Dysmetabolism in Crohn's Disease.
Crohn Disease
Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes.
Crohn Disease
Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients.
Crohn Disease
NGS study of glucocorticoid response genes in inflammatory bowel disease patients.
Cryptosporidiosis
P-Glycoprotein-Mediated Efflux Reduces the In Vivo Efficacy of a Therapeutic Targeting the Gastrointestinal Parasite Cryptosporidium.
Cystic Fibrosis
A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation.
Cystic Fibrosis
A release mechanism for stored ATP in ocular ciliary epithelial cells.
Cystic Fibrosis
A yeast metal resistance protein similar to human cystic fibrosis transmembrane conductance regulator (CFTR) and multidrug resistance-associated protein.
Cystic Fibrosis
ABC1, an ATP binding cassette transporter required for phagocytosis of apoptotic cells, generates a regulated anion flux after expression in Xenopus laevis oocytes.
Cystic Fibrosis
Accumulation of azithromycin and roxithromycin in tracheal epithelial fetal cell lines expressing wild type or mutated cystic fibrosis transmembrane conductance regulator protein (CFTR).
Cystic Fibrosis
Arsenite regulates Cystic Fibrosis Transmembrane Conductance Regulator and P-glycoprotein: evidence of pathway independence.
Cystic Fibrosis
Atomic model of human cystic fibrosis transmembrane conductance regulator: membrane-spanning domains and coupling interfaces.
Cystic Fibrosis
ATP-dependent bacterial transporters and cystic fibrosis: analogy between channels and transporters.
Cystic Fibrosis
Azithromycin increases chloride efflux from cystic fibrosis airway epithelial cells.
Cystic Fibrosis
Bacterial periplasmic permeases as model systems for the superfamily of traffic ATPases, including the multidrug resistance protein and the cystic fibrosis transmembrane conductance regulator.
Cystic Fibrosis
Bacterial periplasmic permeases belong to a family of transport proteins operating from Escherichia coli to human: Traffic ATPases.
Cystic Fibrosis
Building an understanding of cystic fibrosis on the foundation of ABC transporter structures.
Cystic Fibrosis
Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport?
Cystic Fibrosis
Catch me if you can! Novel aspects of cadmium transport in mammalian cells.
Cystic Fibrosis
Cell volume response to hyposmotic shock and elevated cAMP in bovine trabecular meshwork cells.
Cystic Fibrosis
Cellular ATP release by the cystic fibrosis transmembrane conductance regulator.
Cystic Fibrosis
Characterization of the hemolysin transporter, HlyB, using an epitope insertion.
Cystic Fibrosis
Cholestatic properties and hepatic transport of steroid glucuronides.
Cystic Fibrosis
Codon bias and the folding dynamics of the cystic fibrosis transmembrane conductance regulator.
Cystic Fibrosis
Compartmentalized Accumulation of cAMP near complexes of Multidrug Resistance Protein 4 (MRP4) and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Contributes to Drug-induced Diarrhea.
Cystic Fibrosis
Conformational Changes of CFTR upon Phosphorylation and ATP Binding.
Cystic Fibrosis
Conserved allosteric hot spots in the transmembrane domains of cystic fibrosis transmembrane conductance regulator (CFTR) channels and multidrug resistance protein (MRP) pumps.
Cystic Fibrosis
Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators.
Cystic Fibrosis
Correction: Learning from each other: ABC transporter regulation by protein phosphorylation in plant and mammalian systems.
Cystic Fibrosis
CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages.
Cystic Fibrosis
Crucial role for phylogenetically conserved cytoplasmic loop 3 in ABCC4 protein expression.
Cystic Fibrosis
Crystal structure of the ATP-binding subunit of an ABC transporter.
Cystic Fibrosis
Cystic fibrosis transmembrane conductance regulator degradation depends on the lectins Htm1p/EDEM and the Cdc48 protein complex in yeast.
Cystic Fibrosis
Cystic Fibrosis Transmembrane Conductance Regulator: A Molecular Model Defines the Architecture of the Anion Conduction Path and Locates a "Bottleneck" in the Pore.
Cystic Fibrosis
Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1.
Cystic Fibrosis
Differences between cystic fibrosis transmembrane conductance regulator and HisP in the interaction with the adenine ring of ATP.
Cystic Fibrosis
Differential sensitivity of plant and yeast MRP (ABCC)-mediated organic anion transport processes towards sulfonylureas.
Cystic Fibrosis
Effects of P-glycoprotein expression on cyclic AMP and volume-activated ion fluxes and conductances in HT-29 colon adenocarcinoma cells.
Cystic Fibrosis
Effects of the gout-causing Q141K polymorphism and a CFTR ?F508 mimicking mutation on the processing and stability of the ABCG2 protein.
Cystic Fibrosis
Electrodiffusional ATP movement through the cystic fibrosis transmembrane conductance regulator.
Cystic Fibrosis
Erythrocyte membrane ATP binding cassette (ABC) proteins: MRP1 and CFTR as well as CD39 (ecto-apyrase) involved in RBC ATP transport and elevated blood plasma ATP of cystic fibrosis.
Cystic Fibrosis
Evidence that release of adenosine triphosphate from endothelial cells during increased shear stress is vesicular.
Cystic Fibrosis
Expression and purification of the first nucleotide-binding domain and linker region of human multidrug resistance gene product: comparison of fusions to glutathione S-transferase, thioredoxin and maltose-binding protein.
Cystic Fibrosis
Expression of an ATP-binding cassette transporter-encoding gene (YOR1) is required for oligomycin resistance in Saccharomyces cerevisiae.
Cystic Fibrosis
Function, evolution and structure of multidrug resistance protein (MRP).
Cystic Fibrosis
Functional domain analysis of the yeast ABC transporter Ycf1p by site-directed mutagenesis.
Cystic Fibrosis
Functional replacement of the hemolysin A transport signal by a different primary sequence.
Cystic Fibrosis
Glial cells express multiple ATP binding cassette proteins which are involved in ATP release.
Cystic Fibrosis
Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules.
Cystic Fibrosis
Identification of the major phosphorylation domain of murine mdr1b P-glycoprotein. Analysis of the protein kinase A and protein kinase C phosphorylation sites.
Cystic Fibrosis
Immunomodulation by macrolide antibiotics.
Cystic Fibrosis
Impact of polymorphism of Multidrug Resistance-associated Protein 1 (ABCC1) gene on the severity of cystic fibrosis.
Cystic Fibrosis
Impaired transporter associated with antigen processing (TAP) function attributable to a single amino acid alteration in the peptide TAP subunit TAP1.
Cystic Fibrosis
Increased Expression of Plasma-Induced ABCC1 mRNA in Cystic Fibrosis.
Cystic Fibrosis
Inhibiting endoplasmic reticulum (ER)-associated degradation of misfolded Yor1p does not permit ER export despite the presence of a diacidic sorting signal.
Cystic Fibrosis
Inhibitors of ATP-binding cassette transporters suppress interleukin-12 p40 production and major histocompatibility complex II up-regulation in macrophages.
Cystic Fibrosis
Integrated analysis of residue coevolution and protein structure in ABC transporters.
Cystic Fibrosis
Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments.
Cystic Fibrosis
Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.
Cystic Fibrosis
Learning from each other: ABC transporter regulation by protein phosphorylation in plant and mammalian systems.
Cystic Fibrosis
Long-range coupling between the extracellular gates and the intracellular ATP binding domains of multidrug resistance protein pumps and cystic fibrosis transmembrane conductance regulator channels.
Cystic Fibrosis
Long-term azithromycin in cystic fibrosis: another possible mechanism of action?
Cystic Fibrosis
Maltose transport through the inner membrane of E. coli.
Cystic Fibrosis
Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoprotein.
Cystic Fibrosis
Mechanical stress induces release of ATP from Ehrlich ascites tumor cells.
Cystic Fibrosis
Membrane topology and glycosylation of the human multidrug resistance-associated protein.
Cystic Fibrosis
Membrane topology of the integral membrane components, OppB and OppC, of the oligopeptide permease of Salmonella typhimurium.
Cystic Fibrosis
Membrane-integration characteristics of two ABC transporters, CFTR and P-glycoprotein.
Cystic Fibrosis
Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones.
Cystic Fibrosis
Monoclonal antibodies against MDR1 P-glycoprotein inhibit chloride conductance and label a 65-kDa protein in pancreatic zymogen granule membranes.
Cystic Fibrosis
Monoclonal antibodies as a tool for structure-function studies of the MDR1-P-glycoprotein.
Cystic Fibrosis
Mutational analysis of the Saccharomyces cerevisiae ATP-binding cassette transporter protein Ycf1p.
Cystic Fibrosis
Mutational analysis of the yeast a-factor transporter STE6, a member of the ATP binding cassette (ABC) protein superfamily.
Cystic Fibrosis
Mutational disruption of plasma membrane trafficking of Saccharomyces cerevisiae Yor1p, a homologue of mammalian multidrug resistance protein.
Cystic Fibrosis
Mutations that change the position of the putative gamma-phosphate linker in the nucleotide binding domains of CFTR alter channel gating.
Cystic Fibrosis
New insights into cystic fibrosis: molecular switches that regulate CFTR.
Cystic Fibrosis
Octameric stoichiometry of the KATP channel complex.
Cystic Fibrosis
Orphan enzyme or patriarch of a new tribe: the arsenic resistance ATPase of bacterial plasmids.
Cystic Fibrosis
P-glycoprotein expression increases ATP release in respiratory cystic fibrosis cells.
Cystic Fibrosis
P-glycoprotein. ATP hydrolysis by the N-terminal nucleotide-binding domain.
Cystic Fibrosis
Persistent interactions between the two transmembrane clusters dictate the targeting and functional assembly of adenylyl cyclase.
Cystic Fibrosis
Phosphorylation of P-glycoprotein by PKA and PKC modulates swelling-activated Cl- currents.
Cystic Fibrosis
Potentiation of disease-associated CFTR mutants by hydrolyzable ATP analogs.
Cystic Fibrosis
Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.
Cystic Fibrosis
Processing Mutations Disrupt Interactions between the Nucleotide Binding and Transmembrane Domains of P-glycoprotein and the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
Cystic Fibrosis
Protection against oxidative stress in beta thalassemia/hemoglobin E erythrocytes by inhibitors of glutathione efflux transporters.
Cystic Fibrosis
Pseudomonas aeruginosa Cif protein enhances the ubiquitination and proteasomal degradation of the transporter associated with antigen processing (TAP) and reduces major histocompatibility complex (MHC) class I antigen presentation.
Cystic Fibrosis
Quantitative expression patterns of multidrug-resistance P-glycoprotein (MDR1) and differentially spliced cystic-fibrosis transmembrane-conductance regulator mRNA transcripts in human epithelia.
Cystic Fibrosis
R-Domain Phosphorylation by Protein Kinase A Stimulates Dissociation of Unhydrolyzed ATP from the First Nucleotide-Binding Site of the Cystic Fibrosis Transmembrane Conductance Regulator.
Cystic Fibrosis
Secretion of peptides and proteins lacking hydrophobic signal sequences: the role of adenosine triphosphate-driven membrane translocators.
Cystic Fibrosis
Sensitivity of a renal K+ channel (ROMK2) to the inhibitory sulfonylurea compound glibenclamide is enhanced by coexpression with the ATP-binding cassette transporter cystic fibrosis transmembrane regulator.
Cystic Fibrosis
Sequence analysis of the CEN12 region of Saccharomyces cerevisiae on a 43.7 kb fragment of chromosome XII including an open reading frame homologous to the human cystic fibrosis transmembrane conductance regulator protein CFTR.
Cystic Fibrosis
Sequence and structural homology among membrane-associated domains of CFTR and certain transporter proteins.
Cystic Fibrosis
Sequence-specific retention and regulated integration of a nascent membrane protein by the endoplasmic reticulum Sec61 translocon.
Cystic Fibrosis
Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport.
Cystic Fibrosis
Structure and in vitro substrate specificity of the murine multidrug resistance-associated protein.
Cystic Fibrosis
Structure-activity analysis of a CFTR channel potentiator: Distinct molecular parts underlie dual gating effects.
Cystic Fibrosis
Structure-function analysis of the histidine permease and comparison with cystic fibrosis mutations.
Cystic Fibrosis
Suppressor Mutations in the Transmembrane Segments of P-glycoprotein Promote Maturation of Processing Mutants and Disrupt a Subset of Drug-binding Sites.
Cystic Fibrosis
The classification of ATP-binding cassette subfamily A member 3 mutations using the cystic fibrosis transmembrane conductance regulator classification system.
Cystic Fibrosis
The interaction of gut microbes with host ABC transporters.
Cystic Fibrosis
The mechanism of secretion of hemolysin and other polypeptides from gram-negative bacteria.
Cystic Fibrosis
The MglA component of the binding protein-dependent galactose transport system of Salmonella typhimurium is a galactose-stimulated ATPase.
Cystic Fibrosis
The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression.
Cystic Fibrosis
Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts.
Cystic Fibrosis
Understanding how cystic fibrosis mutations disrupt CFTR function: From single molecules to animal models.
Cystic Fibrosis
[MDR (multidrug resistance) in hepatocarcinoma clinical-therapeutic implications]
Cystic Fibrosis
[PMP70, the 70-kDa peroxisomal membrane protein: a member of the ATP-binding cassette transporters]
Cysts
Development of Bifunctional Three-Dimensional Cysts from Chemically Induced Liver Progenitors.
Cysts
Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer.
Cysts
Targeted delivery of a substrate for P-glycoprotein to renal cysts in vitro.
Deafness
[New deafness gene: Progress of research on ABCC1 in biological barriers].
Death, Sudden, Cardiac
ABCB1 gene variants, digoxin and risk of sudden cardiac death in a general population.
Dehydration
Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2.
Delirium
Factors Predisposing to Coma and Delirium: Fentanyl and Midazolam Exposure; CYP3A5, ABCB1, and ABCG2 Genetic Polymorphisms; and Inflammatory Factors*.
Dementia
ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients.
Dementia
Impact of reduced P-glycoprotein function on digoxin concentrations in patients with dementia.
Dementia
Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus.
Dementia
Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines.
Dementia, Vascular
Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer's disease and vascular dementia.
Demyelinating Diseases
ABCB1 gene variants as risk factors and modulators of age of onset of demyelinating disease in Mexican patients.
Demyelinating Diseases
Evidence of oxidative stress in very long chain fatty acid--treated oligodendrocytes and potentialization of ROS production using RNA interference-directed knockdown of ABCD1 and ACOX1 peroxisomal proteins.
Demyelinating Diseases
Impaired plasticity of macrophages in X-linked adrenoleukodystrophy.
Demyelinating Diseases
Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator.
Demyelinating Diseases
The Arabidopsis pxa1 mutant is defective in an ATP-binding cassette transporter-like protein required for peroxisomal fatty acid beta-oxidation.
Dental Caries
Variants on chromosome 4q21 near PKD2 and SIBLINGs are associated with dental caries.
Dermatitis
Metabolome Analysis Reveals Dermal Histamine Accumulation in Murine Dermatitis Provoked by Genetic Deletion of P-Glycoprotein and Breast Cancer Resistance Protein.
Dermatitis, Atopic
ABCB1 in dermatology: roles in skin diseases and their treatment.
Dermatitis, Atopic
Therapeutic effect of kaempferol on atopic dermatitis by attenuation of T cell activity via interaction with Multidrug resistance-associated protein 1.
Dermatitis, Phototoxic
Cellular Phototoxicity Evoked Through the Inhibition of Human ABC Transporter ABCG2 by Cyclin-dependent Kinase Inhibitors In vitro.
Dermatitis, Phototoxic
Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: development of in vitro high-speed screening systems.
Dermatitis, Phototoxic
Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells.
Dermatitis, Phototoxic
Nanoceria-Mediated Drug Delivery for Targeted Photodynamic Therapy on Drug-Resistant Breast Cancer.
Dermatitis, Phototoxic
The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria.
Dermatitis, Phototoxic
Tyrosine kinase inhibitors enhance ciprofloxacin-induced phototoxicity by inhibiting ABCG2.
Dermatofibrosarcoma
The chemoresistance gene ABCG2 (MXR/BCRP1/ABCP1) is not expressed in melanomas but in single neuroendocrine carcinomas of the skin.
Diabetes Mellitus
ABCA1 69C>T Polymorphism and the Risk of Type 2 Diabetes Mellitus: A Systematic Review and Updated Meta-Analysis.
Diabetes Mellitus
ABCC8 variants in MODY12: Review of the literature and report of a case with severe complications.
Diabetes Mellitus
Association of ATP-Binding Cassette Transporter A1 Gene Polymorphisms in Type 2 Diabetes Mellitus among Malaysians.
Diabetes Mellitus
Attenuated function and expression of P-glycoprotein at blood-brain barrier and increased brain distribution of phenobarbital in streptozotocin-induced diabetic mice.
Diabetes Mellitus
Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin.
Diabetes Mellitus
Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats.
Diabetes Mellitus
Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes.
Diabetes Mellitus
Impaired expression and function of breast cancer resistance protein (Bcrp) in brain cortex of streptozocin-induced diabetic rats.
Diabetes Mellitus
Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats.
Diabetes Mellitus
Induction of multidrug resistance-associated protein 2 in liver, intestine and kidney of streptozotocin-induced diabetic rats.
Diabetes Mellitus
Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.
Diabetes Mellitus
Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.
Diabetes Mellitus
Opposite regulation of hepatic breast cancer resistance protein in type 1 and 2 diabetes mellitus.
Diabetes Mellitus
P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats.
Diabetes Mellitus
P-glycoprotein associated with diabetes mellitus and survival of patients with pancreatic cancer: 8-year follow-up.
Diabetes Mellitus
Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging.
Diabetes Mellitus
Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with type 2 diabetes mellitus.
Diabetes Mellitus
The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.
Diabetes Mellitus
The relationship between Multidrug Resistance Protein 1(rs1045642) and Cholesterol 24-hydroxylase (rs754203) genes polymorphism with type 2 diabetes mellitus.
Diabetes Mellitus
Type 2 diabetes mellitus decreases systemic exposure of clopidogrel active metabolite through upregulation of P-glycoprotein in rats.
Diabetes Mellitus, Type 1
Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes.
Diabetes Mellitus, Type 2
A Meta-Analysis of the Associations Between the ATP-Binding Cassette Transporter ABCA1 R219K (rs2230806) Polymorphism and the Risk of Type 2 Diabetes in Asians.
Diabetes Mellitus, Type 2
A novel multidisciplinary intervention for long-term weight loss and glycaemic control in obese patients with diabetes.
Diabetes Mellitus, Type 2
A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabolizing Enzymes and Transporters in Human Duodenum.
Diabetes Mellitus, Type 2
A predictive model for non-completion of an intensive specialist obesity service in a public hospital: a case-control study.
Diabetes Mellitus, Type 2
ABCA1 69C>T Polymorphism and the Risk of Type 2 Diabetes Mellitus: A Systematic Review and Updated Meta-Analysis.
Diabetes Mellitus, Type 2
Abcc5 Knockout Mice Have Lower Fat Mass and Increased Levels of Circulating GLP-1.
Diabetes Mellitus, Type 2
Alteration of pharmacokinetics of grepafloxacin in type 2 diabetic rats.
Diabetes Mellitus, Type 2
Association between serum uric acid related genetic loci and diabetic kidney disease in the Chinese type 2 diabetes patients.
Diabetes Mellitus, Type 2
Association of ATP-Binding Cassette Transporter A1 Gene Polymorphisms in Type 2 Diabetes Mellitus among Malaysians.
Diabetes Mellitus, Type 2
Association of the ABCA1 gene polymorphisms with type 2 DM in a Japanese population.
Diabetes Mellitus, Type 2
Association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in a Mexican population.
Diabetes Mellitus, Type 2
Change in P-glycoprotein and caveolin protein expression in brain striatum capillaries in New Zealand obese mice with type 2 diabetes.
Diabetes Mellitus, Type 2
Correction: A Meta-Analysis of the Associations Between the ATP-Binding Cassette Transporter ABCA1 R219K (rs2230806) Polymorphism and the Risk of Type 2 Diabetes in Asians.
Diabetes Mellitus, Type 2
Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients.
Diabetes Mellitus, Type 2
Evaluating the effect of type 2 diabetes mellitus on CYP450 enzymes and P-gp activities, before and after glycemic control: A protocol for a case-control pharmacokinetic study.
Diabetes Mellitus, Type 2
Hyperglycemia induced down-regulation of renal P-glycoprotein expression.
Diabetes Mellitus, Type 2
Impact of serum amyloid A on cellular cholesterol efflux to serum in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The ATP-binding cassette transporter subfamily A member 1 (ABC-A1) and type 2 diabetes: an association beyond HDL cholesterol.
Diabetes Mellitus, Type 2
The relationship between Multidrug Resistance Protein 1(rs1045642) and Cholesterol 24-hydroxylase (rs754203) genes polymorphism with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Type 2 Diabetes Is Associated with Reduced ATP-Binding Cassette Transporter A1 Gene Expression, Protein and Function.
Diabetes Mellitus, Type 2
Type 2 diabetes mellitus decreases systemic exposure of clopidogrel active metabolite through upregulation of P-glycoprotein in rats.
Diabetes Mellitus, Type 2
Vascular effects of TZDs: new implications.
Diabetes, Gestational
Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes.
Diabetes, Gestational
Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter.
Diabetic Nephropathies
Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport Syndrome.
Diabetic Retinopathy
Differential expression of breast cancer-resistance protein, lung resistance protein, and multidrug resistance protein 1 in retinas of streptozotocin-induced diabetic mice.
Diabetic Retinopathy
High Glucose Decreases Expression and Activity of p-glycoprotein in Cultured Human Retinal Pigment Epithelium Possibly through iNOS Induction.
Diffuse Intrinsic Pontine Glioma
ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.
Digestive System Diseases
Trafficking and transporter disorders in pediatric cholestasis.
Down Syndrome
Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.
Down Syndrome
Vitamin D3 increases the Caspase-3 p12, MTHFR, and P-glycoprotein reducing amyloid-?42 in the kidney of a mouse model for Down syndrome.
Drug Resistant Epilepsy
A multimodal Pepstatin A peptide-based nanoagent for the molecular imaging of P-glycoprotein in the brains of epilepsy rats.
Drug Resistant Epilepsy
ABCB1, ABCC2, SCN1A, SCN2A, GABRA1 gene polymorphisms and drug resistant epilepsy in the Chinese Han population.
Drug Resistant Epilepsy
ABCC2 Polymorphisms and Haplotype are Associated with Drug Resistance in Chinese Epileptic Patients.
Drug Resistant Epilepsy
Advances in PET Imaging of P-Glycoprotein Function at the Blood-Brain Barrier.
Drug Resistant Epilepsy
Analysis of genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of medically refractory epilepsy in an Indian population.
Drug Resistant Epilepsy
Antiepileptic drugs modulate P-glycoproteins in the brain: A mice study with (11)C-desmethylloperamide.
Drug Resistant Epilepsy
Association analysis of intractable epilepsy with C3435T and G2677T/A ABCB1 gene polymorphisms in Iranian patients.
Drug Resistant Epilepsy
Association of ABCB1 gene polymorphism (C1236T and C3435T) with refractory epilepsy in Iraqi patients.
Drug Resistant Epilepsy
Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients.
Drug Resistant Epilepsy
Beneficial effect of tetrandrine on refractory epilepsy via suppressing P-glycoprotein.
Drug Resistant Epilepsy
Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy.
Drug Resistant Epilepsy
Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors.
Drug Resistant Epilepsy
Expression of Multidrug Resistance Genes in Peripheral Blood of Patients with Refractory Epilepsy and the Reverse Effect of Oxcarbazepine on Its Expression.
Drug Resistant Epilepsy
Expression of multidrug resistance type 1 gene (MDR1) P-glycoprotein in intractable epilepsy with different aetiologies: a double-labelling and electron microscopy study.
Drug Resistant Epilepsy
Flavonoid compounds as reversing agents of the P-glycoprotein-mediated multidrug resistance: An in vitro evaluation with focus on antiepileptic drugs.
Drug Resistant Epilepsy
Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.
Drug Resistant Epilepsy
Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models.
Drug Resistant Epilepsy
Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells.
Drug Resistant Epilepsy
Inhibition of p38 mitogen-activated protein kinase signaling reduces multidrug transporter activity and anti-epileptic drug resistance in refractory epileptic rats.
Drug Resistant Epilepsy
Intractable epilepsy and the P-glycoprotein hypothesis.
Drug Resistant Epilepsy
Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain.
Drug Resistant Epilepsy
Involvement of hypoxia-inducible factor-1 alpha in the upregulation of P-glycoprotein in refractory epilepsy.
Drug Resistant Epilepsy
Involvement of p38 MAPK in the Drug Resistance of Refractory Epilepsy Through the Regulation Multidrug Resistance-Associated Protein 1.
Drug Resistant Epilepsy
Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.
Drug Resistant Epilepsy
Lack of association between ABCB1 gene polymorphisms and pharmacoresistant epilepsy: an analysis in a western Chinese pediatric population.
Drug Resistant Epilepsy
Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment.
Drug Resistant Epilepsy
Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions.
Drug Resistant Epilepsy
MDR1 gene expression in brain of patients with medically intractable epilepsy.
Drug Resistant Epilepsy
microRNA-139-5p confers sensitivity to antiepileptic drugs in refractory epilepsy by inhibition of MRP1.
Drug Resistant Epilepsy
mPEG-PLA/TPGS mixed micelles via intranasal administration improved the bioavailability of lamotrigine in the hippocampus.
Drug Resistant Epilepsy
Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures.
Drug Resistant Epilepsy
Multidrug resistance-associated protein 1 decreases the concentrations of antiepileptic drugs in cortical extracellular fluid in amygdale kindling rats.
Drug Resistant Epilepsy
Neural overexpression of multidrug resistance-associated protein 1 and refractory epilepsy: a meta-analysis of nine studies.
Drug Resistant Epilepsy
Neuronal and glial expression of the multidrug resistance gene product in an experimental epilepsy model.
Drug Resistant Epilepsy
New proteins configure a brain drug resistance map in tuberous sclerosis.
Drug Resistant Epilepsy
Overexpression of human MRP1 in neurons causes resistance to antiepileptic drugs in Drosophila seizure mutants.
Drug Resistant Epilepsy
P-glycoprotein alters blood-brain barrier penetration of antiepileptic drugs in rats with medically intractable epilepsy.
Drug Resistant Epilepsy
P-glycoprotein--a clinical target in drug-refractory epilepsy?
Drug Resistant Epilepsy
P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice.
Drug Resistant Epilepsy
Pathophysiologic characteristics of balloon cells in cortical dysplasia.
Drug Resistant Epilepsy
Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats.
Drug Resistant Epilepsy
Potentiation of anti-epileptic drugs effectiveness by pyronaridine in refractory epilepsy.
Drug Resistant Epilepsy
Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis.
Drug Resistant Epilepsy
Reversal of mdr1b-dependent multidrug resistance in a rat astrocyte model by adenoviral-delivered short hairpin RNA.
Drug Resistant Epilepsy
Role of multidrug transporters in pharmacoresistance to antiepileptic drugs.
Drug Resistant Epilepsy
Study of multidrug resistance-associated protein 1 expression of peripheral blood of children intractable epilepsy.
Drug Resistant Epilepsy
The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population.
Drug Resistant Epilepsy
The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy.
Drug Resistant Epilepsy
The multidrug transporter hypothesis of refractory epilepsy: corroboration and contradiction in equal measure.
Drug Resistant Epilepsy
Upregulation of breast cancer resistance protein and major vault protein in drug resistant epilepsy.
Drug Resistant Epilepsy
Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy.
Drug Resistant Epilepsy
Widespread upregulation of drug-resistance proteins in fatal human status epilepticus.
Drug Resistant Epilepsy
[Drug resistant epilepsy. Clinical and neurobiological concepts].
Drug Resistant Epilepsy
[Expression of drug resistance-associated proteins in brain of patients with refractory epilepsy]
Drug-Related Side Effects and Adverse Reactions
A basic conceptual and practical overview of interactions with highly prescribed drugs.
Drug-Related Side Effects and Adverse Reactions
ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study.
Drug-Related Side Effects and Adverse Reactions
ABCG2 transporter: therapeutic and physiologic implications in veterinary species.
Drug-Related Side Effects and Adverse Reactions
Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine.
Drug-Related Side Effects and Adverse Reactions
Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study?.
Drug-Related Side Effects and Adverse Reactions
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer.
Drug-Related Side Effects and Adverse Reactions
Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction.
Drug-Related Side Effects and Adverse Reactions
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.
Drug-Related Side Effects and Adverse Reactions
Brain cyclosporin A levels are determined by ontogenic regulation of mdr1a expression.
Drug-Related Side Effects and Adverse Reactions
Cellular expression and function of naturally occurring variants of the human ABCG2 multidrug transporter.
Drug-Related Side Effects and Adverse Reactions
Cellular Processing of the ABCG2 Transporter-Potential Effects on Gout and Drug Metabolism.
Drug-Related Side Effects and Adverse Reactions
Colchicine toxicity precipitated by interaction with sunitinib.
Drug-Related Side Effects and Adverse Reactions
Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients.
Drug-Related Side Effects and Adverse Reactions
Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice.
Drug-Related Side Effects and Adverse Reactions
CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study.
Drug-Related Side Effects and Adverse Reactions
Does P-glycoprotein play a pivotal role in the drug resistance of an MDR variant, K562/Dox?
Drug-Related Side Effects and Adverse Reactions
Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety.
Drug-Related Side Effects and Adverse Reactions
Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance.
Drug-Related Side Effects and Adverse Reactions
Epilepsy and Alterations of the Blood-Brain Barrier: Cause or Consequence of Epileptic Seizures or Both?
Drug-Related Side Effects and Adverse Reactions
Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene.
Drug-Related Side Effects and Adverse Reactions
Evaluation of Phenotypic and Genotypic Variations of Drug Metabolising Enzymes and Transporters in Chronic Pain Patients Facing Adverse Drug Reactions or Non-Response to Analgesics: A Retrospective Study.
Drug-Related Side Effects and Adverse Reactions
Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
Drug-Related Side Effects and Adverse Reactions
Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
Drug-Related Side Effects and Adverse Reactions
Gender differences in p-glycoprotein: drug toxicity and response.
Drug-Related Side Effects and Adverse Reactions
Genetic advances in gout: potential applications in clinical practice.
Drug-Related Side Effects and Adverse Reactions
Genetic variability among Mexican Mestizo and Amerindian populations based on three ABCB1 polymorphisms.
Drug-Related Side Effects and Adverse Reactions
Genetic Variations of ABCC2 Gene Associated with Adverse Drug Reactions to Valproic Acid in Korean Epileptic Patients.
Drug-Related Side Effects and Adverse Reactions
Impact of genetic variability in the ABCG2 gene on ABCG2 expression, function, and interaction with AT1 receptor antagonist telmisartan.
Drug-Related Side Effects and Adverse Reactions
Importance of P-glycoprotein at blood-tissue barriers.
Drug-Related Side Effects and Adverse Reactions
Insight into the molecular mechanism of P-glycoprotein mediated drug toxicity induced by bioflavonoids: an integrated computational approach.
Drug-Related Side Effects and Adverse Reactions
Medication-related problem type and appearance rate in ambulatory hemodialysis patients.
Drug-Related Side Effects and Adverse Reactions
P-glycoprotein mediated drug interactions in animals and humans with cancer.
Drug-Related Side Effects and Adverse Reactions
Picky ABCG5/G8 and promiscuous ABCG2 - a tale of fatty diets and drug toxicity.
Drug-Related Side Effects and Adverse Reactions
Post-mortem analysis of suicide victims shows ABCB1 haplotype 1236T-2677T-3435T as a candidate predisposing factor behind adverse drug reactions in females.
Drug-Related Side Effects and Adverse Reactions
Post-mortem analysis of suicide victims shows ABCB1 haplotype 1236T-2677T-3435T as a candidate predisposing factor behind adverse drug reactions in females: Erratum.
Drug-Related Side Effects and Adverse Reactions
Prevalence of medication-related problems among patients with renal compromise in an Indian hospital.
Drug-Related Side Effects and Adverse Reactions
Pulchinenosides from Pulsatilla Chinensis Increase P-Glycoprotein Activity and Induce P-Glycoprotein Expression.
Drug-Related Side Effects and Adverse Reactions
Role of ERK1/2 in TNF?-induced internalization of Abcc2 in rat hepatocyte couplets.
Drug-Related Side Effects and Adverse Reactions
SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy.
Drug-Related Side Effects and Adverse Reactions
Telithromycin-induced digoxin toxicity and electrocardiographic changes.
Drug-Related Side Effects and Adverse Reactions
The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes.
Drug-Related Side Effects and Adverse Reactions
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.
Drug-Related Side Effects and Adverse Reactions
The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta.
Drug-Related Side Effects and Adverse Reactions
The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases.
Drug-Related Side Effects and Adverse Reactions
Unravelling the complex drug-drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein.
Dwarfism
Cuticular Defects in Oryza sativa ATP-binding Cassette Transporter G31 Mutant Plants Cause Dwarfism, Elevated Defense Responses and Pathogen Resistance.
Dyslipidemias
Association between ABCB1 Polymorphisms and Ischemic Stroke in Korean Population.
Dyslipidemias
Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients.
Dyslipidemias
HDL elevation and lipid lowering therapy: current scenario and future perspectives.
Dyslipidemias
Pharmacokinetic and Pharmacodynamic Interactions Between the Immunosuppressant Sirolimus and the Lipid-Lowering Drug Ezetimibe in Healthy Volunteers.
Dyslipidemias
The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.
Ectromelia
The multidrug resistance gene mdr1a influences resistance to ectromelia virus infection by mechanisms other than conventional immunity.
Eczema
Cloning, mapping and association studies of the ovine ABCG2 gene with facial eczema disease in sheep.
Embolism
Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis.
Embolism
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Embryo Loss
Human predecidual stromal cells are mesenchymal stromal/stem cells and have a therapeutic effect in an immune-based mouse model of recurrent spontaneous abortion.
Encephalitis
Altered P-glycoprotein expression in AIDS patients with HIV encephalitis.
Encephalomyelitis
Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.
Encephalomyelitis
P-glycoprotein Inhibitor Tariquidar Potentiates Efficacy of Astragaloside IV in Experimental Autoimmune Encephalomyelitis Mice.
Encephalomyelitis, Autoimmune, Experimental
Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
P-glycoprotein Inhibitor Tariquidar Potentiates Efficacy of Astragaloside IV in Experimental Autoimmune Encephalomyelitis Mice.
Endodermal Sinus Tumor
Increased efficiency of testicular tumor chemotherapy by ultrasound microbubble-mediated targeted transfection of siMDR1.
Endometrial Hyperplasia
Expression of multidrug resistance-associated protein in endometrial carcinomas: correlation with clinicopathology and prognosis.
Endometrial Neoplasms
Advances in the molecular genetics of endometrial cancer (Review).
Endometrial Neoplasms
Altered Profile of E1-S Transporters in Endometrial Cancer: Lower Protein Levels of ABCG2 and OST? and Up-Regulation of SLCO1B3 Expression.
Endometrial Neoplasms
Expression of multidrug resistance-associated protein in endometrial carcinomas: correlation with clinicopathology and prognosis.
Endometrial Neoplasms
High rate of expression of multidrug resistance-associated P-glycoprotein in human endometrial carcinoma and normal endometrial tissue.
Endometrial Neoplasms
High rate of MDR-1 and heterogeneous pattern of MRP expression without gene amplification in endometrial cancer.
Endometrial Neoplasms
Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Endometrial Neoplasms
Intrinsic overexpression of two different mechanisms of resistance to chemotherapy (P-glycoprotein and GST-pi) in human endometrial carcinoma.
Endometrial Neoplasms
MDR1 gene expression in endometrial carcinoma.
Endometrial Neoplasms
Reverse correlation between P-glycoprotein expression and proliferative activity in endometrial adenocarcinoma.
Endometrial Neoplasms
SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer.
Endometrial Neoplasms
Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
Endometriosis
Adenosine triphosphate-binding cassette transporter G2 expression in endometriosis and in endometrium from patients with and without endometriosis.
Endometriosis
Augmented epithelial multidrug resistance-associated protein 4 expression in peritoneal endometriosis: regulation by lipoxin A4.
Endometriosis
Expression and significance of CD133 and ABCG2 in endometriosis.
Endometriosis
Expression of AKR1B1, AKR1C3 and other genes of prostaglandin F2? biosynthesis and action in ovarian endometriosis tissue and in model cell lines.
Endometriosis
Studies on Function of P-Glycoprotein in Photodynamic Therapy of Endometriosis.
Endotoxemia
Nitric oxide down-regulates the expression of organic cation transporters (OCT) 1 and 2 in rat kidney during endotoxemia.
Endotoxemia
Regulation of P-glycoprotein in renal proximal tubule epithelial cells by LPS and TNF-alpha.
Endotoxemia
Role of interleukin 1 beta in the regulation of rat intestinal multidrug resistance-associated protein 2 under conditions of experimental endotoxemia.
Enteritis
Expression of P-Glycoprotein in the Intestinal Epithelium of Dogs with Lymphoplasmacytic Enteritis.
Enterocolitis, Necrotizing
P-glycoprotein induction by breast milk attenuates intestinal inflammation in experimental necrotizing enterocolitis.
Eosinophilia
Osteitis in Chronic Rhinosinusitis.
Eosinophilia
P-glycoprotein is a marker of tissue eosinophilia and radiographic inflammation in chronic rhinosinusitis without nasal polyps.
Eosinophilia
Sputum eosinophilia and maximal airway narrowing in Dermatophagoides pteronyssinus allergic rhinitis patients: only rhinitis or rhinitis plus mild asthma?
Eosinophilia
Tissue remodelling in chronic rhinosinusitis - review of literature.
Ependymoma
A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma.
Ependymoma
Overexpression of cyclooxygenase-2 in childhood ependymomas: role of COX-2 inhibitor in growth and multi-drug resistance in vitro.
Ependymoma
P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas.
Epilepsies, Partial
Association of ABCB1 C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy.
Epilepsies, Partial
Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats.
Epilepsies, Partial
Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy.
Epilepsies, Partial
Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.
Epilepsies, Partial
Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy.
Epilepsy
32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016.
Epilepsy
A comprehensive functional and clinical analysis of ABCC2 and its impact on treatment response to carbamazepine.
Epilepsy
A multimodal Pepstatin A peptide-based nanoagent for the molecular imaging of P-glycoprotein in the brains of epilepsy rats.
Epilepsy
A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy.
Epilepsy
A novel approach of targeting refractory epilepsy: Need of an hour.
Epilepsy
A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier.
Epilepsy
A systematic review and meta-analysis of the association of ABCC2/ABCG2 polymorphisms with antiepileptic drug responses in epileptic patients.
Epilepsy
A systematic review and meta-analysis of the role of ABCC2 variants on drug response in patients with epilepsy.
Epilepsy
ABC Transporters And Drug Resistance In Patients With Epilepsy.
Epilepsy
ABCB1 c.-6-180T>G polymorphism and clinical risk factors in a multi-breed cohort of dogs with refractory idiopathic epilepsy.
Epilepsy
ABCB1 c.3435C > T and EPHX1 c.416A > G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients.
Epilepsy
ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis.
Epilepsy
ABCB1 G2677T/A polymorphism is associated with the risk of drug-resistant epilepsy in Asians.
Epilepsy
ABCB1 gene C3435T polymorphism and drug resistance in epilepsy: evidence based on 8,604 subjects.
Epilepsy
ABCB1 Polymorphisms and Drug-Resistant Epilepsy in a Tunisian Population.
Epilepsy
ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.
Epilepsy
ABCB1 variant provides important leads for pharmacogenetics of epilepsy.
Epilepsy
ABCB1, ABCC2, SCN1A, SCN2A, GABRA1 gene polymorphisms and drug resistant epilepsy in the Chinese Han population.
Epilepsy
ABCC2 haplotype is not associated with drug-resistant epilepsy.
Epilepsy
ABCC2 Polymorphisms and Haplotype are Associated with Drug Resistance in Chinese Epileptic Patients.
Epilepsy
ABCC2 rs2273697 and rs3740066 polymorphisms and resistance to antiepileptic drugs in Asia Pacific epilepsy cohorts.
Epilepsy
ABCC2 rs2273697 is associated with valproic acid concentrations in patients with epilepsy on valproic acid monotherapy.
Epilepsy
Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients.
Epilepsy
Acetazolamide Suppresses Multi-Drug Resistance-Related Protein 1 and P-Glycoprotein Expression by Inhibiting Aquaporins Expression in a Mesial Temporal Epilepsy Rat Model.
Epilepsy
Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain.
Epilepsy
Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy: A pilot study.
Epilepsy
Altered GABAA receptor density and unaltered blood-brain barrier transport in a kainate model of epilepsy: an in vivo study using 11C-flumazenil and PET.
Epilepsy
Altered GABAA receptor density and unaltered blood-brain barrier [11C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis.
Epilepsy
Association analysis of intractable epilepsy with C3435T and G2677T/A ABCB1 gene polymorphisms in Iranian patients.
Epilepsy
Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese.
Epilepsy
Association between ABCB1 genetic polymorphism and the effect on epilepsy following phenytoin treatment.
Epilepsy
Association between ABCB1 genotype and seizure outcome in collies with epilepsy.
Epilepsy
Association between ABCB1 polymorphism and response to sodium valproate treatment in Malaysian epilepsy patients.
Epilepsy
Association between ABCB1-T1236C polymorphism and drug-resistant epilepsy in Iranian female patients.
Epilepsy
Association Between Lamotrigine Concentrations and ABCB1 Polymorphisms in Patients With Epilepsy.
Epilepsy
Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy.
Epilepsy
Association between the polymorphisms in the ATP-binding cassette genes ABCB1 and ABCC2 and the risk of drug-resistant epilepsy in a Chinese Han population.
Epilepsy
Association of ABCB1 C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy.
Epilepsy
Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis.
Epilepsy
Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy.
Epilepsy
Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy.
Epilepsy
Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.
Epilepsy
Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses.
Epilepsy
Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
Epilepsy
Associations between the C3435T polymorphism of the ABCB1 gene and drug resistance in epilepsy: a meta-analysis.
Epilepsy
Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy.
Epilepsy
Blockade of endothelin B receptor improves the efficacy of levetiracetam in chronic epileptic rats.
Epilepsy
Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies.
Epilepsy
Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy.
Epilepsy
Clinical Applications of Simultaneous PET/MR Imaging Using (R)-[11C]-Verapamil with Cyclosporin A: Preliminary Results on a Surrogate Marker of Drug-Resistant Epilepsy.
Epilepsy
Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study.
Epilepsy
CNS transporters and Drug delivery in Epilepsy.
Epilepsy
Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats.
Epilepsy
Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach.
Epilepsy
Common ABCB1 polymorphisms associated with susceptibility to infantile spasms in the Chinese Han population.
Epilepsy
Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response.
Epilepsy
Correlation between Nurr1 expression and drug resistance in the brain of rats with epilepsy.
Epilepsy
Correlation of MCT1 and ABCC2 gene polymorphisms with valproic acid resistance in patients with epilepsy on valproic acid monotherapy.
Epilepsy
Cortical expression of IL1-?, Bcl-2, Caspase-3 and 9, SEMA-3a, NT-3 and P-glycoprotein as biological markers of intrinsic severity in drug-resistant temporal lobe epilepsy.
Epilepsy
Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy.
Epilepsy
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
Epilepsy
Development and Validation of a Computational Model Ensemble for the Early Detection of BCRP/ABCG2 Substrates during the Drug Design Stage.
Epilepsy
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
Epilepsy
Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid.
Epilepsy
Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis.
Epilepsy
Downregulation of peripheral PTGS2/COX-2 in response to valproate treatment in patients with epilepsy.
Epilepsy
Drug resistance in cortical and hippocampal slices from resected tissue of epilepsy patients: no significant impact of p-glycoprotein and multidrug resistance-associated proteins.
Epilepsy
Drug resistance in epilepsy and the ABCB1 gene: The clinical perspective.
Epilepsy
Drug transporters in the epileptic brain.
Epilepsy
Dynamic Regulation of P-glycoprotein in Human Brain Capillaries.
Epilepsy
Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain.
Epilepsy
Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy.
Epilepsy
Effects of ABCB1, ABCC2, UGT2B7 and HNF4? genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy.
Epilepsy
Effects of Brain IKK? Gene Silencing by Small Interfering RNA on P-Glycoprotein Expression and Brain Damage in the Rat Kainic Acid-Induced Seizure Model.
Epilepsy
Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With Epilepsy.
Epilepsy
Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.
Epilepsy
Effects of MTHFR and ABCC2 gene polymorphisms on antiepileptic drug responsiveness in Jordanian epileptic patients.
Epilepsy
Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.
Epilepsy
Emodin plays an interventional role in epileptic rats via multidrug resistance gene 1 (MDR1).
Epilepsy
Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells.
Epilepsy
Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy.
Epilepsy
Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy.
Epilepsy
Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs.
Epilepsy
Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese.
Epilepsy
Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy.
Epilepsy
Genetic association analysis of ATP binding cassette protein family reveals a novel association of ABCB1 genetic variants with epilepsy risk, but not with drug-resistance.
Epilepsy
Genetic association analysis of transporters identifies ABCC2 loci for seizure control in women with epilepsy on first-line antiepileptic drugs.
Epilepsy
Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.
Epilepsy
Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.
Epilepsy
Glomerular filtration rate is a major predictor of clearance of oxcarbazepine active metabolite in adult Chinese epileptic patients: A population pharmacokinetic analysis.
Epilepsy
HMGB1 regulates P-glycoprotein expression in status epilepticus rat brains via the RAGE/NF-?B signaling pathway.
Epilepsy
Humanization of the Blood-Brain Barrier Transporter ABCB1 in Mice Disrupts Genomic Locus - Lessons from Three Unsuccessful Approaches.
Epilepsy
Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.
Epilepsy
Imaging P-glycoprotein function in rats using [(11)C]-N-desmethyl-loperamide.
Epilepsy
Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables.
Epilepsy
Impact of ABCB1 Polymorphism on Levetiracetam Serum Concentrations in Epileptic Uygur Children in China.
Epilepsy
Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy.
Epilepsy
Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.
Epilepsy
In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein.
Epilepsy
In vivo P-glycoprotein function before and after epilepsy surgery.
Epilepsy
Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats.
Epilepsy
Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy.
Epilepsy
Inhibition of mTOR Pathway by Rapamycin Decreases P-glycoprotein Expression and Spontaneous Seizures in Pharmacoresistant Epilepsy.
Epilepsy
Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats.
Epilepsy
Inhibitors of multidrug efflux transporters: their membrane and protein interactions.
Epilepsy
Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.
Epilepsy
Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain.
Epilepsy
Is cannabidiol a drug acting on unconventional targets to control drug-resistant epilepsy?
Epilepsy
Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.
Epilepsy
Lack of association between ABCB1 gene polymorphisms and pharmacoresistant epilepsy: an analysis in a western Chinese pediatric population.
Epilepsy
Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy.
Epilepsy
Lack of association between ABCC2 gene variants and treatment response in epilepsy.
Epilepsy
Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy.
Epilepsy
Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy.
Epilepsy
Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy.
Epilepsy
Lack of association of ABCB1 haplotypes on five loci with response to treatment in epilepsy.
Epilepsy
Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions.
Epilepsy
Linkage disequilibrium between polymorphisms of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex partial seizures on treatment with carbamazepine mono-therapy at the Kuala Lumpur Hospital.
Epilepsy
Low dose verapamil as an adjunct therapy for medically refractory epilepsy - An open label pilot study.
Epilepsy
Marked Differences in the Effect of Antiepileptic and Cytostatic Drugs on the Functionality of P-Glycoprotein in Human and Rat Brain Capillary Endothelial Cell Lines.
Epilepsy
MDR-1 and MRP2 Gene Polymorphisms in Mexican Epileptic Pediatric Patients with Complex Partial Seizures.
Epilepsy
Mechanisms of drug resistance in epilepsy: relevance for antiepileptic drug discovery.
Epilepsy
Mechanisms of drug resistance.
Epilepsy
MicroRNA-146a-5p Downregulates the Expression of P-Glycoprotein in Rats with Lithium-Pilocarpine-Induced Status Epilepticus.
Epilepsy
MicroRNA-542-3p Regulates P-glycoprotein Expression in Rat Epilepsy via the Toll-like Receptor 4/Nuclear Factor-kappaB Signaling Pathway.
Epilepsy
MiR-466b-1-3p regulates P-glycoprotein expression in rat cerebral microvascular endothelial cells.
Epilepsy
miR-485's anti-drug resistant epilepsy effects by regulating SV2A/PSD-95 and targeting ABCC1 and neuronal signaling-transduction proteins in hippocampus of rats.
Epilepsy
Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies?
Epilepsy
Modulation and Absorption of Xenobiotics: the Synergistic Role of CYP450 AND P-gp Activities in Cancer and Neurodegenerative Disorders.
Epilepsy
Multi-Omics Data Integration Analysis of an Immune-Related Gene Signature in LGG Patients With Epilepsy.
Epilepsy
Multidrug resistance in epilepsy: a pharmacogenomic update.
Epilepsy
Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures.
Epilepsy
Multidrug resistance in patients undergoing resective epilepsy surgery is not associated with C3435T polymorphism in the ABCB1 (MDR1) gene.
Epilepsy
Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain.
Epilepsy
Multidrug-resistance protein 1 in focal cortical dysplasia.
Epilepsy
Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.
Epilepsy
Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy.
Epilepsy
New anticonvulsant candidates prevent P-glycoprotein (P-gp) overexpression in a pharmacoresistant seizure model in mice.
Epilepsy
Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model.
Epilepsy
No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population.
Epilepsy
Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy.
Epilepsy
Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis.
Epilepsy
Novel therapies for epilepsy in the pipeline.
Epilepsy
Ontogeny of ABC and SLC transporters in the microvessels of developing rat brain.
Epilepsy
P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain.
Epilepsy
P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study.
Epilepsy
P-glycoprotein Expression and Pharmacoresistant Epilepsy: Cause or Consequence?
Epilepsy
P-glycoprotein imaging in temporal lobe epilepsy: in vivo PET experiments with the Pgp substrate [11C]-verapamil.
Epilepsy
P-glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)-[11 C]verapamil PET.
Epilepsy
PET tracers for imaging of ABC transporters at the blood-brain barrier: Principles and Strategies.
Epilepsy
Pharmacogenetic evaluation of ABCB1, Cyp2C9, Cyp2C19 and methylene tetrahydrofolate reductase polymorphisms in teratogenicity of anti-epileptic drugs in women with epilepsy.
Epilepsy
Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models.
Epilepsy
Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats.
Epilepsy
Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil.
Epilepsy
Pharmacoresistant epilepsy and nanotechnology.
Epilepsy
Pluronic P85-coated poly(butylcyanoacrylate) nanoparticles overcome phenytoin resistance in P-glycoprotein overexpressing rats with lithium-pilocarpine-induced chronic temporal lobe epilepsy.
Epilepsy
Polymorphic variants of the multidrug resistance gene Mdr1a and response to antiepileptic drug treatment in the kindling model of epilepsy.
Epilepsy
Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis.
Epilepsy
Polymorphisms in the ABCB1 gene in phenobarbital responsive and resistant idiopathic epileptic Border Collies.
Epilepsy
Polymorphisms of ABCG2, ABCB1 and HNF4? are associated with Lamotrigine trough concentrations in epilepsy patients.
Epilepsy
Possible interplay between the theories of pharmacoresistant epilepsy.
Epilepsy
Potentiation of anti-epileptic drugs effectiveness by pyronaridine in refractory epilepsy.
Epilepsy
Predisposition to epilepsy--does the ABCB1 gene play a role?
Epilepsy
Pregnane X Receptor Not Nuclear Factor-kappa B Up-regulates P-glycoprotein Expression in the Brain of Chronic Epileptic Rats Induced by Kainic Acid.
Epilepsy
Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition.
Epilepsy
Quantification of Dynamic 11C-Phenytoin PET Studies.
Epilepsy
Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity.
Epilepsy
Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis.
Epilepsy
Reversal of P-glycoprotein overexpression by Ginkgo biloba extract in the brains of pentylenetetrazole-kindled and phenytoin-treated mice.
Epilepsy
RLIP76 Gene Variants are not Associated with Drug Response in Turkish Epilepsy Patients.
Epilepsy
RLIP76, a non-ABC transporter, and drug resistance in epilepsy.
Epilepsy
Role of drug efflux carriers in the healthy and diseased brain.
Epilepsy
Role of P-Glycoprotein in Refractoriness of Seizures to Antiepileptic Drugs in Lennox-Gastaut Syndrome.
Epilepsy
Role of P-glycoprotein inhibitors in children with drug-resistant epilepsy.
Epilepsy
Searching for New Leads To Treat Epilepsy: Target-Based Virtual Screening for the Discovery of Anticonvulsant Agents.
Epilepsy
Several major antiepileptic drugs are substrates for human P-glycoprotein.
Epilepsy
Silymarin as a flavonoid-type P-glycoprotein inhibitor with impact on the pharmacokinetics of carbamazepine, oxcarbazepine and phenytoin in rats.
Epilepsy
Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy.
Epilepsy
Sucrose consumption test reveals pharmacoresistant depression-associated behavior in two mouse models of temporal lobe epilepsy.
Epilepsy
Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood-Brain Barrier.
Epilepsy
Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation.
Epilepsy
The ABCC2 c.-24C>T polymorphism increases the risk of resistance to antiepileptic drugs: A meta-analysis.
Epilepsy
The association between polymorphisms in RLIP76 and drug response in epilepsy.
Epilepsy
The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population.
Epilepsy
The drug-transporter gene MDR1 C3435T and G2677T/A polymorphisms and the risk of multidrug-resistant epilepsy in Turkish children.
Epilepsy
The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy.
Epilepsy
The mechanisms of medically refractory temporal lobe epilepsy.
Epilepsy
The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy.
Epilepsy
The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs.
Epilepsy
The possible use of the L-type calcium channel antagonist verapamil in drug-resistant epilepsy.
Epilepsy
The potential role of human multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 2 (MRP2) in the transport of Huperzine A in vitro.
Epilepsy
The recessive model of MRP2 G1249A polymorphism decrease the risk of drug-resistant in Asian Epilepsy: a systematic review and meta-analysis.
Epilepsy
The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation.
Epilepsy
The role of P-glycoprotein (P-gp) and inwardly rectifying potassium (Kir) channels in sudden unexpected death in epilepsy (SUDEP).
Epilepsy
The Sphingosine 1-Phosphate Analogue FTY720 Alleviates Seizure-induced Overexpression of P-Glycoprotein in Rat Hippocampus.
Epilepsy
The transport of antiepileptic drugs by P-glycoprotein.
Epilepsy
Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy.
Epilepsy
Upregulation of breast cancer resistance protein and major vault protein in drug resistant epilepsy.
Epilepsy
Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy.
Epilepsy
Variability in expression of the human MDR1 drug efflux transporter and genetic variation of the ABCB1 gene: implications for drug-resistant epilepsy.
Epilepsy
[11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-responsiveness.
Epilepsy
[A role of P-glycoprotein in neurology].
Epilepsy
[ABC transporters and drug resistance in epilepsy: biological plausibility, pharmacogenetics and precision medicine].
Epilepsy
[Association of a polymorphism in MDR1 C3435T with response to antiepileptic drug treatment in ethic Han Chinese children with epilepsy]
Epilepsy
[Drug resistant epilepsy. Clinical and neurobiological concepts].
Epilepsy
[Effect of ?-asarone on the Function and Expression of P-glycoprotein in Rat Brain Microvascular Endothelial Cells].
Epilepsy
[Expression of multidrug resistance gene and topiramate affect expression of multidrug resistance gene in the hippocampus of spontaneous epileptic rats]
Epilepsy
[Future perspectives in epilepsy treatment]
Epilepsy
[Pharmacogenetic criteria of drug-resistant epilepsy].
Epilepsy, Absence
Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy.
Epilepsy, Generalized
Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy.
Epilepsy, Generalized
The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy.
Epilepsy, Temporal Lobe
32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016.
Epilepsy, Temporal Lobe
Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy: A pilot study.
Epilepsy, Temporal Lobe
Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy.
Epilepsy, Temporal Lobe
Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy.
Epilepsy, Temporal Lobe
Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy.
Epilepsy, Temporal Lobe
Cortical expression of IL1-?, Bcl-2, Caspase-3 and 9, SEMA-3a, NT-3 and P-glycoprotein as biological markers of intrinsic severity in drug-resistant temporal lobe epilepsy.
Epilepsy, Temporal Lobe
Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy.
Epilepsy, Temporal Lobe
Genetic association analysis of ATP binding cassette protein family reveals a novel association of ABCB1 genetic variants with epilepsy risk, but not with drug-resistance.
Epilepsy, Temporal Lobe
In vivo P-glycoprotein function before and after epilepsy surgery.
Epilepsy, Temporal Lobe
Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats.
Epilepsy, Temporal Lobe
Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.
Epilepsy, Temporal Lobe
P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study.
Epilepsy, Temporal Lobe
P-glycoprotein imaging in temporal lobe epilepsy: in vivo PET experiments with the Pgp substrate [11C]-verapamil.
Epilepsy, Temporal Lobe
Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats.
Epilepsy, Temporal Lobe
Pluronic P85-coated poly(butylcyanoacrylate) nanoparticles overcome phenytoin resistance in P-glycoprotein overexpressing rats with lithium-pilocarpine-induced chronic temporal lobe epilepsy.
Epilepsy, Temporal Lobe
The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy.
Epilepsy, Temporal Lobe
The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation.
Epilepsy, Temporal Lobe
Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy.
Epileptic Syndromes
Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: Data from International Pharmacogenetic Cohorts.
Epileptic Syndromes
[Future perspectives in epilepsy treatment]
Epiretinal Membrane
Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy.
Epstein-Barr Virus Infections
Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
Epstein-Barr Virus Infections
Expression of the multidrug resistance protein MRP and the lung-resistance protein LRP in nasal NK/T cell lymphoma: further exploring the role of P53 and WT1 gene.
Erectile Dysfunction
Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.
Erythema Nodosum
NR3C1, ABCB1, TNF and CYP2C19 polymorphisms association with the response to the treatment of erythema nodosum leprosum.
Escherichia coli Infections
E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers.
Esophageal Neoplasms
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Esophageal Neoplasms
ABCB1 Is Upregulated in Acquisition of Taxane Resistance: Lessons from Esophageal Squamous Cell Carcinoma Cell Lines.
Esophageal Neoplasms
ABCG2 gene amplification and expression in esophageal cancer cells with acquired adriamycin resistance.
Esophageal Neoplasms
Association between ABCC2 polymorphism and hematological toxicity in patients with esophageal cancer receiving platinum plus 5-fluorouracil therapy.
Esophageal Neoplasms
Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy.
Esophageal Neoplasms
Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate.
Esophageal Neoplasms
Effects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells.
Esophageal Neoplasms
Enhancing Chemosensitivity in ABCB1- and ABCG2-Overexpressing Cells and Cancer Stem-like Cells by An Aurora Kinase Inhibitor CCT129202.
Esophageal Neoplasms
Epigallocatechin-3-gallate promotes apoptosis and reversal of multidrug resistance in esophageal cancer cells.
Esophageal Neoplasms
Expression of MRP and mdr1 in human gastrointestinal cancer cell lines: a correlation with resistance against doxorubicin.
Esophageal Neoplasms
Genetic and epigenetic aberrations of ABCB1 synergistically boost the acquisition of taxane resistance in esophageal squamous cancer cells.
Esophageal Neoplasms
HOTTIP is upregulated in esophageal cancer and triggers the drug resistance.
Esophageal Neoplasms
Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.
Esophageal Neoplasms
Mithramycin Represses Basal and Cigarette Smoke-Induced Expression of ABCG2 and Inhibits Stem Cell Signaling in Lung and Esophageal Cancer Cells.
Esophageal Neoplasms
Reversal of multidrug resistance by the anti-malaria drug artesunate in the esophageal cancer Eca109/ABCG2 cell line.
Esophageal Neoplasms
Up-regulation of P-glycoprotein is involved in the increased paclitaxel resistance in human esophageal cancer radioresistant cells.
Esophageal Squamous Cell Carcinoma
ABCB1 Is Upregulated in Acquisition of Taxane Resistance: Lessons from Esophageal Squamous Cell Carcinoma Cell Lines.
Esophageal Squamous Cell Carcinoma
ABCC4 copy number variation is associated with susceptibility to esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Association of a genetic variant in ATP-binding cassette sub-family B member 1 gene with poor prognosis in patients with squamous cell carcinoma of the esophagus.
Esophageal Squamous Cell Carcinoma
BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10.
Esophageal Squamous Cell Carcinoma
Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Different response rates to chemotherapy between Japanese and German esophageal squamous cell carcinoma: patients may be influenced by ERCC1 or ABCB1.
Esophageal Squamous Cell Carcinoma
Effects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells.
Esophageal Squamous Cell Carcinoma
Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and SC236 via inhibiting P-glycoprotein activity.
Esophageal Squamous Cell Carcinoma
Polymorphism of FGD4 and myelosuppression in patients with esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma.
Esotropia
Cyclic esotropia with development of a high accommodative convergence to accommodation ratio after surgery for intermittent exotropia.
Essential Hypertension
ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis.
Exanthema
Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.
Exanthema
Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.
Exanthema
Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.
Exanthema
Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Exanthema
Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Patients.
Familial Mediterranean Fever
Association analysis of three ABCB1 (MDR1) gene variants (C1236T, G2677A/T and C3435T) and their genotype/haplotype combinations with the familial Mediterranean fever.
Familial Mediterranean Fever
Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever.
Familial Mediterranean Fever
Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases?
Familial Mediterranean Fever
The 3435T polymorphism in the ABCB1 gene and colchicine unresponsiveness in familial Mediterranean fever.
Fatty Liver
A predictive model for non-completion of an intensive specialist obesity service in a public hospital: a case-control study.
Fatty Liver
Changes in digoxin pharmacokinetics associated with hepatic P-glycoprotein upregulation in rats with non-alcoholic fatty liver disease.
Fatty Liver
Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population.
Febrile Neutropenia
Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients.
Febrile Neutropenia
Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries.
Febrile Neutropenia
Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Fetal Growth Retardation
Alterations of placental cytochrome P450 1A1 and P-glycoprotein in tobacco-induced intrauterine growth retardation in rats.
Fetal Growth Retardation
Growth retardation of fetal rats exposed to nicotine in utero: possible involvement of CYP1A1, CYP2E1, and P-glycoprotein.
Fibroadenoma
HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
Fibrosarcoma
Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N- nitrosourea associated with inhibition of multidrug resistance protein (MRP) function.
Fibrosarcoma
Differential recognition of mdr1a and mdr1b gene products in multidrug resistant mouse tumour cell lines by different monoclonal antibodies.
Fibrosarcoma
Enhanced Cytotoxic Effect of Doxorubicin Conjugated to Glutathione-Stabilized Gold Nanoparticles in Canine Osteosarcoma-In Vitro Studies.
Fibrosarcoma
Expression of cell surface P-glycoprotein by an adriamycin-resistant murine fibrosarcoma.
Fibrosarcoma
Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells.
Fibrosarcoma
HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Fibrosarcoma
Modulation of vinblastine sensitivity by dipyridamole in multidrug resistant fibrosarcoma cells lacking mdr1 expression.
Fibrosarcoma
Molecular analysis of two human doxorubicin-resistant cell lines: evidence for differing multidrug resistance mechanisms.
Fibrosarcoma
Photochemical internalization of therapeutic macromolecular agents: a novel strategy to kill multidrug-resistant cancer cells.
Fibrosarcoma
The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification.
Fibrosarcoma
Tissue selective drug delivery utilizing carrier-mediated transport systems.
Fissure in Ano
Anal canal pressure in anal fissure before and after internal sphincterotomy.
Fissure in Ano
Topical glyceryl trinitrate in the treatment of chronic anal fissure.
Foodborne Diseases
Effects of Maillard reaction products on hilA expression in Salmonella typhimurium.
Gallbladder Neoplasms
ABCB1/4 gallbladder cancer risk variants identified in India also show strong effects in Chileans.
Gallbladder Neoplasms
Characterization of cancer stem-like cells derived from a side population of a human gallbladder carcinoma cell line, SGC-996.
Gallbladder Neoplasms
Common genetic variation and risk of gallbladder cancer in India: a case-control genome-wide association study.
Gallbladder Neoplasms
Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma.
Gallbladder Neoplasms
Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gall bladder cancer tissues.
Gallbladder Neoplasms
[Expression of P-glycoprotein in benign and malignant gallbladder neoplasms]
Gallstones
Altered Bile Transporter Expression and Cholesterol Metabolism in Children With Cholesterol and Pigment Gallstones.
Gallstones
Elevated hepatic MRP3/ABCC3 expression in human obstructive cholestasis is mediated through TNF? and JNK/SAPK signaling pathway.
Gallstones
Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol.
Gallstones
Inhibition of Ceramide Decreased the Expression of ATP-Binding Cassette Transporter G5/8 mRNA in an Animal Model of Cholesterol Gallstone.
Gallstones
[Mechanism of Dahuang Lingxian Capsule for Regulating and Controlling Expression of Hepatocyte Transporters and Bile Metabolism Spectrum in Gallstone Mice].
Ganglioneuroma
Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies.
Ganglioneuroma
Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein.
Gastritis
The importance of P-glycoprotein multidrug transporter activity measurement in patients with Helicobacter pylori infection.
Gastroenteritis
Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2.
Gastroenteritis
Preliminary structural studies of the transcriptional regulator CmeR from Campylobacter jejuni.
Gastroesophageal Reflux
Volume 241, Number 1 (1997), in Article No. RC977772, "A Bidirectional Promoter Connects the p14.5 Gene to the Gene for RNase P and RNase MRP Protein Subunit hPOP1,rdquo; by Gerno Schmiedeknecht, Christa Büchler, and Gerd Schmitz, pages 59-67:
Gastrointestinal Diseases
Ranolazine: new drug. Stable angina: not worth the risk.
Gastrointestinal Neoplasms
ABCG2 expression is related to low 5-ALA photodynamic diagnosis (PDD) efficacy and cancer stem cell phenotype, and suppression of ABCG2 improves the efficacy of PDD.
Gastrointestinal Neoplasms
Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells.
Gastrointestinal Neoplasms
Expression of MRP and mdr1 in human gastrointestinal cancer cell lines: a correlation with resistance against doxorubicin.
Gastrointestinal Neoplasms
Fas signaling promotes chemoresistance in gastrointestinal cancer by up-regulating P-glycoprotein.
Gastrointestinal Neoplasms
Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon.
Gastrointestinal Neoplasms
P-glycoprotein expression and chemosensitivity in highly purified fresh human gastrointestinal cancer cells.
Gastrointestinal Neoplasms
P-glycoprotein-expressing tumor cells are resistant to anticancer drugs in human gastrointestinal cancer.
Gastrointestinal Neoplasms
Prediction of doxorubicin resistance in gastrointestinal cancer by P-glycoprotein staining.
Gastrointestinal Neoplasms
Side populations of gastrointestinal cancers are not enriched in stem cells.
Gastrointestinal Neoplasms
[Detection of multidrug resistant cells in human malignant diseases by monoclonal antibodies and strategy to eradicate resistant malignant cells]
Gastrointestinal Stromal Tumors
Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
Gastrointestinal Stromal Tumors
Expression of P-glycoprotein and Metallothionein in Gastrointestinal Stromal Tumor and Leiomyosarcomas. Clinical Implications.
Gastrointestinal Stromal Tumors
Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors.
Gastroparesis
Review article: metoclopramide and tardive dyskinesia.
Genetic Diseases, Inborn
Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease.
Genetic Diseases, Inborn
Conserved and variable domains of RNase MRP RNA.
Genetic Diseases, Inborn
Cystic fibrosis transmembrane conductance regulator degradation depends on the lectins Htm1p/EDEM and the Cdc48 protein complex in yeast.
Genetic Diseases, Inborn
Genotypic effect of the -565C>T polymorphism in the ABCA1 gene promoter on ABCA1 expression and severity of atherosclerosis.
Genetic Diseases, Inborn
Literature review and report of three cases of Dubin-Johnson syndrome related to ABCC2 gene mutations in children.
Genetic Diseases, Inborn
Plasma Amyloid-? in Patients with Tangier Disease.
Genetic Diseases, Inborn
[Polymerase chain reaction in diagnostic pathology]
Gestational Trophoblastic Disease
ABCB1 and SLCO1B1 gene polymorphisms predict methotrexate-resistant for low-risk gestational trophoblastic neoplasia.
Gingival Hyperplasia
ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients.
Gingival Overgrowth
Effect of periodontal therapy on the course of cyclosporin-induced gingival overgrowth: role of ABCB1 and PAI-1 gene polymorphisms.
Gingival Overgrowth
MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists.
Gingival Overgrowth
P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth.
Gingival Overgrowth
Role of MDR1 gene polymorphisms in gingival overgrowth induced by cyclosporine in transplant patients.
Glaucoma
Multidrug resistance-associated proteins in glaucoma surgery.
Glaucoma
Reduced Annexin A1 Secretion by ABCA1 Causes Retinal Inflammation and Ganglion Cell Apoptosis in a Murine Glaucoma Model.
Glaucoma, Open-Angle
ABCB1 variants confer susceptibility to primary open-angle glaucoma and predict individual differences to latanoprost treatment.
Glaucoma, Open-Angle
Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients.
Glioblastoma
A High-Content Assay Strategy for the Identification and Profiling of ABCG2 Modulators in Live Cells.
Glioblastoma
A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.
Glioblastoma
ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide.
Glioblastoma
ABCB1, ABCG2 and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
Glioblastoma
ABCC3 Expressed by CD56dim CD16+ NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy.
Glioblastoma
ABCG2 influence on the efficiency of photodynamic therapy in glioblastoma cells.
Glioblastoma
ABCG2-mediated suppression of chlorin e6 accumulation and photodynamic therapy efficiency in glioblastoma cell lines can be reversed by KO143.
Glioblastoma
Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells.
Glioblastoma
CCAAT/Enhancer-binding protein delta mediates glioma stem-like cell enrichment and ATP-binding cassette transporter ABCA1 activation for temozolomide resistance in glioblastoma.
Glioblastoma
Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells.
Glioblastoma
Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes.
Glioblastoma
Corrigendum: Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide.
Glioblastoma
Delivery of siRNA in vitro and in vivo using PEI-capped porous silicon nanoparticles to silence MRP1 and inhibit proliferation in glioblastoma.
Glioblastoma
Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance.
Glioblastoma
Drug resistance conferred by MDR1 expression in spheroids formed by glioblastoma cell lines.
Glioblastoma
Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors.
Glioblastoma
Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.
Glioblastoma
Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme.
Glioblastoma
Epothilone B induces glioblastoma cell death via survivin down-regulation.
Glioblastoma
Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Glioblastoma
Expression and function of ABCG2 and XIAP in glioblastomas.
Glioblastoma
Expression of multidrug resistance-associated protein (MRP) in human gliomas.
Glioblastoma
Further exploration of DVD-445 as a lead thioredoxin reductase (TrxR) inhibitor for cancer therapy: Optimization of potency and evaluation of anticancer potential.
Glioblastoma
Gene transfer of human TNF alpha into glioblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity.
Glioblastoma
Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy.
Glioblastoma
Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells.
Glioblastoma
Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule.
Glioblastoma
Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme.
Glioblastoma
LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Glioblastoma
mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line.
Glioblastoma
Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide.
Glioblastoma
miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.
Glioblastoma
Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines.
Glioblastoma
Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein.
Glioblastoma
NADPH/quinone oxidoreductase is a priority target of glioblastoma chemotherapy.
Glioblastoma
New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro.
Glioblastoma
P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.
Glioblastoma
Paradoxical expression of anti-apoptotic and MRP genes on cancer stem-like cell isolated from TJ905 glioblastoma multiforme cell line.
Glioblastoma
Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine.
Glioblastoma
Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines.
Glioblastoma
Pomolic acid induces apoptosis and inhibits multidrug resistance protein MRP1 and migration in glioblastoma cells.
Glioblastoma
Potentiation by alpha-tocopheryl succinate of the etoposide response in multidrug resistance protein 1-expressing glioblastoma cells.
Glioblastoma
Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy.
Glioblastoma
Prognostic significance of the immunohistochemical expression of O-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas.
Glioblastoma
Protein Expression and Functional Relevance of Efflux and Uptake Drug Transporters at the Blood-Brain Barrier of Human Brain and Glioblastoma.
Glioblastoma
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Glioblastoma
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.
Glioblastoma
Screening of potential miRNA therapeutics for the prevention of multi-drug resistance in cancer cells.
Glioblastoma
Single-cell Western blotting after whole-cell imaging to assess cancer chemotherapeutic response.
Glioblastoma
Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro.
Glioblastoma
Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells.
Glioblastoma
Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/?-catenin pathway.
Glioblastoma
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Glioblastoma
Temozolomide: Mechanisms of Action, Repair and Resistance.
Glioblastoma
The ABCG2 resistance network of glioblastoma.
Glioblastoma
The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases the in vitro drug delivery across blood-brain barrier cells.
Glioblastoma
The expression and functional characterization of ABCG2 in brain endothelial cells and vessels.
Glioblastoma
The usefulness of Tc-99m MIBI for evaluating brain tumors: comparative study with Tl-201 and relation with P-glycoprotein
Glioblastoma
TRPC5 mediates TMZ resistance in TMZ-resistant glioblastoma cells via NFATc3-P-gp pathway.
Glioblastoma
Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1.
Glioblastoma
Utility of Magnetic Resonance Perfusion Imaging in Quantifying Active Tumor Fraction and Radiation Necrosis in Recurrent Intracranial Tumors.
Glioblastoma
Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells.
Glioma
?-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Glioma
ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.
Glioma
ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier.
Glioma
ABCG1 maintains high-grade glioma survival in vitro and in vivo.
Glioma
ABCG2 and ABCB1 limit the efficacy of dasatinib in a PDGF-B driven brainstem glioma model.
Glioma
ABCG2 downregulation in glioma stem cells enhances the therapeutic efficacy of demethoxycurcumin.
Glioma
ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma.
Glioma
ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells.
Glioma
Analysis of expression of microRNAs and genes involved in the control of key signaling mechanisms that support or inhibit development of brain tumors of different grades.
Glioma
Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2.
Glioma
Bioinformatics Analysis of the Expression of ATP Binding Cassette Subfamily C Member 3 (ABCC3) in Human Glioma.
Glioma
CCAAT/Enhancer-binding protein delta mediates glioma stem-like cell enrichment and ATP-binding cassette transporter ABCA1 activation for temozolomide resistance in glioblastoma.
Glioma
Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.
Glioma
Comparison of (99m)tc-tetrofosmin and (99m)tc-sestamibi uptake in glioma cell lines: the role of p-glycoprotein expression.
Glioma
Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas.
Glioma
Differences in the Expression Pattern of P-Glycoprotein and MRP1 in Low-Grade and High-Grade Gliomas.
Glioma
Downregulation of ABCG2 protein inhibits migration and invasion in U251 glioma stem cells.
Glioma
Drug-resistance gene expression and progression of astrocytic tumors.
Glioma
Effects of protein kinase C modulators on multidrug resistance in human glioma cells.
Glioma
EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition.
Glioma
Emodin has cytotoxic and protective effects in rat C6 glioma cells: roles of Mdr1a and nuclear factor kappaB in cell survival.
Glioma
Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition.
Glioma
Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Glioma
Expression and function of ABCG2 and XIAP in glioblastomas.
Glioma
Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma.
Glioma
Expression of multidrug resistance protein gene in patients with glioma after chemotherapy.
Glioma
Expression of multidrug resistance-associated protein (MRP) in human gliomas.
Glioma
Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens.
Glioma
Expression pattern of chemoresistance-related genes in human malignant brain tumors: a working knowledge for proper selection of anticancer drugs.
Glioma
Gene transfer of human TNF alpha into glioblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity.
Glioma
Heat Shock Protein Inhibitor 17-Allyamino-17-Demethoxygeldanamycin, a Potent Inductor of Apoptosis in Human Glioma Tumor Cell Lines, Is a Weak Substrate for ABCB1 and ABCG2 Transporters.
Glioma
Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy.
Glioma
Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium.
Glioma
In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.
Glioma
Increased Expression of ABCB6 Enhances Protoporphyrin IX Accumulation and Photodynamic Effect in Human Glioma.
Glioma
Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme.
Glioma
Investigation of imatinib loaded surface decorated biodegradable nanocarriers against glioblastoma cell lines: Intracellular uptake and cytotoxicity studies.
Glioma
Involvement of the glutathione S-conjugate compounds and the MRP protein in Tc-99m-tetrofosmin and Tc-99m-sestamibi uptake in glioma cell lines.
Glioma
Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma.
Glioma
Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Glioma
Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity by regulating autophagy in glioblastoma.
Glioma
LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR-134/Myc/ABCC1 axis in glioma.
Glioma
Low intensity ultrasound promotes the sensitivity of rat brain glioma to Doxorubicin by down-regulating the expressions of p-glucoprotein and multidrug resistance protein 1 in vitro and in vivo.
Glioma
MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors.
Glioma
MiR-135a and MRP1 play pivotal roles in the selective lethality of phenethyl isothiocyanate to malignant glioma cells.
Glioma
miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2.
Glioma
MiR-32 Inhibits Proliferation and Metastasis by Targeting EZH2 in Glioma.
Glioma
miR-9-5p Mediates ABCC1 to Elevate the Sensitivity of Glioma Cells to Temozolomide.
Glioma
Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines.
Glioma
Multidrug resistance gene (MDR1) expression in human brain tumors.
Glioma
Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1.
Glioma
Murine P-glycoprotein on stromal vessels mediates multidrug resistance in intracerebral human glioma xenografts.
Glioma
P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells.
Glioma
P-glycoprotein inhibition of drug resistant cell lines by nanoparticles.
Glioma
Penetration of intra-arterially administered vincristine in experimental brain tumor.
Glioma
Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.
Glioma
Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells.
Glioma
Posttranscriptional regulation of MRP/GS-X pump and gamma-glutamylcysteine synthetase expression by 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea and by cycloheximide in human glioma cells.
Glioma
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.
Glioma
Rapid induction of long-lasting drug efflux activity in brain vascular endothelial cells but not malignant glioma following irradiation.
Glioma
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.
Glioma
Reduction of expression of the multidrug resistance protein (MRP)1 in glioma cells by antisense phosphorothioate oligonucleotides.
Glioma
Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas.
Glioma
Reversal of chemoresistance in malignant gliomas by calcium antagonists: correlation with the expression of multidrug-resistant p-glycoprotein.
Glioma
Reversal of drug resistance mediated by hammerhead ribozyme against multidrug resistance-associated protein 1 in a human glioma cell line.
Glioma
Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP.
Glioma
Spontaneous multidrug transport in human glioma cells is regulated by transforming growth factors type beta.
Glioma
Study of monoglutathionyl conjugates TC-99M-sestamibi and TC-99M-tetrofosmin transport mediated by the multidrug resistance-associated protein isoform 1 in glioma cells.
Glioma
Targeting hyaluronan interactions in spinal cord astrocytomas and diffuse pontine gliomas.
Glioma
Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
Glioma
The ABCG2 transporter is a key molecular determinant of the efficacy of sonodynamic therapy with Photofrin in glioma stem-like cells.
Glioma
The effect of miR-21 on SWOZ2 glioma cells and its biological mechanism.
Glioma
The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma.
Glioma
The sensitivity of glioma cells to pyropheophorbide-?methyl ester-mediated photodynamic therapy is enhanced by inhibiting ABCG2.
Glioma
The side story of stem-like glioma cells.
Glioma
The Use of MR Perfusion Imaging in the Evaluation of Tumor Progression in Gliomas.
Glioma
Transient induction of the MRP/GS-X pump and gamma-glutamylcysteine synthetase by 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3- nitrosourea in human glioma cells.
Glioma
Ultrasound modulates fluorescence strength and ABCG2 mRNA response to aminolevulinic acid in glioma cells.
Glioma
Ultrastructural localization of P-glycoprotein on capillary endothelial cells in human gliomas.
Glioma
Uptake of drugs and expression of P-glycoprotein in the rat 9L glioma.
Glioma
[Expression and Significance of ABCG2 in Human Malignant Glioma.]
Glioma
[Reversion of multidrug resistance (MDR) in human glioma cells by RNA interference (RNAi)]
Glomerulonephritis
Immunization with a bacterial ATP-binding cassette transporter fragment suppresses autoimmunity and prolongs survival in MRL/lpr lupus-prone mice.
Glomerulonephritis
Role of group A streptococcal IgG-binding proteins in triggering experimental glomerulonephritis in the rabbit.
Glucose Intolerance
miR-33a Modulates ABCA1 Expression, Cholesterol Accumulation, and Insulin Secretion in Pancreatic Islets.
Gout
A comprehensive analysis of the association of common variants of ABCG2 with gout.
Gout
A meta-analysis of the associations between the Q141K and Q126X ABCG2 gene variants and gout risk.
Gout
A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Maori, case and control sample sets.
Gout
ABCG transporters and disease.
Gout
ABCG2 as a therapeutic target candidate for gout.
Gout
ABCG2 contributes to the development of gout and hyperuricemia in a genome-wide association study.
Gout
ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload.
Gout
ABCG2 gene polymorphism rs2231142 is associated with gout comorbidities but not allopurinol response in primary gout patients of a Chinese Han male population.
Gout
ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans.
Gout
ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.
Gout
ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches.
Gout
ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinol.
Gout
ABCG2 SNP associated with early-onset gout.
Gout
ABCG2 transporter: therapeutic and physiologic implications in veterinary species.
Gout
ABCG2 variant has opposing effects on onset ages of Parkinson's disease and gout.
Gout
ABCG2/BCRP dysfunction as a major cause of gout.
Gout
ABCG2: the molecular mechanisms of urate secretion and gout.
Gout
Additive composite ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk.
Gout
Association between ABCG2 Q141K polymorphism and gout risk affected by ethnicity and gender: a systematic review and meta-analysis.
Gout
Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study.
Gout
Cellular expression and function of naturally occurring variants of the human ABCG2 multidrug transporter.
Gout
Cellular Processing of the ABCG2 Transporter-Potential Effects on Gout and Drug Metabolism.
Gout
Clinical and genetic features of diuretic-associated gout: a case-control study.
Gout
Clinically relevant mutations in the ABCG2 transporter uncovered by genetic analysis linked to erythrocyte membrane protein expression.
Gout
Colchicine: serious interactions.
Gout
Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.
Gout
Common dysfunctional variants in ABCG2 are a major cause of early-onset gout.
Gout
Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease.
Gout
Common variant of ALPK1 is not associated with gout: a replication study.
Gout
Decreased extra-renal urate excretion is a common cause of hyperuricemia.
Gout
Dysfunctional ABCG2 gene polymorphisms are associated with serum uric acid levels and all-cause mortality in hemodialysis patients.
Gout
Effects of the gout-causing Q141K polymorphism and a CFTR ?F508 mimicking mutation on the processing and stability of the ABCG2 protein.
Gout
Epistatic interaction between PKD2 and ABCG2 influences the pathogenesis of hyperuricemia and gout.
Gout
Evidence for extensive pleiotropy among pharmacogenes.
Gout
Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2.
Gout
Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort.
Gout
Functional non-synonymous variants of ABCG2 and gout risk.
Gout
Functional polymorphisms of the ABCG2 gene are associated with gout disease in the Chinese Han male population.
Gout
Genetic advances in gout: potential applications in clinical practice.
Gout
Genetic analysis of ABCG2 and SLC2A9 gene polymorphisms in gouty arthritis in a Korean population.
Gout
Genetic analysis of ABCG2 gene C421A polymorphism with gout disease in Chinese Han male population.
Gout
Genetic variation in the ABCG2 gene is associated with gout risk in the Chinese Han population.
Gout
Genetics of serum urate concentrations and gout in a high-risk population, patients with chronic kidney disease.
Gout
GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Gout
Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.
Gout
Identification of ABCG2 dysfunction as a major factor contributing to gout.
Gout
Identification of Specific Trafficking Defects of Naturally Occurring Variants of the Human ABCG2 Transporter.
Gout
Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout.
Gout
Impact of genetic variability in the ABCG2 gene on ABCG2 expression, function, and interaction with AT1 receptor antagonist telmisartan.
Gout
In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Gout
Influence of the ABCG2 gout risk 141 K allele on urate metabolism during a fructose challenge.
Gout
Integrating disease and drug-related phenotypes for improved identification of pharmacogenomic variants.
Gout
Interaction of the p.Q141K Variant of the ABCG2 Gene with Clinical Data and Cytokine Levels in Primary Hyperuricemia and Gout.
Gout
Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank.
Gout
Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2.
Gout
Joint Effects of Alcohol Consumption and ABCG2 Q141K on Chronic Tophaceous Gout Risk.
Gout
Jump into a New Fold-A Homology Based Model for the ABCG2/BCRP Multidrug Transporter.
Gout
Mediation analysis to understand genetic relationships between habitual coffee intake and gout.
Gout
Medically Important Alterations in Transport Function and Trafficking of ABCG2.
Gout
Metabolic Interactions of Purine Derivatives with Human ABC Transporter ABCG2: Genetic Testing to Assess Gout Risk.
Gout
Modulation of genetic associations with serum urate levels by body-mass-index in humans.
Gout
Multiple common and rare variants of
Gout
Multiple Membrane Transporters and Some Immune Regulatory Genes are Major Genetic Factors to Gout.
Gout
Novel dysfunctional variant in ABCG2 as a cause of severe tophaceous gout: biochemical, molecular genetics and functional analysis.
Gout
PDK2 and ABCG2 genes polymorphisms are correlated with blood glucose levels and uric acid in Tibetan gout patients.
Gout
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout.
Gout
Polymorphisms of ABCG2 and its impact on clinical relevance.
Gout
Polymorphisms of ABCG2 and SLC22A12 Genes Associated with Gout Risk in Vietnamese Population.
Gout
Polymorphisms of uric transporter proteins in the pathogenesis of gout in a Chinese Han population.
Gout
Population heterogeneity in the genetic control of serum urate.
Gout
Population-specific association between ABCG2 variants and tophaceous disease in people with gout.
Gout
Population-Specific Resequencing Associates the ATP-Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand M?ori and Pacific Men.
Gout
Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin.
Gout
Quantile-Dependent Expressivity of Serum Uric Acid Concentrations.
Gout
Replication of Gout/Urate Concentrations GWAS Susceptibility Loci Associated with Gout in a Han Chinese Population.
Gout
Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12.
Gout
Subtype-specific gout susceptibility loci and enrichment of selection pressure on ABCG2 and ALDH2 identified by subtype genome-wide meta-analyses of clinically defined gout patients.
Gout
Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus.
Gout
The ABCG2 gene Q141K polymorphism contributes to an increased risk of gout: A meta-analysis of 2185 cases.
Gout
The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion.
Gout
The ABCG2/BCRP transporter and its variants - from structure to pathology.
Gout
The association between genetic polymorphisms in ABCG2 and SLC2A9 and urate: an updated systematic review and meta-analysis.
Gout
The association between the polymorphism rs2231142 in the ABCG2 gene and gout risk: a meta-analysis.
Gout
The Challenge of Exploiting ABCG2 in the Clinic.
Gout
The genetics of gout: towards personalised medicine?
Gout
The genetics of hyperuricaemia and gout.
Gout
The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients.
Gout
The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort.
Gout
The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout-An Update.
Gout
The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people.
Gout
The structure of the human ABC transporter ABCG2 reveals a novel mechanism for drug extrusion.
Gout
Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects.
Gout
Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2.
Gout
Urate Transporters in the Kidney: What Clinicians Need to Know.
Gout
Variants in urate transporters, ADH1B, GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank.
Gout
Variants of ALPK1 with ABCG2, SLC2A9, and SLC22A12 increased the positive predictive value for gout.
Gout
[Association of ABCG2 gene C421A polymorphism and susceptibility of primary gout in Han Chinese males].
Gout
[Meta-analysis on relationship between single nucleotide polymorphism of rs2231142 in ABCG2 gene and gout in East Asian population].
Gout
[Recent progress and prospects for research on urate efflux transporter ABCG2].
Graft vs Host Disease
Targeting T Cell Bioenergetics by Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells To Prevent Graft-versus-Host Disease.
Granuloma
Identification of the mouse calcium-binding proteins, MRP 8 and MRP 14, in Schistosoma mansoni-induced granulomas: biochemical and functional characterization.
Hallucinations
Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation.
Hand-Foot Syndrome
Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.
Hand-Foot Syndrome
Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma.
Hand-Foot Syndrome
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
Hand-Foot Syndrome
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.
Hand-Foot Syndrome
[Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients].
Head and Neck Neoplasms
A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.
Head and Neck Neoplasms
A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation.
Head and Neck Neoplasms
Cigarette Smoke Reduces the Efficacy of Cisplatin in Head and Neck Cancer Cells - Role of ABCG2.
Head and Neck Neoplasms
Detection of P-glycoprotein in squamous cell carcinomas of the head and neck.
Head and Neck Neoplasms
Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin.
Head and Neck Neoplasms
p53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy.
Head and Neck Neoplasms
Podoplanin and ABCG2 expression in oral erythroplakia revisited: Potential evidence for cancer stem cells driving the process of field cancerization.
Head and Neck Neoplasms
Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy.
Hearing Disorders
[The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment].
Hearing Loss
Extrusion pump ABCC1 was first linked with nonsyndromic hearing loss in humans by stepwise genetic analysis.
Hearing Loss
Nuclear MRP genes and mitochondrial disease.
Hearing Loss
Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.
Hearing Loss
[New deafness gene: Progress of research on ABCC1 in biological barriers].
Hearing Loss
[The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment].
Heart Arrest
Iron-induced oxidative rat liver injury after non-heart-beating warm ischemia is mediated by tumor necrosis factor ? and prevented by deferoxamine.
Heart Arrest
The effect of cardiac arrest on the blood-testis barrier to albumin, tumor necrosis factor-alpha, pituitary adenylate cyclase activating polypeptide, sucrose, and verapamil in the mouse.
Heart Defects, Congenital
Increased risk for congenital heart defects in children carrying the ABCB1 Gene C3435T polymorphism and maternal periconceptional toxicants exposure.
Heart Defects, Congenital
Placental P-glycoprotein inhibition enhances susceptibility to Di-(2-ethylhexyl)-phthalate induced cardiac malformations in mice: A possibly promising target for congenital heart defects prevention.
Heart Diseases
ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment.
Heart Diseases
Comparison of a neural net-based QSAR algorithm (PCANN) with Hologram- and multiple linear regression-based QSAR approaches: application to 1,4-dihydropyridine-based calcium channel antagonists.
Heart Diseases
Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease.
Heart Diseases
Newborn blood DNA epigenetic variations and signaling pathway genes associated with Tetralogy of Fallot (TOF).
Heart Diseases
Pharmacokinetic model of myocardial (99m)Tc-sestamibi washout.
Heart Failure
Activation of negative regulators of the hypoxia-inducible factor (HIF) pathway in human end-stage heart failure.
Heart Failure
Associations Between Chronic Disease, Polypharmacy, and Medication-Related Problems Among Medicare Beneficiaries.
Heart Failure
Effect of ABCB1 (MDR1) 3435C >T and 2677G >A,T polymorphisms and P-glycoprotein inhibitors on salivary digoxin secretion in congestive heart failure patients.
Heart Failure
Effect of ABCB1 Genotype on Pre- and Post-Cardiac Transplantation Plasma Lipid Concentrations.
Heart Failure
Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration.
Heart Failure
Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients.
Heart Failure
Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients.
Heart Failure
Influence of intermittent hypoxia on myocardial and hepatic P-glycoprotein expression in a rodent model.
Heart Failure
Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha).
Heart Failure
Multidrug resistance proteins preferentially regulate natriuretic peptide-driven cGMP signalling in the heart and vasculature.
Heart Failure
P-glycoprotein makes no contribution to the lower transplacental transfer of digoxin under fetal heart failure, but who should be blamed for?
Heart Failure
Pharmacogenomics of heart failure -- focus on drug disposition and action.
Heart Failure
Sodium tanshinone IIA sulfonate and sodium danshensu open the placental barrier through down-regulation of placental P-glycoprotein in mice: implications in the transplacental digoxin treatment for fetal heart failure.
Heart Failure
Systemic administration of ivabradine, a hyperpolarization-activated cyclic nucleotide-gated channel inhibitor, blocks spontaneous absence seizures.
Heart Failure
Tachycardia-induced heart failure does not alter myocardial P-glycoprotein expression.
Heart Failure
The ATP-Binding Cassette Transporter ABCG2 Protects Against Pressure Overload-Induced Cardiac Hypertrophy and Heart Failure by Promoting Angiogenesis and Antioxidant Response.
Heart Failure
The effect of 17?-ethynylestradiol induced intrahepatic cholestasis of pregnancy on placental P-glycoprotein in mice: Implications in the individualized transplacental digoxin treatment for fetal heart failure.
Heart Failure
The effect of maternal obesity on the expression and functionality of placental P-glycoprotein: Implications in the individualized transplacental digoxin treatment for fetal heart failure.
Heart Failure
Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure.
HELLP Syndrome
Total bile acids in the maternal and fetal compartment in relation to placental ABCG2 expression in preeclamptic pregnancies complicated by HELLP syndrome.
Hematologic Diseases
Association of MDR1 single-nucleotide polymorphisms and haplotype variants with multiple myeloma in Chinese Jiangsu Han population.
Hematologic Diseases
Factors Influencing the Safety and Efficiency of Antifungal Prophylaxis with Posaconazole in Children with Hematological Diseases: From Genetics to Polypharmacotherapy.
Hematologic Diseases
[Clinical significance of leukemia stem/progenitor cell related gene expression in acute leukemia].
Hematologic Diseases
[Expression level of MDR1, and MRP in patients with malignant blood disease and its clinical significance]
Hematologic Neoplasms
12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1.
Hematologic Neoplasms
A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.
Hematologic Neoplasms
Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay.
Hematologic Neoplasms
Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells.
Hematologic Neoplasms
Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates.
Hematologic Neoplasms
Clinical relevance of immunocytochemical detection of multidrug-resistance-associated P-glycoprotein in hematologic malignancies.
Hematologic Neoplasms
Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
Hematologic Neoplasms
Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies.
Hematologic Neoplasms
Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients.
Hematologic Neoplasms
Expression of MDR-1/P-glycoprotein in childhood acute megakaryoblastic leukemia cells.
Hematologic Neoplasms
Expression of the MDR1 and MRP genes in patients with lymphoma with primary bone marrow involvement.
Hematologic Neoplasms
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Hematologic Neoplasms
Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy.
Hematologic Neoplasms
Imaging Multidrug Resistance in Hematological Malignancies.
Hematologic Neoplasms
Impact of ABCB1 Gene (C3435T/A2677G) Polymorphic Sequence Variations on the Outcome of Patients with Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Kashmiri Population: A Case-Control Study.
Hematologic Neoplasms
Importance of detecting multidrug resistance proteins in acute leukemia prognosis and therapy.
Hematologic Neoplasms
In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies.
Hematologic Neoplasms
Is p-glycoprotein a potential target for reversing clinical drug resistance?
Hematologic Neoplasms
Markers and Reporters to Reveal the Hierarchy in Heterogeneous Cancer Stem Cells.
Hematologic Neoplasms
Mechanisms of drug resistance in hematologic malignancies.
Hematologic Neoplasms
Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance.
Hematologic Neoplasms
Multidrug resistance in aggressive lymphoproliferative disorders of T and natural-killer origin.
Hematologic Neoplasms
Non-P-glycoprotein drug export mechanisms of multidrug resistance.
Hematologic Neoplasms
Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet?
Hematologic Neoplasms
Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
Hematologic Neoplasms
P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy.
Hematologic Neoplasms
P-glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporine A containing protocols.
Hematologic Neoplasms
P-glycoprotein in adult hematologic malignancies.
Hematologic Neoplasms
Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis.
Hematologic Neoplasms
The role of P-glycoprotein in drug-resistant hematologic malignancies.
Hematologic Neoplasms
The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
Hematologic Neoplasms
Vincristine resistance development in lymphoblastoid cells under conditions of selective P-glycoprotein inhibition.
Hematologic Neoplasms
[Adavance of Research on Relationship between ABCG2 and Drug Resistance in Hematologic Malignancies - Review.]
Hematologic Neoplasms
[P-glycoprotein expression in hematological malignancies]
Hemochromatosis
Hereditary hemochromatosis disrupts uric acid homeostasis and causes hyperuricemia via altered expression/activity of xanthine oxidase and ABCG2.
Hemochromatosis
[Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs].
Hemorrhoids
Anal manometric findings before and after hemorrhoidectomy: a preliminary report.
Hepatic Encephalopathy
Multidrug resistance-associated protein 4 expression in ammonia-treated cultured rat astrocytes and cerebral cortex of cirrhotic patients with hepatic encephalopathy.
Hepatitis
Overexpression of a p-glycoprotein in hepatocellular carcinomas from woodchuck hepatitis virus-infected woodchucks (Marmota monax).
Hepatitis
Polymorphisms in drug transporter genes (ABCB1, SLCO1B1 and ABCC2) and hepatitis induced by antituberculosis drugs.
Hepatitis
Risk of Mycoplasma pneumoniae-related hepatitis in MP pneumonia pediatric patients: a predictive model construction and assessment.
Hepatitis
[Effects of ursodeoxycholic acid on mRNA expression of MDR3 and FXR in infants with cholestatic hepatitis].
Hepatitis
[Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs].
Hepatitis A
Evaluation of candidate genes associated with hepatitis A and E virus infection in Chinese Han population.
Hepatitis A
Variants in ABCB1, TGFB1, and XRCC1 genes and susceptibility to viral hepatitis A infection in mexican americans.
Hepatitis B
ABCG2 Overexpression Confers Poor Outcomes in Hepatocellular Carcinoma of Elderly Patients.
Hepatitis B
Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.
Hepatitis B
MITA/STING and Its Alternative Splicing Isoform MRP Restrict Hepatitis B Virus Replication.
Hepatitis B
Relationship between ABCC4 SNPs and hepatitis B virus suppression during tenofovir-containing antiretroviral therapy in patients with HIV/HBV coinfection.
Hepatitis B, Chronic
ABCC4, ABCC5 and SLC28A1 polymorphisms: host genome on responses of chronic hepatitis B patients with entecavir treatment.
Hepatitis C
ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms do not affect methadone maintenance treatment in HCV-positive patients.
Hepatitis C
Association of ATP-Binding Cassette Transporter (ABC) Gene Polymorphisms with Viral Load in Patients with Genotype 1 Hepatitis C Virus Infection.
Hepatitis C
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.
Hepatitis C
Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection.
Hepatitis C
Deinduction of P-glycoprotein resulting in delayed viral response during hepatitis C treatment.
Hepatitis C
Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review.
Hepatitis C
Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
Hepatitis C
Establishment of a robust hepatitis C virus replicon cell line over-expressing P-glycoprotein that facilitates analysis of P-gp drug transporter effects on inhibitor antiviral activity.
Hepatitis C
Hepatocyte nuclear factor (HNF) 1 and HNF4 mediate hepatic multidrug resistance protein 2 up-regulation during hepatitis C virus gene expression.
Hepatitis C
Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.
Hepatitis C
Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/??catenin signaling activation (Review).
Hepatitis C
The role of P-glycoprotein in the pharmacokinetics and tissue distribution of a hepatitis C virus protease inhibitor.
Hepatitis C
Up-Regulation of the ATP-Binding Cassette Transporter A1 Inhibits Hepatitis C Virus Infection.
Hepatitis C, Chronic
Anti-HIV and anti-HCV drugs inhibit p-glycoprotein efflux activity in Caco-2 cells and precision-cut rat and human intestinal slices.
Hepatitis C, Chronic
Association Between ABCB1 (MDR1) Gene Polymorphism and Unresponsiveness Combined Therapy in Chronic Hepatitis C virus.
Hepatitis C, Chronic
Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population.
Hepatitis C, Chronic
Deinduction of P-glycoprotein resulting in delayed viral response during hepatitis C treatment.
Hepatitis C, Chronic
Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis.
Hepatitis E
Evaluation of candidate genes associated with hepatitis A and E virus infection in Chinese Han population.
Hepatitis, Chronic
Deletion of tumour necrosis factor ? receptor 1 elicits an increased TH17 immune response in the chronically inflamed liver.
Hepatoblastoma
Contribution of radixin to P-glycoprotein expression and transport activity in mouse small intestine in vivo.
Hepatoblastoma
Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma.
Hepatoblastoma
MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro.
Hepatoblastoma
MicroRNA-101 overexpression by IL-6 and TNF-? inhibits cholesterol efflux by suppressing ATP-binding cassette transporter A1 expression.
Hepatoblastoma
MicroRNA-655-3p regulates Echinacea purpurea mediated activation of ABCG2.
Hepatoblastoma
Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines.
Hepatoblastoma
Significance of P-glycoprotein expression in childhood malignant tumors.
Hepatoblastoma
Threshold for antiproliferative and proapoptotic activity of ttaxol in HepG2 cells expressing human CYP3A4: effect of P-glycoprotein transporters.
Hepatoblastoma
Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and in vitro.
Hepatolenticular Degeneration
Down-regulation of intestinal multidrug resistance-associated protein 2 in long-evans cinnamon rats.
Hepatolenticular Degeneration
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster.
Hepatomegaly
Morphological and functional changes in p-glycoprotein during dexamethasone-induced hepatomegaly.
Herpes Simplex
P-glycoprotein activity in the blood-brain barrier is affected by virus-induced neuroinflammation and antipsychotic treatment.
Herpes Simplex
P-glycoprotein plays an insignificant role in the presentation of antigenic peptides to CD8+ T cells.
Herpes Simplex
Structure and dynamics of membrane-associated ICP47, a viral inhibitor of the MHC I antigen-processing machinery.
Herpes Zoster
Clinical Characteristics, Treatment Effectiveness, and Predictors of Response to Pharmacotherapeutic Interventions Among Patients with Herpetic-Related Neuralgia: A Retrospective Analysis.
Herpes Zoster
Establishment and characterisation of a novel bovine SV40 large T-antigen-transduced foetal hepatocyte-derived cell line.
Herpes Zoster
Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues.
Herpes Zoster
Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters.
Histiocytoma, Malignant Fibrous
Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities.
Histiocytoma, Malignant Fibrous
Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas.
HIV Infections
Brain delivery of transferrin coupled indinavir submicron lipid emulsions--pharmacokinetics and tissue distribution.
HIV Infections
Caveolin-1 reduces HIV-1 infectivity by restoration of HIV Nef mediated impairment of cholesterol efflux by apoA-I.
HIV Infections
Elevated serum macrophage inhibitory factor-related protein (MRP) 8/14 levels in advanced HIV infection and during disease exacerbation.
HIV Infections
Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line.
HIV Infections
Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients.
HIV Infections
Human immunodeficiency virus I-induced expression of P-glycoprotein.
HIV Infections
Neuropharmacokinetic evaluation of lactoferrin-treated indinavir-loaded nanoemulsions: remarkable brain delivery enhancement.
HIV Infections
Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy.
HIV Infections
Role of lymphocyte multidrug resistance protein 1 in HIV infection: expression, function, and consequences of inhibition.
HIV Infections
Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function.
Hodgkin Disease
Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols.
HTLV-I Infections
Adult T-cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung-resistance-protein (LRP) genes.
Huntington Disease
Dysregulated Brain Cholesterol Metabolism Is Linked to Neuroinflammation in Huntington's Disease.
Huntington Disease
Multidrug resistance protein 1 reduces the aggregation of mutant huntingtin in neuronal cells derived from the Huntington's disease R6/2 model.
Huntington Disease
Regulation of P-glycoprotein expression in brain capillaries in Huntington's disease and its impact on brain availability of antipsychotic agents risperidone and paliperidone.
Hydatidiform Mole
Function of P-glycoprotein expressed in placenta and mole.
Hyperalgesia
ABCB1 Polymorphisms and Cold Pressor Pain Responses: Opioid-Dependent Patients on Methadone Maintenance Therapy.
Hyperalgesia
Genetic variants of the P-glycoprotein gene Abcb1b modulate opioid-induced hyperalgesia, tolerance and dependence.
Hyperalgesia
P-glycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia.
Hyperalgesia
Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein.
Hyperbilirubinemia, Neonatal
Modulation of bilirubin neurotoxicity by the Abcb1 transporter in the Ugt1-/- lethal mouse model of neonatal hyperbilirubinemia.
Hypercholesterolemia
Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells.
Hypercholesterolemia
Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin.
Hypercholesterolemia
Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
Hypercholesterolemia
Effects of vitamin E on peroxisome proliferator-activated receptor ? and nuclear factor-erythroid 2-related factor 2 in hypercholesterolemia-induced atherosclerosis.
Hypercholesterolemia
Hydrogen Activates ATP-Binding Cassette Transporter A1-Dependent Efflux Ex Vivo and Improves High-Density Lipoprotein Function in Patients With Hypercholesterolemia: A Double-Blinded, Randomized, and Placebo-Controlled Trial.
Hypercholesterolemia
Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
Hypercholesterolemia
Polymorphisms of uric transporter proteins in the pathogenesis of gout in a Chinese Han population.
Hypercholesterolemia
Slow Excitotoxicity in Alzheimer's Disease.
Hyperglycemia
Hyperglycemia accelerates ATP-binding cassette transporter A1 degradation via an ERK-dependent pathway in macrophages.
Hyperglycemia
Hyperglycemia induced down-regulation of renal P-glycoprotein expression.
Hyperglycemia
Hyperglycemia regulates MDR-1, drug accumulation and ROS levels causing increased toxicity of carboplatin and 5-fluorouracil in MCF-7 cells.
Hyperglycemia
Increase in P-glycoprotein accompanied by activation of protein kinase Calpha and NF-kappaB p65 in the livers of rats with streptozotocin-induced diabetes.
Hyperglycemia
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Hyperglycemia
Rosiglitazone enhances apolipoprotein M (Apom) expression in rat's liver.
Hyperinsulinism
Multiple Gouty Tophi with Bone Erosion and Destruction: A Report of an Early-onset Case in an Obese Patient.
Hyperlipidemia, Familial Combined
Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations.
Hyperlipidemias
Association of ABCB1 (C3435T) and ABCC1 (G2012T) Polymorphisms with Clinical Response to Atorvastatin in Iranian Patients with Primary Hyperlipidemia.
Hyperlipidemias
Cyclosporin A decreases apolipoprotein E secretion from human macrophages via a protein phosphatase 2B-dependent and ATP-binding cassette transporter A1 (ABCA1)-independent pathway.
Hyperlipidemias
Effects of poloxamer 407-induced hyperlipidemia on hepatic multidrug resistance protein 2 (Mrp2/Abcc2) and the pharmacokinetics of mycophenolic acid in rats.
Hyperlipidemias
Effects of serum lipoproteins on cyclosporine A cellular uptake and renal toxicity in vitro.
Hyperlipidemias
The effect of genistein on lipid levels and LDLR, LXR? and ABCG1 expression in postmenopausal women with hyperlipidemia.
Hyperlipidemias
Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations.
Hyperlipoproteinemia Type II
Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments.
Hyperparathyroidism
Dual-phase 99mTc-MIBI imaging and the expressions of P-gp, GST-?, and MRP1 in hyperparathyroidism.
Hyperparathyroidism
P-glycoprotein expression influences the result of 99mTc-MIBI scintigraphy in tertiary hyperparathyroidism.
Hyperparathyroidism, Primary
Clinicopathologic and radiopharmacokinetic factors affecting gamma probe-guided parathyroidectomy.
Hyperparathyroidism, Primary
P-glycoprotein expression is associated with sestamibi washout in primary hyperparathyroidism.
Hyperparathyroidism, Primary
Relation between technetium 99m-methoxyisobutylisonitrile accumulation and multidrug resistance protein in the parathyroid glands.
Hyperparathyroidism, Secondary
Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism.
Hyperparathyroidism, Secondary
Relation between technetium 99m-methoxyisobutylisonitrile accumulation and multidrug resistance protein in the parathyroid glands.
Hyperprolactinemia
Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia.
Hyperprolactinemia
Manifestation of Multidrug Resistance Protein 3 (MRP3) in Liver and Kidney Cells in Cholestasis: Effects of Hyperprolactinemia.
Hyperprolactinemia
Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapine.
Hypersensitivity
Abcb1 gene expression pattern and function of copper detoxification in Fujian oyster, Crassostrea angulata.
Hypersensitivity
Amplification and expression of mdr genes and flanking sequences in verapamil hypersensitive hamster cell lines.
Hypersensitivity
Characterization of a lipophilic antifolate resistance provoked by treatment of mammalian cells with the antiparasitic agent pyrimethamine.
Hypersensitivity
Chemical specificity of the PDR5 multidrug resistance gene product of Saccharomyces cerevisiae based on studies with tri-n-alkyltin chlorides.
Hypersensitivity
Cytotoxicity of nimbolide towards multidrug-resistant tumor cells and hypersensitivity via cellular metabolic modulation.
Hypersensitivity
Evaluation of the Prevalence of Mucous Retention Pseudocyst and its Correlation with the Associated Risk Factors Using Panoramic Radiography and Cone-Beam Computed Tomography.
Hypersensitivity
Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins.
Hypersensitivity
Gain and loss of hypersensitivity to resistance modifiers in multidrug resistant Chinese hamster ovary cells.
Hypersensitivity
Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe.
Hypersensitivity
Ivermectin resistance in nematodes may be caused by alteration of P-glycoprotein homolog.
Hypersensitivity
Loss of an ABC transporter in Arabidopsis thaliana confers hypersensitivity to the anti-cancer drug bleomycin.
Hypersensitivity
Microtubule active agents: beyond the taxane frontier.
Hypersensitivity
Modulation of GSH levels in ABCC1 expressing tumor cells triggers apoptosis through oxidative stress.
Hypersensitivity
Relationship between multidrug resistance, hypersensitivity to resistance modifiers and cell volume in Chinese hamster ovary cells.
Hypersensitivity
Sulfasalazine alleviates neuropathic pain hypersensitivity in mice through inhibition of SGK-1 in the spinal cord.
Hypersensitivity
The genetics of gout: towards personalised medicine?
Hypersensitivity
The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation.
Hypersensitivity
The prevalence of ABCB1:c.227_230delATAG mutation in affected dog breeds from European countries.
Hypersensitivity
[Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs].
Hypertension
A Functional Common Polymorphism of the ABCB1 Gene Is Associated With Chronic Kidney Disease and Hypertension in Chinese.
Hypertension
ABCG2 c.421C>A polymorphism alters nifedipine transport to breast milk in hypertensive breastfeeding women.
Hypertension
ABCG2 rs2231142 variant in hyperuricemia is modified by SLC2A9 and SLC22A12 polymorphisms and cardiovascular risk factors in an elderly community-dwelling population.
Hypertension
Association Between ABCB1 Gene Polymorphism and Renal Function in Patients with Hypertension: A Case-Control Study.
Hypertension
Association between ABCB1 Polymorphisms and Ischemic Stroke in Korean Population.
Hypertension
Associations Between Chronic Disease, Polypharmacy, and Medication-Related Problems Among Medicare Beneficiaries.
Hypertension
Calcineurin inhibitors and hypertension: a role for pharmacogenetics?
Hypertension
Clinical Characteristics, Treatment Effectiveness, and Predictors of Response to Pharmacotherapeutic Interventions Among Patients with Herpetic-Related Neuralgia: A Retrospective Analysis.
Hypertension
Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.
Hypertension
CYP3A5 and ABCB1 genes and hypertension.
Hypertension
Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I-II hypertension.
Hypertension
Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration.
Hypertension
Gene-environment interactions of selected pharmacogenes in arterial hypertension.
Hypertension
Genetic association study of ABCB1 gene polymorphisms with hypertension in Han Chinese population.
Hypertension
Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.
Hypertension
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Hypertension
Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation.
Hypertension
Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.
Hypertension
Influence of intermittent hypoxia on myocardial and hepatic P-glycoprotein expression in a rodent model.
Hypertension
Lovastatin attenuates hypertension induced by renal tubule-specific knockout of ATP-binding cassette transporter A1, by inhibiting epithelial sodium channels.
Hypertension
Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma.
Hypertension
miR-143 and miR-145 promote hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells through regulating ABCA1 expression.
Hypertension
Potential for pharmacokinetic interactions between ambrisentan and cyclosporine.
Hypertension
Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.
Hypertension
Shared gene expression patterns in mesenchymal progenitors derived from lung and epidermis in pulmonary arterial hypertension: identifying key pathways in pulmonary vascular disease.
Hypertension
The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.
Hypertension
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.
Hypertension
Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.
Hypertension
[Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension].
Hypertension, Portal
Inhibition of P-glycoprotein, multidrug resistance-associated protein 2 and cytochrome P450 3A4 improves the oral absorption of octreotide in rats with portal hypertension.
Hypertension, Portal
Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension.
Hypertension, Pulmonary
A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma.
Hypertension, Pulmonary
Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to Hypoxia.
Hypertension, Pulmonary
miR-143 and miR-145 promote hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells through regulating ABCA1 expression.
Hyperthyroidism
Anorectal physiology and transit in patients with disorders of thyroid metabolism.
Hyperthyroidism
Modulation of P-glycoprotein expression in hyperthyroid rat tissues.
Hyperthyroidism
Pharmacotherapeutic Management Strategies for Thyroid Disease-Induced Pericarditis.
Hyperthyroidism
Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5'-triphosphate-binding cassette transporter 1 expression.
Hyperthyroidism
The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin.
Hypertriglyceridemia
Fenofibrate Decreases Hepatic P-Glycoprotein in a Rat Model of Hereditary Hypertriglyceridemia.
Hypertriglyceridemia
Polymorphisms of uric transporter proteins in the pathogenesis of gout in a Chinese Han population.
Hypoalphalipoproteinemias
Association of ATP-Binding Cassette Transporter A1 (ABCA1)-565 C/T Gene Polymorphism with Hypoalphalipoproteinemia and Serum Lipids, IL-6 and CRP Levels.
Hypoalphalipoproteinemias
Novel polypyrimidine variation (IVS46: del T -39...-46) in ABCA1 causes exon skipping and contributes to HDL cholesterol deficiency in a family with premature coronary disease.
Hypoalphalipoproteinemias
Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro.
Hypoalphalipoproteinemias
Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations.
Hypoglycemia
The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review.
Hypopharyngeal Neoplasms
Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines.
Hypotension, Orthostatic
A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression.
Hypotension, Orthostatic
Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers.
Hypotension, Orthostatic
Transporter-mediated Efflux Influences CNS Side Effects: ABCB1, from Antitarget to Target.
Hypothyroidism
ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib.
Hypothyroidism
Pharmacotherapeutic Management Strategies for Thyroid Disease-Induced Pericarditis.
hypoxanthine phosphoribosyltransferase deficiency
GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Hypoxia, Brain
Convulsive Stress Mimics Brain Hypoxia and Promotes the P-Glycoprotein (P-gp) and Erythropoietin Receptor Overexpression. Recombinant Human Erythropoietin Effect on P-gp Activity.
Ichthyosis, Lamellar
Harlequin ichthyosis model mouse reveals alveolar collapse and severe fetal skin barrier defects.
Ichthyosis, Lamellar
Keratinocyte ATP binding cassette transporter expression is regulated by ultraviolet light.
Infarction, Middle Cerebral Artery
ABCC1: a gateway for pharmacological compounds to the ischaemic brain.
Infarction, Middle Cerebral Artery
Alteration in P-glycoprotein at the blood-brain barrier in the early period of MCAO in rats.
Infarction, Middle Cerebral Artery
Deactivation of ATP-Binding Cassette Transporters ABCB1 and ABCC1 Does Not Influence Post-ischemic Neurological Deficits, Secondary Neurodegeneration and Neurogenesis, but Induces Subtle Microglial Morphological Changes.
Infarction, Middle Cerebral Artery
Neuroprotective and neurotoxic effects of cyclosporine A on transient focal ischemia in mdr1a knockout mice.
Infections
A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain.
Infections
A melittin-related peptide from the skin of the Japanese frog, Rana tagoi, with antimicrobial and cytolytic properties.
Infections
A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.
Infections
ABCA1 expression in macrophages of allogeneic hematopoietic stem cell transplantation patients with severe infection undergoing continuous blood purification.
Infections
ABCB1 expression in peptic ulcer patients and its connection with H. pylori Infection.
Infections
ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate.
Infections
ABCG2 in peptic ulcer: gene expression and mutation analysis.
Infections
Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection.
Infections
Acute bovine viral diarrhea virus infection inhibits expression of interferon tau-stimulated genes in bovine endometrium.
Infections
Adenovirus vector infection of non-small-cell lung cancer cells is a trigger for multi-drug resistance mediated by P-glycoprotein.
Infections
Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians.
Infections
Altered Gene Expression Profiles of Wheat Genotypes against Fusarium Head Blight.
Infections
An alternative splicing isoform of MITA antagonizes MITA-mediated induction of type I IFNs.
Infections
An integrated in vitro model for simultaneous assessment of drug uptake, metabolism, and efflux.
Infections
Anti-HIV and anti-HCV drugs inhibit p-glycoprotein efflux activity in Caco-2 cells and precision-cut rat and human intestinal slices.
Infections
Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation.
Infections
C3435T polymorphism of the ABCB1 gene: impact on genetic susceptibility to peptic ulcers.
Infections
Calcium-binding proteins MRP 8 and 14 in a Staphylococcus aureus infection model: role of therapy, inflammation, and infection persistence.
Infections
Characterization of virulence of the Streptococcus suis serotype 2 reference strain Henrichsen S 735 in newborn gnotobiotic pigs.
Infections
Citrobacter rodentium Infection Inhibits Colonic P-glycoprotein Expression.
Infections
Clinical significance of P-glycoprotein expression in acute leukaemia as analysed by immunocytochemistry.
Infections
Combined use of myeloid-related protein 8/14 and procalcitonin as diagnostic markers for acute allograft rejection in kidney transplantation recipients.
Infections
Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population.
Infections
Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations.
Infections
Comparison of reconstruction plate and double flap for reconstruction of an extensive mandibular defect.
Infections
Compartmentalized Accumulation of cAMP near complexes of Multidrug Resistance Protein 4 (MRP4) and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Contributes to Drug-induced Diarrhea.
Infections
Deinduction of P-glycoprotein resulting in delayed viral response during hepatitis C treatment.
Infections
Down-regulation of MARCKS-related protein (MRP) in macrophages infected with Leishmania.
Infections
Dual infection with Helicobacter bilis and Helicobacter hepaticus in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia.
Infections
E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers.
Infections
Effect of colibacillosis or coccidiosis on expression of breast cancer resistance protein in small intestine and liver of chickens.
Infections
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Infections
Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans.
Infections
Elevated serum macrophage inhibitory factor-related protein (MRP) 8/14 levels in advanced HIV infection and during disease exacerbation.
Infections
Evaluation of candidate genes associated with hepatitis A and E virus infection in Chinese Han population.
Infections
Experimental coccidiosis influences the expression of the ABCB1 gene, a physiological important functional marker of intestinal integrity in chickens.
Infections
Expression and characterization of the multidrug resistance-associated protein in insect cells infected with a recombinant baculovirus.
Infections
Expression levels of P-glycoprotein in peripheral blood CD8+ T lymphocytes from HIV-1-infected patients on antiretroviral therapy.
Infections
Expression of breast cancer resistance protein in peripheral T cell subsets from HIV?1?infected patients with antiretroviral therapy.
Infections
Expression of HIF-1? and P-gp in non-small cell lung cancer and the relationship with HPV infection.
Infections
Expression of the human multidrug transporter in insect cells by a recombinant baculovirus.
Infections
Functional reconstruction of human AML reveals stem cell origin and vulnerability of treatment-resistant MLL-rearranged leukemia.
Infections
Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection.
Infections
Histatin-5 induces the reversal of Pdr5p mediated fluconazole resistance in Saccharomyces cerevisae.
Infections
HIV inhibits endothelial reverse cholesterol transport through impacting subcellular Caveolin-1 trafficking.
Infections
HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications in Antiretroviral Drug Disposition.
Infections
HTLV-I alters the multidrug resistance associated protein 1 (ABCC1/MRP1) expression and activity in human T cells.
Infections
Human immunodeficiency virus I-induced expression of P-glycoprotein.
Infections
Identification of the mouse calcium-binding proteins, MRP 8 and MRP 14, in Schistosoma mansoni-induced granulomas: biochemical and functional characterization.
Infections
Impact of cerebral malaria on brain distribution of mefloquine.
Infections
Impact of Neutrophil-Secreted Myeloid Related Proteins 8 and 14 (MRP 8/14) on Leishmaniasis Progression.
Infections
Impact of Pharmacogenetic Determinants of Tacrolimus and Mycophenolate on Adverse Events in Renal Transplant Patients.
Infections
Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy.
Infections
Inactivation of bpsl1039-1040 ATP-binding cassette transporter reduces intracellular survival in macrophages, biofilm formation and virulence in the murine model of Burkholderia pseudomallei infection.
Infections
Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection.
Infections
Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1 infected women.
Infections
Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions.
Infections
Infection of H69AR cells with retroviral particles harboring interfering RNAi significantly reduced the multidrug resistance of these small cell lung cancer cells.
Infections
Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality.
Infections
Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection.
Infections
Investigation of ABCB1 1236 and 2677 SNPs in patients with peptic ulcer.
Infections
Landscape ecology and epidemiology of malaria associated with rubber plantations in Thailand: integrated approaches to malaria ecotoping.
Infections
Malpighamoeba infection compromises fluid secretion and P-glycoprotein detoxification in Malpighian tubules.
Infections
MARCKS-related protein (MRP) is a substrate for the Leishmania major surface protease leishmanolysin (gp63).
Infections
Maternal bacterial infections impact expression of drug transporters in human placenta.
Infections
MDR1 3435T and 1236T alleles delay disease progression to pediatric AIDS but have no effect on HIV-1 vertical transmission.
Infections
MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment.
Infections
MDR1A (ABCB1) DEFICIENT CF-1 MUTANT MICE IS SUSCEPTIBLE TO CEREBRAL MALARIA INDUCED BY PLASMODIUM BERGHEI ANKA.
Infections
MDR1A (ABCB1)-deficient CF-1 mutant mice are susceptible to cerebral malaria induced by Plasmodium berghei ANKA.
Infections
Mechanisms of bilirubin toxicity: clinical implications.
Infections
Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
Infections
Microfluidic assembly of pomegranate-like hierarchical microspheres for efflux regulation in oral drug delivery.
Infections
Molecular model of the outward facing state of the human multidrug resistance protein 4 (MRP4/ABCC4).
Infections
Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/??catenin signaling activation (Review).
Infections
Multidrug resistance protein 1 (MRP1) in rabbit conjunctival epithelial cells: its effect on drug efflux and its regulation by adenoviral infection.
Infections
Mycobacterium tuberculosis induces expression of P-glycoprotein in promonocytic U1 cells chronically infected with HIV type 1.
Infections
Nicotiana plumbaginifolia plants silenced for the ATP-binding cassette transporter gene NpPDR1 show increased susceptibility to a group of fungal and oomycete pathogens.
Infections
Nitric Oxide Synthase-mediated Alteration of Intestinal P-glycoprotein under Hyperglycemic Stress.
Infections
Non-immune binding of human IgG to M-related proteins confers resistance to phagocytosis of group A streptococci in blood.
Infections
P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients.
Infections
P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.
Infections
P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection.
Infections
P-glycoprotein expression in Helicobacter pylori-positive patients: the influence of MDR1 C3435T polymorphism.
Infections
P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors.
Infections
Pentamidine movement across the murine blood-brain and blood-CSF barriers; effect of trypanosome infection, combination therapy, P-glycoprotein and MRP.
Infections
Population pharmacokinetic modeling to establish the role of P-glycoprotein on ciprofloxacin distribution to lung and prostate following intravenous and intratracheal administration to Wistar rats.
Infections
Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function.
Infections
Prion infection impairs cholesterol metabolism in neuronal cells.
Infections
Proteomics identification of novel fibrinogen-binding proteins of Streptococcus suis contributing to antiphagocytosis.
Infections
Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1).
Infections
Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement of nuclear factor-kappaB and c-Jun N-terminal kinase signaling pathways.
Infections
Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response.
Infections
Retroviral transfection of Madin-Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 10(5)- to 10(6)-fold increased cell sensitivity to verocytotoxin. Role of p-glycoprotein in glycolipid synthesis.
Infections
RNAi Inhibits Coriaria Lactone-Induced MDR1b Overexpression in Rat Brain Microvascular Endothelial Cells.
Infections
Role of CgTpo4 in Polyamine and Antimicrobial Peptide Resistance: Determining Virulence in Candida glabrata.
Infections
Role of EfrAB efflux pump in biocide tolerance and antibiotic resistance of Enterococcus faecalis and Enterococcus faecium isolated from traditional fermented foods and the effect of EDTA as EfrAB inhibitor.
Infections
Role of emm and mrp genes in the virulence of group A streptococcal isolate 64/14 in a mouse model of skin infection.
Infections
Role of lymphocyte multidrug resistance protein 1 in HIV infection: expression, function, and consequences of inhibition.
Infections
Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections.
Infections
Roles of Multidrug Resistance Protein 4 in Microbial Infections and Inflammatory Diseases.
Infections
Selective and cytokine-dependent regulation of hepatic transporters and bile acid homeostasis during infectious colitis in mice.
Infections
Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: A pharmacogenetic study.
Infections
Spermiogram part of population with the manifest orchtis during an ongoing epidemic of mumps.
Infections
STAT3 signaling pathway plays importantly genetic and functional roles in HCV infection.
Infections
Tailoring of P-glycoprotein for effective transportation of actives across blood-brain-barrier.
Infections
The Association between ABCB1 C1236T/C3435T SNPs and H. pylori Infection among Jordanians.
Infections
The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental Schistosoma mansoni infection in mice.
Infections
The ERM protein, ezrin, regulates neutrophil transmigration by modulating the apical localization of MRP2 in response to the SipA effector protein during Salmonella Typhimurium infection.
Infections
The expression of P-glycoprotein and cellular kinases is modulated at the transcriptional level by infection and highly active antiretroviral therapy in a primate model of AIDS.
Infections
The human P-glycoprotein transporter enhances the type I interferon response to Listeria monocytogenes infection.
Infections
The importance of P-glycoprotein multidrug transporter activity measurement in patients with Helicobacter pylori infection.
Infections
The influence of P-glycoprotein expression in the standard treatment of Helicobacter pylori infection in Sprague Dawley rats.
Infections
The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
Infections
The non-conserved region of MRP is involved in the virulence of Streptococcus suis serotype 2.
Infections
The Pseudomonas syringae pv. tomato DC3000 PSPTO_0820 multidrug transporter is involved in resistance to plant antimicrobials and bacterial survival during tomato plant infection.
Infections
Trigger factor of Streptococcus suis is involved in stress tolerance and virulence.
Infections
Two novel genes FIND and LIND differentially expressed in deactivated and Listeria-infected human macrophages.
Infections
Variants in ABCB1, TGFB1, and XRCC1 genes and susceptibility to viral hepatitis A infection in mexican americans.
Infections
[Reversal of the multidrug resistance in human hepatocellular carcinoma cells by recombinant adenoviral delivery of the MRP antisense RNA in vitro]
Infections
[Titanium modular revision prosthesis stem in revision hip prosthesis]
Infertility
Adenosine triphosphate-binding cassette superfamily transporter gene expression in severe male infertility.
Infertility
mdr1a deficiency corrects sterility in Niemann-Pick C1 protein deficient female mice.
Infertility, Female
mdr1a deficiency corrects sterility in Niemann-Pick C1 protein deficient female mice.
Infertility, Male
Association of the MDR1 (ABCB1) gene 3435C>T polymorphism with male infertility.
Inflammatory Bowel Diseases
A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis.
Inflammatory Bowel Diseases
A study comparing the efficacy of antimicrobial agents versus enzyme (P-gp) inducers in the treatment of 2,4,6 trinitrobenzenesulfonic acid-induced colitis in rats.
Inflammatory Bowel Diseases
ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach.
Inflammatory Bowel Diseases
Absence of ABCG2-mediated mucosal detoxification in patients with active inflammatory bowel disease is due to impeded protein folding.
Inflammatory Bowel Diseases
Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study.
Inflammatory Bowel Diseases
ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases.
Inflammatory Bowel Diseases
Berberine Upregulates P-Glycoprotein in Human Caco-2 Cells and in an Experimental Model of Colitis in the Rat via Activation of Nrf2-Dependent Mechanisms.
Inflammatory Bowel Diseases
C3435T polymorphism of the ABCB1/MDR1 gene encoding P-glycoprotein in patients with inflammatory bowel disease in a Polish population.
Inflammatory Bowel Diseases
Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis.
Inflammatory Bowel Diseases
Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population.
Inflammatory Bowel Diseases
Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis.
Inflammatory Bowel Diseases
Genetic polymorphism of ABCB1 gene (C3435T) in patients with inflammatory bowel diseases. Is there any gender dependency?
Inflammatory Bowel Diseases
Genetically determined differences in P-glycoprotein function: implications for disease risk.
Inflammatory Bowel Diseases
Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein.
Inflammatory Bowel Diseases
Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression.
Inflammatory Bowel Diseases
Integrating disease and drug-related phenotypes for improved identification of pharmacogenomic variants.
Inflammatory Bowel Diseases
Intestinal inflammation induces adaptation of P-glycoprotein expression and activity.
Inflammatory Bowel Diseases
Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease.
Inflammatory Bowel Diseases
Nitric oxide mediates increased P-glycoprotein activity in interferon-{gamma}-stimulated human intestinal cells.
Inflammatory Bowel Diseases
P-glycoprotein multidrug transporter in inflammatory bowel diseases: More questions than answers.
Inflammatory Bowel Diseases
St. John's wort may ameliorate 2,4,6-trinitrobenzenesulfonic acid colitis off rats through the induction of pregnane X receptors and/or P-glycoproteins.
Inflammatory Bowel Diseases
The importance of the polymorphisms of the ABCB1 gene in disease susceptibility, behavior and response to treatment in inflammatory bowel disease: A literature review.
Inflammatory Bowel Diseases
The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
Up-regulation and cytoprotective role of epithelial multidrug resistance-associated protein 1 in inflammatory bowel disease.
Inflammatory Breast Neoplasms
P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer.
Influenza, Human
ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia.
Influenza, Human
Cyclosporin A inhibits the propagation of influenza virus by interfering with a late event in the virus life cycle.
Influenza, Human
Management of vaccinations in Italy: a national survey after healthcare regionalization.
Influenza, Human
Reversible penetration of alpha-glutathione S-transferase into biological membranes revealed by photosensitized labelling in situ.
Insulin Resistance
ATP-binding cassette transporter A1 (ABCA1) expression in adipose tissue and its modulation with insulin resistance in obesity.
Insulin Resistance
Erratum: ATP-Binding Cassette Transporter A1 (ABCA 1) Expression in Adipose Tissue and Its Modulation with Insulin Resistance in Obesity [Corrigendum].
Insulin Resistance
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study.
Insulin Resistance
Slow Excitotoxicity in Alzheimer's Disease.
Insulin Resistance
Transporters, TBC1D4, and ARID5B Variants to Explain Glycated Hemoglobin Variability in Patients with Type 2 Diabetes.
Insulinoma
Associations of ATP-binding cassette transporter A1 and G1 with insulin secretion in human insulinomas.
Insulinoma
Roles of sulfonylurea receptor 1 and multidrug resistance protein 1 in modulating insulin secretion in human insulinoma.
Intermittent Claudication
Assessment of lumbar spinal canal stenosis by magnetic resonance phlebography.
Intestinal Failure
Liver Inflammation Relates to Decreased Canalicular Bile Transporter Expression in Pediatric Onset Intestinal Failure.
Intestinal Volvulus
Characterization of a half-size ATP-binding cassette transporter gene which may be a useful marker for ivermectin selection in Onchocerca volvulus.
Intestinal Volvulus
Genomic organization and effects of ivermectin selection on Onchocerca volvulus P-glycoprotein.
Intestinal Volvulus
Identification and stage-specific expression of two putative P-glycoprotein coding genes in Onchocerca volvulus.
Intestinal Volvulus
Ivermectin imposes selection pressure on P-glycoprotein from Onchocerca volvulus : linkage disequilibrium and genotype diversity.
Intestinal Volvulus
Use of P-glycoprotein gene probes to investigate anthelmintic resistance in Haemonchus contortus and comparison with Onchocerca volvulus.
Intracranial Aneurysm
Expression and variability of lipid metabolism genes in intracranial aneurysm.
Intussusception
Continence is improved after the Ripstein rectopexy. Different mechanizms in rectal prolapse and rectal intussusception?
Invasive Fungal Infections
Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
Iron Deficiencies
Comparative transcriptome analysis reveals gene network regulating cadmium uptake and translocation in peanut roots under iron deficiency.
Iron Deficiencies
Intake of Maillard reaction products reduces iron bioavailability in male adolescents.
Iron Overload
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients.
Ischemic Attack, Transient
Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
Ischemic Attack, Transient
Association of ABCB1 C3435T Polymorphism with Echocardiographic Index Among Patients with Atherosclerotic Ischemic Stroke and Transient Ischemic Attack.
Ischemic Attack, Transient
Influence of p-glycoprotein on brain Bcl-2 family proteins and cytokines in transient cerebral ischemia.
Ischemic Stroke
ABCB1 hypomethylation is associated with decreased antiplatelet effects of clopidogrel in Chinese ischemic stroke patients.
Ischemic Stroke
Association between ABCB1 Polymorphisms and Ischemic Stroke in Korean Population.
Ischemic Stroke
Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
Ischemic Stroke
Association of ABCB1 C3435T Polymorphism with Echocardiographic Index Among Patients with Atherosclerotic Ischemic Stroke and Transient Ischemic Attack.
Ischemic Stroke
Association of ABCG2 polymorphisms with ischemic stroke in a Chinese population.
Ischemic Stroke
Association of ATP-Binding Cassette Transporter G1 Polymorphisms with Risk of Ischemic Stroke in the Chinese Han Population.
Ischemic Stroke
Association of SLCO1B1 and ABCB1 Genetic Variants with Atorvastatin-induced Myopathy in Patients with Acute Ischemic Stroke.
Ischemic Stroke
ATP-binding cassette transporter A1 R219K polymorphism and ischemic stroke risk in the Chinese population: a meta-analysis.
Ischemic Stroke
Combined influence of ABCB1 genetic polymorphism and DNA methylation on aspirin resistance in Chinese ischemic stroke patients.
Ischemic Stroke
Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis.
Ischemic Stroke
Gene variants associated with ischemic stroke: the cardiovascular health study.
Ischemic Stroke
High-Performance Upconversion Nanoprobes for Multimodal MR Imaging of Acute Ischemic Stroke.
Ischemic Stroke
Natural Vitamin E {alpha}-Tocotrienol Protects Against Ischemic Stroke by Induction of Multidrug Resistance-Associated Protein 1.
Ischemic Stroke
Repression of adenosine triphosphate-binding cassette transporter ABCG2 by estrogen increases intracellular glutathione in brain endothelial cells following ischemic reperfusion injury.
Ischemic Stroke
Role of drug efflux carriers in the healthy and diseased brain.
Ischemic Stroke
S-oxiracetam protect against ischemic stroke via alleviating blood brain barrier dysfunction in rats.
Ischemic Stroke
Spatiotemporal Changes in P-glycoprotein Levels in Brain and Peripheral Tissues Following Ischemic Stroke in Rats.
Ischemic Stroke
The association of ABCC3 promoter methylation with clopidogrel response in Chinese ischemic stroke patients.
Ischemic Stroke
[Association of ABCB1 gene polymorphisms with aspirin resistance in patients with ischemic stroke].
Ischemic Stroke
[Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke].
Ischemic Stroke
[Study on the relationship between ABCB1 gene polymorphism and hemorrhage risk after thrombolysis of cerebral ischemic stroke in Shangqiu area].
Jaundice, Chronic Idiopathic
A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination.
Jaundice, Chronic Idiopathic
A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome.
Jaundice, Chronic Idiopathic
A new mutation of the ATP-binding cassette, sub-family C, member 2 (ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome.
Jaundice, Chronic Idiopathic
A novel ancestral splicing mutation in the multidrug resistance protein 2 gene causes Dubin-Johnson syndrome in Ashkenazi Jewish patients.
Jaundice, Chronic Idiopathic
A potential Dubin-Johnson syndrome imaging agent: synthesis, biodistribution, and microPET imaging.
Jaundice, Chronic Idiopathic
A recurrent ABCC2 p.G693R mutation resulting in loss of function of MRP2 and hyperbilirubinemia in Dubin-Johnson syndrome in China.
Jaundice, Chronic Idiopathic
A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome.
Jaundice, Chronic Idiopathic
A Time-Dependent Model Describes Methotrexate Elimination and Supports Dynamic Modification of MRP2/ABCC2 Activity.
Jaundice, Chronic Idiopathic
ABCC2/Abcc2: a multispecific transporter with dominant excretory functions.
Jaundice, Chronic Idiopathic
Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome.
Jaundice, Chronic Idiopathic
Assignment of the canalicular multispecific organic anion transporter gene (CMOAT) to human chromosome 10q24 and mouse chromosome 19D2 by fluorescent in situ hybridization.
Jaundice, Chronic Idiopathic
Characterization of a novel ABCC2 mutation in infantile Dubin Johnson syndrome.
Jaundice, Chronic Idiopathic
Clinical characteristics and ABCC2 genotype in Dubin-Johnson syndrome: A case report and review of the literature.
Jaundice, Chronic Idiopathic
Clinical, Pathologic, and Genetic Features of Neonatal Dubin-Johnson Syndrome: A Multicenter Study in Japan.
Jaundice, Chronic Idiopathic
Conjugated hyperbilirubinemia after surgery. A diagnosis of Dubin-Johnson syndrome confirmed by genetic testing.
Jaundice, Chronic Idiopathic
Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?
Jaundice, Chronic Idiopathic
Dubin-Johnson syndrome and intrahepatic cholestasis of pregnancy in a Sri Lankan family: a case report.
Jaundice, Chronic Idiopathic
Dubin-Johnson syndrome coinciding with colon cancer and atherosclerosis.
Jaundice, Chronic Idiopathic
Dubin-Johnson-like black liver with normal bilirubin level.
Jaundice, Chronic Idiopathic
Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome.
Jaundice, Chronic Idiopathic
Gene Replacement Therapy for Genetic Hepatocellular Jaundice.
Jaundice, Chronic Idiopathic
Genetic contribution of ABCC2 to Dubin-Johnson syndrome and inherited cholestatic disorders.
Jaundice, Chronic Idiopathic
Hyperbilirubinemia protects against focal ischemia in rats.
Jaundice, Chronic Idiopathic
Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome.
Jaundice, Chronic Idiopathic
Identification of a novel 2026G-->C mutation of the MRP2 gene in a Japanese patient with Dubin-Johnson syndrome.
Jaundice, Chronic Idiopathic
Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome.
Jaundice, Chronic Idiopathic
Improvement of serum bilirubin levels after venesection in a patient with Dubin-Johnson syndrome and HCV-positive chronic liver disease.
Jaundice, Chronic Idiopathic
Literature review and report of three cases of Dubin-Johnson syndrome related to ABCC2 gene mutations in children.
Jaundice, Chronic Idiopathic
Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy.
Jaundice, Chronic Idiopathic
Multiple black hepatocellular adenomas in a male patient.
Jaundice, Chronic Idiopathic
Mutation analysis of the ABCC2 gene in Chinese patients with Dubin-Johnson syndrome.
Jaundice, Chronic Idiopathic
Mutation analysis of the multidrug resistance protein 2 (MRP2) gene in a Japanese patient with Dubin-Johnson syndrome.
Jaundice, Chronic Idiopathic
Mutational analysis of ABCC2 gene in two siblings with neonatal-onset Dubin Johnson syndrome.
Jaundice, Chronic Idiopathic
Mutational analysis of the MRP2 gene and long-term follow-up of Dubin-Johnson syndrome in Japan.
Jaundice, Chronic Idiopathic
Neonatal Dubin-Johnson syndrome: biochemical parameters, characteristics, and genetic variants study.
Jaundice, Chronic Idiopathic
Neonatal Dubin-Johnson syndrome: novel compound heterozygous mutation in the ABCC2 gene.
Jaundice, Chronic Idiopathic
Novel compound heterozygous ABCC2 variants in patients with Dubin-Johnson syndrome and intrahepatic cholestasis of pregnancy.
Jaundice, Chronic Idiopathic
Novel large-scale deletion (whole exon 7) in the ABCC2 gene in a patient with the Dubin-Johnson syndrome.
Jaundice, Chronic Idiopathic
Novel mutations identified in the human multidrug resistance-associated protein 2 (MRP2/ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome.
Jaundice, Chronic Idiopathic
Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes.
Jaundice, Chronic Idiopathic
Rotor-type hyperbilirubinaemia has no defect in the canalicular bilirubin export pump.
Jaundice, Chronic Idiopathic
The apical conjugate efflux pump ABCC2 (MRP2).
Jaundice, Chronic Idiopathic
Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans.
Jaundice, Chronic Idiopathic
[Clinical features and ABCC2 genotypic analysis of an infant with Dubin-Johnson syndrome].
Jaundice, Chronic Idiopathic
[Mechanisms for resistance to anticancer agents and the reversal of the resistance]
Keloid
Enhanced expression of membrane transporter and drug resistance in keloid fibroblasts.
Kidney Diseases
Effect of MDR1 gene polymorphism on progression of end-stage renal disease.
Kidney Diseases
Role of direct oral anticoagulants in patients with kidney disease.
Kidney Diseases
Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport Syndrome.
Kidney Failure, Chronic
A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine.
Kidney Failure, Chronic
Altered nonrenal drug clearance in ESRD.
Kidney Failure, Chronic
Associations Between Chronic Disease, Polypharmacy, and Medication-Related Problems Among Medicare Beneficiaries.
Kidney Failure, Chronic
Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.
Kidney Failure, Chronic
Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion.
Kidney Failure, Chronic
Effect of MDR1 gene polymorphism on progression of end-stage renal disease.
Kidney Failure, Chronic
Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2.
Kidney Neoplasms
Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors.
Kidney Neoplasms
Augmentation by bispecific F(ab')2 reactive with P-glycoprotein and CD3 of cytotoxicity of human effector cells on P-glycoprotein positive human renal cancer cells.
Kidney Neoplasms
Detection of drug resistance and P-glycoprotein in human renal cell carcinomas.
Kidney Neoplasms
Drug resistance in renal tumors of childhood.
Kidney Neoplasms
Effect of ABC transporter expression and mutational status on survival rates of cancer patients.
Kidney Neoplasms
Elevated expression of P-glycoprotein in kidney and urinary bladder cancers.
Kidney Neoplasms
Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.
Kidney Neoplasms
Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma.
Kidney Neoplasms
MDR1 haplotypes modify BEN disease risk: a study in Bulgarian patients with Balkan endemic nephropathy compared to healthy controls.
Kidney Neoplasms
Oncogenic PITX2 Facilitates Tumor Cell Drug Resistance by Inverse Regulation of hOCT3/SLC22A3 and ABC Drug Transporters in Colon and Kidney Cancers.
Kidney Neoplasms
Pituitary homeobox 2 (PITX2) protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1.
Kidney Neoplasms
Regulation of breast cancer resistance protein and P-glycoprotein by ezrin, radixin and moesin in lung, intestinal and renal cancer cell lines.
Kidney Neoplasms
Renal Secretion Pathway-dependent Efflux Transport Enabled Hyperfluorescence Imaging of Kidney Cancer.
Kidney Neoplasms
RLIP76 Targeted Therapy for Kidney Cancer.
Kidney Neoplasms
[Circumvention of the multidrug-resistance in renal cancer by bisbenzylisoquinoline]
Kyphosis
Neurological outcome in surgically treated patients with incomplete closed traumatic cervical spinal cord injury.
Laryngeal Neoplasms
C-fos upregulates P-glycoprotein, contributing to the development of multidrug resistance in HEp-2 laryngeal cancer cells with VCR-induced resistance.
Laryngeal Neoplasms
Circular RNA circ_0004507 contributes to laryngeal cancer progression and cisplatin resistance by sponging miR-873 to upregulate multidrug resistance 1 and multidrug resistance protein 1.
Laryngeal Neoplasms
Effects of ATP-binding cassette transporter G2 in extracellular vesicles on drug resistance of laryngeal cancer cells in in vivo and in vitro.
Laryngeal Neoplasms
Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines.
Laryngeal Neoplasms
Reverse multidrug resistance in laryngeal cancer cells by knockdown MDR1 gene expression.
Laryngeal Neoplasms
Targeting CD133(+) laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles.
Laryngeal Neoplasms
[The correlation of multidrug resistance phenotype with clinical response to chemotherapy in laryngeal cancer]
Leigh Disease
Nuclear MRP genes and mitochondrial disease.
Leiomyoma
ATP-binding cassette ABCC1 is involved in the release of sphingosine 1-phosphate from rat uterine leiomyoma ELT3 cells and late pregnant rat myometrium.
Leiomyosarcoma
Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin.
Leiomyosarcoma
Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas.
Leiomyosarcoma
Expression of P-glycoprotein and Metallothionein in Gastrointestinal Stromal Tumor and Leiomyosarcomas. Clinical Implications.
Leiomyosarcoma
Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib.
Leishmaniasis
Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport.
Leishmaniasis
MARCKS-related protein (MRP) is a substrate for the Leishmania major surface protease leishmanolysin (gp63).
Leishmaniasis, Cutaneous
Evaluation of MDR1 and MRPA genes expression in different types of dry cutaneous leishmaniasis.
Leishmaniasis, Visceral
Decrease of intestinal P-glycoprotein activity by 2n-propylquinoline, a new oral treatment for visceral leishmaniasis.
Leishmaniasis, Visceral
Imipramine exploits histone deacetylase 11 to increase the IL-12/IL-10 ratio in macrophages infected with antimony-resistant Leishmania donovani and clears organ parasites in experimental infection.
Lennox Gastaut Syndrome
Role of P-Glycoprotein in Refractoriness of Seizures to Antiepileptic Drugs in Lennox-Gastaut Syndrome.
Lethargy
Assessing neuroprotective P-glycoprotein activity at the blood-brain barrier in killifish (Fundulus heteroclitus) using behavioural profiles.
Lethargy
Neurotoxic effects of ivermectin administration in genetically engineered mice with targeted insertion of the mutated canine ABCB1 gene.
Leukemia
5-Aminolaevulinic acid-mediated photodynamic therapy in multidrug resistant leukemia cells.
Leukemia
A comparative analysis of molecular genetic and conventional cytogenetic detection of diagnostically important translocations in more than 400 cases of acute leukemia, highlighting the frequency of false-negative conventional cytogenetics.
Leukemia
A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells overexpressing P-glycoprotein.
Leukemia
A novel energy dependent mechanism reducing daunorubicin accumulation in acute myeloid leukemia.
Leukemia
A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.
Leukemia
A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia.
Leukemia
A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells.
Leukemia
ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
Leukemia
ABCB1 C3435T polymorphism is associated with leukemia susceptibility: evidence from a meta-analysis.
Leukemia
ABCB1 genetic variants in leukemias: current insights into treatment outcomes.
Leukemia
ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate.
Leukemia
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome.
Leukemia
Absolute levels of MDR-1, MRP, and BCL-2 MRNA and tumor remission in acute leukemia.
Leukemia
Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists.
Leukemia
Adaptation of mouse leukemia cells L1210 to vincristine. Evidence for expression of P-glycoprotein.
Leukemia
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia.
Leukemia
Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells.
Leukemia
All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance.
Leukemia
Altered conjugate formation and altered apoptosis of multidrug-resistant human leukemia cell line affects susceptibility to killing by activated natural killer (NK) cells.
Leukemia
Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines.
Leukemia
An efficient nanomaterial-based electrochemical biosensor for sensitive recognition of drug-resistant leukemia cells.
Leukemia
Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide.
Leukemia
Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Leukemia
Antitumor effects of cytosine deaminase and thymidine kinase fusion suicide gene under the control of mdr1 promoter in mdr1 positive leukemia cells.
Leukemia
Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells.
Leukemia
Apoptosis Induced by the Curcumin Analogue EF-24 Is Neither Mediated by Oxidative Stress-Related Mechanisms nor Affected by Expression of Main Drug Transporters ABCB1 and ABCG2 in Human Leukemia Cells.
Leukemia
Appearance of nuclear factors that interact with genes for myeloid calcium binding proteins (MRP-8 and MRP-14) in differentiated HL-60 cells.
Leukemia
ARA, a novel ABC transporter, is located at 16p13.1, is deleted in inv(16) leukemias, and is shown to be expressed in primitive hematopoietic precursors.
Leukemia
Arsenic trioxide circumvents multidrug resistance based on different mechanisms in human leukemia cell lines.
Leukemia
Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene.
Leukemia
Assay for determination of daunorubicin in cancer cells with multidrug resistance phenotype.
Leukemia
Assessment of P-gp and MRP1 activities using MultiDrugQuant Assay Kit: a preliminary study of correlation between protein expressions and its functional activities in newly diagnosed acute leukaemia patients.
Leukemia
Assessment of Thiosemicarbazone-Containing Compounds as Potential Antileukemia Agents against P-gp Overexpressing Drug Resistant K562/A02 Cells.
Leukemia
ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein.
Leukemia
Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.
Leukemia
Augmented expression of P-gp/multi-drug resistance gene by all-trans retinoic acid in monocytic leukemic cells.
Leukemia
B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1.
Leukemia
beta(2)-microglobulin induces apoptosis in HL-60 human leukemia cell line and its multidrug resistant variants overexpressing MRP1 but lacking Bax or overexpressing P-glycoprotein.
Leukemia
Beta-tubulin and P-glycoprotein: major determinants of vincristine accumulation in B-CLL cells.
Leukemia
Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein.
Leukemia
Biological characteristics of CD7(+) acute leukemia.
Leukemia
Bisbenzylisoquinoline alkaloids and P-glycoprotein function: A structure activity relationship study.
Leukemia
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Leukemia
Breast cancer resistance protein (BCRP) in acute leukemia.
Leukemia
Breast cancer resistance protein is the enemy of hypericin accumulation and toxicity of hypericin-mediated photodynamic therapy.
Leukemia
Butorphanol, a synthetic opioid, sensitizes ABCB1-mediated multidrug resistance via inhibition of the efflux function of ABCB1 in leukemia cells.
Leukemia
Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor.
Leukemia
CD133-2 (AC141) expression analysis in acute leukemia immunophenotyping in correlation to CD34 and P-glycoprotein.
Leukemia
Cell Death Effects Induced by Sulforaphane and Allyl Isothiocyanate on P-Glycoprotein Positive and Negative Variants in L1210 Cells.
Leukemia
Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
Leukemia
Characterization of an anthracycline-resistant human promyelocyte leukemia (HL-60) cell line with an elevated MDR-1 gene expression.
Leukemia
Chemo- and radiation sensitivity of xenografted acute lymphoblastic leukemias--correlation to the expression of multidrug resistance proteins.
Leukemia
Chemoresistance in the clinic: overview 1994.
Leukemia
Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.
Leukemia
Circadian clock-controlled intestinal expression of the multidrug-resistance gene mdr1a in mice.
Leukemia
Clinical and biological relevance of flow cytometric determination of P-glycoprotein expression in acute non-lymphocytic leukemia.
Leukemia
Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis.
Leukemia
Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
Leukemia
Cloning and expression of two human genes encoding calcium-binding proteins that are regulated during myeloid differentiation.
Leukemia
Co-Encapsulation of Mitoxantrone and ?-Elemene in Solid Lipid Nanoparticles to Overcome Multidrug Resistance in Leukemia.
Leukemia
Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein.
Leukemia
Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.
Leukemia
Comparison of two functional flow cytometric assays to assess P-gp activity in acute leukemia.
Leukemia
Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice.
Leukemia
Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
Leukemia
Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study.
Leukemia
Cytotoxic Activity of Extracts from Plants of Central Argentina on Sensitive and Multidrug-Resistant Leukemia Cells: Isolation of an Active Principle from Gaillardia megapotamica.
Leukemia
Cytotoxic Constituents of the Bark of Hypericum roeperianum towards Multidrug-Resistant Cancer Cells.
Leukemia
Cytotoxic effects of leaf, stem and root extracts of Nerium oleander on leukemia cell lines and role of the p-glycoprotein in this effect.
Leukemia
Cytotoxic responses to aromatic ring and configurational variations in alpha-conidendrin, podophyllotoxin, and sikkimotoxin derivatives.
Leukemia
Cytotoxic T-lymphocytes recognizing P-glycoprotein in murine multidrug-resistant leukemias.
Leukemia
Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin.
Leukemia
Deregulation of folate pathway gene expression correlates with poor prognosis in acute leukemia.
Leukemia
Detection of multidrug resistance markers, P-glycoprotein and mdr1 mRNA, in human leukemia cells.
Leukemia
Detection of P-glycoprotein in human leukemias using monoclonal antibodies.
Leukemia
Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
Leukemia
Difloxacin reverses multidrug-resistance in p388 adr cells via a mechanism independent of p-glycoprotein and without correcting drug transport or subcellular drug distribution.
Leukemia
Discordance of P-glycoprotein expression and function in acute leukemia.
Leukemia
Discovery of a cobalt (III) salen complex that induces apoptosis in Burkitt like lymphoma and leukemia cells, overcoming multidrug resistance in vitro.
Leukemia
Discovery of derivatives of 6(7)-amino-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: novel, hypoxia-selective HIF-1? inhibitors with strong antiestrogenic potency.
Leukemia
Discovery of thiosemicarbazone-containing compounds with potent anti-proliferation activity against drug-resistant K562/A02 cells.
Leukemia
Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).
Leukemia
Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukemia.
Leukemia
Downregulation of microRNA let-7f mediated the Adriamycin resistance in leukemia cell line.
Leukemia
Drug Efflux Transporters and Multidrug Resistance in Acute Leukemia: Therapeutic Impact and Novel Approaches to Mediation.
Leukemia
Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias.
Leukemia
Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase.
Leukemia
Dynamic induction of drug resistance through a stress-responsive enhancer in acute myeloid leukemia.
Leukemia
Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol and tetrandrine on the reversion of multidrug resistance in K562/A02 cells.
Leukemia
Effect of MDR antagonists on the cidal activity of vincristine for cells expressing MDR-1 is superior to those expressing MRP.
Leukemia
Effect of new thioacridine derivatives on P-gp function and on mdr1 gene expression.
Leukemia
Effect of the calmodulin inhibitor trifluoperazine on phosphorylation of P-glycoprotein and topoisomerase II: relationship to modulation of subcellular distribution, DNA damage and cytotoxicity of doxorubicin in multidrug resistant L1210 mouse leukemia cells.
Leukemia
Effects of cis-unsaturated fatty acids on doxorubicin sensitivity in P388/DOX resistant and P388 parental cell lines.
Leukemia
Effects of Naturally Occurring Polymethyoxyflavonoids on Cell Growth, P-Glycoprotein Function, Cell Cycle, and Apoptosis of Daunorubicin-Resistant T Lymphoblastoid Leukemia Cells.
Leukemia
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
Leukemia
Emergence of multidrug resistance in leukemia cells during chemotherapy: mechanisms and prevention.
Leukemia
Emodin reverses leukemia multidrug resistance by competitive inhibition and downregulation of P-glycoprotein.
Leukemia
Enhanced invasiveness in multidrug resistant leukemic cells is associated with overexpression of P-glycoprotein and cellular inhibitor of apoptosis protein.
Leukemia
Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.
Leukemia
Establishment and evaluation of MRK16-magnetic cell sorting assays for detecting low expression of multidrug resistance P-glycoprotein using human leukemia cell lines and peripheral blood cells from healthy donors.
Leukemia
Estimation of ABCB1 concentration in plasma membrane.
Leukemia
Evaluation of multidrug resistance in 46 newly diagnosed patients with acute leukemia.
Leukemia
Evaluation of Multidrug Resistance of Leukemia Using Surface-Enhanced Raman Scattering Method for Clinical Applications.
Leukemia
Expression levels of multidrug resistance-associated protein 4 (MRP4) in human leukemia and lymphoma cell lines, and the inhibitory effects of the MRP-specific inhibitor MK-571 on methotrexate distribution in rats.
Leukemia
Expression of a P-glycoprotein gene is inducible in a multidrug-resistant human leukemia cell line.
Leukemia
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia.
Leukemia
Expression of DNA topoisomerase II alpha and multidrug resistance p-glycoprotein in acute leukemia.
Leukemia
Expression of MRP1 gene in acute leukemia.
Leukemia
Expression of p-glycoprotein in multidrug-resistant human leukemia k562 cells during erythroid-differentiation.
Leukemia
Expression of the IAPs in multidrug resistant tumor cells.
Leukemia
Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias.
Leukemia
Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance.
Leukemia
FK506 reverses adriamycin resistance in a multidrug-resistant human leukemia cell line.
Leukemia
Flow cytometric analysis of glutathione-S-transferase-pi in acute leukemia.
Leukemia
Flow cytometric analysis of P-glycoprotein in normal and leukemic cells.
Leukemia
Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
Leukemia
Fludarabine-resistance associates with ceramide metabolism and leukemia stem cell development in chronic lymphocytic leukemia.
Leukemia
Frequent coexpression of MRP/GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues.
Leukemia
Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers.
Leukemia
Functionally active homodimer of P-glycoprotein in multidrug-resistant tumor cells.
Leukemia
Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cells.
Leukemia
Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents.
Leukemia
High-level expression of P-glycoprotein and 85 kD protein as assessed by flow cytometry and immunocytochemistry in leukemias and malignant lymphomas.
Leukemia
Human leukemia K562 cell mutant (K562/OA200) selected for resistance to okadaic acid (protein phosphatase inhibitor) lacks protein kinase C-epsilon, exhibits multidrug resistance phenotype, and expresses drug pump P-glycoprotein.
Leukemia
Human multidrug-resistant (MRP,p190) myeloid leukemia HL-60/ADR cells in vitro: resistance to the mevalonate pathway inhibitor lovastatin.
Leukemia
Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression.
Leukemia
Identification and characterization of a phenyl-thiazolyl-benzoic acid derivative as a novel RAR/RXR agonist.
Leukemia
Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.
Leukemia
Identification of Chemoresistance-Related Cell-Surface Glycoproteins in Leukemia Cells and Functional Validation of Candidate Glycoproteins.
Leukemia
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
Leukemia
IL-4 inhibits P-glycoprotein in normal and malignant NK cells.
Leukemia
Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole.
Leukemia
In acute leukemia, the polymorphism -211C>T in the promoter region of the multidrug resistance-associated protein 3 (MRP3) does not determine the expression level of the gene.
Leukemia
In vitro cytotoxicity and P-glycoprotein modulating effects of geranylated furocoumarins from Tetradium daniellii.
Leukemia
Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia.
Leukemia
Increased drug accumulation ex vivo with cyclosporin in chronic lymphatic leukemia and its relationship to epitope masking of P-glycoprotein.
Leukemia
Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia.
Leukemia
Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia.
Leukemia
Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells. Sequential analysis of 15 cases at initial presentation and relapsed stage.
Leukemia
Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
Leukemia
Induction of Cross-resistance to ABCB1 Substrates in Venetoclax-resistant Human Leukemia HL60 Cells.
Leukemia
Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells.
Leukemia
Induction of MRP/GS-X pump and cellular resistance to anticancer prostaglandins.
Leukemia
Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Leukemia
Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin.
Leukemia
Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells.
Leukemia
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Leukemia
Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells.
Leukemia
Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells.
Leukemia
Intracellular localization of migration inhibitory factor-related protein (MRP) and detection of cell surface MRP binding sites on human leukemia cell lines.
Leukemia
Investigation of the mechanism involved in the As2O3-regulated decrease in MDR1 expression in leukemia cells.
Leukemia
Involvement of c-Jun N-terminal Kinase in the Reversal of Multidrug Resistance Human Leukemia Cells in Hypoxia by 5-bromotetrandrine.
Leukemia
In vitro and ex vivo anti?tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2?overexpressing leukemia cells.
Leukemia
Is P-glycoprotein a sufficient marker for multidrug resistance in vivo? Immunohistochemical staining for P-glycoprotein in children and adult leukemia: correlation with clinical outcome.
Leukemia
KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein.
Leukemia
KD025, an anti-adipocyte differentiation drug, enhances the efficacy of conventional chemotherapeutic drugs in ABCG2-overexpressing leukemia cells.
Leukemia
Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines.
Leukemia
Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines.
Leukemia
Lack of the multidrug transporter MRP4/ABCC4 defines the PEL-negative blood group and impairs platelet aggregation.
Leukemia
Laminar flow mediated continuous single-cell analysis on a novel poly(dimethylsiloxane) microfluidic chip.
Leukemia
Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells.
Leukemia
Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells.
Leukemia
MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias.
Leukemia
Mechanistic Insights into the Antileukemic Activity of Hyperforin.
Leukemia
Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells.
Leukemia
Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells.
Leukemia
Methylation of SFRP5 is related to multidrug resistance in leukemia cells.
Leukemia
MicroRNA-1246 by Targeting AXIN2 and GSK-3? Overcomes Drug Resistance and Induces Apoptosis in Chemo-resistant Leukemia Cells.
Leukemia
MiR-138 indirectly regulates the MDR1 promoter by NF-?B/p65 silencing.
Leukemia
Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
Leukemia
Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Eastern Cooperative Oncology Group.
Leukemia
Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Leukemia
Multi-drug resistance (MDR1) gene expression in de novo acute leukemia cells: correlations with CD surface markers and treatment outcome.
Leukemia
Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis.
Leukemia
Multidrug resistance (Mdr1) gene expression in peripheral blasts from patients with acute leukemia only rarely increases during disease progression after combination chemotherapy.
Leukemia
Multidrug resistance gene (mdr1) RNA levels in relation to P-glycoprotein content of leukemic cells from patients with acute leukemia.
Leukemia
Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16.
Leukemia
Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.
Leukemia
Multidrug resistance P-glycoprotein dampens SR-BI cholesteryl ester uptake from high density lipoproteins in human leukemia cells.
Leukemia
Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation.
Leukemia
Multidrug resistance protein 4/ ATP binding cassette transporter 4: a new potential therapeutic target for acute myeloid leukemia.
Leukemia
Multidrug resistance protein MRP1, glutathione, and related enzymes. Their importance in acute myeloid leukemia.
Leukemia
Multidrug resistance proteins and other drug transport-related resistance to natural product agents.
Leukemia
Multidrug Resistance Reversal Effects of Aminated Thioxanthones and Interaction with Cytochrome P450 3A4.
Leukemia
Multidrug resistant P-glycoprotein positive L1210/VCR cells are also cross-resistant to cisplatin via a mechanism distinct from P-glycoprotein-mediated drug efflux activity.
Leukemia
Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Leukemia
Multifunctional Gold Nanoparticles Overcome MicroRNA Regulatory Network Mediated-Multidrug Resistant Leukemia.
Leukemia
Multiple resistance mechanisms in acute nonlymphoblastic leukemia (ANLL).
Leukemia
Mutually co-operative interactions between modulators of P-glycoprotein.
Leukemia
Naphthoindole-based analogues of tryptophan and tryptamine: synthesis and cytotoxic properties.
Leukemia
New flow cytometric method for detection of minimally expressed multidrug resistance P-glycoprotein on normal and acute leukemia cells using biotinylated MRK16 and streptavidin-RED670 conjugate.
Leukemia
New uracil analogs as downregulators of ABC transporters in 5-fluorouracil-resistant human leukemia HL-60 cell line.
Leukemia
Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1.
Leukemia
Novel tetramethylpiperidine-substituted phenazines are potent inhibitors of P-glycoprotein activity in a multidrug resistant cancer cell line.
Leukemia
Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cells.
Leukemia
Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells.
Leukemia
Overexpression of GRP78/BiP in P-Glycoprotein-Positive L1210 Cells is Responsible for Altered Response of Cells to Tunicamycin as a Stressor of the Endoplasmic Reticulum.
Leukemia
Overexpression of lncRNA NEAT1 mitigates multidrug resistance by inhibiting ABCG2 in leukemia.
Leukemia
Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
Leukemia
Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro.
Leukemia
Overexpression of P-glycoprotein is associated with a decreased mitochondrial transmembrane potential in doxorubicin-selected K562 human leukemia cells.
Leukemia
Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase.
Leukemia
P-Glycoprotein (P-170) expression in acute leukemias.
Leukemia
P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells.
Leukemia
P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.
Leukemia
P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias.
Leukemia
P-glycoprotein Activity Correlates With Treatment Response in 2 Leukemia Child Patients.
Leukemia
P-glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line.
Leukemia
P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.
Leukemia
P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: Biological and prognosis implications.
Leukemia
P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells.
Leukemia
P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells.
Leukemia
P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma.
Leukemia
p-Glycoprotein expression as a predictor of breast cancer recurrence.
Leukemia
P-glycoprotein expression in acute myeloblastic leukemia analyzed by immunocytochemistry and flow cytometry.
Leukemia
P-glycoprotein in acute nonlymphoblastic leukemia and in the blastic crisis of myeloid leukemia.
Leukemia
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
Leukemia
P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors.
Leukemia
P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N(6) -(3-iodobenzyl)-adenosine-5'-N-methyluronamide in human leukemia cells.
Leukemia
P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway.
Leukemia
P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death.
Leukemia
P-glycoprotein quantitation in acute leukemia.
Leukemia
P-gp Expression and Rh 123 Efflux Assay Have no Impact on Survival in Egyptian Pediatric Acute Lymphoblastic Leukemia Patients.
Leukemia
Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.
Leukemia
Patterns of drug resistance parameters in adult leukemia.
Leukemia
Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.
Leukemia
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
Leukemia
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
Leukemia
Phenylcinnamides as Novel Antimitotic Agents.
Leukemia
Phosphorylation of RNA helicase A by DNA-dependent protein kinase is indispensable for expression of the MDR1 gene product P-glycoprotein in multidrug-resistant human leukemia cells.
Leukemia
Physical mapping of a tandem duplication on the long arm of chromosome 7 associated with a multidrug resistant phenotype.
Leukemia
Plant extracts and betulin from Ligaria cuneifolia inhibit P-glycoprotein function in leukemia cells.
Leukemia
Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.
Leukemia
Potentiation of the vincristine effect on P388 mouse leukemia cells by a newly synthesized dihydropyridine analogue, PAK-200.
Leukemia
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Leukemia
Proapoptotic activity and ABCC1-related multidrug resistance reduction ability of semisynthetic oleanolic acid derivatives DIOXOL and HIMOXOL in human acute promyelocytic leukemia cells.
Leukemia
Production of monoclonal antibodies to P-glycoprotein: its application in detection of soluble and surface P-glycoprotein of leukemia patients.
Leukemia
Prognostic Significance of Multidrug Resistance Gene 1 (MDR1), Multidrug Resistance-related Protein (MRP) and Lung Resistance Protein (LRP) mRNA Expression in Acute Leukemia.
Leukemia
Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Leukemia
Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity.
Leukemia
Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.
Leukemia
Quantitative analysis of human multidrug resistance 1 (MDR1) gene expression by nonisotopic competitive reverse transcriptase polymerase chain reaction assay.
Leukemia
Quantitative study of cellular heterogeneity in doxorubicin uptake and its pharmacological effect on cancer cells.
Leukemia
Quercetin Triggers Induction of Apoptotic and Lysosomal Death of Sensitive and Multidrug Resistant Leukaemia HL60 Cells.
Leukemia
Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
Leukemia
Reduction of cytotoxicity of the alkaloid emetine through P-glycoprotein (MDR1/ABCB1) in human Caco-2 cells and leukemia cell lines.
Leukemia
Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells.
Leukemia
Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
Leukemia
Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin.
Leukemia
Requirement of expression of P-glycoprotein on human natural killer leukemia cells for cell-mediated cytotoxicity.
Leukemia
Resistance factors and proliferative activity in childhood acute nonlymphoblastic leukemia.
Leukemia
Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.
Leukemia
Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells.
Leukemia
Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833.
Leukemia
Retrovirus insertion and transcriptional activation of the multidrug-resistance gene in leukemias treated by a chemotherapeutic agent in vivo.
Leukemia
Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Leukemia
Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels.
Leukemia
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Leukemia
Reversal of mdr1-mediated multidrug resistance in human leukemia cells by a new spin-labeled derivative of podophyllotoxin.
Leukemia
Reversal of multidrug resistance by tacrolimus hydrate.
Leukemia
Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.
Leukemia
Reversal of P-glycoprotein-mediated multidrug resistance with small interference RNA (siRNA) in leukemia cells.
Leukemia
Rhodamine 123: is it an appropriate dye to study P-glycoprotein activity in adriamycin-resistant K562 cells?
Leukemia
Role of ABCB1 C1236T, G2677T, and C3435T genetic polymorphisms in the development of acute leukemia in a Chinese population.
Leukemia
S-adenosylmethionine synthetase is overexpressed in murine neuroblastoma cells resistant to nucleoside analogue inhibitors of S-adenosylhomocysteine hydrolase: a novel mechanism of drug resistance.
Leukemia
Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells.
Leukemia
Screening of Phenanthroquinolizidine Alkaloid Derivatives for Inducing Cell Death of L1210 Leukemia Cells with Negative and Positive P-glycoprotein Expression.
Leukemia
Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cells.
Leukemia
Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells.
Leukemia
Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses.
Leukemia
Simultaneous occurrence of monoclonal gammopathy and acute secondary leukemia with overexpression of P-glycoprotein.
Leukemia
SKP2 siRNA inhibits the degradation of P27kip1 and down-regulates the expression of MRP in HL-60/A cells.
Leukemia
Sodium azulene sulfonate reverses multidrug resistance in K562/A02 cells.
Leukemia
Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
Leukemia
Structure-dependent antitumor activities of novel anthracyclines YM1, YM3, YM4 and YM6: drug transport properties and effects on biomacromolecule synthesis in drug sensitive and resistant leukemia cells.
Leukemia
Suppression of P-glycoprotein expression by antipsychotics trifluoperazine in adriamycin-resistant L1210 mouse leukemia cells.
Leukemia
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Leukemia
Synthesis and structure-activity relationships of novel ecdysteroid dioxolanes as MDR modulators in cancer.
Leukemia
Synthesis of 2-aryl-4-(benzimidazol-2-yl)-1,2-dihydro[1,2,4]triazino-[4,5-a]benzimidazol-1-one derivatives with preferential cytotoxicity against carcinoma cell lines.
Leukemia
Synthesis, biological evaluation and toxicity of novel tetrandrine analogues.
Leukemia
Technetium-99m-tetrofosmin would be a substrate for multidrug resistance-associated protein (MRP): comparison between a leukemia cell line with high MRP gene expression and its parental cell line.
Leukemia
Tetrandrine enhances glucocorticoid receptor translocation possibly via inhibition of P-glycoprotein in daunorubicin-resistant human T lymphoblastoid leukemia cells.
Leukemia
The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias.
Leukemia
The effect of glucosylceramide synthase on P-glycoprotein function in K562/AO2 leukemia drug-resistance cell line.
Leukemia
The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
Leukemia
The expression of multidrug resistance (MDR) molecule in acute leukemia and lymphoma.
Leukemia
The expression of P-glycoprotein in leukemia cells is associated with the upregulated expression of nestin, a class 6 filament protein.
Leukemia
The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.
Leukemia
The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives.
Leukemia
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism.
Leukemia
The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Leukemia
The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Leukemia
The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins.
Leukemia
Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo.
Leukemia
Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines.
Leukemia
Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia.
Leukemia
Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease.
Leukemia
Triorganotin Derivatives Induce Cell Death Effects on L1210 Leukemia Cells at Submicromolar Concentrations Independently of P-glycoprotein Expression.
Leukemia
Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent.
Leukemia
WAVE1 regulates P-glycoprotein expression via Ezrin in leukemia cells.
Leukemia
Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2.
Leukemia
Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).
Leukemia
[Analysis of molecular mechanism involved in development of acute myeloid leukemia].
Leukemia
[Analysis of P-glycoprotein in patients with acute leukemias by flow cytometry]
Leukemia
[Apoptosis of MR2 cells induced by Tanshinone II A combined with arsenic trioxide]
Leukemia
[Arsenic trioxide inhibits P-glycoprotein expression in multidrug-resistant human leukemia K562/ADM cell line that overexpresses mdr-1 gene and enhances their chemotherapeutic sensitivity]
Leukemia
[Chronic myelogenous leukemia with blastic crisis in which expression of P-glycoprotein was associated with resistance to chemotherapy]
Leukemia
[Clinical significance of leukemia stem/progenitor cell related gene expression in acute leukemia].
Leukemia
[Clinical significance of P-glycoprotein and CD34 expression of acute leukemia]
Leukemia
[Detection and analysis of multidrug resistance in 100 cases of acute leukemia]
Leukemia
[Detection of multidrug resistant cells in human malignant diseases by monoclonal antibodies and strategy to eradicate resistant malignant cells]
Leukemia
[Effect of glucosylceramide synthase on P-gp expression by ERK signal transduction pathway in leukemia multi-drug resistance cell line].
Leukemia
[Effect of intracellular acidification on drug resistance of leukemia cells with high P-glycoprotein expression]
Leukemia
[Effects of arsenic trioxide on expressions of vascular endothelial growth factor and P-glycoprotein in multidrug resistant leukemia cell line K562/A02]
Leukemia
[Evaluation of the P-gp pump function on leukemic cell membrane and proper application of its reversal agents with Calcein-AM and flow cytometry]
Leukemia
[Expression and clinical study of multidrug resistance gene and multidrug resistance associated protein gene in acute leukemia]
Leukemia
[Expression of lung resistance protein and multidrug resistance protein genes in bone marrow cells of acute leukemia patients and its clinical significance]
Leukemia
[Expression of lung resistance protein and multidrug resistance-associated protein in naive childhood acute leukemia and their clinical significance]
Leukemia
[Expression of multidrug resistance P-170 and MRP and their correlation with clinical drug resistance in acute leukemia]
Leukemia
[Expression of P-glycoprotein (multidrug-resistance gene product) in haematological tumors]
Leukemia
[Expressions of P-gp, mdr1, MRP and Topo II in acute leukemia patients and their correlation with prognosis]
Leukemia
[Flow cytometric analysis of P-glycoprotein function by rhodamine 123 dye-efflux assay in human leukemia cells]
Leukemia
[Genetic diagnosis for drug resistance in cancers]
Leukemia
[Increasing sensitivity of leukemia cells to imatinib by inhibiting NHE1 and p38MAPK signaling pathway].
Leukemia
[Induction of Anti-leukemic Immunity of Dendritic Cells Derived from Multidrug Resistant Leukemia K562/A02 cells with High Expression of P-glycoprotein and Sensitive K562 cells.]
Leukemia
[Multidrug Resistance-related Proteins and Their Relationship with Acute Leukemia].
Leukemia
[Multidrug resistant P-glycoprotein expression on acute nonlymphocytic leukemia cells at diagnosis]
Leukemia
[NF-? B mediates the effect of glucosylceramide synthase on P-glycoprotein modulation in a drug-resistance leukemia cell line].
Leukemia
[P-glycoprotein expression in hematological malignancies]
Leukemia
[Polymerase chain reaction in diagnostic pathology]
Leukemia
[Prognostic significance of P-glycoprotein expression in acute leukemia in adults]
Leukemia
[Relationship between resistance to chemotherapy and expression of breast cancer resistance protein (BCRP) gene in patients with acute leukemia]
Leukemia
[Significance of functional assay of multidrug resistance for prediction of chemotherapy outcomes in acute leukemia]
Leukemia
[The clinical and biological significance of P-glycoprotein expression in acute nonlymphocytic leukemia]
Leukemia
[The clinical significance of lung resistance-related protein gene (lrp), multidrug resistance-associated protein gene (mrp) and mdr-1/p170 expression in acute leukemia]
Leukemia
[The clinical significance of multidrug resistance associated protein(MRP) gene expression in acute leukemia]
Leukemia
[The relationship between expression of lung resistance-related protein gene or multidrug resistance-associated protein gene and prognosis in newly diagnosed acute leukemia]
Leukemia
[The relationship between multi-drug resistance and proportion of leukemia stem cells and expression of drug transporters in drug-resistant leukemia K562/ADM cells]
Leukemia
[WT1 gene expression in leukemia patients and its correlation with prognosis and multidrug resistance]
Leukemia L1210
Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Leukemia L5178
Novel Anticancer Dimeric Napthoquiones from Diospyros lotus Having Anti-Tumor, Anti-Inflammatory and Multidrug Resistance Reversal Potential: In Vitro, In Vivo and In Silico Evidence.
Leukemia P388
Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
Leukemia P388
[The expression of P-glycoprotein in leukemia P388 cells with induced doxorubicin resistance]
Leukemia, B-Cell
Exploration of Molecular Targets in the Development of New Therapeutics Aimed at Overcoming Multidrug Resistance.
Leukemia, B-Cell
Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine.
Leukemia, Erythroblastic, Acute
Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria.
Leukemia, Erythroblastic, Acute
C-phycocyanin to overcome the multidrug resistance phenotype in human erythroleukemias with or without interaction with ABC transporters.
Leukemia, Erythroblastic, Acute
Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers.
Leukemia, Erythroblastic, Acute
Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin.
Leukemia, Erythroblastic, Acute
Dexniguldipine hydrochloride, a protein-kinase-C-specific inhibitor, affects the cell cycle, differentiation, P-glycoprotein levels, and nuclear protein phosphorylation in Friend erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Differentiation of the P-gp and MRP1 multidrug resistance systems by mobile lipid 1H-NMR spectroscopy and phosphatidylserine externalization.
Leukemia, Erythroblastic, Acute
Drug sequestration in cytoplasmic organelles does not contribute to the diminished sensitivity of anthracyclines in multidrug resistant K562 cells.
Leukemia, Erythroblastic, Acute
Drug-transport and volume-activated chloride channel functions in human erythroleukemia cells: relation to expression level of P-glycoprotein.
Leukemia, Erythroblastic, Acute
Effects of R-enantiomer (GR66234A) and L-enantiomer (GR66235A) of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype.
Leukemia, Erythroblastic, Acute
Functional modulation of multidrug resistance-related P-glycoprotein by Ca(2+)-calmodulin.
Leukemia, Erythroblastic, Acute
Functional studies of P-glycoprotein in inside-out plasma membrane vesicles derived from murine erythroleukemia cells overexpressing MDR 3. Properties and kinetics of the interaction of vinblastine with P-glycoprotein and evidence for its active mediated transport.
Leukemia, Erythroblastic, Acute
Identification of the multidrug-resistance protein (MRP) as the glutathione-S-conjugate export pump of erythrocytes.
Leukemia, Erythroblastic, Acute
In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil.
Leukemia, Erythroblastic, Acute
Inhibition by erythroid differentiation factor (activin A) of P-glycoprotein expression in multidrug-resistant human K562 erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Relation between ABCB1 overexpression and COX2 and ALOX5 genes in human erythroleukemia cell lines.
Leukemia, Erythroblastic, Acute
Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression.
Leukemia, Erythroblastic, Acute
Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines.
Leukemia, Erythroblastic, Acute
TNF-induced apoptosis in multidrug resistant friend erythroleukemia is not influenced by the P-glycoprotein and glutathione status of the cell line.
Leukemia, Erythroblastic, Acute
Transduction of multiple cell types using improved conditions for gene delivery and expression of SV40 pseudovirions packaged in vitro.
Leukemia, Erythroblastic, Acute
Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells.
Leukemia, Erythroblastic, Acute
[Effects of some traditional chinese drugs on mdr1 gene and its expression product in k562/a02 cells.]
Leukemia, Feline
Comparison of protoporphyrin IX content and related gene expression in the tissues of chickens laying brown-shelled eggs.
Leukemia, Feline
Placental expression of the heme transporter, feline leukemia virus subgroup C receptor, is related to maternal iron status in pregnant adolescents.
Leukemia, Feline
Quantitative expression of candidate genes affecting eggshell color
Leukemia, Feline
Quantitative expression of candidate genes affecting eggshell color.
Leukemia, Lymphocytic, Chronic, B-Cell
A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk.
Leukemia, Lymphocytic, Chronic, B-Cell
Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay.
Leukemia, Lymphocytic, Chronic, B-Cell
Beta-tubulin and P-glycoprotein: major determinants of vincristine accumulation in B-CLL cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Different frequencies and effects of ABCB1 T3435C polymorphism on clinical and laboratory features of B cell chronic lymphocytic leukemia in Kurdish patients.
Leukemia, Lymphocytic, Chronic, B-Cell
Drug resistance mechanisms in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of the multidrug resistance-associated protein (mrp) gene in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias.
Leukemia, Lymphocytic, Chronic, B-Cell
Increased drug accumulation ex vivo with cyclosporin in chronic lymphatic leukemia and its relationship to epitope masking of P-glycoprotein.
Leukemia, Lymphocytic, Chronic, B-Cell
MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Multidrug resistance in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and northern blot analysis.
Leukemia, Lymphocytic, Chronic, B-Cell
Quantification of P-glycoprotein in chronic lymphocytic leukemia by flow cytometry.
Leukemia, Lymphocytic, Chronic, B-Cell
Relation of P-glycoprotein expression with spontaneous in vitro apoptosis in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The relevance of multidrug resistance-associated P-glycoprotein expression in the treatment response of B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
[Multidrug resistance in chronic lymphocytic leukemia]
Leukemia, Lymphoid
Characterization and purification of a protein kinase C substrate in human B cells. Identification as lymphocyte-specific protein 1 (LSP1).
Leukemia, Lymphoid
Cytotoxic T-lymphocytes recognizing P-glycoprotein in murine multidrug-resistant leukemias.
Leukemia, Lymphoid
Multidrug resistance gene (mdr1) RNA levels in relation to P-glycoprotein content of leukemic cells from patients with acute leukemia.
Leukemia, Megakaryoblastic, Acute
Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association between C1236T Genetic Variant of ABCB1 Gene and Molecular Response to Imatinib in Indonesian Chronic Myeloid Patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association between the concentration of imatinib in bone marrow mononuclear cells, mutation status of ABCB1 and therapeutic response in patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association of Genetic Polymorphisms in the Influx Transporter SLCO1B3 and the Efflux Transporter ABCB1 With Imatinib Pharmacokinetics in Patients With Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine-N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Decreased expression of microRNA-214 contributes to imatinib mesylate resistance of chronic myeloid leukemia patients by upregulating ABCB1 gene expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Emodin reverses leukemia multidrug resistance by competitive inhibition and downregulation of P-glycoprotein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Impact of ABCB1 Gene (C3435T/A2677G) Polymorphic Sequence Variations on the Outcome of Patients with Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Kashmiri Population: A Case-Control Study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MRP1 and P-glycoprotein expression assays would be useful in the additional detection of treatment non-responders in CML patients without ABL1 mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Overexpression of P-glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polymorphisms in the CYP2A6 and ABCC4 genes are associated with a protective effect on chronic myeloid leukemia in the Brazilian Amazon population.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Prognostic value of P-glycoprotein and leukocyte differentiation antigens in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Selective Cytotoxicity of Piperine Over Multidrug Resistance Leukemic Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Statins inhibit ABCB1 and ABCG2 drug transporters activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The influence of ABCG2 polymorphism on erlotinib efflux in the K562 cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Up-regulation of P-glycoprotein confers acquired resistance to 6-mercaptopurine in human chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Wnt/?-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Chronic myelogenous leukemia with blastic crisis in which expression of P-glycoprotein was associated with resistance to chemotherapy]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Correlation between reversing effect of cepharanthine hydrochloride on multidrug resistance and P-glycoprotein expression and function of K562/ADR cells].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Corrigendum] miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Effect of cryptotanshinone on imatinib sensitivity and P-glycoprotein expression of chronic myeloid leukemia cells].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Functional activity and expression of P-glycoprotein in chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[P-glycoprotein and treatment with plicamycin + hydroxyurea in myeloid blastic crisis of chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Study on the mechanisms of imatinib-resistance of cancer stem-like cells in K562/Vp16 cell line]
Leukemia, Myeloid
Altered expression of the genes regulating apoptosis in multidrug resistant human myeloid leukemia cell lines overexpressing MDR1 or MRP gene.
Leukemia, Myeloid
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Leukemia, Myeloid
Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats.
Leukemia, Myeloid
BME, a novel compound of anthraquinone, down regulated P-glycoprotein expression in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells via generation of reactive oxygen species.
Leukemia, Myeloid
Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines.
Leukemia, Myeloid
Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity.
Leukemia, Myeloid
Detection of 300-kilodalton membrane protein in adriamycin-resistant human tumor cells by a monoclonal antibody MRK18.
Leukemia, Myeloid
Expression of P-glycoprotein mRNA in human gastric tumors.
Leukemia, Myeloid
Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells.
Leukemia, Myeloid
Expression of TRAIL (Apo2L), DR4 (TRAIL receptor 1), DR5 (TRAIL receptor 2) and TRID (TRAIL receptor 3) genes in multidrug resistant human acute myeloid leukemia cell lines that overexpress MDR 1 (HL60/Tax) or MRP (HL60/AR).
Leukemia, Myeloid
Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells.
Leukemia, Myeloid
Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells.
Leukemia, Myeloid
Interaction of CJY, an Isoflavone, with ATPase of P-glycoprotein in Doxorubicin-resistant Human Myelogenous Leukemia (K562/DOX) Cells.
Leukemia, Myeloid
Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Leukemia, Myeloid
Multidrug resistance protein MRP1, glutathione, and related enzymes. Their importance in acute myeloid leukemia.
Leukemia, Myeloid
Nutlin-1 strengthened anti-proliferation and differentiation-inducing activity of ATRA in ATRA-treated p-glycoprotein deregulated human myelocytic leukemia cells.
Leukemia, Myeloid
P-glycoprotein in acute nonlymphoblastic leukemia and in the blastic crisis of myeloid leukemia.
Leukemia, Myeloid
Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance. 170- to 180-kilodalton membrane glycoprotein is an ATPase.
Leukemia, Myeloid
The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives.
Leukemia, Myeloid
The multidrug resistance phenotype confers immunological resistance.
Leukemia, Myeloid, Acute
A comparative analysis of molecular genetic and conventional cytogenetic detection of diagnostically important translocations in more than 400 cases of acute leukemia, highlighting the frequency of false-negative conventional cytogenetics.
Leukemia, Myeloid, Acute
A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.
Leukemia, Myeloid, Acute
A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow.
Leukemia, Myeloid, Acute
A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia.
Leukemia, Myeloid, Acute
ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
Leukemia, Myeloid, Acute
ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients.
Leukemia, Myeloid, Acute
ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia.
Leukemia, Myeloid, Acute
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
Leukemia, Myeloid, Acute
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML.
Leukemia, Myeloid, Acute
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
Leukemia, Myeloid, Acute
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome.
Leukemia, Myeloid, Acute
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission.
Leukemia, Myeloid, Acute
Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-?B-dependent P-glycoprotein upregulation.
Leukemia, Myeloid, Acute
Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia.
Leukemia, Myeloid, Acute
Acute myeloid leukemia cells MOLM-13 and SKM-1 established for resistance by azacytidine are crossresistant to P-glycoprotein substrates.
Leukemia, Myeloid, Acute
Acute myeloid leukemia cells with low P-glycoprotein expression and high rhodamine 123 efflux capacity display high clonogenicity.
Leukemia, Myeloid, Acute
Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.
Leukemia, Myeloid, Acute
Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.
Leukemia, Myeloid, Acute
Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells.
Leukemia, Myeloid, Acute
Analysis of the intron-exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA.
Leukemia, Myeloid, Acute
Anthracycline drugs and MDR expression in human leukemia.
Leukemia, Myeloid, Acute
Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts.
Leukemia, Myeloid, Acute
Assessment of P-glycoprotein expression by immunocytochemistry and flow cytometry using two different monoclonal antibodies coupled with functional efflux analysis in 34 patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results.
Leukemia, Myeloid, Acute
Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype.
Leukemia, Myeloid, Acute
Breast cancer resistance protein (BCRP) gene expression in a cohort of adult Egyptian patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.
Leukemia, Myeloid, Acute
Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
Leukemia, Myeloid, Acute
Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia.
Leukemia, Myeloid, Acute
C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
Leukemia, Myeloid, Acute
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.
Leukemia, Myeloid, Acute
CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome.
Leukemia, Myeloid, Acute
Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group.
Leukemia, Myeloid, Acute
Clinical and biological relevance of flow cytometric determination of P-glycoprotein expression in acute non-lymphocytic leukemia.
Leukemia, Myeloid, Acute
Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine.
Leukemia, Myeloid, Acute
Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.
Leukemia, Myeloid, Acute
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia.
Leukemia, Myeloid, Acute
Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study.
Leukemia, Myeloid, Acute
Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
Leukemia, Myeloid, Acute
Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis.
Leukemia, Myeloid, Acute
Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Comparison of P-glycoprotein expression with in vitro drug sensitivity in fresh blast cells from acute myeloid leukaemia patients.
Leukemia, Myeloid, Acute
Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.
Leukemia, Myeloid, Acute
Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Leukemia, Myeloid, Acute
Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML).
Leukemia, Myeloid, Acute
Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression.
Leukemia, Myeloid, Acute
Deletion of the multidrug resistance protein 1 (MRP1) gene in acute myeloid leukemia patients with inversion 16: expression of MRP1 homologues.
Leukemia, Myeloid, Acute
Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity.
Leukemia, Myeloid, Acute
Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.
Leukemia, Myeloid, Acute
Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia.
Leukemia, Myeloid, Acute
Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
Leukemia, Myeloid, Acute
Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
Leukemia, Myeloid, Acute
Development of Multidrug Resistance in Acute Myeloid Leukemia Is Associated with Alterations of the LPHN1/GAL-9/TIM-3 Signaling Pathway.
Leukemia, Myeloid, Acute
Differential expression and activity of P-glycoprotein and multidrug resistance-associated protein in CD34-positive KG1a leukemic cells.
Leukemia, Myeloid, Acute
Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
Leukemia, Myeloid, Acute
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
Leukemia, Myeloid, Acute
Drug concentration-dependent expression of multidrug resistance-associated protein and P-glycoprotein in the doxorubicin-resistant acute myelogenous leukemia sublines.
Leukemia, Myeloid, Acute
Drug resistance: Still a daunting challenge to the successful treatment of AML.
Leukemia, Myeloid, Acute
Dynamic induction of drug resistance through a stress-responsive enhancer in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Effect of 5637-conditioned medium and recombinant cytokines on P-glycoprotein expression in a human GM-CSF-dependent leukemic myeloid cell line.
Leukemia, Myeloid, Acute
Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
Leukemia, Myeloid, Acute
Erlotinib antagonizes ABC transporters in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.
Leukemia, Myeloid, Acute
Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients.
Leukemia, Myeloid, Acute
Expression of functional markers in acute nonlymphoblastic leukemia.
Leukemia, Myeloid, Acute
Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
Leukemia, Myeloid, Acute
Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome.
Leukemia, Myeloid, Acute
Expression of P-gp in acute myeloid leukemia and the reversal function of As2O3 on drug resistance.
Leukemia, Myeloid, Acute
Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML.
Leukemia, Myeloid, Acute
Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias.
Leukemia, Myeloid, Acute
Expression of the multidrug transporter P-glycoprotein and in vitro chemosensitivity: correlation with in vivo response to chemotherapy in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia.
Leukemia, Myeloid, Acute
Expression of TRAIL (Apo2L), DR4 (TRAIL receptor 1), DR5 (TRAIL receptor 2) and TRID (TRAIL receptor 3) genes in multidrug resistant human acute myeloid leukemia cell lines that overexpress MDR 1 (HL60/Tax) or MRP (HL60/AR).
Leukemia, Myeloid, Acute
Flow cytometric analysis of P-glycoprotein in normal and leukemic cells.
Leukemia, Myeloid, Acute
Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia.
Leukemia, Myeloid, Acute
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.
Leukemia, Myeloid, Acute
Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Functional analysis of P-glycoprotein and multidrug resistance associated protein related multidrug resistance in AML-blasts.
Leukemia, Myeloid, Acute
Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Genomic amplification of chromosome 7 in the Doxorubicin resistant K562 cell line.
Leukemia, Myeloid, Acute
Genomic variation at the MDR1 promoter and P-glycoprotein expression and activity in AML patients.
Leukemia, Myeloid, Acute
Glutathione system, topoisomerase II level and multidrug resistance phenotype in acute myelogenous leukemia before treatment and at relapse.
Leukemia, Myeloid, Acute
High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2.
Leukemia, Myeloid, Acute
Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.
Leukemia, Myeloid, Acute
Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukemia: impact of antibodies, sample source and disease status.
Leukemia, Myeloid, Acute
Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.
Leukemia, Myeloid, Acute
Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells.
Leukemia, Myeloid, Acute
In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy.
Leukemia, Myeloid, Acute
In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome.
Leukemia, Myeloid, Acute
In vitro effect of P-glycoprotein (P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myelogenous leukemia (AML).
Leukemia, Myeloid, Acute
In Vitro Modulation of P-Glycoprotein Activity by Euphorbia intisy Essential Oil on Acute Myeloid Leukemia Cell Line HL-60R.
Leukemia, Myeloid, Acute
Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia.
Leukemia, Myeloid, Acute
Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML).
Leukemia, Myeloid, Acute
Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia.
Leukemia, Myeloid, Acute
Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies.
Leukemia, Myeloid, Acute
Influence of ceramide metabolism on P-glycoprotein function in immature acute myeloid leukemia KG1a cells.
Leukemia, Myeloid, Acute
Interactions between P-glycoprotein and drugs used in the supportive care of acute myeloid leukemia patients.
Leukemia, Myeloid, Acute
JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia.
Leukemia, Myeloid, Acute
Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines.
Leukemia, Myeloid, Acute
Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Leukemia, Myeloid, Acute
Low levels of ABCG2 expression in adult AML blast samples.
Leukemia, Myeloid, Acute
MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
Leukemia, Myeloid, Acute
MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia.
Leukemia, Myeloid, Acute
MDR1/P-GP expression as a prognostic factor in acute leukemias.
Leukemia, Myeloid, Acute
Mechanism study of PEGylated polyester and ?-cyclodextrin integrated micelles on drug resistance reversal in MRP1-overexpressed HL60/ADR cells.
Leukemia, Myeloid, Acute
Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells.
Leukemia, Myeloid, Acute
Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis.
Leukemia, Myeloid, Acute
Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Eastern Cooperative Oncology Group.
Leukemia, Myeloid, Acute
MRP expression in acute myeloid leukemia. An update.
Leukemia, Myeloid, Acute
MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia.
Leukemia, Myeloid, Acute
Multidrug drug resistance in pediatric sarcomas.
Leukemia, Myeloid, Acute
Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis.
Leukemia, Myeloid, Acute
Multidrug resistance (Mdr1) gene expression in peripheral blasts from patients with acute leukemia only rarely increases during disease progression after combination chemotherapy.
Leukemia, Myeloid, Acute
Multidrug resistance and cancer: the role of the human ABC transporter ABCG2.
Leukemia, Myeloid, Acute
Multidrug resistance in acute leukemia: a conserved physiologic function.
Leukemia, Myeloid, Acute
Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
Leukemia, Myeloid, Acute
Multidrug resistance in pediatric malignancies.
Leukemia, Myeloid, Acute
Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity.
Leukemia, Myeloid, Acute
Multidrug resistance protein 4/ ATP binding cassette transporter 4: a new potential therapeutic target for acute myeloid leukemia.
Leukemia, Myeloid, Acute
Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
Multidrug resistance protein MRP1, glutathione, and related enzymes. Their importance in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Multidrug resistance-associated protein (MRP) in haematological malignancies.
Leukemia, Myeloid, Acute
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts.
Leukemia, Myeloid, Acute
Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
Leukemia, Myeloid, Acute
Multiple resistance mechanisms in acute nonlymphoblastic leukemia (ANLL).
Leukemia, Myeloid, Acute
No influence of 3435C>T ABCB1 (MDR1) gene polymorphism on risk of adult acute myeloid leukemia and P-glycoprotein expression in blast cells.
Leukemia, Myeloid, Acute
Novel mechanisms of drug resistance in leukemia.
Leukemia, Myeloid, Acute
Overexpression of lung resistance-related protein and P-glycoprotein and response to induction chemotherapy in acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Overexpression of the ABCB1 drug transporter in acute myeloid leukemia cells is associated with downregulation of latrophilin-1.
Leukemia, Myeloid, Acute
Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A.
Leukemia, Myeloid, Acute
P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation.
Leukemia, Myeloid, Acute
P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML).
Leukemia, Myeloid, Acute
P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.
Leukemia, Myeloid, Acute
P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups.
Leukemia, Myeloid, Acute
P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
Leukemia, Myeloid, Acute
P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: Biological and prognosis implications.
Leukemia, Myeloid, Acute
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia.
Leukemia, Myeloid, Acute
P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Leukemia, Myeloid, Acute
P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia.
Leukemia, Myeloid, Acute
P-glycoprotein expression in acute myeloblastic leukemia analyzed by immunocytochemistry and flow cytometry.
Leukemia, Myeloid, Acute
P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome.
Leukemia, Myeloid, Acute
P-glycoprotein expression in de novo acute myeloid leukemia.
Leukemia, Myeloid, Acute
P-glycoprotein in acute nonlymphoblastic leukemia and in the blastic crisis of myeloid leukemia.
Leukemia, Myeloid, Acute
P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy.
Leukemia, Myeloid, Acute
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
Leukemia, Myeloid, Acute
P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
Leukemia, Myeloid, Acute
P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway.
Leukemia, Myeloid, Acute
P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway.
Leukemia, Myeloid, Acute
P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
Leukemia, Myeloid, Acute
Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.
Leukemia, Myeloid, Acute
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
Leukemia, Myeloid, Acute
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
Polymorphisms of ABCG2 and its impact on clinical relevance.
Leukemia, Myeloid, Acute
Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis.
Leukemia, Myeloid, Acute
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Leukemia, Myeloid, Acute
Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC.
Leukemia, Myeloid, Acute
Prognostic markers in acute leukemia.
Leukemia, Myeloid, Acute
Prognostic relevance of P-glycoprotein expression in breast cancer.
Leukemia, Myeloid, Acute
Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy.
Leukemia, Myeloid, Acute
Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.
Leukemia, Myeloid, Acute
Quantitative analysis of P-glycoprotein, bcl-2 and transferrin receptor allows the stratification of acute myeloid leukemia patients within different prognostic risk classes.
Leukemia, Myeloid, Acute
Rapid induction of P-glycoprotein mRNA and protein expression by cytarabine in HL-60 cells.
Leukemia, Myeloid, Acute
Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
Leukemia, Myeloid, Acute
Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Resistance factors and proliferative activity in childhood acute nonlymphoblastic leukemia.
Leukemia, Myeloid, Acute
Reversal of chemoresistance with small interference RNA (siRNA) in etoposide resistant acute myeloid leukemia cells (HL-60).
Leukemia, Myeloid, Acute
Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng.
Leukemia, Myeloid, Acute
Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure.
Leukemia, Myeloid, Acute
Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials.
Leukemia, Myeloid, Acute
Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses.
Leukemia, Myeloid, Acute
Simultaneous expression of P-glycoprotein and BCL-2 in acute myeloid leukemia blast cells.
Leukemia, Myeloid, Acute
Simultaneous measurement of cellular P-glycoprotein content and function by multiparametric flow-cytometry.
Leukemia, Myeloid, Acute
Suppression Of Aberrant Activation Of NF-?B Pathway In Drug-resistant Leukemia Stem Cells Contributes To Parthenolide-potentiated Reversal Of Drug Resistance In Leukemia.
Leukemia, Myeloid, Acute
Targeted nanopore sequencing for the identification of ABCB1 promoter translocations in cancer.
Leukemia, Myeloid, Acute
Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia.
Leukemia, Myeloid, Acute
The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Leukemia, Myeloid, Acute
The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype.
Leukemia, Myeloid, Acute
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
Leukemia, Myeloid, Acute
Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
Leukemia, Myeloid, Acute
Upregulation of miR-142-3p Improves Drug Sensitivity of Acute Myelogenous Leukemia through Reducing P-Glycoprotein and Repressing Autophagy by Targeting HMGB1.
Leukemia, Myeloid, Acute
Validation and clinical implication of a quantitative real-time PCR determination of MDR1 gene expression: comparison with semi-quantitative PCR in 101 patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
Vincristine-induced expression of P-glycoprotein in MOLM-13 and SKM-1 acute myeloid leukemia cell lines is associated with coexpression of nestin transcript.
Leukemia, Myeloid, Acute
Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).
Leukemia, Myeloid, Acute
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled, trial of the Eastern Cooperative Oncology Group (ECOG 3999).
Leukemia, Myeloid, Acute
[Analysis of molecular mechanism involved in development of acute myeloid leukemia].
Leukemia, Myeloid, Acute
[Cytocidal effects of gemtuzumab ozogamicin (CMA-676) on CD33-expressing acute myeloid leukemia cells, analysis P-glycoprotein and CD34 expression]
Leukemia, Myeloid, Acute
[Expression of lung resistance protein and multidrug resistance protein genes in bone marrow cells of acute leukemia patients and its clinical significance]
Leukemia, Myeloid, Acute
[Expression of lung resistance protein and multidrug resistance-associated protein in naive childhood acute leukemia and their clinical significance]
Leukemia, Myeloid, Acute
[Immunophenotype and P-glycoprotein expression in CD7 positive adult acute myeloid leukemia]
Leukemia, Myeloid, Acute
[Multidrug resistance markers monitoring in acute myeloid leukemia cells]
Leukemia, Myeloid, Acute
[Multidrug resistance mediated by membrane P-glycoprotein in acute myeloid leukemia]
Leukemia, Myeloid, Acute
[Multidrug resistant P-glycoprotein expression on acute nonlymphocytic leukemia cells at diagnosis]
Leukemia, Myeloid, Acute
[P-glycoprotein expression in hematological malignancies]
Leukemia, Myeloid, Acute
[P-glycoprotein expression in radiation-associated acute myeloid leukemia]
Leukemia, Myeloid, Acute
[Predictive value of intracellular accumulation of daunorubicin and P-glycoprotein expression simultaneously determined by flow cytometry in adult acute myeloid leukemias]
Leukemia, Myeloid, Acute
[The clinical and biological significance of P-glycoprotein expression in acute nonlymphocytic leukemia]
Leukemia, Myeloid, Acute
[The clinical significance of lung resistance-related protein gene (lrp), multidrug resistance-associated protein gene (mrp) and mdr-1/p170 expression in acute leukemia]
Leukemia, Myeloid, Acute
[The relationship between expression of lung resistance-related protein gene or multidrug resistance-associated protein gene and prognosis in newly diagnosed acute leukemia]
Leukemia, Promyelocytic, Acute
All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance.
Leukemia, Promyelocytic, Acute
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
Leukemia, Promyelocytic, Acute
Identification and characterization of a phenyl-thiazolyl-benzoic acid derivative as a novel RAR/RXR agonist.
Leukemia, Promyelocytic, Acute
P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells.
Leukemia, Promyelocytic, Acute
Proapoptotic activity and ABCC1-related multidrug resistance reduction ability of semisynthetic oleanolic acid derivatives DIOXOL and HIMOXOL in human acute promyelocytic leukemia cells.
Leukemia, Promyelocytic, Acute
Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses.
Leukemia, Promyelocytic, Acute
Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent.
Leukemia, Promyelocytic, Acute
[Apoptosis of MR2 cells induced by Tanshinone II A combined with arsenic trioxide]
Leukemia, T-Cell
In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants.
Leukemia, T-Cell
Modulation of P-glycoprotein-Mediated Anticancer Drug Accumulation, Cytotoxicity, and ATPase Activity by Flavonoid Interactions.
Leukemia-Lymphoma, Adult T-Cell
Expression of P-glycoprotein in adult T-cell leukemia cells.
Leukemia-Lymphoma, Adult T-Cell
Prognostic significance of multidrug resistance protein in adult T-cell leukemia.
Leukocytosis
Analysis of gene expression profiles in human HL-60 cell exposed to cantharidin using cDNA microarray.
Leukocytosis
[Immunophenotype and P-glycoprotein expression in CD7 positive adult acute myeloid leukemia]
Leukopenia
Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy.
Leukopenia
Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.
Leukopenia
Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers.
Leukopenia
Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.
Leukopenia
Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients.
Leukopenia
Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer.
Leukopenia
Retrovirus-mediated gene transfer of the human multidrug resistance-associated protein into hematopoietic cells protects mice from chemotherapy-induced leukopenia.
Leukopenia
Susceptibility to 6-mercaptopurine toxicity related with NUDT15 and ABCC4 variants in Japanese childhood acute lymphoblastic leukemia.
Leukopenia
The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia.
Leukopenia
Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance.
Lichen Planus
ABCB1 in dermatology: roles in skin diseases and their treatment.
Lichen Planus
Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts.
Lichen Planus, Oral
P-glycoprotein expression in oral lichen planus.
Lichen Planus, Oral
Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus.
Liposarcoma
Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas.
Listeriosis
Two novel genes FIND and LIND differentially expressed in deactivated and Listeria-infected human macrophages.
Liver Cirrhosis
Coordinated Targeting of Galanin Receptors on Cholangiocytes and Hepatic Stellate Cells Ameliorates Liver Fibrosis in Multidrug Resistance Protein 2 Knockout Mice.
Liver Cirrhosis
Effects of liver fibrosis on verapamil pharmacokinetics in rats.
Liver Cirrhosis
Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis.
Liver Cirrhosis
Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension.
Liver Cirrhosis
Pre-Hepatectomy Assessment of Bile Transporter Expression by Gadoxetic Acid-Enhanced MRI in a Rat Model of Liver Cirrhosis.
Liver Cirrhosis
Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model.
Liver Cirrhosis
Vitamin D modulates biliary fibrosis in ABCB4-deficient mice.
Liver Cirrhosis
[Expression of breast cancer resistance protein in liver cirrhosis, hepatocellular carcinoma and peritumoral tissues.]
Liver Cirrhosis, Biliary
A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus.
Liver Cirrhosis, Biliary
BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis.
Liver Cirrhosis, Biliary
Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis.
Liver Cirrhosis, Biliary
Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases.
Liver Cirrhosis, Biliary
Influence of biliary cirrhosis on the detoxification and elimination of a food derived carcinogen.
Liver Cirrhosis, Biliary
Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers.
Liver Cirrhosis, Biliary
Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis.
Liver Cirrhosis, Biliary
Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis.
Liver Diseases
A Heterozygous ABCB4, RUNDC3B, and ABCB1 Deletion Associated With Severe Cholestatic Liver Disease in Adulthood.
Liver Diseases
A predictive model for non-completion of an intensive specialist obesity service in a public hospital: a case-control study.
Liver Diseases
ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate.
Liver Diseases
Adaptive response to increased bile acids: induction of MDR1 gene expression and P-glycoprotein activity in renal epithelial cells.
Liver Diseases
Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2.
Liver Diseases
Bone marrow transplantation results in donor-derived hepatocytes in an animal model of inherited cholestatic liver disease.
Liver Diseases
Changes in digoxin pharmacokinetics associated with hepatic P-glycoprotein upregulation in rats with non-alcoholic fatty liver disease.
Liver Diseases
Clinical characteristics and ABCC2 genotype in Dubin-Johnson syndrome: A case report and review of the literature.
Liver Diseases
Colchicine and the heart.
Liver Diseases
Deleterious Variants in ABCC12 are Detected in Idiopathic Chronic Cholestasis and Cause Intrahepatic Bile Duct Loss in Model Organisms.
Liver Diseases
Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib.
Liver Diseases
Disturbed colocalization of multidrug resistance protein 2 and radixin in human cholestatic liver diseases.
Liver Diseases
Drug interactions: a primer for the gastroenterologist.
Liver Diseases
Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene.
Liver Diseases
Expression of genes involved in xenobiotic metabolism and transport in end-stage liver disease: up-regulation of ABCC4 and CYP1B1.
Liver Diseases
Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis.
Liver Diseases
Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.
Liver Diseases
Hydrophilic bile acids prevent liver damage caused by lack of biliary phospholipid in Mdr2-/- mice.
Liver Diseases
Liver disease associated with canalicular transport defects: current and future therapies.
Liver Diseases
Mechanism for the prevention of cholestasis involving cytochrome P4503A overexpression.
Liver Diseases
Medication-Related Problems in Older People with Multimorbidity in Catalonia: A Real-World Data Study with 5 Years' Follow-Up.
Liver Diseases
Modeling hepatic osteodystrophy in Abcb4 deficient mice.
Liver Diseases
Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease.
Liver Diseases
Regulation of organic anion transport in the liver.
Liver Diseases
Role of ERK1/2 in TNF?-induced internalization of Abcc2 in rat hepatocyte couplets.
Liver Diseases
Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes.
Liver Diseases
Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease.
Liver Diseases
Why are patients with liver disease jaundiced? ATP-binding cassette transporter expression in human liver disease.
Liver Diseases
[Abnormal expression of circulating nuclear factor-?B in hepatocellular carcinoma and reversal of multidrug resistance through intervening its gene transcription].
Liver Diseases
[Paracetamol overdose and experimental cholestasis induced gene expression regulation that codified P-Glycoprotein type 1 in rats]
Liver Failure
Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the -1774delG polymorphism in the Abcc2 gene.
Liver Failure
Hyperammonemia enhances the function and expression of P-glycoprotein and Mrp2 at the blood-brain barrier through NF-?B.
Liver Failure
Increase in P-glycoprotein levels in the blood-brain barrier of partial portal vein ligation /chronic hyperammonemia rats is medicated by ammonia/reactive oxygen species/ERK1/2 activation: In vitro and in vivo studies.
Liver Failure
Liver transplantation in children with progressive familial intrahepatic cholestasis.
Liver Failure
Tienilic acid enhances hyperbilirubinemia in Eisai hyperbilirubinuria rats through hepatic multidrug resistance-associated protein 3 and heme oxygenase-1 induction.
Liver Failure
Unconjugated bilirubin elevation impairs the function and expression of breast cancer resistance protein (BCRP) at the blood-brain barrier in bile duct-ligated rats.
Liver Failure, Acute
Acute liver failure impairs function and expression of breast cancer-resistant protein (BCRP) at rat blood-brain barrier partly via ammonia-ROS-ERK1/2 activation.
Liver Failure, Acute
Altered Function and Expression of ABC Transporters at the Blood-Brain Barrier and Increased Brain Distribution of Phenobarbital in Acute Liver Failure Mice.
Liver Failure, Acute
Differential effect of acute hepatic failure on in vivo and in vitro P-glycoprotein functions in the intestine.
Liver Failure, Acute
Expression and function of P-glycoprotein in rats with carbon tetrachloride-induced acute hepatic failure.
Liver Failure, Acute
Factors affecting the expression and function of P-glycoprotein in rats: drug treatments and diseased states.
Liver Failure, Acute
Function of multidrug resistance-associated protein 2 in acute hepatic failure rats.
Liver Failure, Acute
P-glycoprotein and multidrug resistance-associated protein 2 are oppositely altered in brain of rats with thioacetamide-induced acute liver failure.
Liver Neoplasms
A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells.
Liver Neoplasms
C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells.
Liver Neoplasms
Correlation of expression of multidrug resistance protein and messenger RNA with 99mTc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma.
Liver Neoplasms
Effect of PSC 833, an inhibitor of P-glycoprotein, on 1,2-dimethylhydrazine-induced liver carcinogenesis in rats.
Liver Neoplasms
Enhanced Photothermal-Photodynamic Therapy by Indocyanine Green and Curcumin-Loaded Layered MoS2 Hollow Spheres via Inhibition of P-Glycoprotein.
Liver Neoplasms
Evaluation of TPGS-modified thermo-sensitive Pluronic PF127 hydrogel as a potential carrier to reverse the resistance of P-gp-overexpressing SMMC-7721 cell lines.
Liver Neoplasms
Expression of Multi-drug Resistance-Related Genes MDR3 and MRP as Prognostic Factors in Clinical Liver Cancer Patients.
Liver Neoplasms
Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
Liver Neoplasms
Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling.
Liver Neoplasms
Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms.
Liver Neoplasms
Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes.
Liver Neoplasms
MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells.
Liver Neoplasms
Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line.
Liver Neoplasms
Nude mice multi-drug resistance model of orthotopic transplantation of liver neoplasm and Tc-99m MIBI SPECT on p-glycoprotein.
Liver Neoplasms
Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway.
Liver Neoplasms
Positive Correlation of Oct4 and ABCG2 to Chemotherapeutic Resistance in CD90(+)CD133(+) Liver Cancer Stem Cells.
Liver Neoplasms
Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells.
Liver Neoplasms
The Chinese Herb Jianpijiedu Contributes to the Regulation of OATP1B2 and ABCC2 in a Rat Model of Orthotopic Transplantation Liver Cancer Pretreated with Food Restriction and Diarrhea.
Liver Neoplasms
The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells.
Liver Neoplasms
The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker.
Liver Neoplasms
Transport-Mediated Oxaliplatin Resistance Associated with Endogenous Overexpression of MRP2 in Caco-2 and PANC-1 Cells.
Liver Neoplasms
Veliparib overcomes multidrug resistance in liver cancer cells.
Liver Neoplasms
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster.
Liver Neoplasms, Experimental
Rat nucleolar 7-2 RNA is homologous to mouse mitochondrial RNase mitochondrial RNA-processing RNA.
Lung Diseases
Genetic basis of respiratory distress syndrome.
Lung Diseases
Imaging of activity of multidrug resistance-associated protein 1 in the lungs.
Lung Diseases
Ultrastructural and molecular analysis in fatal neonatal interstitial pneumonia caused by a novel ABCA3 mutation.
Lung Diseases
[Clinical analysis of heterozygous ABCA3 mutations in children].
Lung Diseases, Interstitial
Familial interstitial lung disease in two young Korean sisters.
Lung Diseases, Interstitial
Functional Characterization of ABCA3 Mutations from Infants with Respiratory Distress Syndrome.
Lung Diseases, Interstitial
Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Lung Diseases, Interstitial
Genotype-phenotype correlations for infants and children with ABCA3 deficiency.
Lung Injury
ABCG2pos lung mesenchymal stem cells are a novel pericyte subpopulation that contributes to fibrotic remodeling.
Lung Injury
Upregulation of Multidrug Resistance-Associated Protein 1 by Allyl Isothiocyanate in Human Bronchial Epithelial Cell: Involvement of c-Jun N-Terminal Kinase Signaling Pathway.
Lung Neoplasms
5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
Lung Neoplasms
6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer.
Lung Neoplasms
9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance.
Lung Neoplasms
?-elemene reverses the drug resistance of A549/DDP lung cancer cells by activating intracellular redox system, decreasing mitochondrial membrane potential and P-glycoprotein expression, and inducing apoptosis.
Lung Neoplasms
A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene.
Lung Neoplasms
A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.
Lung Neoplasms
A leukotriene receptor antagonist, ONO-1078, modulates drug sensitivity and leukotriene C4 efflux in lung cancer cells expressing multidrug resistance protein.
Lung Neoplasms
A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer.
Lung Neoplasms
A meta-analysis of ABCG2 gene polymorphism and non-small cell lung cancer outcomes.
Lung Neoplasms
A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene.
Lung Neoplasms
A pharmacogenetics study of platinum-based chemotherapy in lung cancer: ABCG2 polymorphism and its genetic interaction with SLC31A1 are associated with response and survival.
Lung Neoplasms
A potentially functional polymorphism in ABCG2 predicts clinical outcome of non-small cell lung cancer in a Chinese population.
Lung Neoplasms
ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling.
Lung Neoplasms
ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy.
Lung Neoplasms
ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.
Lung Neoplasms
ABCC3 as a marker for multidrug resistance in non-small cell lung cancer.
Lung Neoplasms
ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer.
Lung Neoplasms
ABCG2 localizes to the nucleus and modulates CDH1 expression in lung cancer cells.
Lung Neoplasms
ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines.
Lung Neoplasms
ABCG2-associated resistance to Hoechst 33342 and topotecan in a murine cell model with constitutive expression of side population characteristics.
Lung Neoplasms
Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.
Lung Neoplasms
Activity and mechanism of flavokawain A in inhibiting P-glycoprotein expression in paclitaxel resistance of lung cancer.
Lung Neoplasms
Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer.
Lung Neoplasms
Adenovirus vector infection of non-small-cell lung cancer cells is a trigger for multi-drug resistance mediated by P-glycoprotein.
Lung Neoplasms
Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
Lung Neoplasms
Amplification and expression of mdr1 gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69.
Lung Neoplasms
Amplification of the ABCB1 region accompanied by a short sequence of 200bp from chromosome 2 in lung cancer cells.
Lung Neoplasms
An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
Lung Neoplasms
Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells.
Lung Neoplasms
Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines.
Lung Neoplasms
Anti-proliferative activity and suppression of P-glycoprotein by (-)-antofine, a natural phenanthroindolizidine alkaloid, in paclitaxel-resistant human lung cancer cells.
Lung Neoplasms
Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias.
Lung Neoplasms
Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.
Lung Neoplasms
Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
Lung Neoplasms
Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer.
Lung Neoplasms
Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.
Lung Neoplasms
Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
Lung Neoplasms
Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.
Lung Neoplasms
Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer.
Lung Neoplasms
Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis.
Lung Neoplasms
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Lung Neoplasms
ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.
Lung Neoplasms
Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs.
Lung Neoplasms
Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.
Lung Neoplasms
Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Lung Neoplasms
Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer.
Lung Neoplasms
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.
Lung Neoplasms
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.
Lung Neoplasms
C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Lung Neoplasms
Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model.
Lung Neoplasms
Camptothecin and cisplatin upregulate ABCG2 and MRP2 expression by activating the ATM/NF-?B pathway in lung cancer cells.
Lung Neoplasms
Cariprazine, A Dopamine D?/D? Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer.
Lung Neoplasms
cDNA cloning of a short type of multidrug resistance protein homologue, SMRP, from a human lung cancer cell line.
Lung Neoplasms
Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell.
Lung Neoplasms
Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein.
Lung Neoplasms
Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery.
Lung Neoplasms
Circular RNAcirc_0076305 Promotes Cisplatin (DDP) Resistance of Non-Small Cell Lung Cancer Cells by Regulating ABCC1 Through miR-186-5p.
Lung Neoplasms
Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil.
Lung Neoplasms
Cisplatin in 5% Ethanol Eradicates Cisplatin-Resistant Lung Tumor by Killing Lung Cancer Side Population (SP) Cells and Non-SP Cells.
Lung Neoplasms
Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
Lung Neoplasms
Clinical Significance of p53, P-glycoprotein, and Glutathione S transferase-pi in Advanced Non-Small Cell Lung Cancer.
Lung Neoplasms
Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.
Lung Neoplasms
Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
Lung Neoplasms
Co-delivery of cisplatin and siRNA through hybrid nanocarrier platform for masking resistance to chemotherapy in lung cancer.
Lung Neoplasms
Co-transfection of MDR1 and MRP antisense RNAs abolishes the drug resistance in multidrug-resistant human lung cancer cells.
Lung Neoplasms
Co-transfection of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells.
Lung Neoplasms
Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.
Lung Neoplasms
Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer.
Lung Neoplasms
Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer.
Lung Neoplasms
Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.
Lung Neoplasms
Comprehensive evaluation of the response of genes to the administration of the antitumor drug S-1 using a low density array.
Lung Neoplasms
Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells.
Lung Neoplasms
Cytotoxic action of cyclosporins on human tumor cell lines is not dependent on immunosuppressive activity.
Lung Neoplasms
Danggui Buxue Decoction Sensitizes the Response of Non-Small-Cell Lung Cancer to Gemcitabine via Regulating Deoxycytidine Kinase and P-glycoprotein.
Lung Neoplasms
Deficiency of Functional Iron-Sulfur Domains in ABCE1 Inhibits the Proliferation and Migration of Lung Adenocarcinomas By Regulating the Biogenesis of Beta-Actin In Vitro.
Lung Neoplasms
Deoxyshikonin inhibits cisplatin resistance of non-small-cell lung cancer cells by repressing Akt-mediated ABCB1 expression and function.
Lung Neoplasms
Design, synthesis, and evaluation of a water-soluble antofine analogue with high antiproliferative and antitumor activity.
Lung Neoplasms
Detection of putative cancer stem cells of the side population phenotype in human tumor cell cultures.
Lung Neoplasms
Development of a double-layer microfluidic chip with flow medium for chemotherapy resistance analysis of lung cancer.
Lung Neoplasms
Development of a shear force scanning near-field fluorescence microscope for biological applications.
Lung Neoplasms
Development of a dry powder for inhalation of nanoparticles codelivering cisplatin and ABCC3 siRNA in lung cancer.
Lung Neoplasms
Differentiation of the P-gp and MRP1 multidrug resistance systems by mobile lipid 1H-NMR spectroscopy and phosphatidylserine externalization.
Lung Neoplasms
DNA Methylation of DKK3 Modulates Docetaxel Chemoresistance in Human Nonsmall Cell Lung Cancer Cell.
Lung Neoplasms
Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines.
Lung Neoplasms
Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.
Lung Neoplasms
Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway.
Lung Neoplasms
Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.
Lung Neoplasms
Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer.
Lung Neoplasms
Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.
Lung Neoplasms
Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.
Lung Neoplasms
E2F1 drives chemotherapeutic drug resistance via ABCG2.
Lung Neoplasms
Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line.
Lung Neoplasms
Effect of 5-FU and MTX on the Expression of Drug-resistance Related Cancer Stem Cell Markers in Non-small Cell Lung Cancer Cells.
Lung Neoplasms
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
Lung Neoplasms
Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.
Lung Neoplasms
Effects of OPRM1 and ABCB1 gene polymorphisms on the analgesic effect and dose of sufentanil after thoracoscopic-assisted radical resection of lung cancer.
Lung Neoplasms
Effects of tetramethylpiperidine (TMP)-substituted phenazines on membrane stability and P-glycoprotein function.
Lung Neoplasms
Efficacy of Aidi Injection () on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with non-small cell lung cancer.
Lung Neoplasms
EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.
Lung Neoplasms
Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer.
Lung Neoplasms
Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line.
Lung Neoplasms
Elevated Expression of Nrf-2 and ABCG2 Involved in Multi-drug Resistance of Lung Cancer SP Cells.
Lung Neoplasms
Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.
Lung Neoplasms
Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system.
Lung Neoplasms
Entinostat reverses P-glycoprotein activation in snail-overexpressing adenocarcinoma HCC827 cells.
Lung Neoplasms
Erratum to: RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China.
Lung Neoplasms
Evaluation of chemotherapy response in patients with small cell lung cancer using Technetium-99m-tetrofosmin.
Lung Neoplasms
Experimental and clinical observations of 99mTc-MIBI uptake correlate with P-glycoprotein expression in lung cancer.
Lung Neoplasms
Expression and functional analyses of breast cancer resistance protein in lung cancer.
Lung Neoplasms
Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.
Lung Neoplasms
Expression of drug resistance gene products during progression of lung carcinomas.
Lung Neoplasms
Expression of gamma-glutamylcysteine synthetase (gamma-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs.
Lung Neoplasms
Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
Lung Neoplasms
Expression of multidrug resistance protein and messenger RNA correlate with (99m)Tc-MIBI imaging in patients with lung cancer.
Lung Neoplasms
Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response.
Lung Neoplasms
Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells.
Lung Neoplasms
Expression of P-gp, MRP, LRP, GST-? and TopoII? and intrinsic resistance in human lung cancer cell lines.
Lung Neoplasms
Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer.
Lung Neoplasms
Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer.
Lung Neoplasms
Expression of the multidrug resistance gene (MDR1) in non-small cell lung cancer.
Lung Neoplasms
Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells.
Lung Neoplasms
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Lung Neoplasms
Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer.
Lung Neoplasms
Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer.
Lung Neoplasms
Expression of the multidrug resistance-associated protein 1 (MRP1) and the lung resistance-related protein (LRP) in human lung cancer.
Lung Neoplasms
Expressions of CD44, PCNA and MRP1 in lung cancer tissues and their effects on proliferation and invasion abilities of lung cancer cell line 95D.
Lung Neoplasms
Expressions of Topoisomerase II? and BCRP in Metastatic Cells are Associated with Overall Survival in Small Cell Lung Cancer Patients.
Lung Neoplasms
FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Lung Neoplasms
Functional Alterations of Multidrug Resistance-Associated Proteins 2 and 5, and Breast Cancer Resistance Protein upon Snail-Induced Epithelial-Mesenchymal Transition in HCC827 Cells.
Lung Neoplasms
Functional expression and characterization in Xenopus laevis oocytes of the ABCG2 transporter derived from A549 human lung adenocarcinoma cells.
Lung Neoplasms
Genetic susceptibility of lung cancer associated with common variants in the 3' untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export.
Lung Neoplasms
Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.
Lung Neoplasms
Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy.
Lung Neoplasms
Growth inhibitory effects of antifolates against an adriamycin-resistant human small cell lung cancer cell line.
Lung Neoplasms
Guanosine-induced decrease in side population of lung cancer cells: lack of correlation with ABCG2 expression.
Lung Neoplasms
Heterogeneity of multiorgan metastases of human lung cancer cells genetically engineered to produce cytokines and reversal using chimeric monoclonal antibodies in natural killer cell-depleted severe combined immunodeficient mice.
Lung Neoplasms
Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line.
Lung Neoplasms
Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2.
Lung Neoplasms
Imaging of P-glycoprotein of H69/VP small-cell lung cancer lines by scanning near-field optical microscopy and confocal laser microspectrofluorometer.
Lung Neoplasms
Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
Lung Neoplasms
Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung.
Lung Neoplasms
Immunohistochemical detection of P-glycoprotein and carcinoembryonic antigen in small cell lung cancer: with reference to predictability of response to chemotherapy.
Lung Neoplasms
Immunohistochemical detection of P-glycoprotein in human tumor cells with a low degree of drug resistance.
Lung Neoplasms
Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival.
Lung Neoplasms
Immunohistochemical study of P-glycoprotein distribution in lung cancer.
Lung Neoplasms
Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung.
Lung Neoplasms
Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer.
Lung Neoplasms
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
Lung Neoplasms
Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients.
Lung Neoplasms
Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Lung Neoplasms
Improved flow-cytometric detection of low P-glycoprotein expression in leukaemic blasts by histogram subtraction analysis.
Lung Neoplasms
In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
Lung Neoplasms
Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
Lung Neoplasms
Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer.
Lung Neoplasms
Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer.
Lung Neoplasms
Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell lines.
Lung Neoplasms
Infection of H69AR cells with retroviral particles harboring interfering RNAi significantly reduced the multidrug resistance of these small cell lung cancer cells.
Lung Neoplasms
Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer.
Lung Neoplasms
Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Lung Neoplasms
Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells.
Lung Neoplasms
Inhibition of multidrug resistance-associated protein (MRP) activity by rifampicin in human multidrug-resistant lung tumor cells.
Lung Neoplasms
Inhibitory effect of Ubenimex combined with fluorouracil on multiple drug resistance and P-glycoprotein expression level in non-small lung cancer.
Lung Neoplasms
Integrin-Linked Kinase, Snail and Multidrug Resistance Protein 1: Three concordant players in the progression of non-small cell lung cancer.
Lung Neoplasms
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Lung Neoplasms
Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2.
Lung Neoplasms
Intracellular ATP-binding cassette transporter A3 is expressed in lung cancer cells and modulates susceptibility to cisplatin and paclitaxel.
Lung Neoplasms
Inverse correlation between 99mTc-tetrofosmin uptake and P-glycoprotein in non-small cell lung cancer.
Lung Neoplasms
Itraconazole Alters the Stem Cell Characteristics of A549 and NCI-H460 Human Lung Cancer Cells by Suppressing Wnt Signaling.
Lung Neoplasms
Kinetics of glutathione and daunorubicin efflux from multidrug resistance protein overexpressing small-cell lung cancer cells.
Lung Neoplasms
KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer.
Lung Neoplasms
L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines.
Lung Neoplasms
Lack of expression of P-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients.
Lung Neoplasms
Lipid-like trifunctional block copolymers of ethylene oxide and propylene oxide: effective and cytocompatible modulators of intracellular drug delivery.
Lung Neoplasms
Long non-coding RNA FOXF1 adjacent non-coding developmental regulatory RNA inhibits growth and chemotherapy resistance in non-small cell lung cancer.
Lung Neoplasms
Long-term PM2.5 exposure increases the risk of non-small cell lung cancer (NSCLC) progression by enhancing interleukin-17a (IL-17a)-regulated proliferation and metastasis.
Lung Neoplasms
Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Lung Neoplasms
Low Molecular Weight Heparin Ablates Lung Cancer Cisplatin-Resistance by Inducing Proteasome-Mediated ABCG2 Protein Degradation.
Lung Neoplasms
Lung cancer stem cells-origin, characteristics and therapy.
Lung Neoplasms
Lung resistance protein and multidrug resistance protein in non-small cell lung cancer and their clinical significance.
Lung Neoplasms
Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity.
Lung Neoplasms
Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells.
Lung Neoplasms
MICA enhances sensitivity to cisplatin in patients with extensive small cell lung cancer via downregulation of ABCG2.
Lung Neoplasms
MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1.
Lung Neoplasms
MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer.
Lung Neoplasms
MicroRNA-mediated suppression of P-glycoprotein by quantum dots in lung cancer cells.
Lung Neoplasms
miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1.
Lung Neoplasms
Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP).
Lung Neoplasms
Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
Lung Neoplasms
Moesin-Mediated P-Glycoprotein Activation during Snail-Induced Epithelial-Mesenchymal Transition in Lung Cancer Cells.
Lung Neoplasms
Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Lung Neoplasms
MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs.
Lung Neoplasms
MRP1 modulation by PAK-104P: detection with technetium-99m-MIBI in cultured lung tumor cells.
Lung Neoplasms
MRP1/ABCC1 polymorphism Arg723Gln (2168G>A) is associated with lung cancer susceptibility in Chinese population.
Lung Neoplasms
MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.
Lung Neoplasms
Multidrug resistance genes (MRP) and MDR1 expression in small cell lung cancer xenografts: relationship with response to chemotherapy.
Lung Neoplasms
Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease.
Lung Neoplasms
Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.
Lung Neoplasms
Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport.
Lung Neoplasms
Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively.
Lung Neoplasms
Multidrug resistance proteins and other drug transport-related resistance to natural product agents.
Lung Neoplasms
Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels.
Lung Neoplasms
Multidrug resistance related genes and p53 expression in human non small cell lung cancer.
Lung Neoplasms
Multidrug resistance-associated protein (MRP) gene expression in human lung cancer.
Lung Neoplasms
Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC).
Lung Neoplasms
Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer.
Lung Neoplasms
Multidrug resistance-associated protein gene expression and drug sensitivity in human lung cancer cells.
Lung Neoplasms
Negative Regulation of PTEN by MicroRNA-221 and Its Association with Drug Resistance and Cellular Senescence in Lung Cancer Cells.
Lung Neoplasms
New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.
Lung Neoplasms
Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line.
Lung Neoplasms
Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
Lung Neoplasms
Over-expression of MDR1 in amrubicinol-resistant lung cancer cells.
Lung Neoplasms
Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors.
Lung Neoplasms
P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement.
Lung Neoplasms
P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer.
Lung Neoplasms
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Lung Neoplasms
P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo.
Lung Neoplasms
p53 and P-glycoprotein expression do not correlate with survival in nonsmall cell lung cancer: a long-term study and literature review.
Lung Neoplasms
Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II. Ability to reverse the drug-resistance of H460 human lung cancer cells.
Lung Neoplasms
Paclitaxel-Based chemotherapy for non-small cell lung cancer: predicting the response with 99mTc-tetrofosmin chest imaging.
Lung Neoplasms
Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer.
Lung Neoplasms
Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer.
Lung Neoplasms
Peripheral blood mononuclear cells express antigens associated with multidrug resistance in a small cell lung cancer cell line.
Lung Neoplasms
Perturbation of membrane microdomains in GLC4 multidrug-resistant lung cancer cells--modification of ABCC1 (MRP1) localization and functionality.
Lung Neoplasms
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
Lung Neoplasms
Placental isoform glutathione S-transferase and P-glycoprotein expression in advanced nonsmall cell lung cancer: association with response to treatment and survival.
Lung Neoplasms
Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients.
Lung Neoplasms
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Lung Neoplasms
Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells.
Lung Neoplasms
Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells.
Lung Neoplasms
Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (> T2). Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein express ion.
Lung Neoplasms
Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression.
Lung Neoplasms
Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy.
Lung Neoplasms
Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung.
Lung Neoplasms
Prognostic role of multidrug resistance-associated protein 1 expression and platelet count in operable non-small cell lung cancer.
Lung Neoplasms
Prognostic significance of miR-23b in combination with P-gp, MRP and LRP/MVP expression in non-small cell lung cancer.
Lung Neoplasms
Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
Lung Neoplasms
Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients' overall survival.
Lung Neoplasms
Pulmonary expression of CYP2A13 and ABCB1 is regulated by FOXA2 and their genetic interaction is associated with lung cancer.
Lung Neoplasms
Pyrimido[1?,2?:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
Lung Neoplasms
Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography.
Lung Neoplasms
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Lung Neoplasms
Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line.
Lung Neoplasms
RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China.
Lung Neoplasms
Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer.
Lung Neoplasms
Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides.
Lung Neoplasms
Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression.
Lung Neoplasms
Reversal effect of stephania tetrandra-containing Chinese herb formula SENL on multidrug resistance in lung cancer cell line SW1573/2R120.
Lung Neoplasms
Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
Lung Neoplasms
Reverse of non-small cell lung cancer drug resistance induced by cancer-associated fibroblasts via a paracrine pathway.
Lung Neoplasms
Riboflavin concentration within ABCG2-rich extracellular vesicles is a novel marker for multidrug resistance in malignant cells.
Lung Neoplasms
Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer.
Lung Neoplasms
Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Lung Neoplasms
Secalonic acid D reduced the percentage of side populations by down-regulating the expression of ABCG2.
Lung Neoplasms
Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells.
Lung Neoplasms
Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells.
Lung Neoplasms
SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p.
Lung Neoplasms
Sodium butyrate increases P-gp expression in lung cancer by upregulation of STAT3 and mRNA stabilization of ABCB1.
Lung Neoplasms
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
Lung Neoplasms
Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
Lung Neoplasms
Strategies to inhibit ABCB1- and ABCG2-mediated efflux transport of erlotinib at the blood-brain barrier: a PET study in non-human primates.
Lung Neoplasms
Structural, mechanistic and clinical aspects of MRP1.
Lung Neoplasms
Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells.
Lung Neoplasms
Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21?-Methylmelianodiol in Lung Cancer Cells.
Lung Neoplasms
Suppression of NF-?B signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin -induced apoptosis in lung cancer.
Lung Neoplasms
Targeting Multidrug Resistance Protein 1 (MRP1, ABCC1): Past, Present, and Future.
Lung Neoplasms
Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression.
Lung Neoplasms
Technetium-99m tetrofosmin chest imaging related to p-glycoprotein expression for predicting the response with paclitaxel-based chemotherapy for non-small cell lung cancer.
Lung Neoplasms
Technetium-99m tetrofosmin SPECT predicts chemotherapy response in small cell lung cancer.
Lung Neoplasms
Technetium-99m-hexakis-2-methoxyisobutylisonitrile scintigraphy and multidrug resistance-related protein expression in human primary lung cancer.
Lung Neoplasms
Technetium-99m-tetrofosmin scintigraphy, P-glycoprotein and lung cancer.
Lung Neoplasms
Tetramethylpiperidine-substitution increases the antitumor activity of the riminophenazines for an acquired multidrug-resistant cell line.
Lung Neoplasms
The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line.
Lung Neoplasms
The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.
Lung Neoplasms
The effect of CHRNA3 rs1051730 C>T and ABCB1 rs3842 A>G polymorphisms on non-small cell lung cancer and nicotine dependence in Iranian population.
Lung Neoplasms
The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model.
Lung Neoplasms
The impact of ABCB1 gene polymorphism and its expression on non-small-cell lung cancer development, progression and therapy - preliminary report.
Lung Neoplasms
The influence of a caveolin-1 mutant on the function of P-glycoprotein.
Lung Neoplasms
The Mechanisms of Yu Ping Feng San in Tracking the Cisplatin-Resistance by Regulating ATP-Binding Cassette Transporter and Glutathione S-Transferase in Lung Cancer Cells.
Lung Neoplasms
The P-glycoprotein-related gene family in Leishmania.
Lung Neoplasms
The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome.
Lung Neoplasms
The side population in human lung cancer cell line NCI-H460 is enriched in stem-like cancer cells.
Lung Neoplasms
The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
Lung Neoplasms
The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells.
Lung Neoplasms
The use of simultaneous confidence bands for comparison of single parameter fluorescent intensity data.
Lung Neoplasms
Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
Lung Neoplasms
Tip60-siRNA regulates ABCE1 acetylation to suppress lung cancer growth via activation of the apoptotic signaling pathway.
Lung Neoplasms
Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.
Lung Neoplasms
To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer.
Lung Neoplasms
To predict response chemotherapy using technetium-99m tetrofosmin chest images in patients with untreated small cell lung cancer and compare with p-glycoprotein, multidrug resistance related protein-1, and lung resistance-related protein expression.
Lung Neoplasms
Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters.
Lung Neoplasms
Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotype.
Lung Neoplasms
Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.
Lung Neoplasms
Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.
Lung Neoplasms
Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells.
Lung Neoplasms
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.
Lung Neoplasms
Upregulation of ABCG2 via the PI3K-Akt pathway contributes to acidic microenvironment-induced cisplatin resistance in A549 and LTEP-a-2 lung cancer cells.
Lung Neoplasms
Upregulation of COX-2 in the lung cancer promotes overexpression of multidrug resistance protein 4 (MRP4) via PGE2-dependent pathway.
Lung Neoplasms
Usefulness of 99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer.
Lung Neoplasms
Usefulness of tc-99m MIBI SPECT in predicting multidrug resistance gene expression levels in non-small cell lung cancer--a preliminary report.
Lung Neoplasms
Using technetium-99m methoxyisobutylisonitrile lung single-photon-emission computed tomography to predict response to chemotherapy and compare with P-glycoprotein expression in patients with untreated small cell lung cancer.
Lung Neoplasms
Van der Waals force-driven indomethacin-ss-paclitaxel nanodrugs for reversing multidrug resistance and enhancing NSCLC therapy.
Lung Neoplasms
Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
Lung Neoplasms
YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells.
Lung Neoplasms
[Clinical significance of multidrug resistance-associated protein(MRP) gene expression in non-small cell lung cancer]
Lung Neoplasms
[Compound matrine injection reduces morphine tolerance of the mice with lung cancer by inhibiting expression of multidrug resistance gene 1 and P-glycoprotein].
Lung Neoplasms
[Correlation between 99m Tc-tetrofosmin uptake and P-glycoprotein expression in non-small-cell lung cancer]
Lung Neoplasms
[Correlation of the uptake of technetium-99m methoxyisobutyl isonitrile with expression of multidrug resistance genes mdr-1 and MRP in human lung cancer]
Lung Neoplasms
[Development of drug resistance and alteration of cell cycle in lung cancer: a flow cytometric study]
Lung Neoplasms
[Differential expressions of MDR-1, RRM-1, EGFR and ERCC-1 in primary tumors and metastatic lymph nodes of NSCLC patients].
Lung Neoplasms
[Effect of supplement energy and nourish lung herbs on drug-resistance lung cancer with mechanisms of mitochondrial and caspase signal]
Lung Neoplasms
[Expression and Clinical Significance of ABCC10 in the Patients with Non-small Cell Lung Cancer.]
Lung Neoplasms
[Expression and prognostic significance of multidrug resistance associated protein (MRP) gene in non-small cell lung cancer by in situ hybridization]
Lung Neoplasms
[Expression and Significance of Stem Cell Markers CK19, Notch3, CD133, P75NTR, STRO-1 and ABCG2 in Pulmonary Squamous Carcinomas.]
Lung Neoplasms
[Expression of LRP, MRP and MDR1 in non-small-cell lung cancer and its clinical significance]
Lung Neoplasms
[Expression of MDR1-mRNA, MRP-mRNA and LRP-mRNA in patients with non-small cell lung cancer.]
Lung Neoplasms
[Expression of MRP gene in non-small cell lung cancer and its significance.]
Lung Neoplasms
[Expression of multidrug resistance-associated protein gene in non-small cell lung cancer]
Lung Neoplasms
[Expression of multidrug resistance-associated protein in human non-small cell lung cancer]
Lung Neoplasms
[Expression of multiple drug resistance-associated proteins in non-small cell lung cancer tissues and its clinical significance.]
Lung Neoplasms
[Expression of P-gp, MRP and p53 and their clinical significance in human lung cancer tissues.]
Lung Neoplasms
[Expression of PTEN, p53 and P-glycoprotein in Non-small cell Lung Cancer and Their Predictive Values.]
Lung Neoplasms
[Expression of serum breast drug-resistance protein in predicting chemosensitivity of NSCLC]
Lung Neoplasms
[Immunoelectron microscopic analysis of P-glycoprotein, p53, and Bcl-2 proteins expressions in lung cancer]
Lung Neoplasms
[Immunohistochemical detection of carcinoembryonic antigen and P-glycoprotein in small cell lung cancer at diagnosis and relapse, with special reference to the tissue expression of CEA and response to chemotherapy]
Lung Neoplasms
[Influences of PC cell-derived growth factor and breast cancer resistance protein on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer]
Lung Neoplasms
[Isolation and Biological Characterization of Lung Cancer Stem Cells].
Lung Neoplasms
[Modulation of human small cell lung cancer cell line GLC4/ADR multidrug resistance in the inhibition of multidrug resistance-associated protein and its antisense]
Lung Neoplasms
[MRP expression in non-small cell lung cancer and normal lung tissues and its prognostic significance.]
Lung Neoplasms
[Overexpression and its clinical significance of multi-drug resistance associated genes in lung cancer tissues.]
Lung Neoplasms
[Predictive value of drug resistance-related genes expression in neoadjuvant chemotherapy in patients with non-small cell lung cancer of stage III]
Lung Neoplasms
[Relationship between expression of apoptosis-related genes and multidrug resistance genes in lung cancer tissues and their clinical significance.]
Lung Neoplasms
[Relationships among expressions of hTERT, MDR1, MRP mRNA, and C-myc protein in non-small cell lung cancer.]
Lung Neoplasms
[Study on the relationship among multidrug resistance factor expression of lung cancer tissues and clinicopathological characteristics in patients with lung cancer.]
Lung Neoplasms
[The efflux of intracellular vincristine in drug-resistant human lung cancer cells is not mediated by P-glycoprotein]
Lung Neoplasms
[The expression of MRP gene relates to the pathological features of lung cancer]
Lung Neoplasms
[The relationship between drug sensitivity and expression of drug resistance gene mutations in non-small cell lung cancer]
Lupus Erythematosus, Cutaneous
The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells.
Lupus Erythematosus, Systemic
ABCB1 C1236T, G2677T/A and C3435T polymorphisms in systemic lupus erythematosus patients.
Lupus Erythematosus, Systemic
Clinical relevance of P-glycoprotein activity on peripheral blood mononuclear cells and polymorphonuclear neutrophils to methotrexate in systemic lupus erythematosus patients.
Lupus Erythematosus, Systemic
Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Detection of active P-glycoprotein in systemic lupus erythematosus patients with poor disease control.
Lupus Erythematosus, Systemic
Increased multidrug resistance-associated protein activity in mononuclear cells of patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control.
Lupus Erythematosus, Systemic
Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus.
Lupus Erythematosus, Systemic
P-glycoprotein functions in peripheral-blood CD4+ cells of patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
P-glycoprotein gene MDR1 polymorphisms and susceptibility to systemic lupus erythematosus in Guangxi population: a case-control study.
Lupus Erythematosus, Systemic
Persistent expression and function of P-glycoprotein on peripheral blood lymphocytes identifies corticosteroid resistance in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Relevance of multidrug resistance 1 and P-glycoprotein to drug resistance in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Role of P-glycoprotein on CD69
Lupus Erythematosus, Systemic
Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
The detection of autoantibodies to ATP-binding cassette transporter A1 and its role in the pathogenesis of atherosclerosis in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Variation in the ATP-binding cassette transporter 2 gene is a separate risk factor for systemic lupus erythematosus within the MHC.
Lymphadenitis
S100-positive histiocytes in T-cell-dependent area in human lymph nodes express P-glycoprotein.
Lymphatic Metastasis
ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma.
Lymphatic Metastasis
Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell line.
Lymphatic Metastasis
Expression of the cancer stem cell markers CD44v6 and ABCG2 in tongue cancer: effect of neoadjuvant chemotherapy on local recurrence.
Lymphatic Metastasis
Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas.
Lymphatic Metastasis
Expressions of Multidrug Resistance-Related Genes in Gastric Cancer Tissue and Normal Gastric Mucosal Tissue.
Lymphatic Metastasis
Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma.
Lymphatic Metastasis
Intra-and inter-individual heterogeneity in exon 2 of the MDR1 gene in primary breast carcinoma and healthy individuals.
Lymphatic Metastasis
Multidrug resistance proteins and topoisomerase IIalpha expression in colon cancer: association with metastatic potential.
Lymphatic Metastasis
P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients.
Lymphatic Metastasis
Polymorphisms in DNA repair pathway genes and ABCG2 gene in advanced colorectal cancer: correlation with tumor characteristics and clinical outcome in oxaliplatin-based chemotherapy.
Lymphatic Metastasis
The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.
Lymphatic Metastasis
The expression of multidrug resistance protein in human gastrointestinal tract carcinomas.
Lymphatic Metastasis
The prognostic value of breast cancer resistance protein (BCRB/ABCG2) expression in breast carcinomas.
Lymphatic Metastasis
Upregulation of Breast Cancer Resistance Protein Expression was Decreased in Plasma Membrane of Colon Cancer with Metastasis of Lymphatic Node.
Lymphatic Metastasis
[Expression and Significance of Stem Cell Markers CK19, Notch3, CD133, P75NTR, STRO-1 and ABCG2 in Pulmonary Squamous Carcinomas.]
Lymphatic Metastasis
[Expression features of P-glycoprotein, glutathione S transferase-pi and inhibitor of apoptosis proteins in lymph node metastases of gastrointestinal carcinomas]
Lymphatic Metastasis
[Expression of multidrug resistance-associated protein in human non-small cell lung cancer]
Lymphatic Metastasis
[MRP expression in non-small cell lung cancer and normal lung tissues and its prognostic significance.]
Lymphatic Metastasis
[The clinical significance of P-glycoprotein, lung resistance protein and multidrug resistance related protein expressions in infiltrating breast carcinoma tissues]
Lymphoma
1-[3-(2-Hydroxyethylsulfanyl)propanoyl]-3,5-bis(benzylidene)-4-piperidones: A novel cluster of P-glycoprotein dependent multidrug resistance modulators.
Lymphoma
A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk.
Lymphoma
A longitudinal study of ABC transporter expression in canine multicentric lymphoma.
Lymphoma
A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential.
Lymphoma
A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow.
Lymphoma
ABCG2 transports sulfated conjugates of steroids and xenobiotics.
Lymphoma
Alkylated monoterpene indole alkaloid derivatives as potent P-glycoprotein inhibitors in resistant cancer cells.
Lymphoma
An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line.
Lymphoma
Anticancer and multidrug resistance-reversal effects of solanidine analogs synthetized from pregnadienolone acetate.
Lymphoma
Association between SNPs and hepatotoxicity in patients with primary central nervous system lymphoma on high-dose methotrexate therapy.
Lymphoma
Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
Lymphoma
Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study.
Lymphoma
ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target.
Lymphoma
ATP-binding cassette transporters in primary central nervous system lymphoma: decreased expression of MDR1 P-glycoprotein and breast cancer resistance protein in tumor capillary endothelial cells.
Lymphoma
Biological activity of hydantoin derivatives on P-glycoprotein (ABCB1) of mouse lymphoma cells.
Lymphoma
Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Lymphoma
CD147 mediates chemoresistance in breast cancer via ABCG2 by affecting its cellular localization and dimerization.
Lymphoma
Characterization of vincristine-resistant HOB1 lymphoma cell line showing the classical MDR phenotype and altered expression of membrane glycoproteins.
Lymphoma
Chemistry and biological activity of new 3-benzazepines.
Lymphoma
Chemoprevention and inhibition of P-glycoprotein in cancer cells by Chinese medicinal herbs.
Lymphoma
Chemoresistance in the clinic: overview 1994.
Lymphoma
Clinical relevance of P-glycoprotein expression in haematological malignancies.
Lymphoma
Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas.
Lymphoma
Constituents of Carpobrotus edulis inhibit P-glycoprotein of MDR1-transfected mouse lymphoma cells.
Lymphoma
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
Lymphoma
CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.
Lymphoma
Demonstration of the activity of P-glycoprotein by a semi-automated fluorometric method.
Lymphoma
Detection of multidrug-resistant protein, P-glycoprotein in childhood leukaemia and lymphoma.
Lymphoma
Development of multidrug resistance in a canine lymphoma cell line.
Lymphoma
Development of prednisone resistance in naïve canine lymphoma: Longitudinal evaluation of NR3C1?, ABCB1, and 11?-HSD mRNA expression.
Lymphoma
Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein.
Lymphoma
Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein.
Lymphoma
Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Lymphoma
Discovery of a cobalt (III) salen complex that induces apoptosis in Burkitt like lymphoma and leukemia cells, overcoming multidrug resistance in vitro.
Lymphoma
Downregulation of circular RNA hsa_circ_0000735 boosts prostate cancer sensitivity to docetaxel via sponging miR-7.
Lymphoma
Ecdysteroids sensitize MDR and non-MDR cancer cell lines to doxorubicin, paclitaxel, and vincristine but tend to protect them from cisplatin.
Lymphoma
Effect of MDR antagonists on the cidal activity of vincristine for cells expressing MDR-1 is superior to those expressing MRP.
Lymphoma
Epstein-Barr virus-associated natural killer/T-cell lymphomas.
Lymphoma
Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1.
Lymphoma
Evaluation of cucurbitane-type triterpenoids from Momordica balsamina on P-glycoprotein (ABCB1) by flow cytometry and real-time fluorometry.
Lymphoma
Evaluation of DNA methylation profiles of the CpG island of the ABCB1 gene in dogs with lymphoma.
Lymphoma
Evaluation of P-glycoprotein expression in feline lymphoma and correlation with clinical outcome.
Lymphoma
Evaluation of Side Population Assay using Hoechst 33342 dye in Canine Lymphoma Cells.
Lymphoma
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen.
Lymphoma
Expression levels of multidrug resistance-associated protein 4 (MRP4) in human leukemia and lymphoma cell lines, and the inhibitory effects of the MRP-specific inhibitor MK-571 on methotrexate distribution in rats.
Lymphoma
Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors.
Lymphoma
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.
Lymphoma
Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay.
Lymphoma
Expression of P-glycoprotein and breast cancer resistance protein in three cases of canine lymphoma showing drug resistance.
Lymphoma
Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors.
Lymphoma
Expression of P-Glycoprotein in Non-Hodgkin's Lymphomas.
Lymphoma
Expression of the MDR1 and MRP genes in patients with lymphoma with primary bone marrow involvement.
Lymphoma
Expression of the multidrug resistance protein MRP and the lung-resistance protein LRP in nasal NK/T cell lymphoma: further exploring the role of P53 and WT1 gene.
Lymphoma
Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay.
Lymphoma
Extranodal NK/T-cell lymphoma: diagnosis and treatment cues.
Lymphoma
Flow cytometric assessment of P-glycoprotein and multidrug resistance-associated protein activity and expression in canine lymphoma.
Lymphoma
Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells.
Lymphoma
Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein.
Lymphoma
Genetic polymorphisms predicting methotrexate blood levels and toxicity in adult non-Hodgkin lymphoma.
Lymphoma
Glutathione S-transferase and glutathione peroxidase are essential in the early stage of adriamycin resistance before P-glycoprotein overexpression in HOB1 lymphoma cells.
Lymphoma
High-level expression of MRK 16 and MRK 20 murine monoclonal antibody-define proteins (170,000-180,000 P-glycoprotein and 85,000 protein) in leukaemias and malignant lymphomas.
Lymphoma
High-level expression of P-glycoprotein and 85 kD protein as assessed by flow cytometry and immunocytochemistry in leukemias and malignant lymphomas.
Lymphoma
Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein.
Lymphoma
Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway.
Lymphoma
IL-13 Contributes to Drug Resistance of NK/T-Cell Lymphoma Cells by Regulating ABCC4.
Lymphoma
Imatinib enhances the anti-tumour effect of doxorubicin in canine B-cell lymphoma cell line.
Lymphoma
Immunohistochemical detection of multidrug resistance associated P-glycoprotein in stromal cells of malignant lymphomas.
Lymphoma
Immunohistochemical detection of P-glycoprotein in various subtypes of canine lymphomas.
Lymphoma
Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas.
Lymphoma
Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type.
Lymphoma
Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas.
Lymphoma
Improving the MDR reversal activity of 6,17-epoxylathyrane diterpenes.
Lymphoma
In vitro adjuvant antitumor activity of various classes of semi-synthetic poststerone derivatives.
Lymphoma
In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin.
Lymphoma
In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells.
Lymphoma
Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Lymphoma
Inhibition of P-glycoprotein transport activity in a resistant mouse lymphoma cell line by diterpenic lactones.
Lymphoma
Inhibition of P-glycoprotein transport function by N-acylphenothiazines.
Lymphoma
Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells.
Lymphoma
Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells.
Lymphoma
Interleukin-6 reverses Adriamycin resistance in nasal NK/T-cell lymphoma via downregulation of ABCC4 and inactivation of the JAK2/STAT3/NF-?B/P65 pathway.
Lymphoma
Jatrophane Diterpenes from Euphorbia mellifera and Their Activity as P-Glycoprotein Modulators on Multidrug-Resistant Mouse Lymphoma and Human Colon Adenocarcinoma Cells.
Lymphoma
Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas.
Lymphoma
Macrocyclic diterpenes resensitizing multidrug resistant phenotypes.
Lymphoma
MBR rearrangement and P-glycoprotein expression are not independent prognostic factors like p53 protein in malignant lymphoma.
Lymphoma
MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders.
Lymphoma
Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-?B pathway.
Lymphoma
miR-7 Reverses Breast Cancer Resistance To Chemotherapy By Targeting MRP1 And BCL2.
Lymphoma
Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma.
Lymphoma
Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma.
Lymphoma
Multidrug drug resistance in pediatric sarcomas.
Lymphoma
Multidrug resistance (MDR) genes in haematological malignancies.
Lymphoma
Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16.
Lymphoma
Multidrug resistance in pediatric malignancies.
Lymphoma
Multidrug resistance related proteins in primary cutaneous lymphomas.
Lymphoma
Multidrug resistance-associated protein (MRP) in haematological malignancies.
Lymphoma
Multidrug resistant HOB1 lymphoma cells express P-glycoprotein that does not play the major role in the development of drug resistance to adriamycin.
Lymphoma
N-alkylisatin-based microtubule destabilizers bind to the colchicine site on tubulin and retain efficacy in drug resistant acute lymphoblastic leukemia cell lines with less in vitro neurotoxicity.
Lymphoma
New potent P-glycoprotein inhibitors carrying a polycyclic scaffold.
Lymphoma
NK/T Cell Lymphoma: Updates in Therapy.
Lymphoma
P-glycoprotein - low constitutional expression does not correlate with treatment failure in follicular lymphomas.
Lymphoma
P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma.
Lymphoma
P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance.
Lymphoma
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.
Lymphoma
P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients.
Lymphoma
P-glycoprotein is hyperphosphorylated in multidrug resistant HOB1 lymphoma cells treated with overdose of vincristine.
Lymphoma
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Lymphoma
Pathogenesis and treatment of extranodal natural killer/T-cell lymphoma.
Lymphoma
Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
Lymphoma
Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein.
Lymphoma
Predicting chemotherapy response and comparing with P-glycoprotein expression using technetium-99m tetrofosmin scan in untreated malignant lymphomas.
Lymphoma
Prediction of chemotherapy response in untreated malignant lymphomas using technetium-99m methoxyisobutylisonitrile scan: comparison with P-glycoprotein expression and other prognostic factors. A preliminary peport.
Lymphoma
Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining.
Lymphoma
Preliminary studies on phenothiazine-mediated reversal of multidrug resistance in mouse lymphoma and COLO 320 cells.
Lymphoma
Quantitative Analysis of mRNA for 10 Different Drug Resistance Factors in Dogs with Lymphoma.
Lymphoma
Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma.
Lymphoma
Recurrent intragenic exon rearrangements of SOBP and AUTS2 in non-Hodgkin B-cell lymphoma.
Lymphoma
Regulation of expression of ABCB1 and LRP genes by mitogen-activated protein kinase/extracellular signal-regulated kinase pathway and its role in generation of side population cells in canine lymphoma cell lines.
Lymphoma
Reversing ABCB1-mediated multi-drug resistance from within cells using translocating immune conjugates.
Lymphoma
Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts.
Lymphoma
S100-positive histiocytes in T-cell-dependent area in human lymph nodes express P-glycoprotein.
Lymphoma
Selective drug efflux in multidrug-resistant immunoblastic B lymphoma cells with overexpressed P-glycoprotein.
Lymphoma
Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition.
Lymphoma
Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factors.
Lymphoma
Terpenoids from Euphorbia pedroi as Multidrug-Resistance Reversers.
Lymphoma
The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.
Lymphoma
The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma.
Lymphoma
The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance.
Lymphoma
The frequency and clinical relevance of multidrug resistance protein expression in patients with lymphoma.
Lymphoma
The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives.
Lymphoma
The role of ABCB1 polymorphism as a prognostic marker for primary central nervous system lymphoma.
Lymphoma
The role of MDR-1 in refractory lymphoma.
Lymphoma
Thioridazine induces apoptosis of multidrug-resistant mouse lymphoma cells transfected with the human ABCB1 and inhibits the expression of P-glycoprotein.
Lymphoma
Treatment algorithms for mature T-cell and natural killer-cell neoplasms.
Lymphoma
Tumour-specific cytotoxicity and MDR-reversal activity of dihydropyridines.
Lymphoma
Using technetium-99m-tetrofosmin scan to predict chemotherapy response of malignant lymphomas, compared with P-glycoprotein and multidrug resistance related protein expression.
Lymphoma
[Correlation of cyclooxygenase-2 expression to P-glycoprotein expression in B-cell non-Hodgkin's lymphoma]
Lymphoma
[Correlation of expression levels of multidrug resistance gene 1 (mdr1) mRNA, multidrug resistance-associated protein (MRP), amd P-glycoprotein (P-gp) with chemotherapy efficacy in malignant lymphomas]
Lymphoma
[Detection of multidrug resistant cells in human malignant diseases by monoclonal antibodies and strategy to eradicate resistant malignant cells]
Lymphoma
[Expression of P-glycoprotein (multidrug-resistance gene product) in haematological tumors]
Lymphoma
[The nuclear localization of Y-box binding protein-1 correlates with P-glycoprotein expression in diffuse large B cell lymphoma]
Lymphoma, AIDS-Related
Multidrug resistance in AIDS-related lymphoma.
Lymphoma, B-Cell
A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk.
Lymphoma, B-Cell
A double blinded, placebo-controlled pilot study to examine reduction of CD34 (+)/CD117 (+)/CD133 (+) lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma.
Lymphoma, B-Cell
A longitudinal study of ABC transporter expression in canine multicentric lymphoma.
Lymphoma, B-Cell
A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination.
Lymphoma, B-Cell
ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.
Lymphoma, B-Cell
ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.
Lymphoma, B-Cell
Aptamer-Functionalized DNA Origami for Targeted Codelivery of Antisense Oligonucleotides and Doxorubicin to Enhance Therapy in Drug-Resistant Cancer Cells.
Lymphoma, B-Cell
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Lymphoma, B-Cell
Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma.
Lymphoma, B-Cell
Characterization and localization of side population cells in the lens.
Lymphoma, B-Cell
Development of multidrug resistance in a canine lymphoma cell line.
Lymphoma, B-Cell
Downregulation of circular RNA hsa_circ_0000735 boosts prostate cancer sensitivity to docetaxel via sponging miR-7.
Lymphoma, B-Cell
Effect of CIK on multidrug-resistance reversal and increasing the sensitivity of ADR in K562/ADR cells.
Lymphoma, B-Cell
Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells.
Lymphoma, B-Cell
Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells.
Lymphoma, B-Cell
Enhanced TLR4 Expression on Colon Cancer Cells After Chemotherapy Promotes Cell Survival and Epithelial-Mesenchymal Transition Through Phosphorylation of GSK3?.
Lymphoma, B-Cell
Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.
Lymphoma, B-Cell
Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
Lymphoma, B-Cell
High expression of MDR-1 gene and P-glycoprotein in initial and re-biopsy specimens of relapsed B-cell lymphoma.
Lymphoma, B-Cell
Imatinib enhances the anti-tumour effect of doxorubicin in canine B-cell lymphoma cell line.
Lymphoma, B-Cell
Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Lymphoma, B-Cell
Interaction between CD133 and PI3K-p85 promotes chemoresistance in gastric cancer cells.
Lymphoma, B-Cell
Long Non-Coding RNA OIP5-AS1 Knockdown Enhances CDDP Sensitivity in Osteosarcoma via miR-377-3p/FOSL2 Axis.
Lymphoma, B-Cell
Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-?B pathway.
Lymphoma, B-Cell
miR-7 Reverses Breast Cancer Resistance To Chemotherapy By Targeting MRP1 And BCL2.
Lymphoma, B-Cell
Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells.
Lymphoma, B-Cell
No Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma.
Lymphoma, B-Cell
Overexpression of CD133 enhances chemoresistance to 5-fluorouracil by activating the PI3K/Akt/p70S6K pathway in gastric cancer cells.
Lymphoma, B-Cell
PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers.
Lymphoma, B-Cell
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Lymphoma, B-Cell
Recurrent intragenic exon rearrangements of SOBP and AUTS2 in non-Hodgkin B-cell lymphoma.
Lymphoma, B-Cell
Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Lymphoma, B-Cell
Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Targeting mammalian target of rapamycin to both downregulate and disable the P-glycoprotein pump in multidrug-resistant B-cell lymphoma cell lines.
Lymphoma, B-Cell
The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein.
Lymphoma, B-Cell
[The nuclear localization of Y-box binding protein-1 correlates with P-glycoprotein expression in diffuse large B cell lymphoma]
Lymphoma, Follicular
Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein.
Lymphoma, Follicular
P-glycoprotein - low constitutional expression does not correlate with treatment failure in follicular lymphomas.
Lymphoma, Follicular
[Polymerase chain reaction in diagnostic pathology]
Lymphoma, Large B-Cell, Diffuse
1 alpha,25-(OH)2 vitamin D3 enhances expression of the genes encoding Ca(2+)-binding proteins MRP-8 and MRP-14.
Lymphoma, Large B-Cell, Diffuse
ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.
Lymphoma, Large B-Cell, Diffuse
ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.
Lymphoma, Large B-Cell, Diffuse
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Lymphoma, Large B-Cell, Diffuse
Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-?B pathway.
Lymphoma, Large B-Cell, Diffuse
No Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma.
Lymphoma, Large B-Cell, Diffuse
PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
[The nuclear localization of Y-box binding protein-1 correlates with P-glycoprotein expression in diffuse large B cell lymphoma]
Lymphoma, Mantle-Cell
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen.
Lymphoma, Non-Hodgkin
A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease.
Lymphoma, Non-Hodgkin
An in vitro model to study chemoresistance in non-Hodgkin's lymphoma patients over-expressing mutant p53.
Lymphoma, Non-Hodgkin
Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer.
Lymphoma, Non-Hodgkin
Clinical reversal of multidrug resistance.
Lymphoma, Non-Hodgkin
Clinical Reversal of Multidrug Resistance.
Lymphoma, Non-Hodgkin
Clinicopathologic Significance of Histologic Grade, Pgp, and P53 Expression in Canine Lymphoma.
Lymphoma, Non-Hodgkin
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
Lymphoma, Non-Hodgkin
Cyclophosphamide metabolite inducing apoptosis in RLS mouse lymphosarcoma cells is a substrate for P-glycoprotein.
Lymphoma, Non-Hodgkin
De novo expression of P-glycoprotein associated with poor prognosis in high grade non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line.
Lymphoma, Non-Hodgkin
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Lymphoma, Non-Hodgkin
Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
Lymphoma, Non-Hodgkin
Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia.
Lymphoma, Non-Hodgkin
Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma.
Lymphoma, Non-Hodgkin
Multidrug resistance (MDR) genes in haematological malignancies.
Lymphoma, Non-Hodgkin
Multidrug resistance: clinical relevance in haematological malignancies.
Lymphoma, Non-Hodgkin
P-glycoprotein expression in non-hodgkins-lymphoma.
Lymphoma, Non-Hodgkin
Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Possible role of P-glycoprotein in cyclophosphamide resistance of transplanted mouse RLS lymphosarcoma.
Lymphoma, Non-Hodgkin
Quantitative Analysis of mRNA for 10 Different Drug Resistance Factors in Dogs with Lymphoma.
Lymphoma, Non-Hodgkin
Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma.
Lymphoma, Non-Hodgkin
Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non Hodgkin lymphoma.
Lymphoma, Non-Hodgkin
The expression of multidrug resistance (MDR) molecule in acute leukemia and lymphoma.
Lymphoma, Non-Hodgkin
The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance.
Lymphoma, Non-Hodgkin
The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy.
Lymphoma, Non-Hodgkin
[Correlation of cyclooxygenase-2 expression to P-glycoprotein expression in B-cell non-Hodgkin's lymphoma]
Lymphoma, Non-Hodgkin
[Expression and significance of P-gp/mdr1 mRNA, MRP and LRP in non-Hodgkin's lymphoma]
Lymphoma, Primary Effusion
CD147 mediates chemoresistance in breast cancer via ABCG2 by affecting its cellular localization and dimerization.
Lymphoma, T-Cell
A longitudinal study of ABC transporter expression in canine multicentric lymphoma.
Lymphoma, T-Cell
A Rare Class of New Dimeric Naphthoquinones from Diospyros lotus have Multidrug Reversal and Antiproliferative Effects.
Lymphoma, T-Cell
Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague-Dawley/Cub rats.
Lymphoma, T-Cell
Isolation of Chlorogenic Acid from Soil Borne Fungi Screlotium rolfsii, their Reversal of Multidrug Resistance and anti-proliferative in Mouse Lymphoma cells.
Lymphoma, T-Cell
Multidrug resistance-associated protein-overexpressing teniposide-resistant human lymphomas undergo apoptosis by a tubulin-binding agent.
Lymphoma, T-Cell
New Chalcone Derivative Inhibits ABCB1 in Multidrug Resistant T-cell Lymphoma and Colon Adenocarcinoma Cells.
Lymphoma, T-Cell
Significant activity of ecdysteroids on the resistance to doxorubicin in mammalian cancer cells expressing the human ABCB1 transporter.
Lymphoma, T-Cell, Cutaneous
P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Peripheral
p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.
Lymphoma, T-Cell, Peripheral
The Expressions of P53, Bcl-2, and P-Glycoprotein and Prognostic Impact in Patients with Peripheral T-Cell Lymphoma (PTCL).
Lymphopenia
Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.
Lymphoproliferative Disorders
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen.
Lymphoproliferative Disorders
MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders.
Lymphoproliferative Disorders
P-Glycoprotein Expression in Drug-Resistant Chronic Lymphoproliferative Disorder.
Lysosomal Storage Diseases
Treatment of neutral glycosphingolipid lysosomal storage diseases via inhibition of the ABC drug transporter, MDR1. Cyclosporin A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model.
Macular Degeneration
A subgroup of age-related macular degeneration is associated with mono-allelic sequence variants in the ABCA4 gene.
Macular Degeneration
ABCR, the ATP-binding cassette transporter responsible for Stargardt macular dystrophy, is an efficient target of all-trans-retinal-mediated photooxidative damage in vitro. Implications for retinal disease.
Macular Degeneration
Acute Stress Responses Are Early Molecular Events of Retinal Degeneration in Abca4-/-Rdh8-/- Mice After Light Exposure.
Macular Degeneration
ATP-binding cassette transporter ABCA4: molecular properties and role in vision and macular degeneration.
Macular Degeneration
Correlating the Expression and Functional Activity of ABCA4 Disease Variants With the Phenotype of Patients With Stargardt Disease.
Macular Degeneration
Hunting for disease genes in multi-functional diseases.
Macular Degeneration
Molecular genetic analysis of ABCR gene in Japanese dry form age-related macular degeneration.
Macular Degeneration
Regulated efflux of photoreceptor outer segment-derived cholesterol by human RPE cells.
Macular Degeneration
The effect of lipid environment and retinoids on the ATPase activity of ABCR, the photoreceptor ABC transporter responsible for Stargardt macular dystrophy.
Malaria
A polymorphic drug pump in the malaria parasite.
Malaria
Association between ABCB1 Polymorphisms and Artesunate-Mefloquine Treatment Responses of Patients with Falciparum Malaria on the Thailand-Myanmar Border.
Malaria
Chemosensitization potential of P-glycoprotein inhibitors in malaria parasites.
Malaria
Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione.
Malaria
Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.
Malaria
Genetic and epigenetic changes in host ABCB1 influences malaria susceptibility to Plasmodium falciparum.
Malaria
Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum.
Malaria
Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine.
Malaria
Landscape ecology and epidemiology of malaria associated with rubber plantations in Thailand: integrated approaches to malaria ecotoping.
Malaria
Malaria in pregnancy regulates P-glycoprotein (P-gp/Abcb1a) and ABCA1 efflux transporters in the Mouse Visceral Yolk Sac.
Malaria
MRP 8/14 as marker for Plasmodium falciparum-induced malaria episodes in individuals in a holoendemic area.
Malaria
Multiple transporters associated with malaria parasite responses to chloroquine and quinine.
Malaria
Polymorphism in pfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 associated with resistance to sulfadoxine-pyrimethamine treatment.
Malaria
Polymorphisms within PfMDR1 alter the substrate specificity for anti-malarial drugs in Plasmodium falciparum.
Malaria
The "pushmi-pullyu" of resistance to chloroquine in malaria.
Malaria
The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome.
Malaria
The P-glycoprotein homologues of Plasmodium falciparum: Are they involved in chloroquine resistance?
Malaria
[Drug-resistant gene polymorphisms in Plasmodium falciparum isolated from Bioko Island, Equatorial Guinea in 2018 and 2019].
Malaria, Cerebral
MDR1A (ABCB1) DEFICIENT CF-1 MUTANT MICE IS SUSCEPTIBLE TO CEREBRAL MALARIA INDUCED BY PLASMODIUM BERGHEI ANKA.
Malaria, Cerebral
MDR1A (ABCB1)-deficient CF-1 mutant mice are susceptible to cerebral malaria induced by Plasmodium berghei ANKA.
Malformations of Cortical Development
Expression and cellular distribution of multidrug resistance-related proteins in patients with focal cortical dysplasia.
Malformations of Cortical Development
Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors.
Malformations of Cortical Development
Multidrug-resistance protein 1 in focal cortical dysplasia.
Malformations of Cortical Development
Over-expression of P-glycoprotein in malformations of cortical development.
Malformations of Cortical Development
Widespread upregulation of drug-resistance proteins in fatal human status epilepticus.
Malnutrition
Maternal undernutrition reduces P-glycoprotein in guinea pig placenta and developing brain in late gestation.
Mastitis
Polymorphism of the FAM13A, ABCG2, OPN, LAP3, HCAP-G, PPARGC1A genes and somatic cell count of Jersey cows--preliminary study.
Mastitis
Short communication: The gain-of-function Y581S polymorphism of the ABCG2 transporter increases secretion into milk of danofloxacin at the therapeutic dose for mastitis treatment.
Mastitis
The bovine ATP-binding cassette transporter ABCG2 Tyr581Ser single-nucleotide polymorphism increases milk secretion of the fluoroquinolone danofloxacin.
Mastocytoma
Identification of the biosynthetic leukotriene C4 export pump in murine mastocytoma cells as a homolog of the multidrug-resistance protein.
Mastocytoma
Transport of leukotriene C4 and structurally related conjugates.
Measles
Measles associated diarrhea and pneumonia in south India.
Medulloblastoma
ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma.
Medulloblastoma
ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.
Medulloblastoma
Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines.
Medulloblastoma
Multidrug resistance gene expression in childhood medulloblastoma: correlation with clinical outcome and DNA ploidy in 29 patients.
Melanoma
?Np73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report.
Melanoma
A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells.
Melanoma
A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429.
Melanoma
ABCB1 identifies a subpopulation of uveal melanoma cells with high metastatic propensity.
Melanoma
ABCB1 in dermatology: roles in skin diseases and their treatment.
Melanoma
Antioxidant defenses in a B16 melanoma line resistant to doxorubicin: an in vivo study.
Melanoma
Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression.
Melanoma
ATP-binding cassette transporter ABCB5 gene is expressed with variability in malignant melanoma.
Melanoma
Bispecific antibodies reactive with the multidrug-resistance-related glycoprotein and CD3 induce lysis of multidrug-resistant tumor cells.
Melanoma
Cancer Stem Cells: Lessons From Melanoma.
Melanoma
CDK7 and MITF repress a transcription program involved in survival and drug tolerance in melanoma.
Melanoma
Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies.
Melanoma
Chemotherapeutics, chemoresistance and the management of melanoma.
Melanoma
Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells.
Melanoma
Combined effects of GSTP1 and MRP1 in melanoma drug resistance.
Melanoma
Desensitization of metastatic melanoma cells to therapeutic treatment through repeated exposure to dacarbazine.
Melanoma
Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells.
Melanoma
Differential involvement of glutathione S-transferase mu 1 and multidrug resistance protein 1 in melanoma acquired resistance to vinca alkaloids.
Melanoma
Diversity of the plasma membrane properties of transplantable hamster melanomas with regard to the expression of P-glycoprotein.
Melanoma
Down-regulation of ras and myc expression associated with mdr-1 overexpression in adriamycin-resistant tumor cells.
Melanoma
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.
Melanoma
Elevated circulatory levels of leptin and resistin impair therapeutic efficacy of dacarbazine in melanoma under obese state.
Melanoma
Evaluation of MDR1, LRP, MRP, and topoisomerase IIalpha gene mRNA transcripts before and after interferon-alpha, and correlation with the mRNA expression level of the telomerase subunits hTERT and TEP1 in five unselected human melanoma cell lines.
Melanoma
Expression and activity of P-glycoprotein in transplantable hamster melanomas.
Melanoma
Expression of Multidrug Resistance Transporter ABCB5 in a Murine Model of Human Conjunctival Melanoma.
Melanoma
Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes.
Melanoma
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Melanoma
Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material.
Melanoma
Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects.
Melanoma
Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.
Melanoma
Induction of P-glycoprotein expression on the plasma membrane of human melanoma cells.
Melanoma
Intracellular distribution of anthracyclines in drug resistant cells.
Melanoma
Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines.
Melanoma
Invasive properties of multidrug resistant human melanoma cells.
Melanoma
Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma.
Melanoma
Lack of P-glycoprotein expression in melanoma brain metastases of different melanoma types.
Melanoma
Learning the ABCs of melanoma-initiating cells.
Melanoma
Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection.
Melanoma
Mapping ATP-binding cassette transporter gene expression profiles in melanocytes and melanoma cells.
Melanoma
MDR1 expression is associated with adverse survival in melanoma of the uveal tract.
Melanoma
Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential.
Melanoma
Membrane transport proteins associated with drug resistance expressed in human melanoma.
Melanoma
MiR-15b weakens proliferation and enhances apoptosis of melanoma cells through targeting ABCG2 signaling pathway.
Melanoma
miR-200c Inhibits Melanoma Progression and Drug Resistance through Down-Regulation of Bmi-1.
Melanoma
Modulation of Autophagy by a Thioxanthone Decreases the Viability of Melanoma Cells.
Melanoma
Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells.
Melanoma
Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA.
Melanoma
Multidrug resistance-related proteins in primary choroidal melanomas and in vitro cell lines.
Melanoma
Oenothera paradoxa defatted seeds extract containing pentagalloylglucose and procyanidins potentiates the cytotoxicity of vincristine.
Melanoma
Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.
Melanoma
Overexpression of the ATP binding cassette gene ABCA1 determines resistance to Curcumin in M14 melanoma cells.
Melanoma
Overshoot during phenotypic switching of cancer cell populations.
Melanoma
p-glycoprotein expression in malignant melanoma.
Melanoma
P-glycoprotein expression in primary and metastatic malignant melanoma.
Melanoma
P-glycoprotein gene amplification and expression in multidrug-resistant murine P388 and B16 cell lines.
Melanoma
p53-dependent apoptosis in melanoma cells after treatment with camptothecin.
Melanoma
Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells.
Melanoma
Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta ) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes.
Melanoma
Prognostic impact of the putative cancer stem cell markers ABCG2, CD133, ALDH1A1 and CD44V7/8 in metastatic melanoma.
Melanoma
Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma.
Melanoma
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
Melanoma
SOX2 upregulates side population cells and enhances their chemoresistant ability by transactivating ABCC1 expression contributing to intrinsic resistance to paclitaxel in melanoma.
Melanoma
Targeted gene delivery by intravenous injection of retroviral vectors.
Melanoma
Tea Tree Oil Might Combat Melanoma.
Melanoma
Terpinen-4-ol, the main component of Melaleuca alternifolia (tea tree) oil inhibits the in vitro growth of human melanoma cells.
Melanoma
The chemoresistance gene ABCG2 (MXR/BCRP1/ABCP1) is not expressed in melanomas but in single neuroendocrine carcinomas of the skin.
Melanoma
The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice.
Melanoma
The Human Melanoma Side Population Displays Molecular and Functional Characteristics of Enriched Chemoresistance and Tumorigenesis.
Melanoma
The Metabolic Bioactivation of Caffeic Acid Phenethyl Ester Mediated by Tyrosinase Selectively Inhibits Glutathione S-Transferase.
Melanoma
The multidrug transporter P-glycoprotein: a mediator of melanoma invasion?
Melanoma
The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy.
Melanoma
The Prognostic Value of Tumor Mitotic Rate and Other Clinicopathologic Factors in Patients with Locoregional Recurrences of Melanoma.
Melanoma
What is the relationship between P-glycoprotein and adhesion molecule expression in melanoma cells?
Melanoma
[Association of the ABCB1 gene with risk for uveal melanoma].
Melanoma
[Drug resistance of malignant melanoma. Mechanisms and possible modulation]
Melanoma
[Multidrug resistance in uveal melanoma.]
Melioidosis
Inactivation of bpsl1039-1040 ATP-binding cassette transporter reduces intracellular survival in macrophages, biofilm formation and virulence in the murine model of Burkholderia pseudomallei infection.
Meningioma
Heterogeneity in the expression of markers for drug resistance in brain tumors.
Meningioma
HMGN5 blockade by siRNA enhances apoptosis, suppresses invasion and increases chemosensitivity to temozolomide in meningiomas.
Meningioma
Immunohistochemical study of MRP5 expression in meningiomas.
Meningioma
Intrinsic expression of drug resistance-associated factors in meningiomas.
Meningioma
Multidrug resistance gene (MDR1) expression in human brain tumors.
Meningioma
NANOG overexpression and its correlation with stem cell and differentiation markers in meningiomas of different WHO grades.
Meningioma
Technetium-99m sestamibi single photon emission computed tomography findings correlated with P-glycoprotein expression, encoded by the multidrug resistance gene-1 messenger ribonucleic acid, in intracranial meningiomas.
Meningitis
Comparative evaluation of virulence and pathology of Streptococcus suis serotypes 2 and 9 in experimentally infected growers.
Meningitis
Interaction of fibrinogen and muramidase-released protein promotes the development of Streptococcus suis meningitis.
Meningitis
Relatedness of Streptococcus suis isolates of various serotypes and clinical backgrounds as evaluated by macrorestriction analysis and expression of potential virulence traits.
Mesothelioma
Co-ordinated over-expression of the MRP and gamma-glutamylcysteine synthetase genes, but not MDR1, correlates with doxorubicin resistance in human malignant mesothelioma cell lines.
Mesothelioma
Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums.
Mesothelioma
Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro.
Mesothelioma
Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
Mesothelioma
Pleural mesothelioma side populations have a precursor phenotype.
Mesothelioma
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
Mesothelioma, Malignant
Co-ordinated over-expression of the MRP and gamma-glutamylcysteine synthetase genes, but not MDR1, correlates with doxorubicin resistance in human malignant mesothelioma cell lines.
Mesothelioma, Malignant
Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
Mesothelioma, Malignant
Micro-RNA149 confers taxane resistance to malignant mesothelioma cells via regulation of P-glycoprotein expression.
Mesothelioma, Malignant
Pleural mesothelioma side populations have a precursor phenotype.
Mesothelioma, Malignant
The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma.
Mesothelioma, Malignant
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
Metabolic Diseases
ATP-binding cassette transporter A1: key player in cardiovascular and metabolic disease at local and systemic level.
Metabolic Diseases
X-linked adrenoleukodystrophy: molecular and functional analysis of the ABCD1 gene in Argentinean patients.
Metabolic Syndrome
Association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in a Mexican population.
Metabolic Syndrome
Epigenome-wide association study of metabolic syndrome in African-American adults.
Metabolic Syndrome
Evaluation of the Influence of Genetic Variants of SLC2A9 (GLUT9) and SLC22A12 (URAT1) on the Development of Hyperuricemia and Gout.
Metabolic Syndrome
Fructose-induced metabolic syndrome decreases protein expression and activity of intestinal P-glycoprotein.
Metabolic Syndrome
Genetic contributors to serum uric acid levels in Mexicans and their effect on premature coronary artery disease.
Metabolic Syndrome
Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate.
Metabolic Syndrome
Identification of miR-9-5p as direct regulator of ABCA1 and HDL-driven reverse cholesterol transport in circulating CD14+ cells of patients with metabolic syndrome.
Metabolic Syndrome
Intestinal multidrug resistance-associated protein 2 is down-regulated in fructose-fed rats.
Metabolic Syndrome
Modulation of microRNA Expression in Subjects with Metabolic Syndrome and Decrease of Cholesterol Efflux from Macrophages via microRNA-33-Mediated Attenuation of ATP-Binding Cassette Transporter A1 Expression by Statins.
Metabolic Syndrome
Monascus rice products.
Metabolic Syndrome
Negative results in screening for possible new sequence variations on ATP-binding cassette transporter A1 gene in Turkish adults with metabolic syndrome.
Metabolic Syndrome
Plasma concentrations of plant sterols: physiology and relationship with coronary heart disease.
Metabolic Syndrome
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Miosis
Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine.
Mitochondrial Diseases
Nuclear MRP genes and mitochondrial disease.
Mitochondrial Diseases
The human mitochondrial ribosomal protein genes: mapping of 54 genes to the chromosomes and implications for human disorders.
Mouth Neoplasms
Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squamous cell carcinoma.
Mouth Neoplasms
Expression of podoplanin and ABCG2 in oral erythroplakia correlate with oral cancer development.
Mouth Neoplasms
Highly Eribulin-resistant KBV20C Oral Cancer Cells Can Be Sensitized by Co-treatment with the Third-generation P-Glycoprotein Inhibitor, Elacridar, at a Low Dose.
Mouth Neoplasms
Improvement of the efficacy of 5-aminolevulinic acid-mediated photodynamic treatment in human oral squamous cell carcinoma HSC-4.
Mouth Neoplasms
Solid Matrix Based Lipidic Nanoparticles in Oral Cancer Chemotherapy: Applications and Pharmacokinetics.
Mouth Neoplasms
The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function.
Mucocutaneous Lymph Node Syndrome
ABCC4 Variants Modify Susceptibility to Kawasaki Disease in a Southern Chinese Population.
Mucocutaneous Lymph Node Syndrome
Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease.
Mucositis
Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study.
Mucositis
Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.
Mucositis
Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.
Mucositis
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Mucositis
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Mucositis
TLR Signaling Modulates Side Effects of Anticancer Therapy in the Small Intestine.
Multiple Myeloma
99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients.
Multiple Myeloma
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
Multiple Myeloma
A novel miR-203-DNMT3b-ABCG2 regulatory pathway predisposing colorectal cancer development.
Multiple Myeloma
ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma.
Multiple Myeloma
ABCG2 expression, function, and promoter methylation in human multiple myeloma.
Multiple Myeloma
Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells.
Multiple Myeloma
Association of ABCB1 T-129C polymorphism and multiple myeloma risk in Polish population.
Multiple Myeloma
Baicalein decreases side population proportion via inhibition of ABCG2 in multiple myeloma cell line RPMI 8226 in vitro.
Multiple Myeloma
BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
Multiple Myeloma
Chemoresistance in the clinic: overview 1994.
Multiple Myeloma
Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells.
Multiple Myeloma
Clinical relevance of P-glycoprotein expression in haematological malignancies.
Multiple Myeloma
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).
Multiple Myeloma
Drug resistance in multiple myeloma.
Multiple Myeloma
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Multiple Myeloma
Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation.
Multiple Myeloma
Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma.
Multiple Myeloma
Expression of p170 protein in multiple myeloma: a clinical study.
Multiple Myeloma
Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells.
Multiple Myeloma
Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma.
Multiple Myeloma
Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease.
Multiple Myeloma
GST-pi and P-170 co-expression in multiple myeloma.
Multiple Myeloma
High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia.
Multiple Myeloma
Hsa_Circ_0007841 Enhances Multiple Myeloma Chemotherapy Resistance Through Upregulating ABCG2.
Multiple Myeloma
Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation.
Multiple Myeloma
Impaired breast cancer resistance protein mediated drug transport in plasma cells in multiple myeloma.
Multiple Myeloma
Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma.
Multiple Myeloma
Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.
Multiple Myeloma
Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells.
Multiple Myeloma
Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment.
Multiple Myeloma
Multidrug resistance (MDR) genes in haematological malignancies.
Multiple Myeloma
Multidrug resistance gene expression and ABCB1 SNPs in plasma cell myeloma.
Multiple Myeloma
Multidrug resistance-associated protein (MRP) in haematological malignancies.
Multiple Myeloma
Neither P-gp SNP variants, P-gp expression nor functional P-gp activity predicts MDR in a preliminary study of plasma cell myeloma.
Multiple Myeloma
Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies.
Multiple Myeloma
P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma.
Multiple Myeloma
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy.
Multiple Myeloma
P-glycoprotein expression in multiple myeloma.
Multiple Myeloma
P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD.
Multiple Myeloma
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
Multiple Myeloma
Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein.
Multiple Myeloma
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
Multiple Myeloma
Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium.
Multiple Myeloma
Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining.
Multiple Myeloma
Target therapy of multiple myeloma by PTX-NPs and ABCG2 antibody in a mouse xenograft model.
Multiple Myeloma
Thalidomide alters nuclear architecture without ABCB1 gene modulation in drug-resistant myeloma cells.
Multiple Myeloma
The contribution of ABCG2 G34A and C421A polymorphisms to multiple myeloma susceptibility.
Multiple Myeloma
The expression of the multidrug transporter P-170 glycoprotein in remission phase is associated with early and resistant relapse in multiple myeloma.
Multiple Myeloma
The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
Multiple Myeloma
THE ROLE OF P-GLYCOPROTEIN IN DRUG RESISTANCE IN MULTIPLE MYELOMA.
Multiple Myeloma
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs.
Multiple Myeloma
[Effect of ABCG2 on Side Population Cells and Related Pathways in Multiple Myeloma].
Multiple Sclerosis
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Multiple Sclerosis
Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis.
Multiple Sclerosis
Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis.
Multiple Sclerosis
Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.
Multiple Sclerosis
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Mumps
Spermiogram part of population with the manifest orchtis during an ongoing epidemic of mumps.
Muscle Cramp
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.
Muscle Weakness
Maximal respiratory pressures in myasthenia gravis. Relation to single fiber electromyography.
Muscular Atrophy, Spinal
CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy.
Muscular Diseases
A Pharmacogenomic Dissection of a Rosuvastatin-Induced Rhabdomyolysis Case Evokes the Polygenic Nature of Adverse Drug Reactions.
Muscular Diseases
ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis.
Muscular Diseases
Acute myopathy in a patient with concomitant use of pravastatin and colchicine.
Muscular Diseases
Acute myopathy induced by colchicine in a cyclosporine treated heart transplant recipient: possible role of the multidrug resistance transporter.
Muscular Diseases
Association of SLCO1B1 and ABCB1 Genetic Variants with Atorvastatin-induced Myopathy in Patients with Acute Ischemic Stroke.
Muscular Diseases
Colchicine Myopathy: A Case Series Including Muscle MRI and ABCB1 Polymorphism Data.
Muscular Diseases
Colchicine: serious interactions.
Muscular Diseases
Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
Muscular Diseases
Impaired post-tetanic potentiation of muscle twitch in myasthenia gravis.
Muscular Diseases
Liver and statins: a critical appraisal of the evidence.
Muscular Diseases
The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.
Myasthenia Gravis
ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients.
Myasthenia Gravis
Clinical implications of the type 1/ type 2 balance of helper T cells and P-glycoprotein function in peripheral T lymphocytes of myasthenia gravis patients.
Myasthenia Gravis
Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients.
Myasthenia Gravis
P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus.
Myasthenia Gravis
P-glycoprotein function in peripheral T lymphocyte subsets of myasthenia gravis patients: clinical implications and influence of glucocorticoid administration.
Mycoses
Candida glabrata ATP-binding cassette transporters Cdr1p and Pdh1p expressed in a Saccharomyces cerevisiae strain deficient in membrane transporters show phosphorylation-dependent pumping properties.
Mycoses
Inhibitors of multidrug efflux transporters: their membrane and protein interactions.
Myelodysplastic Syndromes
Analysis of the characteristics of folate binding proteins and its relationship with expression of multidrug resistance P-glycoprotein in myelodysplastic syndromes.
Myelodysplastic Syndromes
CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
Myelodysplastic Syndromes
Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.
Myelodysplastic Syndromes
Development of Multidrug Resistance in Acute Myeloid Leukemia Is Associated with Alterations of the LPHN1/GAL-9/TIM-3 Signaling Pathway.
Myelodysplastic Syndromes
Expression of cd34 and p-glycoprotein - prognostic-significance in primary myelodysplastic syndromes.
Myelodysplastic Syndromes
Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
Myelodysplastic Syndromes
Expression of the multidrug resistance-associated protein in myelodysplastic syndromes.
Myelodysplastic Syndromes
P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma.
Myelodysplastic Syndromes
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Myelodysplastic Syndromes
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.
Myelodysplastic Syndromes
[Analysis of molecular mechanism involved in development of acute myeloid leukemia].
Myelodysplastic Syndromes
[Multi-drug resistance and myelodysplastic syndromes: a possible role for remission inducing agents?]
Myocardial Infarction
A novel Val734Ile variant in the ABCC9 gene associated with myocardial infarction.
Myocardial Infarction
A promoter variant of the ATP-binding cassette transporter A1 gene alters the HDL cholesterol level in the general Japanese population.
Myocardial Infarction
Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
Myocardial Infarction
Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Myocardial Infarction
Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction.
Myocardial Infarction
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Myocardial Infarction
Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction.
Myocardial Infarction
Predicting clopidogrel response using DNA samples linked to an electronic health record.
Myocardial Infarction
Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging.
Myocardial Infarction
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
Myocardial Infarction
Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction.
Myocardial Infarction
The ATP-binding cassette transporter BCRP1/ABCG2 plays a pivotal role in cardiac repair after myocardial infarction via modulation of microvascular endothelial cell survival and function.
Myocardial Ischemia
ABCB1 C3435T polymorphism and the risk of ischemic heart disease: a meta-analysis.
Myocardial Ischemia
Expression of the MDR-1 gene-encoded P-glycoprotein in cardiomyocytes of conscious sheep undergoing acute myocardial ischemia followed by reperfusion.
Myocardial Ischemia
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Myocardial Ischemia
Mutation in ABCA1 predicted risk of ischemic heart disease in the Copenhagen City Heart Study Population.
Myocardial Ischemia
Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging.
Myoclonic Epilepsy, Juvenile
Genetic association analysis of ATP binding cassette protein family reveals a novel association of ABCB1 genetic variants with epilepsy risk, but not with drug-resistance.
Narcolepsy
Pharmacogenetics and Treatment Response in Narcolepsy Type 1: Relevance of the Polymorphisms of the Drug Transporter Gene ABCB1.
Nasal Polyps
Evaluation of the Prevalence of Mucous Retention Pseudocyst and its Correlation with the Associated Risk Factors Using Panoramic Radiography and Cone-Beam Computed Tomography.
Nasal Polyps
Exosomes mediate interepithelial transfer of functional P-glycoprotein in chronic rhinosinusitis with nasal polyps.
Nasal Polyps
Neuronal Differentiation Capability of Nasal Polyps of Chronic Rhinosinusitis.
Nasal Polyps
Osteitis in Chronic Rhinosinusitis.
Nasal Polyps
Osteitis is associated with P-glycoprotein overexpression in patients with chronic sinusitis without nasal polyps.
Nasal Polyps
P-glycoprotein inhibition promotes prednisone retention in human sinonasal polyp explants.
Nasal Polyps
P-glycoprotein inhibition with verapamil overcomes mometasone resistance in Chronic Sinusitis with Nasal Polyps.
Nasal Polyps
P-glycoprotein is a marker of tissue eosinophilia and radiographic inflammation in chronic rhinosinusitis without nasal polyps.
Nasal Polyps
P-glycoprotein promotes epithelial T helper 2-associated cytokine secretion in chronic sinusitis with nasal polyps.
Nasopharyngeal Carcinoma
Abnormal Wnt signaling and overexpression of ABCG2 contributes to drug efflux properties of side population cells in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy.
Nasopharyngeal Carcinoma
Association of ABCC2 and CDDP-Resistance in Two Sublines Resistant to CDDP Derived from a Human Nasopharyngeal Carcinoma Cell Line.
Nasopharyngeal Carcinoma
Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line.
Nasopharyngeal Carcinoma
FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein.
Nasopharyngeal Carcinoma
Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin.
Nasopharyngeal Carcinoma
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Nasopharyngeal Carcinoma
Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG(2).
Nasopharyngeal Carcinoma
Study on the Drug Targets and Molecular Mechanisms of Rhizoma Curcumae in the Treatment of Nasopharyngeal Carcinoma Based on Network Pharmacology.
Nasopharyngeal Carcinoma
The developmental transcription factor IRF6 attenuates ABCG2 gene expression and distinctively reverses stemness phenotype in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Nasopharyngeal Carcinoma
[Construction and identification of eukaryotic plasmid pGC-silencer-U6/Neo/GFP/ABCG2].
Nasopharyngeal Carcinoma
[Different cytotoxicity of NK cells against high and low expression of ATP-binding cassette transporter (ABCG(2);) of human multi-drug resistant nasopharyngeal carcinoma cells.]
Nasopharyngeal Carcinoma
[Expression of ATP-binding cassette transporter genes in nasopharyngeal carcinoma.]
Nasopharyngeal Neoplasms
Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines.
Nasopharyngeal Neoplasms
Overcoming of multidrug resistance by introducing the apoptosis gene, bcl-Xs, into MRP-overexpressing drug resistant cells.
Nasopharyngeal Neoplasms
The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Neoplasm Metastasis
A review of clinical and molecular prognostic factors in osteosarcoma.
Neoplasm Metastasis
ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen.
Neoplasm Metastasis
ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma.
Neoplasm Metastasis
ABCC1-exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1 Shortens Survival of Mice and Patients with Breast Cancer.
Neoplasm Metastasis
Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response.
Neoplasm Metastasis
ABCG2 is a potential prognostic marker of overall survival in patients with clear cell renal cell carcinoma.
Neoplasm Metastasis
ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma.
Neoplasm Metastasis
ABCG2 localizes to the nucleus and modulates CDH1 expression in lung cancer cells.
Neoplasm Metastasis
ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
Neoplasm Metastasis
ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases.
Neoplasm Metastasis
Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.
Neoplasm Metastasis
Bacterial Template Synthesis of Multifunctional Nanospindles for Glutathione Detection and Enhanced Cancer-Specific Chemo-Chemodynamic Therapy.
Neoplasm Metastasis
Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Neoplasm Metastasis
Bridge Linkage Role Played by CD98hc of Anti-Tumor Drug Resistance and Cancer Metastasis on Cisplatin-Resistant Ovarian Cancer Cells.
Neoplasm Metastasis
Cancer stem cell markers in eyelid sebaceous gland carcinoma: high expression of ALDH1, CD133, and ABCG2 correlates with poor prognosis.
Neoplasm Metastasis
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Neoplasm Metastasis
Chemotherapy-Induced IL8 Upregulates MDR1/ABCB1 in Tumor Blood Vessels and Results in Unfavorable Outcome.
Neoplasm Metastasis
Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma.
Neoplasm Metastasis
Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
Neoplasm Metastasis
Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics.
Neoplasm Metastasis
Deadly DAaRTS destroy cancer cells via a tumor microenvironment-mediated trigger.
Neoplasm Metastasis
Depressive Disorder promotes Hepatocellular Carcinoma metastasis via upregulation of ABCG2 gene expression and maintenance of self-renewal.
Neoplasm Metastasis
Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.
Neoplasm Metastasis
Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer.
Neoplasm Metastasis
Drug resistance via radixin-mediated increase of P-glycoprotein membrane expression during SNAI1-induced epithelial-mesenchymal transition in HepG2 cells.
Neoplasm Metastasis
Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality.
Neoplasm Metastasis
Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells.
Neoplasm Metastasis
Effect of Quercetin on ABCC6 Transporter: Implication in HepG2 Migration.
Neoplasm Metastasis
Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells.
Neoplasm Metastasis
Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Neoplasm Metastasis
Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell line.
Neoplasm Metastasis
Expression of ABCG2 and its significance in colorectal cancer.
Neoplasm Metastasis
Expression of Aldehyde Dehydrogenase (ALDH1) and ATP Binding Cassette Transporter G2 (ABCG2) in Iraqi Patients with Colon Cancer and the Relation with Clinicopathological Features.
Neoplasm Metastasis
Expression of multidrug resistance protein in metastatic colorectal carcinomas.
Neoplasm Metastasis
Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1?, EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes.
Neoplasm Metastasis
Expression of multidrug resistance-associated protein (MRP) in head and neck squamous cell carcinoma.
Neoplasm Metastasis
Expression of the cancer stem cell markers CD44v6 and ABCG2 in tongue cancer: effect of neoadjuvant chemotherapy on local recurrence.
Neoplasm Metastasis
Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas.
Neoplasm Metastasis
Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas.
Neoplasm Metastasis
Expressions of Multidrug Resistance-Related Genes in Gastric Cancer Tissue and Normal Gastric Mucosal Tissue.
Neoplasm Metastasis
Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma.
Neoplasm Metastasis
FOXM1/DVL2/Snail axis drives metastasis and chemoresistance of colorectal cancer.
Neoplasm Metastasis
Genetic and Non-genetic Factors Associated With Constipation in Cancer Patients Receiving Opioids.
Neoplasm Metastasis
Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
Neoplasm Metastasis
GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells.
Neoplasm Metastasis
HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
Neoplasm Metastasis
Heterogeneity of multiorgan metastases of human lung cancer cells genetically engineered to produce cytokines and reversal using chimeric monoclonal antibodies in natural killer cell-depleted severe combined immunodeficient mice.
Neoplasm Metastasis
Integrative analysis of two cell lines derived from a non-small-lung cancer patient--a panomics approach.
Neoplasm Metastasis
Intra-and inter-individual heterogeneity in exon 2 of the MDR1 gene in primary breast carcinoma and healthy individuals.
Neoplasm Metastasis
Lung Resistance-Related Protein (LRP) Expression in Malignant Ascitic Cells as a Prognostic Marker for Advanced Ovarian Serous Carcinoma.
Neoplasm Metastasis
Membrane transport proteins associated with drug resistance expressed in human melanoma.
Neoplasm Metastasis
Microvessel density, expression of proto-oncogenes, resistance-related proteins and incidence of metastases in primary ovarian carcinomas.
Neoplasm Metastasis
MiR-32 Inhibits Proliferation and Metastasis by Targeting EZH2 in Glioma.
Neoplasm Metastasis
Moesin-Mediated P-Glycoprotein Activation during Snail-Induced Epithelial-Mesenchymal Transition in Lung Cancer Cells.
Neoplasm Metastasis
MRP and MDR1 gene expression in primary breast carcinomas.
Neoplasm Metastasis
Multidrug resistance and malignancy in human osteosarcoma.
Neoplasm Metastasis
Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively.
Neoplasm Metastasis
Multidrug resistance proteins and topoisomerase IIalpha expression in colon cancer: association with metastatic potential.
Neoplasm Metastasis
Multidrug resistance-associated protein expression in clinical gastric carcinoma.
Neoplasm Metastasis
Nestin delineates pancreatic cancer stem cells in metastatic foci of NOD/Shi-scid IL2R?(null) (NOG) mice.
Neoplasm Metastasis
Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer.
Neoplasm Metastasis
Nitric oxide-releasing micelles with intelligent targeting for enhanced anti-tumor effect of cisplatin in hypoxia.
Neoplasm Metastasis
Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
Neoplasm Metastasis
Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells.
Neoplasm Metastasis
Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients.
Neoplasm Metastasis
P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Neoplasm Metastasis
P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients.
Neoplasm Metastasis
P-glycoprotein expression in gastroesophageal adenocarcinomas, their metastases, and surrounding mucosa: a mapping study.
Neoplasm Metastasis
p-glycoprotein expression in malignant melanoma.
Neoplasm Metastasis
P-glycoprotein expression in primary and metastatic malignant melanoma.
Neoplasm Metastasis
P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder.
Neoplasm Metastasis
P-glycoprotein levels predict poor outcome in patients with osteosarcoma.
Neoplasm Metastasis
P-glycoprotein modulation by valspodar and cyclosporin does not increase tumor uptake of doxorubicin administered via isolated lung perfusion to rats bearing sarcoma lung metastases.
Neoplasm Metastasis
Patterns of Innate or Acquired Resistance to Anticancer Drugs: Our Experience to Overcome It.
Neoplasm Metastasis
pH-activated, mitochondria-targeted, and redox-responsive delivery of paclitaxel nanomicelles to overcome drug resistance and suppress metastasis in lung cancer.
Neoplasm Metastasis
Phthalate exposure promotes chemotherapeutic drug resistance in colon cancer cells.
Neoplasm Metastasis
Polymorphisms in DNA repair pathway genes and ABCG2 gene in advanced colorectal cancer: correlation with tumor characteristics and clinical outcome in oxaliplatin-based chemotherapy.
Neoplasm Metastasis
Prognostic factors in bone sarcomas.
Neoplasm Metastasis
Prognostic impact of cancer stem cell markers ABCB1, NEO1 and HIST1H2AE in colorectal cancer.
Neoplasm Metastasis
Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.
Neoplasm Metastasis
Quantitative site- and structure-specific N-glycoproteomics characterization of differential N-glycosylation in MCF-7/ADR cancer stem cells.
Neoplasm Metastasis
Recent Advances of D-?-tocopherol Polyethylene Glycol 1000 Succinate Based Stimuli-responsive Nanomedicine for Cancer Treatment.
Neoplasm Metastasis
Recent developments in d-?-tocopheryl polyethylene glycol-succinate-based nanomedicine for cancer therapy.
Neoplasm Metastasis
Reporters of Cancer Stem Cells as a Tool for Drug Discovery.
Neoplasm Metastasis
Retinoblastoma CSF metastasis cured by multimodality chemotherapy without radiation.
Neoplasm Metastasis
SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer.
Neoplasm Metastasis
Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2.
Neoplasm Metastasis
Synthesis and biological evaluation of bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potential P-glycoprotein and tumor metastasis inhibitors.
Neoplasm Metastasis
The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer.
Neoplasm Metastasis
The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.
Neoplasm Metastasis
The Effect of P-Glycoprotein (P-gp), Nuclear Factor-Kappa B (Nf-?b), and Aldehyde Dehydrogenase-1 (ALDH-1) Expression on Metastases, Recurrence and Survival in Advanced Breast Cancer Patients
Neoplasm Metastasis
The expression of multidrug resistance protein in human gastrointestinal tract carcinomas.
Neoplasm Metastasis
The Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem Cells.
Neoplasm Metastasis
The prognostic value of breast cancer resistance protein (BCRB/ABCG2) expression in breast carcinomas.
Neoplasm Metastasis
The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment.
Neoplasm Metastasis
The usefulness of Tc-99m MIBI for evaluating brain tumors: comparative study with Tl-201 and relation with P-glycoprotein
Neoplasm Metastasis
Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis.
Neoplasm Metastasis
UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells.
Neoplasm Metastasis
Upregulation of Breast Cancer Resistance Protein Expression was Decreased in Plasma Membrane of Colon Cancer with Metastasis of Lymphatic Node.
Neoplasm Metastasis
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.
Neoplasm Metastasis
Utility of Magnetic Resonance Perfusion Imaging in Quantifying Active Tumor Fraction and Radiation Necrosis in Recurrent Intracranial Tumors.
Neoplasm Metastasis
Vascular Recruitment of Human Retinoblastoma Cells by Multi-Cellular Adhesive Interactions with Circulating Leukocytes.
Neoplasm Metastasis
Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer.
Neoplasm Metastasis
[Expression and clinical implication of multidrug resistance gene and multidrug resistant-associated protein gene in patients with hypopharyngeal squamous cell carcinoma]
Neoplasm Metastasis
[Expression and clinical implication of multidrug resistant-associated protein gene (MRP) in patients with laryngeal squamous cell carcinoma]
Neoplasm Metastasis
[Expression and Significance of Stem Cell Markers CK19, Notch3, CD133, P75NTR, STRO-1 and ABCG2 in Pulmonary Squamous Carcinomas.]
Neoplasm Metastasis
[Expression features of P-glycoprotein, glutathione S transferase-pi and inhibitor of apoptosis proteins in lymph node metastases of gastrointestinal carcinomas]
Neoplasm Metastasis
[Expression of MRP gene in non-small cell lung cancer and its significance.]
Neoplasm Metastasis
[Expression of multidrug resistance-associated protein in human non-small cell lung cancer]
Neoplasm Metastasis
[The clinical significance of P-glycoprotein, lung resistance protein and multidrug resistance related protein expressions in infiltrating breast carcinoma tissues]
Neoplasm, Residual
5-Aminolaevulinic acid-mediated photodynamic therapy in multidrug resistant leukemia cells.
Neoplasm, Residual
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen.
Neoplasm, Residual
Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.
Neoplasm, Residual
Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia.
Neoplasm, Residual
Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy.
Neoplasm, Residual
Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis.
Neoplasm, Residual
Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer.
Neoplasm, Residual
The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy.
Neoplasms
(+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells.
Neoplasms
(5R)-5-hydroxytriptolide (LLDT-8), a novel immunosuppressant in clinical trials, exhibits potent antitumor activity via transcription inhibition.
Neoplasms
(99m)Tc(N)-DBODC(5), a potential radiolabeled probe for SPECT of multidrug resistance: in vitro study.
Neoplasms
18FDG, [18F]FLT, [18F]FAZA, and 11C-methionine are suitable tracers for the diagnosis and in vivo follow-up of the efficacy of chemotherapy by miniPET in both multidrug resistant and sensitive human gynecologic tumor xenografts.
Neoplasms
2'[(18)F]-fluoroethylrhodamine B is a promising radiotracer to measure P-glycoprotein function.
Neoplasms
2,4-bis (p-hydroxyphenyl)-2-butenal (HPB242) induces apoptosis via modulating E7 expression and inhibition of PI3K/Akt pathway in SiHa human cervical cancer cells.
Neoplasms
2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.
Neoplasms
2-Pyrrolinodoxorubicin and its peptide-vectorized form bypass multidrug resistance.
Neoplasms
20(S)-Ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions.
Neoplasms
20(S)-Protopanaxadiol (PPD) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs.
Neoplasms
20S-Protopanaxadiol Inhibits P-Glycoprotein in Multidrug Resistant Cancer Cells.
Neoplasms
3'-O, 4'-O-aromatic acyl substituted 7,8-pyranocoumarins: a new class of P-glycoprotein modulators.
Neoplasms
3,5-diacetyl-1,4-dihydropyridines: synthesis and MDR reversal in tumor cells.
Neoplasms
3,5-dibenzoyl-1,4-dihydropyridines: synthesis and MDR reversal in tumor cells.
Neoplasms
3-(Benzo[d][1,3]dioxol-5-ylamino)-N-(4-fluorophenyl)thiophene-2-carboxamide overcomes cancer chemoresistance via inhibition of angiogenesis and P-glycoprotein efflux pump activity.
Neoplasms
3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function.
Neoplasms
3-Aminomethyl derivatives of 4,11-dihydroxynaphtho[2,3-f]indole-5,10-dione for circumvention of anticancer drug resistance.
Neoplasms
3-benzazecine-based cyclic allene derivatives as highly potent P-glycoprotein inhibitors overcoming doxorubicin multidrug resistance.
Neoplasms
3?-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity.
Neoplasms
3beta-acetyl tormentic acid induces apoptosis of resistant leukemia cells independently of P-gp/ABCB1 activity or expression.
Neoplasms
3D contrast-enhanced MR portography and direct X-ray portography: a correlation study.
Neoplasms
4(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of ?-tubulin.
Neoplasms
4-Hydroxy-6-methoxyaurones with high-affinity binding to cytosolic domain of P-glycoprotein.
Neoplasms
42- and 63-bp anti-MDR1-siRNAs bearing 2'-OMe modifications in nuclease-sensitive sites induce specific and potent gene silencing.
Neoplasms
5-Aminolevulinic Acid Fluorescence in Detection of Peritoneal Metastases.
Neoplasms
5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Neoplasms
6,7-Dimethoxy-2-{2-[4-(1H-1,2,3-triazol-1-yl)phenyl]ethyl}-1,2,3,4-tetrahydroisoquinolines as superior reversal agents for P-glycoprotein-mediated multidrug resistance.
Neoplasms
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.
Neoplasms
7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. Mechanism of action of potential anticancer drugs.
Neoplasms
8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1.
Neoplasms
9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance.
Neoplasms
99mTc glucarate high-resolution imaging of drug sensitive and drug resistant human breast cancer xenografts in SCID mice.
Neoplasms
99mTc-labeling of colchicine using [99mTc(CO)3(H2O)3]+ and [99mTc triple bond N]2+ core for the preparation of potential tumor-targeting agents.
Neoplasms
99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.
Neoplasms
99mTc-MIBI Imaging in the presurgical characterization of thyroid follicular neoplasms: relationship to multidrug resistance protein expression.
Neoplasms
99mTc-MIBI scintigraphy as an indicator of the chemosensitivity of anthracyclines in patients with breast cancer.
Neoplasms
99mTc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between 99mTc-MIBI uptake and P-glycoprotein expression in tumour tissue.
Neoplasms
99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
Neoplasms
99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein.
Neoplasms
99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours.
Neoplasms
99mTc-Sestamibi, a sensitive probe for in vivo imaging of P-glycoprotein inhibition by modulators and mdr1 antisense oligodeoxynucleotides.
Neoplasms
99mTc-tetrofosmin scintigraphy in musculoskeletal tumours: the relationship between P-glycoprotein expression and tetrofosmin uptake in malignant lesions.
Neoplasms
99Tcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant.
Neoplasms
99Tcm-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer.
Neoplasms
?-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Neoplasms
?Np63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis.
Neoplasms
A "no-touch-technique" in mandibular reconstruction with reconstruction plate and free flap transfer.
Neoplasms
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
Neoplasms
A 20(S)-protopanaxadiol derivative PPD12 reverses ABCB1-mediated multidrug resistance with oral bioavailability and low toxicity.
Neoplasms
A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line.
Neoplasms
A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P-glycoprotein gene.
Neoplasms
A benzophenazine derivative, N-beta-dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxy-benzo[a]phenazine-6-carboxamide, as a new antitumor agent against multidrug-resistant and sensitive tumors.
Neoplasms
A Benzopyrane Derivative as a P-Glycoprotein Stimulator: A Potential Agent to Decrease ?-Amyloid Accumulation in Alzheimer's Disease.
Neoplasms
A biophysical model of passive and polarized active transport processes in Caco-2 cells: approaches to uncoupling apical and basolateral membrane events in the intact cell.
Neoplasms
A case of colon cancer recurrence with P-glycoprotein treated by methotrexate, fluorouracil, and leucovorin.
Neoplasms
A case of malignant schwannoma with overexpression of multidrug resistance gene (MDR1) after chemotherapy.
Neoplasms
A case of pulmonary adenocarcinoma with overexpression of multidrug resistance-associated protein and p53 aberration.
Neoplasms
A CD44-Targeting Programmable Drug Delivery System for Enhancing and Sensitizing Chemotherapy to Drug-Resistant Cancer.
Neoplasms
A century of thioxanthones: through synthesis and biological applications.
Neoplasms
A Combined Bioinformatic and Nanoparticle-Based Study Reveal the Role of ABCG2 in the Resistance of Breast Cancer.
Neoplasms
A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators.
Neoplasms
A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.
Neoplasms
A comparison of the modulation of antiblastics cytotoxicity by verapamil and dipyridamole in a human colon carcinoma cell line.
Neoplasms
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
Neoplasms
A computational study of the inhibition mechanisms of P-glycoprotein mediated paclitaxel efflux by kinase inhibitors.
Neoplasms
A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma.
Neoplasms
A diagnostic tool for monitoring multidrug resistance expression in human tumor tissues.
Neoplasms
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
Neoplasms
A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin.
Neoplasms
A dual pH-sensitive liposomal system with charge-reversal and NO generation for overcoming multidrug resistance in cancer.
Neoplasms
A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines.
Neoplasms
A dual-fluorescence high-throughput cell line system for probing multidrug resistance.
Neoplasms
A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model.
Neoplasms
A functional steroid-binding element in an ATP-binding cassette multidrug transporter.
Neoplasms
A Gene Optimization Strategy that Enhances Production of Fully Functional P-Glycoprotein in Pichia pastoris.
Neoplasms
A High Throughput Micro-Chamber Array Device for Single Cell Clonal Cultivation and Tumor Heterogeneity Analysis.
Neoplasms
A high-throughput cell-based assay for inhibitors of ABCG2 activity.
Neoplasms
A highly tumor-targeted nanoparticle of podophyllotoxin penetrated tumor core and regressed multidrug resistant tumors.
Neoplasms
A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation.
Neoplasms
A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function.
Neoplasms
A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma.
Neoplasms
A liquid chromatography-tandem mass spectrometry-based targeted proteomics assay for monitoring P-glycoprotein levels in human breast tissue.
Neoplasms
A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer.
Neoplasms
A longitudinal study of ABC transporter expression in canine multicentric lymphoma.
Neoplasms
A Low Dose of Aripiprazole Has the Strongest Sensitization Effect Among 19 Repositioned Bipolar Drugs in P-gp-overexpressing Drug-resistant Cancer Cells.
Neoplasms
A Machine Learning-Based Prediction Platform for P-Glycoprotein Modulators and Its Validation by Molecular Docking.
Neoplasms
A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity.
Neoplasms
A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Neoplasms
A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature.
Neoplasms
A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug-resistant tumor cells.
Neoplasms
A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells.
Neoplasms
A multifunctional poly(curcumin) nanomedicine for dual-modal targeted delivery, intracellular responsive release, dual-drug treatment and imaging of multidrug resistant cancer cells.
Neoplasms
A myrsinol diterpene isolated from
Neoplasms
A nanoliposome-based photoactivable drug delivery system for enhanced cancer therapy and overcoming treatment resistance.
Neoplasms
A new anticancer compound, Oblongifolin C, inhibits tumor growth and promotes apoptosis in HeLa cells through bax activation.
Neoplasms
A New Class of 1-Aryl-5,6-dihydropyrrolo[2,1-a]isoquinoline Derivatives as Reversers of P-Glycoprotein-Mediated Multidrug Resistance in Tumor Cells.
Neoplasms
A new function of isonitrile as an inhibitor of the Pdr5p multidrug ABC transporter in Saccharomyces cerevisiae.
Neoplasms
A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents.
Neoplasms
A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Neoplasms
A new insight into the reversal of multidrug resistance in cancer by nanodrugs.
Neoplasms
A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells.
Neoplasms
A new monoclonal antibody, P2A8(6), that specifically recognizes a novel epitope on the multidrug resistance-associated protein 1 (MRP1), but not on MRP2 nor MRP3.
Neoplasms
A new P-glycoprotein inhibitor from the caper spurge (Euphorbia lathyris).
Neoplasms
A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor.
Neoplasms
A new type of hazardous chemical: the chemosensitizers of multixenobiotic resistance.
Neoplasms
A Nitric Oxide Storage and Transport System That Protects Activated Macrophages from Endogenous Nitric Oxide Cytotoxicity.
Neoplasms
A novel anti-microtubule agent with carbazole and benzohydrazide structures suppresses tumor cell growth in vivo.
Neoplasms
A novel approach for enriching cancer stem cells from the human SW-13 adrenocortical carcinoma cell line.
Neoplasms
A novel approach to overcome multidrug resistance: utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors.
Neoplasms
A novel areneisonitrile Tc complex inhibits the transport activity of MDR P-glycoprotein.
Neoplasms
A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.
Neoplasms
A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
Neoplasms
A novel bioassay for P-glycoprotein functionality using cytochalasin D.
Neoplasms
A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
Neoplasms
A novel calmodulin antagonist O-(4-ethoxyl-butyl)-berbamine overcomes multidrug resistance in drug-resistant MCF-7/ADR breast carcinoma cells.
Neoplasms
A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.
Neoplasms
A novel compound RY10-4 downregulates P-glycoprotein expression and reverses multidrug-resistant phenotype in human breast cancer MCF-7/ADR cells.
Neoplasms
A novel curcumin derivative which inhibits P-glycoprotein, arrests cell cycle and induces apoptosis in multidrug resistance cells.
Neoplasms
A novel delocalized lipophilic cation-chlorambucil conjugate inhibits P-glycoprotein in HepG2/ADM cells.
Neoplasms
A novel flavonoid from Fissistigma cupreonitens, 5?hydroxy?7,8?dimethoxyflavanone, competitively inhibited the efflux function of human P-glycoprotein and reversed cancer multi-drug resistance.
Neoplasms
A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport.
Neoplasms
A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells.
Neoplasms
A novel individual-cell-based mathematical model based on multicellular tumour spheroids for evaluating doxorubicin-related delivery in avascular regions.
Neoplasms
A novel mechanism governing the transcriptional regulation of ABC transporters in MDR cancer cells.
Neoplasms
A novel method to detect translation of membrane proteins following microvesicle intercellular transfer of nucleic acids.
Neoplasms
A novel miR-203-DNMT3b-ABCG2 regulatory pathway predisposing colorectal cancer development.
Neoplasms
A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer.
Neoplasms
A novel non-natural nucleoside that influences P-glycoprotein activity and mediates drug resistance.
Neoplasms
A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
Neoplasms
A novel synthetic microtubule inhibitor exerts antiproliferative effects in multidrug resistant cancer cells and cancer stem cells.
Neoplasms
A novel taxane active against an orthotopically growing human glioma xenograft.
Neoplasms
A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.
Neoplasms
A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1).
Neoplasms
A nuclear targeted dual-photosensitizer for drug-resistant cancer therapy with NIR activated multiple ROS.
Neoplasms
A P-glycoprotein homologue of Plasmodium falciparum is localized on the digestive vacuole.
Neoplasms
A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile.
Neoplasms
A patient with classic severe primary hyperparathyroidism in whom both Tc-99m MIBI scintigraphy and FDG-PET failed to detect the parathyroid tumor.
Neoplasms
A personalized and long-acting local therapeutic platform combining photothermal therapy and chemotherapy for the treatment of multidrug-resistant colon tumor.
Neoplasms
A pH/ROS cascade-responsive and self-accelerating drug release nanosystem for the targeted treatment of multi-drug-resistant colon cancer.
Neoplasms
A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1(R) in Combination With Paclitaxel in Solid Tumors.
Neoplasms
A Pharmacological Strategy Using Stemofoline for more Efficacious Chemotherapeutic Treatments Against Human Multidrug Resistant Leukemic Cells
Neoplasms
A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer.
Neoplasms
A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer.
Neoplasms
A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors.
Neoplasms
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
Neoplasms
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
Neoplasms
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.
Neoplasms
A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.
Neoplasms
A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.
Neoplasms
A polycation coated liposome as efficient siRNA carrier to overcome multidrug resistance.
Neoplasms
A polymorphic drug pump in the malaria parasite.
Neoplasms
A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity.
Neoplasms
A potentially functional polymorphism in ABCG2 predicts clinical outcome of non-small cell lung cancer in a Chinese population.
Neoplasms
A Prediction Method for P-glycoprotein-Mediated Drug-Drug Interactions at the Human Blood-Brain Barrier From Blood Concentration-Time Profiles, Validated With PET Data.
Neoplasms
A rapid and sensitive UPLC-MS/MS method for determination of HZ08 in rat plasma and tissues: application to a pharmacokinetic study of liposome injections.
Neoplasms
A relationship between multidrug resistance and growth-state dependent cytotoxicity of the lysosomotropic detergent N-dodecylimidazole.
Neoplasms
A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma.
Neoplasms
A role for ABCG2 beyond drug transport: regulation of autophagy.
Neoplasms
A role for P-glycoprotein in regulating cell death.
Neoplasms
A Salmonella nanoparticle mimic overcomes multidrug resistance in tumours.
Neoplasms
A Selective ATP-Binding Cassette Subfamily G Member 2 Efflux Inhibitor Revealed via High-Throughput Flow Cytometry.
Neoplasms
A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Neoplasms
A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and ?-III tubulin mediated tumor drug resistance in vitro.
Neoplasms
A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines.
Neoplasms
A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow.
Neoplasms
A sequentially responsive nanosystem breaches cascaded bio-barriers and suppresses P-glycoprotein function for reversing cancer drug resistance.
Neoplasms
A single active catalytic site is sufficient to promote transport in P-glycoprotein.
Neoplasms
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.
Neoplasms
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.
Neoplasms
A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Neoplasms
A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.
Neoplasms
A Transformable Chimeric Peptide for Cell Encapsulation to Overcome Multidrug Resistance.
Neoplasms
A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways.
Neoplasms
A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.
Neoplasms
ABC efflux transporters at blood-central nervous system barriers and their implications for treating spinal cord disorders.
Neoplasms
ABC transporter gene expression in benign and malignant ovarian tissue.
Neoplasms
ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.
Neoplasms
ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy.
Neoplasms
ABC transporters and neuroblastoma.
Neoplasms
ABC transporters as mediators of drug resistance and contributors to cancer cell biology.
Neoplasms
ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy.
Neoplasms
ABC transporters in cancer: more than just drug efflux pumps.
Neoplasms
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development.
Neoplasms
ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier.
Neoplasms
ABC transporters: Regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma.
Neoplasms
ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer.
Neoplasms
ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942.
Neoplasms
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
Neoplasms
ABCB1 (P-glycoprotein) but not ABCC1 (MRP1) is downregulated in peripheral blood mononuclear cells of spontaneously hypertensive rats.
Neoplasms
ABCB1 (rs1128503) polymorphism and response to chemotherapy in patients with malignant tumors-evidences from a meta-analysis.
Neoplasms
ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition.
Neoplasms
ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling.
Neoplasms
ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers.
Neoplasms
ABCB1 and SLCO1B1 gene polymorphisms predict methotrexate-resistant for low-risk gestational trophoblastic neoplasia.
Neoplasms
ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel.
Neoplasms
ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer.
Neoplasms
ABCB1 genetic polymorphism and risk of upper aerodigestive tract cancers among smokers, tobacco chewers and alcoholics in an Indian population.
Neoplasms
ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136.
Neoplasms
ABCB1 identifies a subpopulation of uveal melanoma cells with high metastatic propensity.
Neoplasms
ABCB1 in dermatology: roles in skin diseases and their treatment.
Neoplasms
ABCB1 is predominantly expressed in human fetal neural stem/progenitor cells at an early development stage.
Neoplasms
ABCB1 pharmacogenetics: progress, pitfalls, and promise.
Neoplasms
ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy.
Neoplasms
ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo.
Neoplasms
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma.
Neoplasms
ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier.
Neoplasms
ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux.
Neoplasms
ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript.
Neoplasms
ABCC1 is related to the protection of the distal nephron against hyperosmolality and high sodium environment: possible implications for cancer chemotherapy.
Neoplasms
ABCC1-exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1 Shortens Survival of Mice and Patients with Breast Cancer.
Neoplasms
Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response.
Neoplasms
ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells.
Neoplasms
ABCC2 (MRP2, cMOAT) Localized in the Nuclear Envelope of Breast Carcinoma Cells Correlates with Poor Clinical Outcome.
Neoplasms
ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.
Neoplasms
ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity.
Neoplasms
ABCC3 Expressed by CD56dim CD16+ NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy.
Neoplasms
ABCC4 copy number variation is associated with susceptibility to esophageal squamous cell carcinoma.
Neoplasms
ABCG transporters: structure, substrate specificities and physiological roles : a brief overview.
Neoplasms
ABCG2 (BCRP) expression in normal and malignant hematopoietic cells.
Neoplasms
ABCG2 (BCRP): a cytoprotectant in normal and malignant stem cells.
Neoplasms
ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions.
Neoplasms
ABCG2 -- a transporter for all seasons.
Neoplasms
ABCG2 confers promotion in gastric cancer through modulating downstream CRKL in vitro combining with biostatistics mining.
Neoplasms
ABCG2 downregulation in glioma stem cells enhances the therapeutic efficacy of demethoxycurcumin.
Neoplasms
ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.
Neoplasms
ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma.
Neoplasms
ABCG2 expression is related to low 5-ALA photodynamic diagnosis (PDD) efficacy and cancer stem cell phenotype, and suppression of ABCG2 improves the efficacy of PDD.
Neoplasms
ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib.
Neoplasms
ABCG2 influence on the efficiency of photodynamic therapy in glioblastoma cells.
Neoplasms
ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
Neoplasms
ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
Neoplasms
ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.
Neoplasms
ABCG2 is a potential marker of tumor-initiating cells in breast cancer.
Neoplasms
ABCG2 is a potential prognostic marker of overall survival in patients with clear cell renal cell carcinoma.
Neoplasms
ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma.
Neoplasms
ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity.
Neoplasms
ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis.
Neoplasms
ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma.
Neoplasms
ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
Neoplasms
ABCG2 is required to control the sonic hedgehog pathway in side population cells with stem-like properties.
Neoplasms
ABCG2 localizes to the nucleus and modulates CDH1 expression in lung cancer cells.
Neoplasms
ABCG2 membrane transporter in mature human erythrocytes is exclusively homodimer.
Neoplasms
ABCG2 Overexpression Confers Poor Outcomes in Hepatocellular Carcinoma of Elderly Patients.
Neoplasms
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.
Neoplasms
ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer.
Neoplasms
ABCG2 regulated by MAPK pathways is associated with cancer progression in laryngeal squamous cell carcinoma.
Neoplasms
ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells.
Neoplasms
ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines.
Neoplasms
ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy.
Neoplasms
ABCG2 transporter: therapeutic and physiologic implications in veterinary species.
Neoplasms
ABCG2 transports anticancer drugs via a closed-to-open switch.
Neoplasms
ABCG2-mediated suppression of chlorin e6 accumulation and photodynamic therapy efficiency in glioblastoma cell lines can be reversed by KO143.
Neoplasms
ABCG2/BCRP: Specific and Nonspecific Modulators.
Neoplasms
ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells.
Neoplasms
ABCG2: a perspective.
Neoplasms
ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy.
Neoplasms
ABCG2: determining its relevance in clinical drug resistance.
Neoplasms
ABCG2: recent discovery of potent and highly selective inhibitors.
Neoplasms
ABCG2: structure, function and role in drug response.
Neoplasms
ABCG2: the key to chemoresistance in cancer stem cells?
Neoplasms
Aberrant activation of Wnt/catenin signaling and overexpression of ABCG2 contributes to apoptosis down regulation and tumor progression of high grade ovarian cancer.
Neoplasms
Aberrantly elevated redox sensing factor Nrf2 promotes cancer stem cell survival via enhanced transcriptional regulation of ABCG2 and Bcl-2/Bmi-1 genes.
Neoplasms
Ability of polymer-bound P-glycoprotein inhibitor ritonavir to overcome multidrug resistance in various resistant neuroblastoma cell lines.
Neoplasms
About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work.
Neoplasms
Absolute levels of MDR-1, MRP, and BCL-2 MRNA and tumor remission in acute leukemia.
Neoplasms
Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein.
Neoplasms
Accurate monitoring of promoter gene methylation with high-resolution melting polymerase chain reaction using the ABCB1 gene as a model.
Neoplasms
Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells.
Neoplasms
Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38.
Neoplasms
Acquired ABC-transporter overexpression in cancer cells: transcriptional induction or Darwinian selection?
Neoplasms
Acquisition of doxorubicin resistance in human leukemia HL-60 cells is reproducibly associated with 7q21 chromosomal anomalies.
Neoplasms
Acquisition of MDR phenotype by leukemic cells is associated with increased caspase-3 activity and a collateral sensitivity to cold stress.
Neoplasms
Acridones circumvent P-glycoprotein-associated multidrug resistance (MDR) in cancer cells.
Neoplasms
Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation.
Neoplasms
Activatable nanomedicine for overcoming hypoxia-induced resistance to chemotherapy and inhibiting tumor growth by inducing collaborative apoptosis and ferroptosis in solid tumors.
Neoplasms
Activation of Alternate Pro-Survival Pathways Accounts for Acquired Sunitinib Resistance in U87MG Glioma Xenografts.
Neoplasms
Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer.
Neoplasms
Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists.
Neoplasms
Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway.
Neoplasms
Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain.
Neoplasms
Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells.
Neoplasms
Activation of the human multidrug resistance-1 (mdr1) gene promoter in response to inhibitors of DNA topoisomerases.
Neoplasms
Activation of the human P-glycoprotein ATPase by trypsin.
Neoplasms
Active participation of membrane lipids in inhibition of multidrug transporter P-glycoprotein.
Neoplasms
Active Tumor-Targeted co-Delivery of Epigallocatechin Gallate and Doxorubicin in Nanoparticles for Combination Gastric Cancer Therapy.
Neoplasms
Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis.
Neoplasms
Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma.
Neoplasms
Activity of drug efflux transporters in tumor cells under hypoxic conditions.
Neoplasms
Activity of Fourteen New Hydantoin Compounds on the Human ABCB1 Efflux Pump.
Neoplasms
Acute exposure to doxorubicin results in increased cardiac P-glycoprotein expression.
Neoplasms
Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts.
Neoplasms
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Neoplasms
Addressing the potential toxicities of the non-specific P-glycoprotein modulation by amalgamation with targeted approach in MDR tumors.
Neoplasms
Adenovirus vector infection of non-small-cell lung cancer cells is a trigger for multi-drug resistance mediated by P-glycoprotein.
Neoplasms
ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning.
Neoplasms
Adrenaline induces chemoresistance in HT-29 colon adenocarcinoma cells.
Neoplasms
Advance In-silico based Predictive In-Vivo Profiling of Novel Potent ?-Glucuronidase Inhibitors.
Neoplasms
Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement.
Neoplasms
Advanced nanoscale carrier-based approaches to overcome biopharmaceutical issues associated with anticancer drug 'Etoposide'.
Neoplasms
Advanced ovarian cancer. Drug resistance, supportive care and dose intensity.
Neoplasms
Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends.
Neoplasms
Advances in the treatment of urothelial tract tumors.
Neoplasms
Adverse Cell Culture Conditions Mimicking the Tumor Microenvironment Upregulate ABCG2 to Mediate Multidrug Resistance and a More Malignant Phenotype.
Neoplasms
Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
Neoplasms
Agents which reverse multidrug-resistance are inhibitors of [3H]vinblastine transport by isolated vesicles.
Neoplasms
Aging-related Repositioned Drugs, Donepezil and Sildenafil Citrate, Increase Apoptosis of Anti-mitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms.
Neoplasms
Algerian Propolis Potentiates Doxorubicin Mediated Anticancer Effect against Human Pancreatic PANC-1 Cancer Cell Line through Cell Cycle Arrest, Apoptosis Induction and P-Glycoprotein Inhibition.
Neoplasms
Alkylated monoterpene indole alkaloid derivatives as potent P-glycoprotein inhibitors in resistant cancer cells.
Neoplasms
Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling.
Neoplasms
alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6,7-dimethoxy-alpha- [(4-methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile (CL 329,753): a novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine A.
Neoplasms
Alpha-Mangostin Reverses Multidrug Resistance by Attenuating the Function of the Multidrug Resistance-Linked ABCG2 Transporter.
Neoplasms
Alteration of Bile Acid and Cholesterol Biosynthesis and Transport by Perfluorononanoic Acid (PFNA) in Mice.
Neoplasms
Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
Neoplasms
Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder.
Neoplasms
Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein.
Neoplasms
Altered expression of beta 1 integrins in renal carcinoma cell lines exposed to vinblastine.
Neoplasms
Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.
Neoplasms
Altered expression of the genes regulating apoptosis in multidrug resistant human myeloid leukemia cell lines overexpressing MDR1 or MRP gene.
Neoplasms
Altered expression of the xenobiotic transporter P-glycoprotein in liver and liver tumours of mummichog Fundulus heteroclitus from a creosote-contaminated environment.
Neoplasms
Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.
Neoplasms
Altering Nitrogen Heterocycles of AZD2461 Affords High Affinity Poly(ADP-ribose) Polymerase-1 Inhibitors with Decreased P-Glycoprotein Interactions.
Neoplasms
Alternating current electrical stimulation enhanced chemotherapy: a novel strategy to bypass multidrug resistance in tumor cells.
Neoplasms
Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.
Neoplasms
Alu-associated interstitial deletions and chromosomal re-arrangement in 2 human multidrug-resistant cell lines.
Neoplasms
AMPK and Cancer.
Neoplasms
Amplification and expression of mdr1 gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69.
Neoplasms
Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer.
Neoplasms
Amplification of the multidrug resistance gene pfmdr1 in Plasmodium falciparum has arisen as multiple independent events.
Neoplasms
Amyrsinol diterpene isolated from a traditional herbal medicine, LANGDU reverses multidrug resistance in breast cancer cells.
Neoplasms
An ABC transporter drives medulloblastoma pathogenesis by regulating Sonic Hedgehog signaling.
Neoplasms
An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.
Neoplasms
An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulfide cross-linking and homology modeling.
Neoplasms
An Energetically Favorable Ligand Entrance Gate of a Multidrug Transporter Revealed by Partial Nudged Elastic Band Simulations.
Neoplasms
An episomally maintained MDR1 gene for gene therapy.
Neoplasms
An extracellular matrix (ECM) model at high malignant colorectal tumor increases chondroitin sulfate chains to promote epithelial-mesenchymal transition and chemoresistance acquisition.
Neoplasms
An in silico approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network.
Neoplasms
An in vitro and in vivo study of a novel zinc complex, zinc N-(2-hydroxyacetophenone)glycinate to overcome multidrug resistance in cancer.
Neoplasms
An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.
Neoplasms
An insight into the structure of 5-spiro aromatic derivatives of imidazolidine-2,4-dione, a new group of very potent inhibitors of tumor multidrug resistance in T-lymphoma cells.
Neoplasms
An isoquinoline alkaloid from the Chinese herbal plant Corydalis yanhusuo W.T. Wang inhibits P-glycoprotein and multidrug resistance-associate protein 1.
Neoplasms
An MDR-EGFP gene fusion allows for direct cellular localization, function and stability assessment of P-glycoprotein.
Neoplasms
An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells.
Neoplasms
An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms.
Neoplasms
An oxygen self-sufficient NIR-responsive nanosystem for enhanced PDT and chemotherapy against hypoxic tumors.
Neoplasms
An update on circumventing multidrug resistance in cancer by targeting P-glycoprotein.
Neoplasms
An updated patent review on P-glycoprotein inhibitors (2011-2018).
Neoplasms
Analogs of a 4-aminothieno[2,3-d]pyrimidine lead (QB13) as modulators of P-glycoprotein substrate specificity.
Neoplasms
Analysis and partial reversal of multidrug resistance to anthelmintics due to P-glycoprotein in Haemonchus contortus eggs using Lens culinaris lectin.
Neoplasms
Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling.
Neoplasms
Analysis of ABCG2 methylation in stool samples of Chinese healthy males by pyrosequencing.
Neoplasms
Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance.
Neoplasms
Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines.
Neoplasms
Analysis of gene expression profiles as a tool to uncover tumor markers of liver cancer progression in a rat model.
Neoplasms
Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells.
Neoplasms
Analysis of P-glycoprotein expression in osteosarcoma.
Neoplasms
Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy.
Neoplasms
Analysis of the effect of the bovine ABCG2 SNP Y581S on transcellular transport of veterinary drugs using new cell culture models.
Neoplasms
Analysis of the Impact of Extracellular Acidity on the Expression and Activity of P-glycoprotein and on the P-glycoprotein-mediated Cytotoxicity of Daunorubicin in Cancer Cell by Microfluidic Chip Technology.
Neoplasms
Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane.
Neoplasms
Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients.
Neoplasms
Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
Neoplasms
Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
Neoplasms
Animal model of drug-resistant tumor progression.
Neoplasms
Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide.
Neoplasms
Anti-ABCG2 scFv antibody of lung adenocarcinoma increases chemosensitivity and induces apoptosis through the activation of mitochondrial pathway.
Neoplasms
Anti-AIDS agents 89. Identification of DCX derivatives as anti-HIV and chemosensitizing dual function agents to overcome P-gp-mediated drug resistance for AIDS therapy.
Neoplasms
Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
Neoplasms
Anti-Cancer Peptides from RAS-P21 AND P53 Proteins.
Neoplasms
Anti-MDR1 siRNA Restores Chemosensitivity in Chemoresistant Breast Carcinoma and Osteosarcoma Cell Lines.
Neoplasms
Anti-proliferative activity and suppression of P-glycoprotein by (-)-antofine, a natural phenanthroindolizidine alkaloid, in paclitaxel-resistant human lung cancer cells.
Neoplasms
Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo.
Neoplasms
Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines.
Neoplasms
Antibodies in the study of multiple drug resistance.
Neoplasms
Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter.
Neoplasms
Antibody C219 recognizes an alpha-helical epitope on P-glycoprotein.
Neoplasms
Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue.
Neoplasms
Anticancer activity of 5-benzylidene-2-phenylimino-1, 3-thiazolidin-4-one (BPT) analogs.
Neoplasms
Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?
Neoplasms
Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.
Neoplasms
Antiepileptic drugs alter the expression of placental carriers: An in vitro study in a human placental cell line.
Neoplasms
Antiestrogens and steroid hormones: substrates of the human P-glycoprotein.
Neoplasms
Antigens associated with multidrug resistance in H69AR, a small cell lung cancer cell line.
Neoplasms
Antioxidant defenses in a B16 melanoma line resistant to doxorubicin: an in vivo study.
Neoplasms
Antiproliferative and cytotoxic activities of furocoumarins of Ducrosia anethifolia.
Neoplasms
Antiproliferative and cytotoxic effects of geldanamycin, cytochalasin E, suramin and thiacetazone in human prostate xenograft tumor histocultures.
Neoplasms
Antiproliferative prostaglandins and the MRP/GS-X pump role in cancer immunosuppression and insight into new strategies in cancer gene therapy.
Neoplasms
ANTIPSYCHOTICS REVERSE P-GLYCOPROTEIN-MEDIATED DOXORUBICIN RESISTANCE IN HUMAN UTERINE SARCOMA MES-SA/Dx5 CELLS: A NOVEL APPROACH TO CANCER CHEMOTHERAPY.
Neoplasms
Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates.
Neoplasms
Antisense targeting of p-glycoprotein expression in tissue culture.
Neoplasms
Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer.
Neoplasms
Antitumor activity of KF22678, a novel thioester derivative of leinamycin.
Neoplasms
Antitumor activity of KW-2170, a novel pyrazoloacridone derivative.
Neoplasms
Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action.
Neoplasms
Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Neoplasms
Antitumor agents 286. Design, synthesis, and structure-activity relationships of 3'R,4'R-disubstituted-2',2'-dimethyldihydropyrano[2,3-f]chromone (DSP) analogues as potent chemosensitizers to overcome multidrug resistance.
Neoplasms
Antitumour activity of DX-8951f: a new camptothecin derivative.
Neoplasms
Antitumour effect and modulation of expression of the ABCB1 gene by perifosine in canine lymphoid tumour cell lines.
Neoplasms
Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells.
Neoplasms
Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.
Neoplasms
Apoptosis induction and inhibition of drug resistant tumor growth in vivo involving daunorubicin-loaded graphene-gold composites.
Neoplasms
Application of an LC-MS/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique.
Neoplasms
Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients.
Neoplasms
Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET?
Neoplasms
Approaches to the treatment of patients with hormone-sensitive prostate cancer.
Neoplasms
Aptamer-Based Erythrocyte-Derived Mimic Vesicles Loaded with siRNA and Doxorubicin for the Targeted Treatment of Multidrug-Resistant Tumors.
Neoplasms
Aptamer-Functionalized DNA Origami for Targeted Codelivery of Antisense Oligonucleotides and Doxorubicin to Enhance Therapy in Drug-Resistant Cancer Cells.
Neoplasms
AQP5 silencing suppresses p38 MAPK signaling and improves drug resistance in colon cancer cells.
Neoplasms
Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?
Neoplasms
Arginine 383 is a crucial residue in ABCG2 biogenesis.
Neoplasms
Arginine 482 to glycine mutation in ABCG2/BCRP increases etoposide transport and resistance to the drug in HEK-293 cells.
Neoplasms
Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding.
Neoplasms
Arsenic exposure transforms human epithelial stem/progenitor cells into a cancer stem-like phenotype.
Neoplasms
Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.
Neoplasms
Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells.
Neoplasms
Aryl- and Heteroaryl-Thiosemicarbazones Derivatives and Its Metal Complexes: A Pharmacological Template.
Neoplasms
Asclepiasterol, a novel C21 steroidal glycoside derived from Asclepias curassavica, reverses tumor multidrug resistance by down-regulating P-glycoprotein expression.
Neoplasms
Asiatic Acid (AA) Sensitizes Multidrug-Resistant Human Lung Adenocarcinoma A549/DDP Cells to Cisplatin (DDP) via Downregulation of P-Glycoprotein (MDR1) and Its Targets.
Neoplasms
Assessing multidrug resistance protein 1-mediated function in cancer cell multidrug resistance by scanning electrochemical microscopy and flow cytometry.
Neoplasms
Assessing stemness and proliferation properties of the newly established colon cancer 'stem' cell line, CSC480 and novel approaches to identify dormant cancer cells.
Neoplasms
Assessing the Stabilization of P-Glycoprotein's Nucleotide-Binding Domains by the Linker, Using Molecular Dynamics.
Neoplasms
Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography.
Neoplasms
Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy.
Neoplasms
Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors.
Neoplasms
Assessment of resistance to paclitaxel of murine tumors by (99m)Tc-MIBI/(201)Tl dual-radionuclide imaging.
Neoplasms
Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma.
Neoplasms
Assessment of the in vitro and in vivo properties of a (99m)Tc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein.
Neoplasms
Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes.
Neoplasms
Association between ABCB1 immunohistochemical expression and overall survival in gastric cancer patients.
Neoplasms
Association between DNA Methylation in the miR-328 5'-Flanking Region and Inter-individual Differences in miR-328 and BCRP Expression in Human Placenta.
Neoplasms
Association between MDR1 gene of gastrointestinal tumors, the expression of P-glycoprotein and resistance to chemotherapeutic drugs.
Neoplasms
Association between the polymorphism of three genes involved in the methylation and efflux of arsenic (As3MT, MRP1, and P-gp) with lung cancer in a Mexican cohort.
Neoplasms
Association of a genetic variant in ATP-binding cassette sub-family B member 1 gene with poor prognosis in patients with squamous cell carcinoma of the esophagus.
Neoplasms
Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype.
Neoplasms
Association of ABCB1 T-129C polymorphism and multiple myeloma risk in Polish population.
Neoplasms
Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy.
Neoplasms
Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
Neoplasms
Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
Neoplasms
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
Neoplasms
Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma.
Neoplasms
Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
Neoplasms
Association of plasma docetaxel levels with ABCB1 gene polymorphisms and tumour response in locally advanced breast cancer patients of South India on neo-adjuvant chemotherapy.
Neoplasms
Association of single nucleotide polymorphisms of ABCB1, OPRM1 and COMT with pain perception in cancer patients.
Neoplasms
Association of tamoxifen biliary excretion rate with prior tamoxifen exposure and increased mdr1b expression.
Neoplasms
Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
Neoplasms
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.
Neoplasms
Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer.
Neoplasms
Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors.
Neoplasms
Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer.
Neoplasms
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer.
Neoplasms
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Neoplasms
Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy.
Neoplasms
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Neoplasms
ATP-binding cassette transporters in primary central nervous system lymphoma: decreased expression of MDR1 P-glycoprotein and breast cancer resistance protein in tumor capillary endothelial cells.
Neoplasms
ATP-binding Cassette Transporters Substantially Reduce Estimates of ALDH-positive Cancer Cells based on Aldefluor and AldeRed588 Assays.
Neoplasms
ATP-binding cassette, subfamily G (ABCG family).
Neoplasms
ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion.
Neoplasms
ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P.
Neoplasms
ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump.
Neoplasms
ATP-dependent thermostabilization of human P-glycoprotein (ABCB1) is blocked by modulators.
Neoplasms
ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells.
Neoplasms
ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines.
Neoplasms
ATPase activity of purified and reconstituted multidrug resistance protein MRP1 from drug-selected H69AR cells.
Neoplasms
Attenuation of Colchicine Toxicity in Drug-resistant Cancer Cells by Co-treatment with Anti-malarial Drugs.
Neoplasms
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Neoplasms
Augmenter of liver regeneration potentiates doxorubicin anticancer efficacy by reducing the expression of ABCB1 and ABCG2 in hepatocellular carcinoma.
Neoplasms
Aureobasidins as new inhibitors of P-glycoprotein in multidrug resistant tumor cells.
Neoplasms
Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter.
Neoplasms
Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.
Neoplasms
Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma.
Neoplasms
Avapritinib: A Selective Inhibitor of KIT and PDGFR? that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
Neoplasms
Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.
Neoplasms
Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats.
Neoplasms
Azoreductase-Responsive Metal-Organic Framework-Based Nanodrug for Enhanced Cancer Therapy via Breaking Hypoxia-induced Chemoresistance.
Neoplasms
B9209-005, an azido derivative of the chemosensitizer dexniguldipine-HCl, photolabels P-glycoprotein.
Neoplasms
Backstabbing P-gp: Side-Chain Cleaved Ecdysteroid 2,3-Dioxolanes Hyper-Sensitize MDR Cancer Cells to Doxorubicin without Efflux Inhibition.
Neoplasms
Bacterial delivery of RNAi effectors: transkingdom RNAi.
Neoplasms
Bacterial Template Synthesis of Multifunctional Nanospindles for Glutathione Detection and Enhanced Cancer-Specific Chemo-Chemodynamic Therapy.
Neoplasms
Barbigerone reverses multidrug resistance in breast MCF-7/ADR cells.
Neoplasms
BCH-1868 [(-)-2-R-dihydroxyphosphinoyl-5-(S)-(guanin-9'-yl-methyl) tetrahydrofuran]: a cyclic nucleoside phosphonate with antitumor activity.
Neoplasms
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Neoplasms
Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.
Neoplasms
Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
Neoplasms
Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients.
Neoplasms
Betulinic acid does not modulate the activity of P-gp/ABCB1 or MRP1/ABCC1 in a non-tumoral renal cell line: Possible utility in multidrug resistance cancer chemotherapy.
Neoplasms
Betulinic Acid Exerts Cytotoxic Activity Against Multidrug-Resistant Tumor Cells via Targeting Autocrine Motility Factor Receptor (AMFR).
Neoplasms
bfr1+, a novel gene of Schizosaccharomyces pombe which confers brefeldin A resistance, is structurally related to the ATP-binding cassette superfamily.
Neoplasms
BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport.
Neoplasms
BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells.
Neoplasms
Bifunctional liposomes reduce the chemotherapy resistance of doxorubicin induced by reactive oxygen species.
Neoplasms
Bile Acids Increase Doxorubicin Sensitivity in ABCC1-expressing Tumour Cells.
Neoplasms
Bile canalicular cationic dye secretion as a model for P-glycoprotein mediated transport.
Neoplasms
Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein.
Neoplasms
Binding of modulators to mouse and human multidrug resistance P-glycoprotein. A computational study.
Neoplasms
Bioavailability of tyrosine kinase inhibitors: an added component of assessment.
Neoplasms
Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder.
Neoplasms
Biochemical Mechanism of Modulation of Human P-glycoprotein by Stemofoline.
Neoplasms
Biochemical, cellular, and pharmacological aspects of the multidrug transporter.
Neoplasms
Biochemical, genetic, and metabolic adaptations of tumor cells that express the typical multidrug-resistance phenotype. Reversion by new therapies.
Neoplasms
Biochemistry and pharmacology of the human multidrug resistance gene product, ABCG2.
Neoplasms
Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Neoplasms
Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug-gene co-delivery to cancer cells.
Neoplasms
Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates.
Neoplasms
Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1).
Neoplasms
Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice.
Neoplasms
Bioinformatics Analysis of the Expression of ATP Binding Cassette Subfamily C Member 3 (ABCC3) in Human Glioma.
Neoplasms
Biologic characteristics of the side population of human small cell lung cancer cell line H446.
Neoplasms
Biological Characterization of an Improved Pyrrole-Based Colchicine Site Agent Identified through Structure-Based Design.
Neoplasms
Biological evaluation of bishydroxymethyl-substituted cage dimeric 1,4-dihydropyridines as a novel class of p-glycoprotein modulating agents in cancer cells.
Neoplasms
Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor.
Neoplasms
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients.
Neoplasms
Biomarkers for predicting response to regional chemo-immunotherapy in liver metastases from colorectal carcinoma.
Neoplasms
Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase does not change its apoptotic stimuli properties in regard to sensitive and multidrug resistant leukaemia HL60 cells.
Neoplasms
Biosynthesis of Phenylnannolone A, a Multidrug Resistance Reversal Agent from the Halotolerant Myxobacterium Nannocystis pusilla B150.
Neoplasms
Biphasic accumulation kinetics of [99mTc]-hexakis-2-methoxyisobutyl isonitrile in tumour cells and its modulation by lipophilic P-glycoprotein ligands.
Neoplasms
BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma.
Neoplasms
Bisbenzylisoquinoline alkaloids and P-glycoprotein function: A structure activity relationship study.
Neoplasms
Bispecific antibodies reactive with the multidrug-resistance-related glycoprotein and CD3 induce lysis of multidrug-resistant tumor cells.
Neoplasms
Blended nanoparticle system based on miscible structurally similar polymers: a safe, simple, targeted, and surprisingly high efficiency vehicle for cancer therapy.
Neoplasms
Blood-Brain Barrier and Breast Cancer Resistance Protein: a limit to the therapy of CNS tumors and neurodegenerative diseases.
Neoplasms
BME, a novel compound of anthraquinone, down regulated P-glycoprotein expression in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells via generation of reactive oxygen species.
Neoplasms
BMS181321 accumulation in rodent and human cells: the role of P-glycoprotein.
Neoplasms
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
Neoplasms
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Neoplasms
Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
Neoplasms
Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Neoplasms
Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.
Neoplasms
Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model.
Neoplasms
Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain.
Neoplasms
Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents.
Neoplasms
BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance.
Neoplasms
Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.
Neoplasms
Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Neoplasms
Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
Neoplasms
Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.
Neoplasms
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.
Neoplasms
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.
Neoplasms
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
Neoplasms
Breast cancer resistance protein is the enemy of hypericin accumulation and toxicity of hypericin-mediated photodynamic therapy.
Neoplasms
Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
Neoplasms
Breast cancer resistance protein/ABCG2 is differentially regulated downstream of extracellular signal-regulated kinase.
Neoplasms
Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer.
Neoplasms
Breast cancer, side population cells and ABCG2 expression.
Neoplasms
Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics.
Neoplasms
Bridge Linkage Role Played by CD98hc of Anti-Tumor Drug Resistance and Cancer Metastasis on Cisplatin-Resistant Ovarian Cancer Cells.
Neoplasms
Bromocriptine enhances the uptake of (99m)Tc-MIBI in patients with hepatocellular carcinoma.
Neoplasms
Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells.
Neoplasms
Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells.
Neoplasms
Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.
Neoplasms
By-passing of P-glycoprotein using immunoliposomes.
Neoplasms
Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies.
Neoplasms
Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy.
Neoplasms
C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
Neoplasms
C-Isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance.
Neoplasms
c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia.
Neoplasms
c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.
Neoplasms
C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
Neoplasms
Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model.
Neoplasms
Caffeic Acid Attenuates Multi-Drug Resistance in Cancer Cells by Inhibiting Efflux Function of Human P-glycoprotein.
Neoplasms
Caged-xanthone from Cratoxylum formosum ssp. pruniflorum inhibits malignant cancer phenotypes in multidrug-resistant human A549 lung cancer cells through down-regulation of NF-?B.
Neoplasms
Calcium signal abnormalities in murine T lymphocytes that express the multidrug transporter P-glycoprotein.
Neoplasms
Can curcumin along with chemotherapeutic drug and lipid provide an effective treatment of metastatic colon cancer and alter multidrug resistance?
Neoplasms
Can long range mechanical interaction between drugs and membrane proteins define the notion of molecular promiscuity? Application to P-glycoprotein-mediated multidrug resistance (MDR).
Neoplasms
Can P-glycoprotein expression on malignant tumor tissues predict opioid transport at the blood-brain barrier in cancer patients?
Neoplasms
Can the assessment of ABCB1 gene expression predict its function in vitro?
Neoplasms
Cancer Cell Membrane Decorated Silica Nanoparticle Loaded with miR495 and Doxorubicin to Overcome Drug Resistance for Effective Lung Cancer Therapy.
Neoplasms
Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement.
Neoplasms
Cancer stem cell characteristics in retinoblastoma.
Neoplasms
Cancer stem cell markers in eyelid sebaceous gland carcinoma: high expression of ALDH1, CD133, and ABCG2 correlates with poor prognosis.
Neoplasms
Cancer stem cell markers in pediatric sarcomas: Sox2 is associated with tumorigenicity in immunodeficient mice.
Neoplasms
Cancer Stem Cell Markers in Relation to Patient Survival Outcomes: Lessons for Integrative Diagnostics and Next-Generation Anticancer Drug Development.
Neoplasms
Cancer stem cells in oesophageal squamous cell carcinoma: Identification, prognostic and treatment perspectives.
Neoplasms
Cancer Stem Cells with Overexpression of Neuronal Markers Enhance Chemoresistance and Invasion in Retinoblastoma.
Neoplasms
Cancer Stem Cells: Lessons From Melanoma.
Neoplasms
Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer.
Neoplasms
Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-?1/SMAD2/3 pathway and ABCC1 transactivation.
Neoplasms
Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor.
Neoplasms
Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N- nitrosourea associated with inhibition of multidrug resistance protein (MRP) function.
Neoplasms
Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance.
Neoplasms
Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET.
Neoplasms
Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells.
Neoplasms
Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters.
Neoplasms
Carrier-Free Delivery of Precise Drug-Chemogene Conjugates for Synergistic Treatment of Drug-Resistant Cancer.
Neoplasms
Carrier-Free Supramolecular Hydrogel Composed of Dual Drugs for Conquering Drug Resistance.
Neoplasms
Casein kinase I-dependent phosphorylation and stability of the yeast multidrug transporter Pdr5p.
Neoplasms
Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells.
Neoplasms
Catalytic transitions in the human MDR1 P-glycoprotein drug binding sites.
Neoplasms
Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells.
Neoplasms
Cationic submicron emulsions overcome multidrug resistance in SGC7901/VCR cells.
Neoplasms
Caveolin-1 affects tumor drug resistance in esophageal squamous cell carcinoma by regulating expressions of P-gp and MRP1.
Neoplasms
Caveolin-1 expression in ovarian carcinoma is MDR1 independent.
Neoplasms
CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells.
Neoplasms
CBP501 suppresses macrophage induced cancer stem cell like features and metastases.
Neoplasms
CC-115, a dual mTOR/DNA-PK inhibitor in clinical trial, is a substrate of ABCG2, a risk factor for CC-115 resistance.
Neoplasms
CCN2 promotes drug resistance in osteosarcoma by enhancing ABCG2 expression.
Neoplasms
cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways.
Neoplasms
Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function.
Neoplasms
Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance.
Neoplasms
Celastrol induces lipophagy via the LXR?/ABCA1 pathway in clear cell renal cell carcinoma.
Neoplasms
Celastrol Inhibits the Proliferation and Decreases Drug Resistance of Cisplatin-Resistant Gastric Cancer SGC7901/DDP Cells.
Neoplasms
Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner.
Neoplasms
Celecoxib Prevents Doxorubicin-Induced Multidrug Resistance in Canine and Mouse Lymphoma Cell Lines.
Neoplasms
Celecoxib Up Regulates the Expression of Drug Efflux Transporter ABCG2 in Breast Cancer Cell Lines.
Neoplasms
Cell surface expression of major histocompatibility class I antigens is modulated by P-glycoprotein transporter.
Neoplasms
Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group.
Neoplasms
Cell-type selective phototoxicity achieved with chlorophyll-a derived photosensitizers in a co-culture system of primary human tumor and normal lung cells.
Neoplasms
Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
Neoplasms
Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro.
Neoplasms
Cellular and biophysical evidence for interactions between adenosine triphosphate and P-glycoprotein substrates: functional implications for adenosine triphosphate/drug cotransport in P-glycoprotein overexpressing tumor cells and in P-glycoprotein low-level expressing erythrocytes.
Neoplasms
Cellular and in vitro transport of glutathione conjugates by MRP.
Neoplasms
Cellular and Molecular Mechanism of Ganoderma (Lingzhi) Against Tumor.
Neoplasms
Cellular communication via microparticles: role in transfer of multidrug resistance in cancer.
Neoplasms
Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
Neoplasms
Cellular expression and function of naturally occurring variants of the human ABCG2 multidrug transporter.
Neoplasms
Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins.
Neoplasms
Cellular functions of vaults and their involvement in multidrug resistance.
Neoplasms
Cellular localization of P-glycoprotein in brain versus gonadal capillaries.
Neoplasms
Cellular pattern of multidrug-resistance gene expression during chemical hepatocarcinogenesis in the rat.
Neoplasms
Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines.
Neoplasms
Cellular Processing of the ABCG2 Transporter-Potential Effects on Gout and Drug Metabolism.
Neoplasms
CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function.
Neoplasms
Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
Neoplasms
Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
Neoplasms
Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells.
Neoplasms
Chabamide induces cell cycle arrest and apoptosis by the Akt/MAPK pathway and inhibition of P-glycoprotein in K562/ADR cells.
Neoplasms
Chamaecypanone C, a novel skeleton microtubule inhibitor, with anticancer activity by trigger caspase 8-Fas/FasL dependent apoptotic pathway in human cancer cells.
Neoplasms
Changes in membrane microdomains and caveolae constituents in multidrug-resistant cancer cells.
Neoplasms
Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids.
Neoplasms
Changes in phospholipase D isoform activity and expression in multidrug-resistant human cancer cells.
Neoplasms
Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.
Neoplasms
Changing picture of cellular drug resistance in human leukemia.
Neoplasms
Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents.
Neoplasms
Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.
Neoplasms
Characteristic clinicopathologic features of Epstein-Barr virus-associated peripheral T-cell lymphoma.
Neoplasms
Characterization and Application of a Nose-Only Exposure Chamber for Inhalation Delivery of Liposomal Drugs and Nucleic Acids to Mice.
Neoplasms
Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity.
Neoplasms
Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier.
Neoplasms
Characterization of a new antibody raised against the NH2 terminus of P-glycoprotein.
Neoplasms
Characterization of a new monoclonal antibody F4 detecting cell surface epitope and P-glycoprotein in drug-resistant human tumor cell lines.
Neoplasms
Characterization of a novel 99mTc-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity.
Neoplasms
Characterization of ABC transporters in human skin.
Neoplasms
Characterization of berberine transport into Coptis japonica cells and the involvement of ABC protein.
Neoplasms
Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.
Neoplasms
Characterization of functional assays of multidrug resistance P-glycoprotein transport activity.
Neoplasms
Characterization of hair-follicle side population cells in mouse epidermis and skin tumors.
Neoplasms
Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells.
Neoplasms
Characterization of MRP RNA-protein interactions within the perinucleolar compartment.
Neoplasms
Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation.
Neoplasms
Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2.
Neoplasms
Characterization of P-glycoprotein transport and inhibition in vivo.
Neoplasms
Characterization of prenylcysteines that interact with P-glycoprotein and inhibit drug transport in tumor cells.
Neoplasms
Characterization of proapoptotic compounds from the bark of Garcinia oblongifolia.
Neoplasms
Characterization of seven kidney tumors by flow cytometry: analysis of cell cycle, DNA content and P-glycoprotein expression.
Neoplasms
Characterization of Stem-Like Cells Directly Isolated From Freshly Resected Laryngeal Squamous Cell Carcinoma Specimens.
Neoplasms
Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1).
Neoplasms
Characterization of the azidopine and vinblastine binding site of P-glycoprotein.
Neoplasms
Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Neoplasms
Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes.
Neoplasms
Characterization of the dexniguldipine binding site in the multidrug resistance-related transport protein P-glycoprotein by photoaffinity labeling and mass spectrometry.
Neoplasms
Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell.
Neoplasms
Characterization of tropane alkaloid aromatic esters that reverse the multidrug-resistance phenotype.
Neoplasms
Charge-reversal-functionalized PLGA nanobubbles as theranostic agents for ultrasonic-imaging-guided combination therapy.
Neoplasms
Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp).
Neoplasms
Chemical structure of phenothiazines and their biological activity.
Neoplasms
Chemogenomic analysis identifies geldanamycins as substrates and inhibitors of ABCB1.
Neoplasms
Chemogenomics Approaches to Rationalizing the Mode-of-Action of Traditional Chinese and Ayurvedic Medicines.
Neoplasms
Chemoprevention and inhibition of P-glycoprotein in cancer cells by Chinese medicinal herbs.
Neoplasms
Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers.
Neoplasms
Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
Neoplasms
Chemoresistance in the clinic: overview 1994.
Neoplasms
Chemoresistance of renal cell carcinoma: 1986-1994.
Neoplasms
Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin).
Neoplasms
Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.
Neoplasms
Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP.
Neoplasms
Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation.
Neoplasms
Chemosensitization of murine fibrosarcoma cells to drugs affected by the multidrug resistance phenotype by the antidepressant trazodone - an experimental-model for the reversal of intrinsic drug-resistance.
Neoplasms
Chemosensitizing steroids: glucocorticoid receptor agonists capable of inhibiting P-glycoprotein function.
Neoplasms
Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.
Neoplasms
Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance.
Neoplasms
Chemotherapeutics, chemoresistance and the management of melanoma.
Neoplasms
Chemotherapy and P-glycoprotein expression in chondrosarcoma.
Neoplasms
Chemotherapy drug resistance--a panel discussion.
Neoplasms
Chemotherapy-Induced IL8 Upregulates MDR1/ABCB1 in Tumor Blood Vessels and Results in Unfavorable Outcome.
Neoplasms
Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif.
Neoplasms
Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.
Neoplasms
Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells.
Neoplasms
Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression.
Neoplasms
Chloroquine resistance in Plasmodium falciparum is not reversed by BIBW-22, a compound reversing the multidrug resistance phenotype in mammalian cancer cells.
Neoplasms
Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross.
Neoplasms
Cholesterol reduces the sensitivity to platinum-based chemotherapy via upregulating ABCG2 in lung adenocarcinoma.
Neoplasms
Cholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene.
Neoplasms
Chorioamnionitis Induces a Specific Signature of Placental ABC Transporters Associated with an Increase of miR-331-5p in the Human Preterm Placenta.
Neoplasms
Chromatin-remodeling complex SWI/SNF controls multidrug resistance by transcriptionally regulating the drug efflux pump ABCB1.
Neoplasms
Chronic cadmium exposure induces transcriptional activation of the Wnt pathway and upregulation of epithelial-to-mesenchymal transition markers in mouse kidney.
Neoplasms
Chronic Imatinib Mesylate Exposure Leads to Reduced Intracellular Drug Accumulation by Induction of the ABCG2 (BCRP) and ABCB1 (MDR1) Drug Transport Pumps.
Neoplasms
Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-transporters.
Neoplasms
Cigarette smoke promotes drug resistance and expansion of cancer stem cell-like side population.
Neoplasms
Cigarette Smoke Reduces the Efficacy of Cisplatin in Head and Neck Cancer Cells - Role of ABCG2.
Neoplasms
Cinnamylidene ketones as potential modulators of multidrug resistance in mouse lymphoma and human colon cancer cell lines.
Neoplasms
Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates.
Neoplasms
circRNA_103615 contributes to tumor progression and cisplatin resistance in NSCLC by regulating ABCB1.
Neoplasms
Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma.
Neoplasms
Circumventing multidrug resistance in cancer by beta-galactoside binding protein, an antiproliferative cytokine.
Neoplasms
Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines.
Neoplasms
Circumvention of multidrug resistance in genitourinary tumors.
Neoplasms
Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases.
Neoplasms
Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.
Neoplasms
Clinical and Prognostic Significance of Cell Sensitivity to Chemotherapy Detected in vitro on Treatment Response and Survival of Leukemia Patients.
Neoplasms
Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas.
Neoplasms
Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it.
Neoplasms
Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics.
Neoplasms
Clinical Pharmacokinetic and Metabolism of PET Radiotracers for Imaging P-glycoprotein in Chemoresistant Tumor of Colorectal Cancer.
Neoplasms
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.
Neoplasms
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Neoplasms
Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma.
Neoplasms
Clinical relevance of P-glycoprotein expression in haematological malignancies.
Neoplasms
Clinical relevance of P-glycoprotein in drug therapy.
Neoplasms
Clinical Significance of ABCB1 Genotyping in Oncology.
Neoplasms
Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
Neoplasms
Clinical significance of mrp gene in primary hepatocellular carcinoma.
Neoplasms
Clinical significance of multidrug resistance and P-glycoprotein expression in patients with gastric carcinoma.
Neoplasms
Clinical significance of multiple drug resistance in human cancers.
Neoplasms
Clinical significance of P-glycoprotein (P-gp) expression in childhood acute lymphoblastic leukemia. Results of a 6-year prospective study.
Neoplasms
Clinical significance of P-glycoprotein and glutathione S-transferase ? expression in gallbladder carcinoma.
Neoplasms
Clinical significance of P-glycoprotein expression analyzed by immunohistochemical staining in cancer tissues.
Neoplasms
Clinical significance of P-glycoprotein immunohistochemistry and doxorubicin binding assay in patients with osteosarcoma.
Neoplasms
Clinical significance of P-glycoprotein in multidrug resistance malignancies.
Neoplasms
Clinical significance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer.
Neoplasms
Clinical studies with modulators of multidrug resistance.
Neoplasms
Clinical trials of agents that reverse multidrug resistance. A literature review.
Neoplasms
Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.
Neoplasms
Clinical trials of P-glycoprotein reversal in solid tumours.
Neoplasms
Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review.
Neoplasms
Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.
Neoplasms
Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.
Neoplasms
Clinically relevant mutations in the ABCG2 transporter uncovered by genetic analysis linked to erythrocyte membrane protein expression.
Neoplasms
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.
Neoplasms
Clitocine Reversal of P-Glycoprotein Associated Multi-Drug Resistance through Down-Regulation of Transcription Factor NF-?B in R-HepG2 Cell Line.
Neoplasms
Cloning and characterization of the rat multidrug resistance-associated protein 1.
Neoplasms
Cloning, overexpression, purification, and characterization of the carboxyl-terminal nucleotide binding domain of P-glycoprotein.
Neoplasms
Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
Neoplasms
CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2.
Neoplasms
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo.
Neoplasms
Co-amplification and over-expression of two mdr genes in a multidrug-resistant human colon carcinoma cell line.
Neoplasms
Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance.
Neoplasms
Co-delivery of cisplatin and siRNA through hybrid nanocarrier platform for masking resistance to chemotherapy in lung cancer.
Neoplasms
Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
Neoplasms
Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells.
Neoplasms
Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment.
Neoplasms
Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III ?-tubulin in drug-resistant breast cancers.
Neoplasms
Co-detection of ALDH1A1, ABCG2, ALCAM and CD133 in three A549 subpopulations at the single cell level by one-step digital RT-PCR.
Neoplasms
Co-expression of pregnane X receptor and ATP-binding cassette sub-family B member 1 in peripheral blood: A prospective indicator for drug resistance prediction in non-small cell lung cancer.
Neoplasms
Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer.
Neoplasms
Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy.
Neoplasms
Co-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemo-resistance.
Neoplasms
Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.
Neoplasms
Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse.
Neoplasms
Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.
Neoplasms
Cobalamin potentiates vinblastine cytotoxicity through downregulation of mdr-1 gene expression in HepG2 cells.
Neoplasms
Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor.
Neoplasms
Collagen/?1 integrin signaling up-regulates the ABCC1/MRP-1 transporter in an ERK/MAPK-dependent manner.
Neoplasms
Collateral sensitivity of resistant MRP1-overexpressing cells to flavonoids and derivatives through GSH efflux.
Neoplasms
Collateral sensitivity to cold stress and differential BCL-2 family expression in new daunomycin-resistant lymphoblastoid cell lines.
Neoplasms
Collateral sensitivity: ABCG2-overexpressing cells are more vulnerable to oxidative stress.
Neoplasms
Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles.
Neoplasms
Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients.
Neoplasms
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Neoplasms
Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp).
Neoplasms
Combined cytogenetic and array-based comparative genomic hybridization analyses of Wilms tumors: amplification and overexpression of the multidrug resistance associated protein 1 gene (MRP1) in a metachronous tumor.
Neoplasms
Combined effects of GSTP1 and MRP1 in melanoma drug resistance.
Neoplasms
Combined localization and real-time functional studies using a GFP-tagged ABCG2 multidrug transporter.
Neoplasms
Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis.
Neoplasms
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
Neoplasms
Commentary: "Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer".
Neoplasms
Comments on: Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer, Fukushima Y, Oshika Y, Tokunaga T, et al., Eur J Cancer 1999, 35, 935-938. Mutant p53 and high expression of MRP are associated in acute myeloblastic leukaemia.
Neoplasms
Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability.
Neoplasms
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
Neoplasms
Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study.
Neoplasms
Communication between multiple drug binding sites on P-glycoprotein.
Neoplasms
Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)
Neoplasms
Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma.
Neoplasms
Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells.
Neoplasms
Comparative study of multidrug resistance evaluated by means of the quantitative immunohistochemical detection of P-glycoprotein and the functional release of rhodamine 123.
Neoplasms
Comparative study of the sensitivities of cancer cells to doxorubicin, and relationships between the effect of the drug-efflux pump P-gp.
Neoplasms
Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes.
Neoplasms
Comparison of effects of surfactants with other MDR reversing agents on intracellular uptake of epirubicin in Caco-2 cell line.
Neoplasms
Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
Neoplasms
Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes.
Neoplasms
Comparison of the mRNA expression of factors related to drug resistance in lung tumors and adjacent normal tissue.
Neoplasms
Comparison of three commercially available antibodies for flow cytometric monitoring of P-glycoprotein expression in tumor cells.
Neoplasms
Compartmentalized Accumulation of cAMP near complexes of Multidrug Resistance Protein 4 (MRP4) and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Contributes to Drug-induced Diarrhea.
Neoplasms
Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.
Neoplasms
Competitive method-based electrochemiluminescent assay with protein-nucleotide conversion for ratio detection to efficiently monitor the drug resistance of cancer cells.
Neoplasms
Complete cDNA sequences encoding the Chinese hamster P-glycoprotein gene family.
Neoplasms
Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells.
Neoplasms
Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1.
Neoplasms
Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function.
Neoplasms
Computational and in vitro Investigation of miRNA-Gene Regulations in Retinoblastoma Pathogenesis: miRNA Mimics Strategy.
Neoplasms
Computational Insights into Allosteric Conformational Modulation of P-Glycoprotein by Substrate and Inhibitor Binding.
Neoplasms
Computational model of intracellular pharmacokinetics of paclitaxel.
Neoplasms
Computer-assisted engineering of programmed drug releasing multilayer nanomedicine via indomethacin-mediated ternary complex for therapy against a multidrug resistant tumor.
Neoplasms
Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein.
Neoplasms
Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
Neoplasms
Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport.
Neoplasms
Conformational changes of P-glycoprotein by nucleotide binding.
Neoplasms
Conformational heterogeneity of P-glycoprotein.
Neoplasms
Consequences of cell-to-cell P-glycoprotein transfer on acquired multidrug resistance in breast cancer: a cell population dynamics model.
Neoplasms
Conserved Walker A Cysteines 431 and 1074 in Human P-glycoprotein Are Accessible to Thiol-Specific Agents in the Apo and ADP-Vanadate Trapped Conformations.
Neoplasms
Constitutive androstane receptor upregulates Abcb1 and Abcg2 at the blood-brain barrier after CITCO activation.
Neoplasms
Constitutive expression of functional P-glycoprotein in rat hepatoma cells.
Neoplasms
Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer.
Neoplasms
Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides.
Neoplasms
Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists.
Neoplasms
Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein.
Neoplasms
Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
Neoplasms
Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles.
Neoplasms
Cooperative P-glycoprotein mediated daunorubicin transport into DNA-loaded plasma membrane vesicles.
Neoplasms
Cooperativity of phospholipid reorganization upon interaction of dipyridamole with surface monolayers on water.
Neoplasms
Coordinate changes in drug resistance and drug-induced conformational transitions in altered-function mutants of the multidrug transporter P-glycoprotein.
Neoplasms
Coordination of transcription factors, NF-Y and C/EBP beta, in the regulation of the mdr1b promoter.
Neoplasms
Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET.
Neoplasms
Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate.
Neoplasms
Correlation between functional and molecular analysis of mdr1 P-glycoprotein in human solid-tumor xenografts.
Neoplasms
Correlation between P-glycoprotein (P-gp) expression in parathyroid and Tc-99m MIBI parathyroid image findings.
Neoplasms
Correlation Between PXR and ABCG2 Patterns of mRNA Expression in a MCF7 Breast Carcinoma Cell Derivative upon Induction by Proinflammatory Cytokines.
Neoplasms
Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein.
Neoplasms
Correlation of bcl-2 with P-glycoprotein expression in chronic lymphocytic leukaemia and other haematological neoplasms but of neither marker with ex vivo chemosensitivity or patient survival.
Neoplasms
Correlation of drug resistance-associated parameters in ovarian tumor biopsies.
Neoplasms
Correlation of expression levels of P-glycoprotein with resistance to adriamycin in a renal adenocarcinoma cell line.
Neoplasms
Correlation of expression of multidrug resistance protein and messenger RNA with 99mTc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma.
Neoplasms
Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor.
Neoplasms
Correlation of MDR1 expression and oncogenic activation in human epithelial ovarian carcinoma.
Neoplasms
Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells.
Neoplasms
Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study.
Neoplasms
Correlation of P-glycoprotein overexpression and cellular prognostic factors in formalin-fixed, paraffin-embedded tumor samples from breast cancer patients.
Neoplasms
Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma.
Neoplasms
Correlations between natural resistance to doxorubicin, proliferative activity, and expression of P-glycoprotein 170 in human kidney tumor cell lines.
Neoplasms
Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: comparison with the National Cancer Institute data.
Neoplasms
Costs of medical care after open or minimally invasive prostate cancer surgery: A population-based analysis.
Neoplasms
Could polymorphisms in ABCB1 gene represent a genetic risk factor for the development of mammary tumors in dogs?
Neoplasms
CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
Neoplasms
CRISPR/Cas9, a new approach to successful knockdown of ABCB1/P-glycoprotein and reversal of chemosensitivity in human epithelial ovarian cancer cell line.
Neoplasms
Critical role of ABCG2 in ALA-photodynamic diagnosis and therapy of human brain tumor.
Neoplasms
Crizotinib (PF-02341066) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the function of P-glycoprotein.
Neoplasms
Crocin Increases Gastric Cancer Cells' Sensitivity to Doxorubicin.
Neoplasms
Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells.
Neoplasms
Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1)
Neoplasms
Cross-Talk Between Neurons and Astrocytes in Response to Bilirubin: Adverse Secondary Impacts.
Neoplasms
Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1.
Neoplasms
Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting.
Neoplasms
Crystal structure of the antigen-binding fragment of a monoclonal antibody specific for the multidrug-resistance-linked ABC transporter human P-glycoprotein.
Neoplasms
Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans.
Neoplasms
CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance.
Neoplasms
Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives.
Neoplasms
Curcumin at Low Doses Potentiates and at High Doses Inhibits ABT-737-Induced Platelet Apoptosis.
Neoplasms
Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway.
Neoplasms
Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals.
Neoplasms
Curcumin reverses doxorubicin resistance in colon cancer cells at the metabolic level.
Neoplasms
Current aspects of the pathology of osteosarcoma.
Neoplasms
Current treatment approaches for NK/T-cell lymphoma.
Neoplasms
Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line.
Neoplasms
Cyclooxygenase-2, angiogenesis, tumor cell proliferation, P-glycoprotein in advanced ovarian serous carcinoma.
Neoplasms
Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype.
Neoplasms
Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice.
Neoplasms
Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes.
Neoplasms
Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Neoplasms
Cyclosporine A increases serum cortisol levels in rabbits.
Neoplasms
Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter.
Neoplasms
Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites.
Neoplasms
CYP3A5*3 Affects Plasma Disposition of Noroxycodone and Dose Escalation in Cancer Patients Receiving Oxycodone.
Neoplasms
Cyparissins A and B, jatrophane diterpenes from Euphorbia cyparissias as Pgp inhibitors and cytotoxic agents against ovarian cancer cell lines.
Neoplasms
Cysteine-scanning mutagenesis provides no evidence for the extracellular accessibility of the nucleotide-binding domains of the multidrug resistance transporter P-glycoprotein.
Neoplasms
Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart.
Neoplasms
Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
Neoplasms
Cytokine-mediated reversal of multidrug resistance.
Neoplasms
Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer.
Neoplasms
Cytosolic superoxide dismutase activity after photodynamic therapy, intracellular distribution of Photofrin II and hypericin, and P-glycoprotein localization in human colon adenocarcinoma.
Neoplasms
Cytotoxic action of cyclosporins on human tumor cell lines is not dependent on immunosuppressive activity.
Neoplasms
Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells.
Neoplasms
Cytotoxic diterpenoid alkaloid from Aconitum japonicum subsp. subcuneatum.
Neoplasms
Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
Neoplasms
Cytotoxicity of 35 medicinal plants from Sudan towards sensitive and multidrug-resistant cancer cells.
Neoplasms
Cytotoxicity of cucurbitacin E from Citrullus colocynthis against multidrug-resistant cancer cells.
Neoplasms
Cytotoxicity of medicinal plants of the West-Canadian Gwich?in Native Americans towards sensitive and multidrug-resistant cancer cells.
Neoplasms
Cytotoxicity of nimbolide towards multidrug-resistant tumor cells and hypersensitivity via cellular metabolic modulation.
Neoplasms
Cytotoxicity of South-African medicinal plants towards sensitive and multidrug-resistant cancer cells.
Neoplasms
d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Neoplasms
DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling.
Neoplasms
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Neoplasms
Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Neoplasms
Danggui Buxue Decoction Sensitizes the Response of Non-Small-Cell Lung Cancer to Gemcitabine via Regulating Deoxycytidine Kinase and P-glycoprotein.
Neoplasms
Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Neoplasms
Dasatinib self-assembled nanoparticles decorated with hyaluronic acid for targeted treatment of tumors to overcome multidrug resistance.
Neoplasms
Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells.
Neoplasms
Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp.
Neoplasms
Deadly DAaRTS destroy cancer cells via a tumor microenvironment-mediated trigger.
Neoplasms
Decellularized matrices as in vitro models of extracellular matrix in tumor tissues at different malignant levels: Mechanism of 5-fluorouracil resistance in colorectal tumor cells.
Neoplasms
Deciphering the antitumoral potential of the bioactive metabolites from medicinal mushroom Inonotus obliquus.
Neoplasms
Decrease in Multidrug Resistance-associated Protein 2 Activities by Knockdown of Phosphatidylinositol 4-phosphate 5-kinase in Hepatocytes and Cancer Cells.
Neoplasms
Decrease of ABCB1 protein expression and increase of G1 phase arrest induced by oleanolic acid in human multidrug-resistant cancer cells.
Neoplasms
Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors.
Neoplasms
Decreased drug resistance of bladder cancer using phytochemicals treatment.
Neoplasms
Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin.
Neoplasms
Decreased P-glycoprotein in a tamoxifen-tolerant breast carcinoma model.
Neoplasms
Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers.
Neoplasms
Degradation of P-glycoprotein by pristimerin contributes to overcoming ABCB1-mediated chemotherapeutic drug resistance in vitro.
Neoplasms
Delivery of short hairpin RNAs by transkingdom RNA interference modulates the classical ABCB1-mediated multidrug-resistant phenotype of cancer cells.
Neoplasms
Demethoxycurcumin Modulates Human P-Glycoprotein Function via Uncompetitive Inhibition of ATPase Hydrolysis Activity.
Neoplasms
Dendrimers, Carotenoids, and Monoclonal Antibodies.
Neoplasms
Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity.
Neoplasms
Depletion of Lipid Efflux Pump ABCG1 Triggers the Intracellular Accumulation of Extracellular Vesicles and Reduces Aggregation and Tumorigenesis of Metastatic Cancer Cells.
Neoplasms
Depletion of mitochondrial DNA up-regulates the expression of MDR1 gene via an increase in mRNA stability.
Neoplasms
Depressive Disorder promotes Hepatocellular Carcinoma metastasis via upregulation of ABCG2 gene expression and maintenance of self-renewal.
Neoplasms
Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.
Neoplasms
Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.
Neoplasms
Design and synthesis of a mitochondria-targeting carrier for small molecule drugs.
Neoplasms
Design of dual drug-loaded dendrimer/carbon dot nanohybrids for fluorescence imaging and enhanced chemotherapy of cancer cells.
Neoplasms
Design of new drug molecules to be used in reversing multidrug resistance in cancer cells.
Neoplasms
Design real-time reversal of tumor multidrug resistance cleverly with shortened carbon nanotubes.
Neoplasms
Design, Biological Evaluation and Molecular Modelling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-glycoprotein Ligand Overcoming Multi-Drug Resistance in Cancer Stem Cells.
Neoplasms
Design, synthesis and biological evaluation of chalcones as reversers of P-glycoprotein-mediated multidrug resistance.
Neoplasms
Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors.
Neoplasms
Design, synthesis and biological evaluation of selective survivin inhibitors.
Neoplasms
Design, synthesis and biological evaluation of thiosemicarbazones, hydrazinobenzothiazoles and arylhydrazones as anticancer agents with a potential to overcome multidrug resistance.
Neoplasms
Design, synthesis, and biological evaluation of (S)-valine thiazole-derived cyclic and noncyclic peptidomimetic oligomers as modulators of human P-glycoprotein (ABCB1).
Neoplasms
Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity.
Neoplasms
Design, synthesis, and discovery of ocotillol-type amide derivatives as orally available modulators of P-glycoprotein-mediated multidrug resistance.
Neoplasms
Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance.
Neoplasms
Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents.
Neoplasms
Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4.
Neoplasms
Designing potent inhibitors against the multidrug resistance P-glycoprotein.
Neoplasms
Desmethyl bosentan displays a similar in vitro interaction profile as bosentan.
Neoplasms
Detailed structural analysis on both human MRP5 and mouse mrp5 transcripts.
Neoplasms
Detection and Quantification of the Evolution Dynamics of Apoptosis Using the PET Voltage Sensor 18F-Fluorobenzyl Triphenyl Phosphonium.
Neoplasms
Detection of 300-kilodalton membrane protein in adriamycin-resistant human tumor cells by a monoclonal antibody MRK18.
Neoplasms
Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols.
Neoplasms
Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123.
Neoplasms
Detection of CD133, Bmi-1, and ABCG2 in ameloblastic tumors.
Neoplasms
Detection of chemoresistance profile of cell lines K562, KB, GLC4 and HL60 through characterisation of the hmdr1, mrp and lrp transcripts.
Neoplasms
Detection of drug resistance and P-glycoprotein in human renal cell carcinomas.
Neoplasms
Detection of drug resistance in human ovarian carcinoma.
Neoplasms
Detection of human P-glycoprotein-like molecule in azole-resistant Candida albicans from HIV+ patients.
Neoplasms
Detection of multidrug resistance gene product (P-glycoprotein) expression in ependymomas.
Neoplasms
Detection of multidrug resistance markers, P-glycoprotein and mdr1 mRNA, in human leukemia cells.
Neoplasms
Detection of murine S180 cells expressing a multidrug resistance phenotype using different in vitro test systems and a monoclonal antibody.
Neoplasms
Detection of P-glycoprotein expression by tumoral cells with NBDL-CsA, a fluorescent derivative of cyclosporin A.
Neoplasms
Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies.
Neoplasms
Detection of P-glycoprotein in human leukemias using monoclonal antibodies.
Neoplasms
Detection of P-glycoprotein in human tumours.
Neoplasms
Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies.
Neoplasms
Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance.
Neoplasms
Detection of P-glycoprotein in solid tumors by flow cytometry.
Neoplasms
Detection of P-glycoprotein in squamous cell carcinomas of the head and neck.
Neoplasms
Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells.
Neoplasms
Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies.
Neoplasms
Detection of P-glycoprotein with four monoclonal antibodies in normal and tumor tissues.
Neoplasms
Detection of putative cancer stem cells of the side population phenotype in human tumor cell cultures.
Neoplasms
Detection of recombinant P-glycoprotein in multidrug resistant cultured cells.
Neoplasms
Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population.
Neoplasms
Detection of soluble P-glycoprotein in culture media and extracellular fluids.
Neoplasms
Detection of structural and functional asymmetries in P-glycoprotein by combining mutagenesis and H/D exchange measurements.
Neoplasms
Detection of the MDR1 P-glycoprotein expression and function.
Neoplasms
Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours.
Neoplasms
Detection of tumor stem cell markers in pancreatic carcinoma cell lines.
Neoplasms
Detention and Identification of Cancer Stem Cells in Esophageal Squamous Cell Carcinoma.
Neoplasms
Determinants of paclitaxel penetration and accumulation in human solid tumor.
Neoplasms
Determinants of paclitaxel uptake, accumulation and retention in solid tumors.
Neoplasms
Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo.
Neoplasms
Determination of the Relationship between Expression and Functional Activity of Multidrug Resistance-Associated Protein 1 using Scanning Electrochemical Microscopy.
Neoplasms
Development and application of a UPLC-MS/MS method for P-glycoprotein quantification in human tumor cells.
Neoplasms
Development and Validation of a Computational Model Ensemble for the Early Detection of BCRP/ABCG2 Substrates during the Drug Design Stage.
Neoplasms
Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
Neoplasms
Development of a Model for Functional Studies of ABCG2 (Breast Cancer Resistance Protein) Efflux Employing a Standard BeWo Clone (B24).
Neoplasms
Development of a novel in vitro 3D intestinal model for permeability evaluations.
Neoplasms
Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer.
Neoplasms
Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells.
Neoplasms
Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008.
Neoplasms
Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids.
Neoplasms
Development of drug resistance in the population of colon cancer cells under the effect of multifunctional protein YB-1.
Neoplasms
Development of dual-acting prodrugs for circumventing multidrug resistance.
Neoplasms
Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance.
Neoplasms
Development of high?resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.
Neoplasms
Development of predictive in silico model for cyclosporine- and aureobasidin-based P-glycoprotein inhibitors employing receptor surface analysis.
Neoplasms
Developmentally regulated expression of P-glycoprotein (multidrug resistance) activity in mouse thymocytes.
Neoplasms
Dexamethasone reduces side population fraction through downregulation of ABCG2 transporter in MCF-7 breast cancer cells.
Neoplasms
Dexamethasone treatment of a canine, but not human, tumour cell line increases chemoresistance independent of P-glycoprotein and multidrug resistance-related protein expression.
Neoplasms
Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.
Neoplasms
DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells.
Neoplasms
Di-2-pyridylketone 4,4-Dimethyl-3-thiosemicarbazone (Dp44mT) Overcomes Multidrug-Resistance by a Novel Mechanism Involving the Hijacking of Lysosomal P-Glycoprotein (Pgp).
Neoplasms
Diagnostics of multidrug resistance in cancer.
Neoplasms
Diallyl trisulfide reverses drug resistance and lowers the ratio of CD133+ cells in conjunction with methotrexate in a human osteosarcoma drug-resistant cell subline.
Neoplasms
Dietary flavonoid fisetin binds to ?-tubulin and disrupts microtubule dynamics in prostate cancer cells.
Neoplasms
Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells.
Neoplasms
Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2).
Neoplasms
Differences between accumulation of 99mTc-MIBI and 201Tl-thallous chloride in tumour cells: role of P-glycoprotein.
Neoplasms
Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: need of comparative clinical trials in resistant patients.
Neoplasms
Differences in Transcript Levels of ABC Transporters Between Pancreatic Adenocarcinoma and Nonneoplastic Tissues.
Neoplasms
Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma.
Neoplasms
Different pattern of MRP localization in ciliated and basal cells from human bronchial epithelium.
Neoplasms
Different regulation of P-glycoprotein function between Caco-2 and Caki-1 cells by ezrin, radixin and moesin proteins.
Neoplasms
Different roles of TM5, TM6, and ECL3 in the oligomerization and function of human ABCG2.
Neoplasms
Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols.
Neoplasms
Differential effect of phenothiazines on MRP1 and P-glycoprotein activity.
Neoplasms
Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Neoplasms
Differential expression and activity of phosphatases and protein kinases in adriamycin sensitive and resistant human breast cancer MCF-7 cells.
Neoplasms
Differential Expression of Ion Channels and Transporters During Hepatocellular Carcinoma Development.
Neoplasms
Differential expression of multidrug resistance gene product, P-glycoprotein, in normal, dysplastic and malignant oral mucosa in India.
Neoplasms
Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer.
Neoplasms
Differential expression of stem cell markers and vascular endothelial growth factor in human retinoblastoma tissue.
Neoplasms
Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
Neoplasms
Differential interactions between statins and P-glycoprotein: Implications for exploiting statins as anticancer agents.
Neoplasms
Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.
Neoplasms
Differential partitioning of Galphai1 with the cellular microtubules: a possible mechanism of development of Taxol resistance in human ovarian carcinoma cells.
Neoplasms
Differential recognition of mdr1a and mdr1b gene products in multidrug resistant mouse tumour cell lines by different monoclonal antibodies.
Neoplasms
Differentiated Human Colorectal Cancer Cells Protect Tumor-Initiating Cells from Irinotecan.
Neoplasms
Differentiation Potential of Human Retinoblastoma Cells.
Neoplasms
Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.
Neoplasms
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
Neoplasms
Dihydro-beta-agarofuran sesquiterpenes: a new class of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in the protozoan parasite Leishmania.
Neoplasms
Dihydrotestosterone induces chemo-resistance of triple-negative breast MDA-MB-231 cancer cells towards doxorubicin independent of ABCG2 and miR-328-3p.
Neoplasms
Dimerization of ABCG2 analysed by bimolecular fluorescence complementation.
Neoplasms
Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).
Neoplasms
Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
Neoplasms
Dipyridamole and its derivatives modify the kinetics of the electron transport in reaction centers from Rhodobacter sphaeroides.
Neoplasms
Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro.
Neoplasms
Direct and indirect P-glycoprotein transfers in MCF7 breast cancer cells.
Neoplasms
Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy.
Neoplasms
Direct binding of chloroquine to the multidrug resistance protein (MRP): possible role for MRP in chloroquine drug transport and resistance in tumor cells.
Neoplasms
Direct current decreases cell viability but not P-glycoprotein expression and function in human multidrug resistant leukemic cells.
Neoplasms
Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein.
Neoplasms
Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene.
Neoplasms
Disclosure of a stem cell phenotype in an oral squamous cell carcinoma cell line induced by BMP-4 via an epithelial-mesenchymal transition.
Neoplasms
Discovery and development of the epothilones : a novel class of antineoplastic drugs.
Neoplasms
Discovery and evaluation of inhibitors of human sphingosine kinase.
Neoplasms
Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169.
Neoplasms
Discovery of 4-acetyl-3-(4-fluorophenyl)-1-(p-tolyl)-5-methylpyrrole as a dual inhibitor of human P-glycoprotein and Staphylococcus aureus Nor A efflux pump.
Neoplasms
Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.
Neoplasms
Discovery of 4-aryl-4H-chromenes as potent apoptosis inducers using a cell- and caspase-based Anti-cancer Screening Apoptosis Program (ASAP): SAR studies and the identification of novel vascular disrupting agents.
Neoplasms
Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance.
Neoplasms
Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
Neoplasms
Discovery of aromatic amides with triazole-core as potent reversal agents against P-glycoprotein-mediated multidrug resistance.
Neoplasms
Discovery of new pyrimidopyrrolizine/indolizine-based derivatives as P-glycoprotein inhibitors: Design, synthesis, cytotoxicity, and MDR reversal activities.
Neoplasms
Discovery of novel antitumor antimitotic agents that also reverse tumor resistance.
Neoplasms
Discovery of Novel Flavonoid Dimers To Reverse Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediated Drug Resistance in Cancers Using a High Throughput Platform with "Click Chemistry".
Neoplasms
Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors.
Neoplasms
Discovery of Thalicthuberine as a Novel Antimitotic Agent from Nature that Disrupts Microtubule Dynamics and Induces Apoptosis in Prostate Cancer Cells.
Neoplasms
Discovery of the inhibitory effect of a phosphatidylinositol derivative on P-glycoprotein by virtual screening followed by in vitro cellular studies.
Neoplasms
Discovery of traditional Chinese medicine monomers and their synthetic intermediates, analogs or derivatives for battling P-gp-mediated multi-drug resistance.
Neoplasms
Discovery to solve multidrug resistance: Design, synthesis, and biological evaluation of novel agents.
Neoplasms
Discrepant flow cytometric expression and function of P-glycoprotein in neuroblastic tumors.
Neoplasms
Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients.
Neoplasms
Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.
Neoplasms
Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?
Neoplasms
Disruption of mdr1a p-glycoprotein gene results in dysfunction of blood-inner ear barrier in mice.
Neoplasms
Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2.
Neoplasms
Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione.
Neoplasms
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Neoplasms
Distinctive polymer micelle designed for siRNA delivery and reversal of MDR1 gene-dependent multidrug resistance.
Neoplasms
Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule.
Neoplasms
Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.
Neoplasms
Diterpenoids from Euphorbia royleana reverse P-glycoprotein-mediated multidrug resistance in cancer cells.
Neoplasms
Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).
Neoplasms
Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells.
Neoplasms
DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo.
Neoplasms
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.
Neoplasms
DNA topoisomerase targeting drugs: mechanisms of action and perspectives.
Neoplasms
DNA-intercalating ligands as anti-cancer drugs: prospects for future design.
Neoplasms
Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?
Neoplasms
Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?
Neoplasms
Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer cell lines?
Neoplasms
Does ABCG2 need a heterodimer partner? Expression and functional evaluation of ABCG2 (Arg 482)*.
Neoplasms
Does P-glycoprotein play a role in anticancer drug pharmacokinetics?
Neoplasms
Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma?
Neoplasms
Dormant cancer cells accumulate high protoporphyrin IX levels and are sensitive to 5-aminolevulinic acid-based photodynamic therapy.
Neoplasms
Double knockout of the MRP gene leads to increased drug sensitivity in vitro.
Neoplasms
Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.
Neoplasms
Double-phase Tc-99m MIBI scintigraphy as a therapeutic predictor in patients with non-Hodgkin's lymphoma.
Neoplasms
Double-phase Tc-99m sestamibi scintimammography to assess angiogenesis and P-glycoprotein expression in patients with untreated breast cancer.
Neoplasms
Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer.
Neoplasms
Down-regulation of intracellular reactive oxygen species attenuates P-glycoprotein-associated chemoresistance in Epstein-Barr virus-positive NK/T-cell lymphoma.
Neoplasms
Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species.
Neoplasms
Down-Regulation of MRP1 Expression in C6/VP16 Cells by Chitosan-MRP1-siRNA Nanoparticles.
Neoplasms
Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol.
Neoplasms
Down-regulation of the P-glycoprotein relevant for multidrug resistance by intracellular acidification through the crosstalk of MAPK signaling pathways.
Neoplasms
Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance.
Neoplasms
Downregulation of ABCG2 protein inhibits migration and invasion in U251 glioma stem cells.
Neoplasms
Downregulation of MDR 1 gene contributes to tyrosine kinase inhibitor induce apoptosis and reduction in tumor metastasis: A gravity to space investigation.
Neoplasms
Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines.
Neoplasms
Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells.
Neoplasms
Doxorubicin and adjudin co-loaded pH-sensitive nanoparticles for the treatment of drug-resistant cancer.
Neoplasms
Doxorubicin and multidrug resistance.
Neoplasms
Doxorubicin delivery enhanced by electroporation to gastrointestinal adenocarcinoma cells with P-gp overexpression.
Neoplasms
Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion.
Neoplasms
Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells.
Neoplasms
Doxorubicin-induced DNA breaks, topoisomerase II activity and gene expression in human melanoma cells.
Neoplasms
Doxorubicin-peptide conjugates overcome multidrug resistance.
Neoplasms
Doxycycline induces expression of P glycoprotein in MCF-7 breast carcinoma cells.
Neoplasms
Dregamine and tabernaemontanine derivatives as ABCB1 modulators on resistant cancer cells.
Neoplasms
Drug binding domains of MRP1 (ABCC1) as revealed by photoaffinity labeling.
Neoplasms
Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis.
Neoplasms
Drug concentration-dependent expression of multidrug resistance-associated protein and P-glycoprotein in the doxorubicin-resistant acute myelogenous leukemia sublines.
Neoplasms
Drug Efflux Transporters Are Overexpressed in Short-Term Tamoxifen-Induced MCF7 Breast Cancer Cells.
Neoplasms
Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells.
Neoplasms
Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.
Neoplasms
Drug promiscuity of P-glycoprotein and its mechanism of interaction with paclitaxel and doxorubicin.
Neoplasms
Drug repurposing and relabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effects.
Neoplasms
Drug resistance and apoptosis in ENU-induced rat brain tumors treated with anti-cancer drugs.
Neoplasms
Drug resistance and cellular adaptation to tumor acidic pH microenvironment.
Neoplasms
Drug resistance and P-glycoprotein expression in endothelial cells of newly formed capillaries induced by tumors.
Neoplasms
Drug resistance and sensitivity of germ cell testicular tumors: evaluation of clinical relevance of MDR1/Pgp, p53, and metallothionein (MT) proteins.
Neoplasms
Drug resistance in hematologic malignancies.
Neoplasms
Drug resistance in multiple myeloma.
Neoplasms
Drug resistance reversal, anti-mutagenicity and antiretroviral effect of phthalimido- and chloroethyl-phenothiazines.
Neoplasms
Drug resistance via radixin-mediated increase of P-glycoprotein membrane expression during SNAI1-induced epithelial-mesenchymal transition in HepG2 cells.
Neoplasms
Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors.
Neoplasms
Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
Neoplasms
Drug resistance: Still a daunting challenge to the successful treatment of AML.
Neoplasms
Drug transport by breast cancer resistance protein.
Neoplasms
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
Neoplasms
Drug-resistance gene expression and progression of astrocytic tumors.
Neoplasms
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Neoplasms
DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
Neoplasms
Dual agent chemoprotection by retroviral co-expression of either MDR1 or MRP1 with the P140K mutant of O6-methylguanine-DNA-methyl transferase.
Neoplasms
Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents.
Neoplasms
Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment.
Neoplasms
Dual inhibitors of P-glycoprotein and tumor cell growth: (re)discovering thioxanthones.
Neoplasms
Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.
Neoplasms
Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells.
Neoplasms
Dual properties of hispidulin: antiproliferative effects on HepG2 cancer cells and selective inhibition of ABCG2 transport activity.
Neoplasms
Dual regulation of P-glycoprotein expression by Trichostatin A in cancer cell lines.
Neoplasms
Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
Neoplasms
Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells.
Neoplasms
Dually Acting Nonclassical 1,4-Dihydropyridines Promote the Anti-Tuberculosis (Tb) Activities of Clofazimine.
Neoplasms
Dynamic ABCG2 expression in human embryonic stem cells provides the basis for stress response.
Neoplasms
Dynamic contrast-enhanced brain perfusion imaging: technique and clinical applications.
Neoplasms
Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.
Neoplasms
E2F1 drives chemotherapeutic drug resistance via ABCG2.
Neoplasms
Ecdysteroid Derivatives that Reverse P-Glycoprotein-Mediated Drug Resistance.
Neoplasms
Ecdysteroids sensitize MDR and non-MDR cancer cell lines to doxorubicin, paclitaxel, and vincristine but tend to protect them from cisplatin.
Neoplasms
Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer.
Neoplasms
Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line.
Neoplasms
Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice.
Neoplasms
Effect of 5-FU and MTX on the Expression of Drug-resistance Related Cancer Stem Cell Markers in Non-small Cell Lung Cancer Cells.
Neoplasms
Effect of ABC transporter expression and mutational status on survival rates of cancer patients.
Neoplasms
Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
Neoplasms
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
Neoplasms
Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Neoplasms
Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
Neoplasms
Effect of ATP binding cassette/multidrug resistance proteins on ATP efflux of Saccharomyces cerevisiae.
Neoplasms
Effect of bovine ABCG2 polymorphism Y581S SNP on secretion into milk of enterolactone, riboflavin and uric acid.
Neoplasms
Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein.
Neoplasms
Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Neoplasms
Effect of chirality on cellular uptake, imaging and photodynamic therapy of photosensitizers derived from chlorophyll-a.
Neoplasms
Effect of chitosan based glycolipid-like nanocarrier in prevention of developing acquired drug resistance in tri-cycle treatment of breast cancer.
Neoplasms
Effect of Cinnamic acid and FOLFOX in diminishing side population and downregulating cancer stem cell markers in colon cancer cell line HT-29.
Neoplasms
Effect of colloidal gold nanoparticles on cell interface and their enhanced intracellular uptake of arsenic trioxide in leukemia cancer cells.
Neoplasms
Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells.
Neoplasms
Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug resistance in colon cancer cell lines.
Neoplasms
Effect of etoposide on experimental testicular teratoma in 129/SvJ mice.
Neoplasms
Effect of expression of P-glycoprotein on technetium-99m methoxyisobutylisonitrile single photon emission computed tomography of brain tumors.
Neoplasms
Effect of hesperidin on mice bearing Ehrlich solid carcinoma maintained on doxorubicin.
Neoplasms
Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells.
Neoplasms
Effect of mitoxantrone liposomes on multidrug-resistant breast cancer cells.
Neoplasms
Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
Neoplasms
Effect of multidrug-resistant P-glycoprotein gene expression on chloroaluminum tetrasulfonate phthalocyanine concentration.
Neoplasms
Effect of NOS1 regulating ABCG2 expression on proliferation and apoptosis of cervical cancer cells.
Neoplasms
Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine.
Neoplasms
Effect of P-glycoprotein expression on outcome in the Ewing family of tumors.
Neoplasms
Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates.
Neoplasms
Effect of piperlongumine on drug resistance reversal in human retinoblastoma HXO-RB44/VCR and SO-Rb50/CBP cell lines.
Neoplasms
Effect of polyoxyl 35 castor oil and Polysorbate 80 on the intestinal absorption of digoxin in vitro.
Neoplasms
Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats.
Neoplasms
Effect of PSC 833, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats.
Neoplasms
Effect of Quercetin on ABCC6 Transporter: Implication in HepG2 Migration.
Neoplasms
Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein.
Neoplasms
Effect of short-term morphine exposure on P-glycoprotein expression and activity in cancer cell lines.
Neoplasms
Effect of SILA-409, a new organosilicon multidrug resistance modifier, on human pancreatic cancer xenografts.
Neoplasms
Effect of Starvation in Reversing Cancer Chemoresistance Based on Drug-Resistance Detection by Dextran Nanoparticles.
Neoplasms
Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells.
Neoplasms
Effect of the allelic variants of ABCB1, CYP2D6 and HTR3B on response of ramosetron to prevent chemotherapy-induced nausea and vomiting in Korean cancer patients.
Neoplasms
Effect of the breast-cancer resistance protein on atypical multidrug resistance.
Neoplasms
Effect of traditional Chinese medicine components on multidrug resistance in tumors mediated by P-glycoprotein.
Neoplasms
Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
Neoplasms
Effect of triterpenoids isolated from the floral spikes of Betula platyphylla var. japonica on P-glycoprotein function.
Neoplasms
Effect of tumor necrosis factor-alpha and interferon-gamma on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells.
Neoplasms
Effect of Variation of ABCB1 and ABCC3 Genotypes on the Survival of Bone Tumor Cases after Chemotherapy.
Neoplasms
Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy.
Neoplasms
Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes.
Neoplasms
Effective down-regulation of Breast Cancer Resistance Protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers.
Neoplasms
Effective knock down of very high ABCG2 expression by a hammerhead ribozyme.
Neoplasms
Effective MDR reversers through phytochemical study of Euphorbia boetica.
Neoplasms
Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells.
Neoplasms
Effector cell analysis of human multidrug-resistant cell killing by mouse-human chimeric antibody against P-glycoprotein.
Neoplasms
Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
Neoplasms
Effects of ATP depletion and phosphate analogues on P-glycoprotein conformation in live cells.
Neoplasms
Effects of ATP-binding cassette transporter G2 in extracellular vesicles on drug resistance of laryngeal cancer cells in in vivo and in vitro.
Neoplasms
Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome p450 3A4 and P-glycoprotein inhibition by baicalein.
Neoplasms
Effects of Black Raspberries and Their Ellagic Acid and Anthocyanin Constituents on Taxane Chemotherapy of Castration-Resistant Prostate Cancer Cells.
Neoplasms
Effects of C7 substitutions in a high affinity microtubule-binding taxane on antitumor activity and drug transport.
Neoplasms
Effects of chronic ethacrynic acid exposure on glutathione conjugation and MRP expression in human colon tumor cells.
Neoplasms
Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
Neoplasms
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
Neoplasms
Effects of Genetic Polymorphisms in the ABCB1 Gene on Clinical Outcomes in Patients with Gastric Cancer Treated by Second-line Chemotherapy.
Neoplasms
Effects of histone deacetylase inhibitors on ATP-binding cassette transporters in lung cancer A549 and colorectal cancer HCT116 cells.
Neoplasms
Effects of hyperthermia on multidrug-resistant human hepatocellular-carcinoma.
Neoplasms
Effects of isoprenoid analogues of SDB-ethylenediamine on multidrug resistant tumor cells alone and in combination with chemotherapeutic drugs.
Neoplasms
Effects of MDR1/P-glycoprotein expression on prognosis in advanced colorectal cancer after surgery.
Neoplasms
Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Neoplasms
Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells.
Neoplasms
Effects of natural nuclear factor-kappa B inhibitors on anticancer drug efflux transporter human P-glycoprotein.
Neoplasms
Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Neoplasms
Effects of paclitaxel on the growth of normal, polyposis, and cancerous human colonic epithelial cells.
Neoplasms
Effects of Piperazine Derivative on Paclitaxel Pharmacokinetics.
Neoplasms
Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines.
Neoplasms
Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2.
Neoplasms
Effects of triclabendazole on secretion of danofloxacin and moxidectin into the milk of sheep: Role of triclabendazole metabolites as inhibitors of the ruminant ABCG2 transporter.
Neoplasms
Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer.
Neoplasms
Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft.
Neoplasms
Efficacy of tamoxifen in combination with docetaxel in patients with advanced non-small-cell lung cancer pretreated with platinum-based chemotherapy.
Neoplasms
Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody.
Neoplasms
Efficient purification and reconstitution of P-glycoprotein for functional and structural studies.
Neoplasms
Efflux Pump Inhibitors: A Strategy to Combat P-Glycoprotein and the NorA Multidrug Resistance Pump.
Neoplasms
Efflux transporters and tight junction expression changes in human gastrointestinal cell lines cultured in defined medium vs serum supplemented medium.
Neoplasms
Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
Neoplasms
Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells.
Neoplasms
Elevated expression of both MDR1 and MMP-2 genes in metastasized lymph node of invasive ductal breast cancer.
Neoplasms
Elevated expression of hepatic proliferative markers during early hepatocarcinogenesis in hepatitis-B virus transgenic mice lacking mdr1a-encoded P-glycoprotein.
Neoplasms
Elevated Expression of Nrf-2 and ABCG2 Involved in Multi-drug Resistance of Lung Cancer SP Cells.
Neoplasms
Elevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells.
Neoplasms
Elevated survivin mediated multidrug resistance and reduced apoptosis in breast cancer stem cells.
Neoplasms
Elimination of drug-resistant myeloma tumor cell lines by monoclonal anti-P-glycoprotein antibody and rabbit complement.
Neoplasms
Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis.
Neoplasms
Elucidation of chemosensitization effect of acridones in cancer cell lines: Combined pharmacophore modeling, 3D QSAR, and molecular dynamics studies.
Neoplasms
Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.
Neoplasms
Emetine resistant mutants of Entamoeba histolytica overexpress mRNAs for multidrug resistance.
Neoplasms
Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P-glycoprotein and MRPs expression.
Neoplasms
Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma.
Neoplasms
Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation.
Neoplasms
Enabling P-glycoprotein inhibition in multidrug resistant cancer through the reverse targeting of a quinidine-PEG conjugate.
Neoplasms
Endoplasmic reticulum stress: major player in size-dependent inhibition of P-glycoprotein by silver nanoparticles in multidrug-resistant breast cancer cells.
Neoplasms
Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).
Neoplasms
Energy coupling to periplasmic binding protein-dependent transport systems: stoichiometry of ATP hydrolysis during transport in vivo.
Neoplasms
Energy dependent transport of xenobiotics and its relevance to multidrug resistance.
Neoplasms
Energy transduction and alternating access of the mammalian ABC transporter P-glycoprotein.
Neoplasms
Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.
Neoplasms
Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.
Neoplasms
Engineering of a Core-Shell Nanoplatform to Overcome Multidrug Resistance via ATP Deprivation.
Neoplasms
Enhanced activity of doxorubicin in drug resistant A549 tumor cells by encapsulation of P-glycoprotein inhibitor in PLGA-based nanovectors.
Neoplasms
Enhanced antitumor activity of different double arms polyethyleneglycol-modified liposomal doxorubicin.
Neoplasms
Enhanced Chemotherapy of Cancer Using pH-Sensitive Mesoporous Silica Nanoparticles to Antagonize P-Glycoprotein-Mediated Drug Resistance.
Neoplasms
Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
Neoplasms
Enhanced expression by the brain matrix of P-glycoprotein in brain capillary endothelial cells.
Neoplasms
Enhanced Expression of ABCB1 and Nrf2 in CD133-Positive Cancer Stem Cells Associates with Doxorubicin Resistance.
Neoplasms
Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance.
Neoplasms
Enhanced gravi- and phototropism in plant mdr mutants mislocalizing the auxin efflux protein PIN1.
Neoplasms
Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea.
Neoplasms
Enhanced Photothermal-Photodynamic Therapy by Indocyanine Green and Curcumin-Loaded Layered MoS2 Hollow Spheres via Inhibition of P-Glycoprotein.
Neoplasms
Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anticancer Drug To Overcome Tumor Multidrug Resistance.
Neoplasms
Enhanced Sensitivity of Cancer Stem Cells to Chemotherapy Using Functionalized Mesoporous Silica Nanoparticles.
Neoplasms
Enhanced shRNA Delivery and ABCG2 Silencing by Charge-Reversible Layered Nanocarriers.
Neoplasms
Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound.
Neoplasms
Enhanced TLR4 Expression on Colon Cancer Cells After Chemotherapy Promotes Cell Survival and Epithelial-Mesenchymal Transition Through Phosphorylation of GSK3?.
Neoplasms
Enhanced transepithelial flux of cimetidine by Madin-Darby canine kidney cells overexpressing human P-glycoprotein.
Neoplasms
Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
Neoplasms
Enhancement of activities of anti-tumor drugs by dipyridamole against multidrug-resistant human hepatoma PLC/PRF/5 cells.
Neoplasms
Enhancement of anticancer drug sensitivity in multidrug resistance cells overexpressing ATP-binding cassette (ABC) transporter ABCC10 by CP55, a synthetic derivative of 5-cyano-6-phenylpyrimidin.
Neoplasms
Enhancement of antimicrobial activity of pump inhibitors associating drugs.
Neoplasms
Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance.
Neoplasms
Enhancement of chlorpromazine antitumor activity by Pluronics F127/L81 nanostructured system against human multidrug resistant leukemia.
Neoplasms
Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and SC236 via inhibiting P-glycoprotein activity.
Neoplasms
Enhancement of reversing effect of cyclosporin A on vincristine resistance by anti-P-glycoprotein monoclonal antibody MRK-16.
Neoplasms
Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system.
Neoplasms
Enhancing Activity of Anticancer Drugs in Multidrug Resistant Tumors by Modulating P-Glycoprotein through Dietary Nutraceuticals.
Neoplasms
Enhancing cancer targeting and anticancer activity by a stimulus-sensitive multifunctional polymer-drug conjugate.
Neoplasms
Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2.
Neoplasms
Enhancing the anti-multiple myeloma efficiency in a cancer stem cell xenograft model by conjugating the ABCG2 antibody with microbubbles for a targeted delivery of ultrasound mediated epirubicin.
Neoplasms
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
Neoplasms
Enzymatic synthesis of [4-methoxy-11C]daunorubicin for functional imaging of P-glycoprotein with PET.
Neoplasms
EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Neoplasms
EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.
Neoplasms
Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP).
Neoplasms
Epidural analgesia with sufentanil in relation to OPRM1 and ABCB1 polymorphisms.
Neoplasms
Epigallocatechin-3-gallate promotes apoptosis and reversal of multidrug resistance in esophageal cancer cells.
Neoplasms
Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy.
Neoplasms
Epigenetic Regulation of MDR1 and BCRP Transporters by HDAC Inhibition.
Neoplasms
Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients.
Neoplasms
Epitope mapping of monoclonal antibodies specific for the 190-kDa multidrug resistance protein (MRP).
Neoplasms
EPO906 (epothilone B): a promising novel microtubule stabilizer.
Neoplasms
Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer.
Neoplasms
Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells.
Neoplasms
Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Neoplasms
Ergosterol reverses multidrug resistance in SGC7901/Adr cells.
Neoplasms
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Neoplasms
Erratum to Algerian Propolis Potentiates Doxorubicin Mediated Anticancer Effect Against Human Pancreatic PANC-1 Cancer Cell Line through Cell Cycle Arrest, Apoptosis Induction and P-Glycoprotein Inhibition.
Neoplasms
Erratum to: Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists.
Neoplasms
ES2 enhances the efficacy of chemotherapeutic agents in ABCB1-overexpressing cancer cells in vitro and in vivo.
Neoplasms
Escape from stress granule sequestration: another way to drug resistance?
Neoplasms
Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.
Neoplasms
Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1.
Neoplasms
Establishment and characterization of two new cell lines derived from human metastatic breast carcinomas.
Neoplasms
Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance.
Neoplasms
Establishment of pancreatic cancer stem cells by flow cytometry and their biological characteristics.
Neoplasms
Establishment of recombinant lentiviral vector with ABCG2 overexpression and effects of the recombinant on human breast cancer MCF-7 cells' biological characteristics.
Neoplasms
Esters of the marine-derived triterpene sipholenol A reverse P-GP-mediated drug resistance.
Neoplasms
Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel.
Neoplasms
Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2.
Neoplasms
Estrogen induces cell proliferation by promoting ABCG2-mediated efflux in endometrial cancer cells.
Neoplasms
Estrogen receptor ? induction by mitoxantrone increases Abcg2 expression in placental trophoblast cells.
Neoplasms
Ethyl acetate extract of herpetospermum pedunculosum alleviates ?-naphthylisothiocyanate-induced cholestasis by activating the farnesoid x receptor and suppressing oxidative stress and inflammation in rats.
Neoplasms
Etoposide-resistant human colon and lung adenocarcinoma cell lines exhibit sensitivity to homoharringtonine.
Neoplasms
Euphoresulanes A-M, structurally diverse jatrophane diterpenoids from Euphorbia esula.
Neoplasms
Euryops pectinatus L. Flower Extract Inhibits P-glycoprotein and Reverses Multi-Drug Resistance in Cancer Cells: A Mechanistic Study.
Neoplasms
Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles.
Neoplasms
Evading Pgp activity in drug-resistant cancer cells: a structural and functional study of antitubulin furan metotica compounds.
Neoplasms
Evaluating the potential of polymer nanoparticles for oral delivery of paclitaxel in drug-resistant cancer.
Neoplasms
Evaluating the specificity of antisense oligonucleotide conjugates. A DNA array analysis.
Neoplasms
Evaluation of 11C-colchicine for PET imaging of multiple drug resistance.
Neoplasms
Evaluation of aminolevulinic acid-mediated protoporphyrin IX fluorescence and enhancement by ABCG2 inhibitors in renal cell carcinoma cells.
Neoplasms
Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma.
Neoplasms
Evaluation of chemotherapy response in patients with small cell lung cancer using Technetium-99m-tetrofosmin.
Neoplasms
Evaluation of diffusion coefficient of P-glycoprotein molecules labeled with green fluorescent protein in living cell membrane.
Neoplasms
Evaluation of DNA methylation profiles of the CpG island of the ABCB1 gene in dogs with lymphoma.
Neoplasms
Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation.
Neoplasms
Evaluation of immunohistochemical expression of P-glycoprotein in neoplasms of the mammary gland in bitches.
Neoplasms
Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging.
Neoplasms
Evaluation of Near Infrared Dyes as Markers of P-Glycoprotein Activity in Tumors.
Neoplasms
Evaluation of newer prognostic markers for adult soft tissue sarcomas.
Neoplasms
Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray.
Neoplasms
Evaluation of P-glycoprotein expression in human oral oncogenesis: correlation with clinicopathological features.
Neoplasms
Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities.
Neoplasms
Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Neoplasms
Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro.
Neoplasms
Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours.
Neoplasms
Evaluation of the first cytostatically active 1-aza-9-oxafluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating properties.
Neoplasms
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Neoplasms
Evaluation of the reversal of multidrug resistance by MDR1 ribonucleic acid interference in a human colon cancer model using a renilla luciferase reporter gene and coelenterazine.
Neoplasms
Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
Neoplasms
Evaluation of TPGS-modified thermo-sensitive Pluronic PF127 hydrogel as a potential carrier to reverse the resistance of P-gp-overexpressing SMMC-7721 cell lines.
Neoplasms
Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Neoplasms
Evidence for a multidrug resistance-associated protein 1 (MRP1)-related transport system in cultured rat liver biliary epithelial cells.
Neoplasms
Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein.
Neoplasms
Evidence for p-glycoprotein modification of insecticide toxicity in mosquitoes of the Culex pipiens complex.
Neoplasms
Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium.
Neoplasms
Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein.
Neoplasms
Evidence of post-translational regulation of P-glycoprotein associated with the expression of a distinctive multiple drug-resistant phenotype in Chinese hamster ovary cells.
Neoplasms
Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma.
Neoplasms
Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy.
Neoplasms
Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model.
Neoplasms
Examination of multidrug resistance in cell lines and primary breast tumours by flow cytometry.
Neoplasms
Exercise training does not affect anthracycline antitumor efficacy while attenuating cardiac dysfunction.
Neoplasms
Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein.
Neoplasms
Exogenous supplement of N-acetylneuraminic acid ameliorates atherosclerosis in apolipoprotein E-deficient mice.
Neoplasms
Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines.
Neoplasms
Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells.
Neoplasms
Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
Neoplasms
Exploring movement and energy in human P-glycoprotein conformational rearrangement.
Neoplasms
Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell line.
Neoplasms
Expression analysis of multidrug resistance associated genes in neuroblastomas.
Neoplasms
Expression analysis of protein kinase C isozymes and multidrug resistance associated genes in ovarian cancer cells.
Neoplasms
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.
Neoplasms
Expression and activity of multidrug resistance protein 1 in a murine thymoma cell line.
Neoplasms
Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells.
Neoplasms
Expression and activity of taxane-metabolizing enzymes in ovarian tumors.
Neoplasms
Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors.
Neoplasms
Expression and clinical significance of multidrug resistance proteins in brain tumors.
Neoplasms
Expression and function of ABCG2 and XIAP in glioblastomas.
Neoplasms
Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines.
Neoplasms
Expression and function of P-glycoprotein in a mouse kidney cell line.
Neoplasms
Expression and function of P-glycoprotein in human mesangial cells.
Neoplasms
Expression and functions of P-glycoprotein (mdr1 gene product) in normal and malignant tissues.
Neoplasms
Expression levels of ABCG2 and CD61 genes in breast cancer tissues of Iranian population.
Neoplasms
Expression levels of MRP1, GST-?, and GSK3? in ovarian cancer and the relationship with drug resistance and prognosis of patients.
Neoplasms
Expression levels of the ABCG2 multidrug transporter in human erythrocytes correspond to pharmacologically relevant genetic variations.
Neoplasms
Expression of a human multidrug resistance gene in human ovarian carcinoma cell lines.
Neoplasms
Expression of a multidrug resistance gene in esophageal adenocarcinoma. Correlation with response to chemotherapy and comparison with gastric adenocarcinoma.
Neoplasms
Expression of a multidrug resistance gene in human cancers.
Neoplasms
Expression of ABC-transport proteins in canine mammary cancer: consequences for chemotherapy.
Neoplasms
Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.
Neoplasms
Expression of ABCG2 and its significance in colorectal cancer.
Neoplasms
Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence.
Neoplasms
Expression of Aldehyde Dehydrogenase (ALDH1) and ATP Binding Cassette Transporter G2 (ABCG2) in Iraqi Patients with Colon Cancer and the Relation with Clinicopathological Features.
Neoplasms
Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors.
Neoplasms
Expression of ATP-binding cassette transporter in human salivary ducts.
Neoplasms
Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.
Neoplasms
Expression of CD147 mediates tumor cells invasion and multidrug resistance in hepatocellular carcinoma.
Neoplasms
Expression of cell surface P-glycoprotein by an adriamycin-resistant murine fibrosarcoma.
Neoplasms
Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples.
Neoplasms
Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualized therapy of the breast cancer patients.
Neoplasms
Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin.
Neoplasms
Expression of gamma-glutamylcysteine synthetase (gamma-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs.
Neoplasms
Expression of HSP27, HSP72 and MRP proteins in in vitro co-culture of colon tumour cell spheroids with normal cells after incubation with rhTGF- beta1 and/or CPT-11.
Neoplasms
Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells.
Neoplasms
Expression of lung resistance protein in epithelioid sarcoma in vitro and in vivo.
Neoplasms
Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay.
Neoplasms
Expression of mdr-1/P-glycoprotein in human neuroblastoma.
Neoplasms
Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney.
Neoplasms
Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gall bladder cancer tissues.
Neoplasms
Expression of MDR1/P glycoprotein in human sarcomas.
Neoplasms
Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours.
Neoplasms
Expression of mdr1/P-glycoprotein and p110 in neuroblastoma.
Neoplasms
Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results.
Neoplasms
Expression of mouse Abcg2 mRNA during hematopoiesis is regulated by alternative use of multiple leader exons and promoters.
Neoplasms
Expression of MRP and cMOAT in childhood neuroblastomas and malignant liver tumors and its relevance to clinical behavior.
Neoplasms
Expression of MRP1 and ABCG2 is associated with adverse clinical outcomes of the papillary thyroid carcinoma with a solid component.
Neoplasms
Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy.
Neoplasms
Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells.
Neoplasms
Expression of multidrug resistance gene product (P-glycoprotein) in transitional cell carcinomas of the upper urinary tract.
Neoplasms
Expression of multidrug resistance membrane transporter (Pgp) and p53 protein in canine mammary tumours.
Neoplasms
Expression of multidrug resistance protein and messenger RNA correlate with (99m)Tc-MIBI imaging in patients with lung cancer.
Neoplasms
Expression of multidrug resistance protein gene in patients with glioma after chemotherapy.
Neoplasms
Expression of multidrug resistance protein in metastatic colorectal carcinomas.
Neoplasms
Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1?, EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes.
Neoplasms
Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer.
Neoplasms
Expression of multidrug resistance-1 and multidrug resistance-associated protein genes in pediatric rhabdomyosarcoma.
Neoplasms
Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples.
Neoplasms
Expression of Multidrug Resistance-Associated P-Glycoprotein in Feline Tumours.
Neoplasms
Expression of multidrug resistance-associated protein (MRP) in head and neck squamous cell carcinoma.
Neoplasms
Expression of multidrug resistance-associated protein (MRP) in human gliomas.
Neoplasms
Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
Neoplasms
Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin.
Neoplasms
Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Neoplasms
Expression of multidrug resistance-related genes (mdrl, MRP, GST-pi and DNA topoisomerase II) in urothelial cancers.
Neoplasms
Expression of multidrug resistance-related markers in gastric cancer.
Neoplasms
Expression of multidrug resistance-related markers in primary neuroblastoma.
Neoplasms
Expression of multidrug-associated protein, P-glycoprotein, P53 and Bcl-2 proteins in bladder cancer and clinical implication.
Neoplasms
Expression of multidrug-resistance associated proteins in human retinoblastoma treated by primary enucleation.
Neoplasms
Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer.
Neoplasms
Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas.
Neoplasms
Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes.
Neoplasms
Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model.
Neoplasms
Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas.
Neoplasms
Expression of P-glycoprotein and C-MOAT in human hepatocellular carcinoma: detection by immunostaining.
Neoplasms
Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers.
Neoplasms
Expression of P-glycoprotein and Metallothionein in Gastrointestinal Stromal Tumor and Leiomyosarcomas. Clinical Implications.
Neoplasms
Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation.
Neoplasms
Expression of P-glycoprotein and multidrug resistance-associated protein is associated with multidrug resistance in gastric cancer.
Neoplasms
Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation.
Neoplasms
Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine.
Neoplasms
Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance.
Neoplasms
Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.
Neoplasms
Expression of P-glycoprotein in high grade osteosarcomas with special emphasis on chondroblastic subtype.
Neoplasms
Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome.
Neoplasms
Expression of P-glycoprotein in human retinoblastoma and its clinical significance.
Neoplasms
Expression of P-glycoprotein in normal muscle cells and myogenic tumors.
Neoplasms
Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer.
Neoplasms
Expression of p-glycoprotein in the normal colorectal epithelium and in colorectal-carcinoma.
Neoplasms
Expression of P-glycoprotein mRNA in human gastric tumors.
Neoplasms
Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies.
Neoplasms
Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Neoplasms
Expression of P-gp in Glioblastoma: What we can Learn from Brain Development.
Neoplasms
Expression of Potential Cancer Stem Cell Marker ABCG2 is Associated with Malignant Behaviors of Hepatocellular Carcinoma.
Neoplasms
Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi.
Neoplasms
Expression of resistance-related proteins in nephroblastoma after chemotherapy.
Neoplasms
Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes.
Neoplasms
Expression of the cancer stem cell markers CD44v6 and ABCG2 in tongue cancer: effect of neoadjuvant chemotherapy on local recurrence.
Neoplasms
Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma.
Neoplasms
Expression of the gene for the multidrug resistance-associated protein in human prostate tissue.
Neoplasms
Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues.
Neoplasms
Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase.
Neoplasms
Expression of the MDR1 and MRP genes in patients with lymphoma with primary bone marrow involvement.
Neoplasms
Expression of the MDR1 gene and P-glycoprotein in canine mast cell tumor cell lines.
Neoplasms
Expression of the mdr1 gene in bone and soft tissue sarcomas of adult patients.
Neoplasms
Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma.
Neoplasms
Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.
Neoplasms
Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy.
Neoplasms
Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas.
Neoplasms
Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma.
Neoplasms
Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas.
Neoplasms
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Neoplasms
Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation.
Neoplasms
Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer.
Neoplasms
Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer.
Neoplasms
Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas.
Neoplasms
Expression of the multidrug resistance-associated protein 1 (MRP1) and the lung resistance-related protein (LRP) in human lung cancer.
Neoplasms
Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay.
Neoplasms
Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas.
Neoplasms
Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors.
Neoplasms
Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas.
Neoplasms
Expression pattern of MRP in human tissues and adult solid tumor cell lines.
Neoplasms
Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray.
Neoplasms
Expression profiling of tumor necrosis factor alpha-induced apoptosis-associated genes in human solid tumor cell lines.
Neoplasms
Expressions of Multidrug Resistance-Related Genes in Gastric Cancer Tissue and Normal Gastric Mucosal Tissue.
Neoplasms
Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer.
Neoplasms
Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance.
Neoplasms
Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 x anti-Pgp bispecific diabody against human multidrug-resistant leukemia.
Neoplasms
Extracellular Vesicles in Chemoresistance.
Neoplasms
Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gp.
Neoplasms
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Neoplasms
Fabrication of hypoxia-responsive and uperconversion nanoparticles-modified RBC micro-vehicles for oxygen delivery and chemotherapy enhancement.
Neoplasms
Factors associated with cytoreducibility among women with ovarian carcinoma.
Neoplasms
False-negative scintigraphy with Tc-99m sestamibi in stage IV neuroblastoma.
Neoplasms
Fas signaling promotes chemoresistance in gastrointestinal cancer by up-regulating P-glycoprotein.
Neoplasms
FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin-proteasome pathway in cancer cells.
Neoplasms
Ferrocene-embedded flavonoids targeting the Achilles heel of multidrug-resistant cancer cells through collateral sensitivity.
Neoplasms
Ferulic acid reverses P-glycoprotein-mediated multidrug resistance via inhibition of PI3K/Akt/NF-?B signaling pathway.
Neoplasms
Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy.
Neoplasms
FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro.
Neoplasms
FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Neoplasms
Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
Neoplasms
Flavonoids as P-gp inhibitors: a systematic review of SARs.
Neoplasms
Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Neoplasms
Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2.
Neoplasms
Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes.
Neoplasms
Flow cytometric analysis of multidrug-resistance-associated antigen (P-glycoprotein) and DNA ploidy in human colon cancer.
Neoplasms
Flow cytometric analysis of P-glycoprotein function using rhodamine 123.
Neoplasms
Fluorescence studies on the nucleotide binding domains of the P-glycoprotein multidrug transporter.
Neoplasms
Fluorescence-based discrimination of breast cancer cells by direct exposure to 5-aminolevulinic acid.
Neoplasms
Fluorescent cellular indicators are extruded by the multidrug resistance protein.
Neoplasms
Fluorescent verapamil derivative for monitoring activity of the multidrug transporter.
Neoplasms
Fluorimetric Methods for Analysis of Permeability, Drug Transport Kinetics, and Inhibition of the ABCB1 Membrane Transporter.
Neoplasms
Fluorinated ?-Diketo Phosphorus Ylides Are Novel Inhibitors of the ABCB1 Efflux Pump of Cancer Cells.
Neoplasms
Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma.
Neoplasms
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Neoplasms
Flurazepam inhibits the P-glycoprotein transport function: an insight to revert multidrug-resistance phenotype.
Neoplasms
Folate and CD44 Receptors Dual-Targeting Hydrophobized Hyaluronic Acid Paclitaxel-Loaded Polymeric Micelles for Overcoming Multidrug Resistance and Improving Tumor Distribution.
Neoplasms
Folate-Targeted Redox-Responsive Polymersomes Loaded with Chemotherapeutic Drugs and Tariquidar to Overcome Drug Resistance.
Neoplasms
Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems.
Neoplasms
Formulation, pharmacokinetic evaluation and cytotoxicity of an enhanced-penetration paclitaxel nanosuspension.
Neoplasms
Frequency and genotype distribution of ABCB1 gene polymorphisms among Maharashtrian population of Central India.
Neoplasms
Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.
Neoplasms
Frequent coexpression of MRP/GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues.
Neoplasms
Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers.
Neoplasms
Frequent down-regulation of ABC transporter genes in prostate cancer.
Neoplasms
Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material.
Neoplasms
Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
Neoplasms
From mixed sigma-2 receptor/P-glycoprotein targeting agents to selective P-glycoprotein modulators: small structural changes address the mechanism of interaction at the efflux pump.
Neoplasms
Function of the ABC signature sequences in the human multidrug resistance protein 1.
Neoplasms
Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.
Neoplasms
Functional analysis of a tryptophan-less P-glycoprotein: a tool for tryptophan insertion and fluorescence spectroscopy.
Neoplasms
Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.
Neoplasms
Functional comparison of single- and double-stranded mdr1 antisense oligodeoxynucleotides in human ovarian cancer cell lines.
Neoplasms
Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.
Neoplasms
Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry.
Neoplasms
Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
Neoplasms
Functional evaluation of multidrug resistance transporter activity in surgical samples of solid tumors.
Neoplasms
Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.
Neoplasms
Functional intracellular P-glycoprotein.
Neoplasms
Functional involvement of P-glycoprotein in blood-brain barrier.
Neoplasms
Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain.
Neoplasms
Functional retention of Tc-99m MIBI in mediastinal lymphomas as a predictor of chemotherapeutic response demonstrated by consecutive thoracic SPECT imaging.
Neoplasms
Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery.
Neoplasms
Functionally active homodimer of P-glycoprotein in multidrug-resistant tumor cells.
Neoplasms
Functionally similar vanadate-induced 8-azidoadenosine 5'-[alpha-(32)P]Diphosphate-trapped transition state intermediates of human P-glycoprotin are generated in the absence and presence of ATP hydrolysis.
Neoplasms
Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells.
Neoplasms
Fungal ABC proteins: pleiotropic drug resistance, stress response and cellular detoxification.
Neoplasms
Further characterization of cyclophosphamide resistance: expression of CD95 and of bcl-2 in a CML cell line.
Neoplasms
Future perspectives for the development of P-glycoprotein modulators.
Neoplasms
G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern.
Neoplasms
GADD45? Determines Chemoresistance and Invasive Growth of Side Population Cells of Human Embryonic Carcinoma.
Neoplasms
Gambogic Acid as a Non-Competitive Inhibitor of ATP-Binding Cassette Transporter B1 Reverses the Multidrug Resistance of Human Epithelial Cancers by Promoting ATP-Binding Cassette Transporter B1 Protein Degradation.
Neoplasms
Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.
Neoplasms
Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer.
Neoplasms
Gamma-tocopheryl quinone stimulates apoptosis in drug-sensitive and multidrug-resistant cancer cells.
Neoplasms
Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells.
Neoplasms
Garcinol downregulates Notch1 signaling via modulating miR-200c and suppresses oncogenic properties of PANC-1 cancer stem-like cells.
Neoplasms
Gastrin regulates ABCG2 to promote the migration, invasion and side populations in pancreatic cancer cells via activation of NF-?B signaling.
Neoplasms
GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers.
Neoplasms
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Neoplasms
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Neoplasms
Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
Neoplasms
Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.
Neoplasms
Gene expression in response to anti-tumour intervention by polysaccharide-K (PSK) in colorectal carcinoma cells.
Neoplasms
Gene Polymorphisms of OPRM1 A118G and ABCB1 C3435T May Influence Opioid Requirements in Chinese Patients with Cancer Pain.
Neoplasms
Generating inhibitors of P-glycoprotein: where to, now?
Neoplasms
Generation and Characterization of an Abcc1 Humanized Mouse Model (hABCC1flx/flx ) with Knockout Capability.
Neoplasms
GENERATION OF NEW CYTOTOXIC HUMAN RIBONUCLEASE VARIANTS DIRECTED TO THE NUCLEUS.
Neoplasms
Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis.
Neoplasms
Genetic and epigenetic aberrations of ABCB1 synergistically boost the acquisition of taxane resistance in esophageal squamous cancer cells.
Neoplasms
Genetic and Non-genetic Factors Associated With Constipation in Cancer Patients Receiving Opioids.
Neoplasms
Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors.
Neoplasms
Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia.
Neoplasms
Genetic susceptibility of lung cancer associated with common variants in the 3' untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export.
Neoplasms
Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population.
Neoplasms
Genetically determined differences in P-glycoprotein function: implications for disease risk.
Neoplasms
Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells.
Neoplasms
Genomic amplification of chromosome 7 in the Doxorubicin resistant K562 cell line.
Neoplasms
Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cells.
Neoplasms
Genomic structure, gene expression, and promoter analysis of human multidrug resistance-associated protein 7.
Neoplasms
Genotype and haplotype analysis of ABCB1 at 1236, 2677 and 3435 among systemic sclerosis patients.
Neoplasms
Genuine functions of P-glycoprotein (ABCB1).
Neoplasms
Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients.
Neoplasms
Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1.
Neoplasms
Ginsenoside metabolites inhibit p-glycoprotein in vitro and in situ using three absorption models.
Neoplasms
Ginsenoside Rg5 overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter: in vitro and in vivo study.
Neoplasms
Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells.
Neoplasms
GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer.
Neoplasms
Global alteration of the drug-binding pocket of human P-glycoprotein (ABCB1) by substitution of fifteen conserved residues reveals a negative correlation between substrate size and transport efficiency.
Neoplasms
Glucocorticoid susceptibility and in vivo ABCB1 activity differ in murine B cell subsets.
Neoplasms
Glucose-induced alteration of accumulation of organotechnetium complexes accumulation in Pgp-negative tumor-bearing mice.
Neoplasms
Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
Neoplasms
Glutathione metabolism and glutathione S-conjugate export ATPase (MRP1/GS-X pump) activity in cancer. I. Differential expression in human cancer cell lines.
Neoplasms
Glutathione metabolism and glutathione S-conjugate export ATPase (MRP1/GS-X pump) activity in cancer. II. Cell-to-cell variability, relation with cellular activation state and functional absence of GS-X pump in lymphocytes.
Neoplasms
Glutathione S-transferase and multidrug-resistant phenotype in transitional cell carcinoma of the bladder.
Neoplasms
Glutathione S-transferase does not play a role in multidrug resistance of L1210/VCR cell line.
Neoplasms
Glutathione S-transferases and P-glycoprotein in normal rat hepatocytes and hepatoma cells: analysis using flow cytometry.
Neoplasms
Glycolytic pyruvate regulates P-Glycoprotein expression in multicellular tumor spheroids via modulation of the intracellular redox state.
Neoplasms
Glycoprotein 170 induces platelet-activating factor receptor membrane expression and confers tumor cell hypersensitivity to NK-dependent cell lysis.
Neoplasms
Glycyrrhizin has a high likelihood to be a victim of drug-drug interactions mediated by hepatic organic anion-transporting polypeptide 1B1/1B3.
Neoplasms
Golgi complex is brefeldin A resistant in multidrug resistant cells.
Neoplasms
GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells.
Neoplasms
GPER signalling in both cancer-associated fibroblasts and breast cancer cells mediates a feedforward IL1?/IL1R1 response.
Neoplasms
Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias.
Neoplasms
Grape Seed Procyanidin Reversal of P-glycoprotein Associated Multi-Drug Resistance via Down-regulation of NF-?B and MAPK/ERK Mediated YB-1 Activity in A2780/T Cells.
Neoplasms
Green Tea Catechin-Based Complex Micelles Combined with Doxorubicin to Overcome Cardiotoxicity and Multidrug Resistance.
Neoplasms
Growth inhibition by dehydrothyrsiferol - a non-Pgp modulator, derived from a marine red alga - in human breast cancer cell lines.
Neoplasms
Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR.
Neoplasms
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.
Neoplasms
Guggulsterone regulates the function and expression of P-glycoprotein in rat brain microvessel endothelial cells.
Neoplasms
H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo.
Neoplasms
Halogenation-guided chemical screening provides insight into tjipanazole biosynthesis by the cyanobacterium Fischerella ambigua.
Neoplasms
Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.
Neoplasms
Heat shock factor-1 knockout induces multidrug resistance gene, MDR1b, and enhances P-glycoprotein (ABCB1)-based drug extrusion in the heart.
Neoplasms
Heat Shock Protein Inhibitor 17-Allyamino-17-Demethoxygeldanamycin, a Potent Inductor of Apoptosis in Human Glioma Tumor Cell Lines, Is a Weak Substrate for ABCB1 and ABCG2 Transporters.
Neoplasms
Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model.
Neoplasms
Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer.
Neoplasms
Hepatic vectorial transport of xenobiotics.
Neoplasms
Hepatobiliary transporter expression in human hepatocellular carcinoma.
Neoplasms
Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation.
Neoplasms
Hepatocyte growth factor (HGF), heat shock proteins (HSPs) and multidrug resistance protein (MRP) expression in co-culture of colon tumor spheroids with normal cells after incubation with interleukin-1beta (IL-1beta) and/or camptothecin (CPT-11).
Neoplasms
Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
Neoplasms
Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance.
Neoplasms
Heterogeneity in P-glycoprotein (multidrug resistance) activity among murine peripheral T cells: correlation with surface phenotype and effector function.
Neoplasms
Heterotargeted Nanococktail with Traceless Linkers for Eradicating Cancer.
Neoplasms
HG-829 Is a Potent Noncompetitive Inhibitor of the ATP-Binding Cassette Multidrug Resistance Transporter ABCB1.
Neoplasms
High expression of ABCG2 is associated with chemotherapy resistance of osteosarcoma.
Neoplasms
High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival.
Neoplasms
High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia.
Neoplasms
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.
Neoplasms
High Levels of Hsp90 Cochaperone p23 Promote Tumor Progression and Poor Prognosis in Breast Cancer by Increasing Lymph Node Metastases and Drug Resistance.
Neoplasms
High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
Neoplasms
High rate of expression of multidrug resistance-associated P-glycoprotein in human endometrial carcinoma and normal endometrial tissue.
Neoplasms
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
Neoplasms
High-level expression of P-glycoprotein and 85 kD protein as assessed by flow cytometry and immunocytochemistry in leukemias and malignant lymphomas.
Neoplasms
High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters.
Neoplasms
High-Throughput Screening for Daunorubicin-Mediated Drug Resistance Identifies Mometasone Furoate as a Novel ABCB1-Reversal Agent.
Neoplasms
High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4).
Neoplasms
Highly sensitive and specific detection of P-glycoprotein function for haematological and solid tumour cells using a novel nucleic acid stain.
Neoplasms
Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma.
Neoplasms
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Neoplasms
Histone deacetylase inhibitor apicidin-mediated drug resistance: involvement of P-glycoprotein.
Neoplasms
Histone Deacetylase Inhibitor Induction of P-Glycoprotein Transcription Requires Both Histone Deacetylase 1 Dissociation and Recruitment of CAAT/Enhancer Binding Protein {beta} and pCAF to the Promoter Region.
Neoplasms
Histone Methyltransferase MLL1 Regulates MDR1 Transcription and Chemoresistance.
Neoplasms
Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein.
Neoplasms
Histopathological features and P-glycoprotein expression in retinoblastoma.
Neoplasms
Histopathological lesions, P-glycoprotein and PCNA expression in zebrafish (Danio rerio) liver after a single exposure to diethylnitrosamine.
Neoplasms
HLA class I and neuroendocrine antigen expression in multidrug resistant small cell lung carcinoma cell lines.
Neoplasms
Homoharringtonine: an effective new natural product in cancer chemotherapy.
Neoplasms
Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance.
Neoplasms
Homology modelling of human P-glycoprotein.
Neoplasms
How to make P-glycoprotein (ABCB1, MDR1) harbor mutations and measure its expression and activity in cell cultures?
Neoplasms
How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein.
Neoplasms
HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Neoplasms
hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations.
Neoplasms
Hsp90 facilitates acquired drug resistance of tumor cells through cholesterol modulation however independent of tumor progression.
Neoplasms
HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
Neoplasms
Huge focal nodular hyperplasia difficult to distinguish from well-differentiated hepatocellular carcinoma.
Neoplasms
Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.
Neoplasms
Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
Neoplasms
Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Neoplasms
Human ABCG2: structure, function, and its role in multidrug resistance.
Neoplasms
Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.
Neoplasms
Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation.
Neoplasms
Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
Neoplasms
Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
Neoplasms
Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.
Neoplasms
Human brain tumors: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells.
Neoplasms
Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells.
Neoplasms
Human Dosimetry and Preliminary Tumor Distribution of 18F-Fluoropaclitaxel in Healthy Volunteers and Newly Diagnosed Breast Cancer Patients Using PET/CT.
Neoplasms
Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression.
Neoplasms
Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.
Neoplasms
Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy.
Neoplasms
Human Platelet Lysate as a Replacement for Fetal Bovine Serum in Limbal Stem Cell Therapy.
Neoplasms
Human tumor cells resistant to verapamil.
Neoplasms
Humanization of the Blood-Brain Barrier Transporter ABCB1 in Mice Disrupts Genomic Locus - Lessons from Three Unsuccessful Approaches.
Neoplasms
Hybrid Mesoporous-Microporous Nanocarriers for Overcoming Multidrug Resistance by Sequential Drug Delivery.
Neoplasms
Hybrid Prodrug Nanoparticles with Tumor Penetration and Programmed Drug Activation for Enhanced Chemoresistant Cancer Therapy.
Neoplasms
Hyperin Enhances the Sensitivity of HCT8/VCR Colon Cancer Cell Line to Vincristine by Down-Regulating P-Glycoprotein.
Neoplasms
Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line.
Neoplasms
Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells.
Neoplasms
Hyperthermia enhances photodynamic therapy by regulation of HCP1 and ABCG2 expressions via high level ROS generation.
Neoplasms
Hypomethylation agent decitabine restores drug sensitivity by depressing P-glycoprotein activity through MAPK signaling pathway.
Neoplasms
Hypouricemic and nephroprotective roles of anthocyanins in hyperuricemic mice.
Neoplasms
Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1? and contributes to chemoresistance in pancreatic cancer cells.
Neoplasms
Hypoxia-Induced Extracellular Acidosis Increases p-Glycoprotein Activity and Chemoresistance in Tumors in Vivo via p38 Signaling Pathway.
Neoplasms
Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.
Neoplasms
HZ08 Reverse P-Glycoprotein Mediated Multidrug Resistance In Vitro and In Vivo.
Neoplasms
ID4 Promotes Breast Cancer Chemotherapy Resistance via CBF1-MRP1 Pathway.
Neoplasms
Identification and characterization of a new tubulin-binding tetrasubstituted brominated pyrrole.
Neoplasms
Identification and characterization of ovarian cancer-initiating cells from primary human tumors.
Neoplasms
Identification and exploration of herb-drug combinations used by cancer patients.
Neoplasms
Identification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA.
Neoplasms
Identification of a distinctive P-glycoprotein-mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated X-irradiation.
Neoplasms
Identification of a functional antioxidant response element within the eighth intron of the human ABCC3 gene.
Neoplasms
Identification of a multidrug resistance associated antigen (P-glycoprotein) in normal human tissues.
Neoplasms
Identification of a multixenobiotic resistance mechanism in Xenopus laevis embryos.
Neoplasms
Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.
Neoplasms
Identification of ABCG2? cells in nasopharyngeal carcinoma cells.
Neoplasms
Identification of CD44 as a Surface Biomarker for Drug Resistance by Surface Proteome Signature Technology.
Neoplasms
Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.
Neoplasms
Identification of domains participating in the substrate specificity and subcellular localization of the multidrug resistance proteins MRP1 and MRP2.
Neoplasms
Identification of Epigenetic Methylation Signatures With Clinical Value in Crohn's Disease.
Neoplasms
Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library.
Neoplasms
Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution.
Neoplasms
Identification of in vivo P-glycoprotein mRNA decay intermediates in normal liver but not in liver tumors.
Neoplasms
Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.
Neoplasms
Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen.
Neoplasms
Identification of new P-glycoprotein inhibitors derived from cardiotonic steroids.
Neoplasms
Identification of Novel Rare ABCC1 Transporter Mutations in Tumor Biopsies of Cancer Patients.
Neoplasms
Identification of NR1I2 genetic variation using resequencing.
Neoplasms
Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients.
Neoplasms
Identification of Possible Binding Sites for Morphine and Nicardipine on the Multidrug Transporter P-Glycoprotein Using Umbrella Sampling Techniques.
Neoplasms
Identification of selenocompounds with promising properties to reverse cancer multidrug resistance.
Neoplasms
Identification of Smac mimetics as novel substrates for p-glycoprotein.
Neoplasms
Identification of the First Diketomorpholine Biosynthetic Pathway Using FAC-MS Technology.
Neoplasms
Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for cyclosporine.
Neoplasms
Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein.
Neoplasms
Identification of the synthetic surfactant nonylphenol ethoxylate: a P-glycoprotein substrate in human urine.
Neoplasms
Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
Neoplasms
Identification of two different states of P-glycoprotein in its catalytic cycle: role of the linker region in the transition between these two states.
Neoplasms
Imaging Multidrug Resistance in Hematological Malignancies.
Neoplasms
Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi.
Neoplasms
Imaging of multidrug resistance in cancer.
Neoplasms
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.
Neoplasms
Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Neoplasms
Immunization with liposome-anchored pegylated peptides modulates doxorubicin sensitivity in P-glycoprotein-expressing P388 cells.
Neoplasms
Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
Neoplasms
Immunoblot detection of P-glycoprotein in human tumors and cell lines.
Neoplasms
Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies.
Neoplasms
Immunocytochemical detection of P-glycoprotein in the management of malignant effusions.
Neoplasms
Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients.
Neoplasms
Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer.
Neoplasms
Immunohistochemical analysis of P-glycoprotein expression in diverse histological types of epithelial ovarian tumors.
Neoplasms
Immunohistochemical analysis of pulmonary and pleural tumors with the monoclonal antibody HYB-612 directed against the multidrug resistance (MDR-1) gene product, P-glycoprotein.
Neoplasms
Immunohistochemical assessment of proliferation markers and altered gene expression in archival specimens of ovarian epithelial tumors.
Neoplasms
Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers.
Neoplasms
Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung.
Neoplasms
Immunohistochemical detection of P-glycoprotein (clone C494) in canine mammary gland tumours.
Neoplasms
Immunohistochemical detection of P-glycoprotein (PGP) and multidrug resistance-associated protein (MRP) in canine cutaneous mast cell tumors.
Neoplasms
Immunohistochemical detection of P-glycoprotein and carcinoembryonic antigen in small cell lung cancer: with reference to predictability of response to chemotherapy.
Neoplasms
Immunohistochemical Detection of P-glycoprotein in Breast Cancer and Its Significance as a Prognostic Factor.
Neoplasms
Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy.
Neoplasms
Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues.
Neoplasms
Immunohistochemical detection of P-glycoprotein in human tumor cells with a low degree of drug resistance.
Neoplasms
Immunohistochemical detection of P-glycoprotein in normal and malignant tissues: a comparative study of three monoclonal antibodies, JSB-1, C 219 and 265/F4, against different epitopes using frozen and paraffin tissue sections.
Neoplasms
Immunohistochemical detection of P-glycoprotein in various subtypes of canine lymphomas.
Neoplasms
Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.
Neoplasms
Immunohistochemical determination of P-glycoprotein in a rat mammary tumour treated with tamoxifen.
Neoplasms
Immunohistochemical evaluation of P-glycoprotein in human malignancies by monoclonal antibody MC57.
Neoplasms
Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival.
Neoplasms
Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type.
Neoplasms
Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer.
Neoplasms
Immunohistochemical Expression of P-glycoprotein and Breast Cancer Resistance Protein in Canine Mammary Hyperplasia, Neoplasia and Supporting Stroma.
Neoplasms
Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Neoplasms
Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas.
Neoplasms
Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis.
Neoplasms
Immunohistochemical localization of P-glycoprotein in adult human ovary and female genital tract of patients with benign gynecological conditions.
Neoplasms
Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables.
Neoplasms
Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma.
Neoplasms
Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors.
Neoplasms
Immunohistochemical study of P-glycoprotein distribution in lung cancer.
Neoplasms
Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung.
Neoplasms
Immunomodulation by macrolide antibiotics.
Neoplasms
Immunomodulatory Protein from Ganoderma microsporum Induces Pro-Death Autophagy through Akt-mTOR-p70S6K Pathway Inhibition in Multidrug Resistant Lung Cancer Cells.
Neoplasms
Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.
Neoplasms
Immunostaining for P-glycoprotein in the diagnosis of thyroid carcinomas.
Neoplasms
Immunosuppressant inhibition of P-glycoprotein function is independent of drug-induced suppression of peptide-prolyl isomerase and calcineurin activity.
Neoplasms
Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast.
Neoplasms
Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy.
Neoplasms
Impact of abcc2 [multidrug resistance-associated protein (mrp) 2], abcc3 (mrp3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.
Neoplasms
Impact of Breast Cancer Resistance Protein Expression on the In Vitro Efficacy of Anticancer Drugs in Pancreatic Cancer Cell Lines.
Neoplasms
Impact of breast cancer resistance protein on cancer treatment outcomes.
Neoplasms
Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.
Neoplasms
Impact of CYP3A5 and ABCB1 Gene Polymorphisms on Fentanyl Pharmacokinetics and Clinical Responses in Cancer Patients Undergoing Conversion to a Transdermal System.
Neoplasms
Impact of Extracellular Acidity on the Activity of P-glycoprotein and the Cytotoxicity of Chemotherapeutic Drugs.
Neoplasms
Impact of genetic variability in the ABCG2 gene on ABCG2 expression, function, and interaction with AT1 receptor antagonist telmisartan.
Neoplasms
Impact of hypoxia-related tumor acidosis on cytotoxicity of different chemotherapeutic drugs in vitro and in vivo.
Neoplasms
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.
Neoplasms
Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.
Neoplasms
Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2.
Neoplasms
Impact of the Recent Mouse P-Glycoprotein Structure for Structure-Based Ligand Design.
Neoplasms
Impaired expression of hepatic multidrug resistance protein 2 is associated with posthepatectomy hyperbilirubinemia in patients with biliary cancer.
Neoplasms
Implementing a pharmacist-led, individualized medication assessment and planning (iMAP) intervention to reduce medication related problems among older adults with cancer.
Neoplasms
Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.
Neoplasms
Importance of ABCC1 for cancer therapy and prognosis.
Neoplasms
Importance of P-glycoprotein at blood-tissue barriers.
Neoplasms
Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter.
Neoplasms
Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.
Neoplasms
Improved expression and purification of human multidrug resistance protein MDR1 from baculovirus-infected insect cells.
Neoplasms
Improving Treatment Efficacy of In Situ Forming Implants via Concurrent Delivery of Chemotherapeutic and Chemosensitizer.
Neoplasms
In silico and in vitro identification of secoisolariciresinol as a re-sensitizer of P-glycoprotein-dependent doxorubicin-resistance NCI/ADR-RES cancer cells.
Neoplasms
In silico identified targeted inhibitors of P-glycoprotein overcome multidrug resistance in human cancer cells in culture.
Neoplasms
In silico model for P-glycoprotein substrate prediction: insights from molecular dynamics and in vitro studies.
Neoplasms
In Silico Prediction of P-glycoprotein Binding: Insights from Molecular Docking Studies.
Neoplasms
In silico prediction of substrate properties for ABC-multidrug transporters.
Neoplasms
In silico screening with benzofurane- and benzopyrane-type MDR-modulators.
Neoplasms
In Silico Targeting Human Multidrug Transporter ABCG2 in Breast Cancer: Database Screening, Molecular Docking, and Molecular Dynamics Study.
Neoplasms
In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent.
Neoplasms
In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour.
Neoplasms
In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin.
Neoplasms
In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Neoplasms
In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Neoplasms
In vitro and in vivo expression of aldehyde dehydrogenase 1 in oral squamous cell carcinoma.
Neoplasms
In vitro and in vivo induction of apoptosis by sphingosine and N, N-dimethylsphingosine in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells.
Neoplasms
In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs.
Neoplasms
In vitro and in vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic tiamulin.
Neoplasms
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Neoplasms
In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines.
Neoplasms
In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumors.
Neoplasms
In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.
Neoplasms
In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance.
Neoplasms
In Vitro Evaluation of the Multidrug Resistance Reversing Activity of Novel Imidazo[4,5-b]pyridine Derivatives.
Neoplasms
In vivo and in vitro modulation of MDR molecules in murine thymocytes.
Neoplasms
In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.
Neoplasms
In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Neoplasms
In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II).
Neoplasms
In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance.
Neoplasms
In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance.
Neoplasms
In vivo expression of P-glycoprotein in a human colon carcinoma xenograft is modulated by therapy with free and monoclonal antibody-conjugated vinca alkaloids.
Neoplasms
In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody.
Neoplasms
In vivo model systems in P-glycoprotein-mediated multidrug resistance.
Neoplasms
In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil.
Neoplasms
In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein.
Neoplasms
Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia.
Neoplasms
Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity.
Neoplasms
Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
Neoplasms
Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer.
Neoplasms
Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles.
Neoplasms
Increased efficiency of testicular tumor chemotherapy by ultrasound microbubble-mediated targeted transfection of siMDR1.
Neoplasms
Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP).
Neoplasms
Increased estrogen sulfation of estradiol 17beta-D-glucuronide in metastatic tumor rat livers.
Neoplasms
Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin.
Neoplasms
Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines.
Neoplasms
Increased P-glycoprotein messenger RNA stability in rat liver tumors in vivo.
Neoplasms
Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin.
Neoplasms
Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein.
Neoplasms
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.
Neoplasms
Increased uptake of antisense oligonucleotides by delivery as double stranded complexes.
Neoplasms
Indomethacin-grafted and pH-sensitive dextran micelles for overcoming inflammation-mediated multidrug resistance in breast cancer.
Neoplasms
Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11.
Neoplasms
Induction of autoantibodies to murine P-glycoprotein: consequences on drug sensitivity in MDR cancer cells and on the expression of mdr genes in organs.
Neoplasms
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
Neoplasms
Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein.
Neoplasms
Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling.
Neoplasms
Induction of intrinsic and extrinsic apoptosis through oxidative stress in drug-resistant cancer by a newly synthesized Schiff base copper chelate.
Neoplasms
Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling.
Neoplasms
Induction of mdr1b mRNA and P-glycoprotein expression by tumor necrosis factor alpha in primary rat hepatocyte cultures.
Neoplasms
Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells.
Neoplasms
Induction of multiple drug resistance in HMEC-1 endothelial cells after long-term exposure to sunitinib.
Neoplasms
Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells.
Neoplasms
Induction of the multidrug-transporter P-glycoprotein by 3'-azido-3'-deoxythymidine (AZT) treatment in tumor cell lines.
Neoplasms
Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.
Neoplasms
Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study.
Neoplasms
Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India.
Neoplasms
Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
Neoplasms
Influence of dexniguldipine-HC1 on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: comparison with other chemosensitisers.
Neoplasms
Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
Neoplasms
Influence of exogenous RAR alpha gene on MDR1 expression and P-glycoprotein function in human and rodent cell lines.
Neoplasms
Influence of hypotonic stress on the biliary excretion of doxorubicin in Wistar and TR- rats.
Neoplasms
Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
Neoplasms
Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.
Neoplasms
Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis.
Neoplasms
Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.
Neoplasms
Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer.
Neoplasms
Influence of the Plasmodium falciparum P-glycoprotein homologue 1 (pfmdr1 gene product) on the antimalarial action of cyclosporin.
Neoplasms
Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT.
Neoplasms
Influence of Water Temperature on the MXR Activity and P-glycoprotein Expression in the Freshwater Snail, Physa acuta (Draparnaud, 1805).
Neoplasms
Influences of glutathione on anionic substrate efflux in tumour cells expressing the multidrug resistance-associated protein, MRP1.
Neoplasms
Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.
Neoplasms
Ingol diterpenoids as P-glycoprotein-dependent multidrug resistance (MDR) reversal agents from Euphorbia marginata.
Neoplasms
Inheritance of chromosome 7 is associated with a drug-resistant phenotype in somatic cell hybrids.
Neoplasms
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.
Neoplasms
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
Neoplasms
Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Neoplasms
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure.
Neoplasms
Inhibition of ABCG2/BCRP transporter by soy isoflavones genistein and daidzein: Effect on plasma and milk levels of danofloxacin in sheep.
Neoplasms
Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals.
Neoplasms
Inhibition of breast cancer resistance protein (ABCG2) in human myeloid dendritic cells induces potent tolerogenic functions during LPS stimulation.
Neoplasms
Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells.
Neoplasms
Inhibition of carrier-mediated uptake of epirubicin reduces cytotoxicity in primary culture of rat hepatocytes.
Neoplasms
Inhibition of CK2? down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells.
Neoplasms
Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acid diesters, novel inhibitors of P-glycoprotein function.
Neoplasms
Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein.
Neoplasms
Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma.
Neoplasms
Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
Neoplasms
Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells.
Neoplasms
Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to tiopronin.
Neoplasms
Inhibition of intestinal P-glycoprotein and effects on etoposide absorption.
Neoplasms
Inhibition of MALAT1 reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer.
Neoplasms
Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells.
Neoplasms
Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance.
Neoplasms
Inhibition of MRP1-mediated efflux in human erythrocytes by mono-anionic bile salts.
Neoplasms
Inhibition of mTOR Pathway by Rapamycin Decreases P-glycoprotein Expression and Spontaneous Seizures in Pharmacoresistant Epilepsy.
Neoplasms
Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog.
Neoplasms
Inhibition of multidrug resistance-associated protein (MRP) activity by rifampicin in human multidrug-resistant lung tumor cells.
Neoplasms
Inhibition of Multidrug Resistance-Linked P-Glycoprotein (ABCB1) Function by 5'-Fluorosulfonylbenzoyl 5'-Adenosine: Evidence for an ATP Analog That Interacts With Both Drug-Substrate- and Nucleotide-Binding Sites.
Neoplasms
Inhibition of multidrug transporter in tumor endothelial cells enhances antiangiogenic effects of low-dose metronomic paclitaxel.
Neoplasms
Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies.
Neoplasms
Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract.
Neoplasms
Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract.
Neoplasms
Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines.
Neoplasms
Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals.
Neoplasms
Inhibition of P-glycoprotein by wogonin is involved with the potentiation of etoposide-induced apoptosis in cancer cells.
Neoplasms
Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells.
Neoplasms
Inhibition of P-glycoprotein function and expression by kaempferol and quercetin.
Neoplasms
Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.
Neoplasms
Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Neoplasms
Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients.
Neoplasms
Inhibition of P-Glycoprotein Mediated Efflux of Paclitaxel by Coumarin Derivatives in Cancer Stem Cells: An In Silico Approach.
Neoplasms
Inhibition of P-glycoprotein mediated multidrug resistance by stemofoline derivatives.
Neoplasms
Inhibition of P-glycoprotein stimulates cell death under Hypoxia-mimicking conditions.
Neoplasms
Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Neoplasms
Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers.
Neoplasms
Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells.
Neoplasms
Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols.
Neoplasms
Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?
Neoplasms
Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs.
Neoplasms
Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells.
Neoplasms
Inhibition of transient receptor potential channel 5 reverses 5-Fluorouracil resistance in human colorectal cancer cells.
Neoplasms
Inhibition of tumor cells multidrug resistance by cucumarioside A2-2, frondoside A and their complexes with cholesterol.
Neoplasms
Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2).
Neoplasms
Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications.
Neoplasms
Inhibitors of multidrug efflux transporters: their membrane and protein interactions.
Neoplasms
Inhibitors of multidrug resistance.
Neoplasms
Inhibitors of p-glycoprotein--lead identification and optimisation.
Neoplasms
Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells.
Neoplasms
Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport.
Neoplasms
Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice.
Neoplasms
Inhibitory effects of epigallocatechin-3-gallate on cell proliferation and the expression of HIF-1? and P-gp in the human pancreatic carcinoma cell line PANC-1.
Neoplasms
Inhibitory effects of polyphenols on p-glycoprotein-mediated transport.
Neoplasms
Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.
Neoplasms
Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl.
Neoplasms
Insight into structural features of phenyltetrazole derivatives as ABCG2 inhibitors for the treatment of multidrug resistance in cancer.
Neoplasms
Insight on Multidrug Resistance and Nanomedicine Approaches to Overcome MDR.
Neoplasms
Integrated analysis of residue coevolution and protein structure in ABC transporters.
Neoplasms
Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study.
Neoplasms
Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors.
Neoplasms
Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma.
Neoplasms
Integrin-Linked Kinase, Snail and Multidrug Resistance Protein 1: Three concordant players in the progression of non-small cell lung cancer.
Neoplasms
Intensely potent doxorubicin analogues: structure-activity relationship.
Neoplasms
Interaction between CD147 and P-glycoprotein and their regulation by ubiquitination in breast cancer cells.
Neoplasms
Interaction field based and hologram based QSAR analysis of propafenone-type modulators of multidrug resistance.
Neoplasms
Interaction of bioactive hydrophobic peptides with the human multidrug transporter.
Neoplasms
Interaction of CCN1 with ?v?3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells.
Neoplasms
Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography.
Neoplasms
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Neoplasms
Interaction of organic chemicals with P-glycoprotein in the adrenal gland, kidney, and a multidrug-resistant KB cell.
Neoplasms
Interaction of P-glycoprotein with anti-tumor drugs: the site, gate and pathway.
Neoplasms
Interaction of P-glycoprotein with defined phospholipid bilayers: a differential scanning calorimetric study.
Neoplasms
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Neoplasms
Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport.
Neoplasms
Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells.
Neoplasms
Interaction of tomato lectin with ABC transporter in cancer cells: Glycosylation confers functional conformation of P-gp.
Neoplasms
Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.
Neoplasms
Interactions between artemisinin derivatives and P-glycoprotein.
Neoplasms
Interactions between Verapamil and Digoxin in Langendorff-Perfused Rat Hearts: The Role of Inhibition of P-glycoprotein in the Heart.
Neoplasms
Interactions between verapamil and digoxin in Langendorff-perfused rat hearts: the role of inhibition of P-glycoprotein in the heart.
Neoplasms
Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions.
Neoplasms
Intercellular Transfer of P-Glycoprotein from the Drug Resistant Human Bladder Cancer Cell Line BIU-87 Does Not Require Cell-to-Cell Contact.
Neoplasms
Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells.
Neoplasms
Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Neoplasms
Interferon alpha2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype.
Neoplasms
Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX.
Neoplasms
Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2.
Neoplasms
Interrogation of multidrug resistance (MDR1) P-glycoprotein (ABCB1) expression in human pancreatic carcinoma cells: correlation of 99mTc-Sestamibi uptake with western blot analysis.
Neoplasms
Intestinal expression of mouse Abcg2/Bcrp gene is under the control of circadian clock-activating transcription factor-4 pathway.
Neoplasms
Intestinal Inflammation Modulates the Epithelial Response to Butyrate in Patients With Inflammatory Bowel Disease.
Neoplasms
Intra-and inter-individual heterogeneity in exon 2 of the MDR1 gene in primary breast carcinoma and healthy individuals.
Neoplasms
Intracellular chloride channels: critical mediators of cell viability and potential targets for cancer therapy.
Neoplasms
Intracellular Doppler Spectroscopy detects altered drug response in SKOV3 tumor spheroids with silenced or inhibited P-glycoprotein.
Neoplasms
Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients.
Neoplasms
Intracellular expression of P-glycoprotein in a human colon tumor cell line.
Neoplasms
Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.
Neoplasms
Intracellular P-glycoprotein in multidrug resistant tumor cells.
Neoplasms
Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance.
Neoplasms
Intracellular trafficking of P-glycoprotein.
Neoplasms
Intratumoral heterogeneity for and epigenetic modulation of mdr-1 expression in murine melanoma.
Neoplasms
Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression.
Neoplasms
Intrinsic expression of drug resistance-associated factors in meningiomas.
Neoplasms
Intrinsic multidrug class 1 and 2 gene expression and localization in rat and human mammary tumors.
Neoplasms
Investigating the dynamic nature of the ABC transporters: ABCB1 and MsbA as examples for the potential synergies of MD theory and EPR applications.
Neoplasms
Investigating the Mechanism of Scutellariae barbata Herba in the Treatment of Colorectal Cancer by Network Pharmacology and Molecular Docking.
Neoplasms
Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy.
Neoplasms
Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.
Neoplasms
Investigation on vitamin E succinate based intelligent hyaluronic acid micelles for overcoming drug resistance and enhancing anticancer efficacy.
Neoplasms
Investigations on the cell metabolomics basis of multidrug resistance from tumor cells by ultra-performance liquid chromatography-mass spectrometry.
Neoplasms
Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells.
Neoplasms
Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells.
Neoplasms
Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells.
Neoplasms
Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1.
Neoplasms
Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1.
Neoplasms
Involvement of oligosaccharide changes in alpha5beta1 integrin in a cisplatin-resistant human squamous cell carcinoma cell line.
Neoplasms
Involvement of the multidrug resistance P-glycoprotein in acetaminophen-induced toxicity in hepatoma-derived HepG2 and Hep3B cells.
Neoplasms
Iodination of verapamil for a stronger induction of death, through GSH efflux, of cancer cells overexpressing MRP1.
Neoplasms
Iodomycin and iodipine, a structural analogue of azidopine, bind to a common domain in hamster P-glycoprotein.
Neoplasms
IPEC-J2 MDR1, a Novel High-Resistance Cell Line with Functional Expression of Human P-glycoprotein (ABCB1) for Drug Screening Studies.
Neoplasms
IRE1?-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells.
Neoplasms
Irinotecan pathway genotype analysis to predict pharmacokinetics.
Neoplasms
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
Neoplasms
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
Neoplasms
Is ATP binding responsible for initiating drug translocation by the multidrug transporter ABCG2?
Neoplasms
Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma?
Neoplasms
Is p-glycoprotein a potential target for reversing clinical drug resistance?
Neoplasms
Is P-glycoprotein relevant for the release of microvesicles by tumor cells?: PS212.
Neoplasms
Is resistance useless? Multidrug resistance and collateral sensitivity.
Neoplasms
Is rhodamine 123 an appropriate fluorescent probe to assess P-glycoprotein mediated multidrug resistance in vinblastine-resistant CHO cells?
Neoplasms
Is the ABCB1 gene associated with the increased risk of gastric cancer development?--preliminary research.
Neoplasms
Isobavachalcone as an Active Membrane Perturbing Agent and Inhibitor of ABCB1 Multidrug Transporter.
Neoplasms
Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells.
Neoplasms
Isolated cardiac recurrence of acute lymphoblastic leukemia characterized by t(11;19) two years after unrelated allogeneic bone marrow transplantation.
Neoplasms
Isolation and characterization of cancer stem cells from medulloblastoma.
Neoplasms
Isolation and Structure Elucidation, Molecular Docking Studies of Screlotiumol from Soil Borne Fungi Screlotium rolfsii and their Reversal of Multidrug Resistance in Mouse Lymphoma Cells.
Neoplasms
Isolation of a novel human canalicular multispecific organic anion transporter, cMOAT2/MRP3, and its expression in cisplatin-resistant cancer cells with decreased ATP-dependent drug transport.
Neoplasms
Isolation of Chlorogenic Acid from Soil Borne Fungi Screlotium rolfsii, their Reversal of Multidrug Resistance and anti-proliferative in Mouse Lymphoma cells.
Neoplasms
Isolation, Structure Elucidation, and Antiproliferative Activity of Butanolides and Lignan Glycosides from the Fruit of Hernandia nymphaeifolia.
Neoplasms
Isopetasin and S-isopetasin as novel P-glycoprotein inhibitors against multidrug-resistant cancer cells.
Neoplasms
Issues in developing drugs for primary brain tumors: barriers and toxicities.
Neoplasms
Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma.
Neoplasms
Jatrophane diterpenes and cancer multidrug resistance - ABCB1 efflux modulation and selective cell death induction.
Neoplasms
Jatrophane diterpenoids with multidrug-resistance modulating activity from the latex of Euphorbia nicaeensis.
Neoplasms
Jump into a New Fold-A Homology Based Model for the ABCG2/BCRP Multidrug Transporter.
Neoplasms
JWA sensitizes P-glycoprotein-mediated drug-resistant choriocarcinoma cells to etoposide via JNK and mitochondrial-associated signal pathway.
Neoplasms
Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc.
Neoplasms
Kaempferol-Mediated Sensitization Enhances Chemotherapeutic Efficacy of Sorafenib Against Hepatocellular Carcinoma: An In Silico and In Vitro Approach.
Neoplasms
KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein.
Neoplasms
KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1.
Neoplasms
Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis.
Neoplasms
Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein.
Neoplasms
Kinetic analysis of fluorescein and dihydrofluorescein effluxes in tumour cells expressing the multidrug resistance protein, MRP1.
Neoplasms
Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC transporter cMOAT/MRP2/ABCC2.
Neoplasms
Kinetic validation of the models for P-glycoprotein ATP hydrolysis and vanadate-induced trapping. Proposal for additional steps.
Neoplasms
Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport.
Neoplasms
Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Neoplasms
Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells.
Neoplasms
Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.
Neoplasms
Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity by regulating autophagy in glioblastoma.
Neoplasms
Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity.
Neoplasms
Knockout of a P-glycoprotein gene increases susceptibility to abamectin and emamectin benzoate in Spodoptera exigua.
Neoplasms
Korean red ginseng extract enhances paclitaxel distribution to mammary tumors and its oral bioavailability by P-glycoprotein inhibition.
Neoplasms
Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance.
Neoplasms
L-1416, a novel MDR reversing agent with possible reduced calcium antagonism.
Neoplasms
L-Canavanine modulates cellular growth, chemosensitivity and P-glycoprotein substrate accumulation in cultured human tumor cell lines.
Neoplasms
Laboratory assessment of P-glycoprotein in cancer chemosensitivity testing.
Neoplasms
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
Neoplasms
Lack of ABCG2 Expression and Side Population Properties in Human Pluripotent Stem Cells.
Neoplasms
Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol.
Neoplasms
Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas.
Neoplasms
Lack of correlation of functional scintigraphy with (99m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma.
Neoplasms
Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer.
Neoplasms
Lack of modulation of MDR1 gene expression by dominant inhibition of cAMP-dependent protein kinase in doxorubicin-resistant MCF-7 breast cancer cells.
Neoplasms
Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells.
Neoplasms
Lactosome-Conjugated siRNA Nanoparticles for Photo-Enhanced Gene Silencing in Cancer Cells.
Neoplasms
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
Neoplasms
Large-scale classification of P-glycoprotein inhibitors using SMILES-based descriptors.
Neoplasms
Large-scale purification of functional human P-glycoprotein (ABCB1).
Neoplasms
Lathyrane diterpenes from Euphorbia lathyris and the potential mechanism to reverse the multi-drug resistance in HepG2/ADR cells.
Neoplasms
Laurus nobilis L. Seed Extract Reveals Collateral Sensitivity in Multidrug-Resistant P-Glycoprotein-Expressing Tumor Cells.
Neoplasms
Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment.
Neoplasms
Leaf Extracts from Dillenia philippinensis Rolfe Exhibit Cytotoxic Activity to both Drug-Sensitive and Multidrug-Resistant Cancer Cells.
Neoplasms
Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin.
Neoplasms
Lentivirus?mediated CD44s expression increases human basal cell carcinoma cell resistance against vismodegib.
Neoplasms
Levistolide A synergistically enhances doxorubicin?induced apoptosis of k562/dox cells by decreasing MDR1 expression through the ubiquitin pathway.
Neoplasms
Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer.
Neoplasms
Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
Neoplasms
Ligand-based modeling of diverse aryalkylamines yields new potent P-glycoprotein inhibitors.
Neoplasms
Light-Activated ROS-Responsive Nanoplatform Codelivering Apatinib and Doxorubicin for Enhanced Chemo-Photodynamic Therapy of Multidrug-Resistant Tumors.
Neoplasms
LightSpot®-FL-1 Fluorescent Probe: An Innovative Tool for Cancer Drug Resistance Analysis by Direct Detection and Quantification of the P-glycoprotein (P-gp) on Monolayer Culture and Spheroid Triple Negative Breast Cancer Models.
Neoplasms
Lignans and norlignans inhibit multidrug resistance protein 1 (MRP1/ABCC1)-mediated transport.
Neoplasms
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
Neoplasms
Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation.
Neoplasms
Lipid regulation of the ABCB1 and ABCG2 multidrug transporters.
Neoplasms
Lipopolysaccharide and the glycoside ring of staurosporine induce CD14 expression on bone marrow granulocytes by different mechanisms.
Neoplasms
Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells.
Neoplasms
Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Neoplasms
Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells.
Neoplasms
Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.
Neoplasms
Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells.
Neoplasms
Liquid chromatography/nuclear magnetic resonance spectroscopy and liquid chromatography/mass spectrometry identification of novel metabolites of the multidrug resistance modulator LY335979 in rat bile and human liver microsomal incubations.
Neoplasms
Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer.
Neoplasms
Localisation of breast cancer resistance protein in microvessel endothelium of human brain.
Neoplasms
Localisation of the multidrug resistance-associated protein, MRP, in resistant large-cell lung tumour cells.
Neoplasms
Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines.
Neoplasms
Localization of putative binding sites for cyclic guanosine monophosphate and the anti-cancer drug 5-fluoro-2'-deoxyuridine-5'-monophosphate on ABCC11 in silico models.
Neoplasms
Localization of the GSH-dependent photolabelling site of an agosterol A analog on human MRP1.
Neoplasms
Localization of the iodomycin binding site in hamster P-glycoprotein.
Neoplasms
Localization of the multidrug resistance-associated 170 kDa P-glycoprotein gene to mouse chromosome 5 and to homogeneously staining regions in multidrug-resistant mouse cells by in situ hybridization.
Neoplasms
Location of a protease-hypersensitive region in the multidrug resistance protein (MRP) by mapping of the epitope of MRP-specific monoclonal antibody QCRL-1.
Neoplasms
Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.
Neoplasms
Long term results of reconstruction plates in lateral mandibular defects. Revision of nine cases.
Neoplasms
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Neoplasms
Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis.
Neoplasms
Loss of O?-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Neoplasms
Loss of VLA-3 (CD49c/CD29) expression in two multidrug resistant Burkitt's lymphoma cell lines.
Neoplasms
Lost in Translation: Regulation of ABCG2 Expression in Human Embryonic Stem Cells.
Neoplasms
Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.
Neoplasms
Low ABCB1 Gene Expression Is an Early Event in Colorectal Carcinogenesis.
Neoplasms
Low expression of MRP1/GS-X pump ATPase in lymphocytes of Walker 256 tumour-bearing rats is associated with cyclopentenone prostaglandin accumulation and cancer immunodeficiency.
Neoplasms
Low levels of ABCG2 expression in adult AML blast samples.
Neoplasms
Low Molecular Weight Heparin Ablates Lung Cancer Cisplatin-Resistance by Inducing Proteasome-Mediated ABCG2 Protein Degradation.
Neoplasms
Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.
Neoplasms
Low-Dose Crizotinib, a Tyrosine Kinase Inhibitor, Highly and Specifically Sensitizes P-Glycoprotein-Overexpressing Chemoresistant Cancer Cells Through Induction of Late Apoptosis in vivo and in vitro.
Neoplasms
Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins, P-glycoprotein and MRP1.
Neoplasms
Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution.
Neoplasms
Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumour PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion.
Neoplasms
Lower antioxidative capacity of multidrug-resistant cancer cells confers collateral sensitivity to protoflavone derivatives.
Neoplasms
Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP.
Neoplasms
Lung resistance protein and multidrug resistance protein in non-small cell lung cancer and their clinical significance.
Neoplasms
Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours.
Neoplasms
Luteolin induces apoptosis in multidrug resistant cancer cells without affecting the drug transporter function: involvement of cell line-specific apoptotic mechanisms.
Neoplasms
LY2228820 induces synergistic anti-cancer effects with anti-microtubule chemotherapeutic agents independent of P-glycoprotein in multidrug resistant cancer cells.
Neoplasms
Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug resistant breast carcinoma.
Neoplasms
Lymphotoxicity and myelotoxicity of doxorubicin and SDZ PSC 833 combined chemotherapies for normal mice.
Neoplasms
Lysine 268 adjacent to transmembrane helix 5 of hamster P-glycoprotein is the major photobinding site of iodomycin in CHO B30 cells.
Neoplasms
Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells.
Neoplasms
M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells.
Neoplasms
MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
Neoplasms
Macelignan: a new modulator of P-glycoprotein in multidrug-resistant cancer cells.
Neoplasms
Magnetic resonance pancreatography (MRP).
Neoplasms
Magnetic resonance pancreatography: comparison of two- and three-dimensional sequences for assessment of intraductal papillary mucinous neoplasm of the pancreas.
Neoplasms
Magnetic-affinity cell sorting of human multidrug-resistant cells.
Neoplasms
Major improvement of the reference method of the French drug resistance network for P-glycoprotein detection in human haematological malignancies.
Neoplasms
Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12.
Neoplasms
Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy.
Neoplasms
Malignant transformation of bronchogenic cyst revealed by 99mTc-MIBI-SPECT.
Neoplasms
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.
Neoplasms
Mana-Hox displays anticancer activity against prostate cancer cells through tubulin depolymerization and DNA damage stress.
Neoplasms
Management of Malignant Rectal Pain and Tenesmus: A Systematic Review.
Neoplasms
Manganese superoxide dismutase expression correlates with chemosensitivity in human gastric cancer cell lines.
Neoplasms
Mapping discontinuous epitopes for MRK-16, UIC2 and 4E3 antibodies to extracellular loops 1 and 4 of human P-glycoprotein.
Neoplasms
Mapping of the MRPm5 epitope to the cytosolic region between transmembrane helices 13 and 14 in the drug and organic anion transporter, MRP1 (ABCC1).
Neoplasms
MARCKS: a case of molecular exaptation?
Neoplasms
Marine natural products as breast cancer resistance protein inhibitors.
Neoplasms
Marine Natural Products as Models to Circumvent Multidrug Resistance.
Neoplasms
Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.
Neoplasms
Markers and Reporters to Reveal the Hierarchy in Heterogeneous Cancer Stem Cells.
Neoplasms
Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity.
Neoplasms
MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts.
Neoplasms
MDM2 Antagonist Nutlin-3a Reverses Mitoxantrone Resistance by Inhibiting Breast Cancer Resistance Protein Mediated Drug Transport.
Neoplasms
mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line.
Neoplasms
Mdm2 inhibitors as a platform for the design of P-glycoprotein inhibitors.
Neoplasms
MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to therapy.
Neoplasms
MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients.
Neoplasms
MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors.
Neoplasms
MDR1 expression is associated with adverse survival in melanoma of the uveal tract.
Neoplasms
MDR1 gene expression in primary and advanced breast cancer.
Neoplasms
Mdr1 gene-expression in a multidrug-resistant human non-hodgkins-lymphoma xenograft model.
Neoplasms
MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase.
Neoplasms
mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy.
Neoplasms
Mdr1 mRNA expression differs between grade III astrocytomas and glioblastomas.
Neoplasms
MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors.
Neoplasms
MDR1 RNA transcripts do not indicate long-term prognosis in colorectal carcinomas.
Neoplasms
Mdr1 transfection causes enhanced apoptosis by paclitaxel: an effect independent of drug efflux function of P-glycoprotein.
Neoplasms
MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin.
Neoplasms
MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells.
Neoplasms
MDR1A deficiency restrains tumor growth in murine colitis-associated carcinogenesis.
Neoplasms
Measurement of P-glycoprotein expression in human neuroblastoma xenografts using in vitro quantitative autoradiography.
Neoplasms
Measurement of P-glycoprotein Function.
Neoplasms
Measuring MDR-1 by Quantitative RT-PCR.
Neoplasms
Mechanism of action of human P-glycoprotein ATPase activity. Photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites.
Neoplasms
Mechanism of allosteric modulation of P-glycoprotein by transport substrates and inhibitors.
Neoplasms
Mechanism of selectivity of an angiogenesis inhibitor from screening a genome-wide set of Saccharomyces cerevisiae deletion strains.
Neoplasms
Mechanism Underlying the Reversal of Drug Resistance in P-Glycoprotein-Expressing Leukemia Cells by Pinoresinol and the Study of a Derivative.
Neoplasms
Mechanisms of glutathione-conjugate efflux from the brain into blood: Involvement of multiple transporters in the course.
Neoplasms
Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors.
Neoplasms
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
Neoplasms
Mechanisms underlying the anticancer activities of the angucycline landomycin E.
Neoplasms
Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles.
Neoplasms
Mechanistic study of PpIX accumulation using the JFCR39 cell panel revealed a role for dynamin 2-mediated exocytosis.
Neoplasms
Medicinal chemistry of anthranilic acid derivatives: A mini review.
Neoplasms
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update.
Neoplasms
Melittin-encapsulating peptide hydrogels for enhanced delivery of impermeable anticancer peptides.
Neoplasms
Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter.
Neoplasms
Membrane insertion, processing, and topology of cystic fibrosis transmembrane conductance regulator (CFTR) in microsomal membranes.
Neoplasms
Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells.
Neoplasms
Membrane topology of the DrrB protein of the doxorubicin transporter of Streptomyces peucetius.
Neoplasms
Membrane transport of dietary phenethyl isothiocyanate by ABCG2 (breast cancer resistance protein).
Neoplasms
Membranous ABCG2 expression in colorectal cancer independently correlates with shortened patient survival.
Neoplasms
Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
Neoplasms
Metabolism and disposition of the novel antileukaemic drug, benzamide riboside, in the isolated perfused rat liver.
Neoplasms
Metabolism and transport of oxazaphosphorines and the clinical implications.
Neoplasms
Metabolism of short-chain ceramide by human cancer cells-Implications for therapeutic approaches.
Neoplasms
Metabolomics analysis of multidrug resistance in colorectal cancer cell and multidrug resistance reversal effect of verapamil.
Neoplasms
Metalloprobes: Fluorescence imaging of multidrug resistance (MDR1) P-Glycoprotein (Pgp)-mediated functional transport activity in cellulo.
Neoplasms
Metalloprobes: synthesis, characterization, and potency of a novel gallium(III) complex in human epidermal carcinoma cells.
Neoplasms
Metastasis to ipsilateral medial retropharyngeal and deep cervical lymph nodes in 22 dogs with thyroid carcinoma.
Neoplasms
Metformin inhibits P-glycoprotein expression via the NF-?B pathway and CRE transcriptional activity through AMPK activation.
Neoplasms
Metformin synergistically suppress tumor growth with doxorubicin and reverse drug resistance by inhibiting the expression and function of P-glycoprotein in MCF7/ADR cells and xenograft models.
Neoplasms
Method to Screen Multidrug Transport Inhibitors Using Yeast Overexpressing a Human MDR Transporter.
Neoplasms
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
Neoplasms
Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.
Neoplasms
Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells.
Neoplasms
Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells.
Neoplasms
Methylene blue reverts multidrug resistance: sensitivity of multidrug resistant cells to this dye and its photodynamic action.
Neoplasms
Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes.
Neoplasms
Microparticle-associated nucleic acids mediate trait dominance in cancer.
Neoplasms
Microparticles induce multifactorial resistance through oncogenic pathways independently of cancer cell type.
Neoplasms
microRNA-29b inhibits cell growth and promotes sensitivity to oxaliplatin in colon cancer by targeting FOLR1.
Neoplasms
MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells.
Neoplasms
Microtubule active agents: beyond the taxane frontier.
Neoplasms
Microtubule-stabilizing properties of the avocado-derived toxins (+)-(R)-persin and (+)-(R)-tetrahydropersin in cancer cells and activity of related synthetic analogs.
Neoplasms
Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumour cells.
Neoplasms
Miltirone Is a Dual Inhibitor of P-Glycoprotein and Cell Growth in Doxorubicin-Resistant HepG2 Cells.
Neoplasms
MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells.
Neoplasms
miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer.
Neoplasms
MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Neoplasms
miR-21 inhibition reverses doxorubicin-resistance and inhibits PC3 human prostate cancer cells proliferation.
Neoplasms
MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells.
Neoplasms
MiR-26b regulates 5-FU-resistance in human colorectal cancer via down-regulation of Pgp.
Neoplasms
MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Neoplasms
miR-506 suppresses cervical cancer cell proliferation both in vitro and in vivo.
Neoplasms
miR106a Promotes the Growth of Transplanted Breast Cancer and Decreases the Sensitivity of Transplanted Tumors to Cisplatin.
Neoplasms
miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.
Neoplasms
Mithramycin Represses Basal and Cigarette Smoke-Induced Expression of ABCG2 and Inhibits Stem Cell Signaling in Lung and Esophageal Cancer Cells.
Neoplasms
Mitochondria of a human multidrug-resistant hepatocellular carcinoma cell line constitutively express inducible nitric oxide synthase in the inner membrane.
Neoplasms
Mitochondria P-glycoprotein confers paclitaxel resistance on ovarian cancer cells.
Neoplasms
Mitochondrial Fuel Dependence on Glutamine Drives Chemo-Resistance in the Cancer Stem Cells of Hepatocellular Carcinoma.
Neoplasms
Mitochondrial localization of ABC transporter ABCG2 and its function in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation.
Neoplasms
Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
Neoplasms
Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma.
Neoplasms
Mode of Action Analyses of Neferine, a Bisbenzylisoquinoline Alkaloid of Lotus (Nelumbo nucifera) against Multidrug-Resistant Tumor Cells.
Neoplasms
Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.
Neoplasms
Modification of C-seco taxoids through ring tethering and substituent replacement leading to effective agents against tumor drug resistance mediated by ?III-Tubulin and P-glycoprotein (P-gp) overexpressions.
Neoplasms
Modified jatrophane diterpenes as modulators of multidrug resistance from Euphorbia dendroides L.
Neoplasms
Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.
Neoplasms
Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine.
Neoplasms
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Neoplasms
Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters.
Neoplasms
Modulation of ABCC1 and ABCG2 Proteins by Ouabain in Human Breast Cancer Cells.
Neoplasms
Modulation of ABCG2 surface expression by Rab5 and Rab21 to overcome multidrug resistance in cancer cells.
Neoplasms
Modulation of anticancer drug-induced P-glycoprotein expression by naringin.
Neoplasms
Modulation of Autophagy by a Thioxanthone Decreases the Viability of Melanoma Cells.
Neoplasms
Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
Neoplasms
Modulation of cancer cell multidrug resistance by an extract of Ficus citrifolia.
Neoplasms
Modulation of Doxorubicin sensitivity and level of p-glycoprotein expression in human colon-carcinoma cells by ectopic and orthotopic environments in nude-mice.
Neoplasms
Modulation of expression of multidrug resistance gene (mdr-1) by adriamycin.
Neoplasms
Modulation of function of multidrug resistance associated-proteins by Kaempferia parviflora extracts and their components.
Neoplasms
Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Neoplasms
Modulation of GSH levels in ABCC1 expressing tumor cells triggers apoptosis through oxidative stress.
Neoplasms
Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells.
Neoplasms
Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors.
Neoplasms
Modulation of liver canalicular transport processes by the tyrosine-kinase inhibitor genistein: implications of genistein metabolism in the rat.
Neoplasms
Modulation of liver X receptor signaling as novel therapy for prostate cancer.
Neoplasms
Modulation of multidrug resistance by cepharanthine in fresh human gastrointestinal tumor cells.
Neoplasms
Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
Neoplasms
Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme.
Neoplasms
Modulation of multidrug resistance P-glycoprotein activity by antiemetic compounds in human doxorubicin-resistant sarcoma cells (MES-SA/Dx-5): implications on cancer therapy.
Neoplasms
Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy.
Neoplasms
Modulation of multidrug resistance protein (MRP1/ABCC1) expression: a novel physiological role for ouabain.
Neoplasms
Modulation of multidrug resistance with antisense oligodeoxynucleotide to mdr1 mRNA.
Neoplasms
Modulation of multidrug-resistance-associated P-glycoprotein in human U-87 MG and HUV-ECC cells with antisense oligodeoxynucleotides to MDR1 mRNA.
Neoplasms
Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators.
Neoplasms
Modulation of P-glycoprotein activity by novel synthetic curcumin derivatives in sensitive and multidrug-resistant T-cell acute lymphoblastic leukemia cell lines.
Neoplasms
Modulation of P-glycoprotein activity by the substituted quinoxalinone compound QA3 in adriamycin-resistant K562/A02 cells.
Neoplasms
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy.
Neoplasms
Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells.
Neoplasms
Modulation of P-glycoprotein function and multidrug resistance in cancer cells by Thai plant extracts.
Neoplasms
Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells.
Neoplasms
Modulation of P-glycoprotein mediated drug accumulation in multidrug resistant CCRF VCR-1000 cells by chemosensitisers.
Neoplasms
Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate.
Neoplasms
Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles.
Neoplasms
Modulation of selenium-dependent glutathione peroxidase activity enhances doxorubicin-induced apoptosis, tumour cell killing and hydroxyl radical production in human NCI/ADR-RES cancer cells despite high-level P-glycoprotein expression.
Neoplasms
Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7).
Neoplasms
Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
Neoplasms
Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine.
Neoplasms
Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
Neoplasms
Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
Neoplasms
Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei.
Neoplasms
Modulation of tumor cell response to chemotherapy by the organ environment.
Neoplasms
Modulation of vinca-alkaloid induced P-glycoprotein expression by indole-3-carbinol.
Neoplasms
Modulators of the human ABCC2: hope from natural sources?
Neoplasms
Modulatory effects of heparin on cellular accumulation and cytotoxicity of doxorubicin in MRP1-overexpressing HL60/doxo cells.
Neoplasms
Moesin-Mediated P-Glycoprotein Activation during Snail-Induced Epithelial-Mesenchymal Transition in Lung Cancer Cells.
Neoplasms
Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas.
Neoplasms
Molecular analysis of the massive GSH transport mechanism mediated by the human Multidrug Resistant Protein 1/ABCC1.
Neoplasms
Molecular analysis of the multidrug transporter, P-glycoprotein.
Neoplasms
Molecular analysis of the multidrug transporter.
Neoplasms
Molecular aspects of breast and ovarian cancer.
Neoplasms
Molecular Basis of Cancer Pain Management: An Updated Review.
Neoplasms
Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studies.
Neoplasms
Molecular biology of breast cancer stem cells: Potential clinical applications.
Neoplasms
Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer.
Neoplasms
Molecular cloning of the murine cMOAT ATPase.
Neoplasms
Molecular cytogenetic analysis of chemoresistant non-Hodgkin's lymphoma patients with p53 abnormalities using fluorescence in situ hybridisation and comparative genomic hybridisation.
Neoplasms
Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein.
Neoplasms
Molecular docking studies and in vitro screening of new dihydropyridine derivatives as human MRP1 inhibitors.
Neoplasms
Molecular Docking studies reveals Rhein from rhubarb (Rheum rhabarbarum) as a putative inhibitor of ATP-binding Cassette Super Family G member 2.
Neoplasms
Molecular docking study of lignanamides from Cannabis sativa against P-glycoprotein.
Neoplasms
Molecular evolutionary analysis of ABCB5: the ancestral gene is a full transporter with potentially deleterious single nucleotide polymorphisms.
Neoplasms
Molecular identification and characterization of rat Abcc1 cDNA: existence of two splicing variants and species difference in drug-resistance profile.
Neoplasms
Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237).
Neoplasms
Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe.
Neoplasms
Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia.
Neoplasms
Molecular mechanisms of apoptosis activation by heat shock in multidrug-resistant Chinese hamster cells.
Neoplasms
Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Neoplasms
Molecular Mimics of Classic P-Glycoprotein Inhibitors as Multidrug Resistance Suppressors and Their Synergistic Effect on Paclitaxel.
Neoplasms
Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer.
Neoplasms
Molecular model of the outward facing state of the human multidrug resistance protein 4 (MRP4/ABCC4).
Neoplasms
Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer.
Neoplasms
Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance.
Neoplasms
Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance.
Neoplasms
Molecular study of P-glycoprotein in multidrug resistance using surface plasmon resonance.
Neoplasms
Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.
Neoplasms
Molecular targets and anticancer potential of indole-3-carbinol and its derivatives.
Neoplasms
Mono- and dicationic Re(I)/(99m)Tc(I) tricarbonyl complexes for the targeting of energized mitochondria.
Neoplasms
Monoclonal anti-P-glycoprotein antibody-dependent killing of multidrug-resistant tumor cells by human mononuclear cells.
Neoplasms
Monoclonal antibodies as a tool for structure-function studies of the MDR1-P-glycoprotein.
Neoplasms
Monoclonal antibodies that inhibit the transport function of the 190-kDa multidrug resistance protein, MRP. Localization of their epitopes to the nucleotide-binding domains of the protein.
Neoplasms
Monoclonal antibodies to P-glycoprotein: preparation and applications to basic and clinical research.
Neoplasms
Monoclonal antibody C219 detection of the multidrug-resistant protein P-glycoprotein in routinely processed tissues: a study of 36 cases of ovarian carcinoma.
Neoplasms
Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.
Neoplasms
Morphologic changes in the tumor and liver in mice with transplanted RLS40 lymphosarcoma during increase of its drug resistance.
Neoplasms
Morphological and molecular characterization of an undifferentiated soft tissue sarcoma cell line and derivative clones.
Neoplasms
Mouse-human chimeric antibody against the multidrug transporter P-glycoprotein.
Neoplasms
Mouse-human chimeric antibody MH171 against the multidrug transporter P-glycoprotein.
Neoplasms
MRP and MDR1 gene expression in primary breast carcinomas.
Neoplasms
MRP expression of testicular cancers and its clinical relevance.
Neoplasms
MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs.
Neoplasms
MRP1 and its role in anticancer drug resistance.
Neoplasms
MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells.
Neoplasms
Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers.
Neoplasms
MRP1 mutated in the L0 region transports SN-38 but not leukotriene C4 or estradiol-17 (beta-D-glucuronate).
Neoplasms
MRP1-dependent collateral sensitivity of multidrug-resistant cancer cells: identifying selective modulators inducing cellular glutathione depletion.
Neoplasms
MRP1-targeted near infrared photoimmunotherapy for drug resistant small cell lung cancer.
Neoplasms
MS-209 Schering.
Neoplasms
MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.
Neoplasms
MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner.
Neoplasms
Mucin antigen expression in gastric carcinomas of young and old adults.
Neoplasms
Multi-functional nanocarriers to overcome tumor drug resistance.
Neoplasms
Multi-kinase inhibitors and cisplatin for head and neck cancer treatment in vitro.
Neoplasms
Multidrug drug resistance in pediatric sarcomas.
Neoplasms
Multidrug efflux pumps: drug binding--gates or cavity?
Neoplasms
Multidrug resistance (MDR) genes in haematological malignancies.
Neoplasms
Multidrug resistance and cancer: the role of the human ABC transporter ABCG2.
Neoplasms
Multidrug resistance and P-glycoprotein expression in human cancer.
Neoplasms
Multidrug resistance and the role of P-glycoprotein knockout mice.
Neoplasms
Multidrug resistance associated proteins in multidrug resistance.
Neoplasms
Multidrug resistance during cancer chemotherapy--biotechnological solutions to a clinical problem.
Neoplasms
Multidrug resistance gene (MDR 1) expression in neuro-axial tumours of children and young adults.
Neoplasms
Multidrug resistance gene (MDR-1) expression in the colonic mucosa of patients with refractory ulcerative colitis.
Neoplasms
Multidrug resistance gene (MDR1) expression in human brain tumors.
Neoplasms
Multidrug resistance gene (P-glycoprotein) expression in the human fetus.
Neoplasms
Multidrug resistance gene and P-glycoprotein expression in anaplastic carcinoma of the thyroid.
Neoplasms
Multidrug resistance gene and P-glycoprotein expression in gastric adenocarcinoma and precursor lesions.
Neoplasms
Multidrug resistance gene expression in pediatric primitive neuroectodermal tumors of the central nervous system.
Neoplasms
Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone.
Neoplasms
Multidrug resistance gene transcript level, and P-glycoprotein expression in paediatric malignant mesenchymal tumours.
Neoplasms
Multidrug resistance genes (MRP) and MDR1 expression in small cell lung cancer xenografts: relationship with response to chemotherapy.
Neoplasms
Multidrug resistance genes and p-glycoprotein in the testis of the rat, mouse, Guinea pig, and human.
Neoplasms
Multidrug resistance in brain tumors: roles of the blood-brain barrier.
Neoplasms
Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
Neoplasms
Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein.
Neoplasms
Multidrug resistance in human cancer.
Neoplasms
Multidrug Resistance in Mammals and Fungi-From MDR to PDR: A Rocky Road from Atomic Structures to Transport Mechanisms.
Neoplasms
Multidrug resistance in mucoepidermoid carcinoma of the parotid gland - immunohistochemical investigations of P-glycoprotein expression.
Neoplasms
Multidrug resistance in oncology: diagnostic and therapeutic approaches.
Neoplasms
Multidrug resistance in ovarian cancer: comparing an immunocytochemical study and ATP-tumor chemosensitivity assay.
Neoplasms
Multidrug resistance in pediatric malignancies.
Neoplasms
Multidrug resistance in pediatric oncology.
Neoplasms
Multidrug Resistance in Primary Tumors and Metastases in Patients with Esophageal Squamous Cell Carcinoma.
Neoplasms
Multidrug resistance in the laboratory and clinic.
Neoplasms
Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.
Neoplasms
Multidrug resistance mediated by P-glycoprotein in haematological malignancies.
Neoplasms
Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP.
Neoplasms
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Neoplasms
Multidrug resistance mediated by the multidrug resistance protein (MRP) gene.
Neoplasms
Multidrug resistance of testis cancers: the study of clinical relevance of P-glycoprotein expression.
Neoplasms
Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy.
Neoplasms
Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents.
Neoplasms
Multidrug resistance phosphoglycoprotein (ABCB1) in the mouse placenta: fetal protection.
Neoplasms
Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux.
Neoplasms
Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter.
Neoplasms
Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.
Neoplasms
Multidrug resistance protein 3 loss promotes tumor formation by inducing senescence escape.
Neoplasms
Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression.
Neoplasms
Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively.
Neoplasms
Multidrug resistance protein functionality: no effect of intracellular or extracellular pH changes.
Neoplasms
Multidrug resistance protein MRP1 reconstituted into lipid vesicles: secondary structure and nucleotide-induced tertiary structure changes.
Neoplasms
Multidrug Resistance Proteins (MRPs) and Cancer Therapy.
Neoplasms
Multidrug resistance proteins and other drug transport-related resistance to natural product agents.
Neoplasms
Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib.
Neoplasms
Multidrug resistance related molecules in human and murine lung.
Neoplasms
Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay.
Neoplasms
Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents.
Neoplasms
Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.
Neoplasms
Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer.
Neoplasms
Multidrug resistance-associated protein (MRP) gene expression in human lung cancer.
Neoplasms
Multidrug resistance-associated protein (MRP) in haematological malignancies.
Neoplasms
Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors.
Neoplasms
Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
Neoplasms
Multidrug resistance-associated protein expression in clinical gastric carcinoma.
Neoplasms
Multidrug resistance-associated protein subfamily transporters and drug resistance.
Neoplasms
Multidrug resistance-associated protein--reduction of expression in human leukaemia cells by antisense phosphorothioate olignucleotides.
Neoplasms
Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Neoplasms
Multidrug resistance-modifying components in human plasma with potential clinical significance.
Neoplasms
Multidrug resistance-related proteins in primary choroidal melanomas and in vitro cell lines.
Neoplasms
Multidrug resistance.
Neoplasms
Multidrug resistance. Clinical opportunities in diagnosis and circumvention.
Neoplasms
Multidrug resistance: a transport system of antitumor agents and xenobiotics.
Neoplasms
Multidrug resistance: clinical relevance in haematological malignancies.
Neoplasms
Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Neoplasms
Multidrug resistance: molecular mechanisms and clinical relevance.
Neoplasms
Multidrug resistant transgenic mice as a novel pharmacologic tool.
Neoplasms
Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells.
Neoplasms
Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
Neoplasms
Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.
Neoplasms
Multidrug transporters of Candida species in clinical azole resistance.
Neoplasms
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.
Neoplasms
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.
Neoplasms
Multidrug-resistance transporters.
Neoplasms
Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).
Neoplasms
Multidrug-resistant cancer cells contain two populations of P-glycoprotein with differently stimulated P-gp ATPase activities: evidence from atomic force microscopy and biochemical analysis.
Neoplasms
Multidrug-resistant colonic cancer cell line LoVoDx is efficiently killed by lymphokine-activated killer cells from patients with carcinoma of the colon.
Neoplasms
Multidrug-resistant hela cells overexpressing MRP1 exhibit sensitivity to cell killing by hyperthermia: interactions with etoposide.
Neoplasms
Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression.
Neoplasms
Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.
Neoplasms
Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1.
Neoplasms
Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Neoplasms
Multifunctional Nanoparticles as Nanocarrier for Vincristine Sulfate Delivery To Overcome Tumor Multidrug Resistance.
Neoplasms
Multifunctional nanoparticles based on a single-molecule modification for the treatment of drug-resistant cancer.
Neoplasms
Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Neoplasms
Multiple black hepatocellular adenomas in a male patient.
Neoplasms
Multiple common and rare variants of
Neoplasms
Multiple drug resistance mechanisms in cancer.
Neoplasms
Multiple drug resistance parameter expression in ovarian cancer.
Neoplasms
Multiple Drug Transport Pathways through Human P-Glycoprotein.
Neoplasms
Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter.
Neoplasms
Multiple Functions Integrated inside a Single Molecule for Amplification of Photodynamic Therapy Activity.
Neoplasms
Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression.
Neoplasms
Multiple Linear Regression Analysis Indicates Association of P-Glycoprotein Substrate or Inhibitor Character with Bitterness Intensity, Measured with a Sensor.
Neoplasms
Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice.
Neoplasms
Multiple physiological functions for multidrug transporter P-glycoprotein?
Neoplasms
Multiple strategies with the synergistic approach for addressing colorectal cancer.
Neoplasms
Multiple transport-active binding sites are available for a single substrate on human P-glycoprotein (ABCB1).
Neoplasms
Multiplex analysis of tumor multidrug-resistance genes expression with photonic suspension array.
Neoplasms
Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.
Neoplasms
Multivalent methionine-functionalized biocompatible block copolymers for targeted small interfering RNA delivery and subsequent reversal effect on adriamycin resistance in human breast cancer cell line MCF-7/ADR.
Neoplasms
Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
Neoplasms
Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity.
Neoplasms
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.
Neoplasms
Mutations of the central tyrosines of putative cholesterol recognition amino acid consensus (CRAC) sequences modify folding, activity, and sterol-sensing of the human ABCG2 multidrug transporter.
Neoplasms
MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs.
Neoplasms
MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma.
Neoplasms
Myeloid-specific genetic ablation of ATP-binding cassette transporter ABCA1 is protective against cancer.
Neoplasms
N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer.
Neoplasms
N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
Neoplasms
N-acetylcysteine enhances multidrug resistance-associated protein 1 mediated doxorubicin resistance.
Neoplasms
N-acetylglycoside of oleanolic acid (aridanin) displays promising cytotoxicity towards human and animal cancer cells, inducing apoptotic, ferroptotic and necroptotic cell death.
Neoplasms
N-alkylisatin-based microtubule destabilizers bind to the colchicine site on tubulin and retain efficacy in drug resistant acute lymphoblastic leukemia cell lines with less in vitro neurotoxicity.
Neoplasms
N-ethylmaleimide increases P-glycoprotein photoaffinity labeling with iodoaryl-azidoprazosin in multidrug resistant cells.
Neoplasms
N-Substituted piperazine derivatives as potential multitarget agents acting on histamine H3 receptor and cancer resistance proteins.
Neoplasms
N6-methyladenosine-induced ERR? triggers chemoresistance of cancer cells through upregulation of ABCB1 and metabolic reprogramming.
Neoplasms
Nano-engineered mesenchymal stem cells as targeted therapeutic carriers.
Neoplasms
Nanocarriers enhance Doxorubicin uptake in drug-resistant ovarian cancer cells.
Neoplasms
Nanoenabled Intracellular Calcium Bursting for Safe and Efficient Reversal of Drug Resistance in Tumor Cells.
Neoplasms
Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer.
Neoplasms
Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
Neoplasms
Nanotherapeutics with suitable properties for advanced anticancer therapy based on HPMA copolymer-bound ritonavir via pH-sensitive spacers.
Neoplasms
Natural allelic variants of bovine ATP-binding cassette transporter ABCG2: increased activity of the Ser581 variant and development of tools for the discovery of new ABCG2 inhibitors.
Neoplasms
Natural killer-cell neoplasms.
Neoplasms
Natural lignans from Arctium lappa modulate P-glycoprotein efflux function in multidrug resistant cancer cells.
Neoplasms
Natural paniceins from mediterranean sponge inhibit the multidrug resistance activity of Patched and increase chemotherapy efficiency on melanoma cells.
Neoplasms
Near-infrared light switching nitric oxide nanoemitter for triple-combination therapy of multidrug resistant cancer.
Neoplasms
Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells.
Neoplasms
Neither P-gp SNP variants, P-gp expression nor functional P-gp activity predicts MDR in a preliminary study of plasma cell myeloma.
Neoplasms
Neoplastic reversal of human ovarian carcinoma cells transfected with connexin43.
Neoplasms
Nephroblastoma: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells.
Neoplasms
Neurodegeneration Caused by Polyglutamine Expansion Is Regulated by P-Glycoprotein in Drosophila melanogaster.
Neoplasms
Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer.
Neoplasms
New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors.
Neoplasms
New anthra[2,3-b]furancarboxamides: A role of positioning of the carboxamide moiety in antitumor properties.
Neoplasms
New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer.
Neoplasms
New Chalcone Derivative Inhibits ABCB1 in Multidrug Resistant T-cell Lymphoma and Colon Adenocarcinoma Cells.
Neoplasms
New highly active taxoids from 9beta-dihydrobaccatin-9,10-acetals. Part 3.
Neoplasms
New horizon of MDR1 (P-glycoprotein) study.
Neoplasms
New indolesulfonamide derivatives targeting the colchicine site of tubulin: synthesis, anti-tumour activity, structure-activity relationships, and molecular modelling.
Neoplasms
New inhibitors of ABCG2 identified by high-throughput screening.
Neoplasms
New insights into COX-2 biology and inhibition.
Neoplasms
New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models.
Neoplasms
New insights into the drug binding, transport and lipid flippase activities of the p-glycoprotein multidrug transporter.
Neoplasms
New insights into the P-glycoprotein-mediated effluxes of rhodamines.
Neoplasms
New potent P-glycoprotein modulators with the cucurbitane scaffold and their synergistic interaction with doxorubicin on resistant cancer cells.
Neoplasms
New uracil analogs as downregulators of ABC transporters in 5-fluorouracil-resistant human leukemia HL-60 cell line.
Neoplasms
New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib.
Neoplasms
New Uses for Old Drugs: Pharmacophore-Based Screening for the Discovery of P-Glycoprotein Inhibitors.
Neoplasms
NF-?B decoy polyplexes decrease P-glycoprotein-mediated multidrug resistance in colorectal cancer cells.
Neoplasms
NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter.
Neoplasms
Nickel-induced cell death and survival pathways in cultured renal proximal tubule cells: roles of reactive oxygen species, ceramide and ABCB1.
Neoplasms
Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice.
Neoplasms
NIR-II light triggered nitric oxide release nanoplatform combined chemo-photothermal therapy for overcoming multidrug resistant cancer.
Neoplasms
NIR-Responsive Polypeptide Nanocomposite Generates NO Gas, Mild Photothermia, and Chemotherapy to Reverse Multidrug-Resistant Cancer.
Neoplasms
Nitric oxide reverses drug resistance by inhibiting ATPase activity of p-glycoprotein in human multi-drug resistant cancer cells.
Neoplasms
Nitric Oxide Stimulated Programmable Drug Release of Nanosystem for Multidrug Resistance Cancer Therapy.
Neoplasms
Nitric oxide-releasing micelles with intelligent targeting for enhanced anti-tumor effect of cisplatin in hypoxia.
Neoplasms
Nitric oxide: Friend or Foe in Cancer Chemotherapy and Drug Resistance: A Perspective.
Neoplasms
Nitrogen Permease Regulator-Like-2 Exhibited Anti-Tumor Effects And Enhanced The Sensitivity Of Colorectal Cancer Cells To Oxaliplatin And 5-Fluorouracil.
Neoplasms
Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma.
Neoplasms
Nobiletin and its derivatives overcome multidrug resistance (MDR) in cancer: total synthesis and discovery of potent MDR reversal agents.
Neoplasms
Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells.
Neoplasms
Nobiletin exhibits potent inhibition on tumor necrosis factor alpha-induced calcification of human aortic valve interstitial cells via targeting ABCG2 and AKR1B1.
Neoplasms
Nobiletin potentiates paclitaxel anticancer efficacy in A549/T xenograft model: Pharmacokinetic and pharmacological study.
Neoplasms
Nocardiopsis species: a potential source of bioactive compounds.
Neoplasms
Non P-glycoprotein novel proteins involved in human cancer multidrug resistance.
Neoplasms
Non-coding polymorphisms in nucleotide binding domain 1 in ABCC1 gene associate with transcript level and survival of patients with breast cancer.
Neoplasms
Non-small cell lung cancer functional imaging: increased hexakis-2-methoxy-isobutyl-isonitrile tumor clearance correlates with resistance to cytotoxic treatment.
Neoplasms
Nonequivalent nucleotide trapping in the two nucleotide binding folds of the human multidrug resistance protein MRP1.
Neoplasms
Nongenotoxic ABCB1 activator tetraphenylphosphonium can contribute to doxorubicin resistance in MX-1 breast cancer cell line.
Neoplasms
Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet?
Neoplasms
Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity.
Neoplasms
Nonlinear intestinal absorption of 5-hydroxytryptamine receptor antagonist caused by absorptive and secretory transporters.
Neoplasms
Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors.
Neoplasms
Nonspecifically enhanced therapeutic effects of vincristine on multidrug-resistant cancers when coencapsulated with quinine in liposomes.
Neoplasms
Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis.
Neoplasms
Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitro.
Neoplasms
Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
Neoplasms
Novel 3,4-Dihydroisocoumarins Inhibit Human P-gp and BCRP in Multidrug Resistant Tumors and Demonstrate Substrate Inhibition of Yeast Pdr5.
Neoplasms
Novel 4-in-1 strategy to combat colon cancer, drug resistance and cancer relapse utilizing functionalized bioinspiring lignin nanoparticle.
Neoplasms
Novel 5-oxo-hexahydroquinoline derivatives: design, synthesis, in vitro P-glycoprotein-mediated multidrug resistance reversal profile and molecular dynamics simulation study.
Neoplasms
Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.
Neoplasms
Novel agents that potentially inhibit irinotecan-induced diarrhea.
Neoplasms
Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
Neoplasms
Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2.
Neoplasms
Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression.
Neoplasms
Novel dihydro-beta-agarofuran sesquiterpenes as potent modulators of human P-glycoprotein dependent multidrug resistance.
Neoplasms
Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.
Neoplasms
Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance.
Neoplasms
Novel features in the structure of P-glycoprotein (ABCB1) in the post-hydrolytic state as determined at 7.9?Å resolution.
Neoplasms
Novel gallium(III) complexes transported by MDR1 P-glycoprotein: potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo.
Neoplasms
Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells.
Neoplasms
Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells.
Neoplasms
Novel Nonsymmetrical 1,4-Dihydropyridines as Inhibitors of Nonsymmetrical MRP-Efflux Pumps for Anticancer Therapy.
Neoplasms
Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy.
Neoplasms
Novel Potent ABCB1 Modulator, Phenethylisoquinoline Alkaloid, Reverses Multidrug Resistance in Cancer Cell.
Neoplasms
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility.
Neoplasms
Novel steroid carbamates reverse multidrug-resistance in cancer therapy and show linkage among efficacy, loci of drug action and P-glycoprotein's cellular localization.
Neoplasms
Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents.
Neoplasms
Novel sulfonate derivatives: potent antimitotic agents.
Neoplasms
Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein.
Neoplasms
Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
Neoplasms
Novel tetramethylpiperidine-substituted phenazines are potent inhibitors of P-glycoprotein activity in a multidrug resistant cancer cell line.
Neoplasms
Novel TrxR1 Inhibitors Show Potential for Glioma Treatment by Suppressing the Invasion and Sensitizing Glioma Cells to Chemotherapy.
Neoplasms
Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid.
Neoplasms
Nrf2-dependent induction of human ABC transporter ABCG2 and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical implications for cancer cell response to photodynamic therapy.
Neoplasms
NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance.
Neoplasms
Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma.
Neoplasms
Nuclear factor-?B signaling inhibitors revert multidrug-resistance in breast cancer cells.
Neoplasms
Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
Neoplasms
Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression.
Neoplasms
Nuclear localization of P-glycoprotein is responsible for protection of the nucleus from doxorubicin in the resistant LoVo cell line.
Neoplasms
Nuclear medicine at the crossroads.
Neoplasms
Nucleotide-induced structural changes in P-glycoprotein observed by electron microscopy.
Neoplasms
Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.
Neoplasms
NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.
Neoplasms
OC144-093, a novel P glycoprotein inhibitor for the enhancement of anti-epileptic therapy.
Neoplasms
Oenothera paradoxa defatted seeds extract containing pentagalloylglucose and procyanidins potentiates the cytotoxicity of vincristine.
Neoplasms
Oleanolic acid inhibits the activity of the multidrug resistance protein ABCC1 (MRP1) but not of the ABCB1 (P-glycoprotein): possible use in cancer chemotherapy.
Neoplasms
Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity.
Neoplasms
Oligomycins as inhibitors of K-Ras plasma membrane localisation.
Neoplasms
Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells.
Neoplasms
Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1).
Neoplasms
Omega-3 Fatty Acid-Enriched Fish Oil and Selenium Combination Modulates Endoplasmic Reticulum Stress Response Elements and Reverses Acquired Gefitinib Resistance in HCC827 Lung Adenocarcinoma Cells.
Neoplasms
On interactions of P-glycoprotein with various anti-tumor drugs by binding free energy calculations.
Neoplasms
On the energy-dependence of Hoechst 33342 transport by the ABC transporter LmrA.
Neoplasms
On the origin of large flexibility of P-glycoprotein in the inward-facing state.
Neoplasms
Oncogenic PITX2 Facilitates Tumor Cell Drug Resistance by Inverse Regulation of hOCT3/SLC22A3 and ABC Drug Transporters in Colon and Kidney Cancers.
Neoplasms
Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer.
Neoplasms
Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
Neoplasms
One molecule two goals: A selective P-glycoprotein modulator increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells.
Neoplasms
One-Step Self-Assembling Nanomicelles for Pirarubicin Delivery To Overcome Multidrug Resistance in Breast Cancer.
Neoplasms
ONT-093 (Ontogen).
Neoplasms
Optimization by Molecular Fine Tuning of Dihydro-?-agarofuran Sesquiterpenoids as Reversers of P-Glycoprotein-Mediated Multidrug Resistance.
Neoplasms
Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates.
Neoplasms
Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.
Neoplasms
Optimization of immunohistochemical detection of P-glycoprotein in chronic lymphoid disorders.
Neoplasms
Optimization of irinotecan chronotherapy with P-glycoprotein inhibition.
Neoplasms
Optimization of marine triterpene sipholenols as inhibitors of breast cancer migration and invasion.
Neoplasms
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
Neoplasms
Optimizing Targeted Inhibitors of P-Glycoprotein Using Computational and Structure-Guided Approaches.
Neoplasms
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Neoplasms
Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers.
Neoplasms
Orally active docetaxel analogue: synthesis of 10-deoxy-10-C-morpholinoethyl docetaxel analogues.
Neoplasms
Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells.
Neoplasms
Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
Neoplasms
Oridonin Targets Multiple Drug-Resistant Tumor Cells as Determined by in Silico and in Vitro Analyses.
Neoplasms
OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.
Neoplasms
Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro.
Neoplasms
Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo.
Neoplasms
Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells.
Neoplasms
OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood Brain Barrier: Implications for Anti-Cancer Therapies.
Neoplasms
OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance.
Neoplasms
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.
Neoplasms
Over-expression of multidrug resistance P-glycoprotein inhibits NK granule-mediated lytic ability without affecting the Fas lytic pathway.
Neoplasms
Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
Neoplasms
Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis.
Neoplasms
Overcoming MDR by ultrasound-induced hyperthermia and P-glycoprotein modulation.
Neoplasms
Overcoming multidrug resistance (MDR) in cancer in vitro and in vivo by a quinoline derivative.
Neoplasms
Overcoming multidrug resistance by a combination of chemotherapy and photothermal therapy mediated by carbon nanohorns.
Neoplasms
Overcoming multidrug resistance by intracellular drug release and inhibiting p-glycoprotein efflux in breast cancer.
Neoplasms
Overcoming multidrug resistance by RNA interference.
Neoplasms
Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1.
Neoplasms
Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.
Neoplasms
Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors.
Neoplasms
Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
Neoplasms
Overcoming Multidrug Resistance in Vitro and in Vivo by a Novel P-glycoprotein Inhibitor 1416.
Neoplasms
Overcoming multidrug resistance of breast cancer cells by the micellar doxorubicin nanoparticles of mPEG-PCL-graft-cellulose.
Neoplasms
Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate.
Neoplasms
Overcoming multidrug resistance: valspodar as a paradigm for nursing care.
Neoplasms
Overcoming of multidrug resistance by VA-033, a novel derivative of apovincaminic acid ester.
Neoplasms
Overcoming of P-glycoprotein-mediated multidrug resistance in K562/A02 cells using riccardin F and pakyonol, bisbibenzyl derivatives from liverworts.
Neoplasms
Overcoming P-Glycoprotein-Mediated Multidrug Resistance in Colorectal Cancer: Potential Reversal Agents among Herbal Medicines.
Neoplasms
Overcoming photodynamic resistance and tumor targeting dual-therapy mediated by indocyanine green conjugated gold nanospheres.
Neoplasms
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.
Neoplasms
Overcoming vincristine resistance in cancer: Computational design and discovery of piperine-inspired P-glycoprotein inhibitors.
Neoplasms
Overexpression of a 40-kDa protein in human multidrug resistant cells.
Neoplasms
Overexpression of a p-glycoprotein in hepatocellular carcinomas from woodchuck hepatitis virus-infected woodchucks (Marmota monax).
Neoplasms
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.
Neoplasms
Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines.
Neoplasms
Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells.
Neoplasms
Overexpression of ABCC1 Confers Drug Resistance to Betulin.
Neoplasms
Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients.
Neoplasms
Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor.
Neoplasms
Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor.
Neoplasms
Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Neoplasms
Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Neoplasms
Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells.
Neoplasms
Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy.
Neoplasms
Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat.
Neoplasms
Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1.
Neoplasms
Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells.
Neoplasms
Overexpression of MDR1 using a retroviral vector differentially regulates genes involved in detoxification and apoptosis and confers radioprotection.
Neoplasms
Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines.
Neoplasms
Overexpression of multidrug resistance protein gene in human cancer cell lines selected for drug resistance to epipodophyllotoxins.
Neoplasms
Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs.
Neoplasms
Overexpression of P-glycoprotein in human lung carcinoma xenografts after fractionated irradiation in vivo.
Neoplasms
Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro.
Neoplasms
Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro.
Neoplasms
Overexpression of P-glycoprotein is associated with a decreased mitochondrial transmembrane potential in doxorubicin-selected K562 human leukemia cells.
Neoplasms
Overexpression of P-glycoprotein, STAT3, phospho-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment.
Neoplasms
Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein.
Neoplasms
Overexpression of the class II P-glycoprotein gene in primary rat hepatocyte culture: evidence for increased mRNA stability.
Neoplasms
Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport.
Neoplasms
Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells.
Neoplasms
Overexpression of ubiquitin carboxyl terminal hydrolase-L1 enhances multidrug resistance and invasion/metastasis in breast cancer by activating the MAPK/Erk signaling pathway.
Neoplasms
Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.
Neoplasms
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.
Neoplasms
Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Neoplasms
Overshoot during phenotypic switching of cancer cell populations.
Neoplasms
Overview of resistance to systemic therapy in patients with breast cancer.
Neoplasms
Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Neoplasms
Oxidative alterations induced in vitro by the photodynamic reaction in doxorubicin-sensitive (LoVo) and -resistant (LoVoDX) colon adenocarcinoma cells.
Neoplasms
Oxidative Stress Promotes Doxorubicin-Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions.
Neoplasms
P-170 glycoprotein expression in gastric and colorectal carcinomas and normal mucosa. An immunocytochemical study.
Neoplasms
P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors.
Neoplasms
P-glycoprotein (ABCB1) modulates collateral sensitivity of a multidrug resistant cell line to verapamil.
Neoplasms
P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen, and restricts their brain penetration.
Neoplasms
P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection.
Neoplasms
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
Neoplasms
P-glycoprotein (Pgp) does not affect the cytotoxicity of flavonoids from Sophora flavescens, which also have no effects on Pgp action.
Neoplasms
P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.
Neoplasms
P-glycoprotein and 'lipid rafts': some ambiguous mutual relationships (floating on them, building them or meeting them by chance?).
Neoplasms
P-glycoprotein and alloimmune T-cell activation.
Neoplasms
P-glycoprotein and drug therapy in organ transplantation.
Neoplasms
P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs.
Neoplasms
P-glycoprotein and multidrug resistance in cancer chemotherapy.
Neoplasms
P-Glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings.
Neoplasms
P-glycoprotein and multidrug resistance.
Neoplasms
P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells.
Neoplasms
P-glycoprotein and tumor progression.
Neoplasms
P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.
Neoplasms
P-Glycoprotein Antibody Decorated Porous Hydrogel Particles for Capture and Release of Drug-Resistant Tumor Cells.
Neoplasms
P-glycoprotein as a drug target in the treatment of multidrug resistant cancer.
Neoplasms
P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas.
Neoplasms
P-glycoprotein associated with diabetes mellitus and survival of patients with pancreatic cancer: 8-year follow-up.
Neoplasms
P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells.
Neoplasms
P-glycoprotein content and mediation of vincristine efflux: correlation with the level of differentiation in luminal epithelium of mouse small intestine.
Neoplasms
P-glycoprotein decreases with T cell maturation but is not responsible for resistance to CD95-induced apoptosis.
Neoplasms
P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.
Neoplasms
P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Neoplasms
P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro.
Neoplasms
P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells.
Neoplasms
P-glycoprotein expression and chemosensitivity in highly purified fresh human gastrointestinal cancer cells.
Neoplasms
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.
Neoplasms
P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells.
Neoplasms
P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma.
Neoplasms
P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma.
Neoplasms
P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy.
Neoplasms
p-Glycoprotein expression as a predictor of breast cancer recurrence.
Neoplasms
P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma.
Neoplasms
P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma.
Neoplasms
P-glycoprotein expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six chemotherapeutic drugs.
Neoplasms
P-glycoprotein expression by human colonic tumor cells influences the growth of tumor cells in vitro.
Neoplasms
P-glycoprotein expression does not change the apoptotic pathway induced by curcumin in HL-60 cells.
Neoplasms
P-glycoprotein expression during tumor progression in the rat liver.
Neoplasms
P-Glycoprotein Expression in Acute Myeloid Leukaemia Cells at Diagnosis: Its relationship to Daunorubicin or Idarubicin Induction Therapy and Survival; Malignancy.
Neoplasms
P-glycoprotein expression in bladder cancer.
Neoplasms
P-glycoprotein expression in brain capillary endothelial cells after focal ischaemia in the rat.
Neoplasms
P-glycoprotein expression in brain tumors.
Neoplasms
P-glycoprotein expression in canine mammary gland tumours related with myoepithelial cells.
Neoplasms
P-glycoprotein expression in cartilaginous tumors.
Neoplasms
P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin.
Neoplasms
P-glycoprotein expression in gastroesophageal adenocarcinomas, their metastases, and surrounding mucosa: a mapping study.
Neoplasms
P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy.
Neoplasms
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.
Neoplasms
P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.
Neoplasms
P-glycoprotein expression in primary and metastatic malignant melanoma.
Neoplasms
P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder.
Neoplasms
P-glycoprotein expression in primary breast cancer.
Neoplasms
P-glycoprotein expression in squamous cell carcinoma of the oral and maxillofacial region.
Neoplasms
P-glycoprotein expression in the squamous cell carcinoma of the tongue base.
Neoplasms
P-glycoprotein expression in treated and untreated human breast cancer.
Neoplasms
P-glycoprotein expression induced by glucose depletion enhanced the chemosensitivity in human hepatocellular carcinoma cell-lines.
Neoplasms
P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.
Neoplasms
P-glycoprotein expression is associated with sestamibi washout in primary hyperparathyroidism.
Neoplasms
P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833.
Neoplasms
P-glycoprotein expression, tumor differentiation, chemosensitivity of tumor-cells in-vitro and clinical outcome in patients with renal-cell carcinoma.
Neoplasms
P-Glycoprotein Expression, Tumor Weight, Age, and Relapse in Patients with Stage I and II Favorable-Histology Wilms' Tumor.
Neoplasms
P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy.
Neoplasms
P-glycoprotein functions as an immunomodulator in healthy human primary nasal epithelial cells.
Neoplasms
P-glycoprotein gene amplification and expression in multidrug-resistant murine P388 and B16 cell lines.
Neoplasms
P-glycoprotein in adult solid tumors. Expression and prognostic significance.
Neoplasms
P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors.
Neoplasms
P-glycoprotein in human sarcoma: evidence for multidrug resistance.
Neoplasms
P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells.
Neoplasms
P-glycoprotein induction and tumor cell-kill dynamics in response to differential doxorubicin dosing strategies: a theoretical pharmacodynamic model.
Neoplasms
P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
Neoplasms
P-glycoprotein inhibition by glibenclamide and related compounds.
Neoplasms
P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer.
Neoplasms
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
Neoplasms
P-Glycoprotein Inhibition; the Past, the Present and the Future.
Neoplasms
P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement.
Neoplasms
P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review.
Neoplasms
P-Glycoprotein inhibitory activity of lipophilic constituents of Echinacea pallida roots in a human proximal tubular cell line.
Neoplasms
P-glycoprotein involvement in cuticular penetration of [14C]thiodicarb in resistant tobacco budworms.
Neoplasms
P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study.
Neoplasms
P-glycoprotein is fully active after multiple tryptophan substitutions.
Neoplasms
P-Glycoprotein is localized in intermediate-density membrane microdomains distinct from classical lipid rafts and caveolar domains.
Neoplasms
P-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosis.
Neoplasms
P-glycoprotein levels predict poor outcome in patients with osteosarcoma.
Neoplasms
P-glycoprotein mediated drug interactions in animals and humans with cancer.
Neoplasms
P-glycoprotein mediated multidrug resistance and its implications for pathology.
Neoplasms
P-glycoprotein mediated multidrug resistance assessment by flow-cytometry in malignant hemopathies.
Neoplasms
P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design.
Neoplasms
P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines.
Neoplasms
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Neoplasms
P-glycoprotein mediates the collateral sensitivity of multidrug resistant cells to steroid hormones.
Neoplasms
P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.
Neoplasms
P-glycoprotein modulates oleanolic acid effects in hepatocytes cancer cells and zebrafish embryos.
Neoplasms
P-glycoprotein modulation by valspodar and cyclosporin does not increase tumor uptake of doxorubicin administered via isolated lung perfusion to rats bearing sarcoma lung metastases.
Neoplasms
P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors.
Neoplasms
P-glycoprotein multidrug resistance and cancer.
Neoplasms
P-glycoprotein plays an insignificant role in the presentation of antigenic peptides to CD8+ T cells.
Neoplasms
P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine.
Neoplasms
P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death.
Neoplasms
P-glycoprotein regulates chemosensitivity in early developmental stages of the mouse.
Neoplasms
P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells.
Neoplasms
P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach.
Neoplasms
P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors.
Neoplasms
P-glycoprotein targeted nanoscale drug carriers.
Neoplasms
P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates.
Neoplasms
P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin.
Neoplasms
P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.
Neoplasms
P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential.
Neoplasms
P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
Neoplasms
P-glycoprotein, multidrug resistance and tumor progression.
Neoplasms
P-glycoprotein--a novel therapeutic target for immunomodulation in clinical transplantation and autoimmunity?
Neoplasms
P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model.
Neoplasms
P-glycoprotein-expressing tumor cells are resistant to anticancer drugs in human gastrointestinal cancer.
Neoplasms
P-glycoprotein-independent apoptosis induction by a novel synthetic compound, MMPT [5-[(4-methylphenyl)methylene]-2-(phenylamino)-4(5H)-thiazolone].
Neoplasms
P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies.
Neoplasms
P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors.
Neoplasms
P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer.
Neoplasms
P-glycoprotein-mediated multidrug resistance and cytotoxic effector cells.
Neoplasms
P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships.
Neoplasms
P-glycoprotein-overexpressing multidrug-resistant cells are resistant to infection by enveloped viruses that enter via the plasma membrane.
Neoplasms
P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
Neoplasms
P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes.
Neoplasms
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.
Neoplasms
P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins.
Neoplasms
P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers.
Neoplasms
P-glycoprotein: so many ways to turn it on.
Neoplasms
P-glycoproteins and multidrug resistance.
Neoplasms
P-glycoproteins: mediators of multidrug resistance.
Neoplasms
P-gp and MRP1 Expression in Parathyroid Tumors Related to Histology, Weight and 99 mTc-Sestamibi Imaging Results.
Neoplasms
P-gp Inhibition by the Anti-psychotic Drug Pimozide Increases Apoptosis, as well as Expression of pRb and pH2AX in Highly Drug-resistant KBV20C Cells.
Neoplasms
P-gp upregulation may be blocked by natural curcuminoids, a novel class of chemoresistance-preventing agent.
Neoplasms
p53 and P-glycoprotein expression do not correlate with survival in nonsmall cell lung cancer: a long-term study and literature review.
Neoplasms
p53 expression and resistance against paclitaxel in patients with metastatic breast cancer.
Neoplasms
p53 mutation, but not in vitro predictor genes of therapeutic efficacy of cisplatin, is clinically relevant in comparing partial and complete responder cases of maxillary squamous cell carcinoma.
Neoplasms
Paclitaxel and quercetin co-loaded functional mesoporous silica nanoparticles overcoming multidrug resistance in breast cancer.
Neoplasms
Paclitaxel modifies the accumulation of tumor-diagnostic tracers in different ways in P-glycoprotein-positive and negative cancer cells.
Neoplasms
Paclitaxel nanoparticles for the potential treatment of brain tumors.
Neoplasms
Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer.
Neoplasms
Paclitaxel-Hyaluronic Nano-Conjugates Prolong Overall Survival in a Preclinical Brain Metastases of Breast Cancer Model.
Neoplasms
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Neoplasms
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of {beta}-tubulin (Asp26Glu) and less stable microtubules.
Neoplasms
Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells.
Neoplasms
Papers to appear in forthcoming issues
Neoplasms
Paradoxical expression of anti-apoptotic and MRP genes on cancer stem-like cell isolated from TJ905 glioblastoma multiforme cell line.
Neoplasms
Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer.
Neoplasms
Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
Neoplasms
Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-?B/COX-2 pathway.
Neoplasms
Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis.
Neoplasms
Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide.
Neoplasms
Patterns of Innate or Acquired Resistance to Anticancer Drugs: Our Experience to Overcome It.
Neoplasms
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies.
Neoplasms
PCAT1/miR-129/ABCB1 axis confers chemoresistance in non-small cell lung cancer.
Neoplasms
PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
Neoplasms
PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.
Neoplasms
Pd-Catalyzed Decarboxylative Olefination: Stereoselective Synthesis of Polysubstituted Butadienes and Macrocyclic P-glycoprotein Inhibitors.
Neoplasms
PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT (MRP2), the multidrug resistance-associated protein.
Neoplasms
PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells.
Neoplasms
Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified.
Neoplasms
Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma.
Neoplasms
Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
Neoplasms
Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Neoplasms
Penetration of intra-arterially administered vincristine in experimental brain tumor.
Neoplasms
Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-?B signaling pathway in a?human breast cancer cell line.
Neoplasms
Peroxisome Proliferator-Activated Receptor-gamma1 Gene Therapy Attenuates Atherosclerosis and Stabilizes Plaques in Apolipoprotein E-Deficient Mice.
Neoplasms
Perplexing Role of P-Glycoprotein in Tumor Microenvironment.
Neoplasms
Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products.
Neoplasms
Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids.
Neoplasms
Pervilleine F, a new tropane alkaloid aromatic ester that reverses multidrug resistance.
Neoplasms
Pervilleines B and C, new tropane alkaloid aromatic esters that reverse the multidrug-resistance in the hollow fiber assay.
Neoplasms
PET imaging of multidrug resistance in tumors using 18F-fluoropaclitaxel.
Neoplasms
Pgp immunochemistry: use with caution: correspondence re: C-H. Kao et al., P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings. Cancer Res., 61: 1412-1414, 2001.
Neoplasms
Pgp-positive leukaemic cells have increased mtDNA but no increased rate of proliferation.
Neoplasms
pH regulation in sensitive and multidrug resistant Ehrlich ascites tumor cells.
Neoplasms
pH-activated, mitochondria-targeted, and redox-responsive delivery of paclitaxel nanomicelles to overcome drug resistance and suppress metastasis in lung cancer.
Neoplasms
pH-responsive polymeric micelles based on poly(2-ethyl-2-oxazoline)-poly(d,l-lactide) for tumor-targeting and controlled delivery of doxorubicin and P-glycoprotein inhibitor.
Neoplasms
Pharmaco(epi)genomics in ovarian cancer.
Neoplasms
Pharmacodynamics of doxorubicin in human bladder tumors.
Neoplasms
Pharmacodynamics of taxol in human head and neck tumors.
Neoplasms
Pharmacogenetic considerations for non-Hodgkin's lymphoma therapy.
Neoplasms
Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial.
Neoplasms
Pharmacogenetics of ATP-binding cassette transporters and clinical implications.
Neoplasms
Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy.
Neoplasms
Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
Neoplasms
Pharmacogenomic Characterization of Cytotoxic Compounds from Salvia officinalis in Cancer Cells.
Neoplasms
Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design.
Neoplasms
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.
Neoplasms
Pharmacokinetic model of myocardial (99m)Tc-sestamibi washout.
Neoplasms
Pharmacokinetic modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates.
Neoplasms
Pharmacokinetic study of infusional valspodar.
Neoplasms
Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats.
Neoplasms
Pharmacologic approaches to reversing multidrug resistance.
Neoplasms
Pharmacologic circumvention of multidrug resistance.
Neoplasms
Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein.
Neoplasms
Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.
Neoplasms
Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.
Neoplasms
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
Neoplasms
Pharmacophore-based drug design and biological evaluation of novel ABCB1 inhibitors.
Neoplasms
Pharmacophoric features for a very potent 5-spirofluorenehydantoin inhibitor of cancer efflux pump ABCB1, based on X-ray analysis.
Neoplasms
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
Neoplasms
Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies.
Neoplasms
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Neoplasms
Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin.
Neoplasms
Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.
Neoplasms
Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies.
Neoplasms
Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer.
Neoplasms
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes.
Neoplasms
Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
Neoplasms
Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
Neoplasms
Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.
Neoplasms
Phase I/II trial of low dose cyclosporin A with EP for advanced non-small cell lung cancer.
Neoplasms
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
Neoplasms
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma.
Neoplasms
Phenothiazine maleates stimulate MRP1 transport activity in human erythrocytes.
Neoplasms
Phenotypic characterization of retinoblastoma for the presence of putative cancer stem-like cell markers by flow cytometry.
Neoplasms
Phenylcinnamides as Novel Antimitotic Agents.
Neoplasms
Phenylnannolones A-C: biosynthesis of new secondary metabolites from the myxobacterium Nannocystis exedens.
Neoplasms
Phorbol ester induced MDR1 expression in K562 cells occurs independently of mitogen-activated protein kinase signaling pathways.
Neoplasms
Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors.
Neoplasms
Phosphorylation of RNA helicase A by DNA-dependent protein kinase is indispensable for expression of the MDR1 gene product P-glycoprotein in multidrug-resistant human leukemia cells.
Neoplasms
Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells.
Neoplasms
Phthalate exposure promotes chemotherapeutic drug resistance in colon cancer cells.
Neoplasms
Physical and biological characteristics of multi drug resistance (MDR): An integral approach considering pH and drug resistance in cancer.
Neoplasms
Physiological Roles of ERM Proteins and Transcriptional Regulators in Supporting Membrane Expression of Efflux Transporters as Factors of Drug Resistance in Cancer.
Neoplasms
Physiological status of silver carp (Hypophthalmichthys molitrix) in the Illinois River: An assessment of fish at the leading edge of the invasion front.
Neoplasms
Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways.
Neoplasms
PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter.
Neoplasms
Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines.
Neoplasms
Pituitary homeobox 2 (PITX2) protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1.
Neoplasms
PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism.
Neoplasms
PKC? inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P.
Neoplasms
Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors.
Neoplasms
Plasma protoporphyrin IX following administration of 5-aminolevulinic acid as a potential tumor marker.
Neoplasms
Platinum(IV) complex-based two-in-one polyprodrug for a combinatorial chemo-photodynamic therapy.
Neoplasms
Pleiotropic over-expression of multidrug-resistance-related genes is correlated to MYCN and max mRNA accumulation during tumour progression in the IGR-N-91 human neuroblastoma model.
Neoplasms
Pleural mesothelioma side populations have a precursor phenotype.
Neoplasms
PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors.
Neoplasms
Podophyllotoxin-polyacrylic acid conjugate micelles: improved anticancer efficacy against multidrug-resistant breast cancer.
Neoplasms
Podoplanin and ABCG2 expression in oral erythroplakia revisited: Potential evidence for cancer stem cells driving the process of field cancerization.
Neoplasms
Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein.
Neoplasms
Polycationic nanodrug covered with hyaluronic acid for treatment of P-glycoprotein overexpressing cancer cells.
Neoplasms
Polyion complex micelles with protein-modified corona for receptor-mediated delivery of oligonucleotides into cells.
Neoplasms
Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling.
Neoplasms
Polymeric micelles for delivery of poorly water-soluble compounds.
Neoplasms
Polymorphisms in DNA repair pathway genes and ABCG2 gene in advanced colorectal cancer: correlation with tumor characteristics and clinical outcome in oxaliplatin-based chemotherapy.
Neoplasms
Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.
Neoplasms
Polymorphisms of ABCG2 and its impact on clinical relevance.
Neoplasms
Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus.
Neoplasms
Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy in vitro and in vivo.
Neoplasms
Polyphenols counteract tumor cell chemoresistance conferred by multidrug resistance proteins.
Neoplasms
Polyphyllin D induces apoptosis in human erythrocytes through Ca(2+) rise and membrane permeabilization.
Neoplasms
Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases.
Neoplasms
Porous Pt nanoparticles loaded with doxorubicin to enable synergistic Chemo-/Electrodynamic Therapy.
Neoplasms
Positive expression of p53, c-erbB2 and MRP proteins is correlated with survival rates of NSCLC patients.
Neoplasms
Possible role of P-glycoprotein in cyclophosphamide resistance of transplanted mouse RLS lymphosarcoma.
Neoplasms
Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines.
Neoplasms
Postnatal development of organic cation transport and mdr gene expression in mouse kidney.
Neoplasms
Posttranscriptional Regulation of the Human ABCG2 Multidrug Transporter Protein by Artificial Mirtrons.
Neoplasms
Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1.
Neoplasms
Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) Derived from the p-Glycoprotein (ABCB1) Modulator Tariquidar.
Neoplasms
Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
Neoplasms
Potent induction of human colon cancer cell uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-alpha (PKC-alpha) pseudosubstrate peptides through a P-glycoprotein-independent mechanism.
Neoplasms
Potential applications of RNA interference technology in the treatment of cancer.
Neoplasms
Potential of Central, Eastern and Western Africa Medicinal Plants for Cancer Therapy: Spotlight on Resistant Cells and Molecular Targets.
Neoplasms
Potential of natural-based anticancer compounds for P-glycoprotein inhibition.
Neoplasms
Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.
Neoplasms
Potentiation by alpha-tocopheryl succinate of the etoposide response in multidrug resistance protein 1-expressing glioblastoma cells.
Neoplasms
Potentiation of anticancer drugs: effects of pentoxifylline on neoplastic cells.
Neoplasms
Potentiation of human natural killer cell activity by recombinant interleukin-2 towards multidrug-resistant human epidermoid carcinoma.
Neoplasms
Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells.
Neoplasms
Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells.
Neoplasms
Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.
Neoplasms
Preclinical Evaluation of the Novel Small-Molecule MSI-N1014 for Treating Drug-Resistant Colon Cancer via the LGR5/?-catenin/miR-142-3p Network and Reducing Cancer-Associated Fibroblast Transformation.
Neoplasms
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
Neoplasms
Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Neoplasms
Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments.
Neoplasms
Predicting ligand interactions with ABC transporters in ADME.
Neoplasms
Predicting multidrug resistance-related protein and P-glycoprotein expression with technetium-99m tetrofosmin mammoscintigraphy.
Neoplasms
Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein.
Neoplasms
Predicting substrates of the human breast cancer resistance protein using a support vector machine method.
Neoplasms
Predicting tumour response.
Neoplasms
Prediction and characterization of P-glycoprotein substrates potentially bound to different sites by emerging chemical pattern and hierarchical cluster analysis.
Neoplasms
Prediction model of human ABCC2/MRP2 efflux pump inhibitors: a QSAR study.
Neoplasms
Prediction of broad spectrum resistance of tumors towards anticancer drugs.
Neoplasms
Prediction of chemotherapeutic response by Technetium 99m--MIBI scintigraphy in breast carcinoma patients.
Neoplasms
Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors.
Neoplasms
Prediction of doxorubicin resistance in gastrointestinal cancer by P-glycoprotein staining.
Neoplasms
Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining.
Neoplasms
Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT.
Neoplasms
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
Neoplasms
Predictive value of (99m)Tc sestamibi scintigraphy in the evaluation of doxorubicin based chemotherapy response in patients with advanced breast cancer.
Neoplasms
Predictors of therapeutic efficacy of 5-aminolevulinic acid-based photodynamic therapy in human prostate cancer.
Neoplasms
Preface: the concept and consequences of multidrug resistance.
Neoplasms
Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function.
Neoplasms
Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung.
Neoplasms
Prenyl-flavonoids as potent inhibitors of the Pdr5p multidrug ABC transporter from Saccharomyces cerevisiae.
Neoplasms
Preoperative localization of parathyroid adenomas with technetium-99m methoxyisobutylisonitrile imaging: relationship with P-glycoprotein expression, oxyphilic cell content, and tumoral tissue volume.
Neoplasms
Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant.
Neoplasms
Previous physical exercise alters the hepatic profile of oxidative-inflammatory status and limits the secondary brain damage induced by severe traumatic brain injury in rats.
Neoplasms
Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness.
Neoplasms
Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells.
Neoplasms
Probing ATP-dependent conformational changes in the multidrug resistance protein 1 (MRP1/ABCC1) in live tumor cells with a novel recombinant single-chain Fv antibody targeted to the extracellular N-terminus.
Neoplasms
Probing cholesterol binding and translocation in P-glycoprotein.
Neoplasms
Probing daunorubicin accumulation defects in non-P-glycoprotein expressing multidrug-resistant cell lines using digitonin.
Neoplasms
Probing multidrug resistance P-glycoprotein transporter activity with SPECT radiopharmaceuticals.
Neoplasms
Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity.
Neoplasms
Progesterone and its metabolites: the potent inhibitors of the transporting activity of P-glycoprotein in the adrenal gland.
Neoplasms
Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells.
Neoplasms
Progesterone regulates the murine multidrug resistance mdr1b gene.
Neoplasms
Prognosis-related molecular markers in pediatric central nervous system tumors.
Neoplasms
Prognostic and Therapeutic Potential Implications of Genetic Variability in Prostaglandin E2 Pathway Genes in Rectal Cancer.
Neoplasms
Prognostic factors in bone sarcomas.
Neoplasms
Prognostic factors in localized extremity osteosarcoma: A systematic review.
Neoplasms
Prognostic impact of cancer stem cell markers ABCB1, NEO1 and HIST1H2AE in colorectal cancer.
Neoplasms
Prognostic impact of membranous ATP-binding cassette Sub-family G member 2 expression in patients with colorectal carcinoma after surgical resection.
Neoplasms
Prognostic impact of the putative cancer stem cell markers ABCG2, CD133, ALDH1A1 and CD44V7/8 in metastatic melanoma.
Neoplasms
Prognostic impact of {triangleup}TAp73 isoform levels and their target genes in colon cancer patients.
Neoplasms
Prognostic relevance of P-glycoprotein expression in breast cancer.
Neoplasms
Prognostic role of multidrug resistance-associated protein 1 expression and platelet count in operable non-small cell lung cancer.
Neoplasms
Prognostic significance of DNA ploidy, S-phase fraction, and P-glycoprotein expression in colorectal cancer.
Neoplasms
Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy; relationship between nestin expression and epithelial to mesenchymal transition related markers.
Neoplasms
Prognostic significance of the expressions of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer.
Neoplasms
Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
Neoplasms
Prognostic value of ABCG2 in moderately and poorly differentiated intrahepatic cholangiocarcinoma.
Neoplasms
Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer.
Neoplasms
Prognostic value of glucosylceramide synthase and P-glycoprotein expression in oral cavity cancer.
Neoplasms
Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases.
Neoplasms
Prognostic value of P-glycoprotein and leukocyte differentiation antigens in chronic myeloid leukemia.
Neoplasms
Prognostic value of P-glycoprotein and proliferative index in advanced low grade serous ovarian carcinomas.
Neoplasms
Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.
Neoplasms
Programmable Codelivery of Doxorubicin and Apatinib Using an Implantable Hierarchical-Structured Fiber Device for Overcoming Cancer Multidrug Resistance.
Neoplasms
Progress in the study of D-?-tocopherol polyethylene glycol 1000 succinate (TPGS) reversing multidrug resistance.
Neoplasms
Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin.
Neoplasms
Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
Neoplasms
Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients' overall survival.
Neoplasms
Prolonged inhibition of P-glycoprotein after exposure to chemotherapeutics increases cell mortality in multidrug resistant cultured cancer cells.
Neoplasms
Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene.
Neoplasms
Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
Neoplasms
Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study.
Neoplasms
Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer--an evolving story.
Neoplasms
Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance.
Neoplasms
Protective effect of Astragalus polysaccharides on ATP binding cassette transporter A1 in THP-1 derived foam cells exposed to tumor necrosis factor-alpha.
Neoplasms
Protective effects of n-Butanol extract and iridoid glycosides of Veronica ciliata Fisch. against ANIT-induced cholestatic liver injury in mice.
Neoplasms
Protein expression of ABCC2 and SLC22A3 associates with prognosis of pancreatic adenocarcinoma.
Neoplasms
Protein expression of ATP-binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients.
Neoplasms
Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport.
Neoplasms
Protein kinase C regulation of p-glycoprotein-mediated xenobiotic secretion in renal proximal tubule.
Neoplasms
Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein.
Neoplasms
Protein kinase C? protects against multidrug resistance in human colon cancer cells.
Neoplasms
Protein phosphatase complex PP5/PPP2R3C dephosphorylates P-glycoprotein/ABCB1 and down-regulates the expression and function.
Neoplasms
Proteins regulating the intercellular transfer and function of P-glycoprotein in multidrug-resistant cancer.
Neoplasms
Proteolytic Cleavage of the Linker Region of the Human P-glycoprotein Modulates Its ATPase Function.
Neoplasms
Protoporphyrin IX accumulation disrupts mitochondrial dynamics and function in ABCG2-deficient hepatocytes.
Neoplasms
Providing a molecular mechanism for P-glycoprotein; why would I bother?
Neoplasms
Proximity of the nucleotide binding domains of the P-glycoprotein multidrug transporter to the membrane surface: a resonance energy transfer study.
Neoplasms
Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells.
Neoplasms
PSC 833, an inhibitor of P-glycoprotein inhibits 1,2-dimethylhydrazine-induced colorectal carcinogenesis in male Fischer F344 rats.
Neoplasms
Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Neoplasms
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.
Neoplasms
Pulmonary expression of CYP2A13 and ABCB1 is regulated by FOXA2 and their genetic interaction is associated with lung cancer.
Neoplasms
Pulmonary surfactants affinity Pluronic-hybridized liposomes enhance the treatment of drug-resistant lung cancer.
Neoplasms
Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2.
Neoplasms
Purification and reconstitution of functional human P-glycoprotein.
Neoplasms
Purification and structural analyses of ABCG2.
Neoplasms
Purine nucleoside analog--sulfinosine modulates diverse mechanisms of cancer progression in multi-drug resistant cancer cell lines.
Neoplasms
Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro.
Neoplasms
Pyrimido[1?,2?:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
Neoplasms
Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo.
Neoplasms
Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1).
Neoplasms
Pyruvate Treatment Restores the Effectiveness of Chemotherapeutic Agents in Human Colon Adenocarcinoma and Pleural Mesothelioma Cells.
Neoplasms
Pyxinol bearing amino acid residues: Easily achievable and promising modulators of P-glycoprotein-mediated multidrug resistance.
Neoplasms
QSAR analysis and molecular modeling of ABCG2-specific inhibitors.
Neoplasms
Quantified 99mTc-MIBI scintigraphy for predicting chemotherapy response in breast cancer patients: factors that influence the level of 99m Tc-MIBI uptake.
Neoplasms
Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells.
Neoplasms
Quantitative Analysis of mRNA for 10 Different Drug Resistance Factors in Dogs with Lymphoma.
Neoplasms
Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging.
Neoplasms
Quantitative expression patterns of multidrug-resistance P-glycoprotein (MDR1) and differentially spliced cystic-fibrosis transmembrane-conductance regulator mRNA transcripts in human epithelia.
Neoplasms
Quantitative site- and structure-specific N-glycoproteomics characterization of differential N-glycosylation in MCF-7/ADR cancer stem cells.
Neoplasms
Quantitative Structure?Activity Relationships for the Flavonoid-Mediated Inhibition of P-Glycoprotein in KB/MDR1 Cells.
Neoplasms
Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells.
Neoplasms
Quercetin acts as a P-gp modulator via impeding signal transduction from nucleotide-binding domain to transmembrane domain.
Neoplasms
Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy.
Neoplasms
Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin.
Neoplasms
Quercetin increased bioavailability and decreased methylation of green tea polyphenols in vitro and in vivo.
Neoplasms
Quercetin overcomes colon cancer cells resistance to chemotherapy by inhibiting solute carrier family 1, member 5 transporter.
Neoplasms
Quercetin reversed MDR in breast cancer cells through down-regulating P-gp expression and eliminating cancer stem cells mediated by YB-1 nuclear translocation.
Neoplasms
Quercetin-glutamic acid conjugate with a non-hydrolysable linker; a novel scaffold for multidrug resistance reversal agents through inhibition of P-glycoprotein.
Neoplasms
Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial.
Neoplasms
Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Neoplasms
R-253 disrupts microtubule networks in multiple tumor cell lines.
Neoplasms
RAB4 interacts with the human P-glycoprotein and modulates its surface expression in multidrug resistant K562 cells.
Neoplasms
Racemic total synthesis and evaluation of the biological activities of the isoquinoline-benzylisoquinoline alkaloid muraricine.
Neoplasms
Rack1 mediates Src binding to drug transporter P-glycoprotein and modulates its activity through regulating Caveolin-1 phosphorylation in breast cancer cells.
Neoplasms
Radiopharmaceuticals for assessment of multidrug resistance P-glycoprotein-mediated drug transport activity.
Neoplasms
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Neoplasms
Radiosynthesis and biological evaluation of 68Ga-labeled colchicine conjugates.
Neoplasms
Radixin knockdown improves the accumulation and efficiency of methotrexate in tumor cells.
Neoplasms
Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin.
Neoplasms
Rapid determination of multidrug resistance-associated protein in cancer cells by capillary electrophoresis immunoassay.
Neoplasms
Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay.
Neoplasms
RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China.
Neoplasms
Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance.
Neoplasms
Rationales for the Use of Cancer Stem Cells Markers in the Staging of Papillary Thyroid Carcinoma.
Neoplasms
Reaction dynamics of ATP hydrolysis catalyzed by P-glycoprotein.
Neoplasms
Reactive oxygen species and near-infrared light dual-responsive indocyanine green-loaded nanohybrids for overcoming tumour multidrug resistance.
Neoplasms
Reactive oxygen species-linked regulation of the multidrug resistance transporter P-glycoprotein in Nox-1 overexpressing prostate tumor spheroids.
Neoplasms
Reactivity of P-glycoprotein monoclonal antibodies in childhood cancers.
Neoplasms
Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin.
Neoplasms
Recent Advances in the Application of Vitamin E TPGS for Drug Delivery.
Neoplasms
Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance.
Neoplasms
Recent Advances in the Studies of Molecular Mechanisms Regulating Multidrug Resistance in Cancer Cells.
Neoplasms
Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy.
Neoplasms
Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.
Neoplasms
Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.
Neoplasms
Recent developments in d-?-tocopheryl polyethylene glycol-succinate-based nanomedicine for cancer therapy.
Neoplasms
Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors.
Neoplasms
Recognition of sulfonylurea receptor (ABCC8/9) ligands by the multidrug resistance transporter P-glycoprotein (ABCB1): functional similarities based on common structural features between two multispecific ABC proteins.
Neoplasms
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.
Neoplasms
Reconstitution of drug transport by purified P-glycoprotein.
Neoplasms
Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis.
Neoplasms
Redox regulation of P-glycoprotein-mediated multidrug resistance in multicellular prostate tumor spheroids.
Neoplasms
Reduction of 99mTc-sestamibi and 99mTc-tetrofosmin uptake in MRP-expressing breast cancer cells under hypoxic conditions is independent of MRP function.
Neoplasms
Reduction of doxorubicin resistance by tetrandrine and dauricine in harringtonine-resistant human leukemia (HL60) cells.
Neoplasms
Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides.
Neoplasms
Reduction of expression of the multidrug resistance protein (MRP)1 in glioma cells by antisense phosphorothioate oligonucleotides.
Neoplasms
Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network.
Neoplasms
Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
Neoplasms
Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies.
Neoplasms
Regulation and Expression of the ATP-binding Cassette (ABC) Transporter ABCG2 in Human Embryonic Stem Cells.
Neoplasms
Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein.
Neoplasms
Regulation Exerted by miRNAs in the Promoter and UTR Sequences: MDR1/P-gp Expression as a Particular Case.
Neoplasms
Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line.
Neoplasms
Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells.
Neoplasms
Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2.
Neoplasms
Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement of nuclear factor-kappaB and c-Jun N-terminal kinase signaling pathways.
Neoplasms
Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity.
Neoplasms
Regulation of organic anion transport in the liver.
Neoplasms
Regulation of stem-like cancer cells by glutamine through ?-catenin pathway mediated by redox signaling.
Neoplasms
Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites.
Neoplasms
Regulation of the multidrug resistance genes by stress signals.
Neoplasms
Regulation of the multidrug resistance transporter P-glycoprotein in multicellular prostate tumor spheroids by hyperthermia and reactive oxygen species.
Neoplasms
Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species.
Neoplasms
Regulation of the stability of P-glycoprotein by ubiquitination.
Neoplasms
Relation between expression pattern of wild-type p53 and multidrug resistance proteins in human nephroblastomas.
Neoplasms
Relation between the regulation of DNA synthesis and the production of two secreted glycoproteins by 12-O-tetradecanoylphorbol-13-acetate in 3T3 cells and in phorbol ester nonresponsive 3T3 variants.
Neoplasms
Relation of Metal-Binding Property and Selective Toxicity of 8-Hydroxyquinoline Derived Mannich Bases Targeting Multidrug Resistant Cancer Cells.
Neoplasms
Relationship between cytotoxic drug response patterns and activity of drug efflux transporters mediating multidrug resistance.
Neoplasms
Relationship between doxorubicin cell sensitivity, drug-induced DNA double-strand breaks, glutathione content and P-glycoprotein in mammalian tumor cells.
Neoplasms
Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells.
Neoplasms
Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma.
Neoplasms
Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma.
Neoplasms
Relationship between paclitaxel activity and pathobiology of human solid tumors.
Neoplasms
Relationship between the urinary excretion mechanisms of drugs and their physicochemical properties.
Neoplasms
Relationship of classical and non-classical risk factors with genetic variants relevant to coronary heart disease.
Neoplasms
Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-pi in human lung tumors.
Neoplasms
Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs.
Neoplasms
Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis.
Neoplasms
Relationships among tenascin expression, DNA ploidy patterns, and multidrug resistance gene product (P-glycoprotein) in human colon carcinoma.
Neoplasms
Relationships among tumor responsiveness, cell sensitivity, doxorubicin cellular pharmacokinetics and drug-induced DNA alterations in two human small-cell lung cancer xenografts.
Neoplasms
Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines.
Neoplasms
Relationships between rhodamine 123 transport, cell volume, and ion-channel function of P-glycoprotein.
Neoplasms
Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas.
Neoplasms
Relevance of mortalin to cancer cell stemness and cancer therapy.
Neoplasms
Relevance of multidrug resistance 1 and P-glycoprotein to drug resistance in patients with systemic lupus erythematosus.
Neoplasms
Relevance of multidrug resistance in the age of targeted therapy.
Neoplasms
Relevance of multidrug resistance proteins on the clinical efficacy of cancer therapy.
Neoplasms
Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis.
Neoplasms
Repetitive doxorubicin treatment of glioblastoma enhances the PGP expression--a special role for endothelial cells.
Neoplasms
Replacing the eleven native tryptophans by directed evolution produces an active P-glycoprotein with site-specific, non-conservative substitutions.
Neoplasms
Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.
Neoplasms
Reporters of Cancer Stem Cells as a Tool for Drug Discovery.
Neoplasms
Repurposing itraconazole as an anticancer agent.
Neoplasms
Resin Glycosides from Ipomoea alba Seeds as Potential Chemosensitizers in Breast Carcinoma Cells.
Neoplasms
Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein.
Neoplasms
Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide.
Neoplasms
Resistance proteins in human kidney, breast, ovarian and lung-carcinoma - a comparative-analysis.
Neoplasms
Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences.
Neoplasms
Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.
Neoplasms
Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells.
Neoplasms
Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells.
Neoplasms
Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line.
Neoplasms
Response of a multidrug-resistant human small-cell lung cancer xenograft to chemotherapy.
Neoplasms
Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors.
Neoplasms
Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer: a phase I study.
Neoplasms
Restoration of chemosensitivity by multifunctional micelles mediated by P-gp siRNA to reverse MDR.
Neoplasms
Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.
Neoplasms
Restoration of MARCK enhances chemosensitivity in cancer.
Neoplasms
Resveratrol and P-glycoprotein Inhibitors Enhance the Anti-skin Cancer Effects of Ursolic Acid.
Neoplasms
Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro.
Neoplasms
Resveratrol mediated cancer cell apoptosis, and modulation of multidrug resistance proteins and metabolic enzymes.
Neoplasms
Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression.
Neoplasms
Retinoic acid-induced apoptosis and regression of a refractory Epstein-Barr virus-containing T cell lymphoma expressing multidrug-resistance phenotypes.
Neoplasms
Retrovirus insertion and transcriptional activation of the multidrug-resistance gene in leukemias treated by a chemotherapeutic agent in vivo.
Neoplasms
Retrovirus-mediated gene transfer of the human multidrug resistance-associated protein into hematopoietic cells protects mice from chemotherapy-induced leukopenia.
Neoplasms
Retrovirus-mediated gene transfer of the multidrug resistance-associated protein (MRP) cDNA protects cells from chemotherapeutic agents.
Neoplasms
Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Neoplasms
Reversal effect of stephania tetrandra-containing Chinese herb formula SENL on multidrug resistance in lung cancer cell line SW1573/2R120.
Neoplasms
Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells.
Neoplasms
Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro.
Neoplasms
Reversal of ABCG2-mediated multidrug resistance by human cathelicidin and its analogs in cancer cells.
Neoplasms
Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor.
Neoplasms
Reversal of cancer multidrug resistance by green tea polyphenols.
Neoplasms
Reversal of chemoresistance in malignant gliomas by calcium antagonists: correlation with the expression of multidrug-resistant p-glycoprotein.
Neoplasms
Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
Neoplasms
Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs.
Neoplasms
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Neoplasms
Reversal of MDR1 gene-dependent multidrug resistance in HL60/HT9 cells using short hairpin RNA expression vectors.
Neoplasms
Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors.
Neoplasms
Reversal of MDR1/P-glycoprotein-Mediated Multidrug Resistance by Vector-Based RNA Interference In Vitro and In Vivo.
Neoplasms
Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs.
Neoplasms
Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486.
Neoplasms
Reversal of multidrug resistance by 4-chloro-N-(3-((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)phenyl)benzamide through the reversible inhibition of P-glycoprotein.
Neoplasms
Reversal of Multidrug Resistance by Apolipoprotein A1-Modified Doxorubicin Liposome for Breast Cancer Treatment.
Neoplasms
Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
Neoplasms
Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes.
Neoplasms
Reversal of multidrug resistance by derivatives of acrivastine.
Neoplasms
Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
Neoplasms
Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function.
Neoplasms
Reversal of multidrug resistance by novel nitrophenyl pyrones, SNF4435C and D.
Neoplasms
Reversal of multidrug resistance by tacrolimus hydrate.
Neoplasms
Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Neoplasms
Reversal of Multidrug Resistance in an Epirubicin-Resistant Gastric Cancer Cell Subline
Neoplasms
Reversal of multidrug resistance in cancer cells by novel asymmetrical 1,4-dihydropyridines.
Neoplasms
Reversal of multidrug resistance in cancer cells by Rhizoma Alismatis extract.
Neoplasms
Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil.
Neoplasms
Reversal of Multidrug Resistance in Mouse Lymphoma Cells by Extracts and Flavonoids from Pistacia integerrima.
Neoplasms
Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
Neoplasms
Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
Neoplasms
Reversal of multidrug resitance by natural substances from plants.
Neoplasms
Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza.
Neoplasms
Reversal of P-glycoprotein and multidrug resistance-associated protein 1 mediated multidrug resistance in cancer cells by HZ08 Isomers, tetrataisohydroquinolin derivatives.
Neoplasms
Reversal of P-glycoprotein and multidrug-resistance protein-mediated drug resistance in KB cells by 5-O-benzoylated taxinine K.
Neoplasms
Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6.
Neoplasms
Reversal of P-glycoprotein-associated multidrug resistance by ivermectin.
Neoplasms
Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells.
Neoplasms
Reversal of P-glycoprotein-mediated multidrug resistance and pharmacokinetics study in rats by WYX-5.
Neoplasms
Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.
Neoplasms
Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate.
Neoplasms
Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Neoplasms
Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver.
Neoplasms
Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng.
Neoplasms
Reversal of P-glycoprotein-mediated multidrug resistance by the novel tetrandrine derivative W6.
Neoplasms
Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase.
Neoplasms
Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs.
Neoplasms
Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARgamma activation by troglitazone.
Neoplasms
Reversal of P-glycoprotein-mediated multidrug resistance is induced by mollugin in MCF-7/adriamycin cells.
Neoplasms
Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
Neoplasms
Reversal of P-glycoprotein-medicated multidrug resistance by LBM-A5 in vitro and a study of its pharmacokinetics in vivo.
Neoplasms
Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Neoplasms
Reversal of P?Glycoprotein-Mediated Multidrug Resistance by Novel Curcumin Analogues in Paclitaxel-resistant Human Breast Cancer Cells.
Neoplasms
Reverse correlation between P-glycoprotein expression and proliferative activity in endometrial adenocarcinoma.
Neoplasms
Reverse of non-small cell lung cancer drug resistance induced by cancer-associated fibroblasts via a paracrine pathway.
Neoplasms
Reversers of the multidrug resistance transporter P-glycoprotein.
Neoplasms
Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein.
Neoplasms
Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein.
Neoplasms
Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-?-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
Neoplasms
Reversion of P-gp-Mediated Drug Resistance in Ovarian Carcinoma Cells with PHPMA-Zosuquidar Conjugates.
Neoplasms
Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives.
Neoplasms
Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
Neoplasms
Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells.
Neoplasms
RNAi-based Knockdown of Multidrug Resistance-associated Protein 1 is Sufficient to Reverse Multidrug Resistance of Human Lung Cells.
Neoplasms
RNAi-mediated silencing of ATP-binding cassette C4 protein inhibits cell growth in MGC80-3 gastric cancer cell lines.
Neoplasms
RNF2 interacts with the linker region of the human P-glycoprotein.
Neoplasms
Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo.
Neoplasms
Role of ABC transporters in the pathogenesis of Alzheimer's disease.
Neoplasms
Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers.
Neoplasms
Role of active drug transporters in refractory multiple myeloma.
Neoplasms
Role of ATP-Binding Cassette Transporter Proteins in CNS tumors: Resistance-based perspectives and clinical updates.
Neoplasms
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
Neoplasms
Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines.
Neoplasms
Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance.
Neoplasms
Role of Four ABC Transporter Genes in Pharmacogenetic Susceptibility to Breast Cancer in Jordanian Patients.
Neoplasms
Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.
Neoplasms
Role of multidrug resistance protein (MRP) in glutathione S-conjugate transport in mammalian cells.
Neoplasms
Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma.
Neoplasms
Role of multidrug resistance-associated proteins in cancer therapeutics: past, present, and future perspectives.
Neoplasms
Role of nitric oxide donor in methotrexate-induced testicular injury via modulation of pro-inflammatory mediators, eNOS and P-glycoprotein.
Neoplasms
Role of Nrf2 in cancer photodynamic therapy: Regulation of human ABC transporter ABCG2.
Neoplasms
Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer--a prospective clinical study.
Neoplasms
Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.
Neoplasms
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs.
Neoplasms
Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells.
Neoplasms
Role of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance.
Neoplasms
Role of the MRP1/ABCC1 multidrug transporter protein in cancer.
Neoplasms
Role of the tumor microenvironment in the activity and expression of the p-glycoprotein in human colon carcinoma cells.
Neoplasms
Role of tumor necrosis factor-alpha in down-regulation of hepatic cytochrome P450 and P-glycoprotein by endotoxin.
Neoplasms
Role of UGT1A1*6 in irinogenetics in Asians.
Neoplasms
Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
Neoplasms
Role of ursolic acid chalcone, a synthetic analogue of ursolic acid, in inhibiting the properties of CD133(+) sphere-forming cells in liver stem cells.
Neoplasms
Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.
Neoplasms
Roles of ABCC1 and ABCC4 in Proliferation and Migration of Breast Cancer Cell Lines.
Neoplasms
Roles of aldo-keto reductase 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Neoplasms
Roles of multidrug resistance genes in breast cancer chemoresistance.
Neoplasms
Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin.
Neoplasms
Roles of Sorcin in Drug Resistance in Cancer: One Protein, Many Mechanisms, for a Novel Potential Anticancer Drug Target.
Neoplasms
ROR1 regulates chemoresistance in Breast Cancer via modulation of drug efflux pump ABCB1.
Neoplasms
RSK1 protects P-glycoprotein/ABCB1 against ubiquitin-proteasomal degradation by downregulating the ubiquitin-conjugating enzyme E2 R1.
Neoplasms
Ruthenium(II) and Platinum(II) Complexes with Biologically Active Aminoflavone Ligands Exhibit In Vitro Anticancer Activity.
Neoplasms
Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma.
Neoplasms
Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells.
Neoplasms
Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest.
Neoplasms
Salmonella enterica serovar Typhimurium modulates P-glycoprotein in the intestinal epithelium.
Neoplasms
Salmonella Overcomes Drug Resistance in Tumor through P-glycoprotein Downregulation.
Neoplasms
Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter.
Neoplasms
Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.
Neoplasms
sATP?binding cassette subfamily G member 2 enhances the multidrug resistance properties of human nasal natural killer/T cell lymphoma side population cells.
Neoplasms
Saturable function of P-glycoprotein as a drug-efflux pump in multidrug-resistant tumour cells.
Neoplasms
Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.
Neoplasms
Schisandrin B--a novel inhibitor of P-glycoprotein.
Neoplasms
Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells.
Neoplasms
Scientists and clinicians test their metal-back to the future with platinum compounds.
Neoplasms
Screening and discovery of novel MDR modifiers from naturally occurring bisbenzylisoquinoline alkaloids.
Neoplasms
Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference.
Neoplasms
Screening dietary flavonoids for the reversal of P-glycoprotein-mediated multidrug resistance in cancer.
Neoplasms
Screening novel, potent multidrug-resistant modulators from imidazole derivatives.
Neoplasms
Screening of potential miRNA therapeutics for the prevention of multi-drug resistance in cancer cells.
Neoplasms
SDZ 280-125: a cyclopeptolide endowed with an in vitro cyclosporin A-like profile of activity for the reversion of the P-glycoprotein-mediated multidrug resistance of tumor cells.
Neoplasms
SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells.
Neoplasms
Search for ABCB1 Modulators Among 2-Amine-5-Arylideneimidazolones as a New Perspective to Overcome Cancer Multidrug Resistance.
Neoplasms
Secalonic acid D induces cell apoptosis in both sensitive and ABCG2-overexpressing multidrug resistant cancer cells through upregulating c-Jun expression.
Neoplasms
Secalonic acid D reduced the percentage of side populations by down-regulating the expression of ABCG2.
Neoplasms
Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents.
Neoplasms
Secondary structure of P-glycoprotein investigated by circular dichroism and amino acid sequence analysis.
Neoplasms
Secretion of peptides and proteins lacking hydrophobic signal sequences: the role of adenosine triphosphate-driven membrane translocators.
Neoplasms
Secretion of platelet-activating factor is mediated by MDR1 P-glycoprotein in cultured human mesangial cells.
Neoplasms
Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients.
Neoplasms
Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected strains of Haemonchus contortus.
Neoplasms
Selective Antiproliferative Withanolides from Species in the Genera Eriolarynx and Deprea.
Neoplasms
Selective enhancement of vincristine cytotoxicity in multidrug-resistant tumor cells by dilantin (phenytoin)
Neoplasms
Selective GPR55 antagonism reduces chemoresistance in cancer cells.
Neoplasms
Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel.
Neoplasms
Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator.
Neoplasms
Selective inhibition of P-gp transporter by goniothalamin derivatives sensitizes resistant cancer cells to chemotherapy.
Neoplasms
Selective modulation of P-glycoprotein-mediated drug resistance.
Neoplasms
Selective susceptibility of transformed T lymphocytes to induction of apoptosis by PSC 833, an inhibitor of P-glycoprotein.
Neoplasms
Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
Neoplasms
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
Neoplasms
Selective toxicity of TGF-alpha-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF.
Neoplasms
Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.
Neoplasms
Selenocoumarins as new multitarget antiproliferative agents: Synthesis, biological evaluation and in silico calculations.
Neoplasms
Self-Assembly Nanoparticles for Overcoming Multidrug Resistance and Imaging-Guided Chemo-Photothermal Synergistic Cancer Therapy.
Neoplasms
Self-emulsifying drug-delivery systems modulate P-glycoprotein activity: role of excipients and formulation aspects.
Neoplasms
Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Neoplasms
Semi-synthetic isoflavones as BACE-1 inhibitors against Alzheimer's disease.
Neoplasms
Sensitive assessment of cytostatic drug resistance-mediating factors MDR1 and MRP in tumors of the gastrointestinal tract by RT-PCR.
Neoplasms
Sensitive immunofluorescence detection of the expression of P-glycoprotein in malignant cells.
Neoplasms
Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection.
Neoplasms
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Neoplasms
Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells.
Neoplasms
Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.
Neoplasms
Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.
Neoplasms
Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Neoplasms
Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters.
Neoplasms
Sequence and structural analysis of the presumed downstream promoter of the canine mdr1 gene.
Neoplasms
Sequence mutations of the substrate binding pocket of stem cell factor and multidrug resistance protein ABCG2 in renal cell cancer: A possible link to treatment resistance.
Neoplasms
Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials.
Neoplasms
Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
Neoplasms
Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Neoplasms
Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug.
Neoplasms
SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells.
Neoplasms
SET Domain-Containing Protein 5 Enhances the Cell Stemness of Non-Small Cell Lung Cancer via the PI3K/Akt/mTOR Pathway.
Neoplasms
Shell-crosslinked Pluronic L121 micelles as a drug delivery vehicle.
Neoplasms
Shikonin circumvents cancer drug resistance by induction of a necroptotic death.
Neoplasms
Sialic acid-binding lectin (leczyme) induces caspase-dependent apoptosis-mediated mitochondrial perturbation in Jurkat cells.
Neoplasms
Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic.
Neoplasms
Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands.
Neoplasms
Sigma receptors: recent advances and new clinical potentials.
Neoplasms
Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells.
Neoplasms
Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells.
Neoplasms
Significance of P-glycoprotein expression in childhood malignant tumors.
Neoplasms
Significant activity of ecdysteroids on the resistance to doxorubicin in mammalian cancer cells expressing the human ABCB1 transporter.
Neoplasms
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Neoplasms
Silencing of ABCG2 by MicroRNA-3163 Inhibits Multidrug Resistance in Retinoblastoma Cancer Stem Cells.
Neoplasms
Silencing of the ABCC4 gene by RNA interference reverses multidrug resistance in human gastric cancer.
Neoplasms
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.
Neoplasms
Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells.
Neoplasms
Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
Neoplasms
Single molecule tracking of P-glycoprotein in live cells reveals dynamic heterogeneity.
Neoplasms
Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response.
Neoplasms
Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition.
Neoplasms
Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients.
Neoplasms
Single photon emission computed tomography and positron emission tomography imaging of multi-drug resistant P-glycoprotein--monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer's disease.
Neoplasms
Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1).
Neoplasms
Single-nucleotide polymorphisms in a short basic motif in the ABC transporter ABCG2 disable its trafficking out of endoplasmic reticulum and reduce cell resistance to anticancer drugs.
Neoplasms
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Neoplasms
Sipholane triterpenoids: chemistry, reversal of ABCB1/P-glycoprotein-mediated multidrug resistance, and pharmacophore modeling.
Neoplasms
Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.
Neoplasms
siRNA-Mediated Down-Regulation of P-glycoprotein in a Xenograft Tumor Model in NOD-SCID Mice.
Neoplasms
siRNAs targeting multidrug transporter genes sensitize breast tumor to doxorubicin in a syngeneic mouse model.
Neoplasms
SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
Neoplasms
Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains.
Neoplasms
Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
Neoplasms
Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro.
Neoplasms
Small and Innovative Molecules as New Strategy to Revert MDR.
Neoplasms
Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells.
Neoplasms
Small molecule kinase inhibitors enhance aminolevulinic acid-mediated protoporphyrin IX fluorescence and PDT response in triple negative breast cancer cell lines.
Neoplasms
Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.
Neoplasms
Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.
Neoplasms
SMAR1 repression by pluripotency factors and consequent chemoresistance in breast cancer stem-like cells is reversed by aspirin.
Neoplasms
Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram.
Neoplasms
Snail-Induced Epithelial-to-Mesenchymal Transition Enhances P-gp-Mediated Multi Drug Resistance in HCC827 Cells.
Neoplasms
Solanine reverses multidrug resistance in human myelogenous leukemia K562/ADM cells by downregulating MRP1 expression.
Neoplasms
Solid lipid nanoparticles with TPGS and Brij 78: A co-delivery vehicle of curcumin and piperine for reversing P-glycoprotein-mediated multidrug resistance
Neoplasms
Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma.
Neoplasms
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
Neoplasms
Sorcin, a calcium binding protein involved in the multidrug resistance mechanisms in cancer cells.
Neoplasms
Source of a micro-nutrient in a semi-synthetic basal diet as a causative factor in inducing urinary calculi in rats and its inhibition by PSC 833, a potent inhibitor of P-glycoprotein.
Neoplasms
SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2.
Neoplasms
Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies.
Neoplasms
Specificity and sensitivity of immunocytochemistry for detecting P-glycoprotein in haematological malignancies.
Neoplasms
Specificity protein 1 is a novel target of 2,4-bis (p-hydroxyphenyl)-2-butenal for the suppression of human oral squamous cell carcinoma cell growth.
Neoplasms
Sphingolipid abnormalities in cancer multidrug resistance: Chicken or egg?
Neoplasms
Spontaneous multidrug transport in human glioma cells is regulated by transforming growth factors type beta.
Neoplasms
Spontaneous reversal of p-glycoprotein expression in multidrug resistant cell lines.
Neoplasms
Stabilized micelles as delivery vehicles for paclitaxel.
Neoplasms
Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference.
Neoplasms
Standardization of a single-cell assay for sensitive detection of multidrug resistance protein expression in normal and malignant cells in archival clinical samples.
Neoplasms
Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
Neoplasms
Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma.
Neoplasms
Stephania Tetrandra and Ginseng-Containing Chinese Herbal Formulation NSENL Reverses Cisplatin Resistance in Lung Cancer Xenografts.
Neoplasms
Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein.
Neoplasms
Stereoselective Modulation of P-Glycoprotein by Chiral Small Molecules.
Neoplasms
Steroid receptor RNA activator inhibits the migration, invasion and stemness characteristics of renal cell carcinoma cells.
Neoplasms
Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis.
Neoplasms
Sterols and triterpenoids from Ganoderma lucidum and their reversal activities of tumor multidrug resistance.
Neoplasms
Stilbenes as multidrug resistance modulators and apoptosis inducers in human adenocarcinoma cells.
Neoplasms
Stimulus-induced expression of the ABCG2 multidrug transporter in HepG2 hepatocarcinoma model cells involves the ERK1/2 cascade and alternative promoters.
Neoplasms
Strategies for inhibition of MDR1 gene expression.
Neoplasms
Strongly amphiphilic photosensitizers are not substrates of the cancer stem cell marker ABCG2 and provides specific and efficient light-triggered drug delivery of an EGFR-targeted cytotoxic drug.
Neoplasms
Structural and functional aspects of P-glycoproteins and related transport proteins.
Neoplasms
Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1.
Neoplasms
Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1).
Neoplasms
Structural Basis of Drug Recognition by the Multidrug Transporter ABCG2.
Neoplasms
Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
Neoplasms
Structural insights into P-glycoprotein (ABCB1) by small angle X-ray scattering and electron crystallography.
Neoplasms
Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport.
Neoplasms
Structural modification of P-glycoprotein induced by OH radicals: Insights from atomistic simulations.
Neoplasms
Structural studies of Multidrug Resistance Protein 1 (MRP1) using "almost" cysless template.
Neoplasms
Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors.
Neoplasms
Structure and ligand-based design of P-glycoprotein inhibitors: a historical perspective.
Neoplasms
Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1.
Neoplasms
Structure of multidrug-resistance proteins of the ATP-binding cassette (ABC) superfamily.
Neoplasms
Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding.
Neoplasms
Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP.
Neoplasms
Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis.
Neoplasms
Structure-activity relationship study of novel 2-aminobenzofuran derivatives as P-glycoprotein inhibitors.
Neoplasms
Structure-activity relationships and evaluation of esterified diterpenoid alkaloid derivatives as antiproliferative agents.
Neoplasms
Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).
Neoplasms
Structure-activity relationships for euphocharacins A-L, a new series of jatrophane diterpenes, as inhibitors of cancer cell P-glycoprotein.
Neoplasms
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Neoplasms
Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance.
Neoplasms
Structure-activity relationships of novel N-acyloxy-1,4-dihydropyridines as P-glycoprotein inhibitors.
Neoplasms
Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein.
Neoplasms
Structure-Based Discovery of Pyrimidine Aminobenzene Derivatives as Potent Oral Reversal Agents against P-gp- and BCRP-Mediated Multidrug Resistance.
Neoplasms
Structure-based interpretation of the mutagenesis database for the nucleotide binding domains of P-glycoprotein.
Neoplasms
Structure-guided probing of the leukotriene C4 binding site in human multidrug resistance protein 1 (MRP1; ABCC1).
Neoplasms
Structures of ABCG2 under turnover conditions reveal a key step in the drug transport mechanism.
Neoplasms
Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain.
Neoplasms
Structures of the Multidrug Transporter P-glycoprotein Reveal Asymmetric ATP Binding and the Mechanism of Polyspecificity.
Neoplasms
Studies of P-glycoprotein in chronic myelogenous leukaemia patients: expression, activity and correlations with CD34 antigen.
Neoplasms
Studies on low-level MDR cells.
Neoplasms
Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.
Neoplasms
Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation.
Neoplasms
Study of therapy resistance in cancer cells with functional proteome analysis.
Neoplasms
Subcellular detection and localization of the drug transporter P-glycoprotein in cultured tumor cells.
Neoplasms
Subcellular distribution and metabolism studies of the potential myocardial imaging agent [99mTc(N)(DBODC)(PNP5)]+.
Neoplasms
Subcellular distribution of ezrin/radixin/moesin and their roles in the cell surface localization and transport function of P-glycoprotein in human colon adenocarcinoma LS180 cells.
Neoplasms
Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium.
Neoplasms
Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells.
Neoplasms
Substituents at the C3' and C3'N positions are critical for taxanes to overcome acquired resistance of cancer cells to paclitaxel.
Neoplasms
Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Neoplasms
Substrate Affinity of Photosensitizers Derived from Chlorophyll-a: The ABCG2 Transporter Affects the Phototoxic Response of Side Population Stem Cell-like Cancer Cells to Photodynamic Therapy.
Neoplasms
Substrate Specificity of Aglaia loheri Active Isolate towards P-glycoprotein in Multidrug-Resistant Cancer Cells.
Neoplasms
Substrate-induced conformational changes in the nucleotide-binding domains of lipid bilayer-associated P-glycoprotein during ATP hydrolysis.
Neoplasms
Subtle Structural Differences Trigger Inhibitory Activity of Propafenone Analogues at the Two Polyspecific ABC Transporters: P-Glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP).
Neoplasms
Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance.
Neoplasms
Sulforaphane and erucin increase MRP1 and MRP2 in human carcinoma cell lines.
Neoplasms
Sulforaphane Regulates NFE2L2/Nrf2-Dependent Xenobiotic Metabolism Phase II and Phase III Enzymes Differently in Human Colorectal Cancer and Untransformed Epithelial Colon Cells.
Neoplasms
Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion.
Neoplasms
Suppressing STAT5 signaling affects osteosarcoma growth and stemness.
Neoplasms
Suppression of ABCG2 inhibits cancer cell proliferation.
Neoplasms
Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport.
Neoplasms
Suppression of Esophageal Cancer Stem-like Cells by SNX-2112 Is Enhanced by STAT3 Silencing.
Neoplasms
Suppression of multi-drug resistance gene expression in the mouse liver by 1,4-bis[2,(3,5-dichloropyridyloxy)]benzene.
Neoplasms
Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents.
Neoplasms
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo.
Neoplasms
Suprafenacine, an indazole-hydrazide agent, targets cancer cells through microtubule destabilization.
Neoplasms
Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation.
Neoplasms
Surface modification of paclitaxel-loaded liposomes using d-?-tocopheryl polyethylene glycol 1000 succinate: Enhanced cellular uptake and cytotoxicity in multidrug resistant breast cancer cells.
Neoplasms
Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
Neoplasms
Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-?B expression in MCF-7/5-FU cells.
Neoplasms
Susceptibility of an emetine-resistant mutant of Entamoeba histolytica to multiple drugs and to channel blockers.
Neoplasms
Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
Neoplasms
Symmetric Bis-chalcones as a New Type of Breast Cancer Resistance Protein Inhibitors with a Mechanism Different from That of Chromones.
Neoplasms
Synchronous rectal and gastric cancer in a fighter pilot: aeromedical concerns.
Neoplasms
Synergic effect between 5?fluorouracil and celecoxib on hypoxic gastric cancer cells.
Neoplasms
Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo.
Neoplasms
Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.
Neoplasms
Synergistic antitumor effect of a ?-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma.
Neoplasms
Synergistic Combination of Sodium Aescinate-Stabilized, Polymer-Free, Twin-Like Nanoparticles to Reverse Paclitaxel Resistance.
Neoplasms
Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance.
Neoplasms
Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis.
Neoplasms
Synergistic interaction between p-glycoprotein modulators and epirubicine on resistant cancer cells.
Neoplasms
Syntheses of taxuspine C derivatives as functional inhibitors of P-glycoprotein, an ATP-associated cell-membrane transporter.
Neoplasms
Synthesis and Anticancer Cytotoxicity of Azaaurones Overcoming Multidrug Resistance.
Neoplasms
Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives.
Neoplasms
Synthesis and bioevaluation of novel benzodipyranone derivatives as P-glycoprotein inhibitors for multidrug resistance reversal agents.
Neoplasms
Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
Neoplasms
Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators.
Neoplasms
Synthesis and biological evaluation of bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potential P-glycoprotein and tumor metastasis inhibitors.
Neoplasms
Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors.
Neoplasms
Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
Neoplasms
Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors.
Neoplasms
Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors.
Neoplasms
Synthesis and biological evaluation of novel larotaxel analogues.
Neoplasms
Synthesis and biological evaluation of pentacyclic strychnos alkaloids as selective modulators of the ABCC10 (MRP7) efflux pump.
Neoplasms
Synthesis and biological evaluation of thiophenylbenzofuran derivatives as potential P-glycoprotein inhibitors.
Neoplasms
Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
Neoplasms
Synthesis and Characterization of a BODIPY Conjugate of the BCR-ABL Kinase Inhibitor Tasigna (Nilotinib): Evidence for Transport of Tasigna and Its Fluorescent Derivative by ABC Drug Transporters.
Neoplasms
Synthesis and characterization of the anticancer and metal binding properties of novel pyrimidinylhydrazone derivatives.
Neoplasms
Synthesis and Cytotoxicity of 7,9-O-Linked Macrocyclic C-Seco Taxoids.
Neoplasms
Synthesis and DFT study on Hantzsch reaction to produce asymmetrical compounds of 1,4-dihydropyridine derivatives for P-glycoprotein inhibition as anticancer agent.
Neoplasms
Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication.
Neoplasms
Synthesis and Investigation of Tetrahydro-?-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
Neoplasms
Synthesis and multidrug-resistance modulating activity of a series of thienothiazines.
Neoplasms
Synthesis and SAR Study of Anticancer Protoflavone Derivatives: Investigation of Cytotoxicity and Interaction with ABCB1 and ABCG2 Multidrug Efflux Transporters.
Neoplasms
Synthesis and structure--activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance.
Neoplasms
Synthesis and structure-activity relationship studies of 4,11-diaminonaphtho[2,3-f]indole-5,10-diones.
Neoplasms
Synthesis of 3-Methylidene-1-tosyl-2,3-dihydroquinolin-4(1H)-ones as Potent Cytotoxic Agents.
Neoplasms
Synthesis of a Dual Functional Anti-MDR Tumor Agent PH II-7 with Elucidations of Anti-Tumor Effects and Mechanisms.
Neoplasms
Synthesis of a Next-Generation Taxoid by Rapid Methylation Amenable for
Neoplasms
Synthesis of Homoverrucosanoid-Derived Esters and Evaluation as MDR Modulators.
Neoplasms
Synthesis, Activity, and Pharmacophore Development for Isatin-beta-thiosemicarbazones with Selective Activity toward Multidrug-Resistant Cells.
Neoplasms
Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
Neoplasms
Synthesis, in silico and in vitro studies of new 1,4-dihydropiridine derivatives for antitumor and P-glycoprotein inhibitory activity.
Neoplasms
Synthesis, Structure-Activity Relationship and Biological Activity of Acridine Derivatives as Potent MDR-Reversing Agents.
Neoplasms
Synthetic peroxides promote apoptosis of cancer cells inhibiting of P-glycoprotein ABCB5.
Neoplasms
Systematic evaluation of multifunctional paclitaxel-loaded polymeric mixed micelles as a potential anticancer remedy to overcome multidrug resistance.
Neoplasms
Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration.
Neoplasms
Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients.
Neoplasms
Tangeretin, a citrus pentamethoxyflavone, antagonizes ABCB1-mediated multidrug resistance by inhibiting its transport function.
Neoplasms
Tanshinone IIA potentiates the efficacy of 5-FU in Colo205 colon cancer cells in vivo through downregulation of P-gp and LC3-II.
Neoplasms
Target therapy of multiple myeloma by PTX-NPs and ABCG2 antibody in a mouse xenograft model.
Neoplasms
Targeted chemotherapy in drug-resistant tumors, noninvasive imaging of P-glycoprotein-mediated functional transport in cancer, and emerging role of Pgp in neurodegenerative diseases.
Neoplasms
Targeted delivery of cabazitaxel by conjugation to albumin-PEG-folate nanoparticles using a cysteine-acrylate linker and simple synthesis conditions.
Neoplasms
Targeted delivery of nucleic acids into xenograft tumors mediated by novel folate-equipped liposomes.
Neoplasms
Targeted gene delivery by intravenous injection of retroviral vectors.
Neoplasms
Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells.
Neoplasms
Targeted multidrug-resistance reversal in tumor based on PEG-PLL-PLGA polymer nano drug delivery system.
Neoplasms
Targeted nanopore sequencing for the identification of ABCB1 promoter translocations in cancer.
Neoplasms
Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing.
Neoplasms
Targeting an extracellular epitope of the human multidrug resistance protein 1 (MRP1) in malignant cells with a novel recombinant single chain Fv antibody.
Neoplasms
Targeting anthracycline-resistant tumor cells with synthetic aloe-emodin glycosides.
Neoplasms
Targeting autophagy augments the activity of DHA-E3 to overcome p-gp mediated multi-drug resistance.
Neoplasms
Targeting c-kit inhibits gefitinib resistant NSCLC cell growth and invasion through attenuations of stemness, EMT and acquired resistance.
Neoplasms
Targeting Cancer Cells using 3-bromopyruvate for Selective Cancer Treatment.
Neoplasms
Targeting CD133(+) laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles.
Neoplasms
Targeting Cellular Metabolism Chemosensitizes the Doxorubicin-Resistant Human Breast Adenocarcinoma Cells.
Neoplasms
Targeting long non-coding RNA DANCR inhibits triple negative breast cancer progression.
Neoplasms
Targeting mitochondrial cell death pathway to overcome drug resistance with a newly developed iron chelate.
Neoplasms
Targeting multidrug resistant tumor cells with a recombinant single-chain FV fragment directed to P-glycoprotein.
Neoplasms
Targeting multidrug-resistant ovarian cancer through estrogen receptor ? dependent ATP depletion caused by hyperactivation of the unfolded protein response.
Neoplasms
Targeting of the Eukaryotic Translation Initiation Factor 4A Against Breast Cancer Stemness.
Neoplasms
Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
Neoplasms
Targeting P-glycoprotein for effective oral anti-cancer chemotherapeutics.
Neoplasms
Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer.
Neoplasms
Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPAR? agonists.
Neoplasms
Targeting the Multidrug ABCG2 Transporter with Flavonoidic Inhibitors: In Vitro Optimization and In Vivo Validation.
Neoplasms
Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo.
Neoplasms
Targeting the Multidrug Transporter Ptch1 Potentiates Chemotherapy Efficiency.
Neoplasms
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.
Neoplasms
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
Neoplasms
Taxifolin Resensitizes Multidrug Resistance Cancer Cells via Uncompetitive Inhibition of P-Glycoprotein Function.
Neoplasms
Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of ?-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
Neoplasms
Taxol: mechanisms of action and resistance.
Neoplasms
Tc-99m MIBI liver imaging for hepatocellular carcinoma: correlation with P-glycoprotein-multidrug-resistance gene expression.
Neoplasms
Tc-99m MIBI SPECT is useful for noninvasively predicting the presence of MDR1 gene-encoded P-glycoprotein in patients with hepatocellular carcinoma.
Neoplasms
Tc-99m MIBI to evaluate children with Ewing's sarcoma.
Neoplasms
Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin.
Neoplasms
Technetium-99m methoxyisobutylisonitrile imaging for parathyroid adenoma: relationship to P-glycoprotein or multidrug resistance-related protein expression.
Neoplasms
Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein.
Neoplasms
Technetium-99m sestamibi single photon emission computed tomography findings correlated with P-glycoprotein expression, encoded by the multidrug resistance gene-1 messenger ribonucleic acid, in intracranial meningiomas.
Neoplasms
Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors.
Neoplasms
Technetium-99m-sestamibi parathyroid scintigraphy: effect of P-glycoprotein, histology and tumor size on detectability.
Neoplasms
Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.
Neoplasms
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Neoplasms
Tenacigenin B derivatives reverse P-glycoprotein-mediated multidrug resistance inHepG2/Dox cells.
Neoplasms
Tenulin and isotenulin inhibit P-glycoprotein function and overcome multidrug resistance in cancer cells.
Neoplasms
Tepoxalin increases chemotherapy efficacy in drug-resistant breast cancer cells overexpressing the multidrug transporter gene ABCB1.
Neoplasms
Terpinen-4-ol, the main component of Melaleuca alternifolia (tea tree) oil inhibits the in vitro growth of human melanoma cells.
Neoplasms
Tetrahydroquinoline/4,5-Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2).
Neoplasms
Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysis.
Neoplasms
Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells.
Neoplasms
Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression.
Neoplasms
Tetrofosmin as predictors of tumour response.
Neoplasms
The (patho)physiological functions of the MRP family.
Neoplasms
The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant.
Neoplasms
The 5-aromatic hydantoin-3-acetate derivatives as inhibitors of the tumour multidrug resistance efflux pump P-glycoprotein (ABCB1): Synthesis, crystallographic and biological studies.
Neoplasms
The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor.
Neoplasms
The ABC family of multidrug transporters in microorganisms.
Neoplasms
The ABC subfamily A transporters: Multifaceted players with incipient potentialities in cancer.
Neoplasms
The ABCG family of membrane-associated transporters: you don't have to be big to be mighty.
Neoplasms
The ABCG2 resistance network of glioblastoma.
Neoplasms
The ABCG2/BCRP transporter and its variants - from structure to pathology.
Neoplasms
The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein--a well-known, yet poorly understood drug transporter.
Neoplasms
The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.
Neoplasms
The activity of latent benzoperimidine esters to inhibit P-glycoprotein and multidrug resistance-associated protein 1 dependent efflux of pirarubicin from several lines of multidrug resistant tumor cells.
Neoplasms
The alpha 1-adrenergic photoaffinity probe [125I]arylazidoprazosin binds to a specific peptide of P-glycoprotein in multidrug-resistant cells.
Neoplasms
The amplification and expression of MDR1 gene in adriamycine resistant cell line of colon cancer cell HR8348.
Neoplasms
The anthelmintic triclabendazole and its metabolites inhibit the membrane transporter ABCG2/BCRP.
Neoplasms
The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis.
Neoplasms
The Anticancer Activity of the Old Neuroleptic Phenothiazine-type Drug Thioridazine.
Neoplasms
The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.
Neoplasms
The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells.
Neoplasms
The antitumor activity of CYB-L10, a human topoisomerase IB catalytic inhibitor.
Neoplasms
The association between genetic variants in the genes for cytochrome P450 B1 and ATP-binding cassette transporter genes and breast cancer risk.
Neoplasms
The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma.
Neoplasms
The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart.
Neoplasms
The ATPase and ATP-binding functions of P-glycoprotein--modulation by interaction with defined phospholipids.
Neoplasms
The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein.
Neoplasms
The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
Neoplasms
The BTK Inhibitor, Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1 and ABCC10 Overexpressing Cells and Tumors.
Neoplasms
The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor.
Neoplasms
The capsular polysaccharide complex of Bacteroides fragilis induces cytokine production from human and murine phagocytic cells.
Neoplasms
The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer.
Neoplasms
The Challenge of Exploiting ABCG2 in the Clinic.
Neoplasms
The Changes of P-glycoprotein Activity by Interferon-? and Tumor Necrosis Factor-? in Primary and Immortalized Human Brain Microvascular Endothelial Cells.
Neoplasms
The chemoresistance gene ABCG2 (MXR/BCRP1/ABCP1) is not expressed in melanomas but in single neuroendocrine carcinomas of the skin.
Neoplasms
The Chinese Herb Jianpijiedu Contributes to the Regulation of OATP1B2 and ABCC2 in a Rat Model of Orthotopic Transplantation Liver Cancer Pretreated with Food Restriction and Diarrhea.
Neoplasms
The Cisplatin-Derived Increase of Mitochondrial Reactive Oxygen Species Enhances the Effectiveness of Photodynamic Therapy via Transporter Regulation.
Neoplasms
The clinical development of new mitotic inhibitors that stabilize the microtubule.
Neoplasms
The clinical role of MDR1 gene expression in human lung cancer.
Neoplasms
The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.
Neoplasms
The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression.
Neoplasms
The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma.
Neoplasms
The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas.
Neoplasms
The conserved glutamate residue adjacent to the Walker-B motif is the catalytic base for ATP hydrolysis in the ATP-binding cassette transporter BmrA.
Neoplasms
The contribution of the ABCG2 C421A polymorphism to cancer susceptibility: a meta-analysis of the current literature.
Neoplasms
The controversial role of ABC transporters in clinical oncology.
Neoplasms
The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.
Neoplasms
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast cancers.
Neoplasms
The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice.
Neoplasms
The cytotoxic effect and the multidrug resistance reversing action of lignans from Phyllanthus amarus.
Neoplasms
The developmental transcription factor IRF6 attenuates ABCG2 gene expression and distinctively reverses stemness phenotype in nasopharyngeal carcinoma.
Neoplasms
The dopamine D3 receptor antagonists PG01037, NGB2904, SB277011A, and U99194 reverse ABCG2 transporter-mediated drug resistance in cancer cell lines.
Neoplasms
The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis.
Neoplasms
The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for novel treatment strategies in COPD.
Neoplasms
The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatment.
Neoplasms
The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma.
Neoplasms
The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance.
Neoplasms
The Effect of Nanosystems on ATP-Binding Cassette Transporters: Understanding the Influence of Nanosystems on Multidrug Resistance Protein-1 and P-glycoprotein.
Neoplasms
The Effect of Optically Induced Dielectrophoresis (ODEP)-Based Cell Manipulation in a Microfluidic System on the Properties of Biological Cells.
Neoplasms
The effect of P-glycoprotein function inhibition with cyclosporine A on the biodistribution of Tc-99m sestamibi.
Neoplasms
The effect of the plasticizer diethylhexyl phthalate on transport activity and expression of P-glycoprotein in parental and doxo-resistant human sarcoma cell lines.
Neoplasms
The Effect of Vitamin D3 and Ketoconazole Combination on VDR-mediated P-gp Expression and Function in Human Colon Adenocarcinoma Cells: Implications in Drug Disposition and Resistance.
Neoplasms
The effects of anthracycline drugs on the conformational distribution of mouse P-glycoprotein explains their transport rate differences.
Neoplasms
The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme.
Neoplasms
The Effects of Iodinated Radiographic Contrast Media on Multidrug-resistant K562/Dox Cells: Mitochondria Impairment and P-glycoprotein Inhibition.
Neoplasms
The effects of subacute inhaled multi-walled carbon nanotube exposure on signaling pathways associated with cholesterol transport and inflammatory markers in the vasculature of wild-type mice.
Neoplasms
The elimination of P-glycoprotein over-expressing cancer cells by antimicrobial cationic peptide NK-2: The unique way of multi-drug resistance modulation.
Neoplasms
The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy.
Neoplasms
The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).
Neoplasms
The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.
Neoplasms
The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels.
Neoplasms
The expression and functional characterization of ABCG2 in brain endothelial cells and vessels.
Neoplasms
The expression of multidrug resistance protein in human gastrointestinal tract carcinomas.
Neoplasms
The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines.
Neoplasms
The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models.
Neoplasms
The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance.
Neoplasms
The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells.
Neoplasms
The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
Neoplasms
The first intracellular loop is essential for the catalytic cycle of the human ABCG2 multidrug resistance transporter.
Neoplasms
The flexibility of P-glycoprotein for its poly-specific drug binding from molecular dynamics simulations.
Neoplasms
The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.
Neoplasms
The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Neoplasms
The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions.
Neoplasms
The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface.
Neoplasms
The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells.
Neoplasms
The harmful effect of ER? on BCRP-mediated drug resistance and cell proliferation in ER?/PR-negative breast cancer.
Neoplasms
The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
Neoplasms
The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2.
Neoplasms
The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.
Neoplasms
The Human Melanoma Side Population Displays Molecular and Functional Characteristics of Enriched Chemoresistance and Tumorigenesis.
Neoplasms
The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy.
Neoplasms
The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.
Neoplasms
The human RNA surveillance factor Up-frameshift 1 inhibits hepatic cancer progression by targeting MRP2/ABCC2.
Neoplasms
The hypoxia-mimetic agent CoCl2 induces chemotherapy resistance in LOVO colorectal cancer cells.
Neoplasms
The immunogenic properties of drug-resistant murine tumor cells do not correlate with expression of the MDR phenotype.
Neoplasms
The impact of ABCB1 gene polymorphism and its expression on non-small-cell lung cancer development, progression and therapy - preliminary report.
Neoplasms
The Impact of the Induction of Multidrug Resistance Transporters in Therapies by Used Drugs: Recent Studies.
Neoplasms
The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence.
Neoplasms
The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
Neoplasms
The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.
Neoplasms
The influence of a caveolin-1 mutant on the function of P-glycoprotein.
Neoplasms
The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.
Neoplasms
The interaction between resistance modifiers such as pyrido[3,2-g]quinoline, aza-oxafluorene and pregnane derivatives with DNA, plasmid DNA and tRNA.
Neoplasms
The interaction of 4-thiazolidinone derivatives containing indolin-2-one moiety with P-glycoprotein studied using K562 cell lines.
Neoplasms
The JAK2 inhibitors CEP-33779 and NVP-BSK805 have high P-gp inhibitory activity and sensitize drug-resistant cancer cells to vincristine.
Neoplasms
The lignan, (-)-sesamin reveals cytotoxicity toward cancer cells: Pharmacogenomic determination of genes associated with sensitivity or resistance.
Neoplasms
The MDR1 (ABCB1) gene polymorphism and its clinical implications.
Neoplasms
The mechanism of action of multidrug-resistance-linked P-glycoprotein.
Neoplasms
The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity.
Neoplasms
The modulatory properties of Si Jun Zi Tang enhancing anticancer of gefitinib by an integrating approach.
Neoplasms
The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research.
Neoplasms
The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1).
Neoplasms
The molecular interaction of a copper chelate with human P-glycoprotein.
Neoplasms
The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates.
Neoplasms
The multidrug resistance P-glycoprotein.
Neoplasms
The multidrug resistance protein is photoaffinity labeled by a quinoline-based drug at multiple sites.
Neoplasms
The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
Neoplasms
The multidrug resistance-associated protein (MRP) is over-expressed and functional in rat hepatoma cells.
Neoplasms
The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers.
Neoplasms
The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy.
Neoplasms
The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane.
Neoplasms
The multidrug-resistance gene MDR1 is expressed in human glial tumors.
Neoplasms
The multidrug-resistance P-glycoprotein (Pgp, MDR1) is an early marker of blood-brain barrier development in the microvessels of the developing human brain.
Neoplasms
The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding.
Neoplasms
The network of P-glycoprotein and microRNAs interactions.
Neoplasms
The nicotinamide phosphoribosyltransferase antagonist FK866 inhibits growth of prostate tumour spheroids and increases doxorubicin retention without changes in drug transporter and cancer stem cell protein expression.
Neoplasms
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism.
Neoplasms
The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter.
Neoplasms
The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance.
Neoplasms
The P-glycoprotein (ABCB1) linker domain encodes high-affinity binding sequences to alpha- and beta-tubulins.
Neoplasms
The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
Neoplasms
The P-glycoprotein homologues of Plasmodium falciparum: Are they involved in chloroquine resistance?
Neoplasms
The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Neoplasms
The PARP inhibitor AZD2461 provides insights into the role of PARP3 inhibition for both synthetic lethality and tolerability with chemotherapy in preclinical models.
Neoplasms
The pfmdr gene homologues of Plasmodium falciparum.
Neoplasms
The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy.
Neoplasms
The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice.
Neoplasms
The phenothiazine, trifluoperazine, is selectively lethal to ABCB1-expressing multidrug resistant cells.
Neoplasms
The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.
Neoplasms
The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines.
Neoplasms
The potent immunosuppressive cyclosporin FR901459 inhibits the human P-glycoprotein and formyl peptide receptor functions.
Neoplasms
The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.
Neoplasms
The potential mechanism of action of Sorcin and its interacting proteins.
Neoplasms
The Potential of Flavonolignans in Prostate Cancer Management.
Neoplasms
The potential protective effect of modafinil in intestinal ischemic reperfusion-induced in rats.
Neoplasms
The presence of P-glycoprotein in L1210 cells directly induces down-regulation of cell surface saccharide targets of concanavalin A.
Neoplasms
The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer.
Neoplasms
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.
Neoplasms
The prognostic value of breast cancer resistance protein (BCRB/ABCG2) expression in breast carcinomas.
Neoplasms
The prognostic value of MDR1 gene expression in primary untreated neuroblastoma.
Neoplasms
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.
Neoplasms
The protoapigenone analog WYC0209 targets CD133+ cells: A potential adjuvant agent against cancer stem cells in urothelial cancer therapy.
Neoplasms
The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP.
Neoplasms
The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis.
Neoplasms
The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids.
Neoplasms
The reference liver - ABC and SLC drug transporters in healthy donor and metastatic livers.
Neoplasms
The regulation of the expression of ABCG2 gene through mitogen-activated protein kinase pathways in canine lymphoid tumor cell lines.
Neoplasms
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
Neoplasms
The relevance of multidrug resistance-associated P-glycoprotein expression in the treatment response of B-cell chronic lymphocytic leukemia.
Neoplasms
The reversal effects of 3-bromopyruvate on multidrug resistance in vitro and in vivo derived from human breast MCF-7/ADR cells.
Neoplasms
The reversion effect of the RNAi-silencing mdr1 gene on multidrug resistance of the leukemia cell HT9.
Neoplasms
The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance.
Neoplasms
The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response.
Neoplasms
The role of a drug-loaded poly (lactic co-glycolic acid) (PLGA) copolymer stent in the treatment of ovarian cancer.
Neoplasms
The role of ABC transporters in clinical practice.
Neoplasms
The role of ABC transporters in progression and clinical outcome of colorectal cancer.
Neoplasms
The role of ABCG2 in modulating responses to anti-cancer photodynamic therapy.
Neoplasms
The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance.
Neoplasms
The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
Neoplasms
The role of cyclosporin A on antibody-dependent monocyte-mediated cytotoxicity against human multidrug-resistant cancer cells.
Neoplasms
The role of emodin on cisplatin resistance reversal of lung adenocarcinoma A549/DDP cell.
Neoplasms
The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer.
Neoplasms
The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.
Neoplasms
The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology.
Neoplasms
The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment.
Neoplasms
The role of multi-drug resistance p-glycoprotein in glucocorticoid function: Studies in animals and relevance in humans.
Neoplasms
The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance.
Neoplasms
The role of nuclear Y-box binding protein 1 as a global marker in drug resistance.
Neoplasms
The role of P-glycoprotein (MDR1) polymorphisms and mutations in colorectal cancer.
Neoplasms
The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy.
Neoplasms
The role of p-glycoprotein, glutathione-s-transferase-pi, thymidylate synthase and metallothionein in the expression of differential sensitivities to antitumor agents in human tumor xenografts.
Neoplasms
The role of reduced growth rate in the development of drug resistance of HOB1 lymphoma cells to vincristine.
Neoplasms
The role of systemic chemotherapy in the treatment of kidney cancer.
Neoplasms
The role of Tc-99m sestamibi imaging in predicting clinical response to chemotherapy in lung cancer.
Neoplasms
The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology.
Neoplasms
The role of the multi-drug resistance 1, p53, b cell lymphoma 2, and bcl 2-associated X genes in the biologic behavior and chemotherapeutic resistance of canine transmissible venereal tumors.
Neoplasms
The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome.
Neoplasms
The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Neoplasms
The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Neoplasms
The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy.
Neoplasms
The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.
Neoplasms
The SMAC mimetic LCL161 is a direct ABCB1/MDR1-ATPase activity modulator and BIRC5/Survivin expression down-regulator in cancer cells.
Neoplasms
The small GTPases Rab5 and RalA regulate intracellular traffic of P-glycoprotein.
Neoplasms
The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study.
Neoplasms
The stabilisation of purified, reconstituted P-glycoprotein by freeze drying with disaccharides.
Neoplasms
The structure of the human ABC transporter ABCG2 reveals a novel mechanism for drug extrusion.
Neoplasms
The structure of the multidrug resistance protein 1 (MRP1/ABCC1). crystallization and single-particle analysis.
Neoplasms
The synthetic ajoene analog SPA3015 induces apoptotic cell death through crosstalk between NF-?B and PPAR? in multidrug-resistant cancer cells.
Neoplasms
The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance.
Neoplasms
The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.
Neoplasms
The tissue dependent expression of hamster P-glycoprotein genes.
Neoplasms
The tissue transglutaminase: a potential target regulating MDR in breast cancer.
Neoplasms
The translocation mechanism of P-glycoprotein.
Neoplasms
The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker.
Neoplasms
The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2.
Neoplasms
The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1).
Neoplasms
The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Neoplasms
The Use of MR Perfusion Imaging in the Evaluation of Tumor Progression in Gliomas.
Neoplasms
The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.
Neoplasms
The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy.
Neoplasms
The value of Tc-99m-tetrofosmin scintigraphy in the assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors.
Neoplasms
The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
Neoplasms
Theoretical insights on helix repacking as the origin of P-glycoprotein promiscuity.
Neoplasms
Theoretical studies on 1,4-dihydropyridine derivatives as P-glycoprotein allosteric inhibitors: insights on symmetry and stereochemistry.
Neoplasms
Theranostic Nanoprobe Mediated Simultaneous Monitoring and Inhibition of P-Glycoprotein Potentiating Multidrug-Resistant Cancer Therapy.
Neoplasms
Therapeutic approach to drug resistant tumors.
Neoplasms
Therapeutic Effect of Cabazitaxel and Blood-Brain Barrier opening in a Patient-Derived Glioblastoma Model.
Neoplasms
Therapeutic Nanoparticles Based on Curcumin and Bamboo Charcoal Nanoparticles for Chemo-Photothermal Synergistic Treatment of Cancer and Radioprotection of Normal Cells.
Neoplasms
Therapeutic Targeting of MDR1 Expression by ROR? Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs.
Neoplasms
Therapy-relevant aberrant expression of MRP3 and BCRP mRNA in TCC-/SCC-bladder cancer tissue of untreated patients.
Neoplasms
Thermosensitivity of multidrug-resistant human gastric and pancreatic carcinoma cells.
Neoplasms
Thioridazine induces apoptosis of multidrug-resistant mouse lymphoma cells transfected with the human ABCB1 and inhibits the expression of P-glycoprotein.
Neoplasms
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds.
Neoplasms
Three steps to cancer: how phosphorylation of tubulin, tubulin tyrosine ligase and P-glycoprotein may generate and sustain cancer.
Neoplasms
Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state.
Neoplasms
Thyroid hormone and P-glycoprotein in tumor cells.
Neoplasms
Tissue distribution and chemical induction of multiple drug resistance genes in rats.
Neoplasms
Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.
Neoplasms
Tissue distribution of the multidrug resistance protein.
Neoplasms
Tissue selective drug delivery utilizing carrier-mediated transport systems.
Neoplasms
Tissue-specific enhancer of the human multidrug-resistance (MDR1) gene.
Neoplasms
Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.
Neoplasms
TNF activates P-glycoprotein in cerebral microvascular endothelial cells.
Neoplasms
TNF-? Modulates P-Glycoprotein Expression and Contributes to Cellular Proliferation via Extracellular Vesicles.
Neoplasms
TNF? and TGF?-1 synergistically increase the cancer stem cell properties of MiaPaCa-2 cells.
Neoplasms
Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity.
Neoplasms
Tomato lectin labels the 180 kD glycoform of P-glycoprotein in rat brain capillary endothelia and mdr tumor cells.
Neoplasms
Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling.
Neoplasms
Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic.
Neoplasms
Topological determinants of internal transmembrane segments in P-glycoprotein sequences.
Neoplasms
Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody.
Neoplasms
Topotecan is a substrate for multidrug resistance associated protein 4.
Neoplasms
Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity.
Neoplasms
Total synthesis of (-)-4-hydroxyzinowol.
Neoplasms
Total synthesis of dendroamide A, a novel cyclic peptide that reverses multiple drug resistance.
Neoplasms
Total synthesis of natural and non-natural ?(5,6)?(12,13)-jatrophane diterpenes and their evaluation as MDR modulators.
Neoplasms
Toward a better pharmacophore description of P-glycoprotein modulators, based on macrocyclic diterpenes from Euphorbia species.
Neoplasms
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
Neoplasms
TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy.
Neoplasms
TPGS-stabilized NaYbF4:Er upconversion nanoparticles for dual-modal fluorescent/CT imaging and anticancer drug delivery to overcome multi-drug resistance.
Neoplasms
Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Neoplasms
Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin.
Neoplasms
TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases.
Neoplasms
Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
Neoplasms
Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants.
Neoplasms
Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotype.
Neoplasms
Transcription of the multidrug resistance gene MDR1: a therapeutic target.
Neoplasms
Transcriptional regulation of ABC drug transporters.
Neoplasms
Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.
Neoplasms
Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Neoplasms
Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.
Neoplasms
Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia.
Neoplasms
Transferrin receptor-targeted redox/pH-sensitive podophyllotoxin prodrug micelles for multidrug-resistant breast cancer therapy.
Neoplasms
Transforming growth factor-? decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells.
Neoplasms
Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells.
Neoplasms
Translational role of natural coumarins and their derivatives as anticancer agents.
Neoplasms
Transmembrane aromatic amino acid distribution in P-glycoprotein. A functional role in broad substrate specificity.
Neoplasms
Transmembrane inhibitors of P-glycoprotein, an ABC transporter.
Neoplasms
Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence.
Neoplasms
Transmembrane orientation and topogenesis of the third and fourth membrane-spanning regions of human P-glycoprotein (MDR1).
Neoplasms
Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function.
Neoplasms
Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
Neoplasms
Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.
Neoplasms
Transport of glutathione and glutathione conjugates by MRP1.
Neoplasms
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.
Neoplasms
Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid.
Neoplasms
Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP.
Neoplasms
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Neoplasms
Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells.
Neoplasms
Transport studies of doxorubicin in model membranes indicate a difference in passive diffusion across and binding at the outer and inner leaflets of the plasma membrane.
Neoplasms
Transporter gene expression in human head and neck squamous cell carcinoma and associated epigenetic regulatory mechanisms.
Neoplasms
Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors.
Neoplasms
Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia.
Neoplasms
Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease.
Neoplasms
Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease.
Neoplasms
Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549/DDP xenograft tumors.
Neoplasms
Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution.
Neoplasms
Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin.
Neoplasms
Tributyltin and triphenyltin exposure promotes in vitro adipogenic differentiation but alters the adipocyte phenotype in rainbow trout.
Neoplasms
Trichoblastic carcinoma ("malignant trichoblastoma") with lymphatic and hematogenous metastases.
Neoplasms
Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer.
Neoplasms
Triggering of Suicidal Erythrocyte Death by Zosuquidar.
Neoplasms
Triple negative breast cancer development can be selectively suppressed by sustaining an elevated level of cellular cyclic AMP through simultaneously blocking its efflux and decomposition.
Neoplasms
Trisindoline synthesis and anticancer activity.
Neoplasms
Triterpenes and Phenolic Compounds from the Fungus Fuscoporia torulosa: Isolation, Structure Determination and Biological Activity.
Neoplasms
Triterpenoids from Momordica balsamina with a Collateral Sensitivity Effect for Tackling Multidrug Resistance in Cancer Cells.
Neoplasms
Triterpenoids with modified A-ring as modulators of P-gp-dependent drug-resistance in cancer cells.
Neoplasms
TRPC5 mediates TMZ resistance in TMZ-resistant glioblastoma cells via NFATc3-P-gp pathway.
Neoplasms
Tubulin polymerizing activity of dictyostatin-1, a polyketide of marine sponge origin.
Neoplasms
Tubulin-?-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
Neoplasms
Tumor cell resistance to topoisomerase II poisons: role for intracellular free calcium in the sensitization by inhibitors or calcium-calmodulin-dependent enzymes.
Neoplasms
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.
Neoplasms
Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
Neoplasms
Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.
Neoplasms
Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1.
Neoplasms
Tumor endothelial expression of P-glycoprotein upon microvesicular transfer of TrpC5 derived from adriamycin-resistant breast cancer cells.
Neoplasms
Tumor formation and drug resistance properties of human glioblastoma side population cells.
Neoplasms
Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier.
Neoplasms
Tumor necrosis factor alpha increases P-glycoprotein expression in a BME-UV in vitro model of mammary epithelial cells.
Neoplasms
Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP.
Neoplasms
Tumor necrosis factor-alpha and lymphotoxin-alpha increase macrophage ABCA1 by gene expression and protein stabilization via different receptors.
Neoplasms
Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer.
Neoplasms
Tumor proliferative compartment, multidrug resistance gene product and apoptosis regulatory p53 and bcl-2 proteins in pediatric acute lymphoblastic leukemia.
Neoplasms
Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma.
Neoplasms
Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells.
Neoplasms
Tumor-specific expression of anti-mdr1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cells.
Neoplasms
Tumor-targeted hybrid protein oxygen carrier to simultaneously enhance hypoxia-dampened chemotherapy and photodynamic therapy at a single dose.
Neoplasms
Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance.
Neoplasms
Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA.
Neoplasms
Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.
Neoplasms
Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance.
Neoplasms
Twist Confers Chemoresistance to Anthracyclines in Bladder Cancer through Upregulating P-Glycoprotein.
Neoplasms
Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression.
Neoplasms
Two novel genes FIND and LIND differentially expressed in deactivated and Listeria-infected human macrophages.
Neoplasms
Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin.
Neoplasms
Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein.
Neoplasms
Tyrosine and phenylalanine restriction sensitizes adriamycin-resistant P388 leukemia cells to adriamycin.
Neoplasms
Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.
Neoplasms
Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.
Neoplasms
Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp.
Neoplasms
Tyrosine Kinase Inhibitors Influence ABCG2 Expression in EGFR-Positive MDCK BCRP Cells via the PI3K/Akt Signaling Pathway.
Neoplasms
Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.
Neoplasms
Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2.
Neoplasms
UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs.
Neoplasms
Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Neoplasms
UMMS-4 enhanced sensitivity of chemotherapeutic agents to ABCB1-overexpressing cells via inhibiting function of ABCB1 transporter.
Neoplasms
Understanding dihydro-?-agarofuran sesquiterpenes from Tripterygium hypoglaucum as the modulators of multi-drug resistance in HepG2/Adr cells.
Neoplasms
Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane.
Neoplasms
Unshielding Multidrug Resistant Cancer through Selective Iron Depletion of P-Glycoprotein-Expressing Cells.
Neoplasms
Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
Neoplasms
Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells.
Neoplasms
Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells.
Neoplasms
Up-regulation of connexin 32 gene by 5-aza-2'-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling.
Neoplasms
Up-regulation of drug resistance-related vaults during dendritic cell development.
Neoplasms
Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.
Neoplasms
Up-regulation of resistance-related proteins in human lung tumors with poor vascularization.
Neoplasms
Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway.
Neoplasms
Upregulation of breast cancer resistance protein and major vault protein in drug resistant epilepsy.
Neoplasms
Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.
Neoplasms
Upregulation of the expression of endogenous Mdr1 P-glycoprotein enhances lipid translocation in MDCK cells transfected with human MRP2.
Neoplasms
Uptake of compounds that selectively kill multidrug-resistant cells: the copper transporter SLC31A1 (CTR1) increases cellular accumulation of the thiosemicarbazone NSC73306.
Neoplasms
Uptake of drugs and expression of P-glycoprotein in the rat 9L glioma.
Neoplasms
Use of membrane vesicles to investigate drug interactions with transporter proteins, P-glycoprotein and multidrug resistance-associated protein.
Neoplasms
Use of recombinant P-glycoprotein fragments to produce antibodies to the multidrug transporter.
Neoplasms
Use of the anionic dye carboxy-2',7'-dichlorofluorescein for sensitive flow cytometric detection of multidrug resistance-associated protein activity.
Neoplasms
Usefulness of 99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer.
Neoplasms
Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles.
Neoplasms
USP24 promotes drug resistance during cancer therapy.
Neoplasms
Utility of Magnetic Resonance Perfusion Imaging in Quantifying Active Tumor Fraction and Radiation Necrosis in Recurrent Intracranial Tumors.
Neoplasms
Validation of a single point flow cytometric assay for determining P-glycoprotein activity in multidrug resistant cell lines.
Neoplasms
Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells.
Neoplasms
Valspodar-modulated chemotherapy in human ovarian cancer cells SK-OV-3 and MDAH-2774.
Neoplasms
Valspodar: current status and perspectives.
Neoplasms
Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
Neoplasms
Van der Waals force-driven indomethacin-ss-paclitaxel nanodrugs for reversing multidrug resistance and enhancing NSCLC therapy.
Neoplasms
Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function.
Neoplasms
Variable effects of sodium butyrate on the expression and function of the MDR1 (P-glycoprotein) gene in colon carcinoma cell lines.
Neoplasms
Variable expression of P-glycoprotein in normal, inflamed, and dysplastic areas in ulcerative colitis.
Neoplasms
Varied clinical significance of ATP-binding cassette C sub-family members for lung adenocarcinoma.
Neoplasms
Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies.
Neoplasms
Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.
Neoplasms
Verapamil and cyclosporin A sensitize human kidney tumor cells to vincristine in absence of membrane P-glycoprotein and without apparent changes in the cytoplasmic free Ca2+ concentration.
Neoplasms
Verapamil competes with doxorubicin for binding to anionic phospholipids resulting in increased internal concentrations and rates of passive transport of doxorubicin.
Neoplasms
Verapamil enhances the sensitivity of oxaliplatin to tumor cells by influencing the PARP pathway.
Neoplasms
Verapamil metabolites: potential P-glycoprotein-mediated multidrug resistance reversal agents.
Neoplasms
Verapamil modulation of multidrug resistance in renal cell carcinoma.
Neoplasms
Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1).
Neoplasms
Virtual screening of ABCC1 transporter nucleotidebinding domains as a therapeutic target in multidrug resistant cancer.
Neoplasms
Visualization of multidrug resistance in vivo.
Neoplasms
Voacamine, a bisindolic alkaloid from Peschiera fuchsiaefolia, enhances the cytotoxic effect of doxorubicin on multidrug-resistant tumor cells.
Neoplasms
Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells.
Neoplasms
Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein.
Neoplasms
Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Neoplasms
VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters.
Neoplasms
Wallichinine reverses ABCB1-mediated cancer multidrug resistance.
Neoplasms
Water-soluble inhibitors of ABCG2 (BCRP) - A fragment-based and computational approach.
Neoplasms
What is the precise role of human MDR 1 protein in chemotherapeutic drug resistance?
Neoplasms
What is the relationship between P-glycoprotein and adhesion molecule expression in melanoma cells?
Neoplasms
Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Neoplasms
Wilforine resensitizes multidrug resistant cancer cells via competitive inhibition of P-glycoprotein.
Neoplasms
Wnt pathway activation and ABCB1 expression account for attenuation of Proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.
Neoplasms
Wnt/?-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
Neoplasms
Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/?-catenin pathway.
Neoplasms
Wogonin potentiates the antitumor action of etoposide and ameliorates its adverse effects.
Neoplasms
Woodchuck p-glycoprotein found in virus-induced hepatocellular carcinomas binds anticancer drugs.
Neoplasms
Xanthine oxidase inhibitory activity and antihyperuricemic effect of Moringa oleifera Lam. leaf hydrolysate rich in phenolics and peptides.
Neoplasms
Xanthines Down-Regulate the Drug Transporter ABCG2 and Reverse Multidrug Resistance.
Neoplasms
Xenobiotic transport differences in mouse mesangial cell clones expressing mdr1 and mdr3.
Neoplasms
XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
Neoplasms
Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
Neoplasms
YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells.
Neoplasms
YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
Neoplasms
Yeast ATP-Binding Cassette Transporters Conferring Multidrug Resistance.
Neoplasms
YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting.
Neoplasms
YQ36: a novel bisindolylmaleimide analogue induces KB/VCR cell death.
Neoplasms
ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein.
Neoplasms
Zhankuic Acids A, B and C from Taiwanofungus Camphoratus Act as Cytotoxicity Enhancers by Regulating P-Glycoprotein in Multi-Drug Resistant Cancer Cells.
Neoplasms
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells.
Neoplasms
Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.
Neoplasms
Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).
Neoplasms
[(11)C]Sorafenib: Radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice.
Neoplasms
[Antitumor drugs and potentiators aiming circumvention of drug resistance]
Neoplasms
[Association of the ABCB1 gene with risk for uveal melanoma].
Neoplasms
[Chemosensitivity of mdr1 gene overexpressed multidrug resistant cancer cells to lidamycin]
Neoplasms
[Clinical analysis of 12 cases of acute myeloid leukemia complicated with synchronous primary solid tumor].
Neoplasms
[Correlation between 99m Tc-tetrofosmin uptake and P-glycoprotein expression in non-small-cell lung cancer]
Neoplasms
[Correlation between uptake of 99Tcm-MIBI and expression of multidrug resistant protein in breast cancer]
Neoplasms
[Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Neoplasms
[Correlation of the uptake of technetium-99m methoxyisobutyl isonitrile with expression of multidrug resistance genes mdr-1 and MRP in human lung cancer]
Neoplasms
[Development of drugs to overcome drug resistance--basic approaches]
Neoplasms
[Differential expressions of MDR-1, RRM-1, EGFR and ERCC-1 in primary tumors and metastatic lymph nodes of NSCLC patients].
Neoplasms
[Drug resistance of malignant melanoma. Mechanisms and possible modulation]
Neoplasms
[Drug sensitivity panel of human cancers transplanted in nude mice]
Neoplasms
[Effects of compound Zhe-Bei granule (CZBG) combined with doxorubicin on expression of membrane transport proteins in K562/A02 cell xenografts]
Neoplasms
[Effects of functional inhibition of p-glycoprotein on radiosensitivity of drug-resistant MCF-7/Adr tumor cells]
Neoplasms
[Effects of hypoxia on expression of P-glycoprotein and multidrug resistance protein in human lung adenocarcinoma A549 cell line]
Neoplasms
[Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16, and their synergistic modulation of multidrug resistance]
Neoplasms
[Expression and clinical implication of multidrug resistance gene and multidrug resistant-associated protein gene in patients with hypopharyngeal squamous cell carcinoma]
Neoplasms
[Expression and Clinical Significance of ABCC10 in the Patients with Non-small Cell Lung Cancer.]
Neoplasms
[Expression and implication of multidrug resistance associated -protein gene in primary hepatocellular carcinoma]
Neoplasms
[Expression and prognostic significance of multidrug resistance associated protein (MRP) gene in non-small cell lung cancer by in situ hybridization]
Neoplasms
[Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma]
Neoplasms
[Expression of anti-apoptotic and multi-drug resistance-associated protein genes in cancer stem cell isolated from TJ905 glioblastoma multiforme cell line]
Neoplasms
[Expression of ATP-binding cassette transporter ABCG2 in gastric carcinoma and its significance]
Neoplasms
[Expression of breast cancer resistance protein and p-glycoprotein in residual breast cancer tissue after chemotherapy and its correlation with cancer stem cells].
Neoplasms
[Expression of glutathione S-transferase, P-glycoprotein, and multidrug resistance-associated protein in neuroblastoma and its clinical significance]
Neoplasms
[Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance]
Neoplasms
[Expression of MRP gene in non-small cell lung cancer and its significance.]
Neoplasms
[Expression of multidrug resistance-associated protein (MRP) and lung resistance protein (LRP) in human rectal carcinomas and its clinical significance]
Neoplasms
[Expression of multidrug resistance-associated protein gene in non-small cell lung cancer]
Neoplasms
[Expression of multidrug resistance-associated protein in human non-small cell lung cancer]
Neoplasms
[Expression of P-glycoprotein (multidrug-resistance gene product) in haematological tumors]
Neoplasms
[Expression of P-glycoprotein 170 (GP 170) and drug resistance in human cancers]
Neoplasms
[Expression of P-glycoprotein as a multidrug resistance gene product in human reactive astrocytes and astrocytoma]
Neoplasms
[Expression of p-glycoprotein in malignant solid human tumors]
Neoplasms
[Functional activity of ABC transporters (markers of multidrug resistance) in human colon adenocarcinoma and normal colonic mucosa]
Neoplasms
[How do cancers resist to chemotherapy?]
Neoplasms
[Hydrophilic regulator hexapeptides as inhibitors of tumor cell multiple drug resistance]
Neoplasms
[Immunohistochemical detection of carcinoembryonic antigen and P-glycoprotein in small cell lung cancer at diagnosis and relapse, with special reference to the tissue expression of CEA and response to chemotherapy]
Neoplasms
[Inhibition of ABC-transporter(s)' function in non-small cell lung cancer cells by platinum drugs]
Neoplasms
[Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].
Neoplasms
[Intravesical instillation of combined adriamycin and verapamil in preventing recurrence of superficial bladder tumor]
Neoplasms
[Isolation and Biological Characterization of Lung Cancer Stem Cells].
Neoplasms
[Malignant adenoma of the cervix: a diagnostic and therapeutic dilemma]
Neoplasms
[MDR (Multiple Drug Resistant) type of resistance to chemotherapy in clinical practice]
Neoplasms
[Mechanism of multidrug resistant tumors and chemotherapeutic approaches against the resistant tumors]
Neoplasms
[Multidrug resistance (MDR) in oncology]
Neoplasms
[Multidrug resistance in acute leukemia]
Neoplasms
[Multidrug resistance of cancer cells mediated by ABC superfamily transporters]
Neoplasms
[Multidrug resistance of testicular cancers. (Detection of P-glycoprotein and MDR1 gene expression and their clinical connection)]
Neoplasms
[Multidrug resistance protein (MRP)]
Neoplasms
[Multidrug resistance]
Neoplasms
[New deafness gene: Progress of research on ABCC1 in biological barriers].
Neoplasms
[Overcoming of multidrug resistance and its clinical application]
Neoplasms
[Overcoming of multidrug resistance by anti-P-glycoprotein monoclonal antibody]
Neoplasms
[P-glycoprotein expression in hematological malignancies]
Neoplasms
[P-glycoprotein inhibition by macrolide antibiotics: The effects on resistance of cancer cells to antineoplastic agents and pharmacokinetics of the agents as P-glycoprotein substrate]
Neoplasms
[P-glycoprotein, a membrane pump that represents a barrier to chemotherapy in cancer patients]
Neoplasms
[Physiologic function of P-glycoprotein]
Neoplasms
[Polymerase chain reaction in diagnostic pathology]
Neoplasms
[Predictive markers for platinum-based chemotherapy]
Neoplasms
[Progression on Multifunctional Nanoparticles Interfering with Cell Membrane Transporters-associated Drug Resistance].
Neoplasms
[Recent advance in the mechanism study of polymeric inhibitors of P-glycoprotein].
Neoplasms
[Relationship between the expression of P-glycoprotein, glutathione S-transferase-pi and thymidylate synthase proteins and adenosine triphosphate tumor chemosensitivity assay in cervical cancer]
Neoplasms
[Reversal effect of haloperidol on doxorubicin resistance and chloride channel inhibition in erythroleukemic cell K562/Dox]
Neoplasms
[Reversing multidrug resistance in breast cancer cell line MCF-7/ADR by small interfering RNA.]
Neoplasms
[Routine chemotherapeutic drug treatment effectiveness predictive molecules and chemotherapeutic drug selection]
Neoplasms
[Structures and functions of xenobiotic efflux pump P-glycoprotein and MRP--important molecular targets for cancer chemotherapy]
Neoplasms
[Study of P-glycoprotein effect on the lipid monolayer properties by the Langmuir-Blodgett technique]
Neoplasms
[Study of pulmonary lesions with (99m)Tc-Tetrafosmin and chest spect. Determination of uptake related factors, diagnostic value and prognosis]
Neoplasms
[Study of the invasiveness and tumour formation of Bcrp1(+) HeLa cervical cancer cells].
Neoplasms
[Study on the relationship among multidrug resistance factor expression of lung cancer tissues and clinicopathological characteristics in patients with lung cancer.]
Neoplasms
[The clinical value of the 99Tcm-MIBI imaging in predicting the prognosis of malignant lymphoma]
Neoplasms
[The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].
Neoplasms
[The correlation between P-glycoprotein and multidrug resistance of squamous carcinoma in oral and maxillofacial region]
Neoplasms
[The correlation of multidrug resistance phenotype with clinical response to chemotherapy in laryngeal cancer]
Neoplasms
[The expression of MRP gene relates to the pathological features of lung cancer]
Neoplasms
[The expression of multiple drug resistance associated genes in ovarian cancer]
Neoplasms
[The predictive factors for the response to platinum/paclitaxel based first-line adjuvant chemotherapy in advanced ovarian cancer]
Neoplasms
[The prevalence of cytostatic-resistant lung tumors in smokers]
Neoplasms
[The role of P-glycoprotein in the liver]
Neoplasms
[Transcriptional regulation of breast cancer resistance protein].
Neoplasms
[Value of rhodamine 123 in the detection of minor amounts of multidrug resistant cells]
Neoplasms
¹?FDG a PET tumor diagnostic tracer is not a substrate of the ABC transporter P-glycoprotein.
Neoplasms, Germ Cell and Embryonal
MRP expression of testicular cancers and its clinical relevance.
Neoplasms, Squamous Cell
[The expression of MRP gene relates to the pathological features of lung cancer]
Nephritis, Hereditary
Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport Syndrome.
Nephrocalcinosis
Toxicological effects of dietary Maillard reaction products in the rat.
Nephrolithiasis
ABCG2 gene polymorphism rs2231142 is associated with gout comorbidities but not allopurinol response in primary gout patients of a Chinese Han male population.
Nephrolithiasis
Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study.
Nephrosis
Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model.
Nephrotic Syndrome
A PRISMA-compliant meta-analysis of MDR1 polymorphisms and idiopathic nephrotic syndrome: Susceptibility and steroid responsiveness.
Nephrotic Syndrome
ABCB1 polymorphisms and steroid treatment in children with idiopathic nephrotic syndrome.
Nephrotic Syndrome
Differential alteration in peripheral T-regulatory and T-effector cells with change in P-glycoprotein expression in Childhood Nephrotic Syndrome: A longitudinal study.
Nephrotic Syndrome
Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms.
Nephrotic Syndrome
Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome.
Nephrotic Syndrome
Expression of multidrug resistance P-glycoprotein on lymphocytes from nephrotic children treated with cyclosporine A and ACE-inhibitor.
Nephrotic Syndrome
Expression of P-glycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response.
Nephrotic Syndrome
Expression of P-glycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids.
Nephrotic Syndrome
Impact of CYP3A4/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome.
Nephrotic Syndrome
MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children.
Nephrotic Syndrome
Overexpression of P-glycoprotein and MRP-1 are pharmacogenomic biomarkers to determine steroid resistant phenotype in childhood idiopathic nephrotic syndrome.
Nephrotic Syndrome
P-Glycoprotein Activity in Steroid-Responsive vs. Steroid-Resistant Nephrotic Syndrome.
Nephrotic Syndrome
Reciprocal Relationship Between HDAC2 and P-Glycoprotein/MRP-1 and Their Role in Steroid Resistance in Childhood Nephrotic Syndrome.
Nephrotic Syndrome
Soluble interleukine-2 receptor and MDR1 gene expression levels as inflammatory biomarkers for prediction of steroid response in children with nephrotic syndrome.
Nephrotic Syndrome
The relationship between renal P-glycoprotein expression and response to steroid therapy in childhood nephrotic syndrome.
Nephrotic Syndrome
Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistance to corticosteroids and calcineurin inhibitors.
Nervous System Diseases
Adenoassociated Virus Serotype 9-Mediated Gene Therapy for X-Linked Adrenoleukodystrophy.
Nervous System Diseases
Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.
Nervous System Diseases
Evaluation of [18F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood-brain barrier in rats: Kinetics, metabolism, and selectivity.
Nervous System Diseases
Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease.
Nervous System Diseases
Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.
Neural Tube Defects
MARCKS: a case of molecular exaptation?
Neuralgia
A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C).
Neuralgia
Mechanism for Increased Expression of UGT2B in the Liver of Mice with Neuropathic Pain.
Neuralgia
Sulfasalazine alleviates neuropathic pain hypersensitivity in mice through inhibition of SGK-1 in the spinal cord.
Neuralgia
[Altered expression of transporter and analgesic of morphine in neuropathic pain mice].
Neuralgia
[Desvenlafaxine and neuropathic pain: additional clinical benefits of a second generation serotonin-noradrenaline reuptake inhibitor].
Neuroblastoma
1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine.
Neuroblastoma
3?-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity.
Neuroblastoma
A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow.
Neuroblastoma
ABC transporters and neuroblastoma.
Neuroblastoma
ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance.
Neuroblastoma
ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux.
Neuroblastoma
ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript.
Neuroblastoma
Ability of polymer-bound P-glycoprotein inhibitor ritonavir to overcome multidrug resistance in various resistant neuroblastoma cell lines.
Neuroblastoma
Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells.
Neuroblastoma
Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients.
Neuroblastoma
Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide.
Neuroblastoma
Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.
Neuroblastoma
Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
Neuroblastoma
Antibody-drug conjugate efficacy in neuroblastoma - role of payload, resistance mechanisms, target density, and antibody internalization.
Neuroblastoma
Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
Neuroblastoma
BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma.
Neuroblastoma
Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells.
Neuroblastoma
Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines.
Neuroblastoma
Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse.
Neuroblastoma
Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line.
Neuroblastoma
Different sensitivity of neurons and neuroblastoma cells to quercetin treatment.
Neuroblastoma
Differential expression of sphingolipids in P-glycoprotein or multidrug resistance-related protein 1 expressing human neuroblastoma cell lines.
Neuroblastoma
Discrepant flow cytometric expression and function of P-glycoprotein in neuroblastic tumors.
Neuroblastoma
DNA (cytosine) methyltransferase overexpression is associated with acquired drug resistance of murine neuroblastoma cells.
Neuroblastoma
Double impact on P-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells.
Neuroblastoma
Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma.
Neuroblastoma
Expression analysis of multidrug resistance associated genes in neuroblastomas.
Neuroblastoma
Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours.
Neuroblastoma
Expression of MRP and cMOAT in childhood neuroblastomas and malignant liver tumors and its relevance to clinical behavior.
Neuroblastoma
Expression of multidrug resistance-related markers in primary neuroblastoma.
Neuroblastoma
Expression of multidrug resistance-related P-glycoprotein shows good prognosis in neuroblastoma.
Neuroblastoma
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.
Neuroblastoma
Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model.
Neuroblastoma
Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies.
Neuroblastoma
Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma.
Neuroblastoma
Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma.
Neuroblastoma
Expression of the multidrug resistance, MDR1, gene in neuroblastomas.
Neuroblastoma
Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma.
Neuroblastoma
Gangliosides do not affect ABC transporter function in human neuroblastoma cells.
Neuroblastoma
Glutathione S-transferase and P-glycoprotein expressions in neuroblastoma.
Neuroblastoma
HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells.
Neuroblastoma
Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen.
Neuroblastoma
In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin.
Neuroblastoma
Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity.
Neuroblastoma
Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter.
Neuroblastoma
Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.
Neuroblastoma
Measurement of P-glycoprotein expression in human neuroblastoma xenografts using in vitro quantitative autoradiography.
Neuroblastoma
Measurement of P-glycoprotein expression in multidrug-resistant human neuroblastoma cell lines using self-competitive binding assay.
Neuroblastoma
MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells.
Neuroblastoma
Multidrug drug resistance in pediatric sarcomas.
Neuroblastoma
Multidrug resistance in pediatric malignancies.
Neuroblastoma
Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines.
Neuroblastoma
Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors.
Neuroblastoma
MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma.
Neuroblastoma
N-(p-azido-3-[125I]iodophenethyl)spiperone binds to specific regions of P-glycoprotein and another multidrug binding protein, spiperophilin, in human neuroblastoma cells.
Neuroblastoma
Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus.
Neuroblastoma
Nitric oxide control of MYCN expression and multi drug resistance genes in tumours of neural origin.
Neuroblastoma
Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells.
Neuroblastoma
Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors.
Neuroblastoma
P-glycoprotein expression and prognosis of neuroblastoma.
Neuroblastoma
P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma.
Neuroblastoma
Presence of classical multidrug resistance and P-glycoprotein expression in human neuroblastoma cells.
Neuroblastoma
Prognostic relevance of P-glycoprotein expression in breast cancer.
Neuroblastoma
Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53.
Neuroblastoma
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Neuroblastoma
Reversal of C1300 murine neuroblastoma multidrug resistance by cremophorEL, a solvent for cyclosporin A.
Neuroblastoma
Reversal of multidrug resistance-associated protein-mediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin.
Neuroblastoma
Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft.
Neuroblastoma
Reversion of p-glycoprotein mediated multidrug-resistance to vincristine and adriamycin by psc-833, a cyclosporine derivative in human neuroblastoma cell-lines.
Neuroblastoma
Role of the MRP1/ABCC1 multidrug transporter protein in cancer.
Neuroblastoma
Screening to Identify Multidrug Resistance-Associated Protein Inhibitors with Neuroblastoma-Selective Cytotoxicity.
Neuroblastoma
Significance of P-glycoprotein expression in childhood malignant tumors.
Neuroblastoma
Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.
Neuroblastoma
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo.
Neuroblastoma
Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.
Neuroblastoma
Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein.
Neuroblastoma
The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome.
Neuroblastoma
Volume-activated chloride channels in neuroblastoma cells are blocked by the antiestrogen toremifene.
Neuroblastoma
YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting.
Neuroblastoma
[131I]MIBG exports via MRP transporters and inhibition of the MRP transporters improves accumulation of [131I]MIBG in neuroblastoma.
Neuroblastoma
[Expression of glutathione S-transferase, P-glycoprotein, and multidrug resistance-associated protein in neuroblastoma and its clinical significance]
Neuroblastoma
[Inhibition of multidrug resistance related P-gp expression in human neuroblastoma by antisense peptide nucleic acid]
Neuroblastoma
[The prognostic significance of P-glycoprotein in children with acute lymphoblastic leukemia and neuroblastoma]
Neurodegenerative Diseases
A de-novo large deletion of 2.8 kb produced in the ABCD1 gene causing adrenoleukodystrophy disease.
Neurodegenerative Diseases
ABCB1 gene variants as risk factors and modulators of age of onset of demyelinating disease in Mexican patients.
Neurodegenerative Diseases
ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.
Neurodegenerative Diseases
Age-dependent decline of blood-brain barrier P-glycoprotein expression in the canine brain.
Neurodegenerative Diseases
Association studies of several cholesterol-related genes (ABCA1, CETP and LIPC) with serum lipids and risk of Alzheimer's disease.
Neurodegenerative Diseases
Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-Glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis.
Neurodegenerative Diseases
Blood-Brain Barrier and Breast Cancer Resistance Protein: a limit to the therapy of CNS tumors and neurodegenerative diseases.
Neurodegenerative Diseases
Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease.
Neurodegenerative Diseases
Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy.
Neurodegenerative Diseases
Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET.
Neurodegenerative Diseases
Humanization of the Blood-Brain Barrier Transporter ABCB1 in Mice Disrupts Genomic Locus - Lessons from Three Unsuccessful Approaches.
Neurodegenerative Diseases
Medicinal chemistry of acridine and its analogues.
Neurodegenerative Diseases
Modulation and Absorption of Xenobiotics: the Synergistic Role of CYP450 AND P-gp Activities in Cancer and Neurodegenerative Disorders.
Neurodegenerative Diseases
P-Glycoprotein Transport of Neurotoxic Pesticides.
Neurodegenerative Diseases
Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials.
Neurodegenerative Diseases
PET radiotracers for imaging P-glycoprotein: the challenge for early diagnosis in AD.
Neurodegenerative Diseases
Probing multidrug resistance P-glycoprotein transporter activity with SPECT radiopharmaceuticals.
Neurodegenerative Diseases
Radiopharmaceuticals for assessing ABC transporters at the blood-brain barrier.
Neurodegenerative Diseases
Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood-Brain Barrier.
Neurodegenerative Diseases
Synthesis and In Vivo Imaging of N-(3-[(11)C]Methoxybenzyl)-2-(3-Methoxyphenyl)ethylaniline as a Potential Targeting Agent for P-glycoprotein.
Neurodegenerative Diseases
Synthesis, molecular structure, and validation of metalloprobes for assessment of MDR1 P-glycoprotein-mediated functional transport.
Neurodegenerative Diseases
Targeted chemotherapy in drug-resistant tumors, noninvasive imaging of P-glycoprotein-mediated functional transport in cancer, and emerging role of Pgp in neurodegenerative diseases.
Neuroectodermal Tumors
Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes.
Neuroectodermal Tumors, Primitive
Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy.
Neuroectodermal Tumors, Primitive
Multidrug resistance gene expression in pediatric primitive neuroectodermal tumors of the central nervous system.
Neuroectodermal Tumors, Primitive, Peripheral
Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone.
Neuroectodermal Tumors, Primitive, Peripheral
Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy.
Neurofibrosarcoma
Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides.
Neuroinflammatory Diseases
A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain.
Neuroinflammatory Diseases
Neuroinflammation activates Mdr1b efflux transport through NFkappaB: promoter analysis in BBB endothelia.
Neuroinflammatory Diseases
P-glycoprotein activity in the blood-brain barrier is affected by virus-induced neuroinflammation and antipsychotic treatment.
Neuroinflammatory Diseases
P-glycoprotein acts as an immunomodulator during neuroinflammation.
Neuroinflammatory Diseases
T lymphocytes impair P-glycoprotein function during neuroinflammation.
Neuroma, Acoustic
Evidence of progenitor cells in the adult human cochlea: sphere formation and identification of ABCG2.
Neurothekeoma
Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas.
Neurotoxicity Syndromes
Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy.
Neutropenia
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.
Neutropenia
ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.
Neutropenia
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Neutropenia
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Neutropenia
ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia.
Neutropenia
ABCB1-1Delta polymorphism can predict hematologic toxicity in dogs treated with vincristine.
Neutropenia
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Neutropenia
Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach.
Neutropenia
Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy.
Neutropenia
Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers.
Neutropenia
Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
Neutropenia
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
Neutropenia
Clinical and pharmacogenetic factors associated with irinotecan toxicity.
Neutropenia
Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
Neutropenia
Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis.
Neutropenia
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3.
Neutropenia
Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population.
Neutropenia
Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.
Neutropenia
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Neutropenia
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Neutropenia
Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers.
Neutropenia
Individualized pharmacotherapy with paclitaxel.
Neutropenia
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
Neutropenia
Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma.
Neutropenia
Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients.
Neutropenia
Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia.
Neutropenia
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Neutropenia
Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124.
Neutropenia
Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
Neutropenia
Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy.
Neutropenia
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
Neutropenia
Role of UGT1A1*6 in irinogenetics in Asians.
Neutropenia
Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
Neutropenia
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
Neutropenia
[Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients].
Nevus, Pigmented
The chemoresistance gene ABCG2 (MXR/BCRP1/ABCP1) is not expressed in melanomas but in single neuroendocrine carcinomas of the skin.
Niemann-Pick Disease, Type C
Progesterone metabolism in human fibroblasts is independent of P-glycoprotein levels and Niemann-Pick type C disease.
Non-alcoholic Fatty Liver Disease
A novel index including SNPs for the screening of nonalcoholic fatty liver disease among elder Chinese: A population-based study.
Non-alcoholic Fatty Liver Disease
Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.
Non-alcoholic Fatty Liver Disease
Changes in digoxin pharmacokinetics associated with hepatic P-glycoprotein upregulation in rats with non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Serum uric acid and non-alcoholic fatty liver disease in non-diabetic Chinese men.
Non-alcoholic Fatty Liver Disease
The pharmacokinetics of mycophenolic acid in rats with orotic acid induced nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III.
Non-alcoholic Fatty Liver Disease
Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease.
Nutrition Disorders
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.
Obesity
ABCC1 confers tissue-specific sensitivity to cortisol versus corticosterone: A rationale for safer glucocorticoid replacement therapy.
Obesity
Association of a polymorphism of ABCB1 with obesity in Japanese individuals.
Obesity
Association of ABCG2 rs2231142-A allele and serum uric acid levels in male and obese individuals in a Han Taiwanese population.
Obesity
Association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in a Mexican population.
Obesity
ATP-binding cassette transporter A1 (ABCA1) expression in adipose tissue and its modulation with insulin resistance in obesity.
Obesity
Erratum: ATP-Binding Cassette Transporter A1 (ABCA 1) Expression in Adipose Tissue and Its Modulation with Insulin Resistance in Obesity [Corrigendum].
Obesity
Genetic contributors to serum uric acid levels in Mexicans and their effect on premature coronary artery disease.
Obesity
High-density lipoprotein metabolism in human apolipoprotein B(100) transgenic/brown adipose tissue deficient mice: a model of obesity-induced hyperinsulinemia.
Obesity
Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.
Obesity
Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Obesity
Lobular Distribution and Variability in Hepatic ATP Binding Cassette Protein B1 (ABCB1, P-gp): Ontogenetic Differences and Potential for Toxicity.
Obesity
Multidrug resistance-associated protein 4 (Mrp4) is a novel genetic factor in the pathogenesis of obesity and diabetes.
Obesity
Multiple Gouty Tophi with Bone Erosion and Destruction: A Report of an Early-onset Case in an Obese Patient.
Obesity
Myeloid related protein 8/14 levels in children with obstructive sleep apnoea.
Obesity
Oral Morphine Pharmacokinetic in Obesity: The Role of P-Glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 Jejunal Contents and Obesity-Associated Biomarkers.
Obesity
P-glycoprotein dysfunction contributes to hepatic steatosis and obesity in mice.
Obesity
Risperidone-Induced Obesity in Children and Adolescents With Autism Spectrum Disorder: Genetic and Clinical Risk Factors.
Obesity
The ATP-binding cassette transporter A1 R230C variant affects HDL cholesterol levels and BMI in the Mexican population: association with obesity and obesity-related comorbidities.
Obesity
The effect of maternal obesity on the expression and functionality of placental P-glycoprotein: Implications in the individualized transplacental digoxin treatment for fetal heart failure.
Obesity
The impact of insulin on chemotherapeutic sensitivity to 5-fluorouracil in gastric cancer cell lines SGC7901, MKN45 and MKN28.
Obesity
The inhibition of hepatic Pxr-Oatp2 pathway mediating decreased hepatic uptake of rosuvastatin in rats with high-fat diet-induced obesity.
Obesity, Maternal
Corrigendum to "The effect of maternal obesity on the expression and functionality of placental P-glycoprotein: Implications in the individualized transplacental digoxin treatment for fetal heart failure" [Placenta 36 (2015) 1138-1147].
Obesity, Maternal
The effect of maternal obesity on the expression and functionality of placental P-glycoprotein: Implications in the individualized transplacental digoxin treatment for fetal heart failure.
Obesity, Morbid
Effects of an Intensive Inpatient Rehabilitation Program in Elderly Patients with Obesity.
Obstetric Labor, Premature
Glucocorticoid regulation of placental breast cancer resistance protein (Bcrp1) in the mouse.
Oligodendroglioma
ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier.
Oligodendroglioma
Heterogeneity in the expression of markers for drug resistance in brain tumors.
Oligospermia
Adenosine triphosphate-binding cassette superfamily transporter gene expression in severe male infertility.
Opioid-Induced Constipation
Genetic Polymorphisms Associated With Constipation and Anticholinergic Symptoms in Patients Receiving Clozapine.
Opioid-Induced Constipation
Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling.
Oropharyngeal Neoplasms
Functional role of miR-148a in oropharyngeal cancer: influence on pregnane X receptor and P-glycoprotein expression.
Osteitis
Osteitis in Chronic Rhinosinusitis.
Osteitis
Osteitis is associated with P-glycoprotein overexpression in patients with chronic sinusitis without nasal polyps.
Osteonecrosis
A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Osteonecrosis
ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation.
Osteonecrosis
ABCB1 polymorphisms associated with osteonecrosis of the femeral head.
Osteonecrosis
Aberrant CpG Islands' Hypermethylation of ABCB1 in Mesenchymal Stem Cells of Patients with Steroid-associated Osteonecrosis.
Osteonecrosis
Association of ABCB1 and CYP450 Gene Polymorphisms and their DNA Methylation Status with Steroid-Induced Osteonecrosis of the Femoral Head in the Chinese Population.
Osteonecrosis
Association of ABCB1 C3435T polymorphism with the susceptibility to osteonecrosis of the femoral head: A meta-analysis.
Osteonecrosis
Combination analysis of NOS3, ABCB1 and IL23R polymorphisms with alcohol-induced osteonecrosis of the femoral head risk in Chinese males.
Osteonecrosis
Effects of p-glycoprotein on steroid-induced osteonecrosis of the femoral head.
Osteonecrosis
Genetic association of the P-glycoprotein gene ABCB1 polymorphisms with the risk for steroid-induced osteonecrosis of the femoral head in Chinese population.
Osteonecrosis
Genetic risk factors for glucocorticoid-induced osteonecrosis: A meta-analysis.
Osteonecrosis
P-glycoprotein overexpression in bone marrow-derived multipotent stromal cells decreases the risk of steroid-induced osteonecrosis in the femoral head.
Osteonecrosis
The effects of P-gp and CYP450 modulated by rifampicin on the steroid-induced osteonecrosis of the femoral head.
Osteonecrosis
VEGF, eNOS, and ABCB1 genetic polymorphisms may increase the risk of osteonecrosis of the femoral head.
Osteoporosis
Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone.
Osteoporosis
Influence of diets rich in Maillard reaction products on calcium bioavailability. Assays in male adolescents and in Caco-2 cells.
Osteosarcoma
99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.
Osteosarcoma
A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma.
Osteosarcoma
A possible role for multidrug resistance-associated protein in the secretion of basic fibroblast growth factor by osteogenic sarcoma cell line (MG-63).
Osteosarcoma
ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma.
Osteosarcoma
ABCB1 (C1236T) Polymorphism Affects P-Glycoprotein-Mediated Transport of Methotrexate, Doxorubicin, Actinomycin D, and Etoposide.
Osteosarcoma
ABCB1 (rs1128503) polymorphism and response to chemotherapy in patients with malignant tumors-evidences from a meta-analysis.
Osteosarcoma
Actin organization associated with the expression of multidrug resistant phenotype in osteosarcoma cells and the effect of actin depolymerization on drug resistance.
Osteosarcoma
Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma.
Osteosarcoma
Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling.
Osteosarcoma
Analysis of P-glycoprotein expression in osteosarcoma.
Osteosarcoma
Anticancer effects of zoledronic acid against human osteosarcoma cells.
Osteosarcoma
Arsenic trioxide inhibits the growth of Adriamycin resistant osteosarcoma cells through inducing apoptosis.
Osteosarcoma
Association between P-glycoprotein expression and response to chemotherapy in patients with osteosarcoma: a systematic and meta-analysis.
Osteosarcoma
Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study.
Osteosarcoma
Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209.
Osteosarcoma
CCN2 promotes drug resistance in osteosarcoma by enhancing ABCG2 expression.
Osteosarcoma
Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAAT? axis.
Osteosarcoma
Clinical significance of P-glycoprotein immunohistochemistry and doxorubicin binding assay in patients with osteosarcoma.
Osteosarcoma
Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
Osteosarcoma
Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.
Osteosarcoma
Correlation of IGF1R expression with ABCG2 and CD44 expressions in human osteosarcoma.
Osteosarcoma
Correlation of p-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas. Pilot study.
Osteosarcoma
Detection of tumor stem cell markers in pancreatic carcinoma cell lines.
Osteosarcoma
Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line.
Osteosarcoma
Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line.
Osteosarcoma
Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study.
Osteosarcoma
Effect of ABCB1 polymorphism on the clinical outcome of osteosarcoma patients after receiving chemotherapy.
Osteosarcoma
Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy.
Osteosarcoma
Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells.
Osteosarcoma
Endosialin?expressing bone sarcoma stem?like cells are highly tumor?initiating and invasive.
Osteosarcoma
Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray.
Osteosarcoma
Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Osteosarcoma
Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas.
Osteosarcoma
Expression of P-glycoprotein in high grade osteosarcomas with special emphasis on chondroblastic subtype.
Osteosarcoma
Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome.
Osteosarcoma
Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using (99m)Tc-sestamibi.
Osteosarcoma
High expression of ABCG2 is associated with chemotherapy resistance of osteosarcoma.
Osteosarcoma
Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription.
Osteosarcoma
Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Osteosarcoma
Icariin Enhances Cytotoxicity of Doxorubicin in Human Multidrug-Resistant Osteosarcoma Cells by Inhibition of ABCB1 and Down-Regulation of the PI3K/Akt Pathway.
Osteosarcoma
Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment.
Osteosarcoma
Identification of CBX3 and ABCA5 as Putative Biomarkers for Tumor Stem Cells in Osteosarcoma.
Osteosarcoma
Improving the cytometric detection of doxorubicin resistance in osteosarcoma cells by determining cellular doxorubicin/DNA ratio.
Osteosarcoma
Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma.
Osteosarcoma
Intracellular pH regulation in U-2 OS human osteosarcoma cells transfected with P-glycoprotein.
Osteosarcoma
Involvement of HIF-1? activation in the doxorubicin resistance of human osteosarcoma cells.
Osteosarcoma
Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells.
Osteosarcoma
Is (99m)Tc-MIBI scintigraphy a predictor of response to pre-operative neoadjuvant chemotherapy in Osteosarcoma?
Osteosarcoma
Lack of correlation of functional scintigraphy with (99m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma.
Osteosarcoma
LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1.
Osteosarcoma
Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis.
Osteosarcoma
Long non-coding RNA ROR regulated ABCB1 to induce cisplatin resistance in osteosarcoma by sponging miR-153-3p.
Osteosarcoma
May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.
Osteosarcoma
Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Osteosarcoma
Multidrug resistance and malignancy in human osteosarcoma.
Osteosarcoma
Multidrug resistance mediated by overexpression of P-glycoprotein in human osteosarcoma in vivo.
Osteosarcoma
Multimodal transfer of MDR by exosomes in human osteosarcoma.
Osteosarcoma
Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.
Osteosarcoma
Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma.
Osteosarcoma
Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma.
Osteosarcoma
NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.
Osteosarcoma
Oestrogen-related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB1.
Osteosarcoma
Optimization of irinotecan chronotherapy with P-glycoprotein inhibition.
Osteosarcoma
Osteoblastic differentiation and P-glycoprotein multidrug resistance in a murine osteosarcoma model.
Osteosarcoma
Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1.
Osteosarcoma
P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma.
Osteosarcoma
P-glycoprotein binds to ezrin at amino acid residues 149 through 242 in the ferm domain and plays a key role in the multi-drug resistance of human osteosarcoma.
Osteosarcoma
P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An immunohistochemical study.
Osteosarcoma
P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.
Osteosarcoma
P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy.
Osteosarcoma
P-glycoprotein levels predict poor outcome in patients with osteosarcoma.
Osteosarcoma
P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
Osteosarcoma
P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells.
Osteosarcoma
Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma.
Osteosarcoma
Pioglitazone, an agonist of PPAR?, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Osteosarcoma
Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein.
Osteosarcoma
Pre-treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin.
Osteosarcoma
Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy.
Osteosarcoma
Prognostic factors in bone sarcomas.
Osteosarcoma
Prognostic value of P-glycoprotein in high-grade osteosarcoma.
Osteosarcoma
Quantitative Assessment of the Association between ABC Polymorphisms and Osteosarcoma Response: a Meta-analysis.
Osteosarcoma
Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance.
Osteosarcoma
Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity.
Osteosarcoma
Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma.
Osteosarcoma
Relationship between P-glycoprotein positivity, doxorubicin binding ability and histologic response to chemotherapy in osteosarcomas.
Osteosarcoma
Resistance of mtDNA-depleted cells to apoptosis.
Osteosarcoma
Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma.
Osteosarcoma
Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein.
Osteosarcoma
Sensitizing osteosarcoma stem cells to doxorubicin-induced apoptosis through retention of doxorubicin and modulation of apoptotic-related proteins.
Osteosarcoma
Silencing SATB1 inhibits the malignant phenotype and increases sensitivity of human osteosarcoma U2OS cells to arsenic trioxide.
Osteosarcoma
SMAR1 attenuates the stemness of osteosarcoma cells via through suppressing ABCG2 transcriptional activity.
Osteosarcoma
Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Osteosarcoma
Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1(®) can Overcome Drug Resistance in Osteosarcoma.
Osteosarcoma
The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis.
Osteosarcoma
The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma.
Osteosarcoma
The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells.
Osteosarcoma
Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis.
Osteosarcoma
Ultrastructural features and P-glycoprotein immunolocalization in Saos-2/DX580 multidrug-resistant human osteosarcoma cells.
Osteosarcoma
Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
Osteosarcoma
[Expression of multidrug resistance-associated protein 1 in osteosarcoma and its relationship with clinicopathologic characteristics]
Osteosarcoma
[P-glycoprotein expression in osteosarcoma]
Ototoxicity
Disruption of mdr1a p-glycoprotein gene results in dysfunction of blood-inner ear barrier in mice.
Ototoxicity
Doxorubicin ototoxicity is induced in mice by combination treatment with cyclosporin A.
Ototoxicity
Genetics of cisplatin ototoxicity: confirming the unexplained?
Ototoxicity
Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients.
Ovarian Neoplasms
A new nanostructured carrier design including oil to enhance the pharmaceutical properties of retinoid therapy and its therapeutic effects on chemo-resistant ovarian cancer.
Ovarian Neoplasms
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
Ovarian Neoplasms
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.
Ovarian Neoplasms
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
Ovarian Neoplasms
ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer.
Ovarian Neoplasms
ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel.
Ovarian Neoplasms
ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients.
Ovarian Neoplasms
Aberrant activation of Wnt/catenin signaling and overexpression of ABCG2 contributes to apoptosis down regulation and tumor progression of high grade ovarian cancer.
Ovarian Neoplasms
Activation of LXR?/? by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer.
Ovarian Neoplasms
Adipocytes induce the resistance of ovarian cancer to carboplatin through ANGPTL4.
Ovarian Neoplasms
Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.
Ovarian Neoplasms
An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
Ovarian Neoplasms
Analysis of Over 10,000 Cases Finds No Association between Previously-Reported Candidate Polymorphisms and Ovarian Cancer Outcome.
Ovarian Neoplasms
ATP-binding cassette transporter A7 accelerates epithelial-to-mesenchymal transition in ovarian cancer cells by upregulating the transforming growth factor-? signaling pathway.
Ovarian Neoplasms
Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Ovarian Neoplasms
Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin.
Ovarian Neoplasms
CCL20 Promotes Ovarian Cancer Chemotherapy Resistance by Regulating ABCB1 Expression.
Ovarian Neoplasms
Clinical Significance of ABCB1 Genotyping in Oncology.
Ovarian Neoplasms
Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer.
Ovarian Neoplasms
Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.
Ovarian Neoplasms
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
Ovarian Neoplasms
CRISPR/Cas9, a new approach to successful knockdown of ABCB1/P-glycoprotein and reversal of chemosensitivity in human epithelial ovarian cancer cell line.
Ovarian Neoplasms
Crocin suppresses multidrug resistance in MRP overexpressing ovarian cancer cell line.
Ovarian Neoplasms
Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
Ovarian Neoplasms
Decursin in Angelica gigas Nakai (AGN) Enhances Doxorubicin Chemosensitivity in NCI/ADR-RES Ovarian Cancer Cells via Inhibition of P-glycoprotein Expression.
Ovarian Neoplasms
Design, synthesis and biological evaluation of novel pyrenyl derivatives as anticancer agents.
Ovarian Neoplasms
Detection of drug resistance in human ovarian carcinoma.
Ovarian Neoplasms
Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance.
Ovarian Neoplasms
Detection of tumor stem cell markers in pancreatic carcinoma cell lines.
Ovarian Neoplasms
Disappearance of a metastatic brain tumor and achievement of long-term survival with a good quality of life after a combination of systemic chemotherapy with the P-glycoprotein inhibitor nifedipine in a patient with ovarian cancer.
Ovarian Neoplasms
Downregulated Salt-inducible Kinase 3 Expression Promotes Chemoresistance in Serous Ovarian Cancer via the ATP-binding Cassette Protein ABCG2.
Ovarian Neoplasms
Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Ovarian Neoplasms
Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
Ovarian Neoplasms
Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.
Ovarian Neoplasms
DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells.
Ovarian Neoplasms
Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy.
Ovarian Neoplasms
EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice.
Ovarian Neoplasms
Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.
Ovarian Neoplasms
Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer.
Ovarian Neoplasms
Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma.
Ovarian Neoplasms
Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells.
Ovarian Neoplasms
Expression levels of MRP1, GST-?, and GSK3? in ovarian cancer and the relationship with drug resistance and prognosis of patients.
Ovarian Neoplasms
Expression levels of TUBB3, ERCC1 and P-gp in ovarian cancer tissues and adjacent normal tissues and their clinical significance.
Ovarian Neoplasms
Expression of BAF57 in ovarian cancer cells and drug sensitivity.
Ovarian Neoplasms
Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer.
Ovarian Neoplasms
Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples.
Ovarian Neoplasms
Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers.
Ovarian Neoplasms
Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance.
Ovarian Neoplasms
Functional comparison of single- and double-stranded mdr1 antisense oligodeoxynucleotides in human ovarian cancer cell lines.
Ovarian Neoplasms
Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer.
Ovarian Neoplasms
Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.
Ovarian Neoplasms
GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.
Ovarian Neoplasms
Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
Ovarian Neoplasms
HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
Ovarian Neoplasms
Identification and characterization of ovarian cancer-initiating cells from primary human tumors.
Ovarian Neoplasms
Identification of semaphorin E as a non-MDR drug resistance gene of human cancers.
Ovarian Neoplasms
Impact of ABCB1 Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer.
Ovarian Neoplasms
Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Ovarian Neoplasms
In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Ovarian Neoplasms
Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.
Ovarian Neoplasms
ISG15 suppresses translation of ABCC2 via ISGylation of hnRNPA2B1 and enhances drug sensitivity in cisplatin resistant ovarian cancer cells.
Ovarian Neoplasms
Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids.
Ovarian Neoplasms
Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
Ovarian Neoplasms
mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
Ovarian Neoplasms
MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.
Ovarian Neoplasms
MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1.
Ovarian Neoplasms
MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Ovarian Neoplasms
Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance.
Ovarian Neoplasms
MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2.
Ovarian Neoplasms
Mitochondria P-glycoprotein confers paclitaxel resistance on ovarian cancer cells.
Ovarian Neoplasms
Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides.
Ovarian Neoplasms
Multidrug resistance in ovarian cancer: comparing an immunocytochemical study and ATP-tumor chemosensitivity assay.
Ovarian Neoplasms
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer.
Ovarian Neoplasms
Multiple drug resistance parameter expression in ovarian cancer.
Ovarian Neoplasms
Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression.
Ovarian Neoplasms
NOS1 upregulates ABCG2 expression contributing to DDP chemoresistance in ovarian cancer cells.
Ovarian Neoplasms
Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
Ovarian Neoplasms
Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition.
Ovarian Neoplasms
P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin.
Ovarian Neoplasms
P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.
Ovarian Neoplasms
Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer.
Ovarian Neoplasms
Papers to appear in forthcoming issues
Ovarian Neoplasms
Peptide transport by the multidrug resistance protein MRP1.
Ovarian Neoplasms
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
Ovarian Neoplasms
Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Ovarian Neoplasms
Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
Ovarian Neoplasms
Physcion-8-O-?-d-glucoside interferes with the nuclear factor-?B pathway and downregulates P-glycoprotein expression to reduce paclitaxel resistance in ovarian cancer cells.
Ovarian Neoplasms
Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome.
Ovarian Neoplasms
Polymorphisms of
Ovarian Neoplasms
Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression.
Ovarian Neoplasms
Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.
Ovarian Neoplasms
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
Ovarian Neoplasms
Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.
Ovarian Neoplasms
Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population.
Ovarian Neoplasms
Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expression.
Ovarian Neoplasms
Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles.
Ovarian Neoplasms
SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer.
Ovarian Neoplasms
Targeted nanopore sequencing for the identification of ABCB1 promoter translocations in cancer.
Ovarian Neoplasms
Targeting multidrug-resistant ovarian cancer through estrogen receptor ? dependent ATP depletion caused by hyperactivation of the unfolded protein response.
Ovarian Neoplasms
The ABCB1 3435C?>?T polymorphism influences docetaxel transportation in ovarian cancer.
Ovarian Neoplasms
The effects of crocetin, extracted from saffron, in chemotherapy against the incidence of multiple drug resistance phenotype.
Ovarian Neoplasms
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
Ovarian Neoplasms
TLR4 and NF?B signaling is critical for taxol resistance in ovarian carcinoma cells.
Ovarian Neoplasms
Two multidrug-resistance (ABCB1) gene polymorphisms as prognostic parameters in women with ovarian cancer.
Ovarian Neoplasms
Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1? in vitro.
Ovarian Neoplasms
[Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells]
Ovarian Neoplasms
[Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer]
Ovarian Neoplasms
[Establishment of cisplatin-induced multidrug resistant human epithelial ovarian cancer cell line 3AO/cDDP and its expressions of multidrug resistance proteins]
Ovarian Neoplasms
[Expression of ATP-binding Cassette Proteins Pgp, MRP1, and MRP3 in Malignant and Benign Ovarian Lesions].
Ovarian Neoplasms
[Mdr-1 ribozyme in the reversal of multidrug resistance in human ovarian cancer]
Ovarian Neoplasms
[Study for drug-resistance of epithelial ovarian cancer by serum protein profiling]
Ovarian Neoplasms
[The expression of multiple drug resistance associated genes in ovarian cancer]
Ovarian Neoplasms
[Value of P-glycoprotein and glutathione S-transferase-pi as chemo-resistant indicators in ovarian cancers]
Overweight
ATP-binding cassette transporter G8 gene as a determinant of apolipoprotein B-100 kinetics in overweight men.
Overweight
Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms.
Overweight
Risperidone-Induced Obesity in Children and Adolescents With Autism Spectrum Disorder: Genetic and Clinical Risk Factors.
Overweight
The expression of ATP-binding cassette transporter A1 in Chinese overweight and obese patients.
Pancreatic Diseases
Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients.
Pancreatic Neoplasms
A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines.
Pancreatic Neoplasms
A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.
Pancreatic Neoplasms
ABCC3 is a novel target for the treatment of pancreatic cancer.
Pancreatic Neoplasms
An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.
Pancreatic Neoplasms
ATP-Binding Cassette Genes Genotype and Expression: A Potential Association with Pancreatic Cancer Development and Chemoresistance?
Pancreatic Neoplasms
Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients.
Pancreatic Neoplasms
Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-?1/SMAD2/3 pathway and ABCC1 transactivation.
Pancreatic Neoplasms
Combination Chemotherapy with Itraconazole for Treating Metastatic Pancreatic Cancer in the Second-line or Additional Setting.
Pancreatic Neoplasms
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
Pancreatic Neoplasms
Detection of multidrug resistant gene 1 in pancreatic cancer.
Pancreatic Neoplasms
Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein.
Pancreatic Neoplasms
Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer.
Pancreatic Neoplasms
Fzd7/Wnt7b signaling contributes to stemness and chemoresistance in pancreatic cancer.
Pancreatic Neoplasms
GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways.
Pancreatic Neoplasms
Gastrin regulates ABCG2 to promote the migration, invasion and side populations in pancreatic cancer cells via activation of NF-?B signaling.
Pancreatic Neoplasms
Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients.
Pancreatic Neoplasms
HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
Pancreatic Neoplasms
hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations.
Pancreatic Neoplasms
Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1? and contributes to chemoresistance in pancreatic cancer cells.
Pancreatic Neoplasms
Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis.
Pancreatic Neoplasms
Impact of Breast Cancer Resistance Protein Expression on the In Vitro Efficacy of Anticancer Drugs in Pancreatic Cancer Cell Lines.
Pancreatic Neoplasms
MiR-331-3p Links to Drug Resistance of Pancreatic Cancer Cells by Activating WNT/?-Catenin Signal via ST7L.
Pancreatic Neoplasms
Multidrug transporter MRP4/ABCC4 as a key determinant of pancreatic cancer aggressiveness.
Pancreatic Neoplasms
Multiple Kinase Pathways Involved in the Different De Novo Sensitivity of Pancreatic Cancer Cell Lines to 17-AAG.
Pancreatic Neoplasms
Nestin and other putative cancer stem cell markers in pancreatic cancer.
Pancreatic Neoplasms
NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression.
Pancreatic Neoplasms
Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Pancreatic Neoplasms
P-glycoprotein associated with diabetes mellitus and survival of patients with pancreatic cancer: 8-year follow-up.
Pancreatic Neoplasms
P-glycoprotein expression is induced in human pancreatic cancer xenografts during treatment with a cell cycle regulator, mimosine.
Pancreatic Neoplasms
Pancreatic cancer cells express CD44 variant 9 and multidrug resistance protein 1 during mitosis.
Pancreatic Neoplasms
Pancreatic Carcinoma Cell Lines Reflect Frequency and Variability of Cancer Stem Cell Markers in Clinical Tissue.
Pancreatic Neoplasms
Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells.
Pancreatic Neoplasms
Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.
Pancreatic Neoplasms
Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
Pancreatic Neoplasms
Photodynamic Therapy Using Photosensitizer-Encapsulated Polymeric Nanoparticle to Overcome ATP-Binding Cassette Transporter Subfamily G2 Function in Pancreatic Cancer.
Pancreatic Neoplasms
PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value.
Pancreatic Neoplasms
Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells.
Pancreatic Neoplasms
Prediction of a Side Effect and Efficacy of Adjuvant Chemotherapy with Gemcitabine for Post Operative Patient of Pancreatic Cancer by a Genetic Polymorphism Analysis.
Pancreatic Neoplasms
Protein Arginine Methyltransferase 3 Enhances Chemoresistance in Pancreatic Cancer by Methylating hnRNPA1 to Increase ABCG2 Expression.
Pancreatic Neoplasms
Protein expression of ABCC2 and SLC22A3 associates with prognosis of pancreatic adenocarcinoma.
Pancreatic Neoplasms
Regulation of ABCG2 expression by Wnt5a through FZD7 in human pancreatic cancer cells.
Pancreatic Neoplasms
Reverting chemoresistance of targeted agents by a ultrasoluble dendritic nanocapsule.
Pancreatic Neoplasms
Selective GPR55 antagonism reduces chemoresistance in cancer cells.
Pancreatic Neoplasms
The ABCC4 gene is a promising target for pancreatic cancer therapy.
Pancreatic Neoplasms
The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2.
Pancreatic Pseudocyst
Diagnosis and management of pancreatic fistulae resulting in pancreatic ascites or pleural effusions in the era of helical CT and magnetic resonance imaging.
Pancreatitis
Magnetic resonance pancreatography (MRP).
Pancreatitis
[Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs].
Pancreatitis, Chronic
LY294002 enhances inhibitory effect of gemcitabine on proliferation of human pancreatic carcinoma PANC-1 cells.
Pancreatitis, Chronic
Magnetic resonance pancreatography (MRP).
Pancreatitis, Chronic
[Dynamic pancreatography with magnetic resonance after functional stimulus with secretin in chronic pancreatitis]
Pancytopenia
Colchicine: serious interactions.
Papilloma
Expression of P-glycoprotein is Positively Correlated with p53 in Human Papilloma Virus Induced Squamous Intraepithelial Lesions of Uterine Cervix: Poor Prognosis Association.
Papilloma
Response of mouse skin tumors to doxorubicin is dependent on carcinogen exposure.
Paraganglioma, Extra-Adrenal
Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas.
Paraproteinemias
Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
Paraproteinemias
Simultaneous occurrence of monoclonal gammopathy and acute secondary leukemia with overexpression of P-glycoprotein.
Parasitemia
MRP 8/14 as marker for Plasmodium falciparum-induced malaria episodes in individuals in a holoendemic area.
Parathyroid Neoplasms
Correlation between P-glycoprotein (P-gp) expression in parathyroid and Tc-99m MIBI parathyroid image findings.
Parathyroid Neoplasms
Detecting parathyroid adenoma using technetium-99m tetrofosmin: comparison with P-glycoprotein and multidrug resistance related protein expression--a preliminary report.
Parathyroid Neoplasms
Hypermethylation of adenosine triphosphate-binding cassette transporter genes in primary hyperparathyroidism and its effect on sestamibi imaging.
Parathyroid Neoplasms
Parathyroid adenoma detected with 99mTc-tetrofosmin dual-phase scintigraphy: a case report.
Parathyroid Neoplasms
Preoperative localization of parathyroid adenomas with technetium-99m methoxyisobutylisonitrile imaging: relationship with P-glycoprotein expression, oxyphilic cell content, and tumoral tissue volume.
Parathyroid Neoplasms
Radionuclide imaging of the parathyroid glands.
Parathyroid Neoplasms
Size and P-glycoprotein expression limit 99mTc-tetrofosmin uptake in parathyroid adenomas.
Parathyroid Neoplasms
Size and P-glycoprotein expression limit 99mTC-tetrofosmin uptake in parathyroid adenomas.
Parathyroid Neoplasms
Technetium-99m methoxyisobutylisonitrile imaging for parathyroid adenoma: relationship to P-glycoprotein or multidrug resistance-related protein expression.
Parathyroid Neoplasms
Technetium-99m-sestamibi parathyroid scintigraphy: effect of P-glycoprotein, histology and tumor size on detectability.
Parathyroid Neoplasms
Using technetium 99m tetrofosmin parathyroid imaging to detect parathyroid adenoma and its relation to P-glycoprotein expression.
Paratuberculosis
Identification of the ABCC4, IER3, and CBFA2T2 candidate genes for resistance to paratuberculosis from sequence-based GWAS in Holstein and Normande dairy cattle.
Paresthesia
ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics.
Parkinson Disease
A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.
Parkinson Disease
ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs.
Parkinson Disease
ABCG2 variant has opposing effects on onset ages of Parkinson's disease and gout.
Parkinson Disease
Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat.
Parkinson Disease
Analysis of MDR1 haplotypes in Parkinson's disease in a white population.
Parkinson Disease
Association of a polymorphism in the ABCB1 gene with Parkinson's disease.
Parkinson Disease
Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease.
Parkinson Disease
Brain Endothelial P-Glycoprotein Level Is Reduced in Parkinson's Disease via a Vitamin D Receptor-Dependent Pathway.
Parkinson Disease
Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA.
Parkinson Disease
Enhanced Neuroprotective Effects of Coadministration of Tetrandrine with Glutathione in Preclinical Model of Parkinson's Disease.
Parkinson Disease
Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease.
Parkinson Disease
Genetic association of NOS1 exon18, NOS1 exon29, ABCB1 1236C/T, and ABCB1 3435C/T polymorphisms with the risk of Parkinson's disease: A meta-analysis.
Parkinson Disease
Genetic variability in ABCB1, occupational pesticide exposure, and Parkinson's disease.
Parkinson Disease
Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease.
Parkinson Disease
Modulation and Absorption of Xenobiotics: the Synergistic Role of CYP450 AND P-gp Activities in Cancer and Neurodegenerative Disorders.
Parkinson Disease
Movement-related potentials in high-functioning autism and Asperger's disorder.
Parkinson Disease
Movement-related potentials in Parkinson's disease. Presence and predictability of temporal and spatial cues.
Parkinson Disease
Neuroscience and hormesis: overview and general findings.
Parkinson Disease
Novel and functional ABCB1 gene variant in sporadic Parkinson's disease.
Parkinson Disease
Overlap between Parkinson disease and Alzheimer disease in ABCA7 functional variants.
Parkinson Disease
P-Glycoprotein Transport of Neurotoxic Pesticides.
Parkinson Disease
P-glycoprotein, multidrug-resistance-associated protein and Parkinson's disease.
Parkinson Disease
Pluronic P85/F68 Micelles of Baicalein Could Interfere with Mitochondria to Overcome MRP2-Mediated Efflux and Offer Improved Anti-Parkinsonian Activity.
Parkinson Disease
Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.
Parkinson Disease
[A role of P-glycoprotein in neurology].
Parotid Neoplasms
Multidrug resistance in mucoepidermoid carcinoma of the parotid gland - immunohistochemical investigations of P-glycoprotein expression.
Pemphigoid, Bullous
ABCB1 gene is associated with the risk of bullous pemphigoid in a polish population.
Pemphigoid, Bullous
ABCB1 in dermatology: roles in skin diseases and their treatment.
Pemphigoid, Bullous
Haplotypes of ABCB1 1236C?>T (rs1128503), 2677G?>T/A (rs2032582), and 3435C?>T (rs1045642) in patients with bullous pemphigoid.
Pemphigoid, Bullous
Immunohistochemical expression of epithelial cell markers in corneas with congenital aniridia and ocular cicatrizing pemphigoid.
Pemphigus
Lack of involvement of P-glycoprotein (P-gp) in pemphigus patients with poor response to steroid therapy.
Peptic Ulcer
ABCB1 expression in peptic ulcer patients and its connection with H. pylori Infection.
Peptic Ulcer
ABCG2 in peptic ulcer: gene expression and mutation analysis.
Peptic Ulcer
C3435T polymorphism of the ABCB1 gene: impact on genetic susceptibility to peptic ulcers.
Peptic Ulcer
Investigation of ABCB1 1236 and 2677 SNPs in patients with peptic ulcer.
Pericardial Effusion
A Possible Drug-Drug Interaction Between Eliquis and Amiodarone Resulting in Hemopericardium.
Pericarditis
Pharmacotherapeutic Management Strategies for Thyroid Disease-Induced Pericarditis.
Peripheral Arterial Disease
Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty.
Peripheral Nervous System Diseases
ABCB1 Single Nucleotide Polymorphism Genotypes as Predictors of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer.
Peripheral Nervous System Diseases
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
Peripheral Nervous System Diseases
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Peripheral Nervous System Diseases
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Peripheral Nervous System Diseases
Peripheral neuropathy in mice transgenic for a human MDR3 P-glycoprotein mini-gene.
Peripheral Nervous System Diseases
Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy.
Peripheral Nervous System Diseases
[Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs].
Periprosthetic Fractures
[Titanium modular revision prosthesis stem in revision hip prosthesis]
Peritonitis
Myeloid-related proteins 8 and 14 contribute to monosodium urate crystal-induced inflammation in gout.
Peritonitis
Secondary peritonitis: severity of disease and activation of peritoneal cells.
Peroxisomal Disorders
CRISPR/Cas9-mediated knockout of Abcd1 and Abcd2 genes in BV-2 cells: novel microglial models for X-linked Adrenoleukodystrophy.
Peroxisomal Disorders
Evidence of oxidative stress in very long chain fatty acid--treated oligodendrocytes and potentialization of ROS production using RNA interference-directed knockdown of ABCD1 and ACOX1 peroxisomal proteins.
Persistent Infection
Calcium-binding proteins MRP 8 and 14 in a Staphylococcus aureus infection model: role of therapy, inflammation, and infection persistence.
Peutz-Jeghers Syndrome
Papers to appear in forthcoming issues
Pheochromocytoma
Tc-99m sestamibi imaging as an indicator of P-glycoprotein expression in metastatic pheochromocytoma.
Photosensitivity Disorders
Cytotoxicity determination without photochemical artifacts.
Photosensitivity Disorders
Inhibition of the ATPase activity of P-glycoprotein by porphyrin photosensitization of multidrug-resistant cells in vitro.
Pituitary Neoplasms
Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
Pituitary Neoplasms
Technetium-99m sestamibi single photon emission computed tomography findings correlated with P-glycoprotein expression in pituitary adenoma.
Placenta, Retained
Is there a place for intra-umbilical oxytocin for the management of retained placenta?
Plasmacytoma
Detection of the multidrug resistant phenotype in human tumours by monoclonal antibodies and the streptavidin-biotinylated phycoerythrin complex method.
Pleural Effusion
MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients.
Pleural Effusion
Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Pleural Effusion
Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.
Pleural Neoplasms
Immunohistochemical analysis of pulmonary and pleural tumors with the monoclonal antibody HYB-612 directed against the multidrug resistance (MDR-1) gene product, P-glycoprotein.
Pneumonia
Cigarette smoke extract combined with LPS down-regulates the expression of MRP2 in chronic pulmonary inflammation may be related to FXR.
Pneumonia
Hepatic Warm Ischemia-Reperfusion-Induced Increase in Pulmonary Capillary Filtration Is Ameliorated by Administration of a Multidrug Resistance-Associated Protein 1 Inhibitor and Leukotriene D4 Antagonist (MK-571) Through Reducing Neutrophil Infiltration and Pulmonary Inflammation and Oxidative Stress in Rats.
Pneumonia
Measles associated diarrhea and pneumonia in south India.
Pneumonia
Mice lacking the multidrug resistance protein 1 are resistant to Streptococcus pneumoniae-induced pneumonia.
Pneumonia
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Pneumonia
Relatedness of Streptococcus suis isolates of various serotypes and clinical backgrounds as evaluated by macrorestriction analysis and expression of potential virulence traits.
Pneumonia
Risk of Mycoplasma pneumoniae-related hepatitis in MP pneumonia pediatric patients: a predictive model construction and assessment.
Pneumonia
Virulence-associated gene profiling of Streptococcus suis isolates by PCR.
Polycystic Kidney Diseases
Restoring multidrug resistance-associated protein 3 attenuates cell proliferation in the polycystic kidney.
Polydactyly
Whole genome resequencing reveals an association of ABCC4 variants with preaxial polydactyly in pigs.
Porphyria Cutanea Tarda
Role of ABCB1 and glutathione S-transferase gene variants in the association of porphyria cutanea tarda and human immunodeficiency virus infection.
Porphyrias
Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.
Porphyrias
Role of ABCB1 and glutathione S-transferase gene variants in the association of porphyria cutanea tarda and human immunodeficiency virus infection.
Porphyrias
[Genetic polymorphisms of human ABC transporter ABCG2: Porphyria risk and ER quality control]
Pre-Eclampsia
A Multi-Objective Approach for Drug Repurposing in Preeclampsia.
Pre-Eclampsia
Expression and clinical significance of ATP-binding cassette transporter 1 in serum and placental tissue in Chinese patients with preeclampsia.
Pre-Eclampsia
Low Serum Levels of ABCA1, an ATP-Binding Cassette Transporter, Are Predictive of Preeclampsia.
Pre-Eclampsia
Value of ABCG2 Q141K and Q126X genotyping in predicting risk of preeclampsia in Chinese Han women population.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ABCB1 polymorphism and susceptibility to acute lymphoblastic leukemia: a meta analysis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ABCB1 Polymorphisms and Childhood Acute Lymphoblastic Leukemia Risk: A Meta-Analysis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ABCC4 functional SNP in the 3' splice acceptor site of exon 8 (G912T) is associated with unfavorable clinical outcome in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Association of ABCC2 with levels and toxicity of methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Association of C3435T, C1236T and C4125A Polymorphisms of the MDR-1 Gene in Egyptian Children with Acute Lymphoblastic Leukaemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ATP Binding Cassette C1 (ABCC1/MRP1)-mediated drug efflux contributes to disease progression in T-lineage acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical significance of P-glycoprotein (P-gp) expression in childhood acute lymphoblastic leukemia. Results of a 6-year prospective study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical significance of the ABCB1 and ABCG2 gene expression levels in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Correction: Association of ABCC2 -24C>T Polymorphism with High-Dose Methotrexate Plasma Concentrations and Toxicities in Childhood Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cytogenetic characterization of chromosomal rearrangement in a human vinblastine-resistant CEM cell line: use of comparative genomic hybridization and fluorescence in situ hybridization.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Downregulation of Renal MRPs Transporters in Acute Lymphoblastic Leukemia Mediated by the IL-6/STAT3/PXR Signaling Pathway.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of functional markers in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of genes implicated in multidrug resistance in acute lymphoblastic leukemia in India.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of multidrug resistance-related genes does not contribute to risk factors in newly diagnosed childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of P-glycoprotein, Cyclin D1 and Ki-67 in Acute Lymphoblastic Leukemia: Relation with Induction Chemotherapy and Overall Survival.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of the multidrug resistance-associated P-glycoprotein (P-170) in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of the multidrug transporter P-glycoprotein is highly correlated with clinical outcome in childhood acute lymphoblastic leukemia: results of a long-term prospective study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genotype Analysis of ABCC1, NCF4 and CBR3 Polymorphism and the Association With Childhood Acute Lymphoblastic Leukemia in Mexican Childhood Population.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
High-Throughput Screening for Daunorubicin-Mediated Drug Resistance Identifies Mometasone Furoate as a Novel ABCB1-Reversal Agent.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Impact of ABCB1 Gene (C3435T/A2677G) Polymorphic Sequence Variations on the Outcome of Patients with Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Kashmiri Population: A Case-Control Study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Increased proapoptotic activity of electron beam irradiated doxorubicin and epirubicin in multidrug-resistant human leukemic cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: no evidence of prognostic impact in follow-up.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Liposomal Sphingomyelin Influences the Cellular Lipid Profile of Human Lymphoblastic Leukemia Cells without Effect on P-Glycoprotein Activity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Low incidence of activity of P-glycoprotein (P-170) in de novo acute lymphoblastic leukemia determined by a flow cytometric assay.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mexican Childhood Acute Lymphoblastic Leukemia: A Pilot Study of the MDR1 and MTHFR Gene Polymorphisms and Their Associations with Clinical Outcomes.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Modulation of P-glycoprotein activity by novel synthetic curcumin derivatives in sensitive and multidrug-resistant T-cell acute lymphoblastic leukemia cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multidrug drug resistance in pediatric sarcomas.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multidrug resistance (Mdr1) gene expression in peripheral blasts from patients with acute leukemia only rarely increases during disease progression after combination chemotherapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multidrug resistance in acute leukemia: a conserved physiologic function.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multidrug resistance in pediatric malignancies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multidrug resistance-associated protein 1 predicts relapse in Iranian childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multidrug resistance-associated protein 4 (MRP4) gene polymorphisms and treatment response in adult acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
P-glycoprotein activity predicts outcome in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prognostic value of protein kinase C, proto-oncogene products and resistance-related proteins in newly diagnosed childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Regulations of ABCB1 and ABCG2 expression through MAPK pathways in acute lymphoblastic leukemia cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Rewired metabolism in drug-resistant leukemia cells: A metabolic switch hallmarked by reduced dependence on exogenous glutamine.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Susceptibility to 6-mercaptopurine toxicity related with NUDT15 and ABCC4 variants in Japanese childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The combined analysis of P-glycoprotein expression and activity predicts outcome in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The expression and clinical significance of murine double minute 2, lysosome-associated membrane protein 1, and P-glycoprotein in pediatric acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology Group.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The role of ATP-binding cassette transporter A2 in childhood acute lymphoblastic leukemia multidrug resistance.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Gene expression of breast cancer resistance protein in adult acute lymphocytic leukemia and its clinical significance.]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[P-glycoprotein expression in hematological malignancies]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[The prognostic significance of P-glycoprotein in children with acute lymphoblastic leukemia and neuroblastoma]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[The relationship between expression of lung resistance-related protein gene or multidrug resistance-associated protein gene and prognosis in newly diagnosed acute leukemia]
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Beta1 integrin blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Cytotoxic action of cyclosporins on human tumor cell lines is not dependent on immunosuppressive activity.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases.
Pregnancy Complications
Inter-individual variations and modulators of MDR1 transport activity in human placenta.
Proctitis
Expression of cytochrome P450 and MDR1 in patients with proctitis.
Prostatic Hyperplasia
Expression of the multidrug resistance gene in human prostate cancer.
Prostatic Neoplasms
17-Beta-estradiol induces neoplastic transformation in prostatic epithelial cells.
Prostatic Neoplasms
32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016.
Prostatic Neoplasms
A cell motility screen reveals role for MARCKS-related protein in adherens junction formation and tumorigenesis.
Prostatic Neoplasms
A novel molecular mechanism for a long non-coding RNA PCAT92 implicated in prostate cancer.
Prostatic Neoplasms
ABCA2 transporter deficiency reduces incidence of TRAMP prostate tumor metastasis and cellular chemotactic migration.
Prostatic Neoplasms
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Prostatic Neoplasms
ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
Prostatic Neoplasms
ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro.
Prostatic Neoplasms
Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38.
Prostatic Neoplasms
Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells.
Prostatic Neoplasms
Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells.
Prostatic Neoplasms
Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer.
Prostatic Neoplasms
Androgenic suppression of ATP-binding cassette transporter A1 expression in LNCaP human prostate cancer cells.
Prostatic Neoplasms
Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
Prostatic Neoplasms
Aspirin enhances multidrug resistance gene 1 expression in human Molt-4 T lymphoma cells.
Prostatic Neoplasms
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.
Prostatic Neoplasms
ATP-binding cassette transporter A1: A promising therapy target for prostate cancer.
Prostatic Neoplasms
Blocking mtDNA replication upregulates the expression of stemness-related genes in prostate cancer cell lines.
Prostatic Neoplasms
Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
Prostatic Neoplasms
Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins.
Prostatic Neoplasms
Clinical Significance of ABCB1 Genotyping in Oncology.
Prostatic Neoplasms
Contrasting roles of the ABCG2 Q141K variant in prostate cancer.
Prostatic Neoplasms
Costs of medical care after open or minimally invasive prostate cancer surgery: A population-based analysis.
Prostatic Neoplasms
CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Prostatic Neoplasms
Development of doxorubicin resistant rat prostate cancer cell lines.
Prostatic Neoplasms
Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer.
Prostatic Neoplasms
Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1.
Prostatic Neoplasms
Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
Prostatic Neoplasms
E2F site in the essential promoter region does not confer S phase-specific transcription of the ABCC10 gene in human prostate cancer cells.
Prostatic Neoplasms
Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide.
Prostatic Neoplasms
Effects of Cabazitaxel in Renal Cell Carcinoma Cell Lines.
Prostatic Neoplasms
EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
Prostatic Neoplasms
Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy.
Prostatic Neoplasms
Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.
Prostatic Neoplasms
Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.
Prostatic Neoplasms
Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer.
Prostatic Neoplasms
Expression of the multidrug resistance gene in human prostate cancer.
Prostatic Neoplasms
Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine.
Prostatic Neoplasms
ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro.
Prostatic Neoplasms
Increased ABCC4 Expression Induced by ERR? Leads to Docetaxel Resistance via Efflux of Docetaxel in Prostate Cancer.
Prostatic Neoplasms
Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer.
Prostatic Neoplasms
Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to Chemotherapy.
Prostatic Neoplasms
MR-perfusion (MRP) and diffusion-weighted imaging (DWI) in prostate cancer: Quantitative and model-based gadobenate dimeglumine MRP parameters in detection of prostate cancer.
Prostatic Neoplasms
Multidrug resistance protein 1 localization in lipid raft domains and prostasomes in prostate cancer cell lines.
Prostatic Neoplasms
Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression.
Prostatic Neoplasms
Nanoways to overcome docetaxel resistance in prostate cancer.
Prostatic Neoplasms
New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Prostatic Neoplasms
NOTCH1 signaling promotes chemoresistance via regulating ABCC1 expression in prostate cancer stem cells.
Prostatic Neoplasms
Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer.
Prostatic Neoplasms
P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.
Prostatic Neoplasms
Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate.
Prostatic Neoplasms
Posttranscriptional Regulation of Human Antigen R by miR-133b Enhances Docetaxel Cytotoxicity Through the Inhibition of ATP-Binding Cassette Subfamily G Member 2 in Prostate Cancer Cells.
Prostatic Neoplasms
Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.
Prostatic Neoplasms
Predictors of therapeutic efficacy of 5-aminolevulinic acid-based photodynamic therapy in human prostate cancer.
Prostatic Neoplasms
Prolonged inhibition of P-glycoprotein after exposure to chemotherapeutics increases cell mortality in multidrug resistant cultured cancer cells.
Prostatic Neoplasms
Prostate cancer: Antiandrogens reverse docetaxel resistance via ABCB1 inhibition.
Prostatic Neoplasms
Protein kinase C epsilon mediates the induction of P-glycoprotein in LNCaP prostate carcinoma cells.
Prostatic Neoplasms
PTEN loss-mediated Akt activation increases the properties of cancer stem-like cell populations in prostate cancer.
Prostatic Neoplasms
Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells.
Prostatic Neoplasms
Replication-incompetent gammaretroviral and lentiviral vector-based insertional mutagenesis screens identify prostate cancer progression genes.
Prostatic Neoplasms
Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition.
Prostatic Neoplasms
Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Prostatic Neoplasms
Shikonin enhances the antitumor effect of cabazitaxel in prostate cancer stem cells and reverses cabazitaxel resistance by inhibiting ABCG2 and ALDH3A1.
Prostatic Neoplasms
Targeting MRP4 expression by anti-androgen treatment reverses MRP4-mediated docetaxel resistance in castration-resistant prostate cancer.
Prostatic Neoplasms
The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
Prostatic Neoplasms
The estrogen receptor variants ?2 and ?5 induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling.
Prostatic Neoplasms
The Potential of Flavonolignans in Prostate Cancer Management.
Prostatic Neoplasms
The role of ATP-binding cassette transporter genes in the progression of prostate cancer.
Prostatic Neoplasms
Therapeutic Targeting of MDR1 Expression by ROR? Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs.
Prostatic Neoplasms
Tubulin-Binding 3,5-Bis(styryl)pyrazoles as Lead Compounds for the Treatment of Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
Prostatic Neoplasms
[Expression of AXL enhances docetaxel-resistance of prostate cancer cells].
Protein Deficiency
Synergistic influence of Abcb1 and Abcc2 on disposition and sterol lowering effects of ezetimibe in rats.
Protein-Energy Malnutrition
The suppressed expression and functional activity of hepatic P-glycoprotein in rats with protein-calorie malnutrition.
Proteinuria
Multidrug resistance-associated protein 2 gene (ABCC2) variant in kidney allograft recipients.
Proteinuria
Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney.
Protoporphyria, Erythropoietic
Impaired expression of ATP-binding cassette transporter G2 and liver damage in erythropoietic protoporphyria.
Protoporphyria, Erythropoietic
Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels.
Protoporphyria, Erythropoietic
Role of ABCG2 in liver injury associated with erythropoietic protoporphyria.
Protoporphyria, Erythropoietic
The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria.
Pruritus
A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus.
Pseudoxanthoma Elasticum
Carotid strain measurement in patients with pseudoxanthoma elasticum - Hint for a different pathomechanism?
Pseudoxanthoma Elasticum
Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6).
Pseudoxanthoma Elasticum
Copy number variation in the ATP-binding cassette transporter ABCC6 gene and ABCC6 pseudogenes in patients with pseudoxanthoma elasticum.
Pseudoxanthoma Elasticum
Gene expression profiling of ABC transporters in dermal fibroblasts of pseudoxanthoma elasticum patients identifies new candidates involved in PXE pathogenesis.
Pseudoxanthoma Elasticum
Membrane insertion and topology of the amino-terminal domain TMD0 of multidrug-resistance associated protein 6 (MRP6).
Pseudoxanthoma Elasticum
Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy.
Pseudoxanthoma Elasticum
Nucleotide binding and nucleotide hydrolysis properties of the ABC transporter MRP6 (ABCC6).
Pseudoxanthoma Elasticum
Pseudoxanthoma elasticum: Point mutations in the ABCC6 gene and a large deletion including also ABCC1 and MYH11.
Pseudoxanthoma Elasticum
SPP1 promoter polymorphisms: identification of the first modifier gene for pseudoxanthoma elasticum.
Psoriasis
A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population.
Psoriasis
ABCB1 in dermatology: roles in skin diseases and their treatment.
Psoriasis
Genetic Study on Small Insertions and Deletions in Psoriasis Reveals a Role in Complex Human Diseases.
Psoriasis
Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis.
Psoriasis
Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts.
Psychomotor Agitation
CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes.
Psychomotor Agitation
Influence of ABCB1 polymorphisms and serum concentrations on venlafaxine response in patients with major depressive disorder.
Puberty, Precocious
Papers to appear in forthcoming issues
Pudendal Neuralgia
Hypothesized summative anal physiology score correlates but poorly predicts incontinence severity.
Pulmonary Alveolar Proteinosis
ABCG1 is required for pulmonary B-1 B cell and natural antibody homeostasis.
Pulmonary Alveolar Proteinosis
Lentivirus-ABCG1 instillation reduces lipid accumulation and improves lung compliance in GM-CSF knock-out mice.
Pulmonary Arterial Hypertension
miR-143 and miR-145 promote hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells through regulating ABCA1 expression.
Pulmonary Arterial Hypertension
Potential for pharmacokinetic interactions between ambrisentan and cyclosporine.
Pulmonary Arterial Hypertension
Shared gene expression patterns in mesenchymal progenitors derived from lung and epidermis in pulmonary arterial hypertension: identifying key pathways in pulmonary vascular disease.
Pulmonary Disease, Chronic Obstructive
A Physiologically Based Pharmacokinetic Model to Predict Potential Drug-Drug Interactions and Inform Dosing of Acumapimod, an Oral p38 MAPK Inhibitor.
Pulmonary Disease, Chronic Obstructive
ABCC1 polymorphisms contribute to level and decline of lung function in two population-based cohorts.
Pulmonary Disease, Chronic Obstructive
AITC induces MRP1 expression by protecting against CS/CSE-mediated DJ-1 protein degradation via activation of the DJ-1/Nrf2 axis.
Pulmonary Disease, Chronic Obstructive
Allyl isothiocyanate treatment alleviates chronic obstructive pulmonary disease through the Nrf2-Notch1 signaling and upregulation of MRP1.
Pulmonary Disease, Chronic Obstructive
Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients.
Pulmonary Disease, Chronic Obstructive
Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.
Pulmonary Disease, Chronic Obstructive
Impact of ABCB1 single-nucleotide polymorphisms on treatment outcomes with salmeterol/fluticasone combination therapy for stable chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Integrated pharmaceutical care programme in patients with chronic diseases.
Pulmonary Disease, Chronic Obstructive
Multidrug resistance-associated protein 1 and lung function decline with or without long-term corticosteroids treatment in COPD.
Pulmonary Disease, Chronic Obstructive
New method for evaluating maximal respiratory pressures: Concurrent validity, test-retest, and inter-rater reliability.
Pulmonary Disease, Chronic Obstructive
The impact of cigarette smoke exposure, COPD, or asthma status on ABC transporter gene expression in human airway epithelial cells.
Pulmonary Disease, Chronic Obstructive
Upregulation of Multidrug Resistance-Associated Protein 1 by Allyl Isothiocyanate in Human Bronchial Epithelial Cell: Involvement of c-Jun N-Terminal Kinase Signaling Pathway.
Pulmonary Embolism
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Pulmonary Emphysema
Danazol induced cholestasis: pathogenetic hypothesis.
Pulmonary Fibrosis
Bleomycin Induces Drug Efflux in Lungs: A pitfall for Pharmacological Studies of Pulmonary Fibrosis.
Pulmonary Fibrosis
Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/??catenin signaling activation (Review).
Purpura, Thrombocytopenic, Idiopathic
Association of ABCB1 gene polymorphisms and haplotypes with therapeutic efficacy of glucocorticoids in Chinese patients with immune thrombocytopenia.
Purpura, Thrombocytopenic, Idiopathic
Cytokine Profile, Apoptosis, Glucocorticoid Receptor, and P-glycoprotein Expression Before and After Megadose Methylprednisolone Treatment in Children With Acute Immune Thrombocytopenia.
Purpura, Thrombocytopenic, Idiopathic
Multidrug resistance-1 (MDR-1) in autoimmune disorders III: increased P-glycoprotein activity in lymphocytes from immune thrombocytopenic purpura patients.
Pyometra
The ABCC4 gene is associated with pyometra in golden retriever dogs.
quinine 3-monooxygenase deficiency
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
Rectal Neoplasms
Concurrent expressions of metallothionein, glutathione S-transferase-pi, and P-glycoprotein in colorectal cancers.
Rectal Neoplasms
Multidrug resistance-associated protein 3 confers resistance to chemoradiotherapy for rectal cancer by regulating reactive oxygen species and caspase-3-dependent apoptotic pathway.
Rectal Neoplasms
Prognostic and Therapeutic Potential Implications of Genetic Variability in Prostaglandin E2 Pathway Genes in Rectal Cancer.
Rectal Prolapse
A new technique for suture rectopexy without resection for rectal prolapse.
Rectal Prolapse
Continence is improved after the Ripstein rectopexy. Different mechanizms in rectal prolapse and rectal intussusception?
Rectocele
Absence of a rectocele may be correlated with reduced internal anal sphincter function in patients with rectal intussusception and fecal incontinence.
Renal Insufficiency
Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy.
Renal Insufficiency
Colchicine: serious interactions.
Renal Insufficiency
Dabigatran: new drug. Continue to use heparin, a better-known option.
Renal Insufficiency
Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
Renal Insufficiency
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Renal Insufficiency
Seventy-five percent nephrectomy and the disposition of inorganic mercury in 2,3-dimercaptopropanesulfonic acid-treated rats lacking functional multidrug-resistance protein 2.
Renal Insufficiency
Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.
Renal Insufficiency
Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .
Renal Insufficiency
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Renal Insufficiency, Chronic
A Functional Common Polymorphism of the ABCB1 Gene Is Associated With Chronic Kidney Disease and Hypertension in Chinese.
Renal Insufficiency, Chronic
ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches.
Renal Insufficiency, Chronic
An update on the lipid nephrotoxicity hypothesis.
Renal Insufficiency, Chronic
Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling.
Renal Insufficiency, Chronic
Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.
Renal Insufficiency, Chronic
Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation.
Renal Insufficiency, Chronic
Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation.
Renal Insufficiency, Chronic
The systems biology of uric acid transporters: the role of remote sensing and signaling.
Renal Insufficiency, Chronic
Uremic Toxins in Organ Crosstalk.
Renal Insufficiency, Chronic
Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease.
Reperfusion Injury
Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
Reperfusion Injury
Effects of Hepatic Ischemia-Reperfusion Injuries and NRF2 on Transcriptional Activities of Bile Transporters in Rats.
Reperfusion Injury
Effects of Hepatic Ischemia-Reperfusion Injury on the P-Glycoprotein Activity at the Liver Canalicular Membrane and Blood-Brain Barrier Determined by In Vivo Administration of Rhodamine 123 in Rats.
Reperfusion Injury
Effects of long-term hepatic ischemia-reperfusion injury on the function of P-glycoprotein in vivo in rats.
Reperfusion Injury
Repression of adenosine triphosphate-binding cassette transporter ABCG2 by estrogen increases intracellular glutathione in brain endothelial cells following ischemic reperfusion injury.
Reperfusion Injury
Transient up-regulation of P-glycoprotein reduces tacrolimus absorption after ischemia-reperfusion injury in rat ileum.
Respiratory Distress Syndrome
ABCA3 is critical for lamellar body biogenesis in vivo.
Respiratory Distress Syndrome
ATP-binding cassette transporter A3 (ABCA3) mutation in a late preterm with respiratory distress syndrome.
Respiratory Distress Syndrome
Novel Mutation in the ATP-Binding Cassette Transporter A3 (ABCA3) Encoding Gene Causes Respiratory Distress Syndrome in A Term Newborn in Southwest Iran.
Respiratory Distress Syndrome
Respiratory distress syndrome due to a novel homozygous ABCA3 mutation in a term neonate.
Respiratory Distress Syndrome, Newborn
Functional Characterization of ABCA3 Mutations from Infants with Respiratory Distress Syndrome.
Respiratory Distress Syndrome, Newborn
[Clinical analysis of heterozygous ABCA3 mutations in children].
Respiratory Insufficiency
ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and morphine pharmacokinetics in children.
Respiratory Insufficiency
Association between ABCB1 gene polymorphisms and fentanyl's adverse effects in Turkish patients undergoing spinal anesthesia.
Respiratory Insufficiency
Buprenorphine-induced respiratory depression and involvement of ABCB1 SNPs in opioid-induced respiratory depression in paediatrics.
Respiratory Insufficiency
Genotype-phenotype correlations for infants and children with ABCA3 deficiency.
Respiratory Insufficiency
Increased drug delivery to the brain by P-glycoprotein inhibition.
Respiratory Insufficiency
Nanoenabled Intracellular Calcium Bursting for Safe and Efficient Reversal of Drug Resistance in Tumor Cells.
Respiratory Insufficiency
Opioid-induced respiratory depression: ABCB1 transporter pharmacogenetics.
Respiratory Insufficiency
P-glycoprotein should be considered as an additional factor contributing to opioid-induced respiratory depression in paediatrics: the buprenorphine example.
Respiratory Insufficiency
Recent advances in opioid pharmacology.
Respiratory Insufficiency
Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine.
Respiratory Insufficiency
Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice.
Respiratory Insufficiency
Unusual long survival despite severe lung disease of a child with biallelic loss of function mutations in ABCA-3.
Retinal Degeneration
Cloning of the canine ABCA4 gene and evaluation in canine cone-rod dystrophies and progressive retinal atrophies.
Retinal Degeneration
Molecular genetic basis for fluoroquinolone-induced retinal degeneration in cats.
Retinal Degeneration
Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence.
Retinal Degeneration
Retinal degeneration in retinitis pigmentosa and neuronal ceroid lipofuscinosis: An overview.
Retinal Diseases
ABCR, the ATP-binding cassette transporter responsible for Stargardt macular dystrophy, is an efficient target of all-trans-retinal-mediated photooxidative damage in vitro. Implications for retinal disease.
Retinal Diseases
Cloning of the canine ABCA4 gene and evaluation in canine cone-rod dystrophies and progressive retinal atrophies.
Retinal Diseases
Identification of genetic variation and haplotype structure of the canine ABCA4 gene for retinal disease association studies.
Retinal Diseases
Identification of splice defects due to noncanonical splice site or deep-intronic variants in ABCA4.
Retinal Diseases
The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease.
Retinal Diseases
The effect of lipid environment and retinoids on the ATPase activity of ABCR, the photoreceptor ABC transporter responsible for Stargardt macular dystrophy.
Retinal Diseases
The rod photoreceptor ATP-binding cassette transporter gene, ABCR, and retinal disease: from monogenic to multifactorial.
Retinal Dystrophies
Generation of two iPS cell lines (FRIMOi003-A and FRIMOi004-A) derived from Stargardt patients carrying ABCA4 compound heterozygous mutations.
Retinal Dystrophies
Host genetic and epigenetic factors in toxoplasmosis.
Retinal Dystrophies
Retinal cone and rod photoreceptor cells exhibit differential susceptibility to light-induced damage.
Retinitis Pigmentosa
Genetic Spectrum of ABCA4-Associated Retinal Degeneration in Poland.
Retinoblastoma
An immunohistochemical analysis of P-glycoprotein in retinoblastoma.
Retinoblastoma
Cancer stem cell characteristics in retinoblastoma.
Retinoblastoma
Characterization of the ATP-binding cassette transporter gene expression profile in Y79: a retinoblastoma cell line.
Retinoblastoma
Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy.
Retinoblastoma
Clinicopathological parameters and expression of P-glycoprotein and MRP-1 in retinoblastoma.
Retinoblastoma
Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation.
Retinoblastoma
Differential expression of stem cell markers and vascular endothelial growth factor in human retinoblastoma tissue.
Retinoblastoma
Differentiation Potential of Human Retinoblastoma Cells.
Retinoblastoma
Dose Optimization Based on Population Pharmacokinetic Modeling of High-Dose Cyclosporine, a P-glycoprotein Inhibitor, in Combination with Systemic Chemotherapy in Pediatric Patients with Retinoblastoma.
Retinoblastoma
Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Retinoblastoma
Expression of multidrug-resistance associated proteins in human retinoblastoma treated by primary enucleation.
Retinoblastoma
Expression of P-glycoprotein in human retinoblastoma and its clinical significance.
Retinoblastoma
Function and expression of ATP-binding cassette transporters in cultured human Y79 retinoblastoma cells.
Retinoblastoma
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Retinoblastoma
Histopathological features and P-glycoprotein expression in retinoblastoma.
Retinoblastoma
Hypoxia-induced lncRNA ANRIL promotes cisplatin resistance in retinoblastoma cells through regulating ABCG2 expression.
Retinoblastoma
miR-214-3p Regulates Multi-Drug Resistance and Apoptosis in Retinoblastoma Cells by Targeting ABCB1 and XIAP.
Retinoblastoma
Molecular determinants of treatment response in human germ cell tumors.
Retinoblastoma
Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein.
Retinoblastoma
Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma.
Retinoblastoma
Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression.
Retinoblastoma
P-glycoprotein expression in retinoblastoma.
Retinoblastoma
Relationship between histopathological features of chemotherapy treated retinoblastoma and P-glycoprotein expression.
Retinoblastoma
Retinoblastoma CSF metastasis cured by multimodality chemotherapy without radiation.
Retinoblastoma
Silencing of ABCG2 by MicroRNA-3163 Inhibits Multidrug Resistance in Retinoblastoma Cancer Stem Cells.
Retinoblastoma
Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma.
Retinoblastoma
The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.
Retinoblastoma
[A gene study on multidrug resistance of retinoblastoma]
Retinoblastoma
[Studies on multidrug resistance associated protein in retinoblastoma]
Rhabdomyolysis
Multiple organ failure after an overdose of less than 0.4 mg/kg of colchicine: role of coingestants and drugs during intensive care management.
Rhabdomyolysis
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Rhabdomyolysis
Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions.
Rhabdomyolysis
Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients' Pharmacogenetic Profile.
Rhabdomyosarcoma
A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow.
Rhabdomyosarcoma
ATP-Binding Cassette Transporter C4 is a Prostaglandin D2 Exporter in HMC-1 cells.
Rhabdomyosarcoma
Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours.
Rhabdomyosarcoma
Expression of multidrug resistance-1 and multidrug resistance-associated protein genes in pediatric rhabdomyosarcoma.
Rhabdomyosarcoma
Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy.
Rhabdomyosarcoma
Expression of multidrug resistance-associated proteins in rhabdomyosarcomas before and after chemotherapy: the relationship between lung resistance-related protein (LRP) and differentiation.
Rhabdomyosarcoma
Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas.
Rhabdomyosarcoma
Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.
Rhabdomyosarcoma
In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin.
Rhabdomyosarcoma
Multidrug drug resistance in pediatric sarcomas.
Rhabdomyosarcoma
Multidrug resistance in pediatric malignancies.
Rhabdomyosarcoma
Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines.
Rhabdomyosarcoma
P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma.
Rhabdomyosarcoma
Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells.
Rhabdomyosarcoma, Alveolar
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Rhabdomyosarcoma, Embryonal
Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.
Rheumatic Diseases
P-glycoprotein in autoimmune rheumatic diseases.
Salmonella Infections
Immunoinformatic approach employing modeling and simulation to design a novel vaccine construct targeting MDR efflux pumps to confer wide protection against typhoidal Salmonella serovars.
Sarcoidosis
Personalized medicine in sarcoidosis: predict responders and nonresponders.
Sarcoma
ABCB1, ABCC1, and LRP gene expressions are altered by LDL, HDL, and serum deprivation in a human doxorubicin-resistant uterine sarcoma cell line.
Sarcoma
Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells.
Sarcoma
Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.
Sarcoma
Antiproliferative effect of pheophorbide a-mediated photodynamic therapy and its synergistic effect with doxorubicin on multiple drug-resistant uterine sarcoma cell MES-SA/Dx5.
Sarcoma
Comparison of an immunoperoxidase "sandwich" staining method and western blot detection of P-glycoprotein in human cell lines and sarcomas.
Sarcoma
Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers.
Sarcoma
Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres.
Sarcoma
Detection and Characterization of CD133 Cancer Stem Cells in Human Solid Tumours.
Sarcoma
Distinct N-glycan glycosylation of P-glycoprotein isolated from the human uterine sarcoma cell line MES-SA/Dx5.
Sarcoma
Doxorubicin selection for MDR1/P-glycoprotein reduces swelling-activated K+ and Cl- currents in MES-SA cells.
Sarcoma
Drug-selected coexpression of human glucocerebrosidase and P-glycoprotein using a bicistronic vector.
Sarcoma
Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells.
Sarcoma
Enhanced antitumor activity of different double arms polyethyleneglycol-modified liposomal doxorubicin.
Sarcoma
Essential Oils, Pituranthos chloranthus and Teucrium ramosissimum, Chemosensitize Resistant Human Uterine Sarcoma MES-SA/Dx5 Cells to Doxorubicin by Inducing Apoptosis and Targeting P-Glycoprotein.
Sarcoma
Euphorbiasteroid reverses P-glycoprotein-mediated multi-drug resistance in human sarcoma cell line MES-SA/Dx5.
Sarcoma
Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities.
Sarcoma
Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Sarcoma
Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin.
Sarcoma
Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas.
Sarcoma
Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas.
Sarcoma
Expression of P-glycoprotein in normal muscle cells and myogenic tumors.
Sarcoma
Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Sarcoma
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Sarcoma
Flow cytometric analysis of P-glycoprotein expression and drug efflux in human soft tissue and bone sarcomas.
Sarcoma
FZD1 activates protein kinase C delta-mediated drug-resistance in multidrug-resistant MES-SA/Dx5 cancer cells.
Sarcoma
Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line.
Sarcoma
Growth inhibitory effects of paclitaxel on human epithelioid sarcoma in vitro: heterogeneity of response and the multidrug resistance phenotype.
Sarcoma
Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.
Sarcoma
Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma.
Sarcoma
Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin.
Sarcoma
Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report.
Sarcoma
Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells.
Sarcoma
May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.
Sarcoma
Modulation of multidrug resistance P-glycoprotein activity by antiemetic compounds in human doxorubicin-resistant sarcoma cells (MES-SA/Dx-5): implications on cancer therapy.
Sarcoma
Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy.
Sarcoma
MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.
Sarcoma
Multidrug drug resistance in pediatric sarcomas.
Sarcoma
Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy.
Sarcoma
Multidrug resistance proteins in primary and metastatic soft-tissue sarcomas: down-regulation of P-glycoprotein during metastatic progression.
Sarcoma
Multidrug resistance.
Sarcoma
Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins.
Sarcoma
N-alkylisatin-based microtubule destabilizers bind to the colchicine site on tubulin and retain efficacy in drug resistant acute lymphoblastic leukemia cell lines with less in vitro neurotoxicity.
Sarcoma
Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas.
Sarcoma
Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein.
Sarcoma
P-glycoprotein expression in soft-tissue sarcomas.
Sarcoma
P-glycoprotein in human sarcoma: evidence for multidrug resistance.
Sarcoma
P-glycoprotein modulation by valspodar and cyclosporin does not increase tumor uptake of doxorubicin administered via isolated lung perfusion to rats bearing sarcoma lung metastases.
Sarcoma
Prognostic relevance of P-glycoprotein expression in breast cancer.
Sarcoma
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Sarcoma
Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance.
Sarcoma
Reverse transcriptase-polymerase chain reaction amplification of MDR1 gene expression in adult soft tissue sarcomas.
Sarcoma
Rhabdomyosarcoma and other soft tissue sarcomas of childhood.
Sarcoma
Significance of P-glycoprotein expression in childhood malignant tumors.
Sarcoma
Simultaneous delivery of chemotherapeutic and thermal-optical agents to cancer cells by a polymeric (PLGA) nanocarrier: an in vitro study.
Sarcoma
Synthesis and uptake of fluorescence-labeled Combi-molecules by P-glycoprotein-proficient and -deficient uterine sarcoma cells MES-SA and MES-SA/DX5.
Sarcoma
The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
Sarcoma
The effect of the plasticizer diethylhexyl phthalate on transport activity and expression of P-glycoprotein in parental and doxo-resistant human sarcoma cell lines.
Sarcoma
Wnt pathway activation and ABCB1 expression account for attenuation of Proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.
Sarcoma
[Polymerase chain reaction in diagnostic pathology]
Sarcoma 180
Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms.
Sarcoma, Alveolar Soft Part
Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance.
Sarcoma, Ewing
Effect of P-glycoprotein expression on outcome in the Ewing family of tumors.
Sarcoma, Ewing
Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone.
Sarcoma, Ewing
Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas.
Sarcoma, Ewing
Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy.
Sarcoma, Ewing
Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells.
Sarcoma, Ewing
Localization of MRP-1 to the outer mitochondrial membrane by the chaperone protein HSP90?.
Sarcoma, Kaposi
A possible role of multidrug resistance-associated protein (MRP) in basic fibroblast growth factor secretion by AIDS-associated Kaposi's sarcoma cells: a survival molecule?
Sarcoma, Kaposi
Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line.
Sarcoma, Kaposi
Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Sarcoma, Kaposi
P-glycoprotein expression and AIDS-related Kaposi's sarcoma.
Sarcoma, Synovial
MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.
Sarcoma, Synovial
Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma.
Sarcoma, Synovial
Synovial sarcoma: immunohistochemical expression of P-glycoprotein and glutathione S transferase-pi and clinical drug resistance.
Sarcopenia
Respiratory Muscle Strength as a Discriminator of Sarcopenia in Community-Dwelling Elderly: A Cross-Sectional Study.
Schistosomiasis
[Expression and clinical significance of P-gp in colonic gland of chronic schistosomiasis patients].
Schistosomiasis mansoni
Identification of the mouse calcium-binding proteins, MRP 8 and MRP 14, in Schistosoma mansoni-induced granulomas: biochemical and functional characterization.
Scleroderma, Systemic
Genotype and haplotype analysis of ABCB1 at 1236, 2677 and 3435 among systemic sclerosis patients.
Seizures
A comprehensive functional and clinical analysis of ABCC2 and its impact on treatment response to carbamazepine.
Seizures
A Novel Approach to Refractory Epilepsy by Targeting Pgp peripherally and centrally: Therapeutic targets and Future perspectives.
Seizures
Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy: A pilot study.
Seizures
Association between ABCB1 genotype and seizure outcome in collies with epilepsy.
Seizures
Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy.
Seizures
Blockade of endothelin B receptor improves the efficacy of levetiracetam in chronic epileptic rats.
Seizures
Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats.
Seizures
Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy.
Seizures
Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study.
Seizures
Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats.
Seizures
Complex time-dependent alterations in the brain expression of different drug efflux transporter genes after status epilepticus.
Seizures
Construction of Pepstatin A-Conjugated ultrasmall SPIONs for targeted positive MR imaging of epilepsy-overexpressed P-glycoprotein.
Seizures
Correlation of MCT1 and ABCC2 gene polymorphisms with valproic acid resistance in patients with epilepsy on valproic acid monotherapy.
Seizures
Cortical expression of IL1-?, Bcl-2, Caspase-3 and 9, SEMA-3a, NT-3 and P-glycoprotein as biological markers of intrinsic severity in drug-resistant temporal lobe epilepsy.
Seizures
COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats.
Seizures
Development of tolerance to levetiracetam in rats with chronic epilepsy.
Seizures
Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid.
Seizures
Effects of Brain IKK? Gene Silencing by Small Interfering RNA on P-Glycoprotein Expression and Brain Damage in the Rat Kainic Acid-Induced Seizure Model.
Seizures
Effects of carbamazepine on the P-gp and CYP3A expression correlated with PXR or NF-?B activity in the bEnd.3 cells.
Seizures
Effects of high frequency electrical stimulation and R-verapamil on seizure susceptibility and glutamate and GABA release in a model of phenytoin-resistant seizures.
Seizures
Emodin plays an interventional role in epileptic rats via multidrug resistance gene 1 (MDR1).
Seizures
Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats.
Seizures
Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats.
Seizures
Genetic association analysis of transporters identifies ABCC2 loci for seizure control in women with epilepsy on first-line antiepileptic drugs.
Seizures
Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain.
Seizures
Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy.
Seizures
Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables.
Seizures
Impact of seizure activity on free extracellular phenytoin concentrations in amygdala-kindled rats.
Seizures
In vivo P-glycoprotein function before and after epilepsy surgery.
Seizures
Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats.
Seizures
Inhibition of blood-brain barrier efflux transporters promotes seizure in pregnant rats: Role of circulating factors.
Seizures
Inhibition of mTOR Pathway by Rapamycin Decreases P-glycoprotein Expression and Spontaneous Seizures in Pharmacoresistant Epilepsy.
Seizures
Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats.
Seizures
Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.
Seizures
Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions.
Seizures
Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance.
Seizures
Linkage disequilibrium between polymorphisms of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex partial seizures on treatment with carbamazepine mono-therapy at the Kuala Lumpur Hospital.
Seizures
Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies?
Seizures
Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures.
Seizures
Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: Data from International Pharmacogenetic Cohorts.
Seizures
Multimodal pathway for brain tumor-related epilepsy patients: Observational study.
Seizures
Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures.
Seizures
Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy.
Seizures
Neuroscience and hormesis: overview and general findings.
Seizures
New anticonvulsant candidates prevent P-glycoprotein (P-gp) overexpression in a pharmacoresistant seizure model in mice.
Seizures
Nonsteroidal anti-inflammatory drugs in clinical and experimental epilepsy.
Seizures
Nuclear factor-kappa B activity regulates brain expression of p-glycoprotein in the kainic Acid-induced seizure rats.
Seizures
Over-expression of P-glycoprotein in malformations of cortical development.
Seizures
Over-expression of P-glycoprotein in the canine brain following spontaneous status epilepticus.
Seizures
Overexpression of human MRP1 in neurons causes resistance to antiepileptic drugs in Drosophila seizure mutants.
Seizures
P-Glycoprotein Contributes To Cell Membrane Depolarization Of Hippocampus And Neocortex In A Model Of Repetitive Seizures Induced By Pentylenetetrazole In Rats.
Seizures
P-gp Protein Expression and Transport Activity in Rodent Seizure Models and Human Epilepsy.
Seizures
Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy.
Seizures
Pharmacogenetics of the Central Nervous System-Toxicity and Relapse Affecting the CNS in Pediatric Acute Lymphoblastic Leukemia.
Seizures
Phenytoin carried by silica core iron oxide nanoparticles reduces the expression of pharmacoresistant seizures in rats.
Seizures
Potential role of drug transporters in the pathogenesis of medically intractable epilepsy.
Seizures
Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition.
Seizures
Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity.
Seizures
Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure.
Seizures
Role of CNS efflux drug transporters in antiepileptic drug delivery: Overcoming CNS efflux drug transport.
Seizures
Role of P-Glycoprotein in Refractoriness of Seizures to Antiepileptic Drugs in Lennox-Gastaut Syndrome.
Seizures
Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling.
Seizures
Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein in the parahippocampal cortex of chronic epileptic rats.
Seizures
Signaling to P-glycoprotein-A new therapeutic target to treat drug-resistant epilepsy?
Seizures
Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation.
Seizures
The Antiepileptic Drug Topiramate is a Substrate for Human P-glycoprotein but Not Multidrug Resistance Proteins.
Seizures
The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy.
Seizures
The mechanisms of medically refractory temporal lobe epilepsy.
Seizures
The P-glycoprotein inhibitor quinidine decreases the threshold for bupivacaine-induced, but not lidocaine-induced, convulsions in rats.
Seizures
Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy.
Seizures
Verapamil as an Adjuvant Treatment for Drug-Resistant Epilepsy.
Seizures
Verapamil attenuates the malignant treatment course in recurrent status epilepticus.
Seizures
Widespread upregulation of drug-resistance proteins in fatal human status epilepticus.
Seizures
[Effect of dizocilpine on P-glycoprotein expression in hippocampus in limbic seizure: experiment with rats]
Seizures
[Effects of Chinese herbal medicine Xifeng Capsule on multidrug resistance-associated protein 1 expression in hippocampus and cortex of rats with lithium-pilocarpine-induced epilepsy].
Seizures
[Expression of multidrug resistance gene and topiramate affect expression of multidrug resistance gene in the hippocampus of spontaneous epileptic rats]
Seminoma
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Seminoma
Multidrug resistance of testis cancers: the study of clinical relevance of P-glycoprotein expression.
Seminoma
[Multidrug resistance of testicular cancers. (Detection of P-glycoprotein and MDR1 gene expression and their clinical connection)]
Sepsis
Combined effect of rifampicin-induced P-glycoprotein expression and lipopolysaccharide-induced intestinal sepsis on the effective permeability and pharmacokinetics of an anti-malarial candidate CDRI 97/78 in rats.
Sepsis
Effects of lipopolysaccharide on intestinal P-glycoprotein expression and activity.
Sepsis
Effects of lipopolysaccharide on P-glycoprotein expression and activity in the liver and kidneys.
Sepsis
Intraabdominal sepsis down-regulates transcription of sodium taurocholate cotransporter and multidrug resistance-associated protein in rats.
Sepsis
Relatedness of Streptococcus suis isolates of various serotypes and clinical backgrounds as evaluated by macrorestriction analysis and expression of potential virulence traits.
Sepsis
Sepsis affects cardiac expression of multidrug resistance protein 5 (MRP5, ABCC5), an ABC-type CGMP export pump.
Sepsis
Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-?B/JNK: a possible role of P-glycoprotein.
Sepsis
Xenobiotic receptors in mediating the effect of sepsis on drug metabolism.
Sertoli Cell Tumor
Papers to appear in forthcoming issues
Severe Combined Immunodeficiency
Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Sinusitis
Evaluation of the Prevalence of Mucous Retention Pseudocyst and its Correlation with the Associated Risk Factors Using Panoramic Radiography and Cone-Beam Computed Tomography.
Sinusitis
Osteitis is associated with P-glycoprotein overexpression in patients with chronic sinusitis without nasal polyps.
Sinusitis
P-glycoprotein inhibition with verapamil overcomes mometasone resistance in Chronic Sinusitis with Nasal Polyps.
Sinusitis
P-glycoprotein promotes epithelial T helper 2-associated cytokine secretion in chronic sinusitis with nasal polyps.
Skin Diseases
ABCB1 in dermatology: roles in skin diseases and their treatment.
Skin Neoplasms
Combined effects of GSTP1 and MRP1 in melanoma drug resistance.
Skin Neoplasms
The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.
Sleep Apnea Syndromes
Characterizing the binding interactions between P-glycoprotein and eight known cardiovascular transport substrates.
Sleep Apnea, Obstructive
Influence of intermittent hypoxia on myocardial and hepatic P-glycoprotein expression in a rodent model.
Sleep Initiation and Maintenance Disorders
Efficacy of the Mantram Repetition Program for Insomnia in Veterans With Posttraumatic Stress Disorder: A Naturalistic Study.
Sleep Initiation and Maintenance Disorders
Mantram Repetition as a Portable Mindfulness Practice: Applications During the COVID-19 Pandemic.
Sleep Initiation and Maintenance Disorders
Mantram Repetition Program Decreases Insomnia Among Homeless Women: A Pilot Study.
Small Cell Lung Carcinoma
6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer.
Small Cell Lung Carcinoma
9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance.
Small Cell Lung Carcinoma
Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.
Small Cell Lung Carcinoma
Amplification and expression of mdr1 gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69.
Small Cell Lung Carcinoma
Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells.
Small Cell Lung Carcinoma
Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell.
Small Cell Lung Carcinoma
Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer.
Small Cell Lung Carcinoma
Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.
Small Cell Lung Carcinoma
Cytotoxic action of cyclosporins on human tumor cell lines is not dependent on immunosuppressive activity.
Small Cell Lung Carcinoma
Development of a shear force scanning near-field fluorescence microscope for biological applications.
Small Cell Lung Carcinoma
Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway.
Small Cell Lung Carcinoma
Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.
Small Cell Lung Carcinoma
Effects of tetramethylpiperidine (TMP)-substituted phenazines on membrane stability and P-glycoprotein function.
Small Cell Lung Carcinoma
Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line.
Small Cell Lung Carcinoma
Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response.
Small Cell Lung Carcinoma
Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer.
Small Cell Lung Carcinoma
Growth inhibitory effects of antifolates against an adriamycin-resistant human small cell lung cancer cell line.
Small Cell Lung Carcinoma
Immunohistochemical detection of P-glycoprotein and carcinoembryonic antigen in small cell lung cancer: with reference to predictability of response to chemotherapy.
Small Cell Lung Carcinoma
Infection of H69AR cells with retroviral particles harboring interfering RNAi significantly reduced the multidrug resistance of these small cell lung cancer cells.
Small Cell Lung Carcinoma
Lack of expression of P-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients.
Small Cell Lung Carcinoma
Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Small Cell Lung Carcinoma
Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines.
Small Cell Lung Carcinoma
MICA enhances sensitivity to cisplatin in patients with extensive small cell lung cancer via downregulation of ABCG2.
Small Cell Lung Carcinoma
miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1.
Small Cell Lung Carcinoma
Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
Small Cell Lung Carcinoma
Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease.
Small Cell Lung Carcinoma
Multidrug resistance related genes and p53 expression in human non small cell lung cancer.
Small Cell Lung Carcinoma
Multidrug resistance-associated protein (MRP) gene expression in human lung cancer.
Small Cell Lung Carcinoma
Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
Small Cell Lung Carcinoma
Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents.
Small Cell Lung Carcinoma
Peripheral blood mononuclear cells express antigens associated with multidrug resistance in a small cell lung cancer cell line.
Small Cell Lung Carcinoma
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
Small Cell Lung Carcinoma
Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy.
Small Cell Lung Carcinoma
Pyrimido[1?,2?:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
Small Cell Lung Carcinoma
Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides.
Small Cell Lung Carcinoma
Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression.
Small Cell Lung Carcinoma
Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells.
Small Cell Lung Carcinoma
Technetium-99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma: relation to patient prognosis and chemotherapy response--a preliminary report.
Small Cell Lung Carcinoma
Tetramethylpiperidine-substitution increases the antitumor activity of the riminophenazines for an acquired multidrug-resistant cell line.
Small Cell Lung Carcinoma
The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug-resistant breast cancer cells is NCA, the nonspecific cross-reacting antigen of carcinoembryonic antigen.
Small Cell Lung Carcinoma
The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line.
Small Cell Lung Carcinoma
The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
Small Cell Lung Carcinoma
The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome.
Small Cell Lung Carcinoma
To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer.
Small Cell Lung Carcinoma
To predict response chemotherapy using technetium-99m tetrofosmin chest images in patients with untreated small cell lung cancer and compare with p-glycoprotein, multidrug resistance related protein-1, and lung resistance-related protein expression.
Small Cell Lung Carcinoma
Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1.
Small Cell Lung Carcinoma
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.
Small Cell Lung Carcinoma
Using technetium-99m methoxyisobutylisonitrile lung single-photon-emission computed tomography to predict response to chemotherapy and compare with P-glycoprotein expression in patients with untreated small cell lung cancer.
Small Cell Lung Carcinoma
[Expression and Clinical Significance of ABCC10 in the Patients with Non-small Cell Lung Cancer.]
Small Cell Lung Carcinoma
[Immunohistochemical detection of carcinoembryonic antigen and P-glycoprotein in small cell lung cancer at diagnosis and relapse, with special reference to the tissue expression of CEA and response to chemotherapy]
Small Cell Lung Carcinoma
[Modulation of human small cell lung cancer cell line GLC4/ADR multidrug resistance in the inhibition of multidrug resistance-associated protein and its antisense]
Spasms, Infantile
Common ABCB1 polymorphisms associated with susceptibility to infantile spasms in the Chinese Han population.
Spinal Dysraphism
A common ABCC2 promoter polymorphism is not a determinant of the risk of spina bifida.
Spinocerebellar Ataxias
Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis.
Spinocerebellar Ataxias
[Differentiation of Cultivated CD45(-)/CD31(+) Mouse Lung Side Population Cells into Vascular Smooth Muscle Cells in vitro].
Spondylarthropathies
Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis.
Spondylitis, Ankylosing
Single nucleotide polymorphisms of ABCB1 gene and response to etanercept treatment in patients with ankylosing spondylitis in a Chinese Han population.
Squamous Cell Carcinoma of Head and Neck
?Np63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis.
Squamous Cell Carcinoma of Head and Neck
ABCG2 regulated by MAPK pathways is associated with cancer progression in laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Ah receptor antagonism represses head and neck tumor cell aggressive phenotype.
Squamous Cell Carcinoma of Head and Neck
Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Cigarette Smoke Reduces the Efficacy of Cisplatin in Head and Neck Cancer Cells - Role of ABCG2.
Squamous Cell Carcinoma of Head and Neck
Circ_0109291 Promotes the Cisplatin Resistance of Oral Squamous Cell Carcinoma by Sponging miR-188-3p to Increase ABCB1 Expression.
Squamous Cell Carcinoma of Head and Neck
Effect of apoptotic and proliferative indices, P-glycoprotein and survivin expression on prognosis in laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Effect of chelidonine on growth, invasion, angiogenesis and gene expression in head and neck cancer cell lines.
Squamous Cell Carcinoma of Head and Neck
Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene.
Squamous Cell Carcinoma of Head and Neck
Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines.
Squamous Cell Carcinoma of Head and Neck
Expression of ABCG2 and Bmi-1 in oral potentially malignant lesions and oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression of CD44, CD44v9, ABCG2, CD24, Bmi-1 and ALDH1 in stage I and II oral squamous cell carcinoma and their association with clinicopathological factors.
Squamous Cell Carcinoma of Head and Neck
Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Squamous Cell Carcinoma of Head and Neck
Expression of multidrug resistance-associated protein (MRP) in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression of multidrug resistance-related genes in oral squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Noninvasive Molecular Detection of Head and Neck Squamous Cell Carcinoma: An Exploratory Analysis.
Squamous Cell Carcinoma of Head and Neck
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Squamous Cell Carcinoma of Head and Neck
Significance of ATP-binding cassette transporter proteins in multidrug resistance of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
The Integration of a Three-Dimensional Spheroid Cell Culture Operation in a Circulating Tumor Cell (CTC) Isolation and Purification Process: A Preliminary Study of the Clinical Significance and Prognostic Role of the CTCs Isolated from the Blood Samples of Head and Neck Cancer Patients.
Squamous Cell Carcinoma of Head and Neck
Transporter gene expression in human head and neck squamous cell carcinoma and associated epigenetic regulatory mechanisms.
Squamous Cell Carcinoma of Head and Neck
[Detection of P-glycoprotein in squamous cell carcinoma of larynx]
Squamous Cell Carcinoma of Head and Neck
[Expression and clinical implication of multidrug resistance gene and multidrug resistant-associated protein gene in patients with hypopharyngeal squamous cell carcinoma]
Squamous Cell Carcinoma of Head and Neck
[Expression and clinical implication of multidrug resistant-associated protein gene (MRP) in patients with laryngeal squamous cell carcinoma]
ST Elevation Myocardial Infarction
Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme.
ST Elevation Myocardial Infarction
Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction.
Staphylococcal Infections
Calcium-binding proteins MRP 8 and 14 in a Staphylococcus aureus infection model: role of therapy, inflammation, and infection persistence.
Stargardt Disease
A subgroup of age-related macular degeneration is associated with mono-allelic sequence variants in the ABCA4 gene.
Stargardt Disease
ABCR unites what ophthalmologists divide(s)
Stargardt Disease
Acute Stress Responses Are Early Molecular Events of Retinal Degeneration in Abca4-/-Rdh8-/- Mice After Light Exposure.
Stargardt Disease
An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4-/- Mice.
Stargardt Disease
Assessment of AAV Dual Vector Safety in theAbca4-/- Mouse Model of Stargardt Disease.
Stargardt Disease
ATP-binding cassette transporter ABCA4 and chemical isomerization protect photoreceptor cells from the toxic accumulation of excess 11-cis-retinal.
Stargardt Disease
Correlating the Expression and Functional Activity of ABCA4 Disease Variants With the Phenotype of Patients With Stargardt Disease.
Stargardt Disease
Familial discordance in Stargardt disease.
Stargardt Disease
Generation of two iPS cell lines (FRIMOi003-A and FRIMOi004-A) derived from Stargardt patients carrying ABCA4 compound heterozygous mutations.
Stargardt Disease
Genetic Spectrum of ABCA4-Associated Retinal Degeneration in Poland.
Stargardt Disease
Genotype/Phenotype analysis of a photoreceptor-specific ATP-binding cassette transporter gene, ABCR, in Stargardt disease.
Stargardt Disease
Identification of splice defects due to noncanonical splice site or deep-intronic variants in ABCA4.
Stargardt Disease
Mutation Spectrum of the ABCA4 Gene in 335 Stargardt Disease Patients From a Multicenter German Cohort-Impact of Selected Deep Intronic Variants and Common SNPs.
Stargardt Disease
Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence.
Stargardt Disease
Mutations in the ABCA4 (ABCR) gene are the major cause of autosomal recessive cone-rod dystrophy.
Stargardt Disease
Phenotype-genotype correlations in a pseudodominant Stargardt disease pedigree due to a novel ABCA4 deletion-insertion variant causing a splicing defect.
Stargardt Disease
Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease.
Stargardt Disease
Stargardt Disease with Preserved Central Vision: identification of a putative novel mutation in ATP-binding cassette transporter gene.
Stargardt Disease
The 2588G-->C mutation in the ABCR gene is a mild frequent founder mutation in the Western European population and allows the classification of ABCR mutations in patients with Stargardt disease.
Starvation
Effects of prebiotic oligosaccharides consumption on the growth and expression profile of cell surface-associated proteins of a potential probiotic Lactobacillus rhamnosus FSMM15.
Starvation
Expression regulation of the yeast PDR5 ATP-binding cassette (ABC) transporter suggests a role in cellular detoxification during the exponential growth phase.
Starvation
Influence of the fluoroquinolone ofloxacin on the intrinsic expression of multidrug resistance phenotype in HCT-8 human colon carcinoma cells.
Starvation
Proteomic analysis of rainbow trout (Oncorhynchus mykiss) intestinal epithelia: physiological acclimation to short-term starvation.
Starvation
The rate of P-glycoprotein activation depends on the metabolic state of the cell.
Starvation
[Separation of the up-regulated genes under nitrogen starvation from Phaeodactylum tricornutum by suppression subtractive hybridization technology]
Status Epilepticus
(R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.
Status Epilepticus
A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier.
Status Epilepticus
Alteration in P-glycoprotein Functionality Affects Intrabrain Distribution of Quinidine More Than Brain Entry-A Study in Rats Subjected to Status Epilepticus by Kainate.
Status Epilepticus
COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats.
Status Epilepticus
High incidence of persistent subtherapeutic levels of the most common AEDs in children with epilepsy receiving polytherapy.
Status Epilepticus
HMGB1 regulates P-glycoprotein expression in status epilepticus rat brains via the RAGE/NF-?B signaling pathway.
Status Epilepticus
MicroRNA-146a-5p Downregulates the Expression of P-Glycoprotein in Rats with Lithium-Pilocarpine-Induced Status Epilepticus.
Status Epilepticus
MK-801 prevents overexpression of multidrug resistance protein 2 after status epilepticus.
Status Epilepticus
Over-expression of P-glycoprotein in the canine brain following spontaneous status epilepticus.
Status Epilepticus
Pilocarpine-Induced Status Epilepticus Is Associated with P-Glycoprotein Induction in Cardiomyocytes, Electrocardiographic Changes, and Sudden Death.
Status Epilepticus
Refractory status epilepticus.
Status Epilepticus
Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus.
Status Epilepticus
Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling.
Status Epilepticus
Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein in the parahippocampal cortex of chronic epileptic rats.
Status Epilepticus
Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation.
Status Epilepticus
Termination of refractory focal status epilepticus by the P-glycoprotein inhibitor verapamil.
Status Epilepticus
Widespread upregulation of drug-resistance proteins in fatal human status epilepticus.
Status Epilepticus
[Expression of multidrug resistance gene and topiramate affect expression of multidrug resistance gene in the hippocampus of spontaneous epileptic rats]
Status Epilepticus
[Over-expression of the P-glycoprotein in the rat brain after status epilepticus and their age difference]
Stevens-Johnson Syndrome
Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy.
Stomach Neoplasms
?-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer.
Stomach Neoplasms
ABCG2 confers promotion in gastric cancer through modulating downstream CRKL in vitro combining with biostatistics mining.
Stomach Neoplasms
Aberrant gene methylation in the lymph nodes provides a possible marker for diagnosing micrometastasis in gastric cancer.
Stomach Neoplasms
Aminopeptidase N (APN/CD13) as a target molecule for scirrhous gastric cancer.
Stomach Neoplasms
Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue.
Stomach Neoplasms
Antitumor spectra of anthracyclines against gastric cancer tissues obtained from surgical specimens with reference to P-glycoprotein expression.
Stomach Neoplasms
Association between ABCB1 immunohistochemical expression and overall survival in gastric cancer patients.
Stomach Neoplasms
Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy.
Stomach Neoplasms
Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer.
Stomach Neoplasms
Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2.
Stomach Neoplasms
Co-expression of CD44 and ABCG2 in spheroid body-forming cells of gastric cancer cell line MKN45.
Stomach Neoplasms
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
Stomach Neoplasms
Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines.
Stomach Neoplasms
Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein (MRP) in human gastric cancer cells.
Stomach Neoplasms
DJ-1 is involved in the multidrug resistance of SGC7901 gastric cancer cells through PTEN/PI3K/Akt/Nrf2 pathway.
Stomach Neoplasms
Effects of Genetic Polymorphisms in the ABCB1 Gene on Clinical Outcomes in Patients with Gastric Cancer Treated by Second-line Chemotherapy.
Stomach Neoplasms
Establishment and partial characterization of an epirubicin-resistant gastric cancer cell line with upregulated ABCB1.
Stomach Neoplasms
Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Stomach Neoplasms
Expression of multidrug resistance-related markers in gastric cancer.
Stomach Neoplasms
Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer.
Stomach Neoplasms
Expression of P-glycoprotein and multidrug resistance-associated protein is associated with multidrug resistance in gastric cancer.
Stomach Neoplasms
Expression of P-glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas.
Stomach Neoplasms
Expression of P-glycoprotein mRNA in human gastric tumors.
Stomach Neoplasms
Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer.
Stomach Neoplasms
FOXO3a-dependent Parkin regulates the development of gastric cancer by targeting ATP-binding cassette transporter E1.
Stomach Neoplasms
Genetic Variation in the ABCB1 Gene May Lead to mRNA Level Chabge: Application to Gastric Cancer Cases.
Stomach Neoplasms
GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer.
Stomach Neoplasms
Glucosamine Reverses P-Glycoprotein-Mediated Multidrug Resistance in the Daunorubicin-Resistant Human Gastric Cancer Cells.
Stomach Neoplasms
Graphene oxide (GO)-based nanosheets with combined chemo/photothermal/photodynamic therapy to overcome gastric cancer (GC) paclitaxel resistance by reducing mitochondria-derived adenosine-triphosphate (ATP).
Stomach Neoplasms
High glucose promotes gastric cancer chemoresistance in vivo and in vitro.
Stomach Neoplasms
Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein.
Stomach Neoplasms
HOXA13, Negatively Regulated by miR-139-5p, Decreases the Sensitivity of Gastric Cancer to 5-Fluorouracil Possibly by Targeting ABCC4.
Stomach Neoplasms
Identification of transporters associated with Etoposide sensitivity of stomach cancer cell lines and methotrexate sensitivity of breast cancer cell lines by quantitative targeted absolute proteomics.
Stomach Neoplasms
Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells.
Stomach Neoplasms
Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice.
Stomach Neoplasms
Interferon regulatory factor-1 reverses chemoresistance by downregulating the expression of P-glycoprotein in gastric cancer.
Stomach Neoplasms
Is the ABCB1 gene associated with the increased risk of gastric cancer development?--preliminary research.
Stomach Neoplasms
Long Non-Coding RNA NEAT1 Serves as Sponge for miR-365a-3p to Promote Gastric Cancer Progression via Regulating ABCC4.
Stomach Neoplasms
Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361.
Stomach Neoplasms
Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines.
Stomach Neoplasms
Manganese superoxide dismutase expression correlates with chemosensitivity in human gastric cancer cell lines.
Stomach Neoplasms
MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese.
Stomach Neoplasms
MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells.
Stomach Neoplasms
MicroRNA-328 acts as an anti-oncogene by targeting ABCG2 in gastric carcinoma.
Stomach Neoplasms
miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1.
Stomach Neoplasms
Mucin antigen expression in gastric carcinomas of young and old adults.
Stomach Neoplasms
Multi-slice CT contrast-enhanced presentations of advanced gastric cancer: associations with histo-differentiation and expression of p53 and P-glycoprotein.
Stomach Neoplasms
Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges.
Stomach Neoplasms
Multidrug resistance-associated protein expression in clinical gastric carcinoma.
Stomach Neoplasms
New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives.
Stomach Neoplasms
New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Stomach Neoplasms
Novel Pt(IV) complexes to overcome multidrug resistance in gastric cancer by targeting P-glycoprotein.
Stomach Neoplasms
Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer.
Stomach Neoplasms
Overexpression of P-glycoprotein in untreated AFP-producing gastric carcinoma.
Stomach Neoplasms
Overexpression of ZNRD1 promotes multidrug-resistant phenotype of gastric cancer cells through upregulation of P-glycoprotein.
Stomach Neoplasms
P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer.
Stomach Neoplasms
P-glycoprotein expression and chemosensitivity in highly purified fresh human gastrointestinal cancer cells.
Stomach Neoplasms
Pivotal roles of peptide transporter PEPT1 and ATP-binding cassette (ABC) transporter ABCG2 in 5-aminolevulinic acid (ALA)-based photocytotoxicity of gastric cancer cells in vitro.
Stomach Neoplasms
Prediction of doxorubicin resistance in gastrointestinal cancer by P-glycoprotein staining.
Stomach Neoplasms
Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells.
Stomach Neoplasms
Prognostic significance of the expressions of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer.
Stomach Neoplasms
Regulation of multidrug resistance by MGr1-antigen in gastric cancer cells.
Stomach Neoplasms
Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Stomach Neoplasms
Reversal of Multidrug Resistance in an Epirubicin-Resistant Gastric Cancer Cell Subline
Stomach Neoplasms
RhoGDI2 up-regulates P-glycoprotein expression via Rac1 in gastric cancer cells.
Stomach Neoplasms
RNAi-mediated silencing of ATP-binding cassette C4 protein inhibits cell growth in MGC80-3 gastric cancer cell lines.
Stomach Neoplasms
Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells.
Stomach Neoplasms
Role of ABCG2 expression driven by cisplatin in platinum-containing chemotherapy for gastric cancer.
Stomach Neoplasms
Significance of MDR-related proteins in the postoperative individualized chemotherapy of gastric cancer.
Stomach Neoplasms
Significantly increased expression of OCT4 and ABCG2 in spheroid body-forming cells of the human gastric cancer MKN-45 cell line.
Stomach Neoplasms
Silencing of the ABCC4 gene by RNA interference reverses multidrug resistance in human gastric cancer.
Stomach Neoplasms
Sonic hedgehog-glioma associated oncogene homolog 1 signaling enhances drug resistance in CD44(+)/Musashi-1(+) gastric cancer stem cells.
Stomach Neoplasms
Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells.
Stomach Neoplasms
The association between chemosensitivity and Pgp, GST-? and Topo II expression in gastric cancer.
Stomach Neoplasms
The Cisplatin-Derived Increase of Mitochondrial Reactive Oxygen Species Enhances the Effectiveness of Photodynamic Therapy via Transporter Regulation.
Stomach Neoplasms
The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer.
Stomach Neoplasms
The impact of insulin on chemotherapeutic sensitivity to 5-fluorouracil in gastric cancer cell lines SGC7901, MKN45 and MKN28.
Stomach Neoplasms
The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers.
Stomach Neoplasms
The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer.
Stomach Neoplasms
The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy.
Stomach Neoplasms
Usefulness of 99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer.
Stomach Neoplasms
[Antitumor effects of chemotherapeutic drugs on fresh human gastric cancer cells and their relationships to expressions of P-glycoprotein and glutathione S transferase-pi]
Stomach Neoplasms
[Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer.]
Stomach Neoplasms
[Correlation of sorcin overexpression to multidrug resistance of human gastric cancer cell line SGC7901]
Stomach Neoplasms
[Expression of ATP-binding cassette transporter ABCG2 in gastric carcinoma and its significance]
Stomach Neoplasms
[Study on the mechanism of DDP-resistance mediated by phosphate JNK in gastric cancer.]
Stomatitis
Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.
Stomatitis
Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2 with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Analysis in Japanese Patients.
Stroke
ABCC1: a gateway for pharmacological compounds to the ischaemic brain.
Stroke
Association between ABCB1 Polymorphisms and Ischemic Stroke in Korean Population.
Stroke
Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
Stroke
Bobath or motor relearning programme? A comparison of two different approaches of physiotherapy in stroke rehabilitation: a randomized controlled study.
Stroke
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke.
Stroke
Deficiency of Brain ATP-Binding Cassette Transporter A-1 Exacerbates Blood-Brain Barrier and White Matter Damage After Stroke.
Stroke
Differential regulation of transport proteins in the periinfarct region following reversible middle cerebral artery occlusion in rats.
Stroke
Gene variants associated with ischemic stroke: the cardiovascular health study.
Stroke
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Stroke
Neural Progenitor Cell-Derived Extracellular Vesicles Enhance Blood-Brain Barrier Integrity by NF-?B (Nuclear Factor-?B)-Dependent Regulation of ABCB1 (ATP-Binding Cassette Transporter B1) in Stroke Mice.
Stroke
Neuroscience and hormesis: overview and general findings.
Stroke
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Stroke
Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Stroke
Spatiotemporal Changes in P-glycoprotein Levels in Brain and Peripheral Tissues Following Ischemic Stroke in Rats.
Stroke
Structure of multidrug-resistance proteins of the ATP-binding cassette (ABC) superfamily.
Stroke
To compare the effectiveness of constraint induced movement therapy versus motor relearning programme to improve motor function of hemiplegic upper extremity after stroke.
Stroke
Walking speed as a predictor of community mobility and quality of life after stroke.
Stroke
[Physiotherapy after stroke--a randomized controlled trial]
Stroke
[The effectiveness of physical therapy methods (Bobath and motor relearning program) in rehabilitation of stroke patients]
Sudden Unexpected Death in Epilepsy
High incidence of persistent subtherapeutic levels of the most common AEDs in children with epilepsy receiving polytherapy.
Sudden Unexpected Death in Epilepsy
The role of P-glycoprotein (P-gp) and inwardly rectifying potassium (Kir) channels in sudden unexpected death in epilepsy (SUDEP).
Tangier Disease
A case of Tangier disease with a novel mutation in the C-terminal region of ATP-binding cassette transporter A1.
Tangier Disease
A novel homozygous ABCA1 variant in an asymptomatic man with profound hypoalphalipoproteinemia.
Tangier Disease
A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier disease.
Tangier Disease
A novel splicing mutation in the ABCA1 gene, causing Tangier disease and familial HDL deficiency in a large family.
Tangier Disease
ABC1: the gene for Tangier disease and beyond.
Tangier Disease
ABCA1 gene polymorphisms and their associations with coronary artery disease and plasma lipids in males from three ethnic populations in Singapore.
Tangier Disease
ATP binding cassette transporter A1--key roles in cellular lipid transport and atherosclerosis.
Tangier Disease
ATP-binding cassette A1 protein and HDL homeostasis.
Tangier Disease
ATP-binding cassette transporter 1 (ABCA1) deficiency decreases platelet reactivity and reduces thromboxane A2 production independently of hematopoietic ABCA1.
Tangier Disease
ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein.
Tangier Disease
ATP-binding cassette transporter A1 contains an NH2-terminal signal anchor sequence that translocates the protein's first hydrophilic domain to the exoplasmic space.
Tangier Disease
ATP-binding cassette transporter A1, fatty acids, and cholesterol absorption.
Tangier Disease
ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipid but not cholesterol efflux.
Tangier Disease
Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease.
Tangier Disease
Double deletions and missense mutations in the first nucleotide-binding fold of the ATP-binding cassette transporter A1 ( ABCA1) gene in Japanese patients with Tangier disease.
Tangier Disease
Dual mechanisms of ABCA1 regulation by geranylgeranyl pyrophosphate.
Tangier Disease
Expression of the ATP-binding cassette transporter gene ABCG1 (ABC8) in Tangier disease.
Tangier Disease
Expression, regulation, and activity of ABCA1 in human cell lines.
Tangier Disease
Functional analysis and transcriptomic profiling of iPSC-derived macrophages and their application in modeling Mendelian disease.
Tangier Disease
Functional loss of ABCA1 in mice causes severe placental malformation, aberrant lipid distribution, and kidney glomerulonephritis as well as high-density lipoprotein cholesterol deficiency.
Tangier Disease
Genotypic effect of the -565C>T polymorphism in the ABCA1 gene promoter on ABCA1 expression and severity of atherosclerosis.
Tangier Disease
Hepatic ABC transporters and triglyceride metabolism.
Tangier Disease
Hepatic ATP-binding cassette transporter A1 is a key molecule in high-density lipoprotein cholesteryl ester metabolism in mice.
Tangier Disease
Human adenovirus modulates surfactant phospholipid trafficking.
Tangier Disease
Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred.
Tangier Disease
Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations.
Tangier Disease
Inhibitors of ATP-binding cassette transporters suppress interleukin-12 p40 production and major histocompatibility complex II up-regulation in macrophages.
Tangier Disease
Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues.
Tangier Disease
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency.
Tangier Disease
Novel mutations in ABCA1 gene in Japanese patients with Tangier disease and familial high density lipoprotein deficiency with coronary heart disease.
Tangier Disease
Novel polypyrimidine variation (IVS46: del T -39...-46) in ABCA1 causes exon skipping and contributes to HDL cholesterol deficiency in a family with premature coronary disease.
Tangier Disease
Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I.
Tangier Disease
Physiological function of ABCG1.
Tangier Disease
Plasma Amyloid-? in Patients with Tangier Disease.
Tangier Disease
POPC/apoA-I discs as a potent lipoprotein modulator in Tangier disease.
Tangier Disease
Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux from late endosomes/lysosomes.
Tangier Disease
Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer.
Tangier Disease
Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro.
Tangier Disease
Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor.
Tangier Disease
Structure, function and regulation of the ABC1 gene product.
Tangier Disease
Study of ABCA1 function in transgenic mice.
Tangier Disease
Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1.
Tangier Disease
The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease.
Tangier Disease
The role of apolipoprotein A-I helix 10 in apolipoprotein-mediated cholesterol efflux via the ATP-binding cassette transporter ABCA1.
Tangier Disease
Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice.
Tangier Disease
Two novel missense mutations in ABCA1 result in altered trafficking and cause severe autosomal recessive HDL deficiency.
Tardive Dyskinesia
Review article: metoclopramide and tardive dyskinesia.
Taste Disorders
Effects of aging on the human taste system.
Tauopathies
Roflumilast ameliorates cognitive deficits in a mouse model of amyloidogenesis and tauopathy: Involvement of nitric oxide status, A? extrusion transporter ABCB1, and reversal by PKA inhibitor H89.
Tauopathies
The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.
Teratoma
Effect of etoposide on experimental testicular teratoma in 129/SvJ mice.
Teratoma
[Multidrug resistance of testicular cancers. (Detection of P-glycoprotein and MDR1 gene expression and their clinical connection)]
Testicular Neoplasms
Immunohistochemical detection of P-glycoprotein and GSTP1-1 in testis cancer.
Testicular Neoplasms
MRP expression of testicular cancers and its clinical relevance.
Testicular Neoplasms
Multidrug resistance of testis cancers: the study of clinical relevance of P-glycoprotein expression.
Testicular Neoplasms
[Multidrug resistance of testicular cancers. (Detection of P-glycoprotein and MDR1 gene expression and their clinical connection)]
Thrombocytopenia
A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Thrombocytopenia
ABCB1-1Delta polymorphism can predict hematologic toxicity in dogs treated with vincristine.
Thrombocytopenia
Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction.
Thrombocytopenia
GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.
Thrombocytopenia
Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers.
Thrombocytopenia
Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma.
Thrombosis
3D contrast-enhanced MR portography and direct X-ray portography: a correlation study.
Thrombosis
ABC Transport Proteins in Cardiovascular Disease-A Brief Summary.
Thrombosis
ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: A meta-analysis.
Thrombosis
ABCC4, a plasma membrane transporter modulating platelet aggregation.
Thrombosis
Activation of the Non-receptor Tyrosine Kinase cSrc in Macrophage-rich Atherosclerotic Plaques of Human Carotid Arteries.
Thrombosis
Development of Left Atrial Thrombus After Coadministration of Dabigatran Etexilate and Phenytoin.
Thrombosis
Intracellular Localization of Endogenous Mouse ABCG1 Is Mimicked by Both ABCG1-L550 and ABCG1-P550-Brief Report.
Thrombosis
Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect.
Thrombosis
Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report.
Thrombosis
Multidrug resistance protein 4 (MRP4/ABCC4) regulates thrombus formation in vitro and in vivo.
Thrombosis
No Association of ABCB1 C3435T Genotype With Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting.
Thrombosis
Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population.
Thrombosis
Reveals of candidate active ingredients in Justicia and its anti-thrombotic action of mechanism based on network pharmacology approach and experimental validation.
Thrombosis
Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein.
Thymoma
Effect of ABC transporter expression and mutational status on survival rates of cancer patients.
Thymoma
Expression and activity of multidrug resistance protein 1 in a murine thymoma cell line.
Thymoma
P-glycoprotein positive, drug resistant invasive lymphoepithelial thymoma: treatment response to chemotherapy with cyclosporin and quinine.
Thymoma
The use of a novel taxane-based P-glycoprotein inhibitor to identify mutations that alter the interaction of the protein with paclitaxel.
Thyroid Cancer, Papillary
A metabolic phenotype based on mitochondrial ribosomal protein expression as a predictor of lymph node metastasis in papillary thyroid carcinoma.
Thyroid Cancer, Papillary
Expression of MRP1 and ABCG2 is associated with adverse clinical outcomes of the papillary thyroid carcinoma with a solid component.
Thyroid Carcinoma, Anaplastic
Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells.
Thyroid Carcinoma, Anaplastic
Expression of multidrug resistance-associated protein (MRP) in anaplastic carcinoma of the thyroid.
Thyroid Carcinoma, Anaplastic
Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Thyroid Diseases
Pharmacotherapeutic Management Strategies for Thyroid Disease-Induced Pericarditis.
Thyroid Diseases
The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin.
Thyroid Neoplasms
A metabolic phenotype based on mitochondrial ribosomal protein expression as a predictor of lymph node metastasis in papillary thyroid carcinoma.
Thyroid Neoplasms
Correspondence Re: Timothy S. Loy, Paul L. Gelven, Dawn Mullins, and Alberto A. Diaz-Arias. Immunostaining for P-glycoprotein in the diagnosis of thyroid carcinomas. Mod Pathol 5:200, 1992.
Thyroid Neoplasms
Expression of multidrug resistance-associated protein (MRP) in thyroid cancers.
Thyroid Neoplasms
Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Thyroid Neoplasms
Immunoexpression of multidrug-resistance protein 2 and cyclooxygenase 2 in medullary thyroid carcinomas.
Thyroid Neoplasms
Immunostaining for P-glycoprotein in the diagnosis of thyroid carcinomas.
Thyroid Neoplasms
Verapamil and cyclosporin A potentiate the effects of chemotherapeutic drugs in the human medullary thyroid carcinoma TT cell line not expressing the 170 kDa P-glycoprotein.
Tics
ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.
Tics
CXCL11 promotes self-renewal and tumorigenicity of ?2?1+ liver tumor-initiating cells through CXCR3/ERK1/2 signaling.
Tics
Synergistic effect of the ?-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
Tics
Transporter-interfering chemicals inhibit P-glycoprotein of yellowfin tuna (Thunnus albacares).
Tongue Neoplasms
Expression of the cancer stem cell markers CD44v6 and ABCG2 in tongue cancer: effect of neoadjuvant chemotherapy on local recurrence.
Torsades de Pointes
An integrated scheme for feature selection and parameter setting in the support vector machine modeling and its application to the prediction of pharmacokinetic properties of drugs.
Torsades de Pointes
Effect of molecular descriptor feature selection in support vector machine classification of pharmacokinetic and toxicological properties of chemical agents.
Toxoplasmosis, Congenital
Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis.
Toxoplasmosis, Congenital
Host genetic and epigenetic factors in toxoplasmosis.
Tremor
Neurotoxic effects of ivermectin administration in genetically engineered mice with targeted insertion of the mutated canine ABCB1 gene.
Triple Negative Breast Neoplasms
ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy.
Triple Negative Breast Neoplasms
Apigenin by targeting hnRNPA2 sensitizes triple-negative breast cancer spheroids to doxorubicin-induced apoptosis and regulates expression of ABCC4 and ABCG2 drug efflux transporters.
Triple Negative Breast Neoplasms
Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Increasing intratumor C/EBP-? LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Triple Negative Breast Neoplasms
Inhibition of protein synthesis and JNK activation are not required for cell death induced by anisomycin and anisomycin analogues.
Triple Negative Breast Neoplasms
LightSpot®-FL-1 Fluorescent Probe: An Innovative Tool for Cancer Drug Resistance Analysis by Direct Detection and Quantification of the P-glycoprotein (P-gp) on Monolayer Culture and Spheroid Triple Negative Breast Cancer Models.
Triple Negative Breast Neoplasms
Methanol Extract of Aerial Parts of Pavetta indica L. Enhances the Cytotoxic Effect of Doxorubicin and Induces Radiation Sensitization in MDA-MB-231 Triple-Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
Peri-foci adipose-derived stem cells promote chemoresistance in breast cancer.
Triple Negative Breast Neoplasms
Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers.
Triple Negative Breast Neoplasms
Screening of potential miRNA therapeutics for the prevention of multi-drug resistance in cancer cells.
Triple Negative Breast Neoplasms
Structure-activity relationships and evaluation of esterified diterpenoid alkaloid derivatives as antiproliferative agents.
Triple Negative Breast Neoplasms
The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Triple Negative Breast Neoplasms
The Long-Term DEHP Exposure Confers Multidrug Resistance of Triple-Negative Breast Cancer Cells through ABC Transporters and Intracellular ROS.
Trypanosomiasis, African
A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors.
Tuberculosis
A lipid-dependent link between activity and oligomerization state of the M. tuberculosis SMR protein TBsmr.
Tuberculosis
ABCC2 Haplotype is Associated With Antituberculosis Drug-Induced Maculopapular Eruption.
Tuberculosis
An attenuated mutant of the Rv1747 ATP-binding cassette transporter of Mycobacterium tuberculosis and a mutant of its cognate kinase, PknF, show increased expression of the efflux pump-related iniBAC operon.
Tuberculosis
Biophysical Characterization of the Tandem FHA Domain Regulatory Module from the Mycobacterium tuberculosis ABC Transporter Rv1747.
Tuberculosis
Comparative study of the effects of anti-tuberculosis drugs and antiretroviral drugs on CYP3A4 and P-glycoprotein.
Tuberculosis
Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
Tuberculosis
Dually Acting Nonclassical 1,4-Dihydropyridines Promote the Anti-Tuberculosis (Tb) Activities of Clofazimine.
Tuberculosis
Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.
Tuberculosis
Genetic variation of ABCB1 (rs1128503, rs1045642) and CYP2E1 rs3813867 with the duration of tuberculosis therapy: a pilot study among tuberculosis patients in Indonesia.
Tuberculosis
Inhibition of ABCG2 efflux pumps renders the Mycobacterium tuberculosis hiding in mesenchymal stem cells responsive to antibiotic treatment.
Tuberculosis
Investigation of ABC transporter from mycobacterial arabinogalactan biosynthetic cluster.
Tuberculosis
Mice lacking the multidrug resistance protein 1 have a transiently impaired immune response during tuberculosis.
Tuberculosis
Mycobacterium tuberculosis enhances macrophage P-glycoprotein (MDR1) expression and activity to promote intracellular survival during anti-TB drug treatment.
Tuberculosis
Mycobacterium tuberculosis induces expression of P-glycoprotein in promonocytic U1 cells chronically infected with HIV type 1.
Tuberculosis
Possible association of rare polymorphism in the ABCB1 gene with rifampin and ethambutol drug-resistant tuberculosis.
Tuberculosis
Prevalence of p-glycoprotein (PGP) expression, function and its effect on efficacy of rifampicin in patients with lymph node tuberculosis.
Tuberculosis
Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells.
Tuberculosis
Rv1458c: a new diagnostic marker for identification of Mycobacterium tuberculosis complex in a novel duplex PCR assay.
Tuberculosis
Serum Rifampicin Levels in Patients with Tuberculosis : Effect of P-Glycoprotein and CYP3A4 Blockers on its Absorption.
Tuberculosis
Structural basis of trehalose recognition by the mycobacterial LpqY-SugABC transporter.
Tuberculosis
[Expression of P-glycoprotein and multidrug resistance-associated protein in peripheral blood mononuclear cells from multidrug resistant tuberculosis patients].
Tuberculosis, Lymph Node
Prevalence of p-glycoprotein (PGP) expression, function and its effect on efficacy of rifampicin in patients with lymph node tuberculosis.
Tuberculosis, Multidrug-Resistant
ABCB1 gene polymorphism associated with clinical factors can predict drug-resistant tuberculosis.
Tuberculosis, Multidrug-Resistant
Possible association of rare polymorphism in the ABCB1 gene with rifampin and ethambutol drug-resistant tuberculosis.
Tuberculosis, Pulmonary
Possible association of rare polymorphism in the ABCB1 gene with rifampin and ethambutol drug-resistant tuberculosis.
Tuberous Sclerosis
Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy.
Tuberous Sclerosis
New proteins configure a brain drug resistance map in tuberous sclerosis.
Urinary Bladder Neoplasms
Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder.
Urinary Bladder Neoplasms
An epirubicin-conjugated nanocarrier with MRI function to overcome lethal multidrug-resistant bladder cancer.
Urinary Bladder Neoplasms
Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer.
Urinary Bladder Neoplasms
ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
Urinary Bladder Neoplasms
BMI1 activates P-glycoprotein via transcription repression of miR-3682-3p and enhances chemoresistance of bladder cancer cell.
Urinary Bladder Neoplasms
Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer.
Urinary Bladder Neoplasms
Correlative expression of glutathione S-transferase-pi and multidrug resistance associated protein in bladder transitional cell carcinoma.
Urinary Bladder Neoplasms
DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling.
Urinary Bladder Neoplasms
Decreased drug resistance of bladder cancer using phytochemicals treatment.
Urinary Bladder Neoplasms
Differential expression of multidrug resistance?related proteins in adriamycin?resistant (pumc?91/ADM) and parental (pumc?91) human bladder cancer cell lines.
Urinary Bladder Neoplasms
DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer.
Urinary Bladder Neoplasms
DNA-ploidy, morphometric-stereological and P-glycoprotein study of superficial bladder carcinomas.
Urinary Bladder Neoplasms
Drug resistance of bladder cancer cells through activation of ABCG2 by FOXM1.
Urinary Bladder Neoplasms
Elevated expression of P-glycoprotein in kidney and urinary bladder cancers.
Urinary Bladder Neoplasms
Ex vivo chemosensitivity to mitomycin C in bladder cancer and its relationship with P-glycoprotein and apoptotic factors.
Urinary Bladder Neoplasms
Expression levels of PEPT1 and ABCG2 play key roles in 5-aminolevulinic acid (ALA)-induced tumor-specific protoporphyrin IX (PpIX) accumulation in bladder cancer.
Urinary Bladder Neoplasms
Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications.
Urinary Bladder Neoplasms
Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
Urinary Bladder Neoplasms
Expression of multidrug-associated protein, P-glycoprotein, P53 and Bcl-2 proteins in bladder cancer and clinical implication.
Urinary Bladder Neoplasms
Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas.
Urinary Bladder Neoplasms
Expressions of P-Glycoprotein, Multidrug Resistance Protein 1 and Annexin A2 as Predictive Factors for Intravesical Recurrence of Bladder Cancer after the Initial Transurethral Resection and Immediate Single Intravesical Instillation of Adriamycin.
Urinary Bladder Neoplasms
Immunohistochemical expression of P-glycoprotein in the rat urinary bladder and the effect of verapamil on intravesical chemotherapy.
Urinary Bladder Neoplasms
Intercellular Transfer of P-Glycoprotein from the Drug Resistant Human Bladder Cancer Cell Line BIU-87 Does Not Require Cell-to-Cell Contact.
Urinary Bladder Neoplasms
Intercellular transfer of P-glycoprotein mediates the formation of stable multi-drug resistance in human bladder cancer BIU-87 cells.
Urinary Bladder Neoplasms
Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study.
Urinary Bladder Neoplasms
Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143.
Urinary Bladder Neoplasms
MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.
Urinary Bladder Neoplasms
Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically By Inducing Endoplasmic Reticulum Stress.
Urinary Bladder Neoplasms
Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Urinary Bladder Neoplasms
Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer.
Urinary Bladder Neoplasms
Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients.
Urinary Bladder Neoplasms
P-glycoprotein expression in bladder cancer.
Urinary Bladder Neoplasms
Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells.
Urinary Bladder Neoplasms
Role of P-glycoprotein in chemoresistant superficial bladder tumours.
Urinary Bladder Neoplasms
Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy.
Urinary Bladder Neoplasms
Twist Confers Chemoresistance to Anthracyclines in Bladder Cancer through Upregulating P-Glycoprotein.
Urinary Bladder Neoplasms
[Detecting multi-drug resistance of bladder cancer for the intravesical chemotherapy]
Urinary Bladder Neoplasms
[Immunological diagnosis of multidrug resistant cancer in urological malignancies]
Urinary Bladder, Overactive
Effects of Anticholinergic Drugs Used for the Therapy of Overactive Bladder on P-Glycoprotein Activity.
Urinary Bladder, Overactive
The role of P-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic OAB drug trospium chloride.
Urinary Calculi
Source of a micro-nutrient in a semi-synthetic basal diet as a causative factor in inducing urinary calculi in rats and its inhibition by PSC 833, a potent inhibitor of P-glycoprotein.
Uterine Cervical Neoplasms
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.
Uterine Cervical Neoplasms
Apoptotic death mode of mitomycin C-treated HeLa cells and cellular localization of mitomycin C-induced P-glycoprotein.
Uterine Cervical Neoplasms
CircASAP1 promotes the development of cervical cancer through sponging miR-338-3p to upregulate RPP25.
Uterine Cervical Neoplasms
Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells.
Uterine Cervical Neoplasms
COX-1 is coupled with mPGES-1 and ABCC4 in human cervix cancer cells.
Uterine Cervical Neoplasms
Effect of bitter melon (Momordica charantia Linn) on level and function of natural killer cells in cervical cancer patients with radiotherapy.
Uterine Cervical Neoplasms
Effect of NOS1 regulating ABCG2 expression on proliferation and apoptosis of cervical cancer cells.
Uterine Cervical Neoplasms
Influence of MDR1 methylation on the curative effect of interventional embolism chemotherapy for cervical cancer.
Uterine Cervical Neoplasms
Kuguacin J isolated from bitter melon leaves modulates paclitaxel sensitivity in drug-resistant human ovarian cancer cells.
Uterine Cervical Neoplasms
Overexpression of trefoil factor 3 (TFF3) contributes to the malignant progression in cervical cancer cells.
Uterine Cervical Neoplasms
Resistance to the antiproliferative effect induced by a short-chain ceramide is associated with an increase of glucosylceramide synthase, P-glycoprotein, and multidrug-resistance gene-1 in cervical cancer cells.
Uterine Cervical Neoplasms
Sensitivity of ASPP and P-gp to neoadjuvant chemotherapy combined with gene therapy in locally advanced cervical cancer.
Uterine Cervical Neoplasms
SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2.
Uterine Cervical Neoplasms
The lactate receptor (HCAR1/GPR81) contributes to doxorubicin chemoresistance via ABCB1 transporter up-regulation in human cervical cancer HeLa cells.
Uterine Cervical Neoplasms
[Relationship between the expression of P-glycoprotein, glutathione S-transferase-pi and thymidylate synthase proteins and adenosine triphosphate tumor chemosensitivity assay in cervical cancer]
Uterine Cervical Neoplasms
[Research of the characterization of Bcrp1(+) HeLa cells].
Uterine Cervical Neoplasms
[Study of the invasiveness and tumour formation of Bcrp1(+) HeLa cervical cancer cells].
Uveitis
Increased local expression of P-glycoprotein on CD4+ T-cells in vitreous of patients with non-infectious uveitis: a pilot study.
Vaccinia
Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system.
Vaccinia
Functional expression of human P-glycoprotein from plasmids using vaccinia virus-bacteriophage T7 RNA polymerase system.
Vaccinia
P-glycoprotein plays an insignificant role in the presentation of antigenic peptides to CD8+ T cells.
Vaccinia
Recombinant vaccinia virus vectors for functional expression of P-glycoprotein in mammalian cells.
Vaginitis
Increased expression and hotspot mutations of the multidrug efflux transporter, CDR1 in azole-resistant Candida albicans isolates from vaginitis patients.
Varicose Veins
3D contrast-enhanced MR portography and direct X-ray portography: a correlation study.
Vascular Diseases
ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden.
Vascular Diseases
Frequencies of four ATP-binding cassette transporter G8 polymorphisms in patients with ischemic vascular diseases.
Vascular Diseases
Shared gene expression patterns in mesenchymal progenitors derived from lung and epidermis in pulmonary arterial hypertension: identifying key pathways in pulmonary vascular disease.
Venous Thromboembolism
Pharmacogenetics role in the safety of acenocoumarol therapy.
Venous Thromboembolism
Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
Venous Thrombosis
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Venous Thrombosis
Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients.
Ventricular Dysfunction
Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to Hypoxia.
Virus Diseases
An alternative splicing isoform of MITA antagonizes MITA-mediated induction of type I IFNs.
Virus Diseases
Association of ATP-Binding Cassette Transporter (ABC) Gene Polymorphisms with Viral Load in Patients with Genotype 1 Hepatitis C Virus Infection.
Virus Diseases
Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibits Extra Villous Trophoblast Migration: The Impact of Bacterial and Viral Infection.
Virus Diseases
Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection.
Virus Diseases
Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection.
Virus Diseases
Role of ABCB1 and glutathione S-transferase gene variants in the association of porphyria cutanea tarda and human immunodeficiency virus infection.
Virus Diseases
The effects of human immunodeficiency virus infection on the expression of the drug efflux proteins P-glycoprotein and breast cancer resistance protein in a human intestine model.
Virus Diseases
The multidrug resistance gene mdr1a influences resistance to ectromelia virus infection by mechanisms other than conventional immunity.
Virus Diseases
Translational role of natural coumarins and their derivatives as anticancer agents.
Virus Diseases
Up-Regulation of the ATP-Binding Cassette Transporter A1 Inhibits Hepatitis C Virus Infection.
Virus Diseases
[P-glycoprotein and human immunodeficiency virus infection.]
Wilms Tumor
Characterization of seven kidney tumors by flow cytometry: analysis of cell cycle, DNA content and P-glycoprotein expression.
Wilms Tumor
Correction: Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.
Wilms Tumor
Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours.
Wilms Tumor
Immune responses against tumour-associated antigen-derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients.
Wilms Tumor
Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.
Wilms Tumor
Nephroblastoma: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells.
Wilms Tumor
P-Glycoprotein Expression, Tumor Weight, Age, and Relapse in Patients with Stage I and II Favorable-Histology Wilms' Tumor.
Wilms Tumor
P-glycoprotein status of favorable-histology Wilms' tumor predicts treatment outcome.
Wilms Tumor
Significance of P-glycoprotein expression in childhood malignant tumors.
X-Linked Combined Immunodeficiency Diseases
Characterization of an MDR1 retroviral bicistronic vector for correction of X-linked severe combined immunodeficiency.
Xanthomatosis
Selective Correction of Genotype Yield by Probucol in HDL-Deficient Mice Propagation.
Xeroderma Pigmentosum
p53 mutation, but not in vitro predictor genes of therapeutic efficacy of cisplatin, is clinically relevant in comparing partial and complete responder cases of maxillary squamous cell carcinoma.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.